[NP Induction_NN ][PP of_IN ][NP NF-KB_NN ][PP during_IN ][NP monocyte_NN differentiation_NN ][PP by_IN ][NP HIV_NN type_NN 1_CD infection_NN ] ._.
[NP The_DT production_NN ][PP of_IN ][NP human_JJ immunodeficiency_NN virus_NN type_NN 1_CD ] (_([NP HIV-1_NN ] )_)[NP progeny_NN ][VP was_VBD followed_VBN ][PP in_IN ][NP the_DT U937_NN promonocytic_JJ cell_NN line_NN ][PP after_IN ][NP stimulation_NN ][PP either_CC with_IN ][NP retinoic_JJ acid_NN ] or_CC[NP PMA_NN ] ,_, and_CC[PP in_IN ][NP purified_VBN human_JJ ][NP monocytes_NNS ] and_CC[NP macrophages_NNS ] ._.
[NP Electrophoretic_JJ mobility_NN shift_NN assays_NNS ] and_CC[NP Southwestern_NN blotting_NN experiments_NNS ][VP were_VBD used_VBN ][VP to_TO detect_VB ][NP the_DT binding_NN ][PP of_IN ][NP cellular_JJ transactivation_NN factor_NN NF-KB_NN ][PP to_TO ][NP the_DT double_JJ repeat-KB_JJ|NN enhancer_NN sequence_NN ][ADJP located_JJ ][PP in_IN ][NP the_DT long_JJ terminal_JJ repeat_NN ] ._.
[NP PMA_NN treatment_NN ] ,_,[CONJP and_CC not_RB ][NP retinoic_JJ acid_NN treatment_NN ][PP of_IN ][NP the_DT U937_NN cells_NNS ][VP acts_VBZ ][PP in_IN ][VP inducing_VBG ][NP NF-KB_NN expression_NN ][PP in_IN ][NP the_DT nuclei_NNS ] ._.
[PP In_IN ][NP nuclear_JJ extracts_NNS ][PP from_IN ][NP monocytes_NNS ] or_CC[NP macrophages_NNS ] ,_,[NP induction_NN ][PP of_IN ][NP NF-KB_NN ][VP occurred_VBD ][SBAR only_RB if_IN ][NP the_DT cells_NNS ][VP were_VBD previously_RB infected_VBN ][PP with_IN ][NP HIV-1_NN ] ._.
[ADVP When_WRB ][NP U937_NN cells_NNS ][VP were_VBD infected_VBN ][PP with_IN ][NP HIV-1_NN ] ,_,[NP no_DT induction_NN ][PP of_IN ][NP NF-KB_NN factor_NN ][VP was_VBD detected_VBN ] ,_, whereas_IN[NP high_JJ level_NN ][PP of_IN ][NP progeny_NN virions_NNS ][VP was_VBD produced_VBN ] ,_,[VP suggesting_VBG ][SBAR that_IN ][NP this_DT factor_NN ][VP was_VBD not_RB required_VBN ][PP for_IN ][NP viral_JJ replication_NN ] ._.
[NP These_DT results_NNS ][VP indicate_VBP ][SBAR that_IN ][PP in_IN ][NP monocytic_JJ cell_NN lineage_NN ] ,_,[NP HIV-1_NN ][VP could_MD mimic_VB ] some_DT[NP differentiation/activation_JJ ][NP stimuli_NNS ][VP allowing_VBG ][NP nuclear_JJ NF-KB_NN expression_NN ] ._.
[NP Positive_JJ and_CC negative_JJ regulation_NN ][PP of_IN ][NP immunoglobulin_NN gene_NN expression_NN ][PP by_IN ][NP a_DT novel_JJ B-cell-specific_JJ enhancer_NN element_NN ] ._.
[NP A_DT new_JJ B-cell-specific_JJ enhancer_NN element_NN ][VP has_VBZ been_VBN identified_VBN ][NP 3'_JJ ][PP of_IN ][NP E4_NN ] and_CC[NP the_DT octamerlike_JJ motifs_NNS ][PP in_IN ][NP the_DT human_JJ immunoglobulin_NN heavy-chain_NN gene_NN enhancer_NN ] ._.
[NP Tandem_JJ copies_NNS ][PP of_IN ][NP this_DT 67-bp_JJ MnlI-AluI_NN fragment_NN ] ,_,[ADVP when_WRB ][VP fused_VBN ][PP to_TO ][NP the_DT chloramphenicol_JJ acetyltransferase_NN gene_NN ][VP driven_VBN ][PP by_IN ][NP the_DT conalbumin_JJ promoter_NN ] ,_,[VP stimulated_VBD ][NP transcription_NN ][PP in_IN ][NP B_NN cells_NNS ][PP but_CC ][PP not_RB in_IN ][NP Jurkat_NN T_NN cells_NNS ] or_CC[NP HeLa_NN cells_NNS ] ._.
[NP Footprinting_NN analysis_NN ][VP revealed_VBD ][SBAR that_IN ][NP the_DT identical_JJ sequence_NN CCGAAACTGAAAAGG_NN ] ,_,[VP designated_VBN ][NP E6_NN ] ,_,[VP was_VBD protected_VBN ][PP by_IN ][NP nuclear_JJ extracts_NNS ][PP from_IN ][NP B_NN cells_NNS ] ,_,[NP T_NN cells_NNS ] ,_, or_CC[NP HeLa_NN cells_NNS ] ._.
[NP Gel_NN mobility_NN shift_NN assays_NNS ][VP using_VBG ][NP a_DT synthetic_JJ E6_NN motif_NN ][VP detected_VBD ][NP a_DT B-cell-specific_JJ complex_NN ][PP in_IN addition_NN to_TO ][NP a_DT ubiquitous_JJ band_NN ][VP found_VBN ][PP also_RB in_IN ][NP T_NN cells_NNS ] and_CC[NP HeLa_NN cells_NNS ] ._.
[PP In_IN agreement_NN with_IN ][NP the_DT results_NNS ][PP of_IN ][NP gel_NN retardation_NN assays_NNS ] ,_,[NP tandem_JJ copies_NNS ][PP of_IN ][NP the_DT E6_NN motif_NN ][VP stimulated_VBD ][NP transcription_NN ][PP in_IN ][NP ARH77_NN ] and_CC[NP Raji_NN ][NP cells_NNS ][PP but_CC ][PP not_RB in_IN ][NP Jurkat_NN ] or_CC[NP HeLa_NN ][NP cells_NNS ] ._.
[ADVP Furthermore_RB ] ,_,[NP a_DT mutant_JJ E6_NN motif_NN ][VP lost_VBD ] both_CC[NP in_FW vitro_FW binding_NN activity_NN ][PP and_CC ][NP in_FW vivo_FW enhancer_NN activity_NN ] ._.
[PP In_IN ][NP striking_JJ contrast_NN ][PP to_TO ][NP the_DT mouse_NN Ig_NN heavy-chain_JJ enhancer_NN ] ,_,[PP in_IN ][NP which_WDT ][NP the_DT octamer_NN motif_NN ][VP acts_VBZ ][PP as_IN ][NP a_DT B-cell-specific_JJ enhancer_NN element_NN ] ,_,[NP the_DT human_JJ enhancer_NN ][VP contains_VBZ ][NP an_DT octamerlike_JJ sequence_NN ][PP with_IN ][NP one_CD base_NN substitution_NN ][NP which_WDT ][VP bound_VBD ][NP octamer-binding_JJ proteins_NNS ][PP with_IN ][NP only_RB very_RB low_JJ affinity_NN ] and_CC[VP showed_VBD ][NP no_DT enhancer_NN activity_NN ][PP of_IN ][NP its_PRP$ own_JJ ] ._.
[ADVP Interestingly_RB ] ,_,[NP the_DT MnlI-AluI_NN fragment_NN ][VP could_MD suppress_VB ][NP the_DT basal-level_JJ activity_NN ][PP of_IN ][NP the_DT conalbumin_JJ promoter_NN ][PP in_IN ] both_CC[NP Jurkat_NN ] and_CC[NP HeLa_NN ][NP cells_NNS ] ._.
[ADVP Moreover_RB ] ,_,[NP simian_JJ virus_NN 40_CD enhancer_NN activity_NN ][VP was_VBD blocked_VBN ][PP by_IN ][NP the_DT MnlI-AluI_NN fragment_NN ][PP in_IN ][NP HeLa_NN cells_NNS ][PP but_CC ][PP not_RB in_IN ][NP B_NN cells_NNS ] ._.
[ADVP Thus_RB ] ,_,[NP the_DT novel_JJ enhancer_NN element_NN ][VP identified_VBN ][PP in_IN ][NP this_DT study_NN ][VP is_VBZ ][ADVP probably_RB ][NP a_DT target_NN site_NN ][PP for_IN ][NP both_CC positive_JJ and_CC negative_JJ factors_NNS ] ._.
[NP The_DT NF_NN kappa_NN B_NN independent_JJ cis-acting_JJ sequences_NNS ][PP in_IN ][NP HIV-1_NN LTR_NN ][ADJP responsive_NN ][PP to_TO ][NP T-cell_NN activation_NN ] ._.
[NP The_DT rate_NN ][PP of_IN ][NP transcription_NN initiation_NN ][VP directed_VBN ][PP by_IN ][NP the_DT long_JJ terminal_JJ repeat_NN ] (_([NP LTR_NN ] )_)[PP of_IN ][NP HIV-1_NN ][VP increases_VBZ ][PP in_IN response_NN to_TO ][NP mitogenic_JJ stimuli_NNS ][PP of_IN ][NP T_NN cells_NNS ] ._.
[ADVP Here_RB ][NP we_PRP ][VP show_VBP ][SBAR that_IN ][NP the_DT response_NN ][PP of_IN ][NP the_DT HIV-1_NN LTR_NN ][VP may_MD be_VB governed_VBN ][PP by_IN ][NP two_CD independent_JJ sequences_NNS ][ADJP located_JJ ][NP 5'_JJ ][PP to_TO ][NP the_DT site_NN ][PP of_IN ][NP transcription_NN initiation_NN sequences_NNS ][NP that_WDT ][VP bind_VBP ] either_CC[NP NFAT-1_NN ] or_CC[NP NF_NN kappa_NN B_NN ] ._.
[NP The_DT rate_NN ][PP of_IN ][NP LTR-directed_JJ gene_NN expression_NN ][VP increased_VBD ][PP in_IN response_NN to_TO ][NP treatment_NN ][PP with_IN ] either_CC[NP a_DT phorbol_NN ester_NN ] or_CC[NP tumor_NN necrosis_NN factor_NN alpha_NN ][SBAR if_IN ] either_CC the_DT[NP NFAT-1_NN ] or_CC[NP NF_NN kappa_NN B_NN ][NP binding_NN sites_NNS ][VP were_VBD deleted_VBN ] ,_, but_CC[VP failed_VBD to_TO respond_VB ][PP to_TO ][NP these_DT mitogenic_JJ stimuli_NNS ][SBAR if_IN ][NP both_DT sequences_NNS ][VP were_VBD ][ADJP absent_JJ ] ._.
[NP The_DT HIV-1_NN mutant_JJ virus_NN ][VP containing_VBG ] both_CC[NP NF_NN kappa_NN B_NN ] and_CC[NP NFAT-1_NN ][NP deletion_NN ][VP was_VBD ][ADJP able_JJ ][VP to_TO replicate_VB ][SBAR although_IN ][PP at_IN ][NP a_DT much_JJ decreased_VBN growth_NN rate_NN ] ,_,[SBAR while_IN ][NP the_DT deletion_NN ][PP of_IN ][NP NFAT-1_NN ][ADVP alone_RB ][VP increased_VBD ][NP the_DT viral_JJ growth_NN rate_NN ][PP in_IN ][NP Jurkat_NN cells_NNS ] ._.
 Neither_CC[NP deletion_NN ][PP of_IN ][NP NF_NN kappa_NN B_NN ] nor_CC[NP deletion_NN ][PP of_IN ][NP NFAT-1_NN ][VP decreased_VBD ][NP activation_NN ][PP of_IN ][NP viral_JJ replication_NN ][PP by_IN ][NP phorbol_NN ester_NN ] ._.
[NP Specific_JJ depletion_NN ][PP of_IN ][NP the_DT B-cell_NN population_NN ][VP induced_VBN ][PP by_IN ][NP aberrant_JJ expression_NN ][PP of_IN ][NP human_JJ interferon_NN regulatory_JJ factor_NN 1_CD gene_NN ][PP in_IN ][NP transgenic_JJ mice_NNS ] ._.
[NP Interferons_NNS ] (_([NP IFNs_NNS ] )_)[VP are_VBP well_RB known_VBN ] both_CC[PP as_IN ][NP antiviral_JJ proteins_NNS ][PP and_CC ][PP as_IN ][NP potent_JJ regulators_NNS ][PP of_IN ][NP cell_NN ][NP growth_NN ] and_CC[NP differentiation_NN ] ._.
[PP In_IN ][NP fact_NN ] ,_,[NP IFNs_NNS ][VP inhibit_VBP ][NP growth_NN ][PP of_IN ][NP various_JJ normal_JJ and_CC transformed_VBN cell_NN types_NNS ] ._.
[ADVP Previously_RB ] ,_,[NP a_DT nuclear_JJ factor_NN ] ,_,[NP IRF-1_NN ] (_([NP interferon_NN regulatory_JJ factor_NN 1_CD ] )_) ,_,[NP which_WDT ][VP binds_VBZ ][PP to_TO ][NP type_NN I_CD IFN_NN ] and_CC[NP some_DT IFN-inducible_JJ gene_NN promoters_NNS ] ,_,[VP was_VBD identified_VBN ] and_CC[VP cloned_VBN ] ._.
[SBAR Since_IN ][NP the_DT IRF-1_NN gene_NN ][VP is_VBZ ] both_CC[NP virus_NN ] and_CC[NP IFN_NN ][ADJP inducible_JJ ] ,_,[NP an_DT intriguing_JJ issue_NN ][VP is_VBZ raised_VBN ][PP as_IN to_TO ][SBAR whether_IN ][NP the_DT IRF-1_NN gene_NN ][VP is_VBZ functioning_VBG ][PP in_IN ][NP IFN-mediated_JJ regulation_NN ][PP of_IN ][NP cell_NN ][NP growth_NN ] and_CC[NP differentiation_NN ] ._.
[PP In_IN ][NP this_DT study_NN ] ,_,[NP we_PRP ][VP generated_VBD ][NP transgenic_JJ mice_NNS ][VP carrying_VBG ][NP the_DT human_JJ IRF-1_NN gene_NN ][VP linked_VBN ][PP to_TO ][NP the_DT human_JJ immunoglobulin_NN heavy-chain_JJ enhancer_NN ] ._.
[PP In_IN ][NP the_DT transgenic_JJ mice_NNS ] ,_,[NP all_PDT the_DT lymphoid_JJ tissues_NNS ][VP examined_VBN ][VP showed_VBD ][NP a_DT dramatic_JJ reduction_NN ][PP in_IN ][NP the_DT number_NN ][PP of_IN ][NP B_NN lymphocytes_NNS ] (_([NP B_NN cells_NNS ] )_) ._.
[NP Preparation_NN ] and_CC[NP analysis_NN ][PP of_IN ][NP bone_NN marrow_NN cells_NNS ][PP from_IN ][NP the_DT chimeric_JJ mice_NNS ][VP indicated_VBD ][SBAR that_IN ][NP the_DT bone_NN marrow_NN ][VP is_VBZ ][NP the_DT effective_JJ site_NN ][PP for_IN ][NP specific_JJ depletion_NN ][PP of_IN ][NP the_DT B-cell_NN population_NN ] ._.
[PP In_IN ][NP fact_NN ] ,_,[NP transgenic_JJ bone_NN marrow_NN cells_NNS ][VP cocultured_VBN ][PP with_IN ][NP a_DT bone_NN marrow-derived_JJ stromal_JJ cell_NN line_NN ][VP revealed_VBD ][NP an_DT altered_JJ B-cell_NN maturation_NN pattern_NN ] ._.
[NP Identification_NN ] and_CC[NP cloning_NN ][PP of_IN ][NP TCF-1_NN ] ,_,[NP a_DT T_NN lymphocyte-specific_JJ transcription_NN factor_NN ][VP containing_VBG ][NP a_DT sequence-specific_JJ HMG_NN box_NN ] ._.
[NP CD3-epsilon_NN expression_NN ][VP is_VBZ controlled_VBN ][PP by_IN ][NP a_DT downstream_JJ T_NN lymphocyte-specific_JJ enhancer_NN element_NN ] ._.
[NP We_PRP ][VP report_VBP ][NP the_DT identification_NN ][PP of_IN ][NP a_DT T_NN cell-specific_JJ transcription_NN factor_NN ] ,_,[NP TCF-1_NN ] ,_,[VP binding_VBG ][PP to_TO ][NP this_DT element_NN ] ._.
[NP The_DT multimerized_JJ recognition_NN motif_NN ][PP of_IN ][NP TCF-1_NN ][VP constituted_VBD ][NP a_DT T_NN cell-specific_JJ enhancer_NN ] ._.
[NP Subsequent_JJ cloning_NN ][PP of_IN ][NP TCF-1_NN ][VP identified_VBD ][NP three_CD splice_NN alternatives_NNS ] ._.
[NP TCF-1_NN ][VP contained_VBD ][NP a_DT single_JJ DNA-binding_JJ HMG_NN box_NN ][ADJP most_RBS closely_RB related_JJ ][PP to_TO ][NP similar_JJ boxes_NNS ][PP in_IN ][NP the_DT putative_JJ mammalian_JJ sex-determining_JJ gene_NN SRY_NN ][PP and_CC ][PP in_IN ][NP the_DT Schizosaccharomyces_FW pombe_FW Mc_NN mating_NN type_NN gene_NN ] ._.
[ADVP TCF-1_NN mRNA_NN ][VP was_VBD expressed_VBN ][ADVP uniquely_RB ][PP in_IN ][NP T_NN lymphocytes_NNS ] ._.
[PP Upon_IN ][NP cotransfection_NN ][PP into_IN ][NP non-T_JJ cells_NNS ] ,_,[NP TCF-1_NN ][VP could_MD transactivate_VB ][PP through_IN ][NP its_PRP$ cognate_JJ motif_NN ] ._.
[NP These_DT results_NNS ][VP identify_VBP ][NP TCF-1_NN ][PP as_IN ][NP a_DT T_NN cell-specific_JJ transcription_NN factor_NN ] ,_,[NP which_WDT ][VP might_MD play_VB ][NP a_DT role_NN ][PP in_IN ][NP the_DT establishment_NN ][PP of_IN ][NP the_DT mature_JJ T_NN cell_NN phenotype_NN ] ._.
[NP Nuclear_JJ factor_NN kappa_NN B_NN ][VP activates_VBZ ][NP proenkephalin_NN transcription_NN ][PP in_IN ][NP T_NN lymphocytes_NNS ] ._.
[PP Upon_IN ][NP activation_NN ] ,_,[NP T_NN lymphocytes_NNS ][VP accumulate_VBP ][NP high_JJ levels_NNS ][PP of_IN ][NP the_DT neuropeptide_NN enkephalin_NN ][NP which_WDT ][VP correlate_VBP ][PP with_IN ][NP high_JJ levels_NNS ][PP of_IN ][NP proenkephalin_NN mRNA_NN ][PP in_IN ][NP the_DT cells_NNS ] ._.
[ADVP Here_RB ][NP we_PRP ][VP investigated_VBD ][NP the_DT transcriptional_JJ basis_NN ][PP for_IN ][NP these_DT changes_NNS ] ._.
[NP The_DT proenkephalin_NN promoter_NN ][VP contains_VBZ ][NP a_DT sequence_NN GGGGACGTCCCC_NN ] ,_,[VP named_VBN ][NP B2_NN ] ,_,[NP which_WDT ][VP is_VBZ ][ADJP similar_JJ ][PP to_TO ][NP the_DT kappa_NN B_NN sequence_NN GGGGACTTTCC_NN ] ,_,[NP the_DT binding_VBG site_NN ][PP of_IN ][NP the_DT transcription_NN factor_NN ][NP nuclear_JJ factor_NN ] (_([NP NF_NN ] )_)[NP -kappa_NN B_NN ] ._.
[NP Activation_NN ][PP of_IN ][NP T_NN lymphocytes_NNS ][VP induces_VBZ ][NP an_DT NF-kappa_NN B-like_JJ binding_NN activity_NN ][PP to_TO ][NP the_DT B2_NN site_NN ] ,_,[ADJP concomitant_JJ ][PP with_IN ][NP activation_NN ][PP of_IN ][NP the_DT proenkephalin_NN promoter_NN ] ._.
[NP Mutations_NNS ][PP at_IN ][NP the_DT B2_NN site_NN ][VP abolish_VBP ][NP this_DT transcriptional_JJ activation_NN ] ._.
[NP The_DT purified_VBN homodimer_NN ] (_([NP two_CD p50s_NNS ] )_)[PP of_IN ][NP the_DT DNA-binding_JJ subunit_NN ][PP of_IN ][NP NF-kappa_NN B_NN ][VP binds_VBZ ][NP the_DT B2_NN site_NN ][PP of_IN ][NP proenkephalin_NN ][ADVP relatively_RB better_JJR ][SBAR than_IN ] does_VBZ the_DT[NP heterotetramer_NN ] (_([NP two_CD p65s_NNS ] plus_CC[NP two_CD p50s_NNS ] )_)[NP form_NN ][PP of_IN ][NP the_DT factor_NN ] ._.
[ADVP Thus_RB ] ,_,[NP it_PRP ][VP appears_VBZ ][SBAR that_IN ][NP the_DT T-cell-specific_JJ activation_NN ][PP of_IN ][NP the_DT proenkephalin_NN promoter_NN ][VP is_VBZ mediated_VBN ][PP by_IN ][NP NF-kappa_NN B_NN ] ._.
[ADVP However_RB ] ,_,[SBAR as_IN ][NP NF-kappa_NN B_NN ][VP is_VBZ ][ADJP ubiquitous_JJ ] and_CC[NP the_DT transcriptional_JJ activation_NN ][PP through_IN ][NP the_DT B2_NN site_NN ][VP is_VBZ ][NP T_NN cell_NN ][ADJP specific_JJ ] ,_,[NP yet_RB another_DT T-cell-specific_JJ factor_NN ][NP which_WDT ][VP synergizes_VBZ ][PP with_IN ][NP NF-kappa_NN B_NN ][VP should_MD be_VB considered_VBN ] ._.
[NP Expression_NN ][PP of_IN ][NP c-jun_NN ] ,_,[NP jun_NN B_NN ] and_CC[NP jun_NN D_NN ][NP proto-oncogenes_NNS ][PP in_IN ][NP human_JJ peripheral-blood_JJ granulocytes_NNS ] ._.
[NP We_PRP ][VP have_VBP found_VBN ][SBAR that_IN ][NP purified_VBN human_JJ peripheral-blood_JJ granulocytes_NNS ][VP express_VBP ][NP constitutively_RB significant_JJ levels_NNS ][PP of_IN ][NP proto-oncogenes_NNS ][NP c-jun_NN ] ,_,[NP jun_NN B_NN ] and_CC[NP jun_NN D_NN ][NP mRNA_NN ] ._.
[PP Upon_IN ][NP functional_JJ activation_NN ][PP of_IN ][NP granulocytes_NNS ][PP by_IN ][NP 4_CD beta-phorbol_NN 12-myristate_NN 13-acetate_NN ] (_([NP PMA_NN ] )_) ,_,[NP the_DT levels_NNS ][PP of_IN ][NP c-jun_NN ] ,_,[NP jun_NN B_NN ] and_CC[NP jun_NN D_NN ][NP transcripts_NNS ][VP were_VBD increased_VBN ] ._.
[NP The_DT three_CD jun_NN genes_NNS ][VP showed_VBD ][NP a_DT similar_JJ time_NN course_NN ][PP in_IN ][NP their_PRP$ induction_NN ][PP by_IN ][NP PMA_NN ] ,_,[NP maximal_JJ mRNA_NN levels_NNS ][VP being_VBG reached_VBN ][PP after_IN ][NP 60_CD min_NN ][PP of_IN ][NP induction_NN ] ._.
[NP These_DT results_NNS ][VP suggest_VBP ][SBAR that_IN ][NP expression_NN ][PP of_IN ][NP c-jun_NN ] ,_,[NP jun_NN B_NN ] and_CC[NP jun_NN D_NN ][NP genes_NNS ][VP might_MD be_VB involved_VBN ][PP in_IN ][NP terminal_JJ granulocyte_NN differentiation_NN ][PP or_CC ][PP in_IN ][VP regulating_VBG ][NP granulocyte_NN functionality_NN ] ._.
[NP Platelet-activating_JJ factor_NN ][VP induces_VBZ ][NP phospholipid_JJ turnover_NN ] ,_,[NP calcium_NN flux_NN ] ,_,[NP arachidonic_JJ acid_NN liberation_NN ] ,_,[NP eicosanoid_NN generation_NN ] ,_, and_CC[NP oncogene_JJ expression_NN ][PP in_IN ][NP a_DT human_JJ B_NN cell_NN line_NN ] ._.
[NP Platelet-activating_JJ factor_NN ][VP is_VBZ ][NP a_DT potent_JJ mediator_NN ][PP of_IN ][NP the_DT inflammatory_JJ response_NN ] ._.
[NP Studies_NNS ][PP of_IN ][NP the_DT actions_NNS ][PP of_IN ][NP platelet-activating_JJ factor_NN ][VP have_VBP centered_VBN ][PP mainly_RB around_IN ][NP neutrophils_NNS ] ,_,[NP monocytes_NNS ] ,_, and_CC[NP platelets_NNS ] ._.
[PP In_IN ][NP this_DT report_NN ][NP we_PRP ][VP begin_VBP to_TO uncover_VB ][NP the_DT influence_NN ][PP of_IN ][NP platelet-activating_NN factor_NN ][PP on_IN ][NP B_NN lymphocytes_NNS ] ._.
[VP Employing_VBG ][NP the_DT EBV-transformed_JJ human_JJ B_NN cell_NN line_NN SKW6.4_NN ] ,_,[NP we_PRP ][VP demonstrate_VBP ][SBAR that_IN ][NP platelet-activating_JJ factor_NN ][ADVP significantly_RB ][VP alters_VBZ ][NP membrane_NN phospholipid_JJ metabolism_NN ][VP indicated_VBN ][PP by_IN ][NP the_DT incorporation_NN ][PP of_IN ][NP 32P_NN ][PP into_IN ][NP phosphatidylcholine_NN ] ,_,[NP phosphatidylinositol_NN ] ,_, and_CC[NP phosphatidic_JJ acid_NN ][PP but_CC ][ADVP not_RB significantly_RB ][PP into_IN ][NP phosphatidylethanolamine_NN ][PP at_IN ][NP concentrations_NNS ][VP ranging_VBG ][PP from_IN ][NP 10(-9)_CD ][PP to_TO ][NP 10(-6)_CD ][NP M_NN ] ._.
[NP The_DT inactive_JJ precursor_NN ] ,_,[NP lyso-platelet-activating_JJ factor_NN ] ,_,[PP at_IN ][NP a_DT concentration_NN ][ADJP as_RB high_JJ ][PP as_IN ][NP 10(-7)_CD M_NN ][VP had_VBD ][NP no_DT effect_NN ][PP on_IN ][NP any_DT ][PP of_IN ][NP the_DT membrane_NN phospholipids_NNS ] ._.
[NP We_PRP ][ADVP also_RB ][VP show_VBP ][SBAR that_IN ][NP platelet-activating_JJ factor_NN ][PP from_IN ][NP 10(-12)_CD to_TO 10(-6)_CD M_NN ][VP induced_VBD ][NP rapid_JJ and_CC significant_JJ elevation_NN ][PP in_IN ][NP intracellular_JJ calcium_NN levels_NNS ] ,_, whereas_IN[NP lyso-platelet-activating_JJ factor_NN ][VP was_VBD ][ADVP again_RB ][ADJP ineffective_JJ ] ._.
[NP We_PRP ][ADVP further_RB ][VP demonstrate_VBP ][NP the_DT impact_NN ][PP of_IN ][NP platelet-activating_JJ factor_NN ][VP binding_VBG ][PP to_TO ][NP B_NN cells_NNS ][PP by_IN ][VP measuring_VBG ][NP platelet-activating_JJ factor_NN ][NP induced_JJ arachidonic_JJ acid_NN release_NN ] and_CC[NP 5-hydroxyeicosatetraenoic_JJ acid_NN production_NN ] ._.
[ADVP Moreover_RB ] ,_,[NP platelet-activating_JJ factor_NN ][VP was_VBD ][ADJP capable_JJ ][PP of_IN ][VP inducing_VBG ][NP transcription_NN ][PP of_IN ][NP the_DT nuclear_JJ proto-oncogenes_NNS ][NP c-fos_NN ] and_CC[NP c-jun_NN ] ._.
[ADVP Finally_RB ][NP we_PRP ][VP explored_VBD ][NP the_DT possible_JJ role_NN ][PP of_IN ][NP 5-hydroxyeicosatetraenoic_JJ acid_NN ][PP as_IN ][NP a_DT regulator_NN ][PP of_IN ][NP arachidonic_JJ acid_NN liberation_NN ][VP demonstrating_VBG ][SBAR that_IN ][NP endogenous_JJ 5-lipoxygenase_NN activity_NN ][VP modulates_VBZ ][NP platelet-activating_JJ factor_NN ][NP induced_JJ arachidonic_JJ acid_NN release_NN ][ADVP perhaps_RB ][VP acting_VBG ][PP at_IN ][NP the_DT level_NN ][PP of_IN ][NP phospholipase_NN A2_NN ] ._.
[PP In_IN ][NP summary_NN ] ,_,[NP platelet-activating_JJ factor_NN ][VP is_VBZ shown_VBN here_RB to_TO have_VB ][NP a_DT direct_JJ and_CC profound_JJ effect_NN ][PP on_IN ][NP a_DT pure_JJ B_NN cell_NN line_NN ] ._.
[NP A_DT novel_JJ HIV-1_NN isolate_JJ ][VP containing_VBG ][NP alterations_NNS ][VP affecting_VBG ][NP the_DT NF-kappa_NN B_NN element_NN ] ._.
[NP Three_CD molecular_JJ clones_NNS ][PP of_IN ][NP HIV-1_NN ] ,_,[VP derived_VBN ][PP from_IN ][NP a_DT single_JJ isolate_NN ] (_([NP AL1_NN ] )_) ,_,[VP exhibited_VBD ][NP distinct_JJ replicative_JJ and_CC cytopathic_JJ properties_NNS ][PP during_IN ][NP propagation_NN ][PP in_IN ][NP a_DT human_JJ T_NN cell_NN line_NN ] ._.
[NP The_DT phenotypic_JJ differences_NNS ][VP observed_VBN ][VP were_VBD ][ADJP attributable_JJ ] ,_,[PP in_IN ][NP large_JJ part_NN ] ,_,[PP to_TO ][NP changes_NNS ][VP affecting_VBG ][NP the_DT viral_JJ LTR_NN ] ._.
[NP Nucleotide_NN sequence_NN ] and_CC[NP PCR_NN analyses_NNS ][VP demonstrated_VBD ][NP the_DT presence_NN ][PP of_IN ][NP novel_JJ ][NP duplications_NNS ] or_CC[NP deletions_NNS ][VP involving_VBG ][NP the_DT NF-kappa_NN B_NN motif_NN ] ._.
[NP These_DT changes_NNS ][PP in_IN ][NP the_DT enhancer_NN element_NN ][VP were_VBD identified_VBN ][PP in_IN ][NP the_DT original_JJ AL1_NN virus_NN stock_NN ] ._.
[NP Subcloning_NN ][PP of_IN ][NP the_DT variant_JJ NF-kappa_NN B_NN segments_NNS ][PP into_IN ][NP LTR-driven_JJ CAT_NN expression_NN vectors_NNS ][VP confirmed_VBD ][NP a_DT correlation_NN ][PP between_IN ][NP promoter_JJ activity_NN ] and_CC[NP replicative/cytopathic_JJ capacity_NN ] ._.
[NP 1,25-Dihydroxyvitamin_NN D3_NN receptor_NN RNA_NN ] :_:[NP expression_NN ][PP in_IN ][NP hematopoietic_JJ cells_NNS ] ._.
[NP 1,25-Dihydroxyvitamin_NN D3_NN ] (_([NP 1,25(OH)2D3_NN ] )_)[VP induces_VBZ ][NP differentiation_NN ] and_CC[VP inhibits_VBZ ][NP proliferation_NN ][PP of_IN ][NP myeloid_JJ leukemic_JJ cells_NNS ][PP from_IN ][NP various_JJ ][NP lines_NNS ] and_CC[NP patients_NNS ] ;_:[NP these_DT effects_NNS ][VP are_VBP probably_RB mediated_VBN ][PP through_IN ][NP the_DT 1,25(OH)2D3_NN receptor_NN ] ._.
[NP Little_JJ ][VP is_VBZ known_VBN ][PP of_IN ][NP expression_NN ][PP of_IN ][NP 1,25(OH)2D3_NN receptor_NN RNA_NN ][PP in_IN ][NP hematopoietic_JJ cells_NNS ] ._.
[NP We_PRP ][VP examined_VBD ][NP the_DT ][NP expression_NN ] and_CC[NP modulation_NN ][PP of_IN ][NP expression_NN ][PP of_IN ][NP 1,25(OH)2D3_NN receptor_NN RNA_NN ][PP in_IN ][NP various_JJ proliferating_VBG and_CC nonproliferating_JJ hematopoietic_JJ cells_NNS ] ._.
[NP Constitutive_JJ expression_NN ][PP of_IN ][NP 1,25(OH)2D3_NN receptor_NN RNA_NN ][VP was_VBD detected_VBN ][PP in_IN ][NP various_JJ kinds_NNS ][PP of_IN ][NP hematopoietic_JJ cells_NNS ] ,_,[PP including_VBG ][NP macrophages_NNS ] and_CC[NP activated_VBN T_NN lymphocytes_NNS ] ,_,[CONJP as_RB well_RB as_IN ][PP in_IN ][NP cell_NN lines_NNS ][NP KG-1_NN ] (_([NP myeloblasts_NNS ] )_) ,_,[NP HL-60_NN ] (_([NP promyelocytes_NNS ] )_) ,_,[NP ML-3_NN ] (_([NP myelomonoblasts_NNS ] )_) ,_,[NP U937_NN ] ,_,[NP THP-1_NN ] (_([NP monoblasts_NNS ] )_) ,_,[NP K562_NN ] (_([NP erythroblasts_NNS ] )_) ,_, and_CC[NP S-LB1_NN ] (_([NP HTLV-1-transfected_JJ T_NN lymphocytes_NNS ] )_) ._.
[NP Receptor_NN transcripts_NNS ][VP were_VBD ][NP 4.6_CD ][NP kilobases_NNS ] (_([NP kb_NN ] )_) ,_, and_CC[NP no_DT variant_JJ sizes_NNS ][VP were_VBD observed_VBN ] ._.
[NP All_DT cell_NN lines_NNS ][VP examined_VBN ][PP in_IN ][NP this_DT group_NN ][ADVP also_RB ][VP expressed_VBD ][NP 1,25(OH)2D3_NN receptors_NNS ] ._.
[NP Most_JJS B_NN lymphocyte_NN lines_NNS ][VP expressed_VBD ][NP negligible_JJ levels_NNS ][PP of_IN ][NP 1,25(OH)2D3_NN receptor_NN RNA_NN and_CC protein_NN ] ;_: however_RB ;_:[NP analysis_NN ][PP of_IN ][NP a_DT lymphoid/myeloid_JJ somatic_JJ hybrid_NN ][VP suggested_VBD ][SBAR that_IN ][NP suppression_NN ][PP of_IN ][NP expression_NN ][PP of_IN ][NP 1,25(OH)2D3_NN receptor_NN RNA_NN ][PP in_IN ][NP B_NN lymphocytes_NNS ][VP may_MD be_VB ][NP a_DT dominant_JJ characteristic_NN ] ._.
[NP HL-60_NN cells_NNS ][VP were_VBD cultured_VBN ][PP with_IN ][NP 10(-7)_CD mol/L_NN ][NP 1,25(OH)2D3_NN ][PP for_IN ][NP 24_CD to_TO 72_CD hours_NNS ] ,_, and_CC[NP levels_NNS ][PP of_IN ][NP expression_NN ][PP of_IN ][NP 1,25(OH)2D3_NN receptor_NN ] and_CC[NP its_PRP$ RNA_NN ][VP were_VBD examined_VBN ] ._.
[NP Levels_NNS ][PP of_IN ][NP RNA_NN ][VP coding_NN ][PP for_IN ][NP the_DT receptor_NN ][VP were_VBD not_RB modulated_VBN ][PP by_IN ][NP exposure_NN ][PP to_TO ][NP high_JJ levels_NNS ][PP of_IN ][NP ligand_NN ] ._.
[NP Levels_NNS ][PP of_IN ][NP occupied_VBN 1,25(OH)2D3_NN receptor_NN protein_NN ][VP increased_VBD ][PP in_IN ][NP these_DT HL-60_NN cells_NNS ] ;_: but_CC[NP the_DT total_JJ number_NN ][PP of_IN ][NP 1,25(OH)2D3_NN receptors_NNS ][VP decreased_VBD ][NP about_RB 50_CD %_NN ][PP at_IN ][NP 24_CD hours_NNS ] and_CC[VP returned_VBD ][PP toward_IN ][NP normal_JJ ][PP at_IN ][NP 72_CD hours_NNS ] ._.
[NP Steady-state_JJ levels_NNS ][PP of_IN ][NP 1,25(OH)2D3_NN receptor_NN RNA_NN ][VP were_VBD not_RB affected_VBN ][PP by_IN ][NP terminal_JJ differentiation_NN ][PP of_IN ][NP HL-60_NN ][PP toward_IN ] either_CC[NP granulocytes_NNS ] or_CC[NP macrophages_NNS ] ._.
[NP Nondividing_JJ macrophages_NNS ][PP from_IN ][NP normal_JJ individuals_NNS ][ADVP also_RB ][VP expressed_VBD ][NP 1,25(OH)2D3_NN receptor_NN RNA_NN ] ._.
[PP In_IN ][NP contrast_NN ] ,_,[NP nondividing_JJ peripheral_JJ blood_NN lymphocytes_NNS ][PP from_IN ][NP normal_JJ individuals_NNS ][VP did_VBD not_RB express_VB ][NP 1,25(OH)2D3_NN receptor_NN RNA_NN ] ;_:[PP with_IN ][NP stimulation_NN ][PP of_IN ][NP proliferation_NN ][PP of_IN ][NP these_DT cells_NNS ] ,_,[NP accumulation_NN ][PP of_IN ][NP 1,25(OH)2D3_NN receptor_NN RNA_NN ][VP increased_VBD ][ADVP markedly_RB ] ._.
[NP Half-life_NN ] (_([NP t1/2_NN ] )_)[PP of_IN ][NP 1,25(OH)2D3_NN receptor_NN RNA_NN ][PP in_IN ][NP T_NN lymphocytes_NNS ][VP was_VBD ][ADJP short_JJ ] (_([NP 1_CD hour_NN ] )_)[SBAR as_IN ][VP determined_VBN ][PP by_IN ][VP measuring_VBG ][NP decay_NN ][PP of_IN ][NP the_DT message_NN ][PP after_IN ][NP addition_NN ][PP of_IN ][NP actinomycin_NN D_NN ] ._.
[ADJP Consistent_JJ ][PP with_IN ][NP this_DT short_JJ t1/2_NN ] ,_,[NP accumulation_NN ][PP of_IN ][NP 1,25(OH)2D3_NN receptor_NN RNA_NN ][VP increased_VBD ][PP in_IN ][NP cells_NNS ][SBAR as_IN ][NP their_PRP$ protein_NN synthesis_NN ][VP was_VBD inhibited_VBN ] ._.
[NP Further_JJ studies_NNS ][VP are_VBP required_VBN ][VP to_TO understand_VB ][NP the_DT physiologic_JJ role_NN ][PP of_IN ][NP 1,25(OH)2D3_NN receptors_NNS ][PP in_IN ][NP myeloid_JJ cells_NNS ] and_CC[NP proliferating_VBG T_NN lymphocytes_NNS ] ._.
[NP Kappa_NN B_NN binding_NN proteins_NNS ][VP are_VBP constitutively_RB expressed_VBN ][PP in_IN ][NP an_DT IL-2_NN autocrine_NN human_JJ T_NN cell_NN line_NN ] ._.
[NP The_DT IL-2_NN ] and_CC[NP the_DT IL-2-R_NN alpha_NN ][NP genes_NNS ][VP are_VBP both_DT expressed_VBN ][ADVP transiently_RB ][PP in_IN ][NP normal_JJ T_NN lymphocytes_NNS ][PP after_IN ][NP Ag_NN ] or_CC[NP mitogen_NN ][NP activation_NN ] ._.
[PP In_IN ][NP contrast_NN ] ,_,[NP the_DT human_JJ T_NN cell_NN line_NN ] ,_,[NP IARC_NN 301_CD ] ,_,[VP expresses_VBZ ][NP these_DT two_CD genes_NNS ][ADVP constitutively_RB ] and_CC[NP we_PRP ][VP have_VBP previously_RB demonstrated_VBN ][SBAR that_IN ][NP its_PRP$ growth_NN ][VP depends_VBZ ][PP on_IN ][NP the_DT autocrine_JJ production_NN ][PP of_IN ][NP this_DT T_NN cell_NN growth_NN factor_NN ] and_CC[NP high_JJ affinity_NN IL-2R_NN ] ._.
[VP To_TO dissect_VB ][NP the_DT molecular_JJ basis_NN ][PP for_IN ][NP the_DT unusual_JJ persistent_JJ expression_NN ][PP of_IN ] the_DT[NP IL-2_NN ] and_CC[NP IL-2-R_NN alpha_NN ][NP genes_NNS ][PP in_IN ][NP these_DT IARC_NN 301_CD T_NN cells_NNS ] ,_,[NP we_PRP ][VP have_VBP analyzed_VBN ][NP the_DT interactions_NNS ][PP of_IN ][NP constitutively_RB expressed_VBN nuclear_JJ proteins_NNS ][PP with_IN ][NP the_DT 5'_JJ flanking_JJ regions_NNS ][PP of_IN ] the_DT[NP IL-2_NN ] and_CC[NP IL-2-R_NN alpha_NN ][NP genes_NNS ][VP using_VBG ][NP both_DT ][NP DNase_NN I_CD footprinting_NN ] and_CC[NP gel_NN retardation_NN ][NP techniques_NNS ] ._.
[NP We_PRP ][VP have_VBP found_VBN ][SBAR that_IN ][NP a_DT region_NN ][PP in_IN ][NP both_DT genes_NNS ] (_([NP -276_CD ] to_TO[NP -250_CD ][PP for_IN ][NP IL-2-R_NN alpha_NN ] and_CC[NP -203_CD ] to_TO[NP -183_CD ][PP for_IN ][NP IL-2_NN ] )_) ,_,[NP which_WDT ][VP corresponds_VBZ ][PP to_TO ][NP a_DT kappa_NN B_NN enhancer_NN element_NN ] ,_,[VP is_VBZ specifically_RB protected_VBN ][PP by_IN ][NP nuclear_JJ proteins_NNS ][PP from_IN ][NP IARC_NN 301_CD ] ._.
[PP In_IN agreement_NN with_IN ][NP this_DT finding_NN ] ,_, both_CC the_DT[NP IL-2_NN ] and_CC[NP IL-2-R_NN alpha_NN ][NP promoters_NNS ][VP are_VBP ][ADJP active_JJ ][PP in_IN ][NP transient_JJ transfection_NN assays_NNS ][PP in_IN ][NP IARC_NN 301_CD cells_NNS ] ._.
[PP In_IN ][NP contrast_NN ] ,_,[NP mutation_NN ][PP of_IN ][NP the_DT kappa_NN B_NN enhancer_NN ][VP results_VBZ ][PP in_IN ][NP markedly_RB attenuated_VBN activities_NNS ][PP of_IN ][NP both_DT promoters_NNS ] ._.
[NP Two_CD proteins_NNS ][VP binding_VBG ][NP the_DT kappa_NN B_NN sequence_NN ] ,_,[NP NF-kappa_NN B_NN ] and_CC[NP KBF1_NN ] ,_,[VP are_VBP constitutively_RB expressed_VBN ][PP in_IN ][NP IARC_NN 301_CD nuclei_NNS ] and_CC[VP induced_VBN ][PP by_IN ][NP PMA_NN ] and_CC[NP PHA_NN ][PP in_IN ][NP Jurkat_NN ] ._.
[NP They_PRP ][VP bind_VBP ][PP to_TO ][NP the_DT kappa_NN B_NN motifs_NNS ][PP with_IN ][NP different_JJ relative_JJ affinities_NNS ][NP that_WDT ][VP may_MD reflect_VB ][NP their_PRP$ different_JJ contribution_NN ][PP in_IN ][NP the_DT expression_NN ][PP of_IN ][NP various_JJ promoters_NNS ] ._.
[NP The_DT functional_JJ domains_NNS ][PP of_IN ][NP the_DT murine_JJ Thy-1_NN gene_NN promoter_NN ] ._.
[NP The_DT Thy-1_NN gene_NN promoter_NN ][VP resembles_VBZ ][NP a_DT "_[[DQS]] housekeeping_JJ "_[[DQE]] promoter_NN ][PP in_IN ][SBAR that_IN ][NP it_PRP ][VP is_VBZ ][ADJP located_JJ ][PP within_IN ][NP a_DT methylation-free_JJ island_NN ] ,_,[VP lacks_VBZ ][NP a_DT canonical_JJ TATA_NN box_NN ] ,_, and_CC[VP displays_VBZ ][NP heterogeneity_NN ][PP in_IN ][NP the_DT 5'-end_JJ termini_NNS ][PP of_IN ][NP the_DT mRNA_NN ] ._.
[VP Using_VBG ][NP transgenic_JJ mice_NNS ] ,_,[NP we_PRP ][VP show_VBP ][SBAR that_IN ][NP this_DT promoter_NN ][VP does_VBZ not_RB confer_VB ][NP any_DT tissue_NN specificity_NN ] and_CC[VP is_VBZ ][ADJP active_JJ ][PP only_RB in_IN ][NP a_DT position-dependent_JJ manner_NN ] ._.
[NP It_PRP ][VP can_MD only_RB be_VB activated_VBN ][PP in_IN ][NP a_DT tissue-specific_JJ manner_NN ][PP by_IN ][NP elements_NNS ][NP that_WDT ][VP lie_VBP ][ADJP downstream_RB ][PP of_IN ][NP the_DT initiation_NN site_NN ] ._.
[NP We_PRP ][VP have_VBP analyzed_VBN ][NP the_DT functional_JJ domains_NNS ][PP of_IN ][NP the_DT minimal_JJ Thy-1_NN promoter_NN ] and_CC[VP show_VB ][SBAR that_IN ][NP the_DT dominant_JJ promoter_NN elements_NNS ][VP consist_VBP ][PP of_IN ][NP multiple_JJ binding_VBG sites_NNS ][PP for_IN ][NP the_DT transcription_NN factor_NN Sp1_NN ] ,_,[NP an_DT inverted_JJ CCAAT_NN box_NN ] ,_, and_CC[NP sequences_VBZ ][ADJP proximal_JJ ][PP to_TO ][NP the_DT transcription_NN start_NN site_NN ] ._.
[NP DNase_NN I_CD and_CC gel_NN mobility_NN shift_NN assays_NNS ][VP show_VBP ][NP the_DT binding_NN ][PP of_IN ][NP a_DT number_NN ][PP of_IN ][NP nuclear_JJ factors_NNS ][PP to_TO ][NP these_DT elements_NNS ] ,_,[PP including_VBG ][NP Sp1_NN ] and_CC[NP CP1_NN ] ._.
[NP Our_PRP$ results_NNS ][VP show_VBP ][SBAR that_IN ][NP the_DT structure_NN ][PP of_IN ][NP this_DT promoter_NN ][ADVP only_RB ][VP permits_VBZ ][NP productive_JJ interactions_NNS ][PP of_IN ][NP the_DT two_CD transcription_NN factors_NNS ][NP Sp1_NN ] and_CC[NP CP1_NN ][PP with_IN ][NP the_DT basal_JJ transcription_NN machinery_NN ][PP in_IN the_DT presence_NN of_IN ][NP enhancer_NN sequences_NNS ] ._.
[NP Comparison_NN ][PP of_IN ][NP constitutive_JJ and_CC inducible_JJ transcriptional_JJ enhancement_NN ][VP mediated_VBN ][PP by_IN ][NP kappa_NN B-related_JJ sequences_NNS ] :_:[NP modulation_NN ][PP of_IN ][NP activity_NN ][PP in_IN ][NP B_NN cells_NNS ][PP by_IN ][NP human_JJ T-cell_NN leukemia_NN virus_NN type_NN I_CD tax_NN gene_NN ] ._.
[NP The_DT kappa_NN B_NN sequence_NN ] (_([NP GGGACTTTCC_NN ] )_)[VP binds_VBZ ][NP a_DT factor_NN ] ,_,[NP NF-kappa_NN B_NN ] ,_,[NP that_WDT ][VP is_VBZ constitutively_RB found_VBN ][PP in_IN ][NP its_PRP$ functional_JJ ,_, DNA_NN binding_NN form_NN ][PP only_RB in_IN ][NP B_NN lymphocytes_NNS ] ._.
[NP A_DT factor_NN ][PP with_IN ][NP apparently_RB indistinguishable_JJ sequence_NN specificity_NN ][VP can_MD be_VB induced_VBN ][PP in_IN ][NP many_JJ other_JJ cell_NN types_NNS ] ,_,[ADVP where_WRB ][NP it_PRP ][VP is_VBZ used_VBN ][VP to_TO regulate_VB ][NP inducible_JJ gene_NN expression_NN ] ._.
[PP For_IN ][NP example_NN ] ,_,[NP kappa_NN B-related_JJ sequences_NNS ][VP have_VBP been_VBN shown_VBN to_TO be_VB ][ADJP important_JJ ][PP for_IN ][NP the_DT transcription_NN ][PP of_IN ][NP a_DT few_JJ inducible_JJ genes_NNS ] ,_,[PP such_JJ as_IN ][NP the_DT interleukin_NN 2_CD receptor_NN alpha-chain_NN gene_NN ] and_CC[NP the_DT beta-interferon_NN gene_NN ] ._.
[ADVP However_RB ] ,_,[NP these_DT genes_NNS ][VP are_VBP ] not_RB[ADJP constitutively_RB active_JJ ][PP in_IN ][NP B_NN lymphocytes_NNS ] ,_,[VP suggesting_VBG ][SBAR that_IN ][NP other_JJ regulatory_JJ mechanisms_NNS ][VP must_MD play_VB ][NP a_DT role_NN ][PP in_IN ][VP determining_VBG ][NP the_DT patterns_NNS ][PP of_IN ][NP expression_NN ] ._.
[NP We_PRP ][VP have_VBP investigated_VBN ][NP the_DT constitutive_JJ and_CC inducible_JJ transcriptional_JJ activity_NN ][VP mediated_VBN ][PP by_IN ][NP five_CD kappa_NN B-related_JJ sequence_NN elements_NNS ][PP in_IN ][NP two_CD different_JJ cell_NN types_NNS ] ._.
[NP We_PRP ][VP show_VBP ][SBAR that_IN ][PP in_IN ][NP S194_NN plasma_NN cells_NNS ][NP the_DT activity_NN ][PP of_IN ][NP each_DT element_NN ][VP correlates_VBZ ][ADVP well_RB ][PP with_IN ][NP the_DT relative_JJ affinity_NN ][PP of_IN ][NP B-cell-derived_JJ NF-kappa_NN B_NN ][PP for_IN ][NP that_DT element_NN ] ._.
[NP This_DT ][VP leads_VBZ ][PP to_TO ][NP significantly_RB lower_RBR transcription_NN enhancement_NN ][PP by_IN ][NP sites_NNS ][VP derived_VBN ][PP from_IN ] the_DT[NP interleukin_NN 2_CD receptor_NN ] or_CC[NP T-cell_NN receptor_NN ][NP genes_NNS ][PP in_IN ][NP S194_NN ][NP cells_NNS ] ._.
[ADVP However_RB ] ,_,[PP in_IN ] either_CC[NP EL-4_NN (_( T_NN ] )_)[NP cells_NNS ] or_CC S194_NN[NP cells_NNS ,_, both_DT ] lower-affinity_JJ sites_NNS can_MD be_VB[PP significantly_RB ][NP induced_VBN by_IN the_DT tax_NN ] gene_NN[NP product_NN of_IN human_JJ T-cell_NN leukemia_NN virus_NN ][VP type_NN ] I_CD ,_,[NP showing_VBG that_IN NF-kappa_NN ][VP B_NN activity_NN can_MD ][PP be_VB modulated_VBN ][NP even_RB in_IN a_DT ][NP B-cell_NN ][ADVP line_NN ] that_WDT[NP constitutively_RB expresses_VBZ ] this_DT
[NP Isolation_NN ][PP of_IN ][NP a_DT rel-related_JJ human_JJ cDNA_NN ][NP that_WDT ][ADVP potentially_RB ][VP encodes_VBZ ][NP the_DT 65-kD_JJ subunit_NN ][PP of_IN ][NP NF-kappa_NN B_NN ] (_([NP published_VBN erratum_NN ][VP appears_VBZ ][PP in_IN ][NP Science_NNP 1991_CD Oct_NNP 4_CD ;_: 254_CD (_( 5028_CD )_) :_: 11_CD ] )_)
[NP A_DT DNA_NN probe_NN ][NP that_WDT ][VP spanned_VBD ][NP a_DT domain_NN ][VP conserved_VBN ][PP among_IN ][NP the_DT proto-oncogene_NN c-rel_NN ] ,_,[NP the_DT Drosophila_NN morphogen_NN dorsal_NN ] ,_, and_CC[NP the_DT p50_NN DNA_NN binding_NN subunit_NN ][PP of_IN ][NP NF-kappa_NN B_NN ][VP was_VBD generated_VBN ][PP from_IN ][NP Jurkat_NN T_NN cell_NN complementary_JJ DNA_NN ][PP with_IN ][NP the_DT polymerase_NN chain_NN reaction_NN ] (_([NP PCR_NN ] )_) and_CC[NP degenerate_JJ oligonucleotides_NNS ] ._.
[NP This_DT probe_NN ][VP was_VBD used_VBN ][VP to_TO identify_VB ][NP a_DT rel-related_JJ complementary_JJ DNA_NN ][NP that_WDT ][VP hybridized_VBD ][PP to_TO ][NP a_DT 2.6-kilobase_JJ messenger_NN RNA_NN ][ADJP present_JJ ][PP in_IN ] human_JJ[NP T_NN ] and_CC[NP B_NN ][NP lymphocytes_NNS ] ._.
[NP In_FW vitro_FW ][NP transcription_NN ] and_CC[NP translation_NN ][PP of_IN ][NP the_DT complementary_JJ DNA_NN ][VP resulted_VBD ][PP in_IN ][NP the_DT synthesis_NN ][PP of_IN ][NP a_DT protein_NN ][PP with_IN ][NP an_DT apparent_JJ molecular_JJ size_NN ][PP of_IN ][NP 65_CD ][NP kilodaltons_NNS ] (_([NP kD_NN ] )_) ._.
[NP The_DT translated_VBN protein_NN ][VP showed_VBD ][NP weak_JJ DNA_NN binding_NN ][PP with_IN ][NP a_DT specificity_NN ][PP for_IN ][NP the_DT kappa_NN B_NN binding_VBG motif_NN ] ._.
[NP This_DT protein-DNA_JJ complex_JJ ][VP comigrated_VBN ][PP with_IN ][NP the_DT complex_NN ][VP obtained_VBN ][PP with_IN ][NP the_DT purified_VBN human_JJ p65_NN NF-kappa_NN B_NN subunit_NN ] and_CC[NP binding_NN ][VP was_VBD inhibited_VBN ][PP by_IN ][NP I_NN kappa_NN B-alpha_NN ] and_CC[NP -beta_NN ][NP proteins_NNS ] ._.
[PP In_IN ][NP addition_NN ] ,_,[NP the_DT 65-kD_JJ protein_NN ][VP associated_VBN ][PP with_IN ][NP the_DT p50_NN subunit_NN ][PP of_IN ][NP NF-kappa_NN B_NN ] and_CC[NP the_DT kappa_NN B_NN probe_NN ][VP to_TO form_VB ][NP a_DT complex_NN ][PP with_IN ][NP the_DT same_JJ electrophoretic_JJ mobility_NN ][PP as_IN ][NP the_DT NF-kappa_NN B-DNA_JJ complex_NN ] ._.
[ADVP Therefore_RB ][NP the_DT rel-related_JJ 65-kD_JJ protein_NN ][VP may_MD represent_VB ][NP the_DT p65_NN subunit_NN ][PP of_IN ][NP the_DT active_JJ NF-kappa_NN B_NN transcription_NN factor_NN complex_NN ] ._.
[NP Lymphocyte_NN glucocorticoid_NN receptor_NN number_NN ][PP in_IN ][NP posttraumatic_JJ stress_NN disorder_NN ] ._.
[NP OBJECTIVE_NN ] :_:[NP The_DT authors_NNS ][NP '_POS objective_NN ][VP was_VBD ][VP to_TO investigate_VB ][NP the_DT possibility_NN ][SBAR that_IN ][NP glucocorticoid_NN receptor_NN changes_NNS ][VP may_MD be_VB involved_VBN ][PP in_IN ][NP the_DT dysregulation_NN ][PP of_IN ] the_DT hypothalamic-pituitary-adrenal_JJ (_([ADJP HPA_JJ ] )_)[NP axis_NN ][PP in_IN ][NP posttraumatic_JJ stress_NN disorder_NN ] (_([NP PTSD_NN ] )_) ._.
[NP METHOD_NN ] :_:[NP They_PRP ][VP measured_VBD ][NP the_DT number_NN ][PP of_IN ][NP lymphocyte_NN cytosolic_JJ glucocorticoid_NN receptors_NNS ] and_CC[NP plasma_NN cortisol_NN concentrations_NNS ] in_IN[NP 15_CD consecutively_RB admitted_VBN male_JJ combat_NN Vietnam_NN veterans_NNS ][PP with_IN ][NP PTSD_NN ][PP and_CC ][PP in_IN ][NP a_DT normal_JJ comparison_NN group_NN ][PP of_IN ][NP 11_CD subjects_NNS ] ._.
[NP RESULTS_NNS ] :_: Both_CC[NP the_DT patients_NNS ] and_CC[NP the_DT normal_JJ comparison_NN subjects_NNS ][VP showed_VBD ][NP a_DT morning-to-afternoon_JJ decline_NN ][PP in_IN ][NP glucocorticoid_NN receptor_NN concentrations_NNS ] ,_,[VP paralleling_VBG ][NP the_DT normal_JJ diurnal_JJ decline_NN ][PP in_IN ][NP cortisol_NN levels_NNS ] ._.
[NP The_DT number_NN ][PP of_IN ][NP glucocorticoid_NN receptors_NNS ][VP was_VBD ][NP 63_CD %_NN ][ADJP greater_JJR ][PP in_IN ][NP the_DT morning_NN ] and_CC[NP 26_CD %_NN ][ADJP greater_JJR ][PP in_IN ][NP the_DT afternoon_NN ][PP in_IN ][NP the_DT patients_NNS ][PP with_IN ][NP PTSD_NN ][PP than_IN ][PP in_IN ][NP the_DT normal_JJ subjects_NNS ] ._.
[NP No_DT group_NN differences_NNS ][PP in_IN ][NP cortisol_NN levels_NNS ][VP were_VBD observed_VBN ] ,_, nor_CC were_VBD[NP glucocorticoid_NN receptor_NN number_NN ] and_CC[NP cortisol_NN levels_NNS ][ADJP correlated_VBD ] ._.
[NP The_DT number_NN ][PP of_IN ][NP morning_NN glucocorticoid_NN receptors_NNS ][VP was_VBD ][ADJP positively_RB correlated_VBN ][PP with_IN ][NP symptoms_NNS ][PP of_IN ][NP PTSD_NN ] and_CC[NP anxiety_NN ] ._.
[NP CONCLUSIONS_NNS ] :_:[NP These_DT results_NNS ][VP provide_VBP ][NP further_JJ evidence_NN ][PP for_IN ][NP a_DT dysregulation_NN ][PP of_IN ][NP the_DT HPA_JJ axis_NN ][PP in_IN ][NP PTSD_NN ] ._.
[NP The_DT finding_NN ][SBAR that_IN ][NP patients_NNS ][PP with_IN ][NP PTSD_NN ][VP had_VBD ][NP a_DT substantially_RB greater_JJR number_NN ][PP of_IN ][NP lymphocyte_NN glucocorticoid_NN receptors_NNS ][PP than_IN ][NP normal_JJ comparison_NN subjects_NNS ][VP is_VBZ ][ADJP consistent_JJ ][PP with_IN ][NP the_DT authors_NNS ][NP '_POS previous_JJ observations_NNS ][PP of_IN ][NP low_JJ 24-hour_JJ urinary_JJ cortisol_NN excretion_NN ][PP in_IN ][NP subjects_NNS ][PP with_IN ][NP PTSD_NN ] ._.
[ADVP Furthermore_RB ] ,_,[NP the_DT receptor_NN changes_NNS ][VP observed_VBN ][VP are_VBP ][ADJP opposite_JJ ][PP of_IN ][NP those_DT ][VP reported_VBN ][PP in_IN ][NP major_JJ depressive_JJ disorder_NN ] ._.
[NP The_DT present_JJ data_NNS ] ,_,[PP along_IN with_IN ][NP other_JJ findings_NNS ][PP of_IN ][NP HPA_JJ abnormalities_NNS ][PP in_IN ][NP PTSD_NN ] ,_,[VP support_VBP ][NP the_DT possibility_NN ][PP of_IN ][NP a_DT greater_JJR negative_JJ feedback_NN sensitivity_NN ][PP at_IN ][NP one_CD or_CC more_JJR levels_NNS ][PP of_IN ][NP the_DT HPA_JJ axis_NN ] ._.
[NP A_DT thymus-specific_JJ member_NN ][PP of_IN ][NP the_DT HMG_NN protein_NN family_NN ][VP regulates_VBZ ][NP the_DT human_JJ T_NN cell_NN receptor_NN C_NN alpha_NN enhancer_NN ] ._.
[NP The_DT human_JJ T_NN cell-specific_JJ transcription_NN factor_NN ][NP TCF-1_NN alpha_NN ][VP plays_VBZ ][NP a_DT key_JJ role_NN ][PP in_IN ][NP the_DT tissue-specific_JJ activation_NN ][PP of_IN ][NP the_DT T_NN cell_NN receptor_NN (_( TCR_NN )_) C_NN alpha_NN enhancer_NN ] and_CC[VP binds_VBZ ][PP to_TO ][NP pyrimidine-rich_JJ elements_NNS ] (_([NP 5'-PyCTTTG-3'_NN ] )_)[ADJP present_JJ ][PP in_IN ][NP a_DT variety_NN ][PP of_IN ][NP other_JJ T_NN cell-specific_JJ control_NN regions_NNS ] ._.
[VP Using_VBG ][NP amino_NN acid_NN sequence_NN information_NN ][VP derived_VBN ][PP from_IN ][NP the_DT DNA_NN affinity-purified_JJ protein_NN ] ,_,[NP we_PRP ][VP have_VBP now_RB isolated_VBN ][NP cDNA_NN clones_NNS ][VP encoding_VBG ][NP TCF-1_NN alpha_NN ] ._.
[NP The_DT TCF-1_NN alpha_NN cDNA_NN ][VP contains_VBZ ][NP a_DT single_JJ 68-amino-acid_JJ domain_NN ][NP that_WDT ][VP is_VBZ ][ADJP homologous_JJ ][PP to_TO ][NP a_DT region_NN ][VP conserved_VBN ][PP among_IN ][NP high-mobility_JJ group_NN ] (_([NP HMG_NN ] )_) and_CC[NP nonhistone_JJ chromosomal_JJ proteins_NNS ] ._.
[NP Expression_NN ][PP of_IN ][NP full-length_JJ and_CC mutant_JJ cDNA_NN clones_NNS ][PP in_IN ][NP bacteria_NNS ][VP reveal_VBP ][SBAR that_IN ][NP the_DT single_JJ HMG_NN motif_NN ] ,_,[NP which_WDT ][VP is_VBZ predicted_VBN to_TO contain_VB ][NP two_CD extended_VBN alpha-helical_JJ segments_NNS ] ,_,[VP is_VBZ ][ADJP sufficient_JJ ][VP to_TO direct_VB ][NP the_DT sequence-specific_JJ binding_NN ][PP of_IN ][NP TCF-1_NN alpha_NN ][PP to_TO ][NP DNA_NN ] ._.
[NP Northern_NN blot_NN experiments_NNS ][VP demonstrate_VBP ][ADVP further_RBR ][SBAR that_IN ][NP TCF-1_NN alpha_NN mRNA_NN ][VP is_VBZ ][ADJP highly_RB tissue_NN specific_JJ ] ,_,[VP found_VBN ][ADVP primarily_RB ][PP in_IN ][NP the_DT ][NP thymus_NN ] or_CC[NP T_NN cell_NN lines_NNS ] ._.
[NP The_DT immature_JJ CEM_NN T_NN cell_NN line_NN ][VP expresses_VBZ ][NP relatively_RB low_JJ levels_NNS ][PP of_IN ][NP TCF-1_NN alpha_NN mRNA_NN ] ,_,[NP which_WDT ][VP are_VBP increased_VBN ][PP upon_IN ][NP activation_NN ][PP of_IN ][NP these_DT cells_NNS ][PP by_IN ][NP phorbol_NN esters_NNS ] ._.
[ADVP Interestingly_RB ] ,_,[NP the_DT cloned_VBN TCF-1_NN alpha_NN protein_NN ][VP is_VBZ ][NP a_DT potent_JJ transcriptional_JJ activator_NN ][PP of_IN ][NP the_DT human_JJ TCR_NN alpha_NN enhancer_NN ][PP in_IN ][NP nonlymphoid_JJ cell_NN lines_NNS ] ,_, whereas_IN[NP the_DT activity_NN ][PP of_IN ][NP the_DT endogenous_JJ protein_NN ][PP in_IN ][NP T_NN cell_NN lines_NNS ][VP is_VBZ ][ADJP strongly_RB dependent_JJ ][PP on_IN ][NP an_DT additional_JJ T_NN cell-specific_JJ protein_NN ][NP that_WDT ][VP interacts_VBZ ][PP with_IN ][NP the_DT core_NN enhancer_NN ] ._.
[NP TCF-1_NN alpha_NN ][VP is_VBZ ][ADJP currently_RB unique_JJ ][PP among_IN ][NP the_DT newly_RB emerging_VBG family_NN ][PP of_IN ][NP DNA-binding_JJ regulatory_JJ proteins_NNS ][NP that_WDT ][VP share_VBP ][NP the_DT HMG_NN motif_NN ][PP in_IN ][NP that_IN ][NP it_PRP ][VP is_VBZ ][NP a_DT highly_RB tissue-specific_JJ RNA_NN polymerase_NN II_CD transcription_NN factor_NN ] ._.
[NP Immune_JJ response_NN ][PP of_IN ][NP peripheral_JJ blood_NN mononuclear_JJ cells_NNS ][PP to_TO ][NP HBx-antigen_NN ][PP of_IN ][NP hepatitis_NN B_NN virus_NN ] ._.
[NP The_DT hepatitis_NN B_NN virus_NN genome_NN ][VP encodes_VBZ ][NP a_DT transcriptional_JJ transactivator_NN protein_NN ][VP designated_VBN ][NP HBxAg_NN ] ._.
[NP We_PRP ][VP have_VBP investigated_VBN ][SBAR whether_IN ][NP this_DT antigen_NN ][VP is_VBZ ][NP a_DT target_NN structure_NN ][PP for_IN ][NP human_JJ T-lymphocytes_NNS ] ._.
[VP Using_VBG ][NP recombinant_JJ HBxAg_NN protein_NN ] ,_,[NP we_PRP ][VP found_VBD ][NP HBxAg-specific_JJ stimulation_NN ][PP of_IN ][NP peripheral_JJ blood_NN mononuclear_JJ cells_NNS ][PP in_IN ][NP patients_NNS ][PP with_IN ][NP acute_JJ hepatitis_NN B_NN virus_NN infection_NN ] (_([NP 6_CD ][PP of_IN ][NP 6_CD ] )_) and_CC[NP chronic_JJ hepatitis_NN B_NN virus_NN infection_NN ] (_([NP 6_CD ][PP of_IN ][NP 17_CD ] )_)[PP but_CC ][PP not_RB in_IN ][NP healthy_JJ individuals_NNS ] ._.
[PP With_IN ][NP HBxAg-specific_JJ synthetic_JJ polypeptides_NNS ] ,_,[NP several_JJ T-cell_NN epitopes_NNS ][VP were_VBD identified_VBN ] ._.
[NP Most_JJS ][VP were_VBD located_JJ ][PP in_IN ][NP the_DT carboxyterminal_JJ half_NN ][PP of_IN ][NP the_DT HBxAg_NN protein_NN ] ._.
[NP Five_CD T-cell_NN clones_NNS ][ADJP specific_JJ ][PP for_IN ][NP a_DT T-cell_NN epitope_NN ][ADJP located_JJ ][PP at_IN ][NP the_DT carboxyterminal_JJ region_NN ][PP of_IN ][NP HBxAg_NN ][VP were_VBD established_VBN ] and_CC[VP found_VBN to_TO belong_VB ][PP to_TO ][NP the_DT CD2/CD4-positive_JJ ,_, CD8-negative_JJ subtype_NN ] ._.
[NP These_DT data_NNS ][VP establish_VBP ][PP for_IN ][NP the_DT first_JJ time_NN ][NP HBxAg_NN ][PP as_IN ][NP an_DT antigen_NN ][PP in_IN ][NP the_DT cellular_JJ immune_JJ response_NN ] ._.
[NP A_DT study_NN ][PP on_IN ][NP the_DT circadian_JJ rhythm_NN ][PP of_IN ][NP glucocorticoid_NN receptor_NN ] ._.
[NP Circadian_JJ rhythm_NN ][PP in_IN ][NP glucocorticoid_NN receptor_NN ] (_([NP GR_NN ] )_)[VP was_VBD studied_VBN ][PP in_IN ] the_DT[NP rat_NN liver_NN ] and_CC[ADJP human_JJ peripheral_JJ ][NP leukocytes_NNS ] ._.
[PP For_IN ][NP rats_NNS ][VP exposed_VBN ][PP to_TO ][NP a_DT natural_JJ environmental_JJ photic_JJ cycle_NN ] or_CC[NP a_DT 12L_NN :_: 12D_NN artificial_JJ light_NN regime_NN ] ,_,[NP peak_JJ values_NNS ][PP of_IN ][NP hepatic_JJ GR_NN ][VP were_VBD detected_VBN ][PP between_IN ][NP 23:00_CD and_CC 02:00_CD h_NN ] ._.
[PP Except_IN for_IN ][NP a_DT 4-hour_JJ advancement_NN ][PP of_IN ][NP the_DT peak_NN ] ,_,[NP a_DT similar_JJ circadian_JJ rhythm_NN ][PP of_IN ][NP hepatic_JJ GR_NN ][VP was_VBD detected_VBN ][PP in_IN ][NP rats_NNS ][VP reared_VBN ][PP under_IN ][NP a_DT reversed_VBN lighting_NN regimen_NNS ] (_([NP 12D_NN :_: 12L_NN ] ;_:[NP lights_NNS ][ADVP on_IN ][PP between_IN ][NP 18:30_CD and_CC 06:30_CD h_NN ] )_) ._.
[PP In_IN ][NP human_JJ leukocytes_NNS ] ,_,[NP the_DT peak_JJ value_NN ][PP of_IN ][NP GR_NN ][VP was_VBD found_VBN to_TO parallel_VB ][NP that_DT ][PP of_IN ][NP plasma_NN cortisol_NN ][PP with_IN ][NP high_JJ and_CC low_JJ values_NNS ][VP detected_VBN ][PP at_IN ][NP 04:00-08:00_CD h_NN ] and_CC[NP 23:00-24:00_CD h_NN ] ,_,[ADVP respectively_RB ] ._.
[PP In_IN ][NP patients_NNS ][VP suffering_VBG ][PP from_IN ][NP Cushing_NN ][NP 's_POS syndrome_NN ] ,_,[NP the_DT circadian_JJ rhythm_NN ][PP of_IN ][NP plasma_NN cortisol_NN ] either_CC[VP disappeared_VBD ] or_CC[VP was_VBD inverted_VBN ][SBAR while_IN ][NP that_DT ][PP of_IN ][NP GR_NN ][VP did_VBD not_RB significantly_RB deviate_VB ][PP from_IN ][NP the_DT normal_JJ subjects_NNS ] ._.
[PP For_IN ][NP apoplexic_JJ patients_NNS ][PP with_IN ][NP lesions_NNS ][VP localized_JJ ][PP to_TO ][NP the_DT base_NN ][PP of_IN ][NP the_DT brain_NN ][SBAR as_IN ][VP indicated_VBN ][PP by_IN ][NP computerized_VBN tomography_NN ] ,_,[NP the_DT diurnal_JJ variation_NN ][PP of_IN ][NP GR_NN ][VP was_VBD abolished_VBN ] ._.
[ADVP Conversely_RB ] ,_,[NP diurnal_JJ rhythmicity_NN ][VP persisted_VBD ][PP in_IN ][NP apoplexy_NN patients_NNS ][NP whose_WP$ lesions_NNS ][VP were_VBD ][PP in_IN ][NP the_DT cerebral_JJ cortex_NN ] ._.
[ADVP Thus_RB ] ,_,[NP we_PRP ][VP postulated_VBD ][SBAR that_IN ][NP the_DT circadian_JJ modification_NN ][PP of_IN ][NP GR_NN ][VP was_VBD ][ADJP independent_JJ ][PP of_IN ][NP the_DT diurnal_JJ fluctuations_NNS ][PP in_IN ][NP plasma_NN cortisol_NN level_NN ] or_CC[NP the_DT circadian_JJ variations_NNS ][PP in_IN ][NP environmental_JJ lighting_NN ] and_CC[SBAR that_IN ][NP the_DT rhythmicity_NN ][VP might_MD be_VB regulated_VBN ][PP by_IN ][NP the_DT '_[[DQS]] circadian_JJ pacemaker_NN ] '_[[DQE]][ADJP located_JJ ][PP in_IN ][NP the_DT human_JJ basal_JJ brain_NN ] ._.
[NP These_DT diurnal_JJ variations_NNS ][PP in_IN ][NP GR_NN ][VP might_MD serve_VB to_TO coordinate_VB ][NP the_DT reactivity_NN ][PP of_IN ][NP the_DT target_NN cells_NNS ][PP to_TO ][NP cortisol_NN ][SBAR because_IN ][NP the_DT diurnal_JJ rhythms_NNS ][PP of_IN ][NP a_DT GR-mediated_JJ response_NN ] ,_,[NP the_DT fractional_JJ inhibition_NN ][PP of_IN ][NP chemotactic_JJ migration_NN rate_NN ][PP of_IN ][NP polymorphonuclear_JJ leukocytes_NNS ][PP by_IN ][NP cortisol_NN ] ,_,[VP were_VBD found_VBN to_TO be_VB ][ADJP synchronous_JJ ][PP with_IN ][NP those_DT ][PP of_IN ][NP GR_NN ] ._.
[NP Multiple_JJ Oct2_NN isoforms_NNS ][VP are_VBP generated_VBN ][PP by_IN ][NP alternative_JJ splicing_NN ] ._.
[NP The_DT interaction_NN ][PP of_IN ][NP the_DT Oct2_NN transcription_NN factor_NN ][PP with_IN ][NP the_DT cognate_JJ octamer_NN motif_NN ATGCAAAT_NN ][VP is_VBZ ][NP a_DT critical_JJ determinant_NN ][PP of_IN ][NP the_DT lymphoid-specific_JJ expression_NN ][PP of_IN ][NP immunoglobulin_NN genes_NNS ] ._.
[NP Ectopic_JJ expression_NN ][PP of_IN ][NP cloned_VBN Oct2_NN cDNA_NN ][VP was_VBD shown_VBN to_TO be_VB ][ADJP sufficient_JJ ][VP to_TO reconstitute_VB ][NP at_IN least_JJS some_DT aspects_NNS ][PP of_IN ][NP this_DT regulation_NN ][PP in_IN ][NP non-lymphoid_JJ cells_NNS ] ._.
[NP We_PRP ][VP describe_VBP ][NP the_DT ][NP isolation_NN ] and_CC[NP characterization_NN ][PP of_IN ][NP multiple_JJ cDNAs_NNS ][VP encoding_VBG ][NP mouse_NN Oct2_NN ][PP from_IN ][NP a_DT mature_JJ B-cell_NN line_NN ] and_CC[NP we_PRP ][VP show_VBP ][SBAR that_IN ][NP a_DT variety_NN ][PP of_IN ][NP isoforms_NNS ][PP of_IN ][NP this_DT transcription_NN factor_NN ][VP is_VBZ generated_VBN ][PP from_IN ][NP a_DT single_JJ gene_NN ][PP by_IN ][NP an_DT alternative_JJ splicing_NN mechanism_NN ] ._.
[NP All_PDT the_DT isoforms_NNS ][VP retain_VBP ][NP the_DT previously_RB characterized_VBN POU-domain_NN ] and_CC[VP are_VBP ][ADVP therefore_RB ][ADJP able_JJ ][VP to_TO bind_VB ][PP to_TO ][NP the_DT octamer_NN motif_NN ] ._.
[NP Different_JJ amounts_NNS ][PP of_IN ][NP the_DT various_JJ isoforms_NNS ][VP are_VBP ][ADJP present_JJ ][PP within_IN ][NP the_DT same_JJ B-cell_NN ][ADVP regardless_RB ][PP of_IN ][NP the_DT developmental_JJ stage_NN ][PP of_IN ][NP B-cell_NN differentiation_NN ] and_CC[ADVP at_IN least_JJS ][NP some_DT ][PP of_IN ][NP the_DT isoforms_NNS ][VP are_VBP conserved_VBN ][PP between_IN ][NP mouse_NN ] and_CC[NP humans_NNS ] ._.
[PP In_IN ][NP cotransfection_NN experiments_NNS ][NP we_PRP ][VP show_VBP ][SBAR that_IN ][NP all_PDT the_DT isoforms_NNS ][VP are_VBP ][ADJP able_JJ ][VP to_TO activate_VB ][NP an_DT octamer_NN ][VP containing_VBG ][NP promoter_NN element_NN ][PP in_IN ][NP fibroblasts_NNS ][VP revealing_VBG ][NP an_DT unexpected_JJ functional_JJ redundancy_NN ] ._.
[ADVP Finally_RB ] ,_,[NP we_PRP ][VP show_VBP ][SBAR that_IN ][NP one_CD ][PP of_IN ][NP the_DT isoforms_NNS ][VP encodes_VBZ ][NP the_DT previously_RB described_VBN lymphoid-specific_JJ Oct2B_NN protein_NN ][NP which_WDT ][VP has_VBZ been_VBN suggested_VBN to_TO be_VB involved_VBN ][PP in_IN ][NP the_DT function_NN ][PP of_IN ][NP the_DT octamer_NN motif_NN ][PP in_IN the_DT context_NN of_IN ] the_DT[NP immunoglobulin_NN heavy-chain_NN ] (_([NP IgH_NN ] )_)[NP enhancer_NN ] ._.
[NP Murine_JJ and_CC human_JJ T-lymphocyte_NN GATA-3_NN factors_NNS ][VP mediate_VBP ][NP transcription_NN ][PP through_IN ][NP a_DT cis-regulatory_JJ element_NN ][PP within_IN ][NP the_DT human_JJ T-cell_NN receptor_NN delta_NN gene_NN enhancer_NN ] ._.
[NP A_DT family_NN ][PP of_IN ][NP transcriptional_JJ activators_NNS ][VP has_VBZ recently_RB been_VBN identified_VBN ][PP in_IN ][NP chickens_NNS ] ;_:[NP these_DT transcriptional_JJ activators_NNS ][VP recognize_VBP ][NP a_DT common_JJ consensus_NN motif_NN ] (_([NP WGATAR_NN ] )_)[PP through_IN ][NP a_DT conserved_VBN C4_NN zinc_NN finger_NN DNA-binding_JJ domain_NN ] ._.
[NP One_CD ][PP of_IN ][NP the_DT members_NNS ][PP of_IN ][NP this_DT multigene_JJ family_NN ] ,_,[NP cGATA-3_NN ] ,_,[VP is_VBZ most_RBS abundantly_RB expressed_VBN ][PP in_IN ][NP the_DT T-lymphocyte_NN cell_NN lineage_NN ] ._.
[NP Analysis_NN ][PP of_IN ][NP human_JJ and_CC murine_JJ GATA-3_NN factors_NNS ][VP shows_VBZ ][NP a_DT striking_JJ degree_NN ][PP of_IN ][NP amino_NN acid_NN sequence_NN identity_NN ] and_CC[NP similar_JJ patterns_NNS ][PP of_IN ][NP tissue_NN specificity_NN ][PP of_IN ][NP expression_NN ][PP in_IN ][NP these_DT three_CD organisms_NNS ] ._.
[NP The_DT murine_JJ and_CC human_JJ factors_NNS ][VP are_VBP abundantly_RB expressed_VBN ][PP in_IN ][NP a_DT variety_NN ][PP of_IN ][NP human_JJ and_CC murine_JJ T-cell_NN lines_NNS ] and_CC[VP can_MD activate_VB ][NP transcription_NN ][PP through_IN ][NP a_DT tissue-specific_JJ GATA-binding_JJ site_NN ][VP identified_VBN ][PP within_IN ][NP the_DT human_JJ T-cell_NN receptor_NN delta_NN gene_NN enhancer_NN ] ._.
[NP We_PRP ][VP infer_VBP ][SBAR that_IN ] the_DT[NP murine_JJ ] and_CC[ADJP human_JJ ][NP GATA-3_NN proteins_NNS ][VP play_VBP ][NP a_DT central_JJ and_CC highly_RB conserved_VBN role_NN ][PP in_IN ][NP vertebrate_NN T-cell-specific_JJ transcriptional_JJ regulation_NN ] ._.
[NP Processing_NN ][PP of_IN ][NP the_DT precursor_NN ][PP of_IN ][NP NF-kappa_NN B_NN ][PP by_IN ][NP the_DT HIV-1_NN protease_NN ][PP during_IN ][NP acute_JJ infection_NN ] ._.
[NP Transcription_NN ][PP of_IN ][NP the_DT human_JJ immunodeficiency_NN virus_NN type-1_NN ] (_([NP HIV-1_NN ] )_)[NP genome_NN ][VP is_VBZ regulated_VBN ][PP in_IN ][NP part_NN ][PP by_IN ][NP cellular_JJ factors_NNS ] and_CC[VP is_VBZ stimulated_VBN ][PP by_IN ][NP activation_NN ][PP of_IN ][NP latently_RB infected_JJ T_NN cells_NNS ] ._.
[NP T-cell_NN activation_NN ][ADVP also_RB ][VP correlates_VBZ ][PP with_IN ][NP the_DT induction_NN ][PP of_IN ][NP the_DT factor_NN NF-kappa_NN B_NN ][NP which_WDT ][VP binds_VBZ ][PP to_TO ][NP two_CD adjacent_JJ sites_NNS ][PP in_IN ][NP the_DT HIV-1_NN long_JJ terminal_JJ repeat_NN ] ._.
[NP This_DT factor_NN ][VP consists_VBZ ][PP of_IN ][NP two_CD DNA-binding_JJ subunits_NNS ][PP of_IN ][NP relative_JJ molecular_JJ mass_NN ][NP 50,000_CD ] (_([NP 50K_CD ] )_)[VP associated_VBN ][PP with_IN ][NP two_CD 65K_CD subunits_NNS ] ._.
[NP It_PRP ][VP is_VBZ ][ADJP located_JJ ][PP in_IN ][NP the_DT nucleus_NN ][PP in_IN ][NP mature_JJ B_NN cells_NNS ] ,_, but_CC[VP is_VBZ ][ADJP present_JJ ][PP in_IN ][NP other_JJ cell_NN types_NNS ][PP as_IN ][NP an_DT inactive_JJ cytoplasmic_JJ complex_NN ] ._.
[NP External_JJ stimuli_NNS ] ,_,[PP including_VBG ][NP those_DT ][NP that_WDT ][VP activate_VBP ][NP T_NN cells_NNS ] ,_,[VP result_VBP ][PP in_IN ][NP nuclear_JJ translocation_NN ][PP of_IN ][NP active_JJ NF-kappa_NN B_NN ] ._.
[NP The_DT cloning_NN ][PP of_IN ][NP the_DT complementary_JJ DNA_NN ][PP for_IN ][NP the_DT 50K_CD subunit_NN ][VP helped_VBD to_TO identify_VB ][NP an_DT exclusively_RB cytoplasmic_JJ 105K_CD precursor_NN ] (_([NP p105_NN ] )_) (_([NP V.B._NNP ] ,_,[NP P.K._NNP ] and_CC[NP A.I._NNP ] ,_,[NP manuscript_NN ][VP submitted_VBN ] )_) ._.
[NP The_DT expression_NN ][PP of_IN ][NP active_JJ NF-kappa_NN B_NN ][VP might_MD therefore_RB also_RB be_VB regulated_VBN ][PP by_IN ][NP the_DT extent_NN ][PP of_IN ][NP processing_NN ][PP of_IN ][NP p105_NN ] ._.
[SBAR Because_IN ][NP HIV-1_NN ][VP requires_VBZ ][NP active_JJ NF-kappa_NN B_NN ][PP for_IN ][NP efficient_JJ transcription_NN ] ,_,[NP we_PRP ][VP tested_VBD ][NP the_DT effect_NN ][PP of_IN ][NP HIV-1_NN infection_NN ][PP on_IN ][NP the_DT processing_NN ][PP of_IN ][NP the_DT human_JJ 105K_CD precursor_NN ] ._.
[NP We_PRP ][VP show_VBP ][ADVP here_RB ][SBAR that_IN ][NP the_DT HIV-1_NN protease_NN ][VP can_MD process_VB ][NP p105_NN ] and_CC[VP increases_VBZ ][NP levels_NNS ][PP of_IN ][NP active_JJ nuclear_JJ NF-kappa_NN B_NN complex_NN ] ._.
[NP Vitamin_NN D_NN receptor_NN expression_NN ][PP in_IN ][NP human_JJ lymphocytes_NNS ] ._.
[NP Signal_NN requirements_NNS ] and_CC[NP characterization_NN ][PP by_IN ][NP western_NN blots_NNS ] and_CC[NP DNA_NN sequencing_NN ] ._.
[NP The_DT signals_NNS ][VP controlling_VBG ][NP the_DT expression_NN ][PP of_IN ][NP the_DT receptor_NN protein_NN ][PP for_IN ][NP 1_CD alpha,25-dihydroxyvitamin_NN D3_NN ][PP in_IN ][NP normal_JJ human_JJ lymphocytes_NNS ] and_CC[NP the_DT relationship_NN ][PP of_IN ][NP this_DT protein_NN ][PP to_TO ][NP the_DT classical_JJ vitamin_NN D_NN receptor_NN ][VP were_VBD examined_VBN ] ._.
[NP Lymphocytes_NNS ][VP activated_VBN ][PP with_IN ][NP the_DT OKT3_NN antibody_NN ][PP to_TO ][NP the_DT T-cell_NN antigen_NN receptor_NN ][VP expressed_VBD ][NP fewer_JJR binding_VBG sites_NNS ][SBAR as_IN ][VP compared_VBN ][PP to_TO ][NP lymphocytes_NNS ][NP that_WDT ][VP were_VBD activated_VBN ][PP by_IN ][NP the_DT polyclonal_JJ activator_NN phytohemagglutinin_NN ] (_([NP PHA_NN ] )_) ._.
[ADVP However_RB ] ,_,[NP combination_NN ][PP of_IN ][NP OKT3_NN ] and_CC[NP phorbol_NN myristate_NN acetate_NN ][VP produced_VBD ][NP a_DT concentration_NN ][PP of_IN ][NP binding_VBG sites_NNS ][ADJP similar_JJ ][PP to_TO ][NP the_DT PHA-activated_JJ cells_NNS ] ._.
[NP The_DT receptor_NN ][PP from_IN ][NP OKT3_NN ] and_CC[ADJP OKT3_NN +_CC phorbol_NN myristate_NN acetate-activated_JJ ][NP lymphocytes_NNS ][VP exhibited_VBD ][NP decreased_VBN binding_NN ][PP to_TO ][NP DNA-cellulose_NN ][VP compared_VBN ][PP to_TO ][NP PHA-activated_JJ lymphocytes_NNS ] ._.
[PP In_IN ][NP lymphocytes_NNS ][VP activated_VBN ][PP either_CC by_IN ][NP PHA_NN ] or_CC[NP OKT3_NN ][PP (_( but_CC ][PP not_RB in_IN ][NP resting_VBG cells_NNS ] )_) ,_,[NP a_DT 50-kDa_JJ species_NNS ][VP cross-reacting_VBG ][PP with_IN ][NP a_DT monoclonal_JJ antibody_NN ][PP against_IN ][NP the_DT intestinal_JJ vitamin_NN D_NN receptor_NN ][VP was_VBD detected_VBN ] ._.
[ADVP Finally_RB ] ,_,[NP RNA_NN ][PP from_IN ][NP activated_VBN lymphocytes_NNS ][VP was_VBD amplified_VBN ][PP by_IN ][NP polymerase_NN chain_NN reaction_NN ][VP using_VBG ][NP oligonucleotide_NN primers_NNS ][VP flanking_VBG ][NP the_DT 196_CD base_NN pair_NN long_JJ region_NN ][VP encoding_VBG ][NP the_DT DNA-binding_JJ domain_NN ][PP of_IN ][NP the_DT human_JJ intestinal_JJ receptor_NN ] ._.
[NP The_DT amplified_VBN product_NN ][VP showed_VBD ][NP an_DT identical_JJ nucleotide_NN sequence_NN ][PP to_TO ][NP the_DT DNA-binding_JJ domain_NN ][PP of_IN ][NP the_DT human_JJ intestinal_JJ receptor_NN ] ._.
[NP These_DT findings_NNS ][VP suggest_VBP ][SBAR that_IN ][NP expression_NN ][PP of_IN ][NP the_DT 1,25-(OH)2D3_NN receptor_NN ][PP in_IN ][NP lymphocytes_NNS ][VP is_VBZ triggered_VBN ][PP by_IN ][NP distinct_JJ and_CC contingent_JJ signals_NNS ] ,_, and_CC[SBAR that_IN ][NP the_DT protein_NN ] and_CC[NP the_DT mRNA_NN ][VP encoding_VBG ][NP it_PRP ][VP are_VBP ][ADJP identical_JJ ][PP to_TO ][NP the_DT classical_JJ vitamin_NN D_NN receptor_NN ] ._.
[NP Cloning_NN ][PP of_IN ][NP murine_JJ TCF-1_NN ] ,_,[NP a_DT T_NN cell-specific_JJ transcription_NN factor_NN ][VP interacting_VBG ][PP with_IN ][NP functional_JJ motifs_NNS ][PP in_IN ][NP the_DT CD3-epsilon_NN and_CC T_NN cell_NN receptor_NN alpha_NN enhancers_NNS ] ._.
[NP CD3-epsilon_NN gene_NN expression_NN ][VP is_VBZ confined_VBN ][PP to_TO ][NP the_DT T_NN cell_NN lineage_NN ] ._.
[NP We_PRP ][VP have_VBP recently_RB identified_VBN ] and_CC[VP cloned_VBN ][NP a_DT human_JJ transcription_NN factor_NN ] ,_,[NP TCF-1_NN ] ,_,[NP that_WDT ][VP binds_VBZ ][PP to_TO ][NP a_DT functional_JJ element_NN ][PP in_IN ][NP the_DT T_NN lymphocyte-specific_JJ enhancer_NN ][PP of_IN ][NP CD3-epsilon_NN ] ._.
[PP In_IN ][NP a_DT panel_NN ][PP of_IN ][NP human_JJ cell_NN lines_NNS ] ,_,[NP TCF-1_NN expression_NN ][VP was_VBD ][ADJP restricted_JJ ][PP to_TO ][NP T_NN lineage_NN cells_NNS ] ._.
[NP TCF-1_NN ][VP belonged_VBD ][PP to_TO ][NP a_DT novel_JJ family_NN ][PP of_IN ][NP genes_NNS ][NP that_WDT ][VP contain_VBP ][NP the_DT so-called_JJ high_JJ mobility_NN group_NN 1_CD (_( HMG_NN )_) box_NN ] ._.
[ADVP Here_RB ][NP we_PRP ][VP report_VBP ][NP the_DT cloning_NN ][PP of_IN ][NP murine_JJ TCF-1_NN ] ._.
[NP Two_CD splice_NN alternatives_NNS ][VP were_VBD identified_VBN ][NP that_WDT ][VP were_VBD not_RB previously_RB observed_VBN ][PP in_IN ][NP human_JJ TCF-1_NN ] ._.
[NP Murine_JJ and_CC human_JJ TCF-1_NN ][VP displayed_VBD ][NP a_DT 95.5_CD %_NN overall_JJ amino_NN acid_NN homology_NN ] ._.
[NP Recombinant_JJ murine_JJ and_CC human_JJ TCF-1_NN ][VP recognized_VBD ][NP the_DT same_JJ sequence_NN motif_NN ][PP in_IN ][NP the_DT CD3-epsilon_NN enhancer_NN ][SBAR as_IN ][VP judged_VBN ][PP by_IN ][NP gel_NN retardation_NN ] and_CC[NP methylation_NN interference_NN ][NP assays_NNS ] ._.
[PP With_IN ][NP the_DT murine_JJ cDNA_NN clones_NNS ][NP several_JJ aspects_NNS ][PP of_IN ][NP TCF-1_NN ][VP were_VBD analyzed_VBN ] ._.
[ADVP First_RB ] ,_,[NP deletion_NN analysis_NN ][VP revealed_VBD ][SBAR that_IN ][NP a_DT region_NN ][PP of_IN ][NP TCF-1_NN ][VP containing_VBG ][NP the_DT HMG_NN box_NN ][VP was_VBD ][ADJP sufficient_JJ ][PP for_IN ][NP sequence-specific_JJ binding_NN ] ._.
[ADVP Second_RB ] ,_,[PP by_IN ][NP high_JJ stringency_NN Northern_NN blotting_NN ] and_CC[NP in_FW situ_FW hybridization_NN ] ,_,[NP TCF-1_NN expression_NN ][VP was_VBD shown_VBN to_TO be_VB confined_VBN ][PP to_TO ][NP the_DT thymus_NN ][PP and_CC ][PP to_TO ][NP the_DT T_NN cell_NN areas_NNS ][PP of_IN ][NP the_DT spleen_NN ] ._.
[ADVP Third_RB ] ,_,[NP TCF-1_NN ][VP bound_VBD ][ADVP specifically_RB ][PP to_TO ][NP a_DT functional_JJ T_NN cell-specific_JJ element_NN ][PP in_IN ] the_DT[NP T_NN cell_NN receptor_NN alpha_NN ] (_([NP TCR-alpha_NN ] )_)[NP enhancer_NN ] ._.
[NP The_DT T_NN lineage-specific_JJ expression_NN ] and_CC[NP the_DT affinity_NN ][PP for_IN ][NP functional_JJ motifs_NNS ][PP in_IN ] the_DT[NP TCR-alpha_NN ] and_CC[NP CD3-epsilon_NN ][NP enhancers_NNS ][VP imply_VBP ][NP an_DT important_JJ role_NN ][PP for_IN ][NP TCF-1_NN ][PP in_IN ][NP the_DT establishment_NN ][PP of_IN ][NP the_DT mature_JJ T_NN cell_NN phenotype_NN ] ._.
[NP HIV_NN enhancer_NN activity_NN ][VP perpetuated_VBN ][PP by_IN ][NP NF-kappa_NN B_NN induction_NN ][PP on_IN ][NP infection_NN ][PP of_IN ][NP monocytes_NNS ] (_([VP see_VB ][NP comments_NNS ] )_)
[NP Permissiveness_NN ][PP to_TO ][NP replication_NN ][PP of_IN ][NP human_JJ immunodeficiency_NN virus_NN ] (_([NP HIV_NN ] )_)[VP differs_VBZ ][PP in_IN ][NP T_NN lymphocytes_NNS ] and_CC[NP macrophages_NNS ] ._.
[PP In_IN ][NP T_NN cells_NNS ] ,_,[NP HIV_NN transcription_NN ][VP is_VBZ poorly_RB detected_VBN ][ADVP in_FW vivo_FW ] ._.
[NP Cloned_VBN ,_, normal_JJ T_NN lymphocytes_NNS ][VP show_VBP ] very_RB little_JJ ,_,[SBAR if_IN ] any_DT ,_,[NP basal_JJ activity_NN ][PP of_IN ][NP the_DT HIV_NN enhancer_NN ] and_CC[NP low_JJ nuclear_JJ expression_NN ][PP of_IN ][NP NF-kappa_NN B_NN ] ,_,[NP a_DT potent_JJ transcriptional_JJ activator_NN ][PP of_IN ][NP the_DT HIV_NN enhancer_NN ] ._.
[PP In_IN ][NP contrast_NN ] ,_,[NP fixed_JJ tissue_NN macrophages_NNS ][VP express_VBP ][NP detectable_JJ HIV_NN proteins_NNS ] ,_,[VP indicating_VBG ][NP permanent_JJ virus_NN transcription_NN ] ._.
[NP One_CD explanation_NN ][PP for_IN ][NP the_DT perpetuation_NN ][PP of_IN ][NP virus_NN infection_NN ][PP in_IN ][NP macrophages_NNS ][VP could_MD be_VB ][NP sustained_JJ nuclear_JJ NF-kappa_NN B_NN expression_NN ] ._.
[ADVP However_RB ] ,_,[NP the_DT U937_NN monocytic_JJ cell_NN line_NN ] ,_,[NP which_WDT ][VP is_VBZ ][ADJP fully_RB permissive_JJ ][PP to_TO ][NP HIV_NN replication_NN ] ,_,[VP is_VBZ known_VBN to_TO express_VB ][NP only_RB low_JJ levels_NNS ][PP of_IN ][NP nuclear_JJ NF-kappa_NN B_NN ] ._.
[NP We_PRP ][VP show_VBP ][ADVP here_RB ][SBAR that_IN ][NP chronic_JJ HIV_VBP infection_NN ][VP results_VBZ ][PP in_IN ] both_CC[NP induction_NN ][PP of_IN ][NP a_DT nuclear_JJ factor_NN ][PP with_IN ][NP antigenic_JJ properties_NNS ][ADJP indistinguishable_JJ ][PP from_IN ][NP those_DT ][PP of_IN ][NP NF-kappa_NN B_NN ] and_CC[NP permanently_RB increased_VBN HIV_NN enhancer_NN activity_NN ] ._.
[NP This_DT phenomenon_NN ] ,_,[NP which_WDT ][VP is_VBZ ][ADJP independent_JJ ][PP of_IN ][NP tumour_NN necrosis_NN factor_NN ] ,_,[VP is_VBZ associated_VBN ][PP with_IN ][NP HIV_NN replication_NN ] ,_, and_CC[VP is_VBZ ] thus_RB[ADJP likely_JJ ][VP to_TO explain_VB ][ADVP at_IN least_JJS ][PP in_IN ][NP part_NN ][NP the_DT perpetuation_NN ][PP of_IN ][NP HIV_NN infection_NN ][PP in_IN ][NP monocytes_NNS ] ._.
[NP Role_NN ][PP for_IN ][NP the_DT Epstein-Barr_JJ virus_NN nuclear_JJ antigen_NN 2_CD ][PP in_IN ][NP viral_JJ promoter_NN switching_VBG ][PP during_IN ][NP initial_JJ stages_NNS ][PP of_IN ][NP infection_NN ] ._.
[PP During_IN ] latent_JJ[NP Epstein-Barr_JJ virus_NN ] (_([NP EBV_NN ] )_)[NP infection_NN ][PP of_IN ][NP human_JJ B_NN lymphocytes_NNS ] ,_,[NP six_CD viral_JJ nuclear_JJ antigen_NN ] (_([NP EBNAs_NNS ] )_)[VP are_VBP expressed_VBN ][PP from_IN ][NP long_JJ primary_JJ transcripts_NNS ][PP by_IN means_NNS of_IN ][NP alternative_JJ splicing_NN ] and_CC[NP alternative_JJ polyadenylylation_NN sites_NNS ] ._.
[NP These_DT transcripts_NNS ][VP initiate_VBP ][PP from_IN ][NP one_CD ][PP of_IN ][NP two_CD promoters_NNS ] ,_,[NP Cp_NN ] or_CC[NP Wp_NN ] ,_,[NP that_WDT ][VP function_VBP ][PP in_IN ][NP a_DT mutually_RB exclusive_JJ fashion_NN ] ._.
[NP Wp_NN ][VP is_VBZ exclusively_RB utilized_VBN ][PP during_IN ][NP the_DT initial_JJ stages_NNS ][PP of_IN ][NP infection_NN ][PP of_IN ][NP primary_JJ B_NN lymphocytes_NNS ] ,_,[VP followed_VBN ][PP by_IN ][NP a_DT switch_NN ][PP to_TO ][NP Cp_NN usage_NN ] ._.
[NP These_DT studies_NNS ][VP have_VBP been_VBN extended_VBN to_TO show_VB ][SBAR that_IN ][LST (_( i_LS ] )_)[NP a_DT mutant_JJ EBV_NN strain_NN ][VP lacking_VBG ][NP the_DT gene_NN ][VP encoding_VBG ][NP EBNA_NN 2_CD ][VP fails_VBZ to_TO switch_VB ][PP from_IN ][NP Wp_NN ][PP to_TO ][NP Cp_NN ][NP usage_NN ][PP in_IN ][NP primary_JJ B_NN lymphocytes_NNS ] ,_,[SBAR although_IN ][NP the_DT virus_NN ][VP contains_VBZ ][NP a_DT functional_JJ Cp_NN ] ;_:[LST (_( ii_LS ] )_)[NP a_DT region_NN ][NP from_IN -429_CD to_TO -245_CD base_NN pairs_NNS ][ADJP upstream_JJ ][PP of_IN ][NP Cp_NN ][VP is_VBZ ][ADJP essential_JJ ][PP for_IN ][NP Cp_NN activity_NN ][PP in_IN ][NP B_NN lymphocytes_NNS ] ,_, but_CC[PP only_RB in_IN ][NP the_DT context_NN ][PP of_IN ][NP upstream_JJ and_CC downstream_JJ sequences_NNS ] ;_:[LST (_( iii_LS ] )_)[NP this_DT region_NN ][VP contains_VBZ ][NP an_DT EBNA_NN 2-dependent_JJ enhancer_NN ] ;_: and_CC[LST (_( iv_LS ] )_)[NP DNase_NN I_CD protection_NN ][VP employing_VBG ][NP nuclear_JJ extracts_NNS ][PP from_IN ][NP B_NN ] and_CC[NP T_NN ][NP lymphocytes_NNS ][VP revealed_VBD ][NP a_DT B-cell-specific_JJ footprint_NN ][PP in_IN ][NP the_DT region_NN ][PP of_IN ][NP the_DT EBNA_NN 2-dependent_JJ enhancer_NN ] ._.
[NP These_DT results_NNS ][VP support_VBP ][NP a_DT model_NN ][PP for_IN ][NP viral_JJ promoter_NN switching_NN ][PP during_IN ][NP the_DT initial_JJ stages_NNS ][PP of_IN ][NP infection_NN ][PP in_IN ][NP which_WDT ][NP Wp_NN activity_NN ][VP leads_VBZ ][PP to_TO ][NP the_DT expression_NN ][PP of_IN ][NP EBNA_NN 2_CD ] ,_, followed_VBN[PP by_IN ][NP activation_NN ][PP of_IN ][NP Cp_NN ][PP through_IN ][NP the_DT EBNA_NN 2-dependent_JJ enhancer_NN ] ._.
[NP Glucocorticoid_NN receptor_NN characteristics_NNS ][PP in_IN ][NP monocytes_NNS ][PP of_IN ][NP patients_NNS ][PP with_IN ][NP corticosteroid-resistant_JJ bronchial_JJ asthma_NN ] ._.
[NP The_DT mechanism_NN ][PP of_IN ][NP corticosteroid_NN resistance_NN ][PP in_IN ][NP bronchial_JJ asthma_NN ][VP has_VBZ been_VBN studied_VBN ][PP by_IN ][VP determining_VBG ][NP the_DT rank_NN order_NN ][PP of_IN ][NP potency_NN ][PP for_IN ][NP different_JJ corticosteroids_NNS ][PP in_IN ][VP inhibiting_VBG ][NP the_DT generation_NN ][PP of_IN ][NP a_DT 3_CD kD_NN molecule_NN ][PP from_IN ][NP peripheral_JJ blood_NN monocytes_NNS ][VP isolated_VBN ][PP from_IN ] corticosteroid-sensitive_JJ (_([ADJP CS_JJ ] )_) and_CC corticosteroid-resistant_JJ (_([ADJP CR_JJ ] )_)[NP asthmatic_JJ subjects_NNS ] ,_,[NP which_WDT ][VP augments_VBZ ][NP leukotriene_NN B4_NN ] (_([NP LTB4_NN ] )_)[NP generation_NN ][PP by_IN ][NP human_JJ neutrophils_NNS ] (_([NP PMN_NN ] )_)[VP stimulated_VBN ][PP by_IN ][NP calcium_NN ionophore_NN ] ._.
[PP In_IN ][NP addition_NN ] ,_,[NP binding_VBG studies_NNS ][PP with_IN ][NP (_( 3H_NN )_) dexamethasone_NN ][VP have_VBP been_VBN performed_VBN ][VP to_TO determine_VB ][NP the_DT dissociation_NN constant_NN ] (_([NP Kd_NN ] )_) and_CC[NP receptor_NN numbers_NNS ] (_([NP Ro_NN ] )_)[PP in_IN ][NP the_DT monocytes_NNS ][PP of_IN ][NP these_DT two_CD groups_NNS ][PP of_IN ][NP subjects_NNS ] ._.
[NP The_DT concentration_NN ][PP of_IN ][NP corticosteroid_NN ][VP producing_VBG ][NP 50_CD %_NN inhibition_NN ] (_([NP IC50_NN ] )_)[VP was_VBD ][NP 600_CD nM_NN ] ,_,[NP 70_CD nM_NN ] ,_, and_CC[NP 0.5_CD nM_NN ][PP for_IN ][NP hydrocortisone_NN ] ,_,[NP methylprednisolone_NN ] ,_, and_CC[NP dexamethasone_NN ] ,_,[ADVP respectively_RB ] ,_,[PP in_IN ][NP monocytes_NNS ][PP from_IN ][NP CS_JJ individuals_NNS ] ._.
[NP There_EX ][VP was_VBD ][NP only_RB weak_JJ inhibition_NN ][PP of_IN ][NP the_DT generation_NN ][PP of_IN ][NP enhancing_NN activity_NN ][PP by_IN ][NP the_DT corticosteroids_NNS ][PP in_IN ][NP the_DT CR_JJ asthmatic_JJ individuals_NNS ] ._.
[NP The_DT dexamethasone_NN Kd_NN ][VP was_VBD ][NP 2.45_CD +/-_CC 0.58_CD nM_NN ] (_([NP mean_NN ] +/-_CC[NP SEM_NN ] ,_,[NP n_NN ][VP =_JJ ][NP 6_CD ] )_)[PP in_IN ] the_DT[NP CS_JJ ][NP group_NN ] and_CC[NP 1.6_CD +/-_CC 0.35_CD nM_NN ] (_([NP mean_NN ] +/-_CC[NP SEM_NN ] ,_,[NP n_NN ][VP =_JJ ][NP 6_CD ] )_)[PP in_IN ] the_DT[NP CR_JJ ][NP group_NN ][PP of_IN ][NP patients_NNS ] (_([NP p_NN ][VP =_JJ ][NP 0.14_CD ] )_) ._.
[NP The_DT Ro_NN ][PP in_IN ][NP the_DT CS_JJ group_NN ][VP was_VBD ][NP 3,605_CD +/-_CC 984_CD binding_VBG sites_NNS ][PP per_IN ][NP nucleus_NN ] (_([NP mean_NN ] +/-_CC[NP SEM_NN ] ,_,[NP n_NN ][VP =_JJ ][NP 6_CD ] )_) and_CC[NP 4,757_CD +/-_CC 692_CD binding_VBG sites_NNS ][PP per_IN ][NP nucleus_NN ] (_([NP mean_NN ] +/-_CC[NP SEM_NN ] ,_,[NP n_NN ][VP =_JJ ][NP 6_CD ] )_)[PP in_IN ][NP the_DT CR_JJ group_NN ] (_([NP p_NN ][VP =_JJ ][NP 0.23_CD ] )_) ._.
[NP These_DT findings_NNS ][VP indicate_VBP ][SBAR that_IN ][NP corticosteroid_NN resistance_NN ][PP in_IN ][NP bronchial_JJ asthma_NN ][VP can_MD not_RB be_VB explained_VBN ][PP by_IN ][NP abnormalities_NNS ][PP in_IN ][NP corticosteroid_NN receptor_NN ][NP characteristics_NNS ] ._.
[NP Tissue-specific_JJ expression_NN ][PP of_IN ][NP the_DT platelet_NN GPIIb_NN gene_NN ] ._.
[NP One_CD ][PP of_IN ][NP the_DT major_JJ objectives_NNS ][PP in_IN ][NP the_DT study_NN ][PP of_IN ][NP thrombogenesis_NN ][VP is_VBZ ][VP to_TO determine_VB ][NP the_DT mechanisms_NNS ][PP by_IN ][NP which_WDT ][NP a_DT hematopoietic_JJ progenitor_NN ][VP is_VBZ activated_VBN ] and_CC[VP committed_VBN ][PP to_TO ][NP the_DT megakaryocytic_JJ lineage_NN ] ._.
[NP Recent_JJ development_NN ][PP of_IN ][NP primary_JJ cultures_NNS ][PP of_IN ][NP human_JJ megakaryocytes_NNS ] and_CC[NP the_DT molecular_JJ cloning_NN ][PP of_IN ][NP genes_NNS ][NP that_WDT ][VP are_VBP ][ADJP specific_JJ ][PP to_TO ][NP this_DT lineage_NN ][VP offer_VBP ][NP the_DT possibility_NN ][PP of_IN ][VP getting_VBG ][NP some_DT insights_NNS ][PP into_IN ][NP the_DT genetic_JJ mechanisms_NNS ][NP that_WDT ][VP control_VBP ][NP megakaryocytopoiesis_NNS ] ._.
[NP One_CD gene_NN ][PP of_IN ][NP interest_NN ][VP is_VBZ ] the_DT[NP glycoprotein_NN IIb_NN ] (_([NP GPIIb_NN ] )_)[NP gene_NN ] ;_:[NP GPIIb_NN ] ,_,[NP the_DT alpha_NN subunit_NN ][PP of_IN ][NP the_DT platelet_NN cytoadhesin_NN GPIIb-IIIa_NN ] ,_,[VP is_VBZ produced_VBN ][PP in_IN ][NP megakaryocytes_NNS ][PP at_IN ][NP an_DT early_JJ stage_NN ][PP of_IN ][NP the_DT differentiation_NN ] ,_, whereas_IN[NP the_DT other_JJ subunit_NN ][PP of_IN ][NP this_DT complex_NN ] ,_,[NP GPIIIa_NN ] ,_,[VP is_VBZ expressed_VBN ][PP in_IN ][NP other_JJ cells_NNS ] ._.
[PP For_IN ][NP these_DT reasons_NNS ] ,_,[NP the_DT 5'-flanking_JJ region_NN ][PP of_IN ][NP the_DT GPIIb_NN gene_NN ][VP was_VBD used_VBN ][VP to_TO identify_VB ][NP the_DT regions_NNS ][NP that_WDT ][VP interact_VBP ][PP with_IN ][NP DNA-binding_JJ nuclear_JJ factors_NNS ] ._.
[NP A_DT fragment_NN ][VP extending_VBG ][PP from_IN ][NP -643_CD ][PP to_TO ][NP +33_CD ][VP is_VBZ ][ADJP capable_JJ ][PP of_IN ][VP controlling_VBG ][NP the_DT tissue-specific_JJ expression_NN ][PP of_IN ][NP the_DT CAT_NN gene_NN ][PP in_IN ][NP transfection_NN experiments_NNS ] ._.
[PP Within_IN ][NP this_DT region_NN ] ,_,[NP we_PRP ][VP have_VBP identified_VBN ][NP several_JJ sequences_NNS ][NP that_WDT ][VP are_VBP implicated_VBN ][PP in_IN ][NP DNA_NN protein_NN interactions_NNS ][SBAR as_IN ][VP shown_VBN ][PP in_IN ][NP DNAse_NN I_NN footprints_NNS ] and_CC[NP gel_NN mobility_NN shift_NN assays_NNS ] ._.
[NP One_CD region_NN ] ,_,[ADJP centered_VBN ][PP at_IN ][NP -54_CD ] ,_,[VP is_VBZ ][ADJP similar_JJ ][PP to_TO ][NP a_DT nuclear_JJ factor_NN E1-binding_JJ site_NN ] ,_, and_CC[NP a_DT region_NN ][ADJP located_JJ ][PP at_IN ][NP position_NN -233_CD ][VP contains_VBZ ][NP a_DT CCAAT_NN motif_NN ] ._.
[NP Two_CD domains_NNS ] centered_VBN[PP at_IN ][NP positions_NNS ][NP -345_CD ] and_CC[NP -540_CD ][ADJP ,_, respectively_RB ] ,_,[VP bind_VBP ][NP proteins_NNS ][NP that_WDT ][VP are_VBP ][ADJP present_JJ ][PP in_IN ][NP megakaryocytic_JJ cells_NNS ] and_CC[NP nonrelated_JJ cells_NNS ][PP as_RB ][ADVP well_RB ] ._.
[ADVP Finally_RB ] ,_,[NP two_CD other_JJ domains_NNS ] ,_,[ADJP located_JJ ][PP at_IN ][NP positions_NNS ][NP -460_CD ] and_CC[NP -510_CD ] ,_,[VP interact_VBP ][PP with_IN ][NP proteins_NNS ][NP that_WDT ][VP are_VBP ][ADJP only_RB present_JJ ][PP in_IN ][NP megakaryocytic_JJ cells_NNS ] ._.
[PP In_IN ][NP addition_NN ] ,_,[NP deletion_NN ][PP of_IN ][NP the_DT region_NN ][VP containing_VBG ][NP these_DT two_CD domains_NNS ][VP results_VBZ ][PP in_IN ][NP a_DT significant_JJ decrease_NN ][PP of_IN ][NP the_DT promoter_NN activity_NN ] ._.
[NP It_PRP ][VP is_VBZ ][ADJP very_RB likely_JJ ][SBAR that_IN ][NP these_DT domains_NNS ][VP bind_VBP ][NP megakaryocyte-specific_JJ nuclear_JJ proteins_NNS ][VP acting_VBG ][PP as_IN ][NP positive_JJ transcription_NN factors_NNS ] ._.
[NP Inhibition_NN ][PP of_IN ][NP protein_NN phosphatases_NNS ][PP by_IN ][NP okadaic_JJ acid_NN ][VP induces_VBZ ][NP AP1_NN ][PP in_IN ][NP human_JJ T_NN cells_NNS ] ._.
[VP To_TO examine_VB ][NP the_DT role_NN ][PP of_IN ][NP protein_NN phosphatases_NNS ][PP in_IN ][NP T_NN cell_NN activation_NN ] ,_,[NP Jurkat_NN cells_NNS ][VP were_VBD treated_VBN ][PP with_IN ][NP okadaic_JJ acid_NN ] ,_,[NP an_DT inhibitor_NN ][PP of_IN ][NP type_NN 1_CD and_CC 2A_NN phosphatases_NNS ] ,_, and_CC[NP nuclear_JJ extracts_NNS ][VP were_VBD examined_VBN ][PP for_IN ][NP the_DT presence_NN ][PP of_IN ][NP AP1_NN ][PP as_IN ][NP a_DT measure_NN ][PP of_IN ][NP early_JJ T_NN cell_NN activation_NN ] ._.
[NP Okadaic_JJ acid_NN ][VP was_VBD found_VBN to_TO be_VB ][NP a_DT potent_JJ inducer_NN ][PP of_IN ][NP AP1_NN ] ._.
[PP In_IN contrast_NN to_TO ][NP phorbol_NN esters_NNS ][PP such_JJ as_IN ][NP phorbol_NN myristate_NN acetate_NN ] (_([NP PMA_NN ] )_) ,_,[NP the_DT induction_NN ][PP of_IN ][NP AP1_NN ][PP by_IN ][NP okadaic_JJ acid_NN ][VP occurs_VBZ ][PP predominantly_RB by_IN ][NP transcriptional_JJ activation_NN ][PP of_IN ] the_DT[NP jun_NN ] and_CC[NP fos_NN ][NP family_NN ][PP of_IN ][NP proto-oncogenes_NNS ] ._.
[ADVP Surprisingly_RB ] ,_,[SBAR while_IN ][NP the_DT addition_NN ][PP of_IN ][NP phytohemagglutinin_NN ][ADVP further_RB ][VP enhanced_VBD ][NP the_DT induction_NN ][PP of_IN ][NP AP1_NN ] ,_,[NP the_DT addition_NN ][PP of_IN ][NP PMA_NN ][VP inhibited_VBD ][NP it_PRP ] ._.
[NP Okadaic_JJ acid_NN treatment_NN ][VP was_VBD found_VBN to_TO dramatically_RB increase_VB ][NP mRNA_NN transcripts_NNS ][PP of_IN ][NP the_DT jun_NN family_NN ][PP of_IN ][NP proto-oncogenes_NNS ][PP including_VBG ][NP c-jun_NN ] ,_,[NP junD_NN ] ,_, and_CC[NP junB_NN ] and_CC[PP to_TO ][NP a_DT lesser_JJR extent_NN ][NP the_DT fos_NN family_NN ][PP including_VBG ][NP c-fos_NN ] and_CC[NP fra-1_NN ] ._.
[PP By_IN ][NP comparison_NN ] ,_,[NP PMA_NN ][VP is_VBZ ][NP a_DT very_RB inefficient_JJ inducer_NN ][PP of_IN ][NP the_DT jun_NN gene_NN family_NN ][PP in_IN ][NP Jurkat_NN cells_NNS ] ._.
[ADJP Similar_JJ ][PP to_TO ][NP its_PRP$ effect_NN ][PP on_IN ][NP the_DT induction_NN ][PP of_IN ][NP AP1_NN ][PP by_IN ][NP okadaic_JJ acid_NN ] ,_,[NP PMA_NN ][VP inhibits_VBZ ][NP the_DT induction_NN ][PP of_IN ][NP c-jun_NN mRNA_NN ][PP by_IN ][NP okadaic_JJ acid_NN ] ._.
[NP Transfection_NN ][PP of_IN ][NP c-jun_NN promoter_NN constructs_NNS ][VP confirmed_VBD ][NP the_DT marked_JJ difference_NN ][PP between_IN ][NP PMA_NN ] and_CC[NP okadaic_JJ acid_NN ][PP in_IN ][VP inducing_VBG ][NP c-jun_NN transcription_NN ] ._.
[NP The_DT induction_NN ][PP of_IN ][NP AP1_NN ][PP by_IN ][NP okadaic_JJ acid_NN ][VP suggests_VBZ ][SBAR that_IN ][NP protein_NN phosphatases_NNS ][NP 1_CD ] and_CC[NP 2A_NN ] (_([NP PP1_NN ] and_CC[NP PP2A_NN ] )_)[VP may_MD be_VB involved_VBN ][PP in_IN ][NP T_NN cell_NN activation_NN ][PP as_IN ][NP important_JJ negative_JJ regulators_NNS ][PP of_IN ][NP the_DT transcription_NN factor_NN AP1_NN ] ._.
[NP Demonstration_NN ][PP of_IN ][NP estrogen_NN ] and_CC[NP progesterone_NN ][NP receptors_NNS ][CONJP as_RB well_RB as_IN ][NP Ki-67_NN ] and_CC[NP p-145_NN ][NP antigens_NNS ][PP in_IN ][NP single_JJ tumor_NN cells_NNS ][PP from_IN ][NP blood_NN ] and_CC[ADJP pleural_JJ ][NP effusions_NNS ][VP using_VBG ][NP a_DT slide_NN assay_NN ] ._.
[NP We_PRP ][VP describe_VBP ][NP a_DT slide_NN assay_NN ][NP that_WDT ][VP allows_VBZ ][NP the_DT demonstration_NN ][PP of_IN ][NP antigens_NNS ][ADJP localized_JJ ][PP in_IN ][NP the_DT nucleus_NN ][PP from_IN ][NP isolated_VBN white_JJ blood_NN cells_NNS ][CONJP as_RB well_RB as_IN ][PP from_IN ][NP single_JJ tumor_NN cells_NNS ][VP derived_VBN ][PP from_IN ][NP malignant_JJ effusions_NNS ] ._.
[PP With_IN ][NP the_DT antibodies_NNS ][NP Ki-67_NN ] and_CC[NP anti-p-145_NN ][NP an_DT increased_VBN rate_NN ][PP of_IN ][NP nuclear_JJ and_CC nucleolar_JJ staining_NN ][VP resulted_VBD ][PP in_IN ][NP cells_NNS ][PP from_IN ][NP highly_RB malignant_JJ lymphomas_NNS ] ._.
[NP An_DT almost_RB identical_JJ reaction_NN ][VP was_VBD obtained_VBN ][ADVP when_WRB ][NP tumor_NN cells_NNS ][PP from_IN ][NP malignant_JJ effusions_NNS ][VP were_VBD tested_VBN ] ._.
[NP Cells_NNS ][VP isolated_VBN ][PP from_IN ][NP the_DT blood_NN ][PP of_IN ][NP patients_NNS ][PP with_IN ][NP leukemic_JJ spread_NN ][PP of_IN ][NP lymphomas_NNS ][PP of_IN ][NP low_JJ malignancy_NN ][VP yielded_VBD ][NP a_DT weak_JJ staining_NN ][ADJP comparable_JJ ][PP to_TO ][NP that_DT ][PP of_IN ][NP normal_JJ mesothelial_JJ cells_NNS ][PP from_IN ][NP non-tumorous_JJ cavity_NN fluids_NNS ] ._.
[NP The_DT detection_NN ][PP of_IN ][NP estrogen_NN ] and_CC[NP progesterone_NN ][NP receptors_NNS ] (_([NP ER_NN ] and_CC[NP PR_NN ] )_)[ADJP localized_JJ ][PP in_IN ][NP the_DT cell_NN nucleus_NN ][VP can_MD be_VB achieved_VBN ][PP by_IN ][NP the_DT same_JJ assay_NN ] ._.
[NP The_DT reaction_NN ][VP is_VBZ enhanced_VBN ][PP by_IN ][NP incubation_NN ][PP of_IN ][NP the_DT tumor_NN cells_NNS ][PP for_IN ][NP 30_CD min_NN ][PP at_IN ][NP 37_CD degrees_NNS C_NN ][PP prior_RB to_TO ][NP fixation_NN ] ._.
[NP Pleural_JJ effusions_NNS ][PP from_IN ][NP 20_CD patients_NNS ][PP with_IN ][NP breast_NN cancer_NN ][VP were_VBD tested_VBN ] ._.
[NP ER_NN ][VP was_VBD ][ADJP positive_JJ ][PP in_IN ][NP 13_CD ] and_CC[NP PR_NN ][VP was_VBD ][ADJP positive_JJ ][PP in_IN ][NP 12_CD ][PP of_IN ][NP the_DT 20_CD samples_NNS ] ._.
[PP In_IN ][NP 5_CD cases_NNS ][NP there_EX ][VP was_VBD ][NP a_DT divergent_JJ reaction_NN ][PP with_IN ][NP ER_NN ] and_CC[NP PR_NN ][NP antibody_NN ] ._.
[NP The_DT hormone_NN receptors_NNS ][PP of_IN ][NP the_DT primary_JJ tumor_NN ][VP were_VBD known_VBN ][PP in_IN ][NP 15_CD ] (_([NP ER_NN ] )_) and_CC[NP 14_CD ] (_([NP PR_NN ] )_)[NP patients_NNS ] ,_,[ADVP respectively_RB ] ._.
[PP In_IN ][NP each_DT cohort_NN ][NP there_EX ][VP was_VBD ][NP only_RB one_CD case_NN ][PP with_IN ][NP a_DT negative_JJ reaction_NN ][PP of_IN ][NP the_DT primary_JJ tumor_NN ] and_CC[NP a_DT positive_JJ reaction_NN ][PP with_IN ][NP the_DT isolated_VBN tumor_NN cells_NNS ][PP from_IN ][NP the_DT pleural_JJ effusions_NNS ] ._.
[NP These_DT results_NNS ][VP indicate_VBP ][SBAR that_IN ][NP the_DT demonstration_NN ][PP of_IN ][NP hormone_NN receptor_NN proteins_NNS ][PP in_IN ][NP cells_NNS ][PP from_IN ][NP malignant_JJ effusions_NNS ][VP is_VBZ ][ADJP possible_JJ ] and_CC[SBAR that_IN ][NP there_EX ][VP is_VBZ ][NP a_DT correlation_NN ][PP with_IN ][NP the_DT status_NN ][PP of_IN ][NP the_DT primary_JJ site_NN ][PP of_IN ][NP cancer_NN ] ._.
[NP Transforming_VBG growth_NN factor-beta_NN ][VP suppresses_VBZ ][NP human_JJ B_NN lymphocyte_NN Ig_NN production_NN ][PP by_IN ][VP inhibiting_VBG ][NP synthesis_NN ] and_CC[NP the_DT switch_NN ][PP from_IN ][NP the_DT membrane_NN form_NN ][PP to_TO ][NP the_DT secreted_JJ form_NN ][PP of_IN ] Ig_NN mRNA_NN ._.
[NP Transforming_VBG growth_NN factor-beta_NN ] (_([NP TGF-beta_NN ] )_)[VP inhibits_VBZ ][NP B_NN cell_NN Ig_NN secretion_NN ] and_CC[VP reduces_VBZ ][NP B_NN cell_NN membrane_NN Ig_NN expression_NN ] ._.
[NP The_DT addition_NN ][PP of_IN ][NP TGF-beta_NN ][PP to_TO ][NP human_JJ B_NN lymphocyte_NN cultures_NNS ][VP stimulated_VBN ][PP with_IN ][NP Staphylococcus_FW aureus_FW Cowan_NN strain_NN I_NN ] and_CC[NP IL-2_NN ][ADVP completely_RB ][VP inhibited_VBD ][NP B_NN cell_NN Ig_NN secretion_NN ] (_([ADVP greater_JJR ][PP than_IN ][NP 90_CD %_NN ] )_) and_CC[VP decreased_VBD ] B_NN cell_NN surface_NN[NP IgM_NN ] ,_,[NP IgD_NN ] ,_,[NP kappa_NN L_NN chain_NN ] ,_, and_CC[NP lambda_NN L_NN chain_NN ][NP expression_NN ] ._.
[PP In_IN ][NP contrast_NN ] ,_,[NP TGF-beta_NN ][VP had_VBD ][NP only_RB minimal_JJ effects_NNS ][PP on_IN ][NP two_CD other_JJ B_NN cell_NN membrane_NN proteins_NNS ] ,_,[NP HLA-DR_NN ] and_CC[NP CD20_NN ] ._.
[NP Internal_JJ labeling_NN ][PP with_IN ][NP (35S)methionine_NN ] and_CC[NP immunoprecipitation_NN ][PP with_IN ][NP anti-IgM_JJ ,_, anti-kappa_JJ ,_, and_CC anti-lambda_JJ antibodies_NNS ][VP revealed_VBD ][NP a_DT striking_JJ reduction_NN ][PP in_IN ][NP kappa_NN L_NN chain_NN ][PP in_IN the_DT presence_NN of_IN ][NP TGF-beta_NN ] ._.
[NP A_DT less_RBR pronounced_JJ reduction_NN ][PP in_IN ][NP lambda_NN L_NN chain_NN ] and_CC[NP microH_NN chain_NN ][VP was_VBD also_RB noted_VBN ] ._.
[NP Northern_NN blot_NN analysis_NN ][PP of_IN ][NP RNA_NN ][VP purified_VBN ][PP from_IN ][NP B_NN cells_NNS ][VP treated_VBN ][PP with_IN ][NP TGF-beta_NN ][PP for_IN ][NP varying_VBG time_NN intervals_NNS ][VP revealed_VBD ][NP a_DT significant_JJ decrease_NN ][PP in_IN ][NP steady_JJ state_NN kappa_NN and_CC lambda_NN L_NN chain_NN mRNA_NN levels_NNS ] ._.
[ADVP Furthermore_RB ] ,_,[NP a_DT significant_JJ decrease_NN ][PP in_IN ][NP the_DT switch_NN ][PP from_IN ][NP the_DT membrane_NN forms_NNS ][PP of_IN ][NP mu_NN ] and_CC[NP gamma_NN ][PP to_TO ][NP their_PRP$ respective_JJ secreted_JJ forms_NNS ][VP was_VBD noted_VBN ][PP in_IN the_DT presence_NN of_IN ][NP TGF-beta_NN ] ._.
[NP Nuclear_JJ run-on_JJ experiments_NNS ][VP demonstrated_VBD ][NP decreased_VBN transcription_NN ][PP of_IN ][NP kappa_NN L_NN chain_NN ] ._.
[NP The_DT effects_NNS ][PP of_IN ][NP TGF-beta_NN ][PP on_IN ][NP two_CD transcriptional_JJ regulatory_JJ factors_NNS ] ,_,[NP Oct-2_NN ] and_CC[NP nuclear_JJ factor_NN ] (_([NP NF_NN ] )_)[NP kappa_NN B_NN ] ,_,[VP known_VBN to_TO be_VB ][ADJP important_JJ ][PP in_IN ][NP Ig_NN gene_NN transcription_NN ][VP were_VBD examined_VBN ] ._.
[NP Oct-2_NN mRNA_NN levels_NNS ] and_CC[NP both_DT ][NP Oct-2_NN ] and_CC[NP NF-kappa_NN B_NN ][NP proteins_NNS ][PP in_IN ][NP nuclear_JJ extracts_NNS ][VP were_VBD not_RB altered_VBN ][PP by_IN ][NP treatment_NN ][PP with_IN ][NP TGF-beta_NN ] ._.
[PP In_IN ][NP contrast_NN ] ,_,[NP levels_NNS ][PP of_IN ][NP the_DT transcriptional_JJ factor_NN AP-1_NN ] ,_,[NP which_WDT ][VP is_VBZ not_RB known_VBN to_TO be_VB ][ADJP important_JJ ][PP in_IN ][NP B_NN cell_NN Ig_NN production_NN ] ,_,[VP were_VBD reduced_VBN ][PP by_IN ][NP TGF-beta_NN ] ._.
[NP These_DT findings_NNS ][VP demonstrate_VBP ][SBAR that_IN ][NP TGF-beta_NN ][VP decreases_VBZ ][NP B_NN lymphocyte_NN Ig_NN secretion_NN ][PP by_IN ][VP inhibiting_VBG ][NP the_DT synthesis_NN ][PP of_IN ][NP Ig_NN mRNA_NN ] and_CC[VP inhibiting_VBG ][NP the_DT switch_NN ][PP from_IN ][NP the_DT membrane_NN form_NN ][PP to_TO ][NP the_DT secreted_JJ forms_NNS ][PP of_IN ][NP mu_NN ] and_CC[NP gamma_NN ][NP mRNA_NN ] ._.
[NP The_DT mechanism_NN ][PP by_IN ][NP which_WDT ][NP TGF-beta_NN ][VP inhibits_VBZ ][NP Ig_NN chain_NN synthesis_NN ][VP is_VBZ ][ADJP unclear_JJ ][SBAR although_IN ][NP it_PRP ][VP does_VBZ not_RB involve_VB ][NP inhibition_NN ][PP of_IN ][NP the_DT binding_NN ][PP of_IN ][NP NF-kappa_NN B_NN ] or_CC[NP Oct-2_NN ][PP to_TO ][NP their_PRP$ respective_JJ target_NN sequences_NNS ] ._.
[NP Differentiation-associated_JJ expression_NN ][PP of_IN ][NP the_DT Epstein-Barr_JJ virus_NN BZLF1_NN transactivator_NN protein_NN ][PP in_IN ][NP oral_JJ hairy_JJ leukoplakia_NN ] ._.
[NP The_DT BZLF1_NN protein_NN ][PP of_IN ][NP Epstein-Barr_JJ virus_NN ] (_([NP EBV_NN ] )_)[VP is_VBZ ][NP a_DT key_JJ immediate-early_JJ protein_NN ][NP which_WDT ][VP has_VBZ been_VBN shown_VBN to_TO disrupt_VB ][NP virus_NN latency_NN ][PP in_IN ][NP EBV-infected_JJ B_NN cells_NNS ] ._.
[NP We_PRP ][VP have_VBP generated_VBN ][NP a_DT monoclonal_JJ antibody_NN ] ,_,[NP BZ1_NN ] ,_,[PP to_TO ][NP BZLF1_NN ][NP which_WDT ][VP reacts_VBZ ][PP in_IN ][NP immunohistology_NN ] ,_,[NP immunoblotting_NN ] ,_, and_CC[NP immunoprecipitation_NN ] and_CC[NP which_WDT ][VP recognizes_VBZ ] both_CC[NP the_DT active_JJ ,_, dimeric_JJ form_NN ] and_CC[NP the_DT inactive_JJ ,_, monomeric_JJ form_NN ][PP of_IN ][NP the_DT protein_NN ] ._.
[NP Biopsies_NNS ][PP of_IN ][NP oral_JJ hairy_JJ leukoplakia_NN ] ,_,[NP an_DT AIDS-associated_JJ lesion_NN ][VP characterized_VBN ][PP by_IN ][NP high-level_JJ EBV_NN replication_NN ] ,_,[VP were_VBD examined_VBN ][PP by_IN ][NP immunohistochemistry_NN ][VP using_VBG ][NP the_DT BZ1_NN monoclonal_JJ antibody_NN ] ._.
[NP A_DT differentiation-associated_JJ pattern_NN ][PP of_IN ][NP BZLF1_NN expression_NN ][VP was_VBD observed_VBN ] ,_,[NP BZ1_NN ][VP reacting_VBG ][PP with_IN ][NP nuclei_NNS ][PP of_IN ][NP the_DT upper_JJ spinous_JJ layer_NN ][PP of_IN ][NP the_DT lesion_NN ] ._.
[NP This_DT finding_NN ][VP suggests_VBZ ][SBAR that_IN ][NP the_DT BZLF1_NN promoter_NN ][VP may_MD be_VB regulated_VBN ][PP by_IN ][NP the_DT degree_NN ][PP of_IN ][NP squamous_JJ differentiation_NN ] ._.
[NP A_DT comparison_NN ][PP of_IN ][NP in_FW situ_FW hybridization_NN ][PP to_TO ][NP EBV_NN DNA_NN ] and_CC[NP viral_JJ capsid_NN antigen_NN staining_VBG ][PP with_IN ][NP BZ1_NN reactivity_NN ][VP suggested_VBD ][SBAR that_IN ][NP BZLF1_NN expression_NN ][VP precedes_VBZ ][NP rampant_JJ virus_NN replication_NN ] ._.
[NP The_DT inability_NN ][VP to_TO detect_VB ][NP EBV_NN ][PP in_IN ][NP the_DT lower_RBR epithelial_JJ layers_NNS ][PP of_IN ][NP oral_JJ hairy_JJ leukoplakia_NN ][VP raises_VBZ ][NP questions_NNS ][PP concerning_VBG ][NP the_DT nature_NN ][PP of_IN ][NP EBV_NN ][NP latency_NN ] and_CC[NP persistence_NN ][PP in_IN ][NP stratified_JJ squamous_JJ epithelium_NN ] ._.
[NP Transactivation_NN ][PP of_IN ][NP the_DT human_JJ immunodeficiency_NN virus_NN promoter_NN ][PP by_IN ][NP human_JJ herpesvirus_NN 6_CD ] (_([NP HHV-6_NN ] )_)[NP strains_VBZ ][NP GS_NN ] and_CC[NP Z-29_NN ][PP in_IN ][NP primary_JJ human_JJ T_NN lymphocytes_NNS ] and_CC[NP identification_NN ][PP of_IN ][NP transactivating_VBG HHV-6_NN (_( GS_NN )_) gene_NN fragments_NNS ] ._.
[NP Human_JJ herpesvirus_NN 6_CD ] (_([NP HHV-6_NN ] )_)[VP can_MD activate_VB ] the_DT[NP human_JJ immunodeficiency_NN virus_NN ] (_([NP HIV_NN ] )_)[NP promoter_NN ] and_CC[VP accelerate_VB ][NP cytopathic_JJ effects_NNS ][PP in_IN ][NP HIV-infected_JJ human_JJ T_NN cells_NNS ] ._.
[NP This_DT study_NN ][VP examines_VBZ ][NP the_DT regions_NNS ][PP of_IN ][NP the_DT HIV_NN promoter_NN ][VP required_VBN ][PP for_IN ][NP HHV-6_NN transactivation_NN ][PP in_IN ][NP a_DT heterogeneous_JJ population_NN ][PP of_IN ][NP primary_JJ human_JJ T_NN lymphocytes_NNS ][PP with_IN ][PP or_CC ][PP without_IN ][NP antigenic_JJ stimulation_NN ] ._.
[NP Two_CD different_JJ strains_NNS ][PP of_IN ][NP HHV-6_NN ] ,_,[NP GS_NN ] and_CC[NP Z29_NN ] ,_,[VP transactivated_VBD ][NP the_DT HIV_NN promoter_NN ] ._.
[NP The_DT GS_NN strain_NN ][VP transactivated_VBD ][NP the_DT promoter_NN ][PP in_IN ][NP both_CC stimulated_VBN and_CC resting_VBG T_NN cells_NNS ] ,_,[SBAR while_IN ][NP the_DT Z29_NN strain_NN ][VP increased_VBD ][NP HIV_NN promoter_NN activity_NN ][PP only_RB in_IN ][NP stimulated_VBN T_NN cells_NNS ] ._.
[NP Three_CD DNA_NN clones_NNS ][VP containing_VBG ][NP HHV-6_NN (_( GS_NN )_) genomic_JJ fragments_NNS ][VP transactivated_VBD ][NP the_DT HIV_NN promoter_NN ][PP in_IN ][NP cotransfected_VBN T_NN cells_NNS ] ._.
[NP A_DT 21.4-kb_JJ DNA_NN clone_NN ] ,_,[NP pZVB70_NN ] ,_,[VP showed_VBD ][NP the_DT highest_JJS transactivating_NN ability_NN ] ,_,[SBAR while_IN ][NP two_CD other_JJ DNA_NN fragments_NNS ] ,_,[NP pZVB10_NN ] (_([NP 6.2_CD kb_NN ] )_) and_CC[NP pZVH14_NN ] (_([NP 8.7_CD kb_NN ] )_) ,_,[VP showed_VBD ][NP lower_JJR activity_NN ] ._.
[NP One_CD ][PP of_IN ][NP these_DT clones_NNS ] ,_,[NP pZVH14_NN ] ,_,[VP activated_VBD ][NP the_DT HIV_NN promoter_NN construct_NN ][VP containing_VBG ][NP a_DT mutation_NN ][PP in_IN ][NP the_DT NF_NN kappa_NN B_NN site_NN ] ._.
[ADVP However_RB ] ,_,[NP this_DT mutated_VBN NF_NN kappa_NN B_NN promoter_NN ][VP was_VBD not_RB transactivated_VBN ][PP during_IN ][NP HHV-6_NN (_( GS_NN )_) infection_NN ][PP or_CC ][PP after_IN ][NP cotransfection_NN ][PP with_IN ][NP pZVB70_NN ] or_CC[NP pZVB10_NN ] ._.
[NP These_DT data_NNS ][VP indicate_VBP ][SBAR that_IN ][NP the_DT NF_NN kappa_NN B_NN sites_NNS ][PP of_IN ][NP the_DT HIV_NN promoter_NN ][VP are_VBP ][ADJP essential_JJ ][PP for_IN ][NP its_PRP$ transactivation_NN ][PP during_IN ][NP HHV-6_NN (_( GS_NN )_) infection_NN ] ._.
[PP By_IN ][VP increasing_VBG ][NP HIV_NN promoter_NN activity_NN ][PP in_IN ][NP primary_JJ T_NN lymphocytes_NNS ] ,_,[NP HHV-6_NN ][VP may_MD consequently_RB increase_VB ][NP HIV_NN replication_NN ] ,_,[VP leading_VBG ][PP to_TO ][NP an_DT increase_NN ][PP in_IN ][NP the_DT cytopathic_JJ effect_NN ][PP on_IN ][NP coinfected_VBN human_JJ T_NN cells_NNS ] ._.
[NP The_DT rhombotin_NN family_NN ][PP of_IN ][NP cysteine-rich_JJ LIM-domain_JJ oncogenes_NNS ] :_:[NP distinct_JJ members_NNS ][VP are_VBP involved_VBN ][PP in_IN ][NP T-cell_NN translocations_NNS ][PP to_TO ][NP human_JJ chromosomes_NNS ][NP 11p15_NN ] and_CC[NP 11p13_NN ] ._.
[NP A_DT chromosomal_NN translocation_NN ][PP in_IN ][NP a_DT T-cell_NN leukemia_NN ][VP involving_VBG ][NP the_DT short_JJ arm_NN ][PP of_IN ][NP human_JJ chromosome_NN 11_CD ][PP at_IN ][NP band_NN 11p15_NN ][VP disrupts_VBZ ][NP the_DT rhombotin_NN gene_NN ] ._.
[NP This_DT gene_NN ][VP encodes_VBZ ][NP a_DT protein_NN ][PP with_IN ][NP duplicated_JJ cysteine-rich_JJ regions_NNS ][VP called_VBN ][NP LIM_NN domains_NNS ] ,_,[NP which_WDT ][VP show_VBP ][NP homology_NN ][PP to_TO ][NP zinc-binding_JJ proteins_NNS ][PP and_CC ][PP to_TO ][NP iron-sulfur_JJ centers_NNS ][PP of_IN ][NP ferredoxins_NNS ] ._.
[NP Two_CD homologues_NNS ][PP of_IN ][NP the_DT rhombotin_NN gene_NN ][VP have_VBP now_RB been_VBN isolated_VBN ] ._.
[NP One_CD ][PP of_IN ][NP these_DT ] ,_,[VP designated_VBN ][NP Rhom-2_NN ] ,_,[VP is_VBZ ][ADJP located_JJ ][PP on_IN ][NP human_JJ chromosome_NN 11_CD ][PP at_IN ][NP band_NN 11p13_NN ] ,_,[ADVP where_WRB ][NP a_DT cluster_NN ][PP of_IN ][NP T-cell_NN leukemia-specific_JJ translocations_NNS ][VP occur_VBP ] ;_:[NP all_DT translocation_NN breakpoints_NNS ][PP at_IN ][NP 11p13_NN ][VP are_VBP ][ADJP upstream_JJ ][PP of_IN ][NP the_DT Rhom-2_NN gene_NN ] ._.
 Human_JJ and_CC[NP mouse_NN ][NP Rhom-2_NN ][VP are_VBP highly_RB conserved_VBN ] and_CC ,_,[PP like_IN ][NP rhombotin_NN ] ,_,[VP encode_VBP ][NP two_CD tandem_JJ cysteine-rich_JJ LIM_NN domains_NNS ] ._.
[NP Rhom-2_NN mRNA_NN ][VP is_VBZ expressed_VBN ][PP in_IN ][NP early_JJ mouse_NN development_NN ][PP in_IN ][NP central_JJ nervous_JJ system_NN ] ,_,[NP lung_NN ] ,_,[NP kidney_NN ] ,_,[NP liver_NN ] ,_, and_CC[NP spleen_NN ] but_CC[NP only_RB very_RB low_JJ levels_NNS ][VP occur_VBP ][PP in_IN ][NP thymus_NN ] ._.
[NP The_DT other_JJ gene_NN ] ,_,[VP designated_VBN ][NP Rhom-3_NN ] ,_,[VP is_VBZ ] not_RB[PP on_IN ][NP chromosome_NN 11_CD ][CONJP but_CC also_RB ][VP retains_VBZ ][NP homology_NN ][PP to_TO ][NP the_DT LIM_NN domain_NN ][PP of_IN ][NP rhombotin_NN ] ._.
[SBAR Since_IN ][NP the_DT Rhom-2_NN gene_NN ][VP is_VBZ ][NP such_JJ a_DT common_JJ site_NN ][PP of_IN ][NP chromosomal_JJ damage_NN ][PP in_IN ][NP T-cell_NN tumors_NNS ] ,_,[NP the_DT consistency_NN ][PP of_IN ][NP translocations_NNS ][PP near_IN ][NP the_DT rhombotin_NN gene_NN ][VP was_VBD further_RB examined_VBN ] ._.
[NP A_DT second_JJ translocation_NN ][ADJP adjacent_JJ ][PP to_TO ][NP rhombotin_NN ][VP was_VBD ][VP found_VBN ] and_CC[PP at_IN ][NP the_DT same_JJ position_NN ][PP as_IN ][PP in_IN ][NP the_DT previous_JJ example_NN ] ._.
[ADVP Therefore_RB ] ,_,[NP chromosome_NN bands_NNS ][NP 11p15_NN ] (_([NP rhombotin_NN ] )_) and_CC[NP 11p13_NN ] (_([NP Rhom-2_NN ] )_)[VP are_VBP ][NP consistent_JJ sites_NNS ][PP of_IN ][NP chromosome_NN translocation_NN ][PP in_IN ][NP T-cell_NN leukemia_NN ] ,_,[SBAR with_IN ][NP the_DT 11p15_NN target_NN ][VP more_RBR rarely_RB involved_VBN ] ._.
[NP The_DT results_NNS ][VP define_VBP ][NP the_DT rhombotin_NN gene_NN family_NN ][PP as_IN ][NP a_DT class_NN ][PP of_IN ][NP T-cell_NN oncogenes_NNS ][PP with_IN ][NP duplicated_JJ cysteine-rich_JJ LIM_NN domains_NNS ] ._.
[NP The_DT human_JJ myelomonocytic_JJ cell_NN line_NN U-937_NN ][PP as_IN ][NP a_DT model_NN ][PP for_IN ][VP studying_VBG ][NP alterations_NNS ][PP in_IN ][NP steroid-induced_JJ monokine_NN gene_NN expression_NN ] :_:[NP marked_JJ enhancement_NN ][PP of_IN ][NP lipopolysaccharide-stimulated_JJ interleukin-1_NN beta_NN messenger_NN RNA_NN levels_NNS ][PP by_IN ][NP 1,25-dihydroxyvitamin_NN D3_NN ] ._.
[NP The_DT active_JJ metabolite_NN ][PP of_IN ][NP vitamin_NN D_NN ] ,_,[NP 1,25-dihydroxyvitamin_NN D3_NN ] (_([NP 1,25-(OH)2D3_NN ] )_) ,_,[VP is_VBZ ][NP a_DT potent_JJ regulator_NN ][PP of_IN ][NP human_JJ monocyte/macrophage_JJ function_NN ][ADVP in_FW vitro_FW ] ._.
[VP To_TO establish_VB ][NP a_DT model_NN ][PP for_IN ][NP 1,25-(OH)2D3_NN regulation_NN ][PP of_IN ][NP human_JJ monocyte_NN monokine_NN synthesis_NN ] ,_,[NP three_CD human_JJ cell_NN lines_NNS ] (_([NP U-937_NN ] ,_,[NP THP-1_NN ] ,_, and_CC[NP HL-60_NN ] )_)[VP were_VBD examined_VBN ][PP for_IN ] :_:[LST 1_LS ] )_)[NP the_DT presence_NN ][PP of_IN ][NP functional_JJ 1,25-(OH)2D3_NN receptors_NNS ] ;_:[LST 2_LS ] )_)[NP the_DT accumulation_NN ][PP of_IN ][NP interleukin-1_NN beta_NN ] (_([NP IL-1_NN beta_NN ] )_)[NP mRNA_NN ] and_CC[NP IL-1_NN beta_NN protein_NN ][PP in_IN response_NN to_TO ][NP lipopolysaccharide_NN ] (_([NP LPS_NN ] )_) ;_: and_CC[LST 3_LS ] )_)[NP the_DT regulation_NN ][PP of_IN ][NP this_DT response_NN ][PP by_IN ][NP 1,25-(OH)2D3_NN ] ._.
[NP All_DT three_CD cell_NN lines_NNS ][VP expressed_VBD ][NP vitamin_NN D_NN receptor_NN ] and_CC[VP had_VBD increased_VBN ][NP levels_NNS ][PP of_IN ][NP IL-1_NN beta_NN mRNA_NN ][PP in_IN response_NN to_TO ][NP LPS_NN ] ._.
[NP Preincubation_NN ][PP of_IN ][NP cells_NNS ][PP with_IN ][NP 1,25-(OH)2D3_NN ][VP augmented_VBD ][NP IL-1_NN beta_NN mRNA_NN levels_NNS ][PP only_RB in_IN ][NP U-937_NN ] and_CC[NP HL-60_NN ][NP cells_NNS ] ._.
[PP From_IN ][NP these_DT data_NNS ] ,_, and_CC[VP taking_VBG ][PP into_IN ][NP consideration_NN ][NP their_PRP$ ][NP state_NN ][PP of_IN ][NP differentiation_NN ] and_CC[NP relative_JJ ease_NN ][PP of_IN ][NP culture_NN ] ,_,[NP U-937_NN ][VP was_VBD chosen_VBN ][PP over_IN ][NP HL-60_NN ] and_CC[NP THP-1_NN ][PP as_IN ][NP the_DT cell_NN line_NN ][NP we_PRP ][ADVP further_RB ][VP characterized_VBD ] ._.
[PP In_IN ][NP U-937_NN cells_NNS ] ,_,[NP optimum_JJ ][NP time_NN ] and_CC[NP dose_NN ][PP of_IN ][NP pretreatment_NN ][PP with_IN ][NP 1,25-(OH)2D3_NN ][VP were_VBD determined_VBN to_TO be_VB ][NP 12-24_CD h_NN ][PP at_IN ][NP a_DT receptor_NN saturating_JJ concentration_NN ][PP of_IN ][NP 1,25-(OH)2D3_NN ] (_([NP 10_CD nM_NN ] )_) ._.
[NP Preincubation_NN ][PP of_IN ][NP cells_NNS ][PP with_IN ][NP 1,25-(OH)2D3_NN ][VP had_VBD ][NP no_DT effect_NN ][PP on_IN ][NP the_DT time_NN course_NN ][PP of_IN ][NP IL-1_NN beta_NN mRNA_NN appearance_NN ][PP in_IN response_NN to_TO ][NP LPS_NN ] ._.
[ADVP However_RB ] ,_,[NP exposure_NN ][PP of_IN ][NP U-937_NN cells_NNS ][PP to_TO ][NP 1,25-(OH)2D3_NN ][VP increased_VBD ][PP by_IN ][NP 200_CD %_NN ][NP the_DT level_NN ][PP of_IN ][NP IL-1_NN beta_NN mRNA_NN ][VP detected_VBD ] and_CC[VP decreased_VBD ][PP by_IN ][NP three_CD orders_NNS ][PP of_IN ][NP magnitude_NN ][NP the_DT concentration_NN ][PP of_IN ][NP LPS_NN ][VP required_VBN to_TO achieve_VB ][NP steady_JJ state_NN mRNA_NN levels_NNS ][ADJP equivalent_JJ ][PP to_TO ][NP those_DT ][VP observed_VBN ][PP in_IN ][NP U-937_NN cells_NNS ][VP not_RB preincubated_VBN ][PP with_IN ]
[NP the_DT hormone.2+o_NN ][NP Cortivazol_NN mediated_VBD induction_NN ][PP of_IN ][NP glucocorticoid_NN receptor_NN messenger_NN ribonucleic_JJ acid_NN ][PP in_IN ][NP wild-type_JJ and_CC dexamethasone-resistant_JJ human_JJ leukemic_NN (_( CEM_NN )_) cells_NNS ] ._.
[NP Cortivazol_NN ][VP is_VBZ ][NP a_DT phenylpyrazolo_JJ glucocorticoid_NN ][PP of_IN ][NP high_JJ potency_NN ] and_CC[NP unusual_JJ structure_NN ] ._.
[PP In_IN ] both_CC wild-type_JJ and_CC highly_RB[NP dexamethasone_NN ] (_([NP dex_NN ] )_)[NP -resistant_JJ clones_NNS ][PP of_IN ][NP the_DT human_JJ leukemic_JJ cell_NN line_NN CEM_NN ] ,_,[NP exposure_NN ][PP to_TO ][NP cortivazol_NN ][VP leads_VBZ ][PP to_TO ][NP cell_NN death_NN ] ._.
[NP It_PRP ][VP has_VBZ been_VBN shown_VBN ][ADVP recently_RB ][SBAR that_IN ][PP in_IN ][NP wild-type_JJ CEM_NN cells_NNS ][PP but_CC ][PP not_RB in_IN ][NP a_DT dex-resistant_JJ ,_, glucocorticoid_NN receptor_NN (_( GR_NN )_) -defective_JJ clone_NN ICR-27_NN TK-3_NN ] ,_,[NP dex_NN ][VP induces_VBZ ][NP GR_NN mRNA_NN ] ._.
[VP To_TO test_VB ][NP the_DT hypothesis_NN ][SBAR that_IN ][NP cortivazol_NN ][VP acts_VBZ ][PP in_IN ][NP dex-resistant_JJ cells_NNS ][PP by_IN ][VP making_VBG ][NP use_NN ][PP of_IN ][NP the_DT residual_JJ GR_NN ][VP found_VBN ][ADVP there_RB ] ,_,[NP wild-type_JJ and_CC dex-resistant_JJ clones_NNS ][VP were_VBD treated_VBN ][PP with_IN ][NP various_JJ concentrations_NNS ][PP of_IN ][NP cortivazol_NN ] and_CC[NP induction_NN ][PP of_IN ][NP GR_NN mRNA_NN ][VP was_VBD studied_VBN ] ._.
[NP Cortivazol_NN ][ADVP significantly_RB ][VP induced_VBD ][NP GR_NN mRNA_NN ][PP in_IN ][NP the_DT normal_JJ CEM-C7_NN ][CONJP as_RB well_RB as_IN ][PP in_IN ][NP two_CD classes_NNS ][PP of_IN ][NP dex-resistant_JJ clones_NNS ] ,_,[SBAR although_IN ][NP the_DT dex-resistant_JJ clones_NNS ][VP needed_VBD ][NP at_IN least_JJS 10_CD times_NNS more_JJR cortivazol_NN ][PP than_IN ][NP the_DT normal_JJ cells_NNS ][PP for_IN ][NP significant_JJ GR_NN mRNA_NN induction_NN ] ._.
[NP Increased_VBN levels_NNS ][PP of_IN ][NP GR_NN mRNA_NN ][VP were_VBD noticed_VBN ][ADVP as_RB early_RB ][PP as_IN ][NP 3_CD h_NN ][PP after_IN ][NP treatment_NN ] ._.
[NP A_DT general_JJ correlation_NN ][PP between_IN ][NP induction_NN ][PP of_IN ][NP GR_NN mRNA_NN ] and_CC[NP lysis_NN ][PP of_IN ][NP the_DT normal_JJ and_CC dex-resistant_JJ cells_NNS ][VP was_VBD found_VBN ] ._.
[NP Positive_JJ induction_NN ][PP of_IN ][NP GR_NN mRNA_NN ][VP might_MD be_VB ][NP one_CD ][PP of_IN ][NP the_DT earliest_JJS crucial_JJ steps_NNS ][PP in_IN ][NP the_DT lysis_NN ][PP of_IN ][NP normal_JJ and_CC dex-resistant_JJ CEM_NN cells_NNS ] ,_, or_CC[VP might_MD serve_VB ][PP as_IN ][NP a_DT marker_NN ][PP for_IN ][NP the_DT process_NN ] ._.
[ADVP However_RB ] ,_,[NP the_DT lysis_NN pathway_NN ][PP in_IN ][NP the_DT dex-resistant_JJ cells_NNS ][VP is_VBZ ][ADJP defective_JJ ][PP in_IN ][SBAR that_IN ][NP dex-resistant_JJ clones_NNS ][VP needed_VBD ][NP significantly_RB more_JJR cortivazol_NN ][PP than_IN ][NP the_DT normal_JJ cells_NNS ][PP for_IN ][NP lysis_NN ][PP of_IN ][NP the_DT cells_NNS ] ._.
[NP Expression_NN ][PP of_IN ][NP 1,25(OH)2D3_NN receptors_NNS ][PP on_IN ][NP alveolar_JJ lymphocytes_NNS ][PP from_IN ][NP patients_NNS ][PP with_IN ][NP pulmonary_JJ granulomatous_JJ diseases_NNS ] ._.
[NP 1,25(OH)2D3_NN ][VP is_VBZ known_VBN to_TO be_VB produced_VBN ][PP at_IN ][NP sites_NNS ][PP of_IN ][NP granulomatous_JJ reactions_NNS ] ._.
[SBAR In_IN ] order_NN to_TO[VP characterize_VB ][NP the_DT cell_NN types_NNS ][NP that_WDT ][VP are_VBP ][NP targets_NNS ][PP for_IN ][NP this_DT immunoregulatory_JJ hormone_NN ] ,_,[NP we_PRP ][VP have_VBP evaluated_VBN ][NP the_DT expression_NN ][PP of_IN ][NP 1,25(OH)2D3_NN receptors_NNS ][PP on_IN ][NP peripheral_JJ blood_NN T-lymphocytes_NNS ] and_CC[NP those_DT ][VP recovered_VBN ][PP from_IN ][NP the_DT lung_NN ][PP by_IN ][NP bronchoalveolar_JJ lavage_NN ][PP from_IN ][NP patients_NNS ][PP with_IN ][NP pulmonary_JJ granulomatous_JJ diseases_NNS ] (_([NP tuberculosis_NN ] and_CC[NP sarcoidosis_NN ] )_)[PP and_CC ][PP from_IN ][NP normal_JJ control_NN subjects_NNS ][VP using_VBG ][NP combined_JJ autoradiographic_JJ and_CC immunohistochemical_JJ techniques_NNS ] ._.
[NP Lavage_NN T-lymphocytes_NNS ][PP from_IN ][NP patients_NNS ][PP with_IN ][NP tuberculosis_NN ][PP or_CC ][PP with_IN ][NP sarcoidosis_NN ] ,_,[CONJP but_CC not_RB ][NP those_DT ][PP from_IN ][NP normal_JJ control_NN subjects_NNS ] ,_,[VP expressed_VBD ][NP 1,25(OH)2D3_NN receptors_NNS ][SBAR as_IN ][VP demonstrated_VBN ][PP by_IN ][NP binding_NN ][PP of_IN ][NP (3H)1,25(OH)2D3_NN ] ,_,[NP which_WDT ][VP was_VBD inhibited_VBN ][PP by_IN ][NP the_DT presence_NN ][PP of_IN ][NP excess_JJ unlabeled_JJ 1,25(OH)2D3_NN ][PP ,_, but_CC ][PP not_RB by_IN ][NP the_DT presence_NN ][PP of_IN ][NP unlabeled_JJ 25(OH)D3_NN ] (_([NP receptor-positive_JJ lymphocytes_NNS ] :_:[NP sarcoidosis_NN ] ,_,[NP 20_CD +/-_CC 12_CD %_NN ] ;_:[NP tuberculosis_NN ] ,_,[NP 31_CD +/-_CC 17_CD %_NN ] )_) ._.
[PP In_IN ][NP contrast_NN ] ,_,[NP blood_NN lymphocytes_NNS ][PP from_IN ][NP patients_NNS ][PP with_IN ][NP granulomatous_JJ diseases_NNS ][VP did_VBD not_RB express_VB ][NP detectable_JJ 1,25(OH)2D3_NN receptors_NNS ] ._.
[NP The_DT percentage_NN ][PP of_IN ][NP lavage_NN T-lymphocytes_NNS ][VP expressing_VBG ][NP 1,25(OH)2D3_NN receptors_NNS ][VP was_VBD ][ADJP significantly_RB greater_JJR ][PP for_IN ][NP patients_NNS ][PP with_IN ][NP tuberculosis_NN ][VP presenting_VBG ][PP with_IN ][NP isolated_VBN hilar_JJ adenopathy_JJ ][PP than_IN ][PP for_IN ][NP patients_NNS ][PP with_IN ][NP pulmonary_JJ ][NP infiltrates_NNS ] and/or_CC[NP cavities_NNS ] ._.
[NP 1,25(OH)2D3_NN receptors_NNS ][VP were_VBD expressed_VBN ][PP to_TO ][NP a_DT greater_JJR extent_NN ][PP on_IN ][NP CD8+_JJ T-lymphocytes_NNS ][PP than_IN ][PP on_IN ][NP CD4+_JJ T-lymphocytes_NNS ][PP in_IN ][NP sarcoidosis_NN ] ,_, whereas_IN[NP a_DT greater_JJR proportion_NN ][PP of_IN ][NP CD4+_JJ ][PP than_IN ][PP of_IN ][NP CD8+_JJ ][NP T-lymphocytes_NNS ][PP from_IN ][NP patients_NNS ][PP with_IN ][NP tuberculosis_NN ][VP were_VBD ][ADJP receptor-positive_JJ ] ._.
[NP These_DT findings_NNS ][VP support_VBP ][NP the_DT conclusion_NN ][SBAR that_IN ][NP the_DT interaction_NN ][PP of_IN ][NP 1,25(OH)2D3_NN ][PP with_IN ][NP its_PRP$ receptor_NN ][PP on_IN ][NP T-lymphocytes_NNS ][VP may_MD play_VB ][NP an_DT important_JJ role_NN ][PP in_IN ][NP the_DT regulation_NN ][PP of_IN ][NP granulomatous_JJ reactions_NNS ] ,_, but_CC[SBAR because_IN ][NP these_DT receptors_NNS ][VP are_VBP expressed_VBN ][PP on_IN ][NP different_JJ lymphocyte_NN populations_NNS ] ,_,[NP the_DT net_JJ effect_NN ][PP of_IN ][NP this_DT potent_JJ immunoregulatory_JJ molecule_NN ][VP is_VBZ ][ADJP likely_RB different_JJ ][PP in_IN ][NP sarcoidosis_NN ] and_CC[NP tuberculosis_NN ] ._.
[NP Inhibition_NN ][PP of_IN ][NP transcription_NN factors_NNS ][VP belonging_VBG ][PP to_TO ][NP the_DT rel/NF-kappa_NN B_NN family_NN ][PP by_IN ][NP a_DT transdominant_JJ negative_JJ mutant_NN ] ._.
[NP The_DT KBF1_NN factor_NN ] ,_,[NP which_WDT ][VP binds_VBZ ][PP to_TO ][NP the_DT enhancer_NN A_NN ][VP located_JJ ][PP in_IN ][NP the_DT promoter_NN ][PP of_IN ][NP the_DT mouse_NN MHC_NN class_NN I_CD gene_NN H-2Kb_NN ] ,_,[VP is_VBZ ][ADJP indistinguishable_JJ ][PP from_IN ][NP the_DT p50_NN DNA_NN binding_NN subunit_NN ][PP of_IN ][NP the_DT transcription_NN factor_NN NF-kappa_NN B_NN ] ,_,[NP which_WDT ][VP regulates_VBZ ][NP a_DT series_NN ][PP of_IN ][NP genes_NNS ][VP involved_VBN ][PP in_IN ][NP immune_JJ and_CC inflammatory_JJ responses_NNS ] ._.
[NP The_DT KBF1/p50_NN factor_NN ][VP binds_VBZ ][PP as_IN ][NP a_DT homodimer_NN ] but_CC[VP can_MD also_RB form_VB ][NP heterodimers_NNS ][PP with_IN ][NP the_DT products_NNS ][PP of_IN ][NP other_JJ members_NNS ][PP of_IN ][NP the_DT same_JJ family_NN ] ,_,[PP like_IN ] the_DT[NP c-rel_NN ] and_CC[NP v-rel_NN ][NP (_( proto_NN )_) oncogenes_NNS ] ._.
[NP The_DT dimerization_NN domain_NN ][PP of_IN ][NP KBF1/p50_NN ][VP is_VBZ contained_VBN ][PP between_IN ][NP amino_NN acids_NNS ][NP 201_CD ] and_CC[NP 367_CD ] ._.
[NP A_DT mutant_NN ][PP of_IN ][NP KBF1/p50_NN (_( delta_NN SP_NN ] )_) ,_,[ADJP unable_JJ ][VP to_TO bind_VB ][PP to_TO ][NP DNA_NN ] but_CC[ADJP able_JJ ][VP to_TO form_VB ][NP homo-_JJ ] or_CC[NP heterodimers_NNS ] ,_,[VP has_VBZ been_VBN constructed_VBN ] ._.
[NP This_DT protein_NN ][VP reduces_VBZ ] or_CC[VP abolishes_VBZ ][ADVP in_FW vitro_FW ][NP the_DT DNA_NN binding_NN activity_NN ][PP of_IN ][NP wild-type_JJ proteins_NNS ][PP of_IN ][NP the_DT same_JJ family_NN ] (_([NP KBF1/p50_NN ] ,_,[NP c-_NN ] and_CC[NP v-rel_NN ] )_) ._.
[NP This_DT mutant_JJ ][ADVP also_RB ][VP functions_NNS ][ADVP in_FW vivo_FW ][PP as_IN ][NP a_DT trans-acting_JJ dominant_JJ negative_JJ regulator_NN ] :_:[NP the_DT transcriptional_JJ inducibility_NN ][PP of_IN ][NP the_DT HIV_NN long_JJ terminal_JJ repeat_NN ] (_([NP which_WDT ][VP contains_VBZ ][NP two_CD potential_JJ NF-kappa_NN B_NN binding_NN sites_NNS ] )_)[PP by_IN ][NP phorbol_NN ester_NN ] (_([NP PMA_NN ] )_)[VP is_VBZ inhibited_VBN ][ADVP when_WRB ][NP it_PRP ][VP is_VBZ co-transfected_VBN ][PP into_IN ][NP CD4+_JJ T_NN cells_NNS ][PP with_IN ][NP the_DT delta_NN SP_NN mutant_NN ] ._.
[ADVP Similarly_RB ] the_DT basal_JJ[CONJP as_RB well_RB as_IN ][NP TNF_NN ] or_CC[ADJP IL1-induced_JJ ][NP activity_NN ][PP of_IN ][NP the_DT MHC_NN class_NN I_CD H-2Kb_NN promoter_NN ][VP can_MD be_VB inhibited_VBN ][PP by_IN ][NP this_DT mutant_NN ][PP in_IN ][NP two_CD different_JJ cell_NN lines_NNS ] ._.
[NP These_DT results_NNS ][VP constitute_VBP ][NP the_DT first_JJ formal_JJ demonstration_NN ][SBAR that_IN ][NP these_DT genes_NNS ][VP are_VBP regulated_VBN ][PP by_IN ][NP members_NNS ][PP of_IN ][NP the_DT rel/NF-kappa_NN B_NN family_NN ] ._.
[NP Human_JJ erythroid_JJ 5-aminolevulinate_NN synthase_NN ] :_:[NP promoter_NN analysis_NN ] and_CC[NP identification_NN ][PP of_IN ][NP an_DT iron-responsive_JJ element_NN ][PP in_IN ][NP the_DT mRNA_NN ] ._.
[NP 5-Aminolevulinate_NN synthase_NN ] (_([NP ALAS_NN ] )_)[VP catalyzes_VBZ ][NP the_DT first_JJ step_NN ][PP of_IN ][NP the_DT heme_NN biosynthetic_JJ pathway_NN ] ._.
[NP cDNA_NN clones_NNS ][PP for_IN ][NP the_DT human_JJ erythroid_JJ ALAS_NN isozyme_NN ][VP were_VBD isolated_VBN ][PP from_IN ][NP a_DT fetal_JJ liver_NN library_NN ] ._.
[NP It_PRP ][VP can_MD be_VB deduced_VBN ][SBAR that_IN ][NP the_DT erythroid_JJ ALAS_NN precursor_NN protein_NN ][VP has_VBZ ][NP a_DT molecular_JJ weight_NN ][PP of_IN ][NP 64.6_CD kd_NN ] ,_, and_CC[VP is_VBZ ][ADJP similar_JJ ][PP in_IN ][NP size_NN ][PP to_TO ][NP the_DT previously_RB isolated_VBN human_JJ housekeeping_JJ ALAS_NN precursor_NN ][PP of_IN ][NP molecular_JJ weight_NN 70.6_CD kd_NN ] ._.
[NP The_DT mature_JJ mitochondrial_JJ forms_NNS ][PP of_IN ] the_DT erythroid_JJ and_CC[NP housekeeping_JJ ][NP ALAS_NN isozymes_NNS ][VP are_VBP predicted_VBN to_TO have_VB ][NP molecular_JJ weights_NNS ][PP of_IN ][NP 59.5_CD kd_NN ] and_CC[NP 64.6_CD kd_NN ] ,_,[ADVP respectively_RB ] ._.
[NP The_DT two_CD isozymes_NNS ][VP show_VBP ][NP little_JJ amino_NN acid_NN identity_NN ][PP in_IN ][NP their_PRP$ N-terminal_JJ signal_NN sequences_NNS ] but_CC[VP have_VBP ][NP considerable_JJ sequence_NN identity_NN ][PP in_IN ][NP the_DT C-terminal_JJ two-thirds_CD ][PP of_IN ][NP their_PRP$ proteins_NNS ] ._.
[NP An_DT analysis_NN ][PP of_IN ][NP the_DT immediate_JJ promoter_NN ][PP of_IN ][NP the_DT human_JJ erythroid_JJ ALAS_NN gene_NN ][VP revealed_VBD ][NP several_JJ putative_JJ erythroid-specific_JJ cis-acting_JJ elements_NNS ][PP including_VBG ] both_PDT[NP a_DT GATA-1_NN ] and_CC[NP an_DT NF-E2_NN ][NP binding_NN site_NN ] ._.
 An_DT[NP iron-responsive_JJ element_NN ] (_([NP IRE_NN ] )_)[NP motif_NN ][VP has_VBZ been_VBN identified_VBN ][PP in_IN ][NP the_DT 5'-untranslated_JJ region_NN ][PP of_IN ][NP the_DT human_JJ erythroid_JJ ALAS_NN mRNA_NN ] ,_, but_CC[VP is_VBZ ] not_RB[ADJP present_JJ ][PP in_IN ][NP the_DT housekeeping_JJ ALAS_NN mRNA_NN ] ._.
[NP Gel_NN retardation_NN experiments_NNS ][VP established_VBD ][SBAR that_IN ][NP this_DT IRE_NN motif_NN ][VP formed_VBD ][NP a_DT ][NP protein-RNA_JJ complex_NN ][PP with_IN ][NP cytosolic_JJ extracts_NNS ][PP from_IN ][NP human_JJ K562_NN cells_NNS ] and_CC[NP this_DT binding_NN ][VP was_VBD strongly_RB competed_VBN ][PP with_IN ][NP IRE_NN transcripts_NNS ][PP from_IN ][NP ferritin_NN ] or_CC[NP transferrin_NN ][NP receptor_NN ][NP mRNAs_NNS ] ._.
[NP A_DT transcript_NN ][PP of_IN ][NP the_DT ALAS_NN IRE_NN ] ,_,[VP mutated_VBN ][PP in_IN ][NP the_DT conserved_VBN loop_NN ][PP of_IN ][NP the_DT IRE_NN ] ,_,[VP did_VBD not_RB readily_RB form_VB ][NP this_DT ][NP protein-RNA_JJ complex_NN ] ._.
[NP These_DT results_NNS ][VP suggest_VBP ][SBAR that_IN ][NP the_DT IRE_NN motif_NN ][PP in_IN ][NP the_DT ALAS_NN mRNA_NN ][VP is_VBZ ][ADJP functional_JJ ] and_CC[VP imply_VBP ][SBAR that_IN ][NP translation_NN ][PP of_IN ][NP the_DT mRNA_NN ][VP is_VBZ controlled_VBN ][PP by_IN ][NP cellular_JJ iron_NN availability_NN ][PP during_IN ][NP erythropoiesis_NN ] ._.
[NP Human_JJ tumor_NN necrosis_NN factor_NN alpha_NN gene_NN regulation_NN ][PP in_IN ][NP phorbol_NN ester_NN stimulated_VBD T_NN and_CC B_NN cell_NN lines_NNS ] ._.
[NP The_DT minimal_JJ region_NN ][PP of_IN ][NP the_DT human_JJ tumor_NN necrosis_NN factor_NN alpha_NN (_( TNF-alpha_NN )_) gene_NN promoter_NN ][ADJP necessary_JJ ][PP for_IN ][NP its_PRP$ transcriptional_JJ induction_NN ][PP by_IN ][NP phorbol_NN esters_NNS ] (_([NP PMA_NN ] )_)[PP in_IN ][NP human_JJ T_NN and_CC B_NN lymphocyte_NN cell_NN lines_NNS ][VP has_VBZ been_VBN localized_JJ ][PP between_IN ][NP -52_CD ] and_CC[NP +89_CD ][NP nucleotides_NNS ] (_([NP nt_NN ] )_)[ADVP relative_JJ ][PP to_TO ][NP the_DT gene_NN ][NP 's_POS transcriptional_JJ start_NN site_NN ] ._.
[NP Comparison_NN ][PP of_IN ][NP these_DT sequences_NNS ][PP to_TO ][NP those_DT ][VP required_VBN ][VP to_TO mediate_VB ][NP virus_NN ] or_CC[NP lipopolysaccharide_NN ] (_([NP LPS_NN ] )_)[NP induction_NN ][PP of_IN ][NP the_DT gene_NN ][VP reveal_VB ][NP significant_JJ differences_NNS ] ,_, and_CC thus_RB ,_,[NP the_DT sequence_NN requirements_NNS ][PP for_IN ][NP PMA_NN induction_NN ][VP are_VBP ][ADJP distinct_JJ ][PP from_IN ][NP those_DT ][NP that_WDT ][VP mediate_VBP ][NP induction_NN ][PP by_IN ][NP virus_NN ] or_CC[NP LPS_NN ] ._.
[SBAR Although_IN ][NP three_CD sites_NNS ][PP in_IN ][NP the_DT TNF-alpha_NN promoter_NN ] (_([NP kappa_NN 1_CD ] ,_,[NP kappa_NN 2_CD ] ,_, and_CC[NP kappa_NN 3_CD ] )_)[ADVP specifically_RB ][VP bind_VBP ][NP the_DT transcription_NN factor_NN NF-kappa_NN B_NN ][PP in_IN ][NP lymphoid_JJ nuclear_JJ extracts_NNS ] ,_,[NP TNF-alpha_NN mRNA_NN induction_NN ][PP by_IN ][NP PMA_NN ][VP does_VBZ not_RB correlate_VB ][PP with_IN ][NP NF-kappa_NN B_NN binding_NN activities_NNS ][VP displayed_VBN ][PP by_IN ][NP different_JJ T_NN and_CC B_NN cell_NN lines_NNS ] ._.
[ADVP Moreover_RB ] ,_,[NP kappa_NN 1_CD ] -_:[NP kappa_NN 3_CD ][VP can_MD each_DT be_VB deleted_VBN ][PP from_IN ][NP the_DT TNF-alpha_NN promoter_NN ][PP with_IN ][NP little_JJ effect_NN ][PP on_IN ][NP the_DT gene_NN ][NP 's_POS inducibility_NN ][PP by_IN ][NP PMA_NN ] ._.
[ADVP Therefore_RB ] ,_,[NP TNF-alpha_NN mRNA_NN induction_NN ][PP by_IN ][NP PMA_NN ] ,_,[PP like_IN ][NP its_PRP$ induction_NN ][PP by_IN ][NP virus_NN ] and_CC[NP LPS_NN ] ,_,[VP is_VBZ not_RB primarily_RB mediated_VBN ][PP by_IN ][NP NF-kappa_NN B_NN ] ,_,[CONJP but_CC rather_RB ][VP is_VBZ mediated_VBN ][PP through_IN ][NP other_JJ ][NP sequences_NNS ] and_CC[NP protein_NN factors_NNS ] ._.
[ADVP Surprisingly_RB ] ,_,[NP multimers_NNS ][PP of_IN ][NP kappa_NN 1_CD ] -_:[NP kappa_NN 3_CD ][VP can_MD confer_VB ][NP PMA_NN inducibility_NN ][PP on_IN ][NP a_DT heterologous_JJ promoter_NN ][PP in_IN ][NP a_DT ][NP B_NN ] (_([NP Raji_NN ] )_) ,_,[CONJP but_CC not_RB ][NP a_DT ][NP T_NN ] (_([NP HUT78_NN ] )_)[NP cell_NN line_NN ] ._.
 However_WRB[NP they_PRP ][VP are_VBP ] not_RB[ADJP functional_JJ ][PP on_IN ][NP a_DT truncated_VBN TNF-alpha_NN promoter_NN ] ,_,[VP indicating_VBG ][SBAR that_IN ][NP promoter_NN context_NN ] and_CC[NP cell_NN type_NN specificity_NN ][VP influence_VBP ][NP the_DT PMA_NN inducible_JJ function_NN ][PP of_IN ][NP these_DT NF-kappa_NN B_NN binding_NN sites_NNS ] ._.
[PP Towards_IN ][NP a_DT molecular_JJ understanding_NN ][PP of_IN ][NP T-cell_NN differentiation_NN ] ._.
[NP Lymphoid_JJ differentiation_NN ][VP is_VBZ ][NP one_CD ][PP of_IN ][NP the_DT best_RBS studied_VBN examples_NNS ][PP of_IN ][NP mammalian_JJ development_NN ] ._.
[ADVP Here_RB ][NP Hans_NNP Clevers_NNP ] and_CC[NP Michael_NNP Owen_NNP ][VP describe_VBP ][ADVP how_WRB ][NP the_DT cloning_NN ][PP of_IN ][NP the_DT genes_NNS ][NP that_WDT ][VP encode_VBP T-cell-specific_JJ membrane_NN proteins_NNS ][VP allows_VBZ ][NP the_DT identification_NN ][PP of_IN ][NP transcription_NN factors_NNS ][NP that_WDT ][VP control_VBP ][NP the_DT expression_NN ][PP of_IN ][NP these_DT T-cell_NN genes_NNS ] ._.
[NP Such_JJ transcription_NN factors_NNS ][VP play_VBP ][NP a_DT key_JJ role_NN ][PP in_IN ][NP the_DT development_NN ][PP of_IN ][NP the_DT mature_JJ T-cell_NN phenotype_NN ][PP by_IN ][VP functioning_VBG ][PP as_IN ] '_[[DQS]][NP master_JJ regulators_NNS ][PP of_IN ][NP T-cell_NN differentiation_NN ] '_[[DQE]] ._.
[NP Regulation_NN ][PP of_IN ][NP jun_NN and_CC fos_NN gene_NN expression_NN ][PP in_IN ][NP human_JJ monocytes_NNS ][PP by_IN ][NP the_DT macrophage_NN colony-stimulating_JJ factor_NN ] ._.
[NP The_DT ][NP macrophage_NN colony-stimulating_JJ factor_NN ] (_([NP M-CSF_NN ] )_)[VP is_VBZ required_VBN ][PP for_IN ][NP the_DT ][NP growth_NN ] and_CC[NP differentiation_NN ][PP of_IN ][NP mononuclear_JJ phagocytes_NNS ] ._.
[ADVP However_RB ] ,_,[NP the_DT signaling_NN events_NNS ][ADJP responsible_JJ ][PP for_IN ][NP these_DT effects_NNS ][VP remain_VBP ][ADJP unclear_JJ ] ._.
[NP The_DT present_JJ studies_NNS ][VP have_VBP examined_VBN ][NP the_DT effects_NNS ][PP of_IN ][NP M-CSF_NN ][PP on_IN ][NP potential_JJ signaling_NN pathways_NNS ][VP involving_VBG ][NP expression_NN ][PP of_IN ] the_DT[NP jun_NN ] and_CC[NP fos_NN ][NP early_JJ response_NN genes_NNS ] ._.
[NP Low_JJ levels_NNS ][PP of_IN ][NP c-jun_NN transcripts_NNS ][VP were_VBD ][ADJP detectable_JJ ][PP in_IN ][NP resting_VBG human_JJ peripheral_JJ blood_NN monocytes_NNS ] ._.
[NP Treatment_NN ][PP of_IN ][NP these_DT cells_NNS ][PP with_IN ][NP 10(3)_CD units/ml_NNS human_JJ recombinant_JJ M-CSF_NN ][VP was_VBD associated_VBN ][PP with_IN ][NP rapid_JJ and_CC transient_JJ increases_NNS ][PP in_IN ][NP c-jun_NN mRNA_NN levels_NNS ] ._.
[NP Nuclear_JJ run-on_JJ assays_NNS ] and_CC[NP mRNA_NN stability_NN studies_NNS ][VP demonstrated_VBD ][SBAR that_IN ][NP M-CSF_NN ][VP regulates_VBZ ][NP c-jun_NN expression_NN ][PP by_IN ] both_CC[NP an_DT increase_NN ][PP in_IN ][NP transcription_NN rate_NN ] and_CC[NP a_DT prolongation_NN ][PP in_IN ][NP the_DT half-life_NN ][PP of_IN ][NP c-jun_NN transcripts_NNS ] ._.
[NP M-CSF_NN treatment_NN ][VP was_VBD also_RB associated_VBN ][PP with_IN ][NP a_DT rapid_JJ induction_NN ][PP of_IN ][NP the_DT jun-B_NN gene_NN ] ,_,[SBAR although_IN ][NP expression_NN ][PP of_IN ][NP this_DT gene_NN ][VP was_VBD prolonged_JJ ][VP compared_VBN ][PP to_TO ][NP that_DT ][PP of_IN ][NP c-jun_NN ] ._.
[NP We_PRP ][ADVP further_RB ][VP demonstrate_VBP ][SBAR that_IN ][NP M-CSF_NN ][VP increases_VBZ ][NP c-fos_NN mRNA_NN levels_NNS ][PP in_IN ][NP human_JJ monocytes_NNS ][PP through_IN ][NP control_NN ][PP at_IN ][NP both_CC the_DT transcriptional_JJ and_CC posttranscriptional_JJ levels_NNS ] ._.
[NP Maximal_JJ induction_NN ][PP of_IN ][NP the_DT c-fos_NN gene_NN ][VP was_VBD followed_VBN ][PP by_IN ][NP that_DT ][PP for_IN ][NP the_DT fos-B_NN gene_NN ] ._.
[ADVP Moreover_RB ] ,_,[NP M-CSF-induced_JJ expression_NN ][PP of_IN ][NP the_DT fos-related_JJ gene_NN ] ,_,[NP fra-1_NN ] ,_,[VP was_VBD delayed_VBN ][VP compared_VBN ][PP to_TO ][NP that_DT ][PP for_IN ][NP both_DT ][NP c-fos_NN ] and_CC[NP fos-B_NN ] ._.
[VP Taken_VBN ][ADVP together_RB ] ,_,[NP the_DT results_NNS ][VP indicate_VBP ][SBAR that_IN ][NP M-CSF_NN treatment_NN ][VP is_VBZ associated_VBN ][PP with_IN ][NP differential_JJ activation_NN ][PP of_IN ][NP multiple_JJ members_NNS ][PP of_IN ][NP the_DT jun/fos_NN family_NN ] and_CC[SBAR that_IN ][NP expression_NN ][PP of_IN ][NP these_DT genes_NNS ][VP could_MD contribute_VB ][PP to_TO ][NP nuclear_JJ signaling_NN mechanisms_NNS ][NP that_WDT ][VP regulate_VBP ][NP a_DT specific_JJ program_NN ][PP of_IN ][NP monocyte_NN differentiation_NN ] ._.
[NP Cloning_NN ][PP of_IN ][NP a_DT human_JJ homeobox_NN gene_NN ][NP that_WDT ][VP resembles_VBZ ][NP a_DT diverged_JJ Drosophila_NN homeobox_NN gene_NN ] and_CC[VP is_VBZ expressed_VBN ][PP in_IN ][NP activated_VBN lymphocytes_NNS ] ._.
[NP A_DT new_JJ homeobox_NN gene_NN ] ,_,[NP HB24_NN ] ,_,[VP has_VBZ been_VBN isolated_VBN ][PP from_IN ][NP a_DT human_JJ B-lymphocyte_NN cDNA_NN library_NN ] ._.
[NP Northern_JJ|NN blot_NN analysis_NN ][PP of_IN ][NP polyadenylated_JJ RNA_NN ][VP purified_VBN ][PP from_IN ][NP activated_VBN human_JJ B_NN cells_NNS ][VP revealed_VBD ][NP a_DT single_JJ mRNA_NN transcript_NN ][PP of_IN ][NP approximately_RB 2.3_CD kb_NN ] ._.
[NP Two_CD cDNA_NN clones_NNS ][VP were_VBD sequenced_VBN ] and_CC[VP provided_VBN ][NP 2,250_CD ][NP nucleotides_NNS ] (_([NP nt_NN ] )_)[PP of_IN ][NP DNA_NN sequence_NN information_NN ] ._.
[NP There_EX ][VP is_VBZ ][NP a_DT single_JJ methionine_NN codon-initiated_JJ open_JJ reading_NN frame_NN ][PP of_IN ][NP 1,458_CD nt_NN ][PP in_IN ][NP frame_NN ][PP with_IN ][NP a_DT homeobox_NN ] and_CC[NP a_DT CAX_NN repeat_NN ] ,_, and_CC[NP the_DT open_JJ reading_NN frame_NN ][VP is_VBZ predicted_VBN to_TO encode_VB ][NP a_DT protein_NN ][PP of_IN ][NP 51,659_CD daltons_NNS ] ._.
[ADVP When_WRB ][NP the_DT homeodomain_NN ][PP from_IN ][NP HB24_NN ][VP was_VBD compared_VBN ][PP to_TO ] known_JJ mammalian_JJ and_CC[NP Drosophila_NN ][NP homeodomains_NNS ][NP it_PRP ][VP was_VBD found_VBN to_TO be_VB ][ADJP only_RB moderately_RB conserved_VBN ] ,_, but_CC[ADVP when_WRB ][NP it_PRP ][VP was_VBD compared_VBN ][PP to_TO ][NP a_DT highly_RB diverged_JJ Drosophila_FW homeodomain_NN ] ,_,[NP H2.0_NN ] ,_,[NP it_PRP ][VP was_VBD found_VBN to_TO be_VB ][NP 80_CD %_NN ][ADJP identical_JJ ] ._.
[NP The_DT HB24_NN mRNA_NN ][VP was_VBD ][ADJP absent_JJ ] or_CC[ADJP present_JJ ][PP at_IN ][NP low_JJ levels_NNS ][PP in_IN ][NP normal_JJ ][NP B_NN ] and_CC[NP T_NN ][NP lymphocytes_NNS ] ;_:[ADVP however_RB ] ,_,[PP with_IN ][NP the_DT appropriate_JJ activation_NN signal_NN ][NP HB24_NN mRNA_NN ][VP was_VBD induced_VBN ][PP within_IN ][NP several_JJ hours_NNS ][PP even_RB in_IN the_DT presence_NN of_IN ][NP cycloheximide_NN ] ._.
[NP Characterization_NN ][PP of_IN ][NP HB24_NN expression_NN ][PP in_IN ][NP lymphoid_JJ ] and_CC[NP select_JJ developing_VBG tissues_NNS ][VP was_VBD performed_VBN ][PP by_IN ][NP in_FW situ_FW hybridization_NN ] ._.
[NP Positive_JJ hybridization_NN ][VP was_VBD found_VBN ][PP in_IN ][NP thymus_NN ] ,_,[NP tonsil_NN ] ,_,[NP bone_NN marrow_NN ] ,_,[NP developing_VBG vessels_NNS ][PP ,_, and_CC ][PP in_IN ][NP fetal_JJ brain_NN ] ._.
[NP HB24_NN ][VP is_VBZ ][ADJP likely_JJ ][VP to_TO have_VB ][NP an_DT important_JJ role_NN ][PP in_IN ][NP lymphocytes_NNS ][CONJP as_RB well_RB as_IN ][PP in_IN ][NP certain_JJ developing_VBG tissues_NNS ] ._.
[NP Severe_JJ 5-fluorouracil_NN toxicity_NN ][ADJP secondary_JJ ][PP to_TO ][NP dihydropyrimidine_NN dehydrogenase_NN deficiency_NN ] ._.
[NP A_DT potentially_RB more_RBR common_JJ pharmacogenetic_JJ syndrome_NN ] ._.
[NP This_DT study_NN ][VP describes_VBZ ][NP the_DT inheritance_NN ][PP of_IN ][NP a_DT defect_NN ][PP in_IN ][NP pyrimidine_NN catabolism_NN ] and_CC[NP its_PRP$ association_NN ][PP with_IN ][NP drug-induced_JJ toxicity_NN ][PP in_IN ][NP a_DT patient_NN ][VP receiving_VBG ][NP 5-fluorouracil_NN ] (_([NP FUra_NN ] )_)[PP as_IN ][NP adjuvant_JJ chemotherapy_NN ][PP for_IN ][NP breast_NN carcinoma_NN ] ._.
[NP The_DT study_NN population_NN ][VP included_VBD ][NP the_DT affected_VBN patient_NN ] (_([NP proband_NN ] )_) ,_,[NP nine_CD ][PP of_IN ][NP her_PRP$ blood_NN relatives_NNS ] ,_, and_CC[NP seven_CD healthy_JJ volunteers_NNS ] ._.
[NP The_DT activity_NN ][PP of_IN ][NP dihydropyrimidine_NN dehydrogenase_NN ] (_([NP DPD_NN ] )_) ,_,[NP the_DT initial_JJ enzyme_NN ][PP of_IN ][NP pyrimidine_NN ] (_( and_CC[NP FUra_NN ] )_)[NP catabolism_NN ] ,_,[PP in_IN ][NP peripheral_JJ blood_NN mononuclear_JJ cells_NNS ][VP was_VBD measured_VBN ][PP in_IN ][NP each_DT subject_NN ][PP by_IN ][NP a_DT specific_JJ radiometric_JJ assay_NN ][VP using_VBG ][NP FUra_NN ][PP as_IN ][NP the_DT substrate_NN ] ._.
[NP The_DT proband_NN ][VP had_VBD ][NP no_DT detectable_JJ DPD_NN activity_NN ] ._.
[ADVP When_WRB ][NP enzyme_NN levels_NNS ][PP in_IN ][NP the_DT ][NP proband_NN ] and_CC[NP relatives_NNS ][VP were_VBD compared_VBN ][PP with_IN ][NP that_DT ] in_NN[NP controls_NNS ] ,_,[NP an_DT autosomal_JJ recessive_JJ pattern_NN ][PP of_IN ][NP inheritance_NN ][VP was_VBD demonstrated_VBN ] ._.
[NP This_DT ][VP is_VBZ ][NP the_DT third_JJ patient_NN ][PP with_IN ][NP severe_JJ FUra_NN toxicity_NN ][ADJP secondary_JJ ][PP to_TO ][NP an_DT alteration_NN ][PP in_IN ][NP pyrimidine_NN catabolism_NN ] and_CC[NP the_DT second_NN ][PP from_IN ][NP our_PRP$ clinic_NN population_NN ][VP suggesting_VBG ][SBAR that_IN ][NP the_DT frequency_NN ][PP of_IN ][NP this_DT genetic_JJ defect_NN ][VP may_MD be_VB ][ADJP greater_JJR ][SBAR than_IN ][ADVP previously_RB ][VP thought_VBN ] ._.
[VP Monitoring_VBG ][NP DPD_NN activity_NN ][VP may_MD be_VB ][ADJP important_JJ ][PP in_IN ][NP the_DT management_NN ][PP of_IN ][NP patients_NNS ][VP experiencing_VBG ][NP severe_JJ toxicity_NN ][ADJP secondary_JJ ][PP to_TO ][NP FUra_NN chemotherapy_NN ] ._.
[NP Characterization_NN ][PP of_IN ][NP an_DT immediate-early_JJ gene_NN ][VP induced_VBN ][PP in_IN ][NP adherent_JJ monocytes_NNS ][NP that_WDT ][VP encodes_VBZ ][NP I_NN kappa_NN B-like_JJ activity_NN ] ._.
[NP We_PRP ][VP have_VBP cloned_VBN ][NP a_DT group_NN ][PP of_IN ][NP cDNAs_NNS ][VP representing_VBG ][NP mRNAs_NNS ][NP that_WDT ][VP are_VBP rapidly_RB induced_VBN ][PP following_VBG ][NP adherence_NN ][PP of_IN ][NP human_JJ monocytes_NNS ] ._.
[NP One_CD ][PP of_IN ][NP the_DT induced_VBN transcripts_NNS ] (_([NP MAD-3_NN ] )_)[VP encodes_VBZ ][NP a_DT protein_NN ][PP of_IN ][NP 317_CD amino_NN acids_NNS ][PP with_IN ][NP one_CD domain_NN ][VP containing_VBG ][NP five_CD tandem_JJ repeats_NNS ][PP of_IN ][NP the_DT cdc10/ankyrin_JJ motif_NN ] ,_,[NP which_WDT ][VP is_VBZ ][NP 60_CD %_NN ][ADJP similar_JJ ] (_([NP 46_CD %_NN ][ADJP identical_JJ ] )_)[PP to_TO ][NP the_DT ankyrin_NN repeat_NN region_NN ][PP of_IN ][NP the_DT precursor_NN ][PP of_IN ][NP NF-kappa_NN B/KBF1_NN p50_NN ] ._.
[NP The_DT C-terminus_NN ][VP has_VBZ ][NP a_DT putative_JJ protein_NN kinase_NN C_NN phosphorylation_NN site_NN ] ._.
[ADVP In_FW vitro_FW ][NP translated_VBN MAD-3_NN protein_NN ][VP was_VBD found_VBN to_TO specifically_RB inhibit_VB ][NP the_DT DNA-binding_JJ activity_NN ][PP of_IN ][NP the_DT p50/p65_NN NF-kappa_NN B_NN complex_NN ][CONJP but_CC not_RB ][NP that_DT ][PP of_IN ][NP the_DT p50/p50_NN KBF1_NN factor_NN ][PP or_CC ][PP of_IN ][NP other_JJ DNA-binding_JJ proteins_NNS ] ._.
[NP The_DT MAD-3_NN cDNA_NN ][VP encodes_VBZ ][NP an_DT I_NN kappa_NN B-like_JJ protein_NN ][NP that_WDT ][VP is_VBZ ][ADJP likely_JJ ][VP to_TO be_VB involved_VBN ][PP in_IN ][NP regulation_NN ][PP of_IN ][NP transcriptional_JJ responses_NNS ][PP to_TO ][NP NF-kappa_NN B_NN ] ,_,[PP including_VBG ][NP adhesion-dependent_JJ pathways_NNS ][PP of_IN ][NP monocyte_NN activation_NN ] ._.
[NP Reactive_JJ oxygen_NN intermediates_NNS ][PP as_IN ][ADJP apparently_RB widely_RB used_VBN ] messengers_NNS[PP in_IN ][NP the_DT activation_NN ][PP of_IN ][NP the_DT ][NP NF-kappa_NN B_NN transcription_NN factor_NN ] and_CC[NP HIV-1_NN ] ._.
[NP Hydrogen_NN peroxide_NN ] and_CC[NP oxygen_NN ][NP radicals_NNS ][VP are_VBP ][NP agents_NNS ][VP commonly_RB produced_VBN ][PP during_IN ][NP inflammatory_JJ processes_NNS ] ._.
[PP In_IN ][NP this_DT study_NN ] ,_,[NP we_PRP ][VP show_VBP ][SBAR that_IN ][NP micromolar_JJ concentrations_NNS ][PP of_IN ][NP H2O2_NN ][VP can_MD induce_VB ][NP the_DT ][NP expression_NN ] and_CC[NP replication_NN ][PP of_IN ][NP HIV-1_NN ][PP in_IN ][NP a_DT human_JJ T_NN cell_NN line_NN ] ._.
[NP The_DT effect_NN ][VP is_VBZ mediated_VBN ][PP by_IN ][NP the_DT NF-kappa_NN B_NN transcription_NN factor_NN ][NP which_WDT ] is_VBZ[ADVP potently_RB ] and_CC[ADVP rapidly_RB ][VP activated_VBN ] by_IN[NP an_DT H2O2_NN treatment_NN ][PP of_IN ][NP cells_NNS ][PP from_IN ][NP its_PRP$ inactive_JJ cytoplasmic_JJ form_NN ] ._.
[NP N-acetyl-L-cysteine_NN ] (_([NP NP_NN ] )_) ,_,[NP a_DT well_RB characterized_VBN antioxidant_NN ][NP which_WDT ][VP counteracts_VBZ ][NP the_DT effects_NNS ][PP of_IN ][NP reactive_JJ oxygen_NN intermediates_NNS ] (_([NP ROI_NN ] )_)[PP in_IN ][NP living_VBG cells_NNS ] ,_,[VP prevented_VBD ][NP the_DT activation_NN ][PP of_IN ][NP NF-kappa_NN B_NN ][PP by_IN ][NP H2O2_NN ] ._.
[NP NP_NN ] and_CC[NP other_JJ thiol_JJ compounds_NNS ][ADVP also_RB ][VP blocked_VBD ][NP the_DT activation_NN ][PP of_IN ][NP NF-kappa_NN B_NN ][PP by_IN ][NP cycloheximide_NN ] ,_,[NP double-stranded_JJ RNA_NN ] ,_,[NP calcium_NN ionophore_NN ] ,_,[NP TNF-alpha_NN ] ,_,[NP active_JJ phorbol_NN ester_NN ] ,_,[NP interleukin-1_NN ] ,_,[NP lipopolysaccharide_NN ] and_CC[NP lectin_NN ] ._.
[NP This_DT ][VP suggests_VBZ ][SBAR that_IN ][NP diverse_JJ agents_NNS ][VP thought_VBN to_TO activate_VB ][NP NF-kappa_NN B_NN ][PP by_IN ][NP distinct_JJ intracellular_JJ pathways_NNS ][VP might_MD all_DT act_VB ][PP through_IN ][NP a_DT common_JJ mechanism_NN ][VP involving_VBG ][NP the_DT synthesis_NN ][PP of_IN ][NP ROI_NN ] ._.
[NP ROI_NN ][VP appear_VBP to_TO serve_VB ][PP as_IN ][NP messengers_NNS ][VP mediating_VBG ][ADVP directly_RB ][ADVP or_CC ][ADVP indirectly_RB ][NP the_DT release_NN ][PP of_IN ][NP the_DT inhibitory_JJ subunit_NN I_NN kappa_NN B_NN ][PP from_IN ][NP NF-kappa_NN B_NN ] ._.
[NP HTLV-1_NN Tax_NN ][VP induces_VBZ ][NP expression_NN ][PP of_IN ][NP various_JJ immediate_JJ early_JJ serum_NN responsive_JJ genes_NNS ] ._.
[NP Human_JJ T-cell_NN leukemia_NN virus_NN type_NN 1_CD ] (_([NP HTLV-1_NN ] )_)[VP is_VBZ ][NP an_DT etiological_JJ agent_NN ][PP of_IN ][NP adult_JJ T-cell_NN leukemia_NN ] (_([NP ATL_NN ] )_) ._.
[NP We_PRP ][VP showed_VBD ][ADVP here_RB ][PP by_IN ][NP mobility-shift_NN assay_NN ][SBAR that_IN ][NP T-cell_NN lines_NNS ][VP transformed_VBN ][PP with_IN ][NP the_DT virus_NN ][VP contained_VBD ][NP high_JJ levels_NNS ][PP of_IN ][NP AP-1_NN activities_NNS ] ._.
[ADJP Consistent_JJ ][PP with_IN ][NP this_DT result_NN ] ,_,[NP these_DT cell_NN lines_NNS ][VP expressed_VBD ][NP increased_VBN levels_NNS ][PP of_IN ][NP mRNAs_NNS ][VP encoding_VBG ][NP the_DT AP-1_NN proteins_NNS ] ,_,[NP c-Fos_NN ] ,_,[NP Fra-1_NN ] ,_,[NP c-Jun_NN ] ,_,[NP JunB_NN ] ,_, and_CC[NP JunD_NN ] ._.
[ADVP Previously_RB ] ,_,[NP transcription_NN ][PP of_IN ][NP the_DT c-fos_NN gene_NN ][VP has_VBZ been_VBN reported_VBN to_TO be_VB transactivated_VBN ][PP by_IN ][NP the_DT viral_JJ transcription_NN factor_NN ] ,_,[NP Tax1_NN ] ._.
[PP By_IN ][VP using_VBG ][NP the_DT human_JJ T-cell_NN line_NN ] (_([NP JPX-9_NN ] )_) ,_,[PP in_IN ][NP which_WDT ][NP expression_NN ][PP of_IN ][NP the_DT Tax1_NN ][VP is_VBZ ][ADJP inducible_JJ ] ,_,[NP we_PRP ][VP showed_VBD ][SBAR that_IN ][NP expression_NN ][PP of_IN ][NP mRNAs_NNS ][PP for_IN ][NP Fra-1_NN ] ,_,[NP c-Jun_NN ] ,_, and_CC[NP JunD_NN ][VP was_VBD also_RB transactivated_VBN ][PP by_IN ][NP Tax1_NN ] ._.
[ADVP Moreover_RB ] ,_,[NP Tax1_NN ][VP activated_VBD ][NP expression_NN ][PP of_IN ][NP two_CD other_JJ transcription_NN factors_NNS ][VP having_VBG ][NP zinc_NN finger_NN motifs_NNS ] ,_,[NP Egr-1_NN ] and_CC[NP Egr-2_NN ] ,_,[PP in_IN ][NP the_DT same_JJ cells_NNS ] ._.
[NP The_DT Tax1-inducible_JJ transcription_NN factors_NNS ][VP identified_VBN ][ADVP here_RB ][VP are_VBP encoded_VBN ][PP by_IN ][NP the_DT members_NNS ][PP of_IN ][NP immediate_JJ early_JJ genes_NNS ][PP under_IN ][NP the_DT control_NN ][PP of_IN ][NP growth_NN signals_NNS ] ._.
 Thus_RB ,_,[NP Tax1_NN ][VP was_VBD suggested_VBN to_TO replace_VB ][NP growth_NN signals_NNS ] ,_,[ADVP at_IN least_JJS ][PP in_IN ][NP part_NN ] ,_,[PP by_IN ][NP this_DT mechanism_NN ] ._.
[NP Contribution_NN ][PP of_IN ][NP NF-kappa_NN B_NN ] and_CC[NP Sp1_NN ][NP binding_NN motifs_NNS ][PP to_TO ][NP the_DT replicative_JJ capacity_NN ][PP of_IN ][NP human_JJ immunodeficiency_NN virus_NN type_NN 1_CD ] :_:[NP distinct_JJ patterns_NNS ][PP of_IN ][NP viral_JJ growth_NN ][VP are_VBP determined_VBN ][PP by_IN ][NP T-cell_NN types_NNS ] ._.
[VP Starting_VBG ][PP with_IN ][NP a_DT replication-incompetent_JJ molecular_JJ clone_NN ][PP of_IN ][NP human_JJ immunodeficiency_NN virus_NN type_NN 1_CD ] ,_,[VP lacking_VBG ] all_PDT the_DT[NP NF-kappa_NN B_NN ] and_CC[NP Sp1_NN ][NP binding_NN sites_NNS ][ADJP present_JJ ][PP in_IN ][NP the_DT native_JJ ][NP long_JJ terminal_JJ repeat_NN ] (_([NP LTR_NN ] )_) ,_,[NP proviruses_NNS ][VP containing_VBG ][NP reconstructed_VBN LTRs_NNS ][PP with_IN ][NP individual_JJ ] or_CC[NP combinations_NNS ][PP of_IN ][NP NF-kappa_NN B_NN ] and_CC[NP Sp1_NN ][NP elements_NNS ][VP were_VBD generated_VBN ] and_CC[VP evaluated_VBN ][PP for_IN ][NP their_PRP$ capacity_NN ][VP to_TO produce_VB ][NP virus_NN progeny_NN ][PP following_VBG ][NP transfection-cocultivation_NN ] ._.
[NP Virus_NN stocks_NNS ][VP obtained_VBN ][PP from_IN ][NP these_DT experiments_NNS ][VP exhibited_VBD ][NP a_DT continuum_NN ][PP of_IN ][NP replicative_JJ capacities_NNS ][PP in_IN ][NP different_JJ human_JJ T-cell_NN types_NNS ][PP depending_VBG ][PP on_IN ][NP which_WDT element_NN (_( s_NNS ] )_)[VP was_VBD ][ADJP present_JJ ][PP in_IN ][NP the_DT LTR_NN ] ._.
[PP For_IN ][NP example_NN ] ,_,[PP in_IN ][NP experiments_NNS ][VP involving_VBG ][NP proviral_JJ clones_NNS ][PP with_IN ][NP LTRs_NNS ][VP containing_VBG ][NP one_CD or_CC two_CD NF-kappa_NN B_NN elements_NNS ] (_( and_CC[NP no_DT Sp1_NN binding_NN sites_NNS ] )_) ,_,[NP a_DT hierarchy_NN ][PP of_IN ][NP cellular_JJ permissivity_NN ][PP to_TO ][NP virus_NN replication_NN ] (_([NP peripheral_JJ blood_NN lymphocytes_NNS ][VP =_JJ ][NP MT4_NN ][ADJP greater_JJR ][PP than_IN ][NP H9_NN ][ADJP greater_JJR ][PP than_IN ][NP CEM_NN ][ADJP greater_JJR ][PP than_IN ][NP Jurkat_NN ] )_)[VP was_VBD observed_VBN ] ._.
[PP Of_IN ][NP note_NN ][VP was_VBD ][NP the_DT associated_VBN emergence_NN ][PP of_IN ][NP second-site_JJ LTR_NN revertants_NNS ][NP which_WDT ][VP involved_VBD ][NP an_DT alteration_NN ][PP of_IN ][NP the_DT TATA_NN box_NN ] ._.
[NP These_DT results_NNS ][VP suggest_VBP ][SBAR that_IN ][NP the_DT human_JJ immunodeficiency_NN virus_NN type_NN 1_CD LTR_NN ][VP possesses_VBZ ][NP functional_JJ redundancy_NN ][NP which_WDT ][VP ensures_VBZ ][NP virus_NN replication_NN ][PP in_IN ][NP different_JJ T-cell_NN types_NNS ] and_CC[VP is_VBZ ][ADJP capable_JJ ][PP of_IN ][VP changing_VBG ][PP depending_VBG ][PP on_IN ][NP the_DT particular_JJ combination_NN ][PP of_IN ][NP transcriptional_JJ factors_NNS ][ADJP present_JJ ] ._.
[NP Enhancement_NN ][PP of_IN ][NP human_JJ immunodeficiency_NN virus_NN 1_CD replication_NN ][PP in_IN ][NP monocytes_NNS ][PP by_IN ][NP 1,25-dihydroxycholecalciferol_NN ] ._.
[NP Human_JJ immunodeficiency_NN virus_NN ] (_([NP HIV_NN ] )_)[NP expression_NN ] and_CC[NP replication_NN ][VP are_VBP ][PP under_IN ][NP tight_JJ regulatory_JJ control_NN ] ._.
[NP We_PRP ][VP demonstrate_VBP ][SBAR that_IN ][NP 1,25-dihydroxycholecalciferol_NN ] (_([NP 1,25-(OH)2D3_NN ] )_)[VP enhances_VBZ ][NP the_DT replication_NN ][PP of_IN ][NP monocyte-_NN ] and_CC[ADJP lymphocyte-tropic_JJ ][NP strains_NNS ][PP of_IN ][NP HIV-1_NN ][PP up_IN to_TO ][ADVP 10,000-fold_RB ][PP in_IN ][NP monocyte_NN cell_NN lines_NNS ] ,_,[NP peripheral_JJ blood_NN monocytes_NNS ] ,_, and_CC[NP unfractionated_JJ peripheral_JJ blood_NN mononuclear_JJ cells_NNS ] ._.
[NP 1,25(OH)2D3_NN ][VP is_VBZ ][ADVP therefore_RB ][NP one_CD ][PP of_IN ][NP the_DT most_RBS potent_JJ regulators_NNS ][PP of_IN ][NP HIV-1_NN replication_NN ][VP described_VBN ][PP to_TO ][NP date_NN ] ._.
[NP Precursors_NNS ][PP of_IN ][NP 1,25(OH)2D3_NN ][VP enhance_VBP ][NP HIV-1_NN replication_NN ][PP in_IN proportion_NN to_TO ][NP their_PRP$ affinity_NN ][PP for_IN ][NP the_DT 1,25(OH)2D3_NN intracellular_JJ receptor_NN ] ,_,[VP suggesting_VBG ][SBAR that_IN ][NP 1,25(OH)2D3_NN ][VP influences_VBZ ][NP HIV-1_NN replication_NN ][PP by_IN ][NP mechanisms_NNS ][VP involving_VBG ][NP this_DT receptor_NN ] ._.
[NP These_DT studies_NNS ][VP may_MD have_VB ][NP important_JJ implications_NNS ][PP for_IN ][NP the_DT design_NN ][PP of_IN ][NP effective_JJ therapy_NN ][PP of_IN ][NP HIV-1_NN infection_NN ] ._.
[NP Inhibition_NN ][PP of_IN ][NP HIV-1_NN replication_NN ] and_CC[NP NF-kappa_NN B_NN activity_NN ][PP by_IN ][NP cysteine_NN ] and_CC[NP cysteine_NN derivatives_NNS ] ._.
[NP HIV-1_NN proviral_JJ DNA_NN ][VP contains_VBZ ][NP two_CD binding_VBG sites_NNS ][PP for_IN ][NP the_DT transcription_NN factor_NN NF-kappa_NN B_NN ] ._.
[NP HIV-1-infected_JJ individuals_NNS ][VP have_VBP ] ,_,[PP on_IN ][NP average_NN ] ,_,[NP abnormally_RB high_JJ levels_NNS ][PP of_IN ][NP tumour_NN necrosis_NN factor_NN alpha_NN ] (_([NP TNF_NN alpha_NN ] )_) and_CC[NP abnormally_RB low_JJ plasma_NN cysteine_NN levels_NNS ] ._.
[NP We_PRP ][ADVP therefore_RB ][VP investigated_VBD ][NP the_DT effects_NNS ][PP of_IN ][NP cysteine_NN ] and_CC[NP related_JJ thiols_NNS ][PP on_IN ][NP HIV-1_NN replication_NN ] and_CC[NP NF-kappa_NN B_NN expression_NN ] ._.
[NP The_DT experiments_NNS ][PP in_IN ][NP this_DT report_NN ][VP show_VBP ][SBAR that_IN ][NP cysteine_NN ] or_CC[NP N-acetylcysteine_NN ] (_([NP NP_NN ] )_)[VP raise_VBP ][NP the_DT intracellular_JJ glutathione_NN (_( GSH_NN )_) level_NN ] and_CC[VP inhibit_VBP ][NP HIV-1_NN replication_NN ][PP in_IN ] persistently_RB infected_JJ[NP Molt-4_NN ] and_CC[NP U937_NN ][NP cells_NNS ] ._.
[ADVP However_RB ] ,_,[NP inhibition_NN ][PP of_IN ][NP HIV-1_NN replication_NN ][VP appears_VBZ not_RB to_TO be_VB directly_RB correlated_VBN ][PP with_IN ][NP GSH_NN levels_NNS ] ._.
[NP Cysteine_NN ] and_CC[NP NP_NN ][ADVP also_RB ][VP inhibit_VBP ][NP NF-kappa_NN B_NN activity_NN ][SBAR as_IN ][VP determined_VBN ][PP by_IN ][NP electrophoretic_JJ mobility_NN shift_NN assays_NNS ] and_CC[NP chloramphenicol_NN acetyl-transferase_NN ] (_([NP CAT_NN ] )_)[NP gene_NN expression_NN ][PP under_IN ][NP control_NN ][PP of_IN ][NP NF-kappa_NN B_NN binding_NN sites_NNS ][PP in_IN ][NP uninfected_JJ cells_NNS ] ._.
[NP This_DT ][VP suggests_VBZ ][SBAR that_IN ][NP the_DT cysteine_NN deficiency_NN ][PP in_IN ][NP HIV-1-infected_JJ individuals_NNS ][VP may_MD cause_VB ][NP an_DT over-expression_NN ][PP of_IN ][NP NF-kappa_NN B-dependent_JJ genes_NNS ] and_CC[VP enhance_VB ][NP HIV-1_NN replication_NN ] ._.
[NP NP_NN ][VP may_MD be_VB considered_VBN ][PP for_IN ][NP the_DT treatment_NN ][PP of_IN ][NP HIV-1-infected_JJ individuals_NNS ] ._.
[NP Glucocorticoid_NN receptors_NNS ][PP in_IN ][NP systemic_JJ lupus_NN erythematosus_NN ] ._.
[NP Glucocorticosteroids_NNS ][VP remain_VBP ][NP the_DT major_JJ treatment_NN modality_NN ][PP for_IN ][NP systemic_JJ lupus_NN erythematosus_NN ] (_([NP SLE_NN ] )_) ,_, but_CC[NP their_PRP$ mechanism_NN ][PP of_IN ][NP action_NN ][VP is_VBZ ][ADJP unclear_JJ ] ._.
[PP Over_IN ][NP the_DT past_JJ decade_NN ][NP it_PRP ][VP has_VBZ become_VBN ][ADJP clear_JJ ][SBAR that_IN ][NP glucocorticosteroid_NN receptors_NNS ][VP play_VBP ][NP a_DT significant_JJ role_NN ][PP in_IN ][NP the_DT mechanism_NN ][PP of_IN ][NP glucocorticosteroid_NN action_NN ] ._.
[NP We_PRP ][VP studied_VBD ][NP glucocorticosteroid_NN receptor_NN ][NP density_NN ] and_CC[NP affinity_NN ][PP on_IN ][NP peripheral_JJ blood_NN mononuclear_JJ cells_NNS ][PP by_IN ][NP the_DT glucocorticosteroid_NN binding_NN assay_NN ][PP in_IN ][NP 33_CD patients_NNS ][PP with_IN ][NP SLE_NN ][NP who_WP ][VP had_VBD taken_VBN ][NP no_DT glucocorticosteroid_NN ][PP for_IN ][NP the_DT previous_JJ 6_CD months_NNS ][PP and_CC ][PP in_IN ][NP 32_CD healthy_JJ controls_NNS ] ._.
[NP Patients_NNS ][NP '_POS disease_NN activity_NN ][VP was_VBD measured_VBN ][PP by_IN ][NP the_DT SLE_NN Disease_NN Activity_NN Index_NN ] (_([NP SLEDAI_NN ] )_) ._.
[NP Glucocorticosteroid_NN receptors_NNS ][PP on_IN ][NP leukocytes_NNS ][PP of_IN ][NP patients_NNS ][PP with_IN ] SLE_NN[VP were_VBD ][ADJP significantly_RB higher_JJR ][PP than_IN ][PP in_IN ][NP healthy_JJ controls_NNS ] (_([NP 4419_CD +/-_CC 306_CD ] vs_CC[NP 3369_CD +/-_CC 196_CD ] ,_,[NP p_NN ][ADJP less_JJR ][PP than_IN ][NP 0.005_CD ] )_) ._.
[NP The_DT binding_NN affinity_NN ][VP was_VBD ] not_RB[ADJP different_JJ ][PP between_IN ][NP patients_NNS ] and_CC[NP controls_NNS ] ._.
[NP There_EX ][VP was_VBD ][NP no_DT correlation_NN ][PP between_IN ][NP glucocorticosteroid_NN receptor_NN number_NN ] and_CC[NP SLE_NN disease_NN activity_NN ] ._.
 (_([NP Changes_NNS ][PP in_IN ][NP leucocytic_JJ estrogen_NN receptor_NN levels_NNS ][PP in_IN ][NP patients_NNS ][PP with_IN ][NP gynecomastia_NN ] )_)
[NP The_DT number_NN ][PP of_IN ][NP estrogen_NN receptor_NN ] (_([NP ER_NN ] )_)[PP in_IN ][NP human_JJ peripheral_JJ leucocytes_NNS ][PP in_IN ][NP 13_CD men_NNS ][PP with_IN ][NP gynecomastia_NNS ][VP were_VBD measured_VBN ][PP by_IN ][NP radioligand_NN binding_NN method_NN ] ._.
[NP The_DT results_NNS ][VP were_VBD compared_VBN ][PP with_IN ][NP those_DT ][PP of_IN ][NP 13_CD sex-_NN and_CC age-matched_JJ healthy_JJ subjects_NNS ] ._.
[NP It_PRP ][VP was_VBD found_VBN ][SBAR that_IN ][NP the_DT number_NN ][PP of_IN ][NP ER_NN ][PP in_IN ][NP leucocytes_NNS ][VP was_VBD significantly_RB increased_VBN ][PP in_IN ][NP gynecomastia_NN ] (_([NP Rs_NN ][PP of_IN ][NP leucocytes_NNS ][VP were_VBD ][NP 1054_CD +/-_CC 254_CD sites/cell_NN ] )_) ._.
[NP It_PRP ][VP suggested_VBD ][SBAR that_IN ][NP increase_NN ][PP of_IN ][NP ER_NN levels_NNS ][VP play_VBP ][NP an_DT important_JJ role_NN ][PP in_IN ][NP the_DT pathogenesis_NN ][PP of_IN ][NP gynecomastia_NN ] ._.
 (_([NP Changes_NNS ][PP in_IN ][NP levels_NNS ][PP of_IN ][NP leucocytic_JJ estrogen_NN receptor_NN ][PP in_IN ][NP patients_NNS ][PP with_IN ][NP menopausal_JJ type_NN II_CD diabetes_NNS ] and_CC[NP its_PRP$ significance_NN ] )_)
[NP The_DT number_NN ][PP of_IN ][NP estrogen_NN receptors_NNS ] (_([NP ER_NN ] )_)[PP in_IN ][NP human_JJ peripheral_JJ leucocytes_NNS ][PP in_IN ][NP 12_CD women_NNS ][PP with_IN ][NP menopausal_JJ type_NN II_CD diabetes_NNS ][VP was_VBD ][NP measured_VBN ][PP with_IN ][NP radio-ligand_JJ binding_NN method_NN ] ._.
[NP The_DT results_NNS ][VP were_VBD compared_VBN ][PP with_IN ][NP those_DT ][PP of_IN ][NP 12_CD menopausal_JJ women_NNS ][PP without_IN ][NP diabetes_NNS ] and_CC[NP 12_CD normal_JJ women_NNS ][PP of_IN ][NP childbearing_JJ age_NN ] ._.
[NP It_PRP ][VP was_VBD found_VBN ][SBAR that_IN ][NP the_DT number_NN ][PP of_IN ][NP ER_NN ][PP in_IN ][NP the_DT patients_NNS ][VP was_VBD significantly_RB decreased_VBN ] ._.
[NP Our_PRP$ data_NNS ][VP indicate_VBP ][SBAR that_IN ][NP decrease_NN ][PP of_IN ][NP ER_NN level_NN ][PP in_IN ][NP leukocytes_NNS ][VP may_MD be_VB ][ADJP related_JJ ][PP to_TO ][NP the_DT pathogenesis_NN ][PP of_IN ][NP type_NN II_CD diabetes_NNS ][PP in_IN ][NP menopausal_JJ period_NN ] ._.
[NP Lymphocyte_NN glucocorticoid_NN receptor_NN binding_NN ][PP during_IN ][NP depression_NN ][PP and_CC ][PP after_IN ][NP clinical_JJ recovery_NN ] ._.
[NP Lymphocyte_NN glucocorticoid_NN receptor_NN binding_NN parameters_NNS ][VP were_VBD studied_VBN ][PP in_IN ][NP 15_CD severely_RB depressed_JJ patients_NNS ][PP during_IN ][NP depression_NN ][PP and_CC ][PP after_IN ][NP clinical_JJ recovery_NN ] ,_, and_CC[PP in_IN ][NP 15_CD healthy_JJ controls_NNS ] ._.
[NP There_EX ][VP was_VBD ][NP no_DT difference_NN ][PP in_IN ][NP glucocorticoid_NN receptor_NN ][NP number_NN ] or_CC[NP affinity_NN ][PP between_IN ][NP depressed_JJ patients_NNS ] and_CC[NP recovered_JJ or_CC control_NN subjects_NNS ] ._.
 Afternoon_NN[NP ACTH_NN ] and_CC[NP cortisol_NN ][NP concentrations_NNS ][VP did_VBD not_RB differ_VB ][ADVP significantly_RB ][PP between_IN ][NP the_DT three_CD groups_NNS ] ._.
[NP No_DT relationship_NN ][VP could_MD be_VB established_VBN ][PP between_IN ][NP glucocorticoid_NN receptor_NN binding_NN ] and_CC[NP antidepressant_JJ medication_NN ] ._.
[NP These_DT data_NNS ][VP support_VBP ][NP the_DT view_NN ][PP of_IN ][NP an_DT impaired_JJ ligand-induced_JJ plasticity_NN ][PP of_IN ][NP glucocorticoid_NN receptor_NN regulation_NN ][CONJP rather_RB than_IN ][NP the_DT hypothesis_NN ][PP of_IN ][NP decreased_VBN glucocorticoid_NN receptor_NN numbers_NNS ][PP during_IN ][NP depression_NN ] ._.
[NP Nuclear_JJ association_NN ][PP of_IN ][NP a_DT T-cell_NN transcription_NN factor_NN ][VP blocked_VBN ][PP by_IN ][NP FK-506_NN ] and_CC[NP cyclosporin_NN A_NN ] (_([VP see_VB ][NP comments_NNS ] )_)
[NP Cyclosporin_NN A_NN ] and_CC[NP FK506_NN ][VP inhibit_VBP ] T-_NN and_CC[ADJP B-cell_NN ][NP activation_NN ] and_CC[NP other_JJ processes_NNS ][ADJP essential_JJ ][PP to_TO ][NP an_DT effective_JJ immune_JJ response_NN ] ._.
[PP In_IN ][NP T_NN lymphocytes_NNS ][NP these_DT drugs_NNS ][VP disrupt_VBP ][NP an_DT unknown_JJ step_NN ][PP in_IN ][NP the_DT transmission_NN ][PP of_IN ][NP signals_NNS ][PP from_IN ][NP the_DT T-cell_NN antigen_NN receptor_NN ][PP to_TO ][NP cytokine_NN genes_NNS ][NP that_WDT ][VP coordinate_VBP ][NP the_DT immune_JJ response_NN ] ._.
[NP The_DT putative_JJ intracellular_JJ receptors_NNS ][PP for_IN ][NP FK506_NN ] and_CC[NP cyclosporin_NN ][VP are_VBP ][NP cis-trans_JJ prolyl_JJ isomerases_NNS ] ._.
[NP Binding_NN ][PP of_IN ][NP the_DT drug_NN ][VP inhibits_VBZ ][NP isomerase_NN activity_NN ] ,_, but_CC[NP studies_NNS ][PP with_IN ][NP other_JJ prolyl_JJ isomerase_NN inhibitors_NNS ] and_CC[NP analysis_NN ][PP of_IN ][NP cyclosporin-resistant_JJ mutants_NNS ][PP in_IN ][NP yeast_NN ][VP suggest_VBP ][SBAR that_IN ][NP the_DT effects_NNS ][PP of_IN ][NP the_DT drug_NN ][VP result_VBP ][PP from_IN ][NP the_DT formation_NN ][PP of_IN ][NP an_DT inhibitory_JJ complex_NN ][PP between_IN ][NP the_DT drug_NN ] and_CC[NP isomerase_NN ][PP ,_, and_CC ][PP not_RB from_IN ][NP inhibition_NN ][PP of_IN ][NP isomerase_NN activity_NN ] ._.
[NP A_DT transcription_NN factor_NN ] ,_,[NP NF-AT_NN ] ,_,[NP which_WDT ][VP is_VBZ ][ADJP essential_JJ ][PP for_IN ][NP early_JJ T-cell_NN gene_NN activation_NN ] ,_,[VP seems_VBZ to_TO be_VB ][NP a_DT specific_JJ target_NN ][PP of_IN ][NP cyclosporin_NN A_NN ] and_CC[NP FK506_NN ][NP action_NN ][SBAR because_IN ][NP transcription_NN ][VP directed_VBN ][PP by_IN ][NP this_DT protein_NN ][VP is_VBZ blocked_VBN ][PP in_IN ][NP T_NN cells_NNS ][VP treated_VBN ][PP with_IN ][NP these_DT drugs_NNS ] ,_,[PP with_IN ][NP little_JJ or_CC no_DT effect_NN ][PP on_IN ][NP other_JJ transcription_NN factors_NNS ][PP such_JJ as_IN ][NP AP-1_NN ] and_CC[NP NF-kappa_NN B_NN ] ._.
[ADVP Here_RB ][NP we_PRP ][VP demonstrate_VBP ][SBAR that_IN ][NP NF-AT_NN ][VP is_VBZ formed_VBN ][ADVP when_WRB ][NP a_DT signal_NN ][PP from_IN ][NP the_DT antigen_NN receptor_NN ][VP induces_VBZ ][NP a_DT pre-existing_JJ cytoplasmic_JJ subunit_NN ][VP to_TO translocate_VB ][PP to_TO ][NP the_DT nucleus_NN ] and_CC[VP combine_VB ][PP with_IN ][NP a_DT newly_RB synthesized_VBN nuclear_JJ subunit_NN ][PP of_IN ][NP NF-AT_NN ] ._.
[NP FK506_NN ] and_CC[NP cyclosporin_NN A_NN ][VP block_VBP ][NP translocation_NN ][PP of_IN ][NP the_DT cytoplasmic_JJ component_NN ][PP without_IN ][VP affecting_VBG ][NP synthesis_NN ][PP of_IN ][NP the_DT nuclear_JJ subunit_NN ] ._.
[NP Regulation_NN ][PP of_IN ][NP M-CSF_NN expression_NN ][PP by_IN ][NP M-CSF_NN ] :_:[NP role_NN ][PP of_IN ][NP protein_NN kinase_NN C_NN ] and_CC[NP transcription_NN factor_NN NF_NN kappa_NN B_NN ] ._.
[NP Macrophage-colony-stimulating_JJ factor_NN ] (_([NP M-CSF_NN ] )_) ,_,[VP also_RB referred_VBN ][PP to_TO ][PP as_IN ][NP CSF-1_NN ] ,_,[VP regulates_VBZ ][NP the_DT ][NP survival_NN ] ,_,[NP growth_NN ] ,_,[NP differentiation_NN ] and_CC[NP functional_JJ activity_NN ][PP of_IN ][NP monocytes_NNS ][PP by_IN ][VP binding_VBG ][PP to_TO ][NP a_DT single_JJ class_NN ][PP of_IN ][NP high-affinity_JJ cell_NN surface_NN receptors_NNS ] ,_,[VP known_VBN to_TO be_VB ][NP the_DT product_NN ][PP of_IN ][NP the_DT c-fms_NN protooncogene_NN ] ._.
[NP The_DT detection_NN ][PP of_IN ] both_CC[NP M-CSF_NN ] and_CC[NP c-fms_NN ][NP expression_NN ][PP by_IN ][NP cells_NNS ][PP of_IN ][NP the_DT monocyte_NN lineage_NN ][VP has_VBZ suggested_VBN ][SBAR that_IN ][NP M-CSF_NN ][VP may_MD act_VB ][PP by_IN ][NP an_DT autocrine_JJ mechanism_NN ] ._.
[ADVP Interestingly_RB ] ,_,[NP it_PRP ][VP has_VBZ been_VBN shown_VBN ][SBAR that_IN ][NP M-CSF_NN ][VP can_MD induce_VB ][NP the_DT expression_NN ][PP of_IN ][NP its_PRP$ own_JJ gene_NN ] ._.
[SBAR Although_IN ][NP sensitivity_NN ][PP to_TO ][NP M-CSF_NN ][VP can_MD be_VB modulated_VBN ][PP by_IN ][NP regulation_NN ][PP of_IN ][NP receptor_NN ][NP expression_NN ] and_CC[NP function_NN ] ,_,[NP M-CSF_NN responsiveness_NN ][VP is_VBZ largely_RB determined_VBN ][PP at_IN ][NP a_DT postreceptor_NN level_NN ] ._.
[PP To_TO ][NP date_NN ] ,_,[NP little_JJ ][VP is_VBZ known_VBN ][PP about_IN ][NP the_DT intracellular_JJ pathway_NN ][PP of_IN ][NP M-CSF_NN signal_NN transduction_NN ] ._.
[NP We_PRP ][VP have_VBP therefore_RB investigated_VBN ][NP the_DT changes_NNS ][PP in_IN ][NP protein_NN kinase_NN C_NN ] (_([NP PKC_NN ] )_)[NP activity_NN ][PP upon_IN ][NP exposure_NN ][PP of_IN ][NP monocytes_NNS ][PP to_TO ][NP M-CSF_NN ] ._.
[NP We_PRP ][VP show_VBP ][SBAR that_IN ][NP M-CSF_NN ][VP activates_VBZ ] and_CC[VP translocates_VBZ ][NP PKC_NN ] ._.
[NP Inhibition_NN ][PP of_IN ][NP PKC_NN ][PP by_IN ][NP the_DT isoquinoline_NN derivative_JJ H7_NN ][VP abolishes_VBZ ][NP induction_NN ][PP of_IN ][NP M-CSF_NN ][PP by_IN ][NP M-CSF_NN ] ._.
[ADVP Furthermore_RB ] ,_,[NP activation_NN ][PP of_IN ][NP PKC_NN ][VP was_VBD ][ADJP pertussis-toxin-sensitive_JJ ] and_CC[VP was_VBD associated_VBN ][PP with_IN ][NP the_DT detection_NN ][PP of_IN ][NP an_DT NF_NN kappa_NN B_NN protein_NN ][PP in_IN ][NP nuclear_JJ extracts_NNS ][PP of_IN ][NP M-CSF-induced_JJ blood_NN monocytes_NNS ][PP but_CC ][PP not_RB in_IN ][NP monocytes_NNS ][VP exposed_VBN ][PP to_TO ][NP medium_NN treatment_NN ][ADVP only_RB ] ._.
[NP The_DT results_NNS ][VP suggest_VBP ][SBAR that_IN ][NP M-CSF_NN induction_NN ][PP of_IN ][NP M-CSF_NN ][VP involves_VBZ ][NP G_NN proteins_NNS ] ,_,[NP PKC_NN ] and_CC[NP NF_NN kappa_NN B_NN ] ._.
[NP NF-kappa_NN B_NN activation_NN ][PP by_IN ][NP tumor_NN necrosis_NN factor_NN alpha_NN ][PP in_IN ][NP the_DT Jurkat_NN T_NN cell_NN line_NN ][VP is_VBZ ][ADJP independent_JJ ][PP of_IN ][NP protein_NN kinase_NN A_NN ] ,_,[NP protein_NN kinase_NN C_NN ] ,_, and_CC[NP Ca(2+)-regulated_JJ kinases_NNS ] ._.
[NP NF-kappa_NN B_NN ][VP is_VBZ ][NP a_DT DNA-binding_JJ regulatory_JJ factor_NN ][ADJP able_JJ ][VP to_TO control_VB ][NP transcription_NN ][PP of_IN ][NP a_DT number_NN ][PP of_IN ][NP genes_NNS ] ,_,[PP including_VBG ][NP human_JJ immunodeficiency_NN virus_NN ] (_([NP HIV_NN ] )_)[NP genes_NNS ] ._.
[PP In_IN ][NP T_NN cells_NNS ] ,_,[NP NF-kappa_NN B_NN ][VP is_VBZ activated_VBN ][PP upon_IN ][NP cellular_JJ treatment_NN ][PP by_IN ][NP phorbol_NN esters_NNS ] and_CC[NP the_DT cytokine_NN ][NP tumor_NN necrosis_NN factor_NN alpha_NN ] (_([NP TNF_NN alpha_NN ] )_) ._.
[PP In_IN ][NP the_DT present_JJ work_NN ] ,_,[NP we_PRP ][VP investigated_VBD ][NP the_DT molecular_JJ events_NNS ][VP leading_VBG ][PP to_TO ][NP NF-kappa_NN B_NN activation_NN ][PP by_IN ][NP TNF_NN alpha_NN ][PP in_IN ][NP a_DT human_JJ T_NN cell_NN line_NN ] (_([NP Jurkat_NN ] )_) and_CC[NP its_PRP$ subclone_JJ JCT6_NN ] ,_,[NP which_WDT ][VP presents_VBZ ][NP a_DT deficiency_NN ][PP in_IN ][NP the_DT PKA_NN transduction_NN pathway_NN ] ._.
[NP We_PRP ][VP found_VBD ][SBAR that_IN ][PP in_IN ][NP both_DT cell_NN lines_NNS ] ,_, both_CC[NP phorbol_NN ester_NN ] and_CC[NP TNF_NN alpha_NN ][VP were_VBD ][ADJP able_JJ ][VP to_TO activate_VB ][NP NF-kappa_NN B_NN ] ._.
[NP Phorbol_NN activation_NN ][VP was_VBD positively_RB modulated_VBN ][PP by_IN ][NP Ca2+_NN influx_NN ][SBAR while_IN ][NP TNF_NN alpha_NN activation_NN ][VP was_VBD ] not_RB ._.
[ADVP Furthermore_RB ] ,_,[SBAR while_IN ][NP PMA_NN activation_NN ][VP was_VBD inhibited_VBN ][PP by_IN ][NP the_DT PKC_NN inhibitor_NN staurosporin_NN ] ,_,[NP the_DT TNF_NN alpha_NN effect_NN ][VP was_VBD ][ADJP unchanged_JJ ] ._.
[NP TNF_NN alpha_NN ][VP did_VBD not_RB activate_VB ][NP cAMP_NN production_NN ] and_CC[NP its_PRP$ signal_NN ][VP was_VBD not_RB modulated_VBN ][PP by_IN ][NP cAMP_NN activators_NNS ] ._.
[ADVP Moreover_RB ] ,_,[NP cAMP_NN activators_NNS ][VP did_VBD not_RB activate_VB ][NP NF-kappa_NN B_NN ][PP in_IN ][NP Jurkat_NN cells_NNS ] ._.
[ADVP Thus_RB ] ,_,[NP TNF_NN alpha-induced_JJ NF-kappa_NN B_NN activation_NN ][VP was_VBD found_VBN to_TO be_VB mediated_VBN ][PP by_IN ][NP none_NN ][PP of_IN ][NP the_DT major_JJ signal-mediating_JJ kinases_NNS ][PP such_JJ as_IN ][NP protein_NN kinase_NN C_NN ] (_([NP PKC_NN ] )_) ,_,[NP protein_NN kinase_NN A_NN ] ,_, or_CC[NP Ca(2+)-regulated_JJ kinases_NNS ] ._.
[ADVP Furthermore_RB ] ,_,[NP we_PRP ][VP found_VBD ][SBAR that_IN ][NP cytoplasmic_JJ acidification_NN ][VP facilitated_VBD ][NP NF-kappa_NN B_NN activation_NN ][PP by_IN ] both_CC[NP TNF_NN alpha_NN ] and_CC[NP PKC_NN ] ,_,[PP by_IN ][NP a_DT mechanism_NN ][NP that_WDT ][VP increases_VBZ ][NP NF-kappa_NN B/I_NN kappa_NN B_NN dissociation_NN ][PP without_IN ][VP affecting_VBG ][NP the_DT NF-kappa_NN B_NN translocation_NN step_NN ] ._.
[NP NF-kappa_NN B_NN activity_NN ][PP in_IN ][NP T_NN cells_NNS ][VP stably_RB expressing_VBG ][NP the_DT Tax_NN protein_NN ][PP of_IN ][NP human_JJ T_NN cell_NN lymphotropic_JJ virus_NN type_NN I_CD ] ._.
[NP The_DT effect_NN ][PP of_IN ][NP constitutive_JJ Tax_NN expression_NN ][PP on_IN ][NP the_DT interaction_NN ][PP of_IN ][NP NF-kappa_NN B_NN ][PP with_IN ][NP its_PRP$ recognition_NN sequence_NN ][PP and_CC ][PP on_IN ][NP NF-kappa_NN B-dependent_JJ gene_NN expression_NN ][VP was_VBD examined_VBN ][PP in_IN ][NP T_NN lymphoid_JJ Jurkat_NN cell_NN lines_NNS ] (_([NP 19D_NN ] and_CC[NP 9J_NN ] )_)[VP stably_RB transformed_VBN ][PP with_IN ][NP a_DT Tax_NN expression_NN vector_NN ] ._.
[NP Tax_NN expressing_NN T_NN cell_NN lines_NNS ][VP contained_VBD ][NP a_DT constitutive_JJ level_NN ][PP of_IN ][NP NF-kappa_NN B_NN binding_NN activity_NN ] ,_,[ADJP detectable_JJ ][PP by_IN ][NP mobility_NN shift_NN assay_NN ] and_CC[NP uv_NN cross-linking_NN ][VP using_VBG ][NP a_DT palindromic_JJ NF-kappa_NN B_NN probe_NN ][ADJP homologous_JJ ][PP to_TO ][NP the_DT interferon_NN beta_NN PRDII_NN site_NN ] ._.
[PP In_IN ][NP Jurkat_NN ] and_CC[NP NC2.10_NN ][NP induction_NN ][PP with_IN ][NP phorbol_NN esters_NNS ] resulted_VBD[PP in_IN ][NP the_DT appearance_NN ][PP of_IN ][NP new_JJ DNA_NN binding_NN proteins_NNS ][PP of_IN ][NP 85_CD ,_, 75_CD ,_, and_CC 54_CD kDa_NN ] ,_, whereas_IN[PP in_IN ][NP Tax_NN expressing_NN cells_NNS ][NP the_DT 85-kDa_JJ protein_NN ] and_CC[NP a_DT 92-kDa_JJ DNA_NN binding_NN protein_NN ][VP were_VBD constitutively_RB induced_VBN ] ._.
[NP Expression_NN ][PP of_IN ][NP Tax_NN protein_NN ][PP in_IN ][NP 19D_NN ] and_CC[NP 9J_NN ][VP resulted_VBD ][PP in_IN ][NP transcription_NN ][PP of_IN ][NP the_DT endogenous_JJ NF-kappa_NN B-dependent_JJ granulocyte-macrophage_JJ colony_NN stimulating_NN factor_NN gene_NN ] and_CC[NP increased_VBD basal_JJ level_NN expression_NN ][PP of_IN ][NP transfected_VBN NF-kappa_NN B-regulated_JJ promoters_NNS ] ._.
[ADVP Nonetheless_RB ][NP transcription_NN ][PP of_IN ] both_CC[NP the_DT endogenous_JJ ] and_CC[NP the_DT transfected_VBN ][NP gene_NN ][VP was_VBD ][ADJP inducible_JJ ][PP by_IN ][NP PMA_NN treatment_NN ] ._.
[NP Tax_NN expression_NN ][PP in_IN ][NP Jurkat_NN T_NN cells_NNS ][VP may_MD alter_VB ][NP the_DT stoichiometry_NN ][PP of_IN ][NP NF-kappa_NN B_NN DNA_NN binding_NN proteins_NNS ] and_CC thus_RB[VP change_VB ][NP the_DT expression_NN ][PP of_IN ][NP NF-kappa_NN B-regulated_JJ promoters_NNS ] ._.
[NP Regulation_NN ][PP of_IN ][NP glucocorticoid_NN receptors_NNS ][PP in_IN ][NP human_JJ mononuclear_JJ cells_NNS ] :_:[NP effects_NNS ][PP of_IN ][NP glucocorticoid_NN treatment_NN ] ,_,[NP Cushing_NN ][NP 's_POS disease_NN ] and_CC[NP ketoconazole_NN ] ._.
[NP Glucocorticoid_NN receptors_NNS ] (_([NP GcR_NN ] )_)[VP were_VBD determined_VBN ][PP by_IN ][NP a_DT whole_JJ cell_NN assay_NN ][PP in_IN ][NP human_JJ mononulear_JJ leukocytes_NNS ] (_([NP hMNL_NN ] )_)[PP from_IN ][NP control_NN subjects_NNS ] ,_,[NP patients_NNS ][VP receiving_VBG ][NP glucocorticoid_NN therapy_NN ][PP for_IN ][NP systemic_JJ diseases_NNS ] and_CC[NP Cushing_NN ][NP 's_POS disease_NN ][NP patients_NNS ][PP with_IN ][PP or_CC ][PP without_IN ][NP ketoconazole_NN therapy_NN ] ._.
[NP Prolonged_JJ corticosteroid_NN treatment_NN ][VP resulted_VBD ][PP in_IN ][NP down-regulation_NN ][PP of_IN ][NP GcR_NN ] ,_,[SBAR while_IN ][NP the_DT mean_NN level_NN ][PP of_IN ][NP GcR_NN ][PP in_IN ][NP Cushing_NN ][NP 's_POS disease_NN ][VP was_VBD ][ADJP normal_JJ ] ._.
[PP In_IN ][NP this_DT group_NN ] ,_,[ADVP however_RB ] ,_,[NP receptor_NN levels_NNS ] and_CC[NP morning_NN plasma_NN cortisol_NN values_NNS ][VP showed_VBD ][NP a_DT negative_JJ correlation_NN ] ,_,[VP indicating_VBG ][NP a_DT subtle_JJ down-regulatory_JJ effect_NN ] ._.
[ADVP Furthermore_RB ] ,_,[NP GcR_NN ][VP were_VBD ][ADJP unaltered_JJ ][SBAR after_IN ][NP these_DT patients_NNS ][VP received_VBD ][NP ketoconazole_NN ] ,_,[PP in_IN spite_NN of_IN ][NP a_DT marked_JJ reduction_NN ][PP in_IN ][NP morning_NN plasma_NN cortisol_NN ] and_CC[NP urinary_JJ free_JJ cortisol_NN ] ._.
[NP We_PRP ][ADVP also_RB ][VP observed_VBD ][SBAR that_IN ][NP ketoconazole_NN ][VP was_VBD ][NP a_DT weak_JJ competitor_NN ][PP of_IN ][NP GcR_NN ][PP in_IN ][NP intact_JJ cells_NNS ] ,_,[SBAR although_IN ][NP it_PRP ][ADVP significantly_RB ][VP inhibited_VBD ][NP (3H)_NN dexamethasone_NN binding_NN ][PP in_IN ][NP cytosolic_JJ preparations_NNS ][PP from_IN ][NP rat_NN tissues_NNS ] ._.
[NP The_DT results_NNS ][VP suggested_VBD ][SBAR that_IN ][NP GcR_NN ][PP in_IN ][NP hMNL_NN ][VP are_VBP down-regulated_VBN ][PP by_IN ][NP synthetic_JJ steroids_NNS ][VP given_VBN ][ADVP in_FW vivo_FW ] ,_, but_CC[NP they_PRP ][VP showed_VBD ][NP very_RB mild_JJ down-regulation_NN ][PP in_IN ][NP hypercortisolemic_JJ patients_NNS ][VP suffering_VBG ][PP from_IN ][NP Cushing_NN ][NP 's_POS disease_NN ] ._.
[ADVP Finally_RB ] ,_,[NP we_PRP ][VP did_VBD not_RB observed_VBN ] either_CC[NP up-regulation_NN ] or_CC[NP antagonism_NN ][PP of_IN ][NP GcR_NN ][PP by_IN ][NP ketoconazole_NN treatment_NN ] ,_,[PP at_IN ][NP the_DT time_NN ][ADVP that_IN ][NP cortisol_NN levels_NNS ][PP of_IN ][NP patients_NNS ][PP with_IN ][NP Cushing_NN ][NP 's_POS disease_NN ][VP were_VBD reduced_VBN ] ._.
[NP This_DT ][VP indicates_VBZ ][SBAR that_IN ][NP the_DT beneficial_JJ effects_NNS ][PP of_IN ][NP ketoconazole_NN ][PP in_IN ][NP Cushing_NN ][NP 's_POS disease_NN ][VP are_VBP ][PP due_JJ ][PP to_TO ][NP adrenal_JJ cortisol_NN suppression_NN ][PP and_CC ][PP not_RB to_TO ][NP interaction_NN ][PP with_IN ][NP GcR_NN ][PP of_IN ][NP target_NN cells_NNS ] ,_, and_CC[SBAR that_IN ][NP the_DT process_NN ][PP of_IN ][NP GcR_NN regulation_NN ][PP in_IN ][NP hMNL_NN ][VP is_VBZ ][NP a_DT complex_JJ phenomenon_NN ][VP awaiting_VBG ][NP further_RBR elucidation_NN ] ._.
[NP Glucocorticoid_NN receptors_NNS ][PP in_IN ][NP lymphocytes_NNS ][PP in_IN ][NP anorexia_NN nervosa_NN ] ._.
[NP OBJECTIVE_NN ] :_:[NP The_DT aim_NN ][VP was_VBD ][VP to_TO explore_VB ][NP the_DT down-regulation_NN ][PP of_IN ][NP the_DT glucocorticoid_NN receptors_NNS ][PP during_IN ][NP hypercortisolaemia_NN ][PP in_IN ][NP anorexia_NN nervosa_NN ] ._.
[NP DESIGN_NN ] :_:[NP Urine_NN ] and_CC[NP plasma_NN ][NP samples_NNS ][VP were_VBD obtained_VBN ][PP for_IN ][NP cortisol_NN determination_NN ] and_CC[NP blood_NN lymphocytes_NNS ][VP were_VBD isolated_VBN ][PP for_IN ][NP receptor_NN binding_NN studies_NNS ] ._.
[NP PATIENTS_NNS ] :_:[NP Sixteen_CD anorexic_JJ patients_NNS ] ,_,[ADJP aged_JJ ][NP 16-27_CD years_NNS ] ,_,[PP with_IN ][NP a_DT mean_NN +/-_CC SEM_NN body_NN mass_NN index_NN ][PP of_IN ][NP 14.2_CD +/-_CC 2.0_CD ] (_([VP ranging_VBG ][PP from_IN ][NP 11.1_CD ][PP to_TO ][NP 17.4_CD ] )_) ,_, and_CC[NP 15_CD normal_JJ women_NNS ][VP were_VBD studied_VBN ] ._.
[NP Six_CD patients_NNS ][VP were_VBD reinvestigated_VBN ][PP after_IN ][NP a_DT significant_JJ weight_NN gain_NN ] ._.
[NP MEASUREMENTS_NNS ] :_:[NP The_DT ][NP binding_NN ][NP capacity_NN ] and_CC[NP affinity_NN ][PP of_IN ][NP the_DT glucocorticoid_NN receptors_NNS ][VP were_VBD measured_VBN ][PP with_IN ][NP dexamethasone_NN ][PP as_IN ][NP ligand_NN ][PP on_IN ][NP lymphocytes_NNS ] ._.
[NP RESULTS_NNS ] :_:[PP In_IN ][NP patients_NNS ] ,_,[NP both_DT total_JJ and_CC free_JJ plasma_NN cortisol_NN concentrations_NNS ][VP were_VBD ][ADJP higher_JJR ][PP than_IN ][PP in_IN ][NP the_DT normal_JJ women_NNS ] ,_,[SBAR as_IN ] was_VBD[NP their_PRP$ urinary_JJ free_JJ cortisol_NN ] ;_:[NP the_DT number_NN ][PP of_IN ][NP glucocorticoid_NN receptors_NNS ][PP per_IN ][NP cell_NN ] (_([NP Ro_NN ] )_) and_CC[NP the_DT binding_NN affinity_NN ] (_([NP Kd_NN ] )_)[PP for_IN ][NP dexamethasone_NN ][VP were_VBD ] ,_,[ADVP however_RB ] ,_,[ADJP not_RB significantly_RB different_JJ ] (_([NP Ro_NN ] :_:[NP 7687_CD +/-_CC 1750_CD vs_CC 7347_CD +/-_CC 1285_CD sites/cell_NN ] ;_:[NP Kd_NN ] :_:[NP 7.7_CD +/-_CC 2.4_CD vs_CC 7.4_CD +/-_CC 1.7_CD nM_NN ][PP at_IN ][NP 24_CD degrees_NNS C_NN ] )_) ._.
[PP After_IN ][NP weight_NN gain_NN ] (_([NP 14_CD +/-_CC 2_CD to_TO 16_CD +/-_CC 2_CD kg/m2_NN ] )_) ,_,[NP receptor_NN numbers_NNS ][VP were_VBD ][NP 8421_CD +/-_CC 2126_CD ] (_( pre_JJ|RB )_) and_CC[NP 9011_CD +/-_CC 500_CD ] (_( post_JJ|RB )_)[NP sites/cell_NN ] ,_,[NP which_WDT ][VP are_VBP ] not_RB[ADJP significantly_RB different_JJ ] (_([NP P_NN ][ADJP greater_JJR ][PP than_IN ][NP 0.2_CD ] )_) ;_:[NP the_DT Kd_NN ][VP was_VBD ][ADJP unchanged_JJ ] (_([NP 9.3_CD +/-_CC 2.6_CD vs_CC 9.2_CD +/-_CC 2.4_CD nM_NN ] )_) ._.
[NP CONCLUSIONS_NNS ][NP Hypercortisolaemia_NN ][VP does_VBZ not_RB down-regulate_VB ][NP the_DT lymphocyte_NN glucocorticoid_NN receptors_NNS ][PP in_IN ][NP anorexia_NN nervosa_NN ] and_CC[NP a_DT post-receptor_JJ defect_NN ][VP might_MD be_VB involved_VBN ][PP in_IN ][NP peripheral_JJ tissue_NN resistance_NN ][PP to_TO ][NP the_DT effects_NNS ][PP of_IN ][NP glucocorticoid_NN hormones_NNS ][PP in_IN ][NP undernutrition_NN ] ._.
[NP Tumor_NN necrosis_NN factor-alpha_NN mRNA_NN accumulation_NN ][PP in_IN ][NP human_JJ myelomonocytic_JJ cell_NN lines_NNS ] ._.
[NP Role_NN ][PP of_IN ][NP transcriptional_JJ regulation_NN ][PP by_IN ][NP DNA_NN sequence_NN motifs_NNS ] and_CC[NP mRNA_NN stabilization_NN ] ._.
[NP The_DT cytokine_NN TNF_NN ][VP mediates_VBZ ][NP many_JJ ][PP of_IN ][NP the_DT pathologic_JJ signs_NNS ][PP of_IN ][NP cachexia_NN ] ,_,[NP inflammation_NN ] ,_, and_CC[NP sepsis_NN ] ._.
[NP The_DT current_JJ work_NN ][VP describes_VBZ ][NP the_DT regulation_NN ][PP of_IN ][NP TNF_NN ][PP in_IN ][NP human_JJ myelomonocytic_JJ cell_NN lines_NNS ][PP after_IN ][NP PMA_NN stimulation_NN ] ._.
[NP The_DT cell_NN lines_NNS ][VP exhibit_VBP ][NP a_DT low_JJ level_NN ][PP of_IN ][NP constitutive_JJ TNF_NN mRNA_NN expression_NN ] ._.
[PP Within_IN ][NP 2_CD to_TO 4_CD h_NN ][PP of_IN ][NP PMA_NN exposure_NN ] ,_,[NP steady_JJ state_NN levels_NNS ][PP of_IN ][NP TNF_NN mRNA_NN ][VP are_VBP markedly_RB elevated_JJ ][PP in_IN ][NP all_DT myelomonocytic_JJ cell_NN lines_NNS ][VP studied_VBN ] ._.
[NP This_DT rise_NN ][VP is_VBZ ][PP due_JJ ][PP to_TO ][NP increased_VBN mRNA_NN stability_NN ] ,_,[NP which_WDT ][VP increased_VBD ][PP by_IN ][NP almost_RB twofold_RB ][PP ,_, and_CC ][PP to_TO ][NP an_DT overall_JJ increase_NN ][PP in_IN ][NP transcription_NN ] ,_,[NP which_WDT ][VP rises_VBZ ][PP by_IN ][NP more_JJR than_IN sixfold_RB ] ._.
[PP At_IN ][NP the_DT level_NN ][PP of_IN ][NP the_DT genomic_JJ TNF_NN gene_NN ] ,_,[NP a_DT DNase_NN I_CD hypersensitive_JJ site_NN ][VP is_VBZ detected_VBN ][PP within_IN ][NP the_DT TNF_NN promoter_NN ][PP between_IN ][NP -200_CD to_TO -100_CD bp_NN ][PP relative_JJ to_TO ][NP the_DT transcription_NN initiation_NN site_NN ] ._.
[SBAR Although_IN ][ADJP absent_JJ ][PP in_IN ][NP nonexpressing_VBG erythroleukemia_NN cell_NN lines_NNS ] ,_,[NP the_DT DNase_NN I_CD site_NN ][VP is_VBZ ][ADJP present_JJ ][PP in_IN ][NP uninduced_JJ myelomonocytic_JJ cell_NN lines_NNS ] and_CC[VP is_VBZ not_RB changed_VBN ][PP after_IN ][NP PMA_NN induction_NN ] ._.
[NP The_DT PMA_NN induction_NN ][PP of_IN ][NP c-fos_NN mRNA_NN ][VP correlated_VBD ][ADVP well_RB ][PP with_IN ][NP TNF_NN gene_NN induction_NN ] ;_:[NP expression_NN ][PP of_IN ][NP genes_NNS ][VP encoding_VBG ][NP other_JJ proteins_NNS ][PP in_IN ][NP the_DT AP-1_NN complex_NN ] (_([NP junB_NN ] and_CC[NP junD_NN ] )_)[VP were_VBD also_RB induced_VBN ][PP by_IN ][NP PMA_NN ] ._.
[NP The_DT nuclear_JJ extracts_NNS ][PP from_IN ][NP resting_VBG and_CC induced_VBN ML-1_NN cells_NNS ][VP contain_VBP ][NP proteins_NNS ][VP binding_VBG ][ADVP specifically_RB ][PP to_TO ][NP the_DT ][NP AP-1_NN ] ,_,[NP AP-2_NN ] ,_, and_CC[NP NF_NN kappa_NN B_NN sequence_NN ][ADJP located_JJ ][PP within_IN ][NP the_DT TNF_NN promoter_NN ] ._.
[NP PMA_NN induction_NN ][VP increases_VBZ ][NP the_DT level_NN ][PP of_IN ][NP a_DT number_NN ][PP of_IN ][NP specific_JJ binding_VBG complexes_NNS ][PP relative_JJ to_TO ][NP the_DT resting_VBG cells_NNS ] ._.
[NP The_DT regulatory_JJ mechanisms_NNS ][PP of_IN ][NP the_DT human_JJ and_CC murine_JJ TNF_NN genes_NNS ][VP are_VBP discussed_VBN ] ._.
[NP USF-related_JJ transcription_NN factor_NN ] ,_,[NP HIV-TF1_NN ] ,_,[VP stimulates_VBZ ][NP transcription_NN ][PP of_IN ][NP human_JJ immunodeficiency_NN virus-1_NN ] ._.
[NP The_DT transcription_NN factor_NN HIV-TF1_NN ] ,_,[NP which_WDT ][VP binds_VBZ ][PP to_TO ][NP a_DT region_NN ][NP about_IN 60_CD bp_NN ][ADJP upstream_JJ ][PP from_IN ][NP the_DT enhancer_NN ][PP of_IN ][NP the_DT human_JJ immunodeficiency_NN virus-1_NN ] (_([NP HIV-1_NN ] )_) ,_,[VP was_VBD purified_VBN ][PP from_IN ][NP human_JJ B_NN cells_NNS ] ._.
[NP HIV-TF1_NN ][VP had_VBD ][NP a_DT molecular_JJ weight_NN ][PP of_IN ][NP 39,000_CD ] ._.
[NP Binding_NN ][PP of_IN ][NP HIV-TF1_NN ][PP to_TO ][NP the_DT HIV_NN ][NP long_JJ terminal_JJ repeat_NN ] (_([NP LTR_NN ] )_)[VP activated_VBD ][NP transcription_NN ][PP from_IN ][NP the_DT HIV_NN promoter_NN ][ADVP in_FW vitro_FW ] ._.
[NP The_DT HIV-TF1-binding_JJ site_NN ][PP in_IN ][NP HIV_NN LTR_NN ][VP was_VBD ][ADJP similar_JJ ][PP to_TO ][NP the_DT site_NN ][VP recognized_VBN ][PP by_IN ][NP upstream_JJ stimulatory_JJ factor_NN ] (_([NP USF_NN ] )_)[PP in_IN ][NP the_DT adenovirus_NN major_JJ late_JJ promoter_NN ] ._.
[NP DNA-binding_JJ properties_NNS ][PP of_IN ][NP HIV-TF1_NN ][VP suggested_VBD ][SBAR that_IN ][NP HIV-TF1_NN ][VP might_MD be_VB ][ADJP identical_JJ ] or_CC[ADJP related_JJ ][PP to_TO ][NP USF_NN ] ._.
[ADVP Interestingly_RB ] ,_,[NP treatment_NN ][PP of_IN ][NP purified_VBN HIV-TF1_NN ][PP by_IN ][NP phosphatase_NN ][ADVP greatly_RB ][VP reduced_VBD ][NP its_PRP$ DNA-binding_JJ activity_NN ] ,_,[VP suggesting_VBG ][SBAR that_IN ][NP phosphorylation_NN ][PP of_IN ][NP HIV-TF1_NN ][VP was_VBD ][ADJP essential_JJ ][PP for_IN ][NP DNA_NN binding_NN ] ._.
[NP The_DT disruption_NN ][PP of_IN ][NP HIV-TF1-binding_JJ site_NN ][VP induced_VBD ][NP a_DT ][NP 60_CD %_NN ][NP decrease_NN ][PP in_IN ][NP the_DT level_NN ][PP of_IN ][NP transcription_NN ][PP from_IN ][NP the_DT HIV_NN promoter_NN ][ADVP in_FW vivo_FW ] ._.
[NP These_DT results_NNS ][VP suggest_VBP ][SBAR that_IN ][NP HIV-TF1_NN ][VP is_VBZ involved_VBN ][PP in_IN ][NP transcriptional_JJ regulation_NN ][PP of_IN ][NP HIV-1_NN ] ._.
[NP The_DT effect_NN ][PP of_IN ][NP toremifene_NN therapy_NN ][PP on_IN ][NP serum_NN immunoglobulin_NN levels_NNS ][PP in_IN ][NP breast_NN cancer_NN ] ._.
[NP Estrogens_NNS ] and_CC[NP anti-estrogens_NNS ][VP enhance_VBP ][NP the_DT number_NN ][PP of_IN ][NP immunoglobulin_NN (_( Ig_NN )_) -secreting_NN cells_NNS ][PP in_IN ][NP pokeweed_NN mitogen_NN (_( PWM_NN )_) -stimulated_JJ lymphocyte_NN cultures_NNS ] ._.
[NP Lymphocytes_NNS ][PP from_IN ][NP patients_NNS ][NP who_WP ][VP have_VBP received_VBN ][NP anti-estrogen_NN therapy_NN ][VP show_VBP ][NP similar_JJ enhancement_NN ][PP of_IN ][NP Ig-secreting_JJ cells_NNS ][PP after_IN ][NP PWM_NN stimulation_NN ] ._.
[PP In_IN ][NP this_DT study_NN ][NP the_DT effect_NN ][PP of_IN ][NP anti-estrogen_NN (_( toremifene_NN )_) therapy_NN ][PP on_IN ][NP serum_NN immunoglobulin_NN ] (_([NP IgA_NN ] ,_,[NP IgM_NN ] ,_,[NP IgG_NN ] )_)[NP levels_NNS ][PP in_IN ][NP breast_NN cancer_NN patients_NNS ][VP was_VBD investigated_VBN ] ._.
[NP Serum_NN Ig_NN levels_NNS ][VP were_VBD followed_VBN ][NP up_RB to_TO two_CD years_NNS ][PP after_IN ][PP or_CC ][PP during_IN ][NP the_DT therapy_NN ] ._.
[NP An_DT unexpected_JJ finding_NN ][VP was_VBD ][SBAR that_IN ][NP the_DT Ig_NN levels_NNS ][VP decreased_VBD ][PP during_IN ][NP the_DT follow-up_JJ period_NN ] ._.
[NP This_DT decrease_NN ][VP was_VBD seen_VBN ][PP in_IN ][NP patients_NNS ][NP who_WP ][VP responded_VBD ][PP to_TO ][NP the_DT therapy_NN ][CONJP as_RB well_RB as_IN ][PP in_IN ][NP those_DT ][NP who_WP ][VP did_VBD ] not_RB ._.
[NP HIV1_NN infection_NN ][PP of_IN ][NP human_JJ ][NP monocytes_NNS ] and_CC[NP macrophages_NNS ][VP promotes_VBZ ][NP induction_NN ] or_CC[NP translocation_NN ][PP of_IN ][NP NF-KB-related_JJ factors_NNS ] ._.
[PP In_IN ][NP 1991_CD ] ,_,[NP we_PRP ][VP demonstrated_VBD ] ,_,[VP using_VBG ][NP electrophoretic_JJ mobility_NN shift_NN assays_NNS ] ,_,[SBAR that_IN ][NP 3_CD different_JJ factors_NNS ] (_([VP termed_VBN ][NP B1_NN ] ,_,[NP B2_NN ] and_CC[NP B3_NN ] )_)[PP with_IN ][NP affinity_NN ][PP for_IN ][NP the_DT KB-enhancer_JJ|NN target_NN sequence_NN ][VP were_VBD specifically_RB detected_VBN ][PP in_IN ][NP nuclear_JJ extracts_NNS ][PP from_IN ][NP HIV1-infected_JJ ][NP monocytes_NNS ] and_CC[NP macrophages_NNS ] ._.
[NP The_DT B2_NN factor_NN ][VP was_VBD induced_VBN ][PP in_IN ][NP the_DT nuclei_NNS ][PP of_IN ][NP these_DT cells_NNS ][PP only_RB upon_IN ][NP HIV1_NN infection_NN ] ._.
[NP The_DT B3_NN factor_NN ][VP was_VBD ][ADJP only_RB slightly_RB evident_JJ ][PP in_IN ][NP nuclei_NNS ][PP of_IN ][NP uninfected_JJ cells_NNS ] but_CC[VP was_VBD ][ADJP readily_RB detectable_JJ ][PP in_IN ][NP nuclei_NNS ][PP of_IN ][NP infected_JJ monocytes_NNS ] ._.
[NP Its_PRP$ expression_NN ][VP remained_VBD ][ADJP very_RB low_JJ ][PP in_IN ][NP nuclei_NNS ][PP of_IN ][NP HIV1-infected_JJ macrophages_NNS ] ._.
[PP In_IN ][NP this_DT paper_NN ] ,_,[NP we_PRP ][VP demonstrate_VBP ][SBAR that_IN ][NP the_DT B2_NN factor_NN ][VP is_VBZ expressed_VBN ][PP in_IN ][NP the_DT cytosol_NN ][PP of_IN ][NP monocytes_NNS ] and_CC[NP macrophages_NNS ][PP as_IN ][NP a_DT DNA-binding_JJ protein_NN ] ,_,[VP indicating_VBG ][SBAR that_IN ][NP it_PRP ][VP is_VBZ not_RB associated_VBN ][PP with_IN ][NP an_DT inhibitor_NN ] (_([NP IKB_NN ] )_) ._.
[NP This_DT factor_NN ][VP remained_VBD ][ADJP clustered_VBN ][PP in_IN ][NP the_DT cytosol_NN ] and_CC[VP was_VBD translocated_VBN ][PP to_TO ][NP the_DT nuclei_NNS ][PP only_RB after_IN ][NP HIV1_NN infection_NN ] ._.
[NP The_DT B3_NN factor_NN ][VP is_VBZ detected_VBN ][PP in_IN ][NP the_DT cytosol_NN ] only_RB[ADVP when_WRB ][NP cells_NNS ][VP are_VBP ][ADJP HIV1-infected_JJ ] ._.
[NP The_DT role_NN ][PP of_IN ][NP HIV1_NN infection_NN ][PP in_IN ][NP the_DT expression_NN ] and_CC[NP the_DT translocation_NN ][PP of_IN ][NP these_DT factors_NNS ][VP is_VBZ discussed_VBN ] ._.
[NP Induction_NN ][PP of_IN ][NP NF-kappa_NN B_NN ][PP during_IN ][NP monocyte_NN differentiation_NN ][VP is_VBZ associated_VBN ][PP with_IN ][NP activation_NN ][PP of_IN ][NP HIV-gene_JJ expression_NN ] ._.
[NP Cells_NNS ][PP of_IN ][NP the_DT monocyte-macrophage_JJ lineage_NN ][VP are_VBP ][NP important_JJ targets_NNS ][PP of_IN ][NP HIV_NN infection_NN ] ._.
[NP We_PRP ][VP report_VBP ][ADVP here_RB ][SBAR that_IN ][NP the_DT phenotypic_JJ differentiation_NN ][PP of_IN ][NP monocyte_NN cell_NN lines_NNS ][VP induced_VBN ][PP by_IN ][NP phorbol_NN esters_NNS ] or_CC[NP tumour_NN necrosis_NN factor_NN alpha_NN ] (_([NP TNF_NN alpha_NN ] )_)[VP is_VBZ associated_VBN ][PP with_IN ][NP expression_NN ][PP of_IN ][NP nuclear_JJ factor_NN kappa_NN B_NN ] (_([NP NF-kappa_NN B_NN ] )_) ._.
[PP In_IN parallel_NN with_IN ][NP such_JJ differentiation_NN ] ,_,[NP HIV_NN transcription_NN ] ,_,[VP monitored_VBN ][VP using_VBG ][NP an_DT HIV_NN long_JJ terminal_JJ repeat_NN reporter_NN gene_NN construct_NN ] ,_,[VP is_VBZ activated_VBN ][PP in_IN ][NP such_JJ cells_NNS ][PP under_IN ][NP the_DT influence_NN ][PP of_IN ][NP enhanced_VBN NF-kappa_NN B_NN expression_NN ] ._.
[ADVP Also_RB ] ,_,[PP in_IN ][NP a_DT promonocyte_JJ cell_NN line_NN ][ADJP chronically_RB infected_VBN ][PP with_IN ][NP HIV_NN ] ,_,[NP NF-kappa_NN B_NN expression_NN ] and_CC[NP HIV_NN transcription_NN ][VP were_VBD enhanced_VBN ][PP on_IN ][NP stimulation_NN ][PP with_IN ][NP phorbol_NN ester_NN ] or_CC[NP TNF_NN alpha_NN ] ._.
[ADVP Thus_RB ] ,_,[NP stimulation_NN ][PP of_IN ][NP monocyte_NN cell_NN lines_NNS ][PP by_IN ][NP phorbol_NN esters_NNS ] or_CC[NP TNF_NN alpha_NN ][VP induces_VBZ ][NP cell_NN differentiation_NN ] and_CC[VP activates_VBZ ][NP HIV_NN transcription_NN ] ._.
[NP Such_PDT a_DT process_NN ][VP may_MD have_VB ][NP fundamental_JJ implications_NNS ][PP in_IN ][NP AIDS_NN pathogenesis_NN ][ADVP in_FW vivo_FW ] and_CC[VP may_MD be_VB ][ADJP important_JJ ][PP in_IN ][NP disease_NN progression_NN ][VP induced_VBN ][PP by_IN ][NP opportunistic_JJ infections_NNS ][ADVP directly_RB ] or_CC[ADVP indirectly_RB ][VP involving_VBG ][NP macrophages_NNS ] ._.
[NP A_DT nuclear_JJ factor_NN NF-GM2_NN ][NP that_WDT ][VP interacts_VBZ ][PP with_IN ][NP a_DT regulatory_JJ region_NN ][PP of_IN ][NP the_DT GM-CSF_NN gene_NN ][ADJP essential_JJ ][PP for_IN ][NP its_PRP$ induction_NN ][PP in_IN responses_NNS to_TO ][NP T-cell_NN activation_NN ] :_:[NP purification_NN ][PP from_IN ][NP human_JJ T-cell_NN leukemia_NN line_NN Jurkat_NN cells_NNS ] and_CC[NP similarity_NN ][PP to_TO ][NP NF-kappa_NN B_NN ] ._.
[NP Activation_NN ][PP of_IN ][NP T_NN cells_NNS ][PP by_IN ][NP antigen_NN ] ,_,[NP lectin_NN ] ,_, or_CC[NP a_DT combination_NN ][PP of_IN ][NP phorbol-12-myristate_NN acetate_NN ] (_([NP PMA_NN ] )_) and_CC[NP calcium_NN ionophore_NN ] (_([NP A23187_NN ] )_)[VP leads_VBZ ][PP to_TO ][NP the_DT induction_NN ][PP of_IN ][NP genes_NNS ][PP for_IN ][NP a_DT set_NN ][PP of_IN ][NP lymphokines_NNS ] ,_,[PP including_VBG ][NP granulocyte-macrophage_JJ colony-stimulating_JJ factor_NN ] (_([NP GM-CSF_NN ] )_) ._.
[NP We_PRP ][VP demonstrated_VBD ][PP in_IN ][NP earlier_JJR studies_NNS ][SBAR that_IN ][NP the_DT upstream_JJ region_NN ][PP of_IN ][NP the_DT mouse_NN GM-CSF_NN promoter_NN ][PP at_IN ][NP positions_NNS ][PP between_IN ][NP -95_CD ] and_CC[NP -73_CD ][VP is_VBZ ][ADJP essential_JJ ][PP for_IN ][NP transcriptional_JJ activation_NN ][PP in_IN response_NN to_TO ][NP PMA/A23187_NN ] ._.
[NP This_DT region_NN ][VP contains_VBZ ][NP two_CD DNA-binding_JJ motifs_NNS ] ,_,[NP GM2_NN ] and_CC[NP GC-box_NN ] ._.
[NP The_DT GM2_NN sequence_NN ] (_([NP GGTAGTTCCC_NN ] )_)[VP is_VBZ recognized_VBN ][PP by_IN ][NP an_DT inducible_JJ factor_NN NF-GM2_NN ] ;_:[NP the_DT other_JJ ] (_([NP CCGCCC_NN ] )_)[PP by_IN ][NP constitutive_JJ factors_NNS ][NP A1_NN ] ,_,[NP A2_NN ] ,_, and_CC[NP B_NN ] ._.
[VP To_TO elucidate_VB ][NP the_DT mechanism_NN ][PP of_IN ][NP GM-CSF_NN gene_NN activation_NN ] ,_,[NP we_PRP ][VP have_VBP purified_VBN ][NP the_DT inducible_JJ factor_NN NF-GM2_NN ][PP from_IN ][NP the_DT nuclear_JJ extract_NN ][PP of_IN ][NP stimulated_VBN Jurkat_NN cells_NNS ][PP on_IN the_DT basis_NN of_IN ][NP specific_JJ DNA-binding_JJ activity_NN ] ._.
[NP The_DT purified_VBN NF-GM2_NN ][VP consists_VBZ ][PP of_IN ][NP 50_CD ] (_([NP p50_NN ] )_) and_CC[NP 65_CD ][NP kDa_NN ] (_([NP p65_NN ] )_)[NP polypeptides_NNS ] and_CC[VP has_VBZ ][NP a_DT binding_NN activity_NN ][ADJP specific_JJ ][PP for_IN ] both_CC the_DT[NP GM-CSF_NN ] and_CC[NP immunoglobulin_NN kappa_NN ] (_([NP GGAAAGTCCC_NN ] )_)[NP enhancers_NNS ] ._.
[NP Electrophoretically_RB purified_VBN p50_NN ][ADVP alone_RB ][VP can_MD form_VB ][NP a_DT protein-DNA_JJ complex_NN ] ,_, but_CC[PP in_IN ][NP the_DT mixture_NN ] ,_,[NP p50_NN ][VP associates_VBZ ][ADVP preferentially_RB ][PP with_IN ][NP p65_NN ][VP to_TO form_VB ][NP the_DT NF-GM2_NN complex_NN ] ._.
[PP In_IN ][NP addition_NN ] ,_,[NP p65_NN ][VP gave_VBD ][ADVP per_FW se_FW ] ,_,[PP with_IN ][NP low_JJ affinity_NN ] ,_,[NP a_DT protein-DNA_JJ complex_NN ][NP that_WDT ][VP migrated_VBD ][ADVP more_RBR slowly_RB ][PP than_IN ][NP native_JJ NF-GM2_NN complex_NN ] ._.
[ADVP Furthermore_RB ] ,_,[NP an_DT antiserum_NN ][PP against_IN ][NP KBF1_NN ] (_([ADJP identical_JJ ][PP to_TO ][NP 50_CD kDa_NN NF-kappa_NN B_NN protein_NN ] )_)[VP reacted_VBD ][PP with_IN ][NP the_DT p50_NN ][PP of_IN ][NP NF-GM2_NN ] ,_,[VP indicating_VBG ][SBAR that_IN ][NP the_DT NF-GM2_NN polypeptide_NN ][VP can_MD not_RB be_VB immunologically_RB differentiated_VBN ][PP from_IN ][NP the_DT 50_CD kDa_NN subunit_NN ][PP of_IN ][NP NF-kappa_NN B_NN ] ._.
[NP The_DT purified_VBN NF-GM2_NN ][VP activated_VBD ][NP in_FW vitro_FW transcription_NN ][PP from_IN ][NP the_DT kappa_NN B_NN enhancer_NN ] ,_,[SBAR while_IN ][NP it_PRP ][VP failed_VBD to_TO stimulate_VB ][NP transcription_NN ][PP from_IN ][NP the_DT GM-CSF_NN promoter_NN ][VP harboring_VBG ][NP the_DT GM2_NN sequence_NN ] ._.
[NP This_DT ][VP suggests_VBZ ][SBAR that_IN ][NP the_DT activation_NN mechanism_NN ][PP of_IN ][NP the_DT GM-CSF_NN gene_NN ][PP through_IN ][NP the_DT GM2/GC-box_JJ|NN sequence_NN ][VP is_VBZ ][ADJP different_JJ ][PP from_IN ][NP that_DT ][PP of_IN ][NP genes_NNS ][VP carrying_VBG ][NP the_DT kappa_NN B_NN enhancer_NN ][ADVP alone_RB ] ._.
[NP Glucocorticoid_NN receptors_NNS ][PP in_IN ][NP normal_JJ leukocytes_NNS ] :_:[NP effects_NNS ][PP of_IN ][NP age_NN ] ,_,[NP gender_NN ] ,_,[NP season_NN ] ,_, and_CC[NP plasma_NN cortisol_NN concentrations_NNS ] ._.
[NP We_PRP ][VP measured_VBD ][NP glucocorticoid_NN receptors_NNS ] (_([NP GR_NN ] )_)[PP in_IN ][NP mononuclear_JJ leukocytes_NNS ] (_([NP MNL_NN ] )_)[VP isolated_VBN ][PP from_IN ][NP peripheral_JJ blood_NN ][PP of_IN ][NP 145_CD apparently_RB healthy_JJ volunteers_NNS ] (_([NP 86_CD men_NNS ] and_CC[NP 59_CD women_NNS ] )_) ._.
[NP An_DT age-related_JJ decrease_NN ][PP in_IN ][NP the_DT number_NN ][PP of_IN ][NP GR_NN ][VP was_VBD suggested_VBN ][PP between_IN ][NP subjects_NNS ][ADJP younger_JJR ][PP than_IN ][NP 20_CD years_NNS ] and_CC[NP elderly_JJ subjects_NNS ] ;_:[NP there_EX ][VP was_VBD ][NP no_DT apparent_JJ seasonal_JJ variation_NN ][PP in_IN ][NP GR_NN ] ._.
[NP Gender_NN difference_NN ][PP in_IN ][NP the_DT number_NN ][PP of_IN ][NP GR_NN ][VP was_VBD ] not_RB[ADJP significant_JJ ] ,_,[SBAR although_IN ][NP women_NNS ][VP showed_VBD ][NP slightly_RB fewer_JJR GR_NN ] ._.
[NP Eight_CD patients_NNS ][PP with_IN ][NP dermatomyositis/polymyositis_NN ][VP were_VBD examined_VBN ][VP to_TO determine_VB ][SBAR whether_IN ][NP the_DT number_NN ][PP of_IN ][NP GR_NN ][PP in_IN ][NP MNL_NN ][VP could_MD be_VB down-regulated_VBN ][PP by_IN ][NP their_PRP$ cognate_JJ ligands_NNS ] ._.
[NP The_DT number_NN ][PP of_IN ][NP GR_NN ][PP in_IN ][NP MNL_NN ][PP from_IN ][NP these_DT patients_NNS ][VP was_VBD significantly_RB decreased_VBN ][NP one_CD month_NN ][PP after_IN ][NP the_DT initiation_NN ][PP of_IN ][NP prednisolone_NN therapy_NN ] ._.
[ADVP However_RB ] ,_,[PP in_IN ][NP normal_JJ subjects_NNS ] ,_,[NP the_DT GR_NN ][PP in_IN ][NP MNL_NN ][VP did_VBD not_RB demonstrate_VB ][NP circadian_JJ variation_NN ] ,_,[PP in_IN contrast_NN to_TO ][NP concentrations_NNS ][PP of_IN ][NP plasma_NN cortisol_NN ] ._.
[NP Anti-CD2_JJ receptor_NN antibodies_NNS ][VP activate_VBP ][NP the_DT HIV_NN long_JJ terminal_JJ repeat_NN ][PP in_IN ][NP T_NN lymphocytes_NNS ] ._.
[NP The_DT CD2_NN T_NN lymphocyte_NN glycoprotein_NN surface_NN molecule_NN ][VP mediates_VBZ ] both_CC[NP cell_NN to_TO cell_NN adhesion_NN ] and_CC[NP T_NN cell_NN activation_NN ] ,_,[NP two_CD processes_NNS ][NP that_WDT ][VP are_VBP involved_VBN ][PP in_IN ][NP the_DT spread_NN ][PP of_IN ][NP HIV_NN infection_NN ] ._.
[NP Treatment_NN ][PP of_IN ][NP chronically_RB HIV-infected_JJ PBMC_NN ][PP with_IN ][NP anti-CD2_JJ mAb_NN ][VP has_VBZ been_VBN shown_VBN to_TO induce_VB ][NP the_DT expression_NN ][PP of_IN ][NP infectious_JJ virus_NN ][PP from_IN ][NP these_DT cultures_NNS ] ._.
[PP In_IN ][NP this_DT study_NN ][NP we_PRP ][VP investigated_VBD ][NP the_DT mechanisms_NNS ][ADVP whereby_WRB ][NP anti-CD2_JJ antibodies_NNS ][VP stimulate_VBP ][NP viral_JJ production_NN ] ._.
[NP We_PRP ][VP demonstrate_VBP ][SBAR that_IN ][NP treatment_NN ][PP of_IN ][NP transiently_RB transfected_VBN T_NN lymphocytes_NNS ][PP with_IN ][NP anti-CD2_JJ antibodies_NNS ][VP results_VBZ ][PP in_IN ][NP activation_NN ][PP of_IN ][NP the_DT HIV_NN long_JJ terminal_JJ repeat_NN ] ._.
[ADVP Furthermore_RB ] ,_,[NP CAT_NN assays_NNS ][VP using_VBG ][NP mutated_VBN HIV_NN long_JJ terminal_JJ repeat-CAT_NN constructs_NNS ] and_CC[NP gel_NN shift_NN assays_NNS ][VP demonstrate_VBP ][SBAR that_IN ][NP this_DT activation_NN ][VP is_VBZ ][ADJP dependent_JJ ][PP on_IN ][NP the_DT NF-kappa_NN B_NN enhancer_NN ] ._.
[NP These_DT studies_NNS ][VP suggest_VBP ][SBAR that_IN ][NP interaction_NN ][PP of_IN ][NP CD2_NN ][PP with_IN ][NP its_PRP$ natural_JJ ligand_NN ] ,_,[NP LFA-3_NN ] ,_,[VP may_MD play_VB ][NP a_DT role_NN ][PP in_IN ][NP regulation_NN ][PP of_IN ][NP HIV_NN expression_NN ] ._.
[NP Nuclear_JJ transcription_NN factors_NNS ][NP that_WDT ][VP bind_VBP ][PP to_TO ][NP elements_NNS ][PP of_IN ][NP the_DT IL-2_NN promoter_NN ] ._.
[NP Induction_NN requirements_NNS ][PP in_IN ][NP primary_JJ human_JJ T_NN cells_NNS ] ._.
[NP Prior_JJ studies_NNS ][VP have_VBP identified_VBN ][NP several_JJ elements_NNS ][NP that_WDT ][VP contribute_VBP ][PP to_TO ][NP the_DT activity_NN ][PP of_IN ][NP the_DT IL-2_NN promoter_NN ][PP in_IN ][NP the_DT stimulated_VBN T_NN cell_NN line_NN ] ,_,[NP Jurkat_NN ] ._.
[NP The_DT sites_NNS ] and_CC[NP their_PRP$ corresponding_JJ nuclear_JJ binding_VBG factors_NNS ][VP include_VBP ] :_:[NP NF-kappa_NN B_NN ] ,_,[NP AP-1_NN ] ,_,[NP AP-3_NN ] ,_,[NP OCT-1_NN ] ,_, and_CC[NP NF-AT_NN ] ._.
[NP The_DT latter_JJ ] "_[[DQS]][NP nuclear_JJ factor_NN ][PP for_IN ][NP activated_VBN T_NN cells_NNS ] "_[[DQE]][ADVP likely_RB ][VP contributes_VBZ ][PP to_TO ][NP the_DT tissue_NN specificity_NN ][PP of_IN ][NP IL-2_NN gene_NN expression_NN ] ._.
[VP Using_VBG ][NP electrophoretic_JJ mobility_NN shift_NN assays_NNS ] ,_,[NP we_PRP ][VP have_VBP studied_VBN ][NP these_DT ][NP transcription_NN factors_NNS ][PP in_IN ][NP primary_JJ T_NN cells_NNS ][PP from_IN ][NP human_JJ blood_NN ][VP to_TO verify_VB ][NP their_PRP$ presence_NN ][PP in_IN ][NP a_DT physiologic_JJ setting_NN ] and_CC[VP to_TO identify_VB ][NP the_DT signals_NNS ][NP that_WDT ][VP stimulate_VBP ][NP factor_NN activity_NN ] ._.
[NP All_DT factors_NNS ][VP are_VBP induced_VBN ][PP in_IN ][NP the_DT nuclei_NNS ][PP of_IN ][NP T_NN cells_NNS ][PP upon_IN ][NP activation_NN ][PP with_IN ][NP mitogens_NNS ][PP but_CC ][PP not_RB with_IN ][NP exogenous_JJ IL-2_NN growth_NN factor_NN ] ._.
[ADVP However_RB ] ,_,[NP the_DT signaling_NN requirements_NNS ] and_CC[NP sensitivity_NN ][PP to_TO ][NP protein_NN synthesis_NN inhibitors_NNS ][VP differ_VBP ][ADVP considerably_RB ] ._.
[NP Only_RB the_DT activities_NNS ][PP for_IN ][NP NF-AT_NN ] and_CC[NP AP-1_NN ][NP sites_NNS ][VP require_VBP ][NP two_CD signals_NNS ][PP for_IN ][NP optimal_JJ induction_NN ] ,_,[PP i.e._FW ] ,_,[NP PMA_NN ] plus_CC either_CC[NP lectin_NN ] or_CC[NP antibody_NN ][PP to_TO ] the_DT[NP CD3_NN ] or_CC[NP CD28_NN ][NP surface_NN molecules_NNS ] ._.
[NP Other_JJ factors_NNS ][VP are_VBP induced_VBN ][PP by_IN ][NP lectin_NN ] ,_,[NP antibody_NN ] ,_, and/or_CC[NP PMA_NN ][ADVP alone_RB ] ._.
[PP After_IN ][NP appropriate_JJ stimulation_NN ] ,_, both_CC[NP NF-AT_NN ] and_CC[NP AP-1_NN ][VP are_VBP ][ADJP peculiarly_RB sensitive_JJ ][PP to_TO ][NP the_DT protein_NN synthesis_NN inhibitor_NN anisomycin_NN ] ._.
[NP Our_PRP$ data_NNS ][VP correlate_VBP ][NP the_DT activity_NN ][PP of_IN ][NP NF-AT_NN ] and_CC[NP AP-1_NN ][PP in_IN ][NP gel_NN shift_NN assays_NNS ][PP with_IN ][NP the_DT two_CD signals_NNS requirements_NNS ][PP for_IN ][NP IL-2_NN gene_NN expression_NN ] ._.
[NP An_DT erythroid_JJ specific_JJ enhancer_NN ][ADJP upstream_JJ ][PP to_TO ][NP the_DT gene_NN ][VP encoding_VBG ][NP the_DT cell-type_JJ specific_JJ transcription_NN factor_NN GATA-1_NN ] ._.
[NP The_DT transcription_NN factor_NN GATA-1_NN ][VP is_VBZ expressed_VBN ][PP in_IN ][NP a_DT subset_NN ][PP of_IN ][NP hemopoietic_JJ cells_NNS ] ,_,[ADVP where_WRB ][NP it_PRP ][VP mediates_VBZ ][NP the_DT cell-type_JJ specific_JJ expression_NN ][PP of_IN ][NP several_JJ genes_NNS ] ._.
[NP We_PRP ][VP have_VBP cloned_VBN ] the_DT[NP mouse_NN ] and_CC[NP human_JJ ][NP GATA-1_NN genes_NNS ] ._.
[NP A_DT region_NN ][ADJP upstream_JJ ][PP to_TO ][NP the_DT first_JJ exon_NN ] ,_, and_CC[VP highly_RB conserved_VBN ][PP between_IN ][NP mouse_NN ] and_CC[NP man_NN ] ,_,[VP acts_VBZ ][PP as_IN ][NP an_DT erythroid_JJ specific_JJ enhancer_NN ][PP in_IN ][NP transient_JJ assays_NNS ] ,_,[SBAR if_IN ][VP linked_VBN ][PP to_TO ][NP the_DT GATA-1_NN ][PP or_CC ][PP to_TO ][NP the_DT SV40_NN ][NP promoter_NN ] ._.
[NP The_DT activity_NN ][PP of_IN ][NP the_DT enhancer_NN ][VP is_VBZ ][ADJP almost_RB completely_RB dependent_JJ ][PP on_IN ][NP the_DT integrity_NN ][PP of_IN ][NP a_DT dimeric_JJ GATA-1_NN binding_NN site_NN ] ._.
[NP Demonstration_NN ][PP of_IN ][NP a_DT 1,25-dihydroxyvitamin_NN D3-responsive_JJ protein_NN ][PP in_IN ][NP human_JJ lymphocytes_NNS ] :_:[NP immunologic_JJ crossreactivity_NN ] and_CC[NP inverse_JJ regulation_NN ][PP with_IN ][NP the_DT vitamin_NN D_NN receptor_NN ] ._.
[VP Using_VBG ][NP Western_NN blot_NN analysis_NN ][PP with_IN ][NP a_DT monoclonal_JJ antibody_NN ][VP recognizing_VBG ][NP a_DT 17-amino_NN acid_NN epitope_NN ][PP of_IN ] the_DT[NP 1,25-dihydroxyvitamin_NN D3_NN ] (_([NP 1,25(OH)2D3_NN ] )_)[NP receptor_NN ] ,_,[NP we_PRP ][VP have_VBP detected_VBN ][NP two_CD crossreacting_VBG proteins_NNS ][PP in_IN ][NP activated_VBN normal_JJ human_JJ lymphocytes_NNS ] ._.
[NP The_DT smaller_JJR ][PP of_IN ][NP the_DT two_CD proteins_NNS ] (_([NP 50_CD kDa_NN ] )_)[VP was_VBD ][ADJP indistinguishable_JJ ][PP from_IN ][NP the_DT classical_JJ 1,25(OH)2D3_NN receptor_NN ] and_CC ,_,[ADJP similar_JJ ][PP to_TO ][NP the_DT classical_JJ 1,25(OH)2D3_NN receptor_NN ] ,_,[VP was_VBD ][VP upregulated_VBN ][PP in_IN ][NP a_DT dose-dependent_JJ fashion_NN ][PP by_IN ][NP 1,25(OH)2D3_NN ] ._.
[NP The_DT larger_JJR crossreacting_VBG protein_NN ][VP exhibited_VBD ][NP an_DT electrophoretic_JJ mobility_NN ][PP of_IN ][NP 80_CD kDa_NN ] ,_,[VP was_VBD localized_JJ ][PP in_IN ][NP the_DT cell_NN cytosol_NN ] ,_, and_CC[VP appeared_VBD to_TO be_VB ][ADJP specific_JJ ][PP for_IN ][NP activated_VBN lymphocytes_NNS ][SBAR since_IN ][NP it_PRP ][VP was_VBD not_RB detected_VBN ][PP in_IN ][NP several_JJ other_JJ human_JJ cells_NNS ][PP including_VBG ][NP monocytes_NNS ] ._.
[ADVP More_RBR strikingly_RB ] ,_,[NP the_DT 80-kDa_JJ protein_NN ][VP was_VBD downregulated_VBN ][PP in_IN ][NP a_DT dose-dependent_JJ fashion_NN ][PP by_IN ][NP 1,25(OH)2D3_NN ] ;_:[NP this_DT effect_NN ][VP was_VBD ][ADJP independent_JJ ][PP of_IN ][NP the_DT mode_NN ][PP of_IN ][NP lymphocyte_NN activation_NN ] and_CC[ADJP specific_JJ ][PP for_IN ][NP the_DT 1,25(OH)2D3_NN metabolite_NN ][PP of_IN ][NP vitamin_NN D3_NN ] ._.
[ADVP However_RB ] ,_,[NP two_CD potent_JJ immunosuppressive_JJ agents_NNS ] ,_,[NP glucocorticoids_NNS ] and_CC[NP cyclosporin_NN A_DT ] ,_,[ADVP also_RB ][VP inhibited_VBD ][NP the_DT 80-kDa_JJ protein_NN ] ._.
[NP T-helper-cell_JJ determinants_NNS ][PP in_IN ][NP protein_NN antigens_NNS ][VP are_VBP ][ADVP preferentially_RB located_JJ ][PP in_IN ][NP cysteine-rich_JJ antigen_NN segments_NNS ][ADJP resistant_JJ ][PP to_TO ][NP proteolytic_JJ cleavage_NN ][PP by_IN ][NP cathepsin_NN ][NP B_NN ] ,_,[NP L_NN ] ,_, and_CC[NP D_NN ] ._.
[NP We_PRP ][VP report_VBP ][PP on_IN ][NP a_DT computer_NN algorithm_NN ][ADJP capable_JJ ][PP of_IN ][VP predicting_VBG ][NP the_DT location_NN ][PP of_IN ][NP T-helper-cell_NN epitopes_NNS ][PP in_IN ][NP protein_NN ][NP antigen_NN ] (_([NP Ag_NN ] )_)[PP by_IN ][VP analysing_VBG ][NP the_DT Ag_NN amino_NN acid_NN sequence_NN ] ._.
[NP The_DT algorithm_NN ][VP was_VBD constructed_VBN ][PP with_IN ][NP the_DT aim_NN ][PP of_IN ][VP identifying_VBG ][NP segments_NNS ][PP in_IN ][NP Ag_NN ][NP which_WDT ][VP are_VBP ][ADJP resistant_JJ ][PP to_TO ][NP proteolytic_JJ degradation_NN ][PP by_IN ][NP the_DT enzymes_NNS cathepsin_NN ][NP B_NN ] ,_,[NP L_NN ] ,_, and_CC[NP D_NN ] ._.
[NP These_DT ][VP are_VBP ][NP prominent_JJ enzymes_NNS ][PP in_IN ][NP the_DT endocytic_JJ pathway_NN ][PP through_IN ][NP which_WDT ][NP soluble_JJ protein_NN Ag_NN ][VP enter_VBP ][NP APC_NN ] ,_, and_CC[NP resistant_JJ segments_NNS ][PP in_IN ][NP Ag_NN ][VP may_MD ] ,_,[ADVP therefore_RB ] ,_,[VP be_VB expected_VBN to_TO contain_VB ][NP more_JJR T-cell_NN determinants_NNS ][PP than_IN ][NP susceptible_JJ segments_NNS ] ._.
[PP From_IN ][NP information_NN ][ADJP available_JJ ][PP in_IN ][NP the_DT literature_NN ][PP on_IN ][NP the_DT substrate_JJ specificity_NN ][PP of_IN ][NP the_DT three_CD enzymes_NNS ] ,_,[NP it_PRP ][VP is_VBZ ][ADJP clear_JJ ][SBAR that_IN ][NP a_DT cysteine_NN ][VP is_VBZ not_RB accepted_VBN ][PP in_IN ][NP any_DT ][PP of_IN ] the_DT[NP S2_NN ] ,_,[NP S1_NN ] ,_,[NP S1'_NN ] ,_, and_CC[NP S2'_NN ][NP subsites_NNS ][PP of_IN ][NP cathepsin_NN ][NP B_NN ] and_CC[NP L_NN ][PP ,_, and_CC ][PP not_RB in_IN ] the_DT[NP S1_NN ] and_CC[NP S1'_NN ][NP subsites_NNS ][PP of_IN ][NP cathepsin_NN D_NN ] ._.
[ADVP Moreover_RB ] ,_,[NP we_PRP ][VP have_VBP noticed_VBN ][SBAR that_IN ][NP cysteine-containing_JJ T-cell_NN determinants_NNS ][PP in_IN ][NP a_DT number_NN ][PP of_IN ][NP protein_NN Ag_NN ][VP are_VBP ][ADJP particularly_RB rich_JJ ][PP in_IN ][NP the_DT amino_NN acids_NNS ][NP alanine_NN ] ,_,[NP glycine_NN ] ,_,[NP lysine_NN ] ,_,[NP leucine_NN ] ,_,[NP serine_NN ] ,_,[NP threonine_NN ] ,_, and_CC[NP valine_NN ] ._.
[PP By_IN ][VP searching_VBG ][NP protein_NN Ag_NN ][PP for_IN ][NP clusters_NNS ][PP of_IN ][NP amino_NN acids_NNS ][VP containing_VBG ][NP cysteine_NN ] and_CC[NP two_CD ][PP of_IN ][NP the_DT other_JJ amino_NN acids_NNS ][NP we_PRP ][VP were_VBD ][ADJP able_JJ ][VP to_TO predict_VB ][NP 17_CD out_IN of_IN 23_CD empirically_RB known_VBN T-cell_NN determinants_NNS ][PP in_IN ][NP the_DT Ag_NN ][PP with_IN ][NP a_DT relatively_RB low_JJ number_NN ][PP of_IN ] false_JJ (_([ADJP positive_JJ ] )_)[NP predictions_NNS ] ._.
[ADVP Furthermore_RB ] ,_,[NP we_PRP ][VP present_VBP ][NP a_DT new_JJ principle_NN ][PP for_IN ][VP searching_VBG ][NP Ag_NN ][PP for_IN ][NP potential_JJ amphipatic_JJ alpha-helical_JJ protein_NN segments_NNS ] ._.
[NP Such_JJ segments_NNS ][VP accord_VBP ][ADVP well_RB ][PP with_IN ][NP empirically_RB known_JJ T-cell_NN determinants_NNS ] and_CC[NP our_PRP$ algorithm_NN ][VP produces_VBZ ][NP a_DT lower_JJR number_NN ][PP of_IN ][NP false_JJ positive_JJ predictions_NNS ][PP than_IN ][NP the_DT principle_NN ][PP based_VBN ][PP on_IN ][NP discrete_JJ Fourier_NN transformations_NNS ][VP previously_RB described_VBN ] ._.
[NP A_DT human_JJ putative_JJ lymphocyte_NN G0/G1_NN switch_NN gene_NN ][VP containing_VBG ][NP a_DT CpG-rich_JJ island_NN ][VP encodes_VBZ ][NP a_DT small_JJ basic_JJ protein_NN ][PP with_IN ][NP the_DT potential_NN ][VP to_TO be_VB phosphorylated_VBN ] ._.
[NP Genes_NNS ][VP actively_RB involved_VBN ][PP in_IN ][NP the_DT G0/G1_NN switch_NN ] (_([NP G0S_NN genes_NNS ] )_)[VP may_MD be_VB differentially_RB expressed_VBN ][PP during_IN ][NP the_DT lectin-induced_JJ switch_NN ][PP of_IN ][NP lymphocytes_NNS ][PP from_IN ][NP the_DT G0_NN ][PP to_TO ][NP the_DT G1_NN phases_NNS ][PP of_IN ][NP the_DT cell_NN cycle_NN ] ._.
[NP This_DT paper_NN ][VP presents_VBZ ][NP studies_NNS ][PP of_IN ][NP G0S2_NN ] ,_,[NP a_DT member_NN ][PP of_IN ][NP a_DT set_NN ][PP of_IN ][NP putative_JJ G0S_NN genes_NNS ] ,_,[PP for_IN ][NP which_WDT ][NP cDNAs_NNS ][VP were_VBD cloned_VBN ] and_CC[VP selected_VBN ][PP on_IN the_DT basis_NN of_IN ][NP differential_JJ cDNA_NN hybridization_NN ] ._.
[NP G0S2_NN mRNA_NN ][VP increases_VBZ ][ADVP transiently_RB ][PP within_IN ][NP 1-2_CD hr_NN ][PP of_IN ][NP the_DT addition_NN ][PP of_IN ][NP lectin_NN ] or_CC[NP cycloheximide_NN ][PP to_TO ][NP cultured_VBN blood_NN mononuclear_JJ cells_NNS ] ._.
[NP Comparison_NN ][PP of_IN ][NP a_DT nearly_RB full-length_JJ cDNA_NN sequence_NN ][PP with_IN ][NP the_DT corresponding_JJ genomic_JJ sequence_NN ][VP reveals_VBZ ][NP one_CD small_JJ intron_NN ] and_CC[NP an_DT open_JJ reading_NN frame_NN ][PP in_IN ][NP the_DT second_JJ exon_NN ] ._.
[NP The_DT derived_VBN 103-amino-acid_JJ basic_JJ protein_NN ][VP has_VBZ ][NP two_CD potential_JJ alpha-helical_JJ domains_NNS ][VP separated_VBN ][PP by_IN ][NP a_DT hydrophobic_JJ region_NN ][PP with_IN ][NP the_DT potential_NN ][VP to_TO generate_VB ][NP turns_NNS ] and_CC[VP assume_VB ][NP a_DT beta-sheet_JJ conformation_NN ] ._.
[ADJP Consistent_JJ ][PP with_IN ][NP involvement_NN ][PP in_IN ][NP the_DT G0/G1_NN switch_NN ] ,_,[NP the_DT protein_NN ][VP contains_VBZ ][NP potential_JJ sites_NNS ][PP for_IN ][NP phosphorylation_NN ][PP by_IN ][NP protein_NN kinase_NN C_NN ] and_CC[NP casein_NN kinase_NN II_CD ] ._.
[NP The_DT gene_NN ][VP contains_VBZ ][NP a_DT CpG-rich_JJ island_NN ][VP suggesting_VBG ][NP expression_NN ][PP in_IN ][NP the_DT germ_NN line_NN ] ._.
[NP An_DT upstream_JJ segment_NN ][VP contains_VBZ ][NP tandem_JJ dinucleotide_NN repeats_NNS (CT)19/(CA)16_NN ] ._.
[NP There_EX ][VP is_VBZ ][NP a_DT suitably_RB located_JJ TATA_NN box_NN ] ,_, but_CC[NP potential_JJ sites_NNS ][PP for_IN ][NP CCAAT-box_NN binding_NN factors_NNS ][VP are_VBP ][ADJP far_RB upstream_JJ ] ,_,[ADJP embedded_JJ ][PP in_IN ][NP a_DT 42-nucleotide_JJ repeat_NN element_NN ] ._.
[NP Potential_JJ sites_NNS ][PP for_IN ][NP transcription_NN factors_NNS ][NP AP1_NN ] ,_,[NP AP2_NN ] ,_, and_CC[NP AP3_NN ][VP are_VBP ][ADJP consistent_JJ ][PP with_IN ][NP rapid_JJ transcriptional_JJ activation_NN ][PP in_IN response_NN to_TO ][NP inducing_VBG agents_NNS ] ._.
[NP Synergism_NN ][PP between_IN ][NP two_CD distinct_JJ elements_NNS ][PP of_IN ][NP the_DT HTLV-I_NN enhancer_NN ][PP during_IN ][NP activation_NN ][PP by_IN ][NP the_DT trans-activator_NN ][PP of_IN ][NP HTLV-I_NN ] ._.
[NP We_PRP ][VP have_VBP conducted_VBN ][NP functional_JJ studies_NNS ][PP of_IN ][NP the_DT enhancer_NN elements_NNS ][PP of_IN ][NP human_JJ T-cell_NN leukemia_NN virus_NN type_NN I_CD ] (_([NP HTLV-I_NN ] )_)[VP using_VBG ][NP the_DT human_JJ T-cell_NN lines_NNS ][NP Jurkat_NN ] and_CC[NP MOLT_NN 4_CD ] ,_,[NP which_WDT ][VP are_VBP ][ADJP negative_JJ ][PP for_IN ][NP HTLV-I_NN ] ,_, and_CC[NP MT-2_NN ] and_CC[NP TL-Mor_NN ] ,_,[NP which_WDT ][VP carry_VBP ][NP the_DT proviral_JJ genome_NN ][PP of_IN ][NP HTLV-I_NN ] ._.
[NP Two_CD distinct_JJ elements_NNS ][VP have_VBP been_VBN implicated_VBN ][PP in_IN ][NP function_NN ][PP of_IN ][NP the_DT HTLV-I_NN enhancer_NN ] ._.
[NP One_CD ][VP is_VBZ ] the_DT 21-base-pair_JJ (_([NP bp_NN ] )_)[NP core_NN element_NN ][NP that_WDT ][VP is_VBZ ][ADJP responsible_JJ ][PP for_IN ][NP trans-activation_NN ][PP by_IN ][NP the_DT HTLV-I_NN trans-activator_NN p40tax_NN ] and_CC[NP that_WDT ][VP has_VBZ ][NP the_DT ability_NN ][VP to_TO bind_VB ][PP to_TO ][NP cyclic-AMP_NN responsive_JJ element_NN binding_NN factor_NN (_( CREB_NN )_) -like_JJ factor_NN (_( s_NNS ] )_) ._.
[NP The_DT other_JJ ][VP is_VBZ ][NP a_DT region_NN ][ADJP interposed_VBN ][PP between_IN ][NP the_DT 21-bp_JJ elements_NNS ] ._.
[PP In_IN ][NP this_DT study_NN ][NP we_PRP ][VP demonstrate_VBP ][SBAR that_IN ][NP a_DT subfragment_NN ] (_([NP C26_NN ] )_)[PP in_IN ][NP the_DT region_NN ][PP between_IN ][NP the_DT 21-bp_JJ elements_NNS ][VP is_VBZ involved_VBN ][PP in_IN ][NP trans-activation_NN ][PP by_IN ][NP p40tax_NN ] ,_,[PP possibly_RB through_IN ][NP binding_NN ][PP to_TO ][NP an_DT NF-kappa_NN B-like_JJ nuclear_JJ ][NP factor_NN ] or_CC[NP factors_NNS ] ._.
[NP Formation_NN ][PP of_IN ][NP the_DT protein-DNA_JJ complex_NN ][PP with_IN ][NP the_DT C26_NN subfragment_NN ][VP was_VBD positively_RB affected_VBN ][PP by_IN ][NP p40tax_NN ] ._.
[NP The_DT C26_NN element_NN ][VP conferred_VBD ][NP partial_JJ responsiveness_NN ][PP to_TO ][NP p40tax_NN ][ADVP when_WRB ][VP linked_VBN ][PP to_TO ][NP one_CD copy_NN ][PP of_IN ][NP the_DT 21-bp_JJ element_NN ][NP that_WDT ] ,_,[PP by_IN ][NP itself_PRP ] ,_,[VP showed_VBD ][NP little_JJ activation_NN ][PP in_IN response_NN to_TO ][NP p40tax_NN ] ._.
[ADVP However_RB ] ,_,[NP the_DT C26_NN element_NN ][ADVP alone_RB ] ,_,[ADVP even_RB ][ADVP when_WRB ][VP repeated_VBN ] ,_,[VP could_MD not_RB be_VB activated_VBN ][PP by_IN ][NP p40tax_NN ] ,_,[PP unlike_IN ][NP other_JJ NF-kappa_NN B-binding_JJ elements_NNS ] ._.
[PP In_IN ][NP contrast_NN ] ,_,[NP the_DT C26_NN element_NN ][NP itself_PRP ][VP was_VBD profoundly_RB activated_VBN ][PP upon_IN ][NP stimulation_NN ][PP with_IN ][NP 12-O-tetradecanoylphorbol-13-acetate_NN ] ._.
[NP These_DT findings_NNS ][ADVP therefore_RB ][VP suggest_VBP ][SBAR that_IN ][NP the_DT HTLV-I_NN enhancer_NN ][VP contains_VBZ ][NP multiple_JJ functional_JJ elements_NNS ] ,_,[PP including_VBG ][NP binding_VBG sites_NNS ][PP for_IN ][NP at_IN least_JJS CREB-_NN and_CC NF-kappa_NN B-like_JJ factors_NNS ] ,_,[NP which_WDT ][ADVP synergistically_RB ][VP cooperate_VBP ][PP in_IN ][NP activation_NN ][PP of_IN ][NP the_DT HTLV-I_NN enhancer_NN ][PP in_IN response_NN to_TO ][NP p40tax_NN ] ._.
[NP Our_PRP$ results_NNS ][ADVP also_RB ][VP demonstrate_VBP ][SBAR that_IN ][NP TPA-dependent_JJ activation_NN ][PP of_IN ][NP the_DT HTLV-I_NN enhancer_NN ][VP may_MD be_VB mediated_VBN ][PP through_IN ][NP the_DT C26_NN element_NN ] ._.
[NP v-erbA_NN overexpression_NN ][VP is_VBZ required_VBN to_TO extinguish_VB ][NP c-erbA_NN function_NN ][PP in_IN ][NP erythroid_JJ cell_NN differentiation_NN ] and_CC[NP regulation_NN ][PP of_IN ][NP the_DT erbA_NN target_NN gene_NN CAII_NN ] ._.
[NP The_DT v-erbA_NN oncoprotein_NN ][VP represents_VBZ ][NP a_DT retrovirus-transduced_JJ oncogenic_JJ version_NN ][PP of_IN ][NP the_DT thyroid_NN hormone_NN (_( T3/T4_NN )_) receptor_NN c-erbA_NN (_( type_NN alpha_NN ] )_) ._.
[NP It_PRP ][VP contributes_VBZ ][PP to_TO ][NP virus-induced_JJ erythroleukemia_NN ][PP by_IN ][ADVP efficiently_RB ][VP arresting_VBG ][NP differentiation_NN ][PP of_IN ][NP red_JJ cell_NN progenitors_NNS ][PP and_CC ][PP by_IN ][VP suppressing_VBG ][NP transcription_NN ][PP of_IN ][NP erythrocyte-specific_JJ genes_NNS ] ._.
[ADVP Here_RB ] ,_,[NP we_PRP ][VP show_VBP ][SBAR that_IN ][NP v-erbA_NN ] and_CC[NP c-erbA_NN ][VP bind_VBP ][ADVP directly_RB ][PP to_TO ][NP sequences_NNS ][PP within_IN ][NP the_DT promoter_NN ][PP of_IN ][NP the_DT erythrocyte-specific_JJ ][NP carbonic_JJ anhydrase_NN II_CD ] (_([NP CAII_NN ] )_) ,_,[NP a_DT gene_NN ][NP whose_WP$ transcription_NN ][VP is_VBZ efficiently_RB suppressed_VBN ][PP by_IN ][NP v-erbA_NN ] ._.
[NP This_DT erbA-binding_JJ site_NN ][VP confers_VBZ ][NP thyroid_NN hormone_NN responsiveness_NN ][PP to_TO ][NP a_DT heterologous_JJ promoter_NN ][PP in_IN ][NP transient_JJ expression_NN experiments_NNS ] and_CC[VP is_VBZ ][NP a_DT target_NN ][PP for_IN ][NP efficient_JJ down-regulation_NN ][PP of_IN ][NP CAII_NN transcription_NN ][PP by_IN ][NP the_DT v-erbA_NN oncoprotein_NN ] ._.
[PP In_IN ][NP stably_RB transformed_VBN erythroblasts_NNS ][VP coexpressing_VBG ][NP the_DT v-erbA_NN oncoprotein_NN ] and_CC[NP the_DT c-erbA/T3_NN receptor_NN ][PP at_IN ][NP an_DT approximately_RB equimolar_JJ ratio_NN ] ,_,[NP c-erbA_NN activity_NN ][VP is_VBZ ][ADJP dominant_JJ ][PP over_IN ][NP v-erbA_NN ] ._.
[NP T3_NN ][ADVP efficiently_RB ][VP induced_VBD ][NP erythroid_JJ differentiation_NN ][PP in_IN ][NP these_DT cells_NNS ] ,_, thus_RB[VP overcoming_VBG ][NP the_DT v-erbA-mediated_JJ differentiation_NN arrest_NN ] ._.
[ADVP Likewise_RB ] ,_,[NP T3_NN ][VP activated_VBD ][NP CAII_NN transcription_NN ][CONJP as_RB well_RB as_IN ][NP transient_JJ expression_NN ][PP of_IN ][NP a_DT T3-responsive_JJ reporter_NN gene_NN ][VP containing_VBG ][NP the_DT CAII-specific_JJ erbA-binding_JJ site_NN ] ._.
[NP The_DT c-erbA-dependent_JJ activation_NN ][PP of_IN ][NP this_DT CAII_NN reporter_NN construct_NN ][VP could_MD only_RB be_VB suppressed_VBN ][PP by_IN ][NP very_RB high_JJ amounts_NNS ][PP of_IN ][NP v-erbA_NN ] ._.
[NP Our_PRP$ results_NNS ][VP suggest_VBP ][SBAR that_IN ][NP overexpression_NN ][PP of_IN ][NP v-erbA_NN ][VP is_VBZ required_VBN ][PP for_IN ][NP its_PRP$ function_NN ][PP as_IN ][NP an_DT oncoprotein_NN ] ._.
[NP Inhibition_NN ][PP of_IN ][NP phorbol_NN ester-induced_JJ monocytic_JJ differentiation_NN ][PP by_IN ][NP dexamethasone_NN ][VP is_VBZ associated_VBN ][PP with_IN ][NP down-regulation_NN ][PP of_IN ][NP c-fos_NN ] and_CC[NP c-jun_NN ] (_([NP AP-1_NN ] )_) ._.
[NP Previous_JJ studies_NNS ][VP have_VBP shown_VBN ][SBAR that_IN ][NP treatment_NN ][PP of_IN ][NP human_JJ myeloid_JJ leukemia_NN cells_NNS ][PP with_IN ][NP 12-O-tetradecanoylphorbol-13-acetate_NN ] (_([NP TPA_NN ] )_)[VP is_VBZ associated_VBN ][PP with_IN ][NP induction_NN ][PP of_IN ][NP monocytic_JJ ][NP differentiation_NN ] and_CC[NP expression_NN ][PP of_IN ] the_DT[NP c-jun_NN ] and_CC[NP c-fos_NN ][NP early_JJ response_NN genes_NNS ] ._.
[NP The_DT present_JJ work_NN ][VP demonstrates_VBZ ][SBAR that_IN ][NP the_DT glucocorticoid_NN dexamethasone_NN ][VP inhibits_VBZ ][NP TPA-induced_JJ increases_NNS ][PP in_IN ][NP c-jun_NN ] and_CC[NP c-fos_NN ][NP mRNA_NN levels_NNS ][PP in_IN ][NP U-937_NN leukemia_NN cells_NNS ] ._.
[NP These_DT findings_NNS ][VP were_VBD associated_VBN ][PP with_IN ][NP a_DT block_NN ][PP in_IN ][NP appearance_NN ][PP of_IN ][NP the_DT monocytic_JJ phenotype_NN ] ,_,[PP including_VBG ][NP inhibition_NN ][PP of_IN ][NP TPA-induced_JJ increases_NNS ][PP in_IN ][NP lamin_NN A_NN ] ,_,[NP lamin_NN C_NN ] ,_, and_CC[NP vimentin_NN transcripts_NNS ] ._.
[NP Other_JJ studies_NNS ][VP have_VBP demonstrated_VBN ][SBAR that_IN ][NP TPA-induced_JJ monocytic_JJ ][NP differentiation_NN ] and_CC[NP expression_NN ][PP of_IN ] the_DT[NP c-jun_NN ] and_CC[NP c-fos_NN ][NP genes_NNS ][PP in_IN ][NP myeloid_JJ leukemia_NN cells_NNS ][VP are_VBP regulated_VBN ][PP by_IN ][NP protein_NN kinase_NN C_NN ] (_([NP PKC_NN ] )_) ._.
[NP The_DT finding_NN ][SBAR that_IN ][NP dexamethasone_NN ][VP has_VBZ ][NP no_DT effect_NN ][PP on_IN ][NP TPA-induced_JJ activation_NN ][PP of_IN ][NP PKC_NN ][VP suggests_VBZ ][SBAR that_IN ][NP this_DT glucocorticoid_NN ][VP inhibits_VBZ ][NP signals_NNS ][ADJP downstream_JJ ] or_CC[ADJP parallel_JJ ][PP to_TO ][NP this_DT enzyme_NN ] ._.
[NP Nuclear_JJ run-on_JJ assays_NNS ][VP demonstrate_VBP ][SBAR that_IN ] :_:[LST (_( 1_LS ] )_)[NP induction_NN ][PP of_IN ][NP c-jun_NN ] and_CC[NP c-fos_NN ][NP expression_NN ][PP by_IN ][NP TPA_NN ][VP is_VBZ regulated_VBN ][PP by_IN ][NP transcriptional_JJ mechanisms_NNS ] ,_,[LST (_( 2_LS ] )_)[NP TPA-induced_JJ expression_NN ][PP of_IN ][NP c-jun_NN ] and_CC[NP c-fos_NN ][VP does_VBZ not_RB require_VB ][NP protein_NN synthesis_NN ] ,_, and_CC[LST (_( 3_LS ] )_)[NP TPA-induced_JJ expression_NN ][PP of_IN ][NP both_DT genes_NNS ][VP is_VBZ inhibited_VBN ][PP at_IN ][NP the_DT transcriptional_JJ level_NN ][PP by_IN ][NP dexamethasone_NN ] ._.
[VP To_TO further_RB define_VB ][NP the_DT effects_NNS ][PP of_IN ][NP dexamethasone_NN ][PP at_IN ][NP the_DT molecular_JJ level_NN ] ,_,[NP we_PRP ][VP prepared_VBD ][NP a_DT series_NN ][PP of_IN ][NP deleted_VBN c-jun_NN promoter_NN fragments_NNS ][VP linked_VBN ][PP to_TO ] the_DT[NP chloramphenicol_NN acetyltransferase_NN ] (_([NP CAT_NN ] )_)[NP gene_NN ] ._.
[NP Increases_NNS ][PP in_IN ][NP CAT_NN activity_NN ][PP during_IN ][NP transient_JJ expression_NN ][PP of_IN ][NP these_DT constructs_NNS ][PP in_IN ][NP TPA-treated_JJ U-937_NN cells_NNS ][VP could_MD be_VB assigned_VBN ][PP to_TO ][NP the_DT region_NN ] (_([NP -97_CD ] to_TO[NP -20_CD ] )_)[PP of_IN ][NP the_DT promoter_NN ][NP that_WDT ][VP contains_VBZ ][NP the_DT AP-1_NN binding_NN site_NN ] ._.
[NP This_DT induction_NN ][PP of_IN ][NP CAT_NN activity_NN ][VP was_VBD ][ADJP sensitive_JJ ][PP to_TO ][NP dexamethasone_NN ] ._.
[NP These_DT findings_NNS ][VP suggest_VBP ][SBAR that_IN ][NP dexamethasone_NN ][VP down-regulates_VBZ ][NP TPA-induced_JJ transcription_NN ][PP of_IN ][NP the_DT c-jun_NN gene_NN ][PP during_IN ][NP monocytic_JJ differentiation_NN ][PP by_IN ][VP inhibiting_VBG ][NP activation_NN ][PP of_IN ][NP the_DT AP-1_NN site_NN ] ._.
[NP Charybdotoxin-sensitive_JJ ,_, Ca(2+)-dependent_JJ membrane_NN potential_JJ changes_NNS ][VP are_VBP not_RB involved_VBN ][PP in_IN ][NP human_JJ T_NN or_CC B_NN cell_NN ][NP activation_NN ] and_CC[NP proliferation_NN ] ._.
[NP The_DT involvement_NN ][PP of_IN ][NP ion_NN channels_NNS ][PP in_IN ][NP B_NN and_CC T_NN lymphocyte_NN activation_NN ][VP is_VBZ supported_VBN ][PP by_IN ][NP many_JJ reports_NNS ][PP of_IN ][NP changes_NNS ][PP in_IN ][NP ion_NN fluxes_NNS ] and_CC[NP membrane_NN potential_NN ][PP after_IN ][NP mitogen_NN binding_NN ] ._.
[NP Human_JJ T_NN and_CC B_NN lymphocytes_NNS ][VP demonstrate_VBP ][NP an_DT early_JJ and_CC transient_JJ hyperpolarization_NN ][PP after_IN ][NP ligand_JJ binding_NN ] ._.
[SBAR Inasmuch_RB as_IN ][NP the_DT change_NN ][PP in_IN ][NP membrane_NN potential_NN ][VP is_VBZ ][ADJP dependent_JJ ][PP on_IN ][NP elevation_NN ][PP of_IN ][NP free_JJ cytosolic_JJ calcium_NN ] ,_,[NP the_DT hyperpolarization_NN ][VP is_VBZ ][ADVP presumably_RB ][PP through_IN ][NP opening_NN ][PP of_IN ][NP Ca(2+)-stimulated_JJ K+_NN channels_NNS ] ._.
[NP We_PRP ][VP have_VBP used_VBN ][NP charybdotoxin_NN ] ,_,[NP a_DT known_JJ inhibitor_NN ][PP of_IN ][NP Ca(2+)-dependent_JJ K+_NN channels_NNS ] ,_,[VP to_TO study_VB ][NP the_DT role_NN ][PP of_IN ][NP these_DT channels_NNS ][PP in_IN ][NP lymphocyte_NN ][NP activation_NN ] and_CC[NP mitogenesis_NN ] ._.
[NP We_PRP ][VP demonstrate_VBP ][SBAR that_IN ][NP charybdotoxin_NN ][VP inhibits_VBZ ][NP the_DT ligand-induced_JJ transient_JJ membrane_NN hyperpolarization_NN ][PP in_IN ][NP B_NN ] and_CC[NP T_NN ][NP cells_NNS ][PP in_IN ][NP a_DT dose-dependent_JJ fashion_NN ] ,_,[PP without_IN ][VP affecting_VBG ][NP changes_NNS ][PP in_IN ][NP cytosolic_JJ Ca2+_NN ] ._.
[ADVP However_RB ] ,_,[NP blockade_NN ][PP of_IN ][NP the_DT Ca(2+)-activated_JJ K+_NN channel_NN ][VP is_VBZ not_RB associated_VBN ][PP with_IN ][NP changes_NNS ][PP in_IN ][NP cell-cycle_JJ gene_NN activation_NN ] ,_,[NP IL-2_NN production_NN ] ,_,[NP IL-2R_NN expression_NN ] or_CC[NP B_NN ] and_CC[NP T_NN ][NP cell_NN mitogenesis_NN ] ._.
[NP These_DT results_NNS ][VP imply_VBP ][SBAR that_IN ][NP membrane_NN potential_JJ changes_NNS ][ADJP secondary_JJ ][PP to_TO ][NP the_DT ligand-dependent_JJ opening_NN ][PP of_IN ][NP Ca(2+)-activated_JJ K+_NN channels_NNS ][VP are_VBP not_RB involved_VBN ][PP in_IN ][NP B_NN ] and_CC[NP T_NN ][NP lymphocyte_NN ][NP activation_NN ] and_CC[NP mitogenesis_NN ] ._.
[NP Evaluation_NN ][PP of_IN ][NP the_DT role_NN ][PP of_IN ][NP ligand_NN ] and_CC[NP thermal_JJ activation_NN ][PP of_IN ][NP specific_JJ DNA_NN binding_NN ][PP by_IN ][ADVP in_FW vitro_FW ][NP synthesized_VBN human_JJ glucocorticoid_NN receptor_NN ] ._.
[NP We_PRP ][VP have_VBP used_VBN ][NP a_DT DNA-binding/immunoprecipitation_JJ assay_NN ][VP to_TO analyze_VB ][NP the_DT capacity_NN ][PP of_IN ][NP human_JJ glucocorticoid_NN receptor_NN ] (_([NP hGR_NN ] )_) ,_,[VP generated_VBN ][PP in_IN ][NP rabbit_NN reticulocyte_NN lysates_NNS ] ,_,[VP to_TO bind_VB ][NP DNA_NN ] ._.
[ADVP In_FW vitro_FW ][NP translated_VBN hGR_NN ][VP was_VBD ][ADJP indistinguishable_JJ ][PP from_IN ][NP native_JJ hGR_NN ] ,_,[SBAR as_IN ][VP determined_VBN ][PP by_IN ][NP migration_NN ][PP on_IN ][NP sodium_NN dodecyl_NN sulfate-polyacrylamide_JJ gels_NNS ] ,_,[NP sedimentation_NN ][PP on_IN ][NP sucrose_NN density_NN gradients_NNS ] ,_, and_CC[NP reactivity_NN ][PP with_IN ][NP antipeptide_JJ antibodies_NNS ][VP generated_VBN ][PP against_IN ][NP hGR_NN ] ._.
[PP In_IN ][NP addition_NN ] ,_,[NP cell-free_JJ synthesized_VBN hGR_NN ][VP was_VBD ][ADJP capable_JJ ][PP of_IN ][NP specific_JJ binding_NN ][PP to_TO ][NP glucocorticoid_NN response_NN element_NN (_( GRE_NN )_) -containing_JJ DNA_NN fragments_NNS ] ._.
[VP Using_VBG ][NP this_DT assay_NN system_NN ] ,_,[NP we_PRP ][VP have_VBP evaluated_VBN ][NP the_DT contributions_NNS ][PP of_IN ][NP ligand_NN binding_NN ] and_CC[NP heat_NN activation_NN ][PP to_TO ][NP DNA_NN binding_NN ][PP by_IN ][NP these_DT glucocorticoid_NN receptors_NNS ] ._.
[ADVP In_FW vitro_FW ][NP translated_VBN hGR_NN ][VP was_VBD ][ADJP capable_JJ ][PP of_IN ][NP selective_JJ DNA_NN binding_NN ][PP even_RB in_IN the_DT absence_NN of_IN ][NP glucocorticoid_NN ] ._.
[NP Treatment_NN ][PP with_IN ][NP dexamethasone_NN ] or_CC[NP the_DT antiglucocorticoid_JJ RU486_NN ][VP had_VBD ][NP no_DT additional_JJ effect_NN ][PP on_IN ][NP the_DT DNA-binding_JJ capacity_NN ][ADVP when_WRB ][NP receptor_NN preparations_NNS ][VP were_VBD maintained_VBN ][PP at_IN ][NP 0_CD C_NN ] (_([NP no_DT activation_NN ] )_) ._.
[PP In_IN ][NP contrast_NN ] ,_,[NP addition_NN ][PP of_IN ] either_CC[NP ligand_NN ] or_CC[NP antagonist_NN ][PP in_IN ][NP combination_NN ][PP with_IN ][NP a_DT heat_NN activation_NN step_NN ][VP promoted_VBD ][NP DNA_NN binding_NN ][PP by_IN ][NP approximately_RB 3-fold_RB ][PP over_IN ][NP that_DT ][PP of_IN ][NP heat-activated_JJ unliganded_JJ receptors_NNS ] ._.
[NP Agonist_NN ] (_([NP dexamethasone_NN ] )_)[VP was_VBD ][ADJP slightly_RB more_JJR effective_JJ ][PP in_IN ][VP supporting_VBG ][NP specific_JJ DNA_NN binding_NN ][PP than_IN ][NP antagonist_NN ] (_([NP RU486_NN ] )_) ._.
[NP DNA_NN binding_NN ][PP by_IN ][ADVP in_FW vitro_FW ][NP synthesized_VBN GR_NN ][VP was_VBD blocked_VBN ][PP by_IN ][NP the_DT addition_NN ][PP of_IN ][NP sodium_NN molybdate_NN ][PP to_TO ][NP the_DT receptor_NN preparations_NNS ][PP before_IN ][NP steroid_NN addition_NN ] and_CC[NP thermal_JJ activation_NN ] ._.
[NP Addition_NN ][PP of_IN ][NP KCl_NN ][VP resulted_VBD ][PP in_IN ][NP less_RBR DNA_NN binding_NN ][PP either_CC due_JJ to_TO ][NP blockage_NN ][PP of_IN ][NP DNA-receptor_JJ complex_NN formation_NN ] or_CC[NP disruption_NN ][PP of_IN ][NP the_DT complexes_NNS ] ._.
[NP The_DT specificity_NN ][PP of_IN ][NP DNA_NN binding_NN ][PP by_IN ][NP cell-free_JJ synthesized_VBN hGR_NN ][VP was_VBD analyzed_VBN ][ADVP further_RB ][PP by_IN ][VP examining_VBG ][NP the_DT abilities_NNS ][PP of_IN ][NP various_JJ DNAs_NNS ][VP to_TO compete_VB ][PP for_IN ][VP binding_VBG ][PP to_TO ][NP a_DT naturally_RB occurring_VBG GRE_NN ][VP found_VBD ][PP in_IN ][NP the_DT mouse_NN mammary_JJ tumor_NN virus-long_JJ terminal_JJ repeat_NN ] ._.
[NP Oligonucleotides_NNS ][VP containing_VBG ][NP the_DT consensus_NN GRE_NN ][VP were_VBD ][NP the_DT most_RBS efficient_JJ competitors_NNS ] ,_, and_CC[NP fragments_NNS ][VP containing_VBG ][NP regulatory_JJ sequences_NNS ][PP from_IN ][NP glucocorticoid-repressible_JJ genes_NNS ][VP were_VBD ][ADJP somewhat_RB competitive_JJ ] ,_, whereas_IN[NP single_JJ stranded_JJ oligonucleotides_NNS ][VP were_VBD ][ADJP unable_JJ ][VP to_TO compete_VB ][PP for_IN ][NP mouse_NN mammary_JJ tumor_NN virus-long_JJ terminal_JJ repeat_NN DNA_NN binding_NN ] ,_,[PP except_IN ][ADVP when_WRB ][NP competitor_NN ][VP was_VBD ][ADJP present_JJ ][PP at_IN ][NP extremely_RB high_JJ concentrations_NNS ] ._.
[ADVP Together_RB ][NP these_DT studies_NNS ][VP indicate_VBP ][SBAR that_IN ][NP hGR_NN ][VP synthesized_VBN ][PP in_IN ][NP rabbit_NN reticulocyte_NN lysates_NNS ][VP displays_VBZ ][NP many_JJ ][PP of_IN ][NP the_DT same_JJ properties_NNS ] ,_,[PP including_VBG ][NP GRE-specific_JJ DNA_NN binding_NN ] ,_,[VP observed_VBN ][PP for_IN ][NP glucocorticoid_NN receptor_NN ][ADJP present_JJ ][PP in_IN ][NP cytosolic_JJ extracts_NNS ][PP of_IN ][NP mammalian_JJ ][NP cells_NNS ] and_CC[NP tissues_NNS ] ._.
[NP Similarities_NNS ][PP between_IN ][NP the_DT effects_NNS ][PP of_IN ][NP dexamethasone_NN ] and_CC[NP RU486_NN ][VP suggest_VBP ][SBAR that_IN ][NP the_DT antiglucocorticoid_JJ properties_NNS ][PP of_IN ][NP RU486_NN ][VP do_VBP not_RB occur_VB ][PP at_IN ][NP the_DT level_NN ][PP of_IN ][NP specific_JJ DNA_NN binding_NN ] ._.
[NP One_CD base_NN pair_NN change_NN ][VP abolishes_VBZ ][NP the_DT T_NN cell-restricted_JJ activity_NN ][PP of_IN ][NP a_DT kB-like_JJ proto-enhancer_NN element_NN ][PP from_IN ][NP the_DT interleukin_NN 2_CD promoter_NN ] ._.
[NP The_DT inducible_JJ ,_, T_NN cell-specific_JJ enhancers_NNS ][PP of_IN ] murine_JJ and_CC human_JJ[NP Interleukin_NN 2_CD ] (_([NP Il-2_NN ] )_)[NP genes_NNS ][VP contain_VBP ][NP the_DT kB-like_JJ sequence_NN GGGATTTCACC_NN ][PP as_IN ][NP an_DT essential_JJ cis-acting_JJ enhancer_NN motif_NN ] ._.
[ADVP When_WRB ][VP cloned_VBN ][PP in_IN ][NP multiple_JJ copies_NNS ][NP this_DT so-called_JJ ][NP TCEd_NN ] (_([NP distal_JJ T_NN cell_NN element_NN ] )_)[VP acts_VBZ ][PP as_IN ][NP an_DT inducible_JJ proto-enhancer_NN element_NN ][PP in_IN ][NP E14_NN T_NN lymphoma_NN cells_NNS ][PP ,_, but_CC ][PP not_RB in_IN ][NP HeLa_NN cells_NNS ] ._.
[PP In_IN ][NP extracts_NNS ][PP of_IN ][NP induced_VBN ,_, Il-2_NN secreting_NN El4_NN cells_NNS ][NP three_CD individual_JJ protein_NN factors_NNS ][VP bind_VBP ][PP to_TO ][NP TCEd_NN DNA_NN ] ._.
[NP The_DT binding_NN ][PP of_IN ][NP the_DT most_RBS prominent_JJ factor_NN ] ,_,[VP named_VBN ][NP TCF-1_NN ] (_([NP T_NN cell_NN factor_NN 1_CD ] )_) ,_,[VP is_VBZ correlated_VBN ][PP with_IN ][NP the_DT proto-enhancer_NN activity_NN ][PP of_IN ][NP TCEd_NN ] ._.
[NP TCF-1_NN ][VP consists_VBZ ][PP of_IN ][NP two_CD polypeptides_NNS ][PP of_IN ][ADVP about_RB ][NP 50_CD kD_NN ] and_CC[NP 105_CD kD_NN ] ;_:[NP the_DT former_JJ ][VP seems_VBZ to_TO be_VB ][ADJP related_JJ ][PP to_TO ][NP the_DT ][NP 50_CD kD_NN ][NP polypeptide_NN ][PP of_IN ][NP NF-kB_NN ] ._.
[NP Purified_VBN NF-kB_NN ][VP is_VBZ ][ADJP also_RB able_JJ ][VP to_TO bind_VB ][PP to_TO ][NP the_DT TCEd_NN ] ,_, but_CC[NP TCF-1_NN ][VP binds_VBZ ][ADVP stronger_JJR ][PP than_IN ][NP NF-kB_NN ][PP to_TO ][NP TCEd_NN DNA_NN ] ._.
[NP The_DT conversion_NN ][PP of_IN ][NP the_DT TCEd_NN ][PP to_TO ][NP a_DT '_[[DQS]] perfect_JJ '_[[DQE]] NF-kB_NN binding_NN site_NN ][VP leads_VBZ ][PP to_TO ][NP a_DT tighter_JJR binding_NN ][PP of_IN ][NP NF-kB_NN ][PP to_TO ][NP TCEd_NN DNA_NN ] and_CC ,_,[PP as_IN ][NP a_DT functional_JJ consequence_NN ] ,_,[PP to_TO ][NP the_DT activity_NN ][PP of_IN ][NP the_DT '_[[DQS]] converted_VBN '_[[DQE]] TCEd_NN motifs_NNS ][PP in_IN ][NP HeLa_NN cells_NNS ] ._.
[ADVP Thus_RB ] ,_,[NP the_DT substitution_NN ][PP of_IN ][NP the_DT underlined_VBN A_NN residue_NN ][PP to_TO ][NP a_DT C_NN ][PP within_IN ][NP the_DT GGGATTTCACC_NN motif_NN ][VP abolishes_VBZ ][NP its_PRP$ T_NN cell-restricted_JJ activity_NN ] and_CC[VP leads_VBZ ][PP to_TO ][NP its_PRP$ ][VP functioning_VBG ][PP in_IN ] both_CC[NP El4_NN cells_NNS ] and_CC[NP HeLa_NN cells_NNS ] ._.
[NP These_DT results_NNS ][VP indicate_VBP ][SBAR that_IN ][NP lymphocyte-specific_JJ factors_NNS ][VP binding_VBG ][PP to_TO ][NP the_DT TCEd_NN ][VP are_VBP involved_VBN ][PP in_IN ][NP the_DT control_NN ][PP of_IN ][NP T_NN cell_NN specific-transcription_NN ][PP of_IN ][NP the_DT Il-2_NN gene_NN ] ._.
[NP Negative_JJ regulation_NN ][PP of_IN ][NP human_JJ immunodeficiency_NN virus_NN type_NN 1_CD expression_NN ][PP in_IN ][NP monocytes_NNS ] :_:[NP role_NN ][PP of_IN ][NP the_DT 65-kDa_JJ plus_CC 50-kDa_JJ NF-kappa_NN B_NN dimer_NN ] ._.
[SBAR Although_IN ][NP monocytic_JJ cells_NNS ][VP can_MD provide_VB ][NP a_DT reservoir_NN ][PP for_IN ][NP viral_JJ production_NN ][ADVP in_FW vivo_FW ] ,_,[NP their_PRP$ regulation_NN ][PP of_IN ][NP human_JJ immunodeficiency_NN virus_NN type_NN 1_CD ] (_([NP HIV-1_NN ] )_)[NP transcription_NN ][VP can_MD be_VB ] either_CC[ADJP latent_JJ ] ,_,[ADJP restricted_JJ ] ,_, or_CC[ADJP productive_JJ ] ._.
[NP These_DT differences_NNS ][PP in_IN ][NP gene_NN expression_NN ][VP have_VBP not_RB been_VBN ][ADJP molecularly_RB defined_VBN ] ._.
[PP In_IN ][NP THP-1_NN cells_NNS ][PP with_IN ][NP restricted_JJ HIV_NN expression_NN ] ,_,[NP there_EX ][VP is_VBZ ][NP an_DT absence_NN ][PP of_IN ][NP DNA-protein_JJ binding_NN complex_NN formation_NN ][PP with_IN ][NP the_DT HIV-1_NN promoter-enhancer_NN ][VP associated_VBN ][PP with_IN ][ADVP markedly_RB less_JJR ][NP viral_JJ RNA_NN production_NN ] ._.
[NP This_DT absence_NN ][PP of_IN ][NP binding_NN ][VP was_VBD ][ADJP localized_JJ ][PP to_TO ][NP the_DT NF-kappa_NN B_NN region_NN ][PP of_IN ][NP the_DT HIV-1_NN enhancer_NN ] ;_:[NP the_DT 65-kDa_JJ plus_CC 50-kDa_JJ NF-kappa_NN B_NN heterodimer_NN ][VP was_VBD ][ADJP preferentially_RB lost_VBN ] ._.
[VP Adding_VBG ][NP purified_VBN NF-kappa_NN B_NN protein_NN ][PP to_TO ][NP nuclear_JJ extracts_NNS ][PP from_IN ][NP cells_NNS ][PP with_IN ][NP restricted_JJ expression_NN ][VP overcomes_VBZ ][NP this_DT lack_NN ][PP of_IN ][NP binding_NN ] ._.
[PP In_IN ][NP addition_NN ] ,_,[NP treatment_NN ][PP of_IN ][NP these_DT nuclear_JJ extracts_NNS ][PP with_IN ][NP sodium_NN deoxycholate_NN ][VP restored_VBD ][NP their_PRP$ ability_NN ][VP to_TO form_VB ][NP the_DT heterodimer_NN ] ,_,[VP suggesting_VBG ][NP the_DT presence_NN ][PP of_IN ][NP an_DT inhibitor_NN ][PP of_IN ][NP NF-kappa_NN B_NN activity_NN ] ._.
[ADVP Furthermore_RB ] ,_,[NP treatment_NN ][PP of_IN ][NP nuclear_JJ extracts_NNS ][PP from_IN ][NP these_DT cells_NNS ][NP that_WDT ][VP had_VBD ][NP restricted_JJ expression_NN ][PP with_IN ][NP lipopolysaccharide_NN ][VP increased_VBD ][NP viral_JJ production_NN ] and_CC[NP NF-kappa_NN B_NN activity_NN ] ._.
[NP Antiserum_NN ][ADJP specific_JJ ][PP for_IN ][NP NF-kappa_NN B_NN binding_NN proteins_NNS ] ,_,[CONJP but_CC not_RB ][NP c-rel-specific_JJ antiserum_NN ] ,_,[VP disrupted_VBD ][NP heterodimer_NN complex_NN formation_NN ] ._.
[ADVP Thus_RB ] ,_,[NP both_DT NF-kappa_NN B-binding_JJ complexes_NNS ][VP are_VBP needed_VBN ][PP for_IN ][NP optimal_JJ viral_JJ transcription_NN ] ._.
[NP Binding_NN ][PP of_IN ][NP the_DT 65-kDa_JJ plus_CC 50-kDa_JJ heterodimer_NN ][PP to_TO ][NP the_DT HIV-1_NN enhancer_NN ][VP can_MD be_VB negatively_RB regulated_VBN ][PP in_IN ][NP monocytes_NNS ] ,_,[VP providing_VBG ][NP one_CD mechanism_NN ][VP restricting_VBG ][NP HIV-1_NN gene_NN expression_NN ] ._.
[NP Isolation_NN ][PP of_IN ][NP a_DT candidate_NN ][NP repressor/activator_NN ] ,_,[NP NF-E1_NN ] (_([NP YY-1_NN ,_, delta_NN ] )_) ,_,[NP that_WDT ][VP binds_VBZ ][PP to_TO ][NP the_DT immunoglobulin_NN kappa_NN 3'_JJ enhancer_NN ] and_CC[NP the_DT immunoglobulin_NN heavy-chain_NN mu_NN E1_NN site_NN ] ._.
[NP We_PRP ][VP have_VBP determined_VBN ][SBAR that_IN ][NP the_DT developmental_JJ control_NN ][PP of_IN ][NP immunoglobulin_NN kappa_NN 3'_JJ enhancer_NN (_( kappa_NN E3'_NN )_) activity_NN ][VP is_VBZ ][NP the_DT result_NN ][PP of_IN ][NP the_DT combined_JJ influence_NN ][PP of_IN ][NP positive-_JJ and_CC negative-acting_JJ elements_NNS ] ._.
[NP We_PRP ][VP show_VBP ][SBAR that_IN ][NP a_DT central_JJ core_NN ][PP in_IN ][NP the_DT kappa_NN E3'_NN enhancer_NN ][VP is_VBZ ][ADJP active_JJ ][PP at_IN ][NP the_DT pre-B-cell_JJ stage_NN ] but_CC[VP is_VBZ repressed_VBN ][PP by_IN ][NP flanking_VBG negative-acting_JJ elements_NNS ] ._.
[NP The_DT negative-acting_JJ sequences_NNS ][VP repress_VBP ][NP enhancer_NN activity_NN ][PP in_IN ] a_DT[NP position-_NN ] and_CC[ADJP orientation-independent_JJ ][NP manner_NN ][PP at_IN ][NP the_DT pre-B-cell_JJ stage_NN ] ._.
[NP We_PRP ][VP have_VBP isolated_VBN ][NP a_DT human_JJ cDNA_NN clone_NN ][VP encoding_VBG ][NP a_DT zinc_NN finger_NN protein_NN ] (_([NP NF-E1_NN ] )_)[NP that_WDT ][VP binds_VBZ ][PP to_TO ][NP the_DT negative-acting_JJ segment_NN ][PP of_IN ][NP the_DT kappa_NN E3'_NN enhancer_NN ] ._.
[NP This_DT protein_NN ][ADVP also_RB ][VP binds_VBZ ][PP to_TO ][NP the_DT immunoglobulin_NN heavy-chain_NN enhancer_NN mu_NN E1_NN site_NN ] ._.
[NP NF-E1_NN ][VP is_VBZ encoded_VBN ][PP by_IN ][NP the_DT same_JJ gene_NN ][PP as_IN ][NP the_DT YY-1_NN protein_NN ] ,_,[NP which_WDT ][VP binds_VBZ ][PP to_TO ][NP the_DT adeno-associated_JJ virus_NN P5_NN promoter_NN ] ._.
[NP NF-E1_NN ][VP is_VBZ ][ADVP also_RB ][NP the_DT human_JJ homologue_NN ][PP of_IN ][NP the_DT mouse_NN delta_NN protein_NN ] ,_,[NP which_WDT ][VP binds_VBZ ][PP to_TO ][NP ribosomal_JJ protein_NN gene_NN promoters_NNS ] ._.
[NP The_DT predicted_VBN amino_NN acid_NN sequence_NN ][PP of_IN ][NP this_DT protein_NN ][VP contains_VBZ ][NP features_NNS ][ADJP characteristic_JJ ][PP of_IN ][NP transcriptional_JJ activators_NNS ][CONJP as_RB well_RB as_IN ][NP transcriptional_JJ repressors_NNS ] ._.
[NP Cotransfection_NN studies_NNS ][PP with_IN ][NP this_DT cDNA_NN ][VP indicate_VBP ][SBAR that_IN ][NP it_PRP ][VP can_MD repress_VB ][NP basal_JJ promoter_NN activity_NN ] ._.
[NP The_DT apparent_JJ dual_JJ function_NN ][PP of_IN ][NP this_DT protein_NN ][VP is_VBZ discussed_VBN ] ._.
[NP Clone_NN pAT_NN 133_CD ][VP identifies_VBZ ][NP a_DT gene_NN ][NP that_WDT ][VP encodes_VBZ ][NP another_DT human_JJ member_NN ][PP of_IN ][NP a_DT class_NN ][PP of_IN ][NP growth_NN factor-induced_JJ genes_NNS ][PP with_IN ][NP almost_RB identical_JJ zinc-finger_NN domains_NNS ] ._.
[NP We_PRP ][VP report_VBP ][NP the_DT ][NP structure_NN ] and_CC[NP regulation_NN ][PP of_IN ][NP a_DT gene_NN ][VP represented_VBN ][PP by_IN ][NP clone_NN pAT_NN 133_CD ] ,_,[NP which_WDT ][VP is_VBZ induced_VBN ][PP upon_IN ][NP transition_NN ][PP from_IN ][NP a_DT resting_JJ state_NN ] (_([NP G0_NN ] )_)[PP through_IN ][NP the_DT early_JJ phase_NN ][PP of_IN ][NP the_DT cell_NN cycle_NN ] (_([NP G1_NN ] )_) ._.
[NP The_DT pAT_NN 133_CD gene_NN ][VP is_VBZ immediately_RB induced_VBN ] ,_,[PP with_IN ][NP FOS-like_JJ kinetics_NNS ] ,_,[PP in_IN ][NP human_JJ T_NN cells_NNS ][PP and_CC ][PP in_IN ][NP fibroblasts_NNS ] ._.
[NP Primary_JJ structure_NN analysis_NN ][VP showed_VBD ][SBAR that_IN ][NP the_DT encoded_VBN protein_NN ][VP contains_VBZ ][NP three_CD tandem_JJ zinc-finger_NN sequences_NNS ][PP of_IN ][NP the_DT type_NN Cys2-Xaa12-His2_NN ] ._.
[NP This_DT zinc-finger_NN region_NN ] ,_,[NP which_WDT ][VP is_VBZ thought_VBN to_TO bind_VB ][NP DNA_NN ][PP in_IN ][NP a_DT sequence-specific_JJ manner_NN ] ,_,[VP is_VBZ ][ADJP similar_JJ ] (_([NP greater_JJR than_IN 80_CD %_NN ][PP on_IN ][NP the_DT amino_NN acid_NN level_NN ] )_)[PP to_TO ][NP two_CD previously_RB described_VBN transcription_NN factors_NNS ][NP pAT_NN 225/EGR1_NN ] and_CC[NP pAT_NN 591/EGR2_NN ] ._.
[PP Except_IN for_IN ][NP the_DT conserved_VBN zinc-finger_NN domains_NNS ] ,_,[NP the_DT amino_NN acid_NN sequences_NNS ][PP of_IN ][NP the_DT three_CD proteins_NNS ][VP are_VBP ][ADJP distinct_JJ ] ._.
[NP This_DT structural_JJ similarity_NN ][VP suggests_VBZ ][SBAR that_IN ][NP the_DT pAT_NN 133_CD gene_NN ][VP encodes_VBZ ][NP a_DT transcription_NN factor_NN ][PP with_IN ][NP a_DT specific_JJ biological_JJ function_NN ] ._.
[VP Comparing_VBG ][NP the_DT regulation_NN ][PP of_IN ][NP these_DT related_JJ zinc-finger-encoding_JJ genes_NNS ][VP showed_VBD ][NP coordinate_JJ induction_NN ][PP upon_IN ][NP mitogenic_JJ stimulation_NN ][PP of_IN ][NP resting_VBG T_NN lymphocytes_NNS ][PP and_CC ][PP of_IN ][NP resting_VBG fibroblasts_NNS ] ._.
[ADVP However_RB ] ,_,[PP upon_IN ][NP transition_NN ][PP from_IN ][NP a_DT proliferating_JJ ] (_([NP G1_NN ] )_)[PP to_TO ][NP a_DT resting_JJ ][NP state_NN ][PP of_IN ][NP the_DT cell_NN cycle_NN ][NP the_DT three_CD genes_NNS ][VP were_VBD differently_RB regulated_VBN ] ._.
[PP In_IN ][NP human_JJ histiocytic_JJ U937_NN cells_NNS ][NP mRNA_NN ][PP of_IN ][NP clone_NN pAT_NN 133_CD ][VP was_VBD constitutively_RB expressed_VBN ] ,_, whereas_IN[NP mRNA_NN ][PP of_IN ][NP pAT_NN 225/EGR1_NN ][VP was_VBD induced_VBN ][PP upon_IN ][NP induction_NN ][PP of_IN ][NP terminal_JJ differentiation_NN ] ._.
[PP In_IN ][NP contrast_NN ][NP mRNA_NN ][VP representing_VBG ][NP pAT_NN 591/EGR2_NN ][VP was_VBD not_RB expressed_VBN ][PP in_IN ][NP these_DT cells_NNS ] ._.
[NP This_DT difference_NN ][PP in_IN ][NP gene_NN regulation_NN ][VP suggests_VBZ ][NP distinct_JJ biological_JJ roles_NNS ][PP in_IN ][NP the_DT control_NN ][PP of_IN ][NP cell_NN proliferation_NN ][PP for_IN ][NP the_DT respective_JJ proteins_NNS ] ._.
[NP cAMP-dependent_JJ regulation_NN ][PP of_IN ][NP proenkephalin_NN ][PP by_IN ][NP JunD_NN ] and_CC[NP JunB_NN ] :_:[NP positive_JJ and_CC negative_JJ effects_NNS ][PP of_IN ][NP AP-1_NN proteins_NNS ] ._.
[NP We_PRP ][VP demonstrate_VBP ][SBAR that_IN ][NP JunD_NN ] ,_,[NP a_DT component_NN ][PP of_IN ][NP the_DT AP-1_NN transcription_NN factor_NN complex_NN ] ,_,[VP activates_VBZ ][NP transcription_NN ][PP of_IN ][NP the_DT human_JJ proenkephalin_NN gene_NN ][PP in_IN ][NP a_DT fashion_NN ][NP that_WDT ][VP is_VBZ ][ADJP completely_RB dependent_JJ ][PP upon_IN ][NP the_DT cAMP-dependent_JJ protein_NN kinase_NN ] ,_,[NP protein_NN kinase_NN A_NN ] ._.
[NP Activation_NN ][PP of_IN ][NP proenkephalin_NN transcription_NN ][PP by_IN ][NP JunD_NN ][VP is_VBZ ][ADJP dependent_JJ ][PP upon_IN ] a_DT previously_RB characterized_VBN[NP cAMP-_NN ] ,_,[NP phorbol_NN ester-_NN ] ,_, and_CC[ADJP Ca(2+)-inducible_JJ ][NP enhancer_NN ] ,_, and_CC[NP JunD_NN ][VP is_VBZ shown_VBN to_TO bind_VB ][NP the_DT enhancer_NN ][PP as_IN ][NP a_DT homodimer_NN ] ._.
[NP Another_DT component_NN ][PP of_IN ][NP the_DT AP-1_NN transcription_NN complex_NN ] ,_,[NP JunB_NN ] ,_,[VP is_VBZ shown_VBN to_TO inhibit_VB ][NP activation_NN ][VP mediated_VBN ][PP by_IN ][NP JunD_NN ] ._.
[PP As_IN ][NP a_DT homodimer_NN ][NP JunB_NN ][VP is_VBZ ][ADJP unable_JJ ][VP to_TO bind_VB ][NP the_DT enhancer_NN ] ;_: however_RB[PP in_IN the_DT presence_NN of_IN ][NP c-Fos_NN ] ,_,[NP high-affinity_JJ binding_NN ][VP is_VBZ observed_VBN ] ._.
[ADVP Furthermore_RB ] ,_,[NP JunD_NN ][VP is_VBZ shown_VBN to_TO activate_VB ][NP transcription_NN ][PP of_IN ][NP genes_NNS ][VP linked_VBN ][PP to_TO ] both_CC[NP cAMP_NN ] and_CC[NP phorbol_NN ester_NN ][NP response_NN elements_NNS ][PP in_IN ][NP a_DT protein_NN kinase_NN A-dependent_JJ fashion_NN ] ,_,[ADVP further_RB ][VP blurring_VBG ][NP the_DT distinction_NN ][PP between_IN ][NP these_DT response_NN elements_NNS ] ._.
[NP These_DT results_NNS ][VP demonstrate_VBP ][SBAR that_IN ][NP the_DT transcriptional_JJ activity_NN ][PP of_IN ][NP an_DT AP-1-related_JJ protein_NN ][VP is_VBZ regulated_VBN ][PP by_IN ][NP the_DT cAMP-dependent_JJ second-messenger_NN pathway_NN ] and_CC[VP suggest_VBP ][SBAR that_IN ][NP JunD_NN ] and_CC[NP other_JJ AP-1-related_JJ proteins_NNS ][VP may_MD play_VB ][NP an_DT important_JJ role_NN ][PP in_IN ][NP the_DT regulation_NN ][PP of_IN ][NP gene_NN expression_NN ][PP by_IN ][NP cAMP-dependent_JJ intracellular_JJ signaling_NN pathways_NNS ] ._.
[NP Glucocorticoid_NN resistance_NN ][PP in_IN ][NP chronic_JJ asthma_NN ] ._.
[NP Glucocorticoid_NN pharmacokinetics_NNS ] ,_,[NP glucocorticoid_NN receptor_NN characteristics_NNS ] ,_, and_CC[NP inhibition_NN ][PP of_IN ][NP peripheral_JJ blood_NN T_NN cell_NN proliferation_NN ][PP by_IN ][NP glucocorticoids_NNS ][ADJP in_FW vitro_FW ] ._.
[NP A_DT total_NN ][PP of_IN ][NP 37_CD chronic_JJ ,_, severe_JJ ,_, nonsmoking_JJ asthmatic_JJ patients_NNS ][PP with_IN ][NP documented_JJ|VBN reversible_JJ airways_NNS obstruction_NN ][VP were_VBD classified_VBN ][PP as_IN ][ADJP glucocorticoid-sensitive_JJ ] or_CC[ADJP -resistant_JJ ][PP on_IN the_DT basis_NN of_IN ][NP changes_NNS ][PP in_IN ][NP FEV1_NN ] ,_,[NP FVC_NN ] ,_, and_CC[NP peak_JJ expiratory_NN flow_NN ] (_([NP PEF_NN ] )_)[PP after_IN ][NP oral_JJ prednisolone_NN ] ._.
[NP The_DT resistant_JJ patients_NNS ][VP showed_VBD ][NP no_DT significant_JJ improvements_NNS ][PP in_IN ][NP airflow_NN limitation_NN ] ._.
[NP Phytohemagglutinin_NN (_( PHA_NN )_) -induced_JJ proliferation_NN ][PP of_IN ][NP peripheral_JJ blood_NN T_NN lymphocytes_NNS ][PP from_IN ][NP the_DT sensitive_JJ ][CONJP but_CC not_RB ][NP the_DT resistant_JJ ][NP asthmatic_JJ patients_NNS ] was_VBD significantly_RB (_([NP p_NN ][ADJP less_JJR ][PP than_IN ][NP 0.01_CD ] )_)[VP inhibited_VBN ][PP by_IN ][NP dexamethasone_NN ] (_([NP 10(-7)_CD mol/L_NN ] )_) ,_,[VP reflecting_VBG ][NP a_DT shift_NN ][PP of_IN ][NP the_DT dose-response_JJ curve_NN ] ._.
[ADVP When_WRB ][NP all_PDT the_DT asthmatic_JJ patients_NNS ][VP were_VBD analyzed_VBN ][ADVP together_RB ] ,_,[NP there_EX ][VP was_VBD ][NP a_DT significant_JJ correlation_NN ][PP between_IN ][NP the_DT degree_NN ][PP of_IN ][NP sensitivity_NN ][PP of_IN ][NP T_NN cells_NNS ][PP to_TO ][NP dexamethasone_NN ] and_CC[NP the_DT clinical_JJ responsiveness_NN ][PP to_TO ][NP prednisolone_JJ ] (_([NP p_NN ][ADJP less_RBR ][PP than_IN ][NP 0.01_CD ] )_) ._.
[NP No_DT differences_NNS ][VP were_VBD observed_VBN ][PP between_IN ][NP six_CD ][PP of_IN ][NP the_DT sensitive_JJ and_CC resistant_JJ patients_NNS ][PP in_IN ][NP the_DT clearance_NN ][PP of_IN ][NP plasma_NN prednisolone_JJ ][VP derived_VBN ][PP from_IN ][NP orally_RB administered_VBN prednisone_NN ] ._.
[NP Peripheral_JJ blood_NN mononuclear_JJ cell_NN glucocorticoid_NN receptors_NNS ][VP were_VBD also_RB characterized_VBN ][PP in_IN ][NP five_CD sensitive_JJ ] and_CC[NP seven_CD resistant_JJ ][NP patients_NNS ] ._.
[NP The_DT ][NP numbers_NNS ] and_CC[NP binding_NN affinities_NNS ][PP of_IN ][NP these_DT receptors_NNS ][VP could_MD not_RB account_VB ][PP for_IN ][NP the_DT observed_VBN difference_NN ][PP in_IN ][NP the_DT susceptibility_NN ][PP of_IN ][NP these_DT cells_NNS ][PP to_TO ][NP functional_JJ inhibition_NN ][PP by_IN ][NP dexamethasone_NN ][ADJP in_FW vitro_FW ] ._.
[NP These_DT results_NNS ][VP suggest_VBP ][SBAR that_IN ][NP clinical_JJ glucocorticoid_NN resistance_NN ][PP in_IN ][NP chronic_JJ asthma_NN ][VP does_VBZ not_RB reflect_VB ][NP abnormal_JJ glucocorticoid_NN clearance_NN ] but_CC[VP may_MD be_VB ] due_JJ[ADVP at_IN least_JJS ][ADVP partly_RB ][PP to_TO ][NP a_DT relative_JJ insensitivity_NN ][PP of_IN ][NP T_NN lymphocytes_NNS ][PP to_TO ][NP glucocorticoids_NNS ] ._.
[NP This_DT lack_NN ][PP of_IN ][NP sensitivity_NN ][VP is_VBZ ][ADJP unexplained_JJ ] but_CC[VP is_VBZ ] not_RB[ADJP attributable_JJ ][PP to_TO ][NP abnormalities_NNS ][PP of_IN ][NP cellular_JJ glucocorticoid_NN receptors_NNS ] ._.
[NP Regulation_NN ][PP of_IN ][NP interleukin-1_NN beta_NN production_NN ][PP by_IN ][NP glucocorticoids_NNS ][PP in_IN ][NP human_JJ monocytes_NNS ] :_:[NP the_DT mechanism_NN ][PP of_IN ][NP action_NN ][VP depends_VBZ ][PP on_IN ][NP the_DT activation_NN signal_NN ] ._.
[NP Glucocorticoids_NNS ][VP are_VBP known_VBN to_TO downregulate_VB ][NP interleukin-1_NN beta_NN production_NN ][PP in_IN ][NP monocytic_JJ cells_NNS ][PP by_IN ][NP two_CD different_JJ mechanims_NNS ] :_:[NP direct_JJ inhibition_NN ][PP of_IN ][NP the_DT gene_NN transcription_NN ] and_CC[NP destabilization_NN ][PP of_IN ][NP the_DT preformed_JJ interleukin-1_NN beta_NN mRNA_NN ] ._.
[ADVP Now_RB ][NP we_PRP ][VP have_VBP examined_VBN ][NP the_DT effect_NN ][PP of_IN ][NP the_DT nature_NN ][PP of_IN ][NP the_DT monocyte_NN activating_NN signal_NN ][PP on_IN ][NP these_DT two_CD inhibitory_JJ mechanims_NNS ] ._.
[ADVP When_WRB ][NP human_JJ monocytes_NNS ][VP were_VBD preincubated_VBN ][PP with_IN ][NP dexamethasone_NN ][PP for_IN ][NP 1_CD hour_NN ] and_CC then_RB[VP stimulated_VBN ][PP either_CC with_IN ][NP bacterial_JJ lipopolysaccharide_NN ] or_CC[NP phorbol_NN myristate_NN ] ,_,[NP it_PRP ][VP was_VBD found_VBN ][SBAR that_IN ][NP dexamethasone_NN ][VP inhibited_VBD ][NP the_DT lipopolysaccharide-induced_JJ interleukin-1_NN beta_NN protein_NN production_NN ] ,_, but_CC[NP the_DT phorbol_NN myristate-induced_JJ production_NN ][VP was_VBD increased_VBN ][NP 3-10_CD fold_RB ] ._.
[NP This_DT difference_NN ][VP was_VBD also_RB seen_VBN ][PP at_IN ][NP the_DT mRNA_NN level_NN ] ._.
[ADVP When_WRB ][NP dexamethasone_NN ][VP was_VBD added_VBN ][PP to_TO ][NP the_DT cultures_NNS ][NP 3_CD hours_NNS ][PP after_IN ][NP the_DT stimulators_NNS ] ,_,[NP it_PRP ][ADVP clearly_RB ][VP decreased_VBD ][NP the_DT interleukin-1_NN beta_NN mRNA_NN levels_NNS ][ADVP regardless_RB ][PP of_IN ][NP the_DT stimulator_NN ][VP used_VBN ] (_([SBAR although_IN ][NP the_DT effect_NN ][VP was_VBD ][ADJP clearly_RB weaker_JJR ][PP on_IN ][NP the_DT PMA-induced_JJ mRNA_NN ] )_) ._.
[ADVP Thus_RB ][NP these_DT data_NNS ][VP suggest_VBP ][SBAR that_IN ][NP the_DT phorbol_NN myristate-induced_JJ signal_NN ] (_([NP prolonged_JJ protein_NN kinase_NN C_NN activation_NN ] ?_. )_)[VP can_MD not_RB be_VB inhibited_VBN ][PP by_IN ][NP prior_JJ incubation_NN ][PP with_IN ][NP dexamethasone_NN ] and_CC[NP it_PRP ][ADVP also_RB ][VP protects_VBZ ][NP the_DT induced_VBN mRNA_NN ][PP for_IN ][NP the_DT degradative_JJ action_NN ][PP of_IN ][NP dexamethasone_NN ] ._.
[NP Identification_NN ][PP of_IN ][NP transcriptional_JJ suppressor_NN proteins_NNS ][NP that_WDT ][VP bind_VBP ][PP to_TO ][NP the_DT negative_JJ regulatory_JJ element_NN ][PP of_IN ][NP the_DT human_JJ immunodeficiency_NN virus_NN type_NN 1_CD ] ._.
[NP Two_CD different_JJ proteins_NNS ][NP which_WDT ][ADVP independently_RB ][VP bound_VBD ][PP to_TO ][NP neighboring_VBG sequences_NNS ][PP within_IN ][NP the_DT negative_JJ regulatory_JJ element_NN ] (_([NP NRE_NN ] )_)[PP of_IN ][NP human_JJ immunodeficiency_NN virus_NN type_NN 1_CD ] (_([NP HIV-1_NN ] )_)[VP were_VBD detected_VBN ][PP in_IN ][NP the_DT nuclear_JJ extract_NN ][PP of_IN ][NP a_DT virus-infected_JJ human_JJ T_NN cell_NN line_NN ] ._.
[NP One_CD ][PP of_IN ][NP the_DT factors_NNS ][VP bound_VBD ][PP to_TO ][NP a_DT novel_JJ dyad_NN symmetrical_JJ sequence_NN ] ._.
[NP This_DT sequence_NN ][VP is_VBZ well_RB conserved_VBN ][PP in_IN ][NP various_JJ HIV-1_NN isolates_NNS ] and_CC[NP partial_JJ homology_NN ][VP was_VBD found_VBN ][PP with_IN ][NP the_DT promoter_JJ region_NN ][PP of_IN ][NP the_DT human_JJ retinoblastoma_NN gene_NN ] ._.
[NP Similar_JJ DNA_NN binding_NN activity_NN ][VP was_VBD detected_VBN ][PP in_IN ][NP a_DT variety_NN ][PP of_IN ][NP virus-uninfected_JJ human_JJ ][NP T_NN cell_NN lines_NNS ] and_CC[NP HeLa_NN cells_NNS ][PP by_IN means_NNS of_IN ][NP a_DT gel_NN mobility_NN shift_NN assay_NN ] ._.
[NP The_DT other_JJ factor_NN ][VP bound_VBN ][PP to_TO ][NP a_DT putative_JJ AP-1_NN recognition_NN sequence_NN ][VP predicted_VBD ][PP for_IN ][NP the_DT HIV-1_NN NRE_NN ] ._.
[ADVP However_RB ] ,_,[NP this_DT factor_NN ][VP did_VBD not_RB bind_VB ][PP to_TO ][NP a_DT typical_JJ AP-1_NN site_NN ] ._.
[NP The_DT insertion_NN ][PP of_IN ][NP multiple_JJ copies_NNS ][PP of_IN ][NP the_DT binding_VBG site_NN ][PP for_IN ][NP the_DT former_JJ or_CC latter_JJ factor_NN ][PP into_IN ][NP a_DT heterologous_JJ promoter_NN ][VP reduced_VBD ][NP the_DT promoter_NN activity_NN ][PP to_TO ][NP one-tenth_CD ] or_CC[NP one-third_CD ] ,_,[ADVP respectively_RB ] ._.
[ADVP Thus_RB ] ,_,[NP each_DT factor_NN ][VP may_MD function_VB ][PP as_IN ][NP a_DT novel_JJ negative_JJ regulator_NN ][PP of_IN ][NP transcription_NN ] ._.
[NP Constitutive_JJ activation_NN ][PP of_IN ][NP NF-kB_NN ][PP in_IN ][NP human_JJ thymocytes_NNS ] ._.
[NP NF-kB_NN ][VP is_VBZ ][NP a_DT eukaryotic_JJ transcription_NN regulatory_JJ factor_NN ] ._.
[PP In_IN ][NP T_NN cells_NNS ] and_CC[NP T_NN cell_NN lines_NNS ] ,_,[NP NF-kB_NN ][VP is_VBZ bound_VBN ][PP to_TO ][NP a_DT cytoplasmic_JJ proteic_JJ inhibitor_NN ] ,_,[NP the_DT IkB_NN ] ._.
[NP Treatment_NN ][PP of_IN ][NP T_NN cells_NNS ][PP with_IN ][NP mitogens_NNS ] (_([NP phorbol_NN esters_NNS ] )_) or_CC[NP cytokines_NNS ] (_([NP TNF_NN alpha_NN ] )_)[VP induces_VBZ ][NP NF-kB_NN nuclear_JJ translocation_NN ] and_CC[NP the_DT subsequent_JJ expression_NN ][PP of_IN ][NP NF-kB_NN dependent_JJ T_NN cell_NN genes_NNS ] ._.
[ADVP Here_RB ][NP we_PRP ][VP examined_VBD ][NP the_DT activation_NN ][PP of_IN ][NP NF-kB_NN ][PP in_IN ][NP human_JJ T_NN cell_NN thymic_JJ progenitors_NNS ] ._.
[NP We_PRP ][VP report_VBP ][NP differences_NNS ][PP in_IN ][NP (Ca2+)i_NN requirement_NN ][NP for_IN ][NP NF-kB_NN activation_NN ][PP in_IN ][NP thymocytes_NNS ][SBAR as_IN ][VP compared_VBN ][PP to_TO ][NP mature_JJ T_NN cells_NNS ] ._.
[ADVP Furthermore_RB ] ,_,[NP our_PRP$ results_NNS ][VP indicated_VBD ][SBAR that_IN ][NP thymocytes_NNS ][VP have_VBP ][NP a_DT constitutively_RB active_JJ form_NN ][PP of_IN ][NP NF-kB_NN ] ,_,[VP suggesting_VBG ][SBAR that_IN ][NP they_PRP ][VP are_VBP activated_VBN ][ADVP in_FW vivo_FW ] ._.
[NP The_DT role_NN ][PP of_IN ][NP jun_NN and_CC fos_NN gene_NN family_NN members_NNS ][PP in_IN ][NP 12-O-tetradecanoylphorbol-13-acetate_NN induced_VBD hemopoietic_JJ differentiation_NN ] ._.
[NP Terminal_JJ differentiation_NN ][PP of_IN ][NP the_DT leukemic_JJ cell_NN lines_NNS ][NP U-937_NN ] and_CC[NP HL-60_NN ][PP by_IN ][NP 12-O-tetradecanoylphorbol-13-acetate_NN ][VP is_VBZ accompanied_VBN ][PP by_IN ][NP marked_JJ changes_NNS ][PP in_IN ][NP gene_NN expression_NN ] ._.
[PP In_IN ][NP this_DT study_NN ] ,_,[NP we_PRP ][VP demonstrate_VBP ][SBAR that_IN ][NP the_DT expression_NN ][PP of_IN ][NP jun_NN and_CC fos_NN gene_NN family_NN members_NNS ][VP is_VBZ induced_VBN ][PP with_IN ][NP variable_JJ kinetics_NNS ][PP during_IN ][NP 12-O-tetradecanoylphorbol-13-acetate_NN induced_VBD differentiation_NN ] ,_,[PP with_IN ][NP c-jun_NN expression_NN ][ADVP best_RB ][VP paralleling_JJ ][NP differentiation_NN ] ._.
[NP The_DT generation_NN ][PP of_IN ][NP AP-1_NN complexes_NNS ] ,_,[SBAR as_IN ][VP measured_VBN ][PP by_IN ][NP DNA_NN binding_NN activity_NN ] ,_,[ADVP closely_RB ][VP parallels_VBZ ][NP morphological_JJ differentiation_NN ] ._.
[ADVP Furthermore_RB ] ,_,[NP the_DT ability_NN ][PP of_IN ][NP these_DT complexes_NNS ][VP to_TO regulate_VB ][NP gene_NN expression_NN ][VP is_VBZ demonstrated_VBN ][PP by_IN ][NP increased_VBN transcription_NN ][PP from_IN ][NP an_DT AP-1_NN driven_VBN reporter_NN construct_NN ] and_CC[NP marked_JJ increases_NNS ][PP in_IN ][NP the_DT expression_NN ][PP of_IN ][NP endogenous_JJ AP-1_NN regulated_JJ genes_NNS ] ._.
[NP Differentiation_NN assays_NNS ][VP using_VBG ][NP water_NN soluble_JJ phorbol_NN esters_NNS ][VP reveal_VBP ][SBAR that_IN ][NP differentiation_NN ][VP becomes_VBZ ][ADJP irreversible_JJ ][ADVP soon_RB ][SBAR after_IN ][NP AP-1_NN ][VP appears_VBZ ] ._.
[NP This_DT tight_JJ correlation_NN ][PP between_IN ][NP c-jun_NN expression_NN ] ,_,[NP the_DT generation_NN ][PP of_IN ][NP AP-1_NN activity_NN ] ,_, and_CC[NP differentiation_NN ][VP suggests_VBZ ][NP a_DT critical_JJ role_NN ][PP for_IN ] this_DT[NP gene_NN ] and_CC[ADJP transcriptional_JJ ][NP complex_NN ][PP during_IN ][NP this_DT process_NN ] ._.
[NP TCF-1_NN ] ,_,[NP a_DT T_NN cell-specific_JJ transcription_NN factor_NN ][PP of_IN ][NP the_DT HMG_NN box_NN family_NN ] ,_,[VP interacts_VBZ ][PP with_IN ][NP sequence_NN motifs_NNS ][PP in_IN ] the_DT[NP TCR_NN beta_NN ] and_CC[NP TCR_NN delta_NN ][NP enhancers_NNS ] ._.
[NP We_PRP ][VP have_VBP recently_RB identified_VBN ] and_CC[VP cloned_VBN ][NP TCF-1_NN ] ,_,[NP a_DT T_NN cell-specific_JJ transcription_NN factor_NN ][PP with_IN ][NP specificity_NN ][PP for_IN ][NP the_DT AACAAAG_NN motif_NN ][PP in_IN ][NP the_DT CD3_NN epsilon_NN enhancer_NN ][PP and_CC ][PP for_IN ][NP the_DT TTCAAAG_NN motif_NN ][PP in_IN ][NP the_DT TCR_NN alpha_NN enhancer_NN ] ._.
[NP TCF-1_NN ][VP belongs_VBZ ][PP to_TO ][NP the_DT family_NN ][PP of_IN ][NP transcription-regulating_JJ proteins_NNS ][NP which_WDT ][VP share_VBP ][NP a_DT region_NN ][PP of_IN ][NP homology_NN ][VP termed_VBN ][NP the_DT HMG-box_NN ] ._.
[ADVP Here_RB ] ,_,[NP we_PRP ][VP show_VBP ][PP by_IN ][NP gel_NN retardation_NN analysis_NN ][SBAR that_IN ][NP TCF-1_NN ][ADVP specifically_RB ][VP recognizes_VBZ ][NP the_DT T_NN beta_NN 5_CD element_NN ][PP of_IN ][NP the_DT TCR_NN beta_NN enhancer_NN ] and_CC[NP the_DT T_NN delta_NN 7_CD element_NN ][PP of_IN ][NP the_DT TCR_NN delta_NN enhancer_NN ] ._.
[NP Comparison_NN ][PP of_IN ][NP the_DT sequences_NNS ][PP of_IN ][NP all_DT elements_NNS ][VP recognized_VBN ][PP by_IN ][NP TCF-1_NN ][VP defines_VBZ ][NP a_DT consensus_NN motif_NN A/T_NN A/T_NN C_NN A_NN A/G_NN A_NN G_NN ] ._.
[NP These_DT observations_NNS ][VP imply_VBP ][SBAR that_IN ][NP TCF-1_NN ][VP is_VBZ involved_VBN ][PP in_IN ][NP the_DT control_NN ][PP of_IN ][NP several_JJ T_NN cell-specific_JJ genes_NNS ] and_CC[VP might_MD thus_RB play_VB ][NP an_DT important_JJ role_NN ][PP in_IN ][NP the_DT ][NP establishment_NN ] and_CC[NP maintenance_NN ][PP of_IN ][NP the_DT mature_JJ T_NN cell_NN phenotype_NN ] ._.
[NP The_DT cellular_JJ oncogene_NN c-myb_NN ][VP can_MD interact_VB ][ADVP synergistically_RB ][PP with_IN ][NP the_DT Epstein-Barr_JJ virus_NN BZLF1_NN transactivator_NN ][PP in_IN ][NP lymphoid_JJ cells_NNS ] ._.
[NP Regulation_NN ][PP of_IN ][NP replicative_JJ functions_NNS ][PP in_IN ] the_DT[NP Epstein-Barr_JJ virus_NN ] (_([NP EBV_NN ] )_)[NP genome_NN ][VP is_VBZ mediated_VBN ][PP through_IN ][NP activation_NN ][PP of_IN ][NP a_DT virally_RB encoded_VBN transcription_NN factor_NN ] ,_,[NP Z_NN ] (_([NP BZLF1_NN ] )_) ._.
[NP We_PRP ][VP have_VBP shown_VBN ][SBAR that_IN ][NP the_DT Z_NN gene_NN product_NN ] ,_,[NP which_WDT ][VP binds_VBZ ][PP to_TO ][NP AP-1_NN sites_NNS ][PP as_IN ][NP a_DT homodimer_NN ] and_CC[VP has_VBZ ][NP sequence_NN similarity_NN ][PP to_TO ][NP c-Fos_NN ] ,_,[VP can_MD efficiently_RB activate_VB ][NP the_DT EBV_NN early_JJ promoter_NN ] ,_,[NP BMRF1_NN ] ,_,[PP in_IN ][NP certain_JJ cell_NN types_NNS ] (_([NP i.e._FW ] ,_,[NP HeLa_NN cells_NNS ] )_)[CONJP but_CC not_RB ][NP others_NNS ] (_([NP i.e._FW ] ,_,[NP Jurkat_NN cells_NNS ] )_) ._.
[ADVP Here_RB ][NP we_PRP ][VP demonstrate_VBP ][SBAR that_IN ][NP the_DT c-myb_NN proto-oncogene_NN product_NN ] ,_,[NP which_WDT ][VP is_VBZ ][NP itself_PRP ][NP a_DT DNA-binding_JJ protein_NN ] and_CC[NP transcriptional_JJ transactivator_NN ] ,_,[VP can_MD interact_VB ][ADVP synergistically_RB ][PP with_IN ][NP Z_NN ][PP in_IN ][VP activating_VBG ][NP the_DT BMRF1_NN promoter_NN ][PP in_IN ][NP Jurkat_NN cells_NNS ] (_([NP a_DT T-cell_NN line_NN ] )_) or_CC[NP Raji_NN cells_NNS ] (_([NP an_DT EBV-positive_JJ B-cell_NN ] )_) ,_, whereas_IN[NP the_DT c-myb_NN gene_NN product_NN ][PP by_IN ][NP itself_PRP ][VP has_VBZ ][NP little_JJ effect_NN ] ._.
[NP The_DT simian_JJ virus_NN 40_CD early_JJ promoter_NN ][VP is_VBZ also_RB synergistically_RB activated_VBN ][PP by_IN ][NP the_DT Z/c-myb_NN combination_NN ] ._.
[NP Synergistic_JJ transactivation_NN ][PP of_IN ][NP the_DT BMRF1_NN promoter_NN ][PP by_IN ][NP the_DT Z/c-myb_NN combination_NN ][VP appears_VBZ to_TO involve_VB ][NP direct_JJ binding_NN ][PP by_IN ][NP the_DT Z_NN protein_NN ][CONJP but_CC not_RB ][NP the_DT c-myb_NN protein_NN ] ._.
[NP A_DT 30-bp_JJ sequence_NN ][PP in_IN ][NP the_DT BMRF1_NN promoter_NN ][NP which_WDT ][VP contains_VBZ ][NP a_DT Z_NN binding_NN site_NN ] (_([NP a_DT consensus_NN AP-1_NN site_NN ] )_)[VP is_VBZ ][ADJP sufficient_JJ ][VP to_TO transfer_VB ][NP high-level_JJ lymphoid-specific_JJ responsiveness_NN ][PP to_TO ][NP the_DT Z/c-myb_NN combination_NN ][PP to_TO ][NP a_DT heterologous_JJ promoter_NN ] ._.
[SBAR That_IN ][NP the_DT c-myb_NN oncogene_NN product_NN ][VP can_MD interact_VB ][ADVP synergistically_RB ][PP with_IN ][NP an_DT EBV-encoded_JJ member_NN ][PP of_IN ][NP the_DT leucine_NN zipper_NN protein_NN family_NN ][VP suggests_VBZ ][NP c-myb_NN ][VP is_VBZ ][ADJP likely_JJ ][VP to_TO engage_VB ][PP in_IN ][NP similar_JJ interactions_NNS ][PP with_IN ][NP cellularly_RB encoded_VBN transcription_NN factors_NNS ] ._.
[NP The_DT 29-kDa_JJ proteins_NNS ][VP phosphorylated_VBN ][PP in_IN ][NP thrombin-activated_JJ human_JJ platelets_NNS ][VP are_VBP ][NP forms_NNS ][PP of_IN ][NP the_DT estrogen_NN receptor-related_JJ 27-kDa_JJ heat_NN shock_NN protein_NN ] ._.
[NP Thrombin_NN ][VP plays_VBZ ][NP a_DT critical_JJ role_NN ][PP in_IN ][NP platelet_NN activation_NN ] ,_,[NP hemostasis_NN ] ,_, and_CC[NP thrombosis_NN ] ._.
[NP Cellular_JJ activation_NN ][PP by_IN ][NP thrombin_NN ][VP leads_VBZ ][PP to_TO ][NP the_DT phosphorylation_NN ][PP of_IN ][NP multiple_JJ proteins_NNS ] ,_,[NP most_JJS ][PP of_IN ][NP which_WDT ][VP are_VBP ][ADJP unidentified_JJ ] ._.
[NP We_PRP ][VP have_VBP characterized_VBN ][NP several_JJ 29-kDa_JJ proteins_NNS ][NP that_WDT ][VP are_VBP rapidly_RB phosphorylated_VBN ][PP following_VBG ][NP exposure_NN ][PP of_IN ][NP intact_JJ human_JJ platelets_NNS ][PP to_TO ][NP thrombin_NN ] ._.
[NP A_DT murine_JJ monoclonal_JJ antibody_NN ][VP raised_VBN ][PP to_TO ][NP an_DT unidentified_JJ estrogen_NN receptor-related_JJ 29-kDa_JJ protein_NN ][ADVP selectively_RB ][VP recognized_VBD ][NP these_DT proteins_NNS ][CONJP as_RB well_RB as_IN ][NP a_DT more_RBR basic_JJ ,_, unphosphorylated_JJ 27-kDa_JJ protein_NN ] ._.
[NP Cellular_JJ activation_NN ][PP by_IN ][NP thrombin_NN ][VP led_VBN ][PP to_TO ][NP a_DT marked_JJ shift_NN ][PP in_IN ][NP the_DT proportion_NN ][PP of_IN ][NP protein_NN ][PP from_IN ][NP the_DT 27-kDa_JJ unphosphorylated_JJ form_NN ][PP to_TO ][NP the_DT 29-kDa_JJ phosphoprotein_NN species_NNS ] ._.
[VP Using_VBG ][NP this_DT antibody_NN ] ,_,[NP we_PRP ][VP isolated_VBD ] and_CC[VP sequenced_VBD ][NP a_DT human_JJ cDNA_NN clone_NN ][VP encoding_VBG ][NP a_DT protein_NN ][NP that_WDT ][VP was_VBD ][ADJP identical_JJ ][PP to_TO ][NP the_DT mammalian_JJ 27-kDa_JJ heat_NN shock_NN protein_NN ] (_([NP HSP27_NN ] )_) ,_,[NP a_DT protein_NN ][PP of_IN ][NP uncertain_JJ function_NN ][NP that_WDT ][VP is_VBZ known_VBN ][VP to_TO be_VB phosphorylated_VBN ][PP to_TO ][NP several_JJ forms_NNS ] and_CC[VP to_TO be_VB transcriptionally_RB induced_VBN ][PP by_IN ][NP estrogen_NN ] ._.
[NP The_DT 29-kDa_JJ proteins_NNS ][VP were_VBD confirmed_VBN to_TO be_VB ][NP phosphorylated_VBN forms_NNS ][PP of_IN ][NP HSP27_NN ][PP by_IN ][NP immunoprecipitation_NN studies_NNS ] ._.
[ADVP Thus_RB ] ,_,[NP the_DT "_[[DQS]] estrogen_NN receptor-related_JJ protein_NN ] "_[[DQE]][VP is_VBZ ][NP HSP27_NN ] ,_, and_CC[NP the_DT three_CD major_JJ 29-kDa_JJ proteins_NNS ][VP phosphorylated_VBN ][PP in_IN ][NP thrombin-activated_JJ platelets_NNS ][VP are_VBP ][NP forms_NNS ][PP of_IN ][NP HSP27_NN ] ._.
[NP These_DT data_NNS ][VP suggest_VBP ][NP a_DT role_NN ][PP for_IN ][NP HSP27_NN ][PP in_IN ][NP the_DT signal_NN transduction_NN events_NNS ][PP of_IN ][NP platelet_NN activation_NN ] ._.
[NP Characterization_NN ][PP of_IN ][NP a_DT cofactor_NN ][NP that_WDT ][VP regulates_VBZ ][NP dimerization_NN ][PP of_IN ][NP a_DT mammalian_JJ homeodomain_NN protein_NN ] ._.
[NP Dimerization_NN ][PP among_IN ][NP transcription_NN factors_NNS ][VP has_VBZ become_VBN ][NP a_DT recurrent_JJ theme_NN ][PP in_IN ][NP the_DT regulation_NN ][PP of_IN ][NP eukaryotic_JJ gene_NN expression_NN ] ._.
[NP Hepatocyte_NN nuclear_JJ factor-1_NN alpha_NN ] (_([NP HNF-1_NN alpha_NN ] )_)[VP is_VBZ ][NP a_DT homeodomain-containing_JJ protein_NN ][NP that_WDT ][VP functions_VBZ ][PP as_IN ][NP a_DT dimer_NN ] ._.
[NP A_DT dimerization_NN cofactor_NN ][PP of_IN ][NP HNF-1_NN alpha_NN ] (_([NP DCoH_NN ] )_)[VP was_VBD identified_VBN ][NP that_WDT ][VP displayed_VBD ][NP a_DT restricted_JJ tissue_NN distribution_NN ] and_CC[VP did_VBD not_RB bind_VB ][PP to_TO ][NP DNA_NN ] ,_,[CONJP but_CC ,_, rather_RB ] ,_,[VP selectively_RB stabilized_VBD ][NP HNF-1_NN alpha_NN dimers_NNS ] ._.
[NP The_DT formation_NN ][PP of_IN ][NP a_DT stable_JJ tetrameric_JJ DCoH-HNF-1_NN alpha_NN complex_NN ] ,_,[NP which_WDT ][VP required_VBD ][NP the_DT dimerization_NN domain_NN ][PP of_IN ][NP HNF-1_NN alpha_NN ] ,_,[VP did_VBD not_RB change_VB ][NP the_DT DNA_NN binding_NN characteristics_NNS ][PP of_IN ][NP HNF-1_NN alpha_NN ] ,_, but_CC[VP enhanced_VBD ][NP its_PRP$ transcriptional_JJ activity_NN ] ._.
[ADVP However_RB ] ,_,[NP DCoH_NN ][VP did_VBD not_RB confer_VB ][NP transcriptional_JJ activation_NN ][PP to_TO ][NP the_DT GAL4_NN DNA_NN binding_NN domain_NN ] ._.
[NP These_DT results_NNS ][VP indicate_VBP ][SBAR that_IN ][NP DCoH_NN ][VP regulates_VBZ ][NP formation_NN ][PP of_IN ][NP transcriptionally_RB active_JJ tetrameric_JJ complexes_NNS ] and_CC[VP may_MD contribute_VB ][PP to_TO ][NP the_DT developmental_JJ specificity_NN ][PP of_IN ][NP the_DT complex_NN ] ._.
[NP High_JJ affinity_NN aldosterone_NN ][VP binding_VBG ][PP to_TO ][NP plasma_NN membrane_NN rich_JJ fractions_NNS ][PP from_IN ][NP mononuclear_JJ leukocytes_NNS ] :_: is_VBZ[NP there_EX ][NP a_DT membrane_NN receptor_NN ][PP for_IN ][NP mineralocorticoids_NNS ] ?_.
[NP In_FW vitro_FW effects_NNS ][PP of_IN ][NP aldosterone_NN ][PP on_IN ][NP the_DT intracellular_JJ concentrations_NNS ][PP of_IN ][NP sodium_NN ] ,_,[NP potassium_NN ] and_CC[NP calcium_NN ] ,_,[NP cell_NN volume_NN ] and_CC[NP the_DT sodium-proton-antiport_NN ][VP have_VBP been_VBN described_VBN ][PP in_IN ][NP intact_JJ ][NP human_JJ mononuclear_JJ leukocytes_NNS ] (_([NP HML_NN ] )_) ._.
[PP In_IN ][NP the_DT present_JJ paper_NN ] ,_,[NP the_DT binding_NN ][PP of_IN ][NP a_DT (125I)-labeled_JJ aldosterone_NN derivative_JJ ][PP to_TO ][NP plasma_NN membrane_NN ][NP rich_JJ fractions_NNS ][PP of_IN ][NP HML_NN ][VP was_VBD studied_VBN ] ._.
[NP High_JJ affinity_NN binding_NN ][PP of_IN ][NP the_DT radioligand_NN ][PP with_IN ][NP an_DT apparent_JJ Kd_NN ][PP of_IN ][NP approximately_RB 0.1_CD nM_NN ][VP was_VBD found_VBN ] ._.
[NP Aldosterone_NN ][VP displaced_VBD ][NP the_DT tracer_NN ][PP at_IN ][NP a_DT similar_JJ Kd_NN ] ._.
 Both_CC[NP canrenone_NN ] and_CC[NP cortisol_NN ][VP were_VBD ][ADJP inactive_JJ ][PP as_IN ][NP ligands_NNS ][PP up_RB to_TO ][NP concentrations_NNS ][PP of_IN ][NP 0.1_CD microM_NN ] ._.
[NP The_DT findings_NNS ][VP are_VBP ][NP the_DT first_JJ ][VP to_TO demonstrate_VB ][NP membrane_NN binding_NN sites_NNS ][PP with_IN ][NP a_DT high_JJ affinity_NN ][PP for_IN ][NP aldosterone_NN ][PP ,_, but_CC ][PP not_RB for_IN ][NP cortisol_NN ] ._.
[NP These_DT data_NNS ][VP are_VBP ][ADJP perfectly_RB compatible_JJ ][PP with_IN ][NP major_JJ properties_NNS ][PP of_IN ][NP steroidal_JJ effects_NNS ][PP on_IN ][NP the_DT sodium-proton-antiport_NN ][PP in_IN ][NP HML_NN ] and_CC thus_RB[VP very_RB likely_RB represent_VBP ][NP membrane_NN receptors_NNS ][PP for_IN ][NP aldosterone_NN ] ._.
[NP Transcription_NN factor_NN requirements_NNS ][PP for_IN ][NP U2_NN snRNA-encoding_JJ gene_NN activation_NN ][PP in_IN ][NP B_NN lymphoid_JJ cells_NNS ] ._.
[NP Transcription_NN ][PP of_IN ][NP a_DT human_JJ U2_NN small_JJ nuclear_JJ RNA_NN (_( snRNA_NN )_) -encoding_JJ gene_NN ][PP in_IN ][NP HeLa_NN cells_NNS ][VP requires_VBZ ][NP a_DT distal_JJ enhancer_NN element_NN ] ,_,[NP which_WDT ][VP is_VBZ composed_VBN ][PP of_IN ][NP one_CD ][NP octamer_NN motif_NN ] (_([NP Oct_NN ] )_) and_CC[NP three_CD Sp_NN 1-binding_JJ sites_NNS ] ._.
[VP To_TO study_VB ][NP the_DT transcription_NN factor_NN requirement_NN ][PP in_IN ][NP B-cells_NNS ] ,_,[NP different_JJ U2_NN enhancer_NN constructions_NNS ][VP were_VBD transfected_VBN ][PP into_IN ][NP the_DT lymphoid_JJ cell_NN line_NN ] ,_,[NP BJA-B_NN ] ._.
[NP The_DT results_NNS ][VP showed_VBD ][SBAR that_IN ][NP the_DT activation_NN ][PP of_IN ][NP U2_NN snRNA_NN transcription_NN ][PP in_IN ][NP B-cells_NNS ][ADVP also_RB ][VP requires_VBZ ][NP an_DT enhancer_NN ][VP comprising_VBG ] both_CC[NP the_DT Oct_NN ] and_CC[NP at_IN least_JJS one_CD Sp_NN 1-binding_JJ site_NN ] ._.
[NP Deletion_NN ][PP of_IN ][NP all_PDT the_DT Sp_NN 1-binding_JJ sites_NNS ][PP from_IN ][NP the_DT enhancer_NN ][VP reduces_VBZ ][NP transcription_NN ][PP by_IN ][NP 80-90_CD %_NN ][PP in_IN ][NP HeLa_NN ] ,_,[CONJP as_RB well_RB as_IN ][PP in_IN ][NP BJA-B_NN ][NP cells_NNS ] ,_, whereas_IN[NP the_DT removal_NN ][PP of_IN ][NP the_DT octamer-binding_JJ site_NN ][VP reduces_VBZ ][NP transcription_NN ][PP to_TO ][NP levels_NNS ][PP below_IN ][NP detection_NN ][PP in_IN ][NP both_DT cell_NN types_NNS ] ._.
[NP Enhancers_NNS ][VP containing_VBG ][NP a_DT single_JJ Oct_NN ][VP have_VBP ] ,_,[ADVP nevertheless_RB ] ,_,[NP the_DT capacity_NN ][VP to_TO partially_RB activate_VB ][NP U2_NN snRNA_NN transcription_NN ][PP in_IN ][NP both_DT HeLa_NN cells_NNS ] ,_,[PP in_IN ][NP which_WDT ][NP only_RB OTF-1_NN ][VP is_VBZ expressed_VBN ][PP ,_, and_CC ][PP in_IN ][NP BJA-B_NN cells_NNS ][PP in_IN ][NP which_WDT ][NP OTF-2_NN ][VP is_VBZ ][NP the_DT predominantly_RB expressed_VBN octamer-binding_JJ factor_NN ] ._.
[NP The_DT most_RBS likely_JJ interpretation_NN ][PP of_IN ][NP our_PRP$ results_NNS ][VP is_VBZ ][SBAR that_IN ] both_CC[NP the_DT ubiquitous_JJ transcription_NN factor_NN ] ,_,[NP OTF-1_NN ] ,_, and_CC[NP the_DT B-cell-specific_JJ transcription_NN factor_NN ] ,_,[NP OTF-2_NN ] ,_,[VP can_MD activate_VB ][NP U2_NN snRNA_NN transcription_NN ] ._.
[NP The_DT results_NNS ][ADVP also_RB ][VP revealed_VBD ][NP a_DT similar_JJ functional_JJ cooperation_NN ][PP between_IN ][NP the_DT transcription_NN factors_NNS ][NP which_WDT ][VP bind_VBP ][PP to_TO ][NP the_DT Oct_NN ] and_CC[NP the_DT adjacent_JJ Sp_NN 1-binding_JJ ][NP site_NN ][PP in_IN ][NP BJA-B_NN cells_NNS ] ,_,[SBAR as_IN ][VP has_VBZ been_VBN observed_VBN ][PP in_IN ][NP HeLa_NN cells_NNS ] ,_,[SBAR since_IN ][NP a_DT template_NN ][NP which_WDT ][VP contains_VBZ ][NP a_DT weak_JJ binding_VBG site_NN ][PP for_IN ][NP OTFs_NNS ][VP expresses_VBZ ][NP wild-type_JJ levels_NNS ][PP of_IN ][NP U2_NN snRNA_NN ][PP in_IN ][NP both_DT cell_NN types_NNS ][ADVP when_WRB ][NP the_DT weak_JJ octamer-binding_JJ site_NN ][VP is_VBZ combined_VBN ][PP with_IN ][NP a_DT Sp_NN 1-binding_JJ site_NN ] ._.
[NP Cortisol_NN receptor_NN resistance_NN ] :_:[NP the_DT variability_NN ][PP of_IN ][NP its_PRP$ ][NP clinical_JJ presentation_NN ] and_CC[NP response_NN ][PP to_TO ][NP treatment_NN ] ._.
[NP Primary_JJ (_( partial_JJ )_) cortisol_NN receptor_NN resistance_NN ][VP was_VBD previously_RB reported_VBN ][PP in_IN ][NP a_DT total_NN ][PP of_IN ][NP 7_CD patients_NNS ] and_CC[NP 14_CD asymptomatic_JJ family_NN members_NNS ] ._.
[NP Its_PRP$ occurrence_NN ][VP is_VBZ considered_VBN to_TO be_VB ][ADJP extremely_RB rare_JJ ] ._.
[PP In_IN ][NP the_DT present_JJ study_NN ][NP we_PRP ][VP report_VBP ][PP on_IN ][NP 6_CD patients_NNS ] (_([NP 2_CD males_NNS ] and_CC[NP 4_CD females_NNS ] )_)[PP with_IN ][NP the_DT syndrome_NN ] ._.
[NP The_DT first_JJ male_JJ patient_NN ][VP presented_VBD ][PP with_IN ][NP mild_JJ hypertension_NN ] ._.
[NP Hydrochlorothiazide_NN therapy_NN ][VP resulted_VBD ][PP in_IN ][NP life-threatening_JJ hypokalemia_NN ] ._.
[NP The_DT second_JJ male_JJ patient_NN ][VP had_VBD ][NP slight_JJ hypertension_NN ][PP without_IN ][NP hypokalemia_NN ] ._.
[NP All_DT four_CD female_JJ patients_NNS ][VP presented_VBD ][PP between_IN ][NP the_DT age_NN ][PP of_IN ][NP 20-30_CD yr_NN ][PP with_IN ][NP acne_NN ] ,_,[NP hirsutism_NN ] ,_, and_CC[NP irregular_JJ menstruations_NNS ] ._.
[NP Low_JJ dose_NN dexamethasone_NN therapy_NN ] (_([NP 1-1.5_CD mg/day_NN ] )_)[VP was_VBD ][PP of_IN ][NP clinical_JJ benefit_NN ][PP in_IN ][NP these_DT patients_NNS ] ._.
[NP All_DT patients_NNS ][VP showed_VBD ][NP insufficient_JJ suppression_NN ][PP of_IN ][NP serum_NN cortisol_NN concentrations_NNS ][PP in_IN ][NP the_DT overnight_JJ 1-mg_JJ dexamethasone_NN test_NN ] ._.
[NP The_DT diurnal_JJ rhythm_NN ][PP of_IN ][NP ACTH_NN ] and_CC[NP cortisol_NN ][VP was_VBD ][ADJP intact_JJ ] ,_,[PP albeit_IN ][PP at_IN ][NP an_DT elevated_JJ level_NN ] ._.
[NP There_EX ][VP was_VBD ][NP a_DT normal_JJ increase_NN ][PP in_IN ][NP ACTH_NN ] ,_,[NP cortisol_NN ] ,_, and_CC[NP GH_NN ] (_([PP except_IN ][PP in_IN ][NP one_CD obese_JJ patient_NN ] )_)[PP in_IN response_NN to_TO ][NP insulin-induced_JJ hypoglycemia_NN ] ,_,[SBAR while_IN ][NP cortisol_NN production_NN ][VP was_VBD elevated_JJ ][PP in_IN ][NP three_CD patients_NNS ] ._.
[NP Circulating_VBG adrenal_JJ androgen_NN levels_NNS ][VP were_VBD increased_VBN ][PP in_IN ][NP all_DT patients_NNS ] ._.
[NP Glucocorticoid_NN receptors_NNS ][VP were_VBD investigated_VBN ][PP in_IN ][NP a_DT whole_JJ cell_NN dexamethasone_NN binding_NN assay_NN ][PP in_IN ][NP mononuclear_JJ leukocytes_NNS ] ._.
[PP In_IN ][NP the_DT first_JJ male_JJ patient_NN ] ,_,[NP the_DT number_NN ][PP of_IN ][NP receptors_NNS ][VP was_VBD ][ADJP very_RB low_JJ ] ,_,[SBAR while_IN ][NP the_DT affinity_NN ][VP was_VBD ][ADJP lower_JJR ][PP than_IN ][NP that_DT ][PP in_IN ][NP controls_NNS ] ._.
[NP A_DT lowered_JJ affinity_NN ][PP to_TO ][NP dexamethasone_NN ][VP was_VBD found_VBN ][PP in_IN ][NP one_CD female_JJ patient_NN ] ,_,[SBAR while_IN ][NP a_DT lowered_JJ number_NN ][PP of_IN ][NP receptors_NNS ][VP was_VBD found_VBN ][PP in_IN ][NP three_CD patients_NNS ] ._.
[PP In_IN ][NP the_DT second_JJ male_JJ patient_NN ] ,_,[NP no_DT abnormalities_NNS ][VP were_VBD found_VBN ] ._.
[PP As_IN ][NP a_DT bioassay_NN ][PP for_IN ][NP glucocorticoid_NN action_NN ][NP we_PRP ][ADVP also_RB ][VP measured_VBD ][NP dexamethasone_NN suppressibility_NN ][PP of_IN ][NP mitogen-stimulated_JJ incorporation_NN ][PP of_IN ][NP (3H)thymidine_NN ][PP in_IN ][NP mononuclear_JJ leukocytes_NNS ] ._.
[PP In_IN ][NP the_DT male_JJ patient_NN ][PP with_IN ][NP normal_JJ receptor_NN status_NN ] ,_,[NP dexamethasone_NN suppressibility_NN ][PP of_IN ][NP (3H)thymidine_NN incorporation_NN ][VP was_VBD ][ADJP significantly_RB lower_JJR ][PP than_IN ][NP that_DT ][PP in_IN ][NP healthy_JJ controls_NNS ][PP with_IN respect_NN to_TO ] both_CC[NP maximal_JJ suppression_NN ] and_CC[NP IC50_NN ] ._.
[NP Partial_JJ cortisol_NN receptor_NN resistance_NN ][VP might_MD be_VB ][ADJP less_RBR rare_JJ ][SBAR than_IN ][VP previously_RB thought_VBN ] ._.
[PP In_IN ][NP the_DT six_CD patients_NNS ][VP presented_VBN ] ,_,[NP at_IN least_JJS three_CD different_JJ forms_NNS ][VP can_MD be_VB recognized_VBN ] ._.
[NP Therapy_NN ][PP with_IN ][NP dexamethasone_NN ][VP was_VBD ][ADJP successful_JJ ][PP in_IN ][NP female_JJ patients_NNS ][PP with_IN ][NP acne_NN ] and_CC[NP hirsutism_NN ] ,_,[SBAR as_IN ][NP the_DT secondary_JJ increase_NN ][PP in_IN ][NP the_DT production_NN ][PP of_IN ][NP adrenal_JJ androgens_NNS ][VP was_VBD effectively_RB controlled_VBN ] ._.
[NP Kappa_NN B-specific_JJ DNA_NN binding_NN proteins_NNS ][VP are_VBP differentially_RB inhibited_VBN ][PP by_IN ][NP enhancer_NN mutations_NNS ] and_CC[NP biological_JJ oxidation_NN ] ._.
[NP Kappa_NN B_NN ] (_([NP kappa_NN B_NN ] )_)[NP enhancer_NN binding_NN proteins_NNS ][VP isolated_VBN ][PP from_IN ][NP the_DT nuclei_NNS ][PP of_IN ][NP activated_VBN human_JJ T_NN cells_NNS ][VP produce_VBP ][NP two_CD distinct_JJ nucleoprotein_NN complexes_NNS ][ADVP when_WRB ][VP incubated_VBN ][PP with_IN ][NP the_DT kappa_NN B_NN element_NN ][PP from_IN ] the_DT[NP interleukin-2_NN receptor-alpha_NN ] (_([NP IL-2R_NN alpha_NN ] )_)[NP gene_NN ] ._.
[NP These_DT two_CD DNA-protein_JJ complexes_NNS ][VP are_VBP composed_VBN ][PP of_IN ][NP at_IN least_JJS four_CD host_NN proteins_NNS ] (_([NP p50_NN ] ,_,[NP p55_NN ] ,_,[NP p75_NN ] ,_,[NP p85_NN ] )_) ,_,[NP each_DT ][PP of_IN ][NP which_WDT ][VP shares_VBZ ][NP structural_JJ similarity_NN ][PP with_IN ][NP the_DT v-rel_NN oncogene_NN product_NN ] ._.
[NP Nuclear_JJ expression_NN ][PP of_IN ][NP these_DT proteins_NNS ][VP is_VBZ induced_VBN ][PP with_IN ][NP distinctly_RB biphasic_JJ kinetics_NNS ][PP following_VBG ][NP phorbol_NN ester_NN activation_NN ][PP of_IN ][NP T_NN cells_NNS ] (_([NP p55/p75_NN early_JJ ] and_CC[NP p50/p85_NN late_JJ ] )_) ._.
[NP DNA-protein_JJ crosslinking_NN studies_NNS ][VP have_VBP revealed_VBN ][SBAR that_IN ] the_DT[ADVP more_RBR rapidly_RB ][NP migrating_VBG B2_NN complex_NN ][VP contains_VBZ ] both_CC[NP p50_NN ] and_CC[NP p55_NN ][SBAR while_IN ] the_DT[ADVP more_RBR slowly_RB ][NP migrating_VBG B1_NN complex_NN ][VP is_VBZ composed_VBN ][PP of_IN ][NP p50_NN ] ,_,[NP p55_NN ] ,_,[NP p75_NN ] ,_, and_CC[NP p85_NN ] ._.
[NP Site-directed_JJ mutagenesis_NN ][PP of_IN ][NP the_DT wild-type_JJ IL-2R_NN alpha_NN kappa_NN B_NN enhancer_NN ] (_([NP GGGGAATCTCCC_NN ] )_)[VP has_VBZ revealed_VBN ][SBAR that_IN ][NP the_DT binding_NN ][PP of_IN ][NP p50_NN ] and_CC[NP p55_NN ] (_([NP B2_NN complex_NN ] )_)[VP is_VBZ ][ADJP particularly_RB sensitive_JJ ][PP to_TO ][NP alteration_NN ][PP of_IN ][NP the_DT 5'_JJ triplet_NN ][PP of_IN ][NP deoxyguanosine_NN residues_NNS ] ._.
[PP In_IN ][NP contrast_NN ] ,_,[NP formation_NN ][PP of_IN ][NP the_DT B1_NN complex_NN ] ,_,[VP reflecting_VBG ][NP the_DT binding_NN ][PP of_IN ][NP p75_NN ] and_CC[NP p85_NN ] ,_,[ADVP critically_RB ][VP depends_VBZ ][PP upon_IN ][NP the_DT more_RBR 3'_JJ sequences_NNS ][PP of_IN ][NP this_DT enhancer_NN element_NN ] ._.
[NP DNA_NN binding_NN ][PP by_IN ][NP all_DT four_CD ][PP of_IN ][NP these_DT Rel-related_JJ factors_NNS ][VP is_VBZ blocked_VBN ][PP by_IN ][NP selective_JJ chemical_JJ modification_NN ][PP of_IN ][NP lysine_NN ] and_CC[NP arginine_NN ][NP residues_NNS ] ,_,[VP suggesting_VBG ][SBAR that_IN ][NP both_DT ][PP of_IN ][NP these_DT basic_JJ amino_NN acids_NNS ][VP are_VBP required_VBN ][PP for_IN ][VP binding_VBG ][PP to_TO ][NP the_DT kappa_NN B_NN element_NN ] ._.
[ADVP Similarly_RB ] ,_,[NP covalent_JJ modification_NN ][PP of_IN ][NP free_JJ sulfhydryl_NN groups_NNS ][PP with_IN ][NP diamide_NN ] (_([ADJP reversible_JJ ] )_) or_CC[NP N-ethylmaleimide_NN ] (_([ADJP irreversible_JJ ] )_)[VP results_VBZ ][PP in_IN ][NP a_DT complete_JJ loss_NN ][PP of_IN ][NP DNA_NN binding_NN activity_NN ] ._.
[PP In_IN ][NP contrast_NN ] ,_,[NP mild_JJ oxidation_NN ][PP with_IN ][NP glucose_NN oxidase_NN ][ADVP selectively_RB ][VP inhibits_VBZ ][NP p75_NN ] and_CC[NP p85_NN ][NP binding_NN ][SBAR while_IN ][VP not_RB blocking_VBG ][NP p50_NN ] and_CC[NP p55_NN ][NP interactions_NNS ] ._.
[NP These_DT findings_NNS ][VP suggest_VBP ][SBAR that_IN ][NP reduced_VBN cysteine_NN thiols_NNS ][VP play_VBP ][NP an_DT important_JJ role_NN ][PP in_IN ][NP the_DT DNA_NN binding_NN activity_NN ][PP of_IN ][NP this_DT family_NN ][PP of_IN ][NP Rel-related_JJ transcription_NN factors_NNS ] ._.
[NP A_DT novel_JJ mitogen-inducible_JJ gene_NN product_NN ][ADJP related_JJ ][PP to_TO ][NP p50/p105-NF-kappa_NN B_NN ][VP participates_VBZ ][PP in_IN ][NP transactivation_NN ][PP through_IN ][NP a_DT kappa_NN B_NN site_NN ] ._.
[NP A_DT Rel-related_JJ ,_, mitogen-inducible_JJ ,_, kappa_NN B-binding_JJ protein_NN ][VP has_VBZ been_VBN cloned_VBN ][PP as_IN ][NP an_DT immediate-early_JJ activation_NN gene_NN ][PP of_IN ][NP human_JJ peripheral_JJ blood_NN T_NN cells_NNS ] ._.
[NP The_DT cDNA_NN ][VP has_VBZ ][NP an_DT open_JJ reading_NN frame_NN ][PP of_IN ][NP 900_CD amino_NN acids_NNS ][ADJP capable_JJ ][PP of_IN ][VP encoding_VBG ][NP a_DT 97-kDa_JJ protein_NN ] ._.
[NP This_DT protein_NN ][VP is_VBZ ][ADJP most_RBS similar_JJ ][PP to_TO ][NP the_DT 105-kDa_JJ precursor_NN polypeptide_NN ][PP of_IN ][NP p50-NF-kappa_NN B_NN ] ._.
[PP Like_IN ][NP the_DT 105-kDa_JJ precursor_NN ] ,_,[NP it_PRP ][VP contains_VBZ ][NP an_DT amino-terminal_JJ Rel-related_JJ domain_NN ][PP of_IN ][NP about_IN 300_CD amino_NN acids_NNS ] and_CC[NP a_DT carboxy-terminal_JJ domain_NN ][VP containing_VBG ] six_CD[NP full_JJ cell_NN cycle_NN ] or_CC[NP ankyrin_NN ][NP repeats_NNS ] ._.
[NP In_FW vitro-translated_JJ proteins_NNS ] ,_,[VP truncated_VBN ][ADVP downstream_RB ][PP of_IN ][NP the_DT Rel_NN domain_NN ] and_CC[VP excluding_VBG ][NP the_DT repeats_NNS ] ,_,[VP bind_VBP ][NP kappa_NN B_NN sites_NNS ] ._.
[NP We_PRP ][VP refer_VBP ][PP to_TO ][NP the_DT kappa_NN B-binding_JJ ] ,_,[NP truncated_VBN protein_NN ][PP as_IN ][NP p50B_NN ][PP by_IN ][NP analogy_NN ][PP with_IN ][NP p50-NF-kappa_NN B_NN ][PP and_CC ][PP to_TO ][NP the_DT full-length_JJ protein_NN ][PP as_IN ][NP p97_NN ] ._.
[NP p50B_NN ][VP is_VBZ ][ADJP able_JJ ][VP to_TO form_VB ][NP heteromeric_JJ kappa_NN B-binding_JJ complexes_NNS ][PP with_IN ][NP RelB_NN ] ,_,[CONJP as_RB well_RB as_IN ][PP with_IN ][NP p65_NN ] and_CC[NP p50_NN ] ,_,[NP the_DT two_CD subunits_NNS ][PP of_IN ][NP NF-kappa_NN B_NN ] ._.
[NP Transient-transfection_NN experiments_NNS ][PP in_IN ][NP embryonal_JJ carcinoma_NN cells_NNS ][VP demonstrate_VBP ][NP a_DT functional_JJ cooperation_NN ][PP between_IN ][NP p50B_NN ] and_CC[NP RelB_NN ] or_CC[NP p65_NN ][PP in_IN ][NP transactivation_NN ][PP of_IN ][NP a_DT reporter_NN plasmid_NN ][ADJP dependent_JJ ][PP on_IN ][NP a_DT kappa_NN B_NN site_NN ] ._.
[NP The_DT data_NNS ][VP imply_VBP ][NP the_DT existence_NN ][PP of_IN ][NP a_DT complex_JJ family_NN ][PP of_IN ][NP NF-kappa_NN B-like_JJ transcription_NN factors_NNS ] ._.
 (_([NP Changes_NNS ][PP in_IN ][NP leucocytic_JJ estrogen_NN receptor_NN levels_NNS ][PP in_IN ][NP patients_NNS ][PP with_IN ][NP climacteric_JJ syndrome_NN ] and_CC[NP therapeutic_JJ effect_NN ][PP of_IN ][NP liuwei_FW dihuang_FW pills_NNS ] )_)
[NP The_DT numbers_NNS ][PP of_IN ][NP estrogen_NN receptor_NN ] (_([NP ER_NN ] )_)[PP in_IN ][NP human_JJ peripheral_JJ leucocytes_NNS ][PP in_IN ][NP 22_CD women_NNS ][PP with_IN ][NP climacteric_JJ syndrome_NN ][VP were_VBD measured_VBN ][PP by_IN ][NP radioligand_NN method_NN ] ._.
[NP The_DT results_NNS ][VP were_VBD compared_VBN ][PP with_IN ][NP those_DT ][PP of_IN ][NP 12_CD normal_JJ child-bearing-age_JJ women_NNS ] ._.
[NP It_PRP ][VP wat_VBD found_VBN ][SBAR that_IN ][NP the_DT contents_NNS ][PP of_IN ][NP leucocytic_JJ ER_NN ][PP in_IN ][NP climacteric_JJ syndrome_NN patients_NNS ][VP were_VBD ][ADJP significantly_RB lower_JJR ][PP than_IN ][NP normal_JJ child-bearing-age_JJ women_NNS ] ._.
[NP The_DT authors_NNS ][VP used_VBD ][NP a_DT Chinese_JJ prescription_NN ] --_:[NP Liuwei_FW Dihuang_FW Pills_NNS ] (_([NP LDP_NN ] )_)[VP to_TO treat_VB ][NP the_DT patients_NNS ][PP for_IN ][NP 2_CD months_NNS ] ._.
[NP The_DT numbers_NNS ][PP of_IN ][NP leucocytic_JJ ER_NN ][VP were_VBD significantly_RB increased_VBN ][PP after_IN ][NP treatment_NN ] ._.
[NP The_DT data_NNS ][VP indicate_VBP ][SBAR that_IN ][NP decrease_NN ][PP of_IN ][NP ER_NN levels_NNS ][PP in_IN ][NP cell_NN ][VP may_MD involve_VB ][PP in_IN ][NP the_DT pathogenesis_NN ][PP of_IN ][NP climacteric_JJ syndrome_NN ] ._.
[NP LDP_NN ][CONJP not_RB only_RB ][VP increases_VBZ ][NP plasma_NN estradiol_NN levels_NNS ] ,_,[CONJP but_CC also_RB ][VP increases_VBZ ][NP the_DT leucocytic_JJ ER_NN levels_NNS ] ._.
[NP This_DT ][VP may_MD be_VB ][NP the_DT basis_NN ][PP of_IN ][NP the_DT therapeutic_JJ effect_NN ][PP on_IN ][NP the_DT disease_NN ] ._.
[NP A_DT novel_JJ primer_NN extension_NN method_NN ][VP to_TO detect_VB ][NP the_DT number_NN ][PP of_IN ][NP CAG_NN repeats_NNS ][PP in_IN ][NP the_DT androgen_NN receptor_NN gene_NN ][PP in_IN ][NP families_NNS ][PP with_IN ][NP X-linked_JJ spinal_JJ and_CC bulbar_JJ muscular_JJ atrophy_NN ] ._.
[NP X-linked_JJ spinal_JJ and_CC bulbar_JJ muscular_JJ atrophy_NN ] (_([NP SBMA_NN ] )_) ,_,[NP an_DT adult-onset_JJ form_NN ][PP of_IN ][NP motor_NN neuron_NN disease_NN ] ,_,[VP was_VBD recently_RB reported_VBN to_TO be_VB caused_VBN ][PP by_IN ][NP amplification_NN ][PP of_IN ][NP the_DT CAG_NN repeats_NNS ][PP in_IN ][NP the_DT androgen_NN receptor_NN gene_NN ] ._.
[NP We_PRP ][VP report_VBP ][ADVP here_RB ][NP a_DT simple_JJ and_CC rapid_JJ strategy_NN ][VP to_TO detect_VB ][NP the_DT precise_JJ number_NN ][PP of_IN ][NP the_DT CAGs_NNS ] ._.
[SBAR After_IN ][NP the_DT DNA_NN fragment_NN ][VP containing_VBG ][NP the_DT CAG_NN repeats_NNS ][VP is_VBZ amplified_VBN ][PP by_IN ][NP the_DT polymerase_NN chain_NN reaction_NN ] ,_,[NP a_DT primer_NN extension_NN ][VP is_VBZ carried_VBN ][PRT out_RP ] ;_:[NP the_DT extension_NN ][PP of_IN ][NP the_DT end-labelled_JJ reverse_JJ primer_NN ][ADJP adjacent_JJ ][PP to_TO ][NP 3'_JJ end_NN ][PP of_IN ][NP CAG_NN repeats_NNS ][VP stops_VBZ ][PP at_IN ][NP the_DT first_JJ T_NN ][PP after_IN ][NP CAG_NN repeats_NNS ][PP with_IN ][NP the_DT incorporation_NN ][PP of_IN ][NP dideoxy_JJ ATP_NN ][PP in_IN ][NP the_DT reaction_NN mixture_NN ] ._.
[NP The_DT resultant_JJ primer_NN products_NNS ][VP are_VBP analysed_VBN ][PP by_IN ][VP denaturing_VBG ][NP polyacrylamide_NN gel_NN electrophoresis_NN ] and_CC[NP autoradiography_NN ] ._.
[NP This_DT method_NN ][VP could_MD be_VB ][ADJP quite_RB useful_JJ ][VP to_TO detect_VB ][CONJP not_RB only_RB ][NP CAG_NN repeats_NNS ][PP in_IN ][NP SBMA_NN ][CONJP but_CC also_RB ] other_JJ polymorphic_JJ[NP dinucleotide_JJ ] and_CC[NP trinucleotide_JJ ][NP repeats_NNS ] ._.
[NP Activity_NN ][PP of_IN ][NP the_DT kappa_NN B_NN enhancer_NN ][PP of_IN ][NP the_DT interleukin-2_NN receptor_NN alpha_NN chain_NN ][PP in_IN ][NP somatic_JJ cell_NN hybrids_NNS ][VP is_VBZ accompanied_VBN ][PP by_IN ][NP the_DT nuclear_JJ localization_NN ][PP of_IN ][NP NF-kappa_NN B_NN ] ._.
[NP The_DT two_CD nuclear_JJ proteins_NNS NF-kappa_NN B_NN ] (_([VP consisting_VBG ][PP of_IN ][NP subunits_NNS ][NP p50_NN ] and_CC[NP p65_NN ] )_) and_CC[NP the_DT DNA-binding_JJ subunit_NN ][PP of_IN ][NP NF-kappa_NN B_NN ] (_([NP p50_NN ] )_)[PP by_IN ][NP itself_PRP ] ,_,[VP also_RB called_VBN ][NP KBF1_NN ] ,_,[VP are_VBP constitutively_RB expressed_VBN ] and_CC[VP localized_JJ ][PP in_IN ][NP the_DT nucleus_NN ][PP of_IN ][NP the_DT human_JJ T-cell_NN line_NN IARC_NN 301.5_CD ] ._.
[SBAR In_IN ] order_NN to_TO[VP define_VB ][NP the_DT roles_NNS ][PP of_IN ][NP these_DT two_CD factors_NNS ] ,_,[NP which_WDT ][VP bind_VBP ][PP to_TO ][NP the_DT same_JJ kappa_NN B_NN enhancers_NNS ] ,_,[PP in_IN ][NP transcription_NN activation_NN ][NP we_PRP ][VP have_VBP prepared_VBN ][NP somatic_JJ cell_NN hybrids_NNS ][PP between_IN ][NP IARC_NN 301.5_CD ] and_CC[NP a_DT murine_JJ myeloma_NN ] ._.
[NP Most_JJS hybrids_NNS ][VP express_VBP ] both_CC[NP KBF1_NN ] and_CC[NP NF-kappa_NN B_NN ][PP in_IN ][NP their_PRP$ nuclei_NNS ] ,_, but_CC[NP one_CD hybrid_NN ][VP expresses_VBZ ][NP only_RB KBF1_NN ] ._.
[NP The_DT kappa_NN B_NN enhancer_NN ][PP of_IN ][NP the_DT gene_NN ][VP encoding_VBG ] the_DT[NP interleukin-2_NN ] (_([NP IL-2_NN ] )_)[NP receptor_NN alpha_NN chain_NN ] (_([NP IL-2R_NN alpha_NN ] )_)[VP is_VBZ ][ADJP functional_JJ ][PP only_RB in_IN ][NP the_DT hybrids_NNS ][VP expressing_VBG ][NP nuclear_JJ NF-kappa_NN B_NN ] ._.
[NP These_DT findings_NNS ][VP show_VBP ][SBAR that_IN ][NP nuclear_JJ NF-kappa_NN B_NN ][VP is_VBZ ][ADJP necessary_JJ ][VP to_TO activate_VB ][NP the_DT kappa_NN B_NN enhancer_NN ] ,_,[SBAR while_IN ][NP KBF1_NN ][PP by_IN ][NP itself_PRP ][VP is_VBZ ] not_RB[ADJP sufficient_JJ ] ._.
[NP We_PRP ][VP propose_VBP ][SBAR that_IN ][NP KBF1_NN ][VP is_VBZ ][NP a_DT competitive_JJ inhibitor_NN ][PP of_IN ][NP NF-kappa_NN B_NN ] and_CC[VP discuss_VB ][ADVP how_WRB ][NP these_DT factors_NNS ][VP may_MD be_VB involved_VBN ][PP in_IN ][NP the_DT transient_JJ expression_NN ][PP of_IN ][NP IL-2_NN ] and_CC[NP IL-2_NN alpha_NN ][NP genes_NNS ][PP during_IN ][NP the_DT immune_JJ response_NN ] ._.
[NP Influence_NN ][PP of_IN ][NP estradiol_NN ] and_CC[NP tamoxifen_NN ][PP on_IN ][NP susceptibility_NN ][PP of_IN ][NP human_JJ breast_NN cancer_NN cell_NN lines_NNS ][PP to_TO ][NP lysis_NN ][PP by_IN ][NP lymphokine-activated_JJ killer_NN cells_NNS ] ._.
[NP The_DT design_NN ][PP of_IN ][NP combination_NN hormonal_JJ and_CC immunotherapeutic_JJ protocols_NNS ][PP for_IN ][NP breast_NN cancer_NN patients_NNS ][VP may_MD be_VB facilitated_VBN ][PP by_IN ][NP analysis_NN ][PP of_IN ][NP preclinical_JJ in_FW vitro_FW model_JJ systems_NNS ] ._.
 Estrogen_NN receptor_NN positive_JJ (_([ADJP ER+_JJ ] :_:[NP MCF-7_NN ] )_) and_CC negative_JJ (_([ADJP ER-_JJ ] :_:[NP MDA-MB-231_NN ] )_)[NP human_JJ breast_NN cancer_NN cell_NN lines_NNS ][VP were_VBD utilized_VBN ][VP to_TO evaluate_VB ][NP the_DT effects_NNS ][PP of_IN ][NP tamoxifen_NN ] (_([NP TAM_NN ] )_) and_CC[NP estradiol_NN ] (_([NP E2_NN ] )_)[PP on_IN ][NP modulation_NN ][PP of_IN ][NP breast_NN cancer_NN target_NN susceptibility_NN ][PP to_TO ][NP lysis_NN ][PP by_IN ][NP lymphokine-activated_JJ killer_NN ] (_([NP LAK_NN ] )_)[NP cells_NNS ] ._.
[NP E2-stimulated_JJ ER+_JJ cells_NNS ][VP were_VBD ][ADJP more_RBR susceptible_JJ ][PP to_TO ][NP lysis_NN ][PP by_IN ][NP LAK_NN cells_NNS ][PP than_IN ] corresponding_VBG TAM-treated_JJ or_CC[NP control_NN ][NP cells_NNS ] ,_,[SBAR while_IN ][NP treatment_NN ][PP of_IN ][NP ER-_JJ cells_NNS ][PP with_IN ] either_CC[NP E2_NN ] or_CC[NP TAM_NN ][ADVP alone_RB ][VP did_VBD not_RB alter_VB ][PP from_IN ][NP control_NN ][NP their_PRP$ susceptibility_NN ][PP to_TO ][NP this_DT immune-mediated_JJ lysis_NN ] ._.
[NP All_DT ER+_JJ and_CC ER-_JJ cells_NNS ][VP tested_VBN ][VP remained_VBD ][ADJP sensitive_JJ ][PP after_IN ][NP treatment_NN ][PP with_IN ][NP TAM_NN ][PP to_TO ][NP lysis_NN ][PP by_IN ][NP LAK_NN cells_NNS ] ._.
[PP In_IN ][NP addition_NN ] ,_, an_DT[NP adenocarcinoma_NN ] reactive_JJ[ADJP human-mouse_JJ chimeric_JJ ][NP monoclonal_JJ antibody_NN ] (_([NP ING-1_NN ] )_)[VP was_VBD ][ADJP able_JJ ][VP to_TO significantly_RB boost_VB ][ADVP in_FW vivo_FW ][NP generated_VBN LAK_NN cell-mediated_JJ lysis_NN ][PP of_IN ][NP control_NN ] ,_,[ADJP E2-treated_JJ ] ,_, and_CC[ADJP TAM-treated_JJ ][ADJP ER+_JJ ] and_CC[ADJP ER-_JJ ][NP cells_NNS ] ._.
[NP These_DT in_FW vitro_FW results_NNS ][VP provide_VBP ][NP a_DT preclinical_JJ rationale_NN ][PP for_IN ][NP in_FW vivo_FW testing_NN ][PP of_IN ][NP TAM_NN ] ,_,[NP interleukin-2_NN ] (_([NP IL-2_NN ] )_) ,_, and_CC[NP breast_NN cancer_NN reactive_JJ antibody-dependent_JJ cellular_JJ cytotoxicity_NN ][VP facilitating_VBG ][NP antibody_NN ][PP in_IN ][NP patients_NNS ][PP with_IN ] refractory_JJ or_CC[NP high_JJ risk_NN ][NP breast_NN cancer_NN ] ._.
[NP Glucocorticoid_NN receptor_NN ] and_CC[NP inhibition_NN ][PP of_IN ][NP 3-O-methyl-D-glucose_NN uptake_NN ][PP by_IN ][NP glucocorticoids_NNS ][PP in_IN ][NP peripheral_JJ blood_NN leukocytes_NNS ][PP from_IN ][NP normal_JJ humans_NNS ] :_:[NP correlation_NN ][PP between_IN ][NP receptor_NN level_NN ] and_CC[NP hormone_NN effect_NN ][ADVP in_FW vitro_FW ] ._.
[NP We_PRP ][VP have_VBP measured_VBN ][NP the_DT glucocorticoid_NN receptor_NN concentration_NN ][PP in_IN ][NP mononuclear_JJ and_CC polymorphonuclear_JJ leukocytes_NNS ] ,_,[NP both_DT ][PP of_IN ][NP which_WDT ][VP were_VBD isolated_VBN ][PP from_IN ][NP peripheral_JJ blood_NN ][PP from_IN ][NP ten_CD healthy_JJ male_JJ volunteers_NNS ] ._.
[PP In_IN ][NP parallel_NN ] ,_,[NP the_DT inhibitory_JJ effect_NN ][PP of_IN ][NP dexamethasone_NN ][PP on_IN ][NP 3-O-methyl-D-glucose_NN uptake_NN ][VP was_VBD assayed_VBN ][PP in_IN ][NP the_DT corresponding_JJ mononuclear_JJ leukocytes_NNS ] ._.
[NP The_DT glucocorticoid_NN receptor_NN levels_NNS ][PP in_IN ][NP mononuclear_JJ leukocytes_NNS ][VP correlated_VBD ][PP with_IN ][NP those_DT ][PP in_IN ][NP polymorphonuclear_JJ leukocytes_NNS ] ,_, and_CC[NP there_EX ][VP was_VBD ][NP a_DT linear_JJ relationship_NN ][PP between_IN ][NP the_DT cellular_JJ glucocorticoid_NN receptor_NN levels_NNS ] and_CC[NP glucocorticoid-mediated_JJ inhibition_NN ][PP of_IN ][NP the_DT uptake_NN ][PP of_IN ][NP 3-O-methyl-D-glucose_NN ][PP in_IN ][NP mononuclear_JJ leukocytes_NNS ] ._.
[ADVP When_WRB ][NP mononuclear_JJ leukocytes_NNS ][VP were_VBD incubated_VBN ][PP in_IN the_DT presence_NN of_IN ][NP 8-bromo-cAMP_NN ] ,_,[NP cellular_JJ glucocorticoid_NN receptor_NN levels_NNS ][VP increased_VBD ] and_CC[NP a_DT more_RBR pronounced_JJ inhibitory_JJ effect_NN ][PP of_IN ][NP dexamethasone_NN ][VP was_VBD observed_VBN ][PP on_IN ][NP the_DT transport_NN ][PP of_IN ][NP 3-O-methyl-D-glucose_NN ] ._.
[NP We_PRP ][VP conclude_VBP ][SBAR that_IN ][NP the_DT cellular_JJ glucocorticoid_NN receptor_NN levels_NNS ][PP in_IN ][NP peripheral_JJ blood_NN leukocytes_NNS ][VP reflect_VBP ][NP in_FW vitro_FW responsiveness_NN ][PP to_TO ][NP glucocorticoids_NNS ][PP in_IN ][NP mononuclear_JJ leukocytes_NNS ][PP from_IN ][NP healthy_JJ males_NNS ] ,_, and_CC[SBAR that_IN ][NP the_DT individual_JJ responsiveness_NN ][VP may_MD alter_VB ][PP upon_IN ][NP changes_NNS ][PP in_IN ][NP the_DT cellular_JJ levels_NNS ][PP of_IN ][NP glucocorticoid_NN receptor_NN ] ._.
[NP Stimulation_NN ][PP of_IN ][NP interferon_NN beta_NN gene_NN transcription_NN ][ADVP in_FW vitro_FW ][PP by_IN ][NP purified_VBN NF-kappa_NN B_NN ] and_CC[NP a_DT novel_JJ TH_NN protein_NN ] ._.
 The_DT human_JJ[NP interferon_NN beta_NN ] (_([NP IFN-beta_NN ] )_)[NP regulatory_JJ element_NN ][VP consists_VBZ ][PP of_IN ][NP multiple_JJ enhanson_NN domains_NNS ][NP which_WDT ][VP are_VBP ][NP targets_NNS ][PP for_IN ][NP transcription_NN factors_NNS ][VP involved_VBN ][PP in_IN ][NP inducible_JJ expression_NN ][PP of_IN ][NP the_DT promoter_NN ] ._.
[VP To_TO further_RB characterize_VB ][NP the_DT protein-DNA_JJ interactions_NNS ][VP mediating_VBG ][NP IFN-beta_NN induction_NN ] ,_,[NP positive_JJ regulatory_JJ domain_NN ] (_([NP PRD_NN ] )_)[NP II_CD binding_NN proteins_NNS ][VP were_VBD purified_VBN ][PP from_IN ][NP phorbol_NN ester_NN ][NP induced_JJ Jurkat_NN T-cells_NNS ][PP and_CC ][PP from_IN ][NP IFN_NN ][ADJP primed_VBN ] ,_,[NP cycloheximide/polyinosinic-polycytidylic_JJ acid_NN ][ADJP treated_VBN ] HeLa_NN S3_NN cells_NNS ._.
[PP From_IN ][NP HeLa_NN cells_NNS ] ,_,[NP two_CD major_JJ proteins_NNS ][PP of_IN ][NP 52_CD ] and_CC[NP 45_CD ][NP kilodaltons_NNS ] (_([NP kD_NN ] )_)[VP copurified_VBD ][PP with_IN ][NP DNA_NN binding_NN activity_NN ] ,_, whereas_IN[PP from_IN ][NP T-cells_NNS ] ,_,[NP four_CD proteins_NNS ] --_:[NP a_DT major_JJ protein_NN ][PP of_IN ][NP 52_CD kD_NN ] and_CC[NP three_CD minor_JJ proteins_NNS ][PP of_IN ][NP 82_CD ,_, 67_CD ,_, and_CC 43-47_CD kD_NN ] --_:[VP were_VBD purified_VBN ] ._.
[ADVP Also_RB ] ,_, an_DT[NP induction_NN ][NP specific_JJ DNA_NN binding_NN protein_NN ][VP was_VBD purified_VBN ][PP from_IN ][NP HeLa_NN cells_NNS ][NP that_WDT ][VP interacted_VBD ][PP with_IN ][NP the_DT (_( AAGTGA_NN )_) 4_CD tetrahexamer_NN sequence_NN ] and_CC[NP the_DT PRDI_NN domain_NN ] ._.
[NP This_DT protein_NN ][VP is_VBZ ][ADJP immunologically_RB distinct_JJ ][PP from_IN ][NP IRF-1/ISGF2_NN ] ._.
 Uninduced_JJ or_CC[NP Sendai_NN virus_NN ][NP induced_JJ HeLa_NN extracts_NNS ][VP were_VBD used_VBN ][VP to_TO examine_VB ][NP transcription_NN ][ADVP in_FW vitro_FW ][VP using_VBG ][NP a_DT series_NN ][PP of_IN ][NP IFN_NN beta_NN promoter_NN deletions_NNS ] ._.
[NP Deletions_NNS ][ADJP upstream_JJ ][PP of_IN ][NP the_DT PRDII_NN element_NN ][VP increased_VBD ][NP transcription_NN ][PP in_IN ][NP the_DT uninduced_JJ extract_NN ] ,_,[VP indicating_VBG ][NP predominantly_RB negative_JJ regulation_NN ][PP of_IN ][NP the_DT promoter_NN ] ._.
[NP A_DT 2-4-fold_JJ increase_NN ][PP in_IN ][NP IFN-beta_NN promoter_NN transcription_NN ][VP was_VBD observed_VBN ][PP in_IN ][NP Sendai_NN virus_NN ][NP induced_JJ extracts_NNS ] ,_, and_CC[NP deletion_NN ][PP of_IN ][NP PRDI_NN ] and_CC[NP PRDII_NN ][NP elements_NNS ][VP decreased_VBD ][NP this_DT induced_VBN level_NN ][PP of_IN ][NP transcription_NN ] ._.
[ADVP When_WRB ][NP purified_VBN PRDII_NN ] and_CC[NP tetrahexamer_NN binding_NN proteins_NNS ][VP were_VBD added_VBN ][PP to_TO ][NP the_DT induced_VBN extract_NN ] ,_,[NP a_DT 4-fold_JJ increase_NN ][PP in_IN ][NP transcription_NN ][VP was_VBD observed_VBN ] ._.
[NP These_DT experiments_NNS ][VP demonstrate_VBP ][SBAR that_IN ][NP it_PRP ][VP is_VBZ ][ADJP possible_JJ ][VP to_TO modulate_VB ][NP IFN-beta_NN transcription_NN ][ADVP in_FW vitro_FW ] but_CC[VP indicate_VBP ][SBAR that_IN ][NP additional_JJ proteins_NNS ][VP may_MD be_VB required_VBN to_TO fully_RB activate_VB ][NP IFN-beta_NN transcription_NN ] ._.
[NP Structure_NN function_NN analysis_NN ][PP of_IN ][NP vitamin_NN D_NN analogs_NNS ][PP with_IN ][NP C-ring_NN modifications_NNS ] ._.
[NP Analogs_NNS ][PP of_IN ][NP 1_CD alpha,25-dihydroxyvitamin_NN D3_NN ] (_([NP 1_CD alpha,25-(OH)_NN 2D3_NN ] )_)[PP with_IN ][NP substitutions_NNS ][PP on_IN ][NP C-11_NN ][VP were_VBD synthesized_VBN ] ._.
[NP Small_JJ apolar_JJ substitutions_NNS ] (_([NP 11_CD alpha-methyl_NN ] ,_,[NP 11_CD alpha-fluoromethyl_NN ] )_)[VP did_VBD not_RB markedly_RB decrease_VB ][NP the_DT affinity_NN ][PP for_IN ][NP the_DT vitamin_NN D_NN receptor_NN ] ,_, but_CC larger_JJR (_([NP 11_CD alpha-chloromethyl_NN ] or_CC[NP 11_CD alpha-_NN ][NP or_CC 11_CD beta-phenyl_NN ] )_)[NP or_CC more_RBR polar_JJ substitutions_NNS ] (_([NP 11_CD alpha-hydroxymethyl_NN ] ,_,[NP 11_CD alpha-(2-hydroxyethyl_NN ] )_)[VP decreased_VBD ][NP the_DT affinity_NN ][PP to_TO ][NP less_JJR than_IN 5_CD %_NN ][PP of_IN ][NP that_DT ][PP of_IN ][NP 1_CD alpha,25-OH)2D3_NN ] ._.
[NP Their_PRP$ affinity_NN ][PP for_IN ][NP the_DT vitamin_NN D-binding_JJ protein_NN ] ,_,[ADVP however_RB ] ,_,[VP increased_VBD ][ADVP up_RB to_TO 4-fold_RB ] ._.
[NP The_DT biological_JJ activity_NN ][PP of_IN ][NP 11_CD alpha-methyl-1_NN alpha,25-(OH)2D3_NN ][ADVP closely_RB ][VP resembled_VBD ][NP that_DT ][PP of_IN ][NP the_DT natural_JJ hormone_NN ][PP on_IN ][NP normal_JJ and_CC leukemic_JJ ][NP cell_NN proliferation_NN ] and_CC[NP bone_NN resorption_NN ] ,_, whereas_IN[NP its_PRP$ in_FW vivo_FW effect_NN ][PP on_IN ][NP calcium_NN metabolism_NN ][PP of_IN ][NP the_DT rachitic_JJ chick_NN ][VP was_VBD ][NP about_IN 50_CD %_NN ][PP of_IN ][NP that_DT ][PP of_IN ][NP 1_CD alpha,25-(OH)2D3_NN ] ._.
[NP The_DT 11_CD beta-methyl_NN analog_NN ][VP had_VBD ] a_DT[ADVP greater_JJR than_IN 10-fold_RB ][NP lower_JJR activity_NN ] ._.
[NP The_DT differentiating_JJ effects_NNS ][PP of_IN ][NP the_DT other_JJ C-11_NN analogs_NNS ][PP on_IN ][NP human_JJ promyeloid_JJ leukemia_NN cells_NNS ] (_([NP HL-60_NN ] )_)[VP agreed_VBD ][ADVP well_RB ][PP with_IN ][NP their_PRP$ ][NP bone-resorbing_JJ activity_NN ] and_CC[NP receptor_NN affinity_NN ] ,_, but_CC[NP they_PRP ][VP demonstrated_VBD ][NP lower_JJR calcemic_JJ effects_NNS ][ADVP in_FW vivo_FW ] ._.
[NP Large_JJ or_CC polar_JJ substitutions_NNS ][PP on_IN ][NP C-11_NN ][PP of_IN ][NP 1_CD alpha,25-(OH)2D3_NN ][ADVP thus_RB ][VP impair_VBP ][NP the_DT binding_NN ][PP of_IN ][NP the_DT vitamin_NN D_NN receptor_NN ] but_CC[VP increase_VBP ][NP the_DT affinity_NN ][PP to_TO ][NP vitamin_NN D-binding_JJ protein_NN ] ._.
[NP The_DT effects_NNS ][PP of_IN ][NP many_JJ C-11-substituted_JJ 1_CD alpha,25-(OH)2D3_NN analogs_NNS ][PP on_IN ][NP HL-60_NN cell_NN differentiation_NN ][VP exceeded_VBD ][NP their_PRP$ activity_NN ][PP on_IN ][NP calcium_NN metabolism_NN ] ._.
[NP Transcriptional_JJ regulation_NN ][PP during_IN ][NP T-cell_NN development_NN ] :_:[NP the_DT alpha_NN TCR_NN gene_NN ][PP as_IN ][NP a_DT molecular_JJ model_NN ] ._.
[NP The_DT regulation_NN ][PP of_IN ][NP gene_NN expression_NN ][PP during_IN ][NP lymphocyte_NN differentiation_NN ][VP is_VBZ ][NP a_DT complex_JJ process_NN ][VP involving_VBG ][NP interactions_NNS ][PP between_IN ][NP multiple_JJ positive_JJ and_CC negative_JJ transcriptional_JJ regulatory_JJ elements_NNS ] ._.
[PP In_IN ][NP this_DT article_NN ] ,_,[NP transcriptional_JJ regulation_NN ][PP of_IN ][NP the_DT archetypal_JJ T-cell-specific_JJ gene_NN ] ,_,[NP alpha_NN TCR_NN ] ,_,[VP is_VBZ discussed_VBN ] ._.
[NP Major_JJ recent_JJ developments_NNS ] ,_,[PP including_VBG ][NP the_DT identification_NN ][PP of_IN ][NP novel_JJ families_NNS ][PP of_IN ][NP transcription_NN factors_NNS ][NP that_WDT ][VP regulate_VBP ][NP multiple_JJ T-cell_NN genes_NNS ][PP during_IN ][NP thymocyte_NN ontogeny_NN ] and_CC[NP T-cell_NN activation_NN ] ,_,[VP are_VBP described_VBN ] ._.
[NP Cortisol_NN resistance_NN ][PP in_IN ][NP acquired_VBN immunodeficiency_NN syndrome_NN ] ._.
[NP This_DT study_NN ][VP concerns_VBZ ][NP 9_CD iv_NN drug_NN abusers_NNS ][PP with_IN ][NP acquired_VBN immunodeficiency_NN syndrome_NN ] (_([NP AIDS_NN ] )_)[NP who_WP ][VP developed_VBD ][NP hypercortisolism_NN ][PP without_IN ][NP the_DT ][NP clinical_JJ signs_NNS ] or_CC[NP metabolic_JJ consequences_NNS ][PP of_IN ][NP hypercortisolism_NN ] ._.
[NP All_DT patients_NNS ][VP were_VBD characterized_VBN ][PP by_IN ][NP an_DT Addisonian_JJ picture_NN ] (_([NP weakness_NN ] ,_,[NP weight_NN loss_NN ] ,_,[NP hypotension_NN ] ,_,[NP hyponatremia_NN ] ,_, and_CC[NP intense_JJ mucocutaneous_JJ melanosis_NN ] )_) ._.
[NP An_DT acquired_JJ form_NN ][PP of_IN ][NP peripheral_JJ resistance_NN ][PP to_TO ][NP glucocorticoids_NNS ][VP was_VBD suspected_VBN ] ._.
[NP We_PRP ] ,_,[ADVP therefore_RB ] ,_,[VP examined_VBD ][NP glucocorticoid_NN receptor_NN characteristics_NNS ][PP on_IN ][NP mononuclear_JJ leukocytes_NNS ][PP by_IN ][VP measuring_VBG ][NP (3H)dexamethasone_NN binding_NN ] and_CC[NP the_DT effect_NN ][PP of_IN ][NP dexamethasone_NN ][PP on_IN ][NP (3H)thymidine_NN incorporation_NN ] ,_,[NP which_WDT ][VP is_VBZ ][NP one_CD ][PP of_IN ][NP the_DT effects_NNS ][PP of_IN ][NP glucocorticoid_NN receptor_NN activation_NN ] ._.
[NP Glucocorticoid_NN receptor_NN density_NN ][VP was_VBD increased_VBN ][PP in_IN ][NP AIDS_NN patients_NNS ][PP with_IN ][NP an_DT Addisonian_JJ picture_NN ] (_([NP group_NN 1_CD ] ;_:[NP 16.2_CD +/-_CC 9.4_CD fmol/million_NN cells_NNS ] )_)[VP compared_VBN ][PP to_TO ][NP values_NNS ][PP in_IN ][NP 12_CD AIDS_NN patients_NNS ][PP without_IN ][NP an_DT Addisonian_JJ picture_NN ] (_([NP group_NN 2_CD ] ;_:[NP 6.05_CD +/-_CC 2.6_CD fmol/million_NN cells_NNS ] ;_:[NP P_NN ][NP less_JJR than_IN 0.01_CD ] )_) and_CC[NP sex-_NN ] and_CC[ADJP age-matched_JJ ][NP controls_NNS ] (_([NP 3.15_CD +/-_CC 2.3_CD fmol/million_NN cells_NNS ] ;_:[NP P_NN ][NP less_JJR than_IN 0.01_CD ] )_) ._.
[NP The_DT affinity_NN ][PP of_IN ][NP glucocorticoid_NN receptors_NNS ] (_([NP Kd_NN ] )_)[VP was_VBD strikingly_RB decreased_VBN ] (_([NP 9.36_CD +/-_CC 3.44_CD nM_NN ][PP in_IN ][NP group_NN 1_CD ] ;_:[NP 3.2_CD +/-_CC 1.5_CD nM_NN ][PP in_IN ][NP group_NN 2_CD ] ;_:[NP 2.0_CD +/-_CC 0.8_CD nM_NN ][PP in_IN ][NP controls_NNS ] ;_:[NP P_NN ][NP less_JJR than_IN 0.01_CD ] )_) ._.
[NP (3H)Thymidine_NN incorporation_NN ][VP was_VBD decreased_VBN ][ADVP dose-dependently_RB ][PP by_IN ][NP dexamethasone_NN ][PP in_IN ][NP controls_NNS ] and_CC[NP patients_NNS ] ;_:[NP the_DT effect_NN ][VP was_VBD significantly_RB blunted_VBN ] (_([NP P_NN ][NP less_JJR than_IN 0.05_CD ] )_)[PP in_IN ][NP group_NN 1_CD patients_NNS ] ,_,[NP which_WDT ][VP suggests_VBZ ][SBAR that_IN ][NP activation_NN ][PP of_IN ][NP glucocorticoid_NN receptor_NN ][VP is_VBZ ][ADJP impaired_JJ ][PP as_IN ][NP a_DT result_NN ][PP of_IN ][NP the_DT glucocorticoid_NN receptor_NN abnormality_NN ] ._.
[PP In_IN ][NP conclusion_NN ] ,_,[NP AIDS_NN patients_NNS ][PP with_IN ][NP hypercortisolism_NN ] and_CC[NP clinical_JJ features_NNS ][PP of_IN ][NP peripheral_JJ resistance_NN ][PP to_TO ][NP glucocorticoids_NNS ][VP are_VBP characterized_VBN ][PP by_IN ][NP abnormal_JJ glucocorticoid_NN receptors_NNS ][PP on_IN ][NP lymphocytes_NNS ] ._.
[NP Resistance_NN ][PP to_TO ][NP glucocorticoids_NNS ][VP implies_VBZ ][NP a_DT complex_JJ change_NN ][PP in_IN ][NP immune-endocrine_JJ function_NN ] ,_,[NP which_WDT ][VP may_MD be_VB ][ADJP important_JJ ][PP in_IN ][NP the_DT course_NN ][PP of_IN ][NP immunodeficiency_NN syndrome_NN ] ._.
[NP Induction_NN ][PP of_IN ][NP monocytic_JJ differentiation_NN ] and_CC[NP NF-kappa_NN B-like_JJ activities_NNS ][PP by_IN ][NP human_JJ immunodeficiency_NN virus_NN 1_CD infection_NN ][PP of_IN ][NP myelomonoblastic_JJ cells_NNS ] ._.
[NP The_DT effects_NNS ][PP of_IN ][NP human_JJ immunodeficiency_NN virus_NN 1_CD ] (_([NP HIV-1_NN ] )_)[NP infection_NN ][PP on_IN ][NP cellular_JJ differentiation_NN ] and_CC[NP NF-kappa_NN B_NN DNA_NN binding_NN activity_NN ][VP have_VBP been_VBN investigated_VBN ][PP in_IN ][NP a_DT new_JJ model_NN ][PP of_IN ][NP myeloid_JJ differentiation_NN ] ._.
[NP PLB-985_NN cells_NNS ][VP represent_VBP ][NP a_DT bipotential_JJ myelomonoblastic_JJ cell_NN population_NN ][ADJP capable_JJ ][PP of_IN ][NP either_CC granulocytic_JJ or_CC monocytic_JJ differentiation_NN ][PP after_IN ][NP induction_NN ][PP with_IN ][NP appropriate_JJ inducers_NNS ] ._.
[PP By_IN virtue_NN of_IN ][NP the_DT presence_NN ][PP of_IN ][NP CD4_NN ][PP on_IN ][NP the_DT cell_NN surface_NN ] ,_,[NP PLB-985_NN cells_NNS ][VP were_VBD chronically_RB infected_VBN ][PP with_IN ][NP HIV-1_NN strain_NN IIIB_NN ] ._.
[NP PLB-IIIB_NN cells_NNS ][ADVP clearly_RB ][VP possessed_VBD ][NP a_DT more_RBR monocytic_JJ phenotype_NN ][PP than_IN ][NP the_DT parental_JJ myeloblasts_NNS ] ,_,[SBAR as_IN ][VP determined_VBN ][PP by_IN ][NP differential_JJ staining_NN ] ,_,[NP increased_VBN expression_NN ][PP of_IN ][NP the_DT myeloid-specific_JJ surface_NN markers_NNS ] ,_, and_CC[NP transcription_NN ][PP of_IN ][NP the_DT c-fms_NN proto-oncogene_NN ] ._.
[NP NF-kappa_NN B_NN binding_NN activity_NN ][VP was_VBD ][ADJP inducible_JJ ][PP by_IN ][NP tumor_NN necrosis_NN factor_NN ] and_CC[NP phorbol_NN myristate_NN acetate_NN ][PP in_IN ][NP PLB-985_NN ] ._.
[ADVP However_RB ] ,_,[PP in_IN ][NP PLB-IIIB_NN cells_NNS ] ,_,[NP constitutive_JJ expression_NN ][PP of_IN ][NP a_DT novel_JJ NF-kappa_NN B_NN complex_NN ][VP was_VBD detected_VBN ] ,_,[VP composed_VBN ][PP of_IN ][NP proteins_NNS ][VP ranging_VBG ][PP between_IN ][NP 70_CD and_CC 110_CD kD_NN ] ._.
[NP These_DT proteins_NNS ][VP interacted_VBD ][PP specifically_RB with_IN ][NP the_DT symmetric_JJ NF-kappa_NN B_NN site_NN ][PP from_IN ] the_DT[NP interferon_NN beta_NN ] (_([NP IFN-beta_NN ] )_)[NP promoter_NN ] ._.
[NP Mutations_NNS ][VP affecting_VBG ][NP the_DT 5'_JJ guanine_JJ residues_NNS ][PP of_IN ][NP the_DT kappa_NN B_NN site_NN ][VP were_VBD ][ADJP unable_JJ ][VP to_TO compete_VB ][PP for_IN ][NP these_DT NF-kappa_NN B-related_JJ proteins_NNS ] ._.
[NP Inducibility_NN ][PP of_IN ] endogenous_JJ[NP IFN-beta_NN ] and_CC[NP IFN-alpha_NN ][NP RNA_NN ][VP was_VBD also_RB increased_VBN ][PP in_IN ][NP PLB-IIIB_NN cells_NNS ] ._.
[NP These_DT studies_NNS ][VP indicate_VBP ][SBAR that_IN ][NP HIV-1_NN infection_NN ][PP of_IN ][NP myelomonoblastic_JJ cells_NNS ][VP may_MD select_VB ][PP for_IN ][NP a_DT more_RBR mature_JJ monocytic_JJ phenotype_NN ] and_CC[SBAR that_IN ][NP unique_JJ subunit_NN associations_NNS ][PP of_IN ][NP NF-kappa_NN B_NN DNA_NN binding_NN proteins_NNS ][VP may_MD contribute_VB ][PP to_TO ][NP differential_JJ NF-kappa_NN B-mediated_JJ gene_NN expression_NN ] ._.
[NP The_DT AP-1_NN site_NN ][PP at_IN ][NP -150_CD bp_NN ] ,_,[CONJP but_CC not_RB ][NP the_DT NF-kappa_NN B_NN site_NN ] ,_,[VP is_VBZ ][ADJP likely_JJ ][VP to_TO represent_VB ][NP the_DT major_JJ target_NN ][PP of_IN ][NP protein_NN kinase_NN C_NN ][PP in_IN ][NP the_DT interleukin_NN 2_CD promoter_NN ] ._.
[NP Stimulation_NN ][PP of_IN ][NP T_NN cells_NNS ][PP with_IN ][NP antigen_NN ][VP results_VBZ ][PP in_IN ][NP activation_NN ][PP of_IN ][NP several_JJ kinases_NNS ] ,_,[PP including_VBG ][NP protein_NN kinase_NN C_NN ] (_([NP PKC_NN ] )_) ,_,[NP that_WDT ][VP may_MD mediate_VB ][NP the_DT later_JJ induction_NN ][PP of_IN ][NP activation-related_JJ genes_NNS ] ._.
[NP We_PRP ][VP have_VBP examined_VBN ][NP the_DT potential_JJ role_NN ][PP of_IN ][NP PKC_NN ][PP in_IN ][NP induction_NN ][PP of_IN ] the_DT[NP interleukin_NN 2_CD ] (_([NP IL-2_NN ] )_)[NP gene_NN ][PP in_IN ][NP T_NN cells_NNS ][VP stimulated_VBN ][PP through_IN ][NP the_DT T_NN cell_NN receptor/CD3_NN complex_NN ] ._.
[NP We_PRP ][VP have_VBP previously_RB shown_VBN ][SBAR that_IN ][NP prolonged_JJ treatment_NN ][PP of_IN ][NP the_DT untransformed_JJ T_NN cell_NN clone_NN Ar-5_NN ][PP with_IN ][NP phorbol_NN esters_NNS ][VP results_VBZ ][PP in_IN ][NP downmodulation_NN ][PP of_IN ] the_DT[NP alpha_NN ] and_CC[NP beta_NN ][NP isozymes_NNS ][PP of_IN ][NP PKC_NN ] ,_, and_CC[VP abrogates_VBZ ][NP induction_NN ][PP of_IN ][NP IL-2_NN mRNA_NN ] and_CC[NP protein_NN ] ._.
[ADVP Here_RB ][NP we_PRP ][VP show_VBP ][SBAR that_IN ][NP phorbol_NN ester_NN treatment_NN ][ADVP also_RB ][VP abolishes_VBZ ][NP induction_NN ][PP of_IN ][NP chloramphenicol_JJ acetyltransferase_NN activity_NN ][PP in_IN ][NP Ar-5_NN cells_NNS ][VP transfected_VBN ][PP with_IN ][NP a_DT plasmid_NN ][VP containing_VBG ][NP the_DT IL-2_NN promoter_NN ][VP linked_VBN ][PP to_TO ][NP this_DT reporter_NN gene_NN ] ._.
[NP The_DT IL-2_NN promoter_NN ][VP contains_VBZ ][NP binding_VBG sites_NNS ][PP for_IN ][NP nuclear_JJ factors_NNS ][PP including_VBG ][NP NFAT-1_NN ] ,_,[NP Oct_NN ] ,_,[NP NF-kappa_NN B_NN ] ,_, and_CC[NP AP-1_NN ] ,_,[NP which_WDT ][VP are_VBP ][ADJP all_DT potentially_RB sensitive_JJ ][PP to_TO ][NP activation_NN ][PP of_IN ][NP PKC_NN ] ._.
[NP We_PRP ][VP show_VBP ][SBAR that_IN ][NP induction_NN ][PP of_IN ][NP a_DT trimer_NN ][PP of_IN ] the_DT[NP NFAT_NN ] and_CC[NP Oct_NN ][NP sites_NNS ][VP is_VBZ ] not_RB[ADJP sensitive_JJ ][PP to_TO ][NP phorbol_NN ester_NN treatment_NN ] ,_, and_CC[SBAR that_IN ][NP mutations_NNS ][PP in_IN ][NP the_DT NF-kappa_NN B_NN site_NN ][VP have_VBP ][NP no_DT effect_NN ][PP on_IN ][NP inducibility_NN ][PP of_IN ][NP the_DT IL-2_NN promoter_NN ] ._.
[PP In_IN ][NP contrast_NN ] ,_,[NP mutations_NNS ][PP in_IN ][NP the_DT AP-1_NN site_NN ][ADJP located_JJ ][PP at_IN ][NP -150_CD bp_NN ][ADVP almost_RB completely_RB ][VP abrogate_VBP ][NP induction_NN ][PP of_IN ][NP the_DT IL-2_NN promoter_NN ] ,_, and_CC[NP appearance_NN ][PP of_IN ][NP an_DT inducible_JJ nuclear_JJ factor_NN ][VP binding_VBG ][PP to_TO ][NP this_DT site_NN ][VP is_VBZ ][ADJP sensitive_JJ ][PP to_TO ][NP PKC_NN depletion_NN ] ._.
[ADVP Moreover_RB ] ,_,[NP cotransfections_NNS ][PP with_IN ][NP c-fos_NN ] and_CC[NP c-jun_NN ][NP expression_NN plasmids_NNS ][ADVP markedly_RB ][VP enhance_VBP ][NP induction_NN ][PP of_IN ][NP the_DT IL-2_NN promoter_NN ][PP in_IN ][NP minimally_RB stimulated_VBN T_NN cells_NNS ] ._.
[NP Our_PRP$ results_NNS ][VP indicate_VBP ][SBAR that_IN ][NP the_DT AP-1_NN site_NN ][PP at_IN ][NP -150_CD bp_NN ][VP represents_VBZ ][NP a_DT major_JJ ] ,_,[SBAR if_IN ] not_RB[NP the_DT only_JJ ] ,_,[NP site_NN ][PP of_IN ][NP PKC_NN responsiveness_NN ][PP in_IN ][NP the_DT IL-2_NN promoter_NN ] ._.
[NP Interleukin_NN 6-induced_JJ differentiation_NN ][PP of_IN ][NP a_DT human_JJ B_NN cell_NN line_NN ][PP into_IN ][NP IgM-secreting_JJ plasma_NN cells_NNS ][VP is_VBZ mediated_VBN ][PP by_IN ][NP c-fos_NN ] ._.
[NP The_DT role_NN ][PP of_IN ][NP the_DT protooncogene_NN c-fos_NN ][PP in_IN ][NP interleukin_NN (_( IL_NN )_) 6-induced_JJ B_NN cell_NN differentiation_NN ][VP was_VBD assessed_VBN ] ._.
[NP Treatment_NN ][PP of_IN ][NP SKW_NN 6.4_CD cells_NNS ][PP with_IN ][NP IL_NN 6_CD ][VP induced_VBD ][NP a_DT transient_JJ and_CC early_JJ stimulation_NN ][PP of_IN ][NP c-fos_NN sense_NN mRNA_NN expression_NN ] ._.
[NP The_DT effect_NN ][VP appeared_VBD ][PP within_IN ][NP 30_CD min_NN ] and_CC[VP returned_VBD ][PP to_TO ][NP basal_JJ levels_NNS ][PP after_IN ][NP 2_CD h_NN ] ._.
[NP The_DT addition_NN ][PP of_IN ][NP antisense_JJ oligonucleotides_NNS ][PP to_TO ][NP c-fos_NN ][ADVP significantly_RB ][VP inhibited_VBD ][NP IL_NN 6-induced_JJ IgM_NN production_NN ][PP by_IN ][NP SKW_NN 6.4_CD cells_NNS ] (_([NP p_NN ][NP less_JJR than_IN 0.001_CD ] )_) ,_, whereas_IN[NP control_NN oligonucleotides_NNS ][VP had_VBD ][NP no_DT inhibitory_JJ effect_NN ] ._.
[NP These_DT results_NNS ][VP indicate_VBP ][SBAR that_IN ][NP activation_NN ][PP of_IN ][NP c-fos_NN ][VP is_VBZ involved_VBN ][PP in_IN ][NP IL_NN 6-induced_JJ differentiation_NN ][PP of_IN ][NP SKW_NN 6.4_CD cells_NNS ][PP into_IN ][NP IgM-secreting_JJ cells_NNS ] ._.
[NP Binding_NN ][PP of_IN ][NP erythroid_JJ and_CC non-erythroid_JJ nuclear_JJ proteins_NNS ][PP to_TO ][NP the_DT silencer_NN ][PP of_IN ][NP the_DT human_JJ epsilon-globin-encoding_JJ gene_NN ] ._.
[VP To_TO clarify_VB ][NP the_DT molecular_JJ mechanisms_NNS ][VP involved_VBN ][PP in_IN ][NP the_DT developmental_JJ control_NN ][PP of_IN ][NP hemoglobin-encoding_JJ genes_NNS ][NP we_PRP ][VP have_VBP been_VBN studying_VBG ][NP the_DT expression_NN ][PP of_IN ][NP these_DT genes_NNS ][PP in_IN ][NP human_JJ cells_NNS ][PP in_IN ][NP continuous_JJ culture_NN ] ._.
[NP We_PRP ][VP have_VBP previously_RB reported_VBN ][NP the_DT presence_NN ][PP of_IN ][NP a_DT transcriptional_JJ control_NN element_NN ][PP with_IN ][NP the_DT properties_NNS ][PP of_IN ][NP a_DT silencer_NN ][VP extending_VBG ][PP from_IN ][NP -392_CD ][PP to_TO ][NP -177_CD ][NP bp_NN ][PP relative_JJ to_TO ][NP the_DT cap_NN site_NN ][PP of_IN ][NP the_DT human_JJ epsilon-globin-encoding_JJ gene_NN ] (_([NP Cao_NNP ][NP et_FW ][NP al._FW ] ,_,[NP Proc.Natl.Acad.Sci.USA_NNP 86_CD (_( 1989_CD )_) 5306-5309_CD ] )_) ._.
[NP We_PRP ][ADVP also_RB ][VP showed_VBD ][SBAR that_IN ][NP this_DT silencer_NN ][VP has_VBZ ][NP stronger_JJR inhibitory_JJ activity_NN ][PP in_IN ][NP HeLa_NN cells_NNS ] ,_,[SBAR as_IN ][VP compared_VBN ][PP to_TO ][NP K562_NN human_JJ erythroleukemia_NN cells_NNS ] ._.
[VP Using_VBG ][NP deletion_NN mutants_NNS ] and_CC[NP cis-cloned_JJ synthetic_JJ oligodeoxyribonucleotides_NNS ][PP in_IN ][NP transient_JJ expression_NN assays_NNS ] ,_,[NP nucleotide_NN sequences_NNS ][ADJP responsible_JJ ][PP for_IN ][NP this_DT effect_NN ][VP have_VBP now_RB been_VBN further_RBR delimited_VBN ][PP to_TO ][NP 44_CD bp_NN ][ADJP located_JJ ][PP from_IN ][NP -294_CD ][PP to_TO ][NP -251_CD ][NP bp_NN ] ._.
[NP Gel_NN electrophoresis_NN mobility_NN shift_NN assays_NNS ] and_CC[NP DNaseI_NN footprinting_NN assays_NNS ][VP demonstrate_VBP ][SBAR that_IN ][NP these_DT negative_JJ regulatory_JJ sequences_NNS ][VP are_VBP recognized_VBN ][ADVP differently_RB ][PP by_IN ][NP proteins_NNS ][ADJP present_JJ ][PP in_IN ][NP nuclear_JJ extracts_NNS ][VP obtained_VBN ][PP from_IN ][NP HeLa_NN ] and_CC[NP K562_NN ][NP cells_NNS ] ._.
[NP Two_CD binding_VBG proteins_NNS ][VP are_VBP detected_VBN ][PP in_IN ][NP K562_NN nuclear_JJ extracts_NNS ] ,_,[SBAR while_IN ][NP only_RB one_CD ][VP is_VBZ found_VBN ][PP in_IN ][NP extracts_NNS ][PP from_IN ][NP HeLa_NN cells_NNS ] ._.
[NP Possible_JJ mechanisms_NNS ][PP by_IN ][NP which_WDT ][NP these_DT proteins_NNS ][VP may_MD regulate_VB ][NP transcription_NN ][PP of_IN ][NP the_DT epsilon-globin-encoding_JJ gene_NN ][PP in_IN ][NP erythroid_JJ and_CC non-erythroid_JJ cells_NNS ][VP are_VBP discussed_VBN ] ._.
[NP Gangliosides_NN ][VP suppress_VBP ][NP tumor_NN necrosis_NN factor_NN production_NN ][PP in_IN ][NP human_JJ monocytes_NNS ] ._.
[NP Both_CC normal_JJ and_CC malignant_JJ cells_NNS ][VP contain_VBP ][NP gangliosides_NNS ][PP as_IN ][NP important_JJ cell_NN membrane_NN constituents_NNS ][NP that_WDT ] ,_,[PP after_IN ][VP being_VBG shed_VBN ] ,_,[VP may_MD influence_VB ][NP cells_NNS ][PP of_IN ][NP the_DT immune_JJ system_NN ] ._.
[NP We_PRP ][VP have_VBP studied_VBN ][NP the_DT impact_NN ][PP of_IN ][NP gangliosides_NNS ][PP on_IN ][NP the_DT expression_NN ][PP of_IN ][NP TNF_NN ][PP in_IN ][NP blood_NN monocytes_NNS ][PP and_CC ][PP in_IN ][NP the_DT monocytic_JJ cell_NN line_NN Mono_NN Mac_NN 6_CD ] ._.
[SBAR Although_IN ][PP under_IN ][NP standard_JJ culture_NN conditions_NNS ] ,_,[NP bovine_JJ brain_NN gangliosides_NNS ] (_([NP 100_CD micrograms/ml_NNS ] )_)[VP suppressed_VBD ][NP LPS-stimulated_JJ TNF_NN production_NN ][ADVP 5-fold_RB ][PP in_IN ][NP PBMC_NN ] and_CC[ADVP 10-fold_RB ][PP in_IN ][NP Mono_NN Mac_NN 6_CD cells_NNS ] ,_,[NP suppression_NN ][VP was_VBD ][ADJP more_RBR efficient_JJ ][PP under_IN ][NP serum-free_JJ conditions_NNS ] ._.
[VP Looking_VBG ][PP at_IN ][NP highly_RB purified_VBN gangliosides_NNS ] ,_,[NP GD3_NN ] ,_,[NP GD1a_NN ] ,_,[NP GM3_NN ] ,_,[NP GM2_NN ] ,_, and_CC[NP GM1_NN ][VP were_VBD ][ADJP all_DT effective_JJ ][PP in_IN ][VP reducing_VBG ][NP TNF_NN production_NN ][PP in_IN ][NP PBMC_NN ][PP ,_, and_CC ][PP in_IN ][NP Mono_NN Mac_NN 6_CD ][PP by_IN ][NP factor_NN ][NP 10_CD ] to_TO[NP 50_CD ] ._.
[NP The_DT suppressive_JJ activity_NN ][VP was_VBD lost_VBN ][PP in_IN ][NP molecules_NNS ] ,_,[VP lacking_VBG ][NP the_DT sugar_NN moiety_NN ] or_CC[NP the_DT lipid_NN moiety_NN ] ._.
[NP Gangliosides_NNS ][VP appear_VBP to_TO act_VB ][PP at_IN ][NP an_DT early_JJ step_NN ][PP of_IN ][NP activation_NN ][PP in_IN ][NP that_IN ][NP TNF_NN transcripts_NNS ][VP were_VBD reduced_VBN ] and_CC[NP the_DT mobilization_NN ][PP of_IN ][NP the_DT nuclear_JJ factor_NN kappa_NN B_NN ][VP was_VBD blocked_VBN ] ._.
[ADVP Furthermore_RB ] ,_,[PP in_IN ][NP time_NN kinetics_NNS ] ,_,[NP gangliosides_NNS ][VP were_VBD ][ADJP effective_JJ ][PP for_IN ][NP up_RB to_TO 30_CD min_NN ][PP after_IN ][NP addition_NN ][PP of_IN ][NP LPS_NN ] ,_, but_CC[ADVP not_RB thereafter_RB ] ._.
[ADVP However_RB ] ,_,[NP the_DT expression_NN ][PP of_IN ][NP the_DT CD14_NN Ag_NN ] ,_,[NP a_DT receptor_NN molecule_NN ][PP for_IN ][NP LPS-LPS_NN binding_NN protein_NN complexes_NNS ] ,_,[VP was_VBD unaffected_JJ ][PP by_IN ][NP gangliosides_NNS ] ._.
[ADVP Finally_RB ] ,_,[ADVP when_WRB ][VP using_VBG ][NP Staphylococcus_FW aureus_FW ] or_CC[NP platelet_NN activating_NN factor_NN ][PP as_IN ][NP a_DT stimulus_NN ] ,_,[NP gangliosides_NNS ][VP were_VBD ][ADJP able_JJ ][VP to_TO suppress_VB ][NP TNF_NN production_NN ][PP in_IN ][NP Mono_NN Mac_NN 6_CD cells_NNS ][PP by_IN ][NP factor_NN ][NP 5_CD ] to_TO[NP 10_CD ] ,_,[PP as_RB ][ADVP well_RB ] ._.
[PP On_IN ][NP the_DT other_JJ hand_NN ] ,_,[NP phorbol_NN ester-induced_JJ production_NN ][PP of_IN ][NP O2-_NN ][VP was_VBD ][ADJP similar_JJ ][PP in_IN ][NP cells_NNS ][VP treated_VBN ][PP with_IN ][PP and_CC ][PP without_IN ][NP gangliosides_NNS ] ._.
[VP Taken_VBN ][ADVP together_RB ] ,_,[NP our_PRP$ data_NNS ][VP demonstrate_VBP ][SBAR that_IN ][NP TNF_NN gene_NN expression_NN ][PP in_IN ][NP monocytes_NNS ][VP induced_VBN ][PP by_IN ][NP different_JJ types_NNS ][PP of_IN ][NP stimuli_NNS ][VP can_MD be_VB blocked_VBN ][PP by_IN ][NP gangliosides_NNS ][PP at_IN ][NP an_DT early_JJ step_NN ][PP of_IN ][NP signal_JJ transduction_NN ] ._.
[NP T_NN cell-specific_JJ negative_JJ regulation_NN ][PP of_IN ][NP transcription_NN ][PP of_IN ][NP the_DT human_JJ cytokine_NN IL-4_NN ] ._.
[NP IL-4_NN ][VP secreted_VBN ][PP by_IN ][NP activated_VBN T_NN cells_NNS ][VP is_VBZ ][NP a_DT pleiotropic_JJ cytokine_NN ][VP affecting_VBG ][NP growth_NN ] and_CC[NP differentiation_NN ][PP of_IN ][NP diverse_JJ cell_NN types_NNS ][PP such_JJ as_IN ][NP T_NN cells_NNS ] ,_,[NP B_NN cells_NNS ] ,_, and_CC[NP mast_NN cells_NNS ] ._.
[NP We_PRP ][VP investigated_VBD ][NP the_DT upstream_JJ regulatory_JJ elements_NNS ][PP of_IN ][NP the_DT human_JJ IL-4_NN promoter_NN ] ._.
[NP A_DT novel_JJ T_NN cell-specific_JJ negative_JJ regulatory_JJ element_NN ] (_([NP NRE_NN ] )_)[VP composed_VBN ][PP of_IN ][NP two_CD protein-binding_JJ sites_NNS ][VP were_VBD mapped_VBN ][PP in_IN ][NP the_DT 5'_JJ flanking_JJ region_NN ][PP of_IN ][NP the_DT IL-4_NN gene_NN ] :_:[NP -311CTCCCTTCT-303_NN ] (_([NP NRE-I_NN ] )_) and_CC[NP -288CTTTTTGCTT-TGC-300_NN ] (_([NP NRE-II_NN ] )_) ._.
[NP A_DT T_NN cell-specific_JJ protein_NN Neg-1_NN ] and_CC[NP a_DT ubiquitous_JJ protein_NN Neg-2_NN ][VP binding_VBG ][PP to_TO ][NP NRE-I_NN ] and_CC[NP NRE-II_NN ] ,_,[ADVP respectively_RB ] ,_,[VP were_VBD identified_VBN ] ._.
[ADVP Furthermore_RB ] ,_,[NP a_DT positive_JJ regulatory_JJ element_NN ][VP was_VBD found_VBN ][NP 45_CD bp_NN ][ADVP downstream_RB ][PP of_IN ][NP the_DT NRE_NN ] ._.
[NP The_DT enhancer_NN activity_NN ][PP of_IN ][NP the_DT PRE_NN ][VP was_VBD completely_RB suppressed_VBN ][ADVP when_WRB ][NP the_DT NRE_NN ][VP was_VBD ][ADJP present_JJ ] ._.
[NP These_DT data_NNS ][VP suggest_VBP ][SBAR that_IN ][NP IL-4_NN promoter_NN activity_NN ][VP is_VBZ normally_RB down-regulated_VBN ][PP by_IN ][NP an_DT NRE_NN ][PP via_IN ][NP repression_NN ][PP of_IN ][NP the_DT enhancer_NN positive_JJ regulatory_JJ element_NN ] ._.
[NP These_DT data_NNS ][VP may_MD have_VB ][NP implications_NNS ][PP for_IN ][NP the_DT stringent_JJ control_NN ][PP of_IN ][NP IL-4_NN expression_NN ][PP in_IN ][NP T_NN cells_NNS ] ._.
 (_([NP Regulatory_JJ effect_NN ][PP of_IN ][NP insulin_NN ][PP on_IN ][NP glucocorticoid_NN receptor_NN ][PP in_IN ][NP human_JJ peripheral_JJ leukocytes_NNS ] )_)
[NP The_DT regulatory_JJ effect_NN ][PP of_IN ][NP insulin_NN ][PP on_IN ][NP the_DT specific_JJ binding_VBG power_NN ][PP of_IN ][NP glucocorticoid_NN receptor_NN ] (_([NP GR_NN ] )_)[PP of_IN ][NP human_JJ leukocytes_NNS ][VP was_VBD assessed_VBN ][PP by_IN ][NP the_DT unoccupied_JJ receptor_NN sites_NNS ][ADJP capable_JJ ][PP of_IN ][VP combining_VBG ][PP with_IN ][NP (3H)_NN labelled_JJ dexamethasone_NN ][VP measured_VBN ][PP at_IN ][NP 3_CD and_CC 24_CD h_NN ][PP after_IN ][NP incubation_NN ][PP with_IN ][NP various_JJ concentrations_NNS ][PP of_IN ][NP insulin_NN ][VP added_VBN ][PP to_TO ][NP the_DT medium_NN ] ._.
[PP After_IN ][NP 3_CD h_NN incubation_NN ][NP the_DT specific_JJ binding_VBG power_NN ][PP with_IN ][NP (3H)_NN Dex_NN ][VP was_VBD decreased_VBN ][PP by_IN ][NP 23.3_CD +/-_CC 10.0_CD ] ,_,[NP 32.2_CD +/-_CC 13.2_CD ] and_CC[NP 54.3_CD +/-_CC 9.2_CD ][NP %_NN ] (_([NP P_NN ][ADJP greater_JJR ][PP than_IN ][NP 0.05_CD ] ,_,[NP P_NN ][ADJP greater_JJR ][PP than_IN ][NP 0.05_CD ] and_CC[NP P_NN ][ADJP less_JJR ][PP than_IN ][NP 0.01_CD ][SBAR as_IN ][VP compared_VBN ][PP with_IN ][NP the_DT control_NN value_NN ][PP of_IN ][NP 100_CD ][PP in_IN the_DT absence_NN of_IN ][NP insulin_NN ] )_)[ADVP respectively_RB ][PP in_IN the_DT presence_NN of_IN ][NP 20_CD mU/L_NN ] (_([NP physiological_JJ testing_NN concentration_NN ] )_) ,_,[NP 200_CD mU/L_NN ] (_([NP physiological_JJ upper_JJ limit_NN ] )_) and_CC[NP 2,000_CD mU/L_NN ] (_([NP pharmacological_JJ concentration_NN ] )_)[NP insulin_NN ][PP in_IN ][NP the_DT incubation_NN medium_NN ] ._.
[PP After_IN ][NP 24_CD h_NN incubation_NN ][NP the_DT decrease_NN ][PP of_IN ][NP these_DT values_NNS ][VP increased_VBD ][ADVP respectively_RB ][PP to_TO ][NP 43.5_CD +/-_CC 19.0_CD ] ,_,[NP 56.1_CD +/-_CC 20.7_CD ] and_CC[NP 80.2_CD +/-_CC 15.5_CD ] (_([NP P_NN ][ADJP less_JJR ][PP than_IN ][NP 0.05_CD ] ,_,[NP P_NN ][ADJP less_JJR ][PP than_IN ][NP 0.01_CD ] and_CC[NP P_NN ][ADJP less_JJR ][PP than_IN ][NP 0.01_CD ][VP compared_VBN ][PP with_IN ][NP control_NN ] )_) ._.
[ADVP Thus_RB ][NP the_DT inhibitory_JJ effect_NN ][PP of_IN ][NP insulin_NN ][PP on_IN ][NP the_DT GR_NN binding_NN power_NN ][VP is_VBZ ] both_CC[NP dose-_NN ] and_CC[ADJP time-dependent_JJ ] ,_,[NP which_WDT ][ADVP strongly_RB ][VP suggests_VBZ ][SBAR that_IN ][NP GR_NN ][VP is_VBZ tonically_RB controlled_VBN ][PP by_IN ][NP insulin_NN concentration_NN change_NN ][PP under_IN ][NP physiological_JJ conditions_NNS ] ._.
[NP Human_JJ T_NN cell_NN activation_NN ][PP through_IN ][NP the_DT activation-inducer_JJ molecule/CD69_NN ][VP enhances_VBZ ][NP the_DT activity_NN ][PP of_IN ][NP transcription_NN factor_NN AP-1_NN ] ._.
[NP The_DT induction_NN ][PP of_IN ][NP the_DT AP-1_NN transcription_NN factor_NN ][VP has_VBZ been_VBN ascribed_VBN ][PP to_TO ][NP the_DT early_JJ events_NNS ][VP leading_VBG ][PP to_TO ][NP T_NN cell_NN ][NP differentiation_NN ] and_CC[NP activation_NN ] ._.
[NP We_PRP ][VP have_VBP studied_VBN ][NP the_DT regulation_NN ][PP of_IN ][NP AP-1_NN activity_NN ][PP in_IN ][NP human_JJ peripheral_JJ blood_NN T_NN lymphocytes_NNS ][VP stimulated_VBN ][PP through_IN ][NP the_DT activation_NN inducer_NN molecule_NN (_( AIM_NN )_) /CD69_NN activation_NN pathway_NN ] ._.
[NP Phorbol_NN esters_NNS ][VP are_VBP required_VBN ][VP to_TO induce_VB ][NP AIM/CD69_NN cell-surface_JJ expression_NN ][CONJP as_RB well_RB as_IN ][PP for_IN ][VP triggering_VBG ][NP the_DT proliferation_NN ][PP of_IN ][NP T_NN cells_NNS ][PP in_IN conjunction_NN with_IN ][NP anti-AIM_JJ mAb_NN ] ._.
[NP Mobility_NN shift_NN assays_NNS ][VP showed_VBD ][SBAR that_IN ][NP addition_NN ][PP of_IN ][NP anti-AIM_JJ mAb_NN ][PP to_TO ][NP PMA-treated_JJ T_NN lymphocytes_NNS ][ADVP markedly_RB ][VP enhanced_VBD ][NP the_DT binding_NN activity_NN ][PP of_IN ][NP AP-1_NN ][PP to_TO ][NP its_PRP$ cognate_JJ sequence_NN ] ,_,[NP the_DT phorbol_NN ester_NN response_NN element_NN ] ._.
[PP In_IN ][NP contrast_NN ] ,_,[NP anti-AIM_NN mAb_NN ][VP did_VBD not_RB induce_VB ][NP any_DT change_NN ][PP in_IN ][NP the_DT binding_NN activity_NN ][PP of_IN ][NP NF-kappa_NN B_NN ] ,_,[NP a_DT transcription_NN factor_NN ][NP whose_WP$ activity_NN ][VP is_VBZ also_RB regulated_VBN ][PP by_IN ][NP protein_NN kinase_NN C_NN ] ._.
[NP The_DT increase_NN ][PP in_IN ][NP AP-1-binding_JJ activity_NN ][VP was_VBD accompanied_VBN ][PP by_IN ][NP the_DT marked_JJ stimulation_NN ][PP of_IN ][NP the_DT transcription_NN ][PP of_IN ][NP c-fos_NN ][CONJP but_CC not_RB ][NP that_DT ][PP of_IN ][NP c-jun_NN ] ._.
[NP Blockade_NN ][PP of_IN ][NP the_DT DNA-binding_JJ complexes_NNS ][PP with_IN ][NP an_DT anti-Fos_JJ mAb_NN ][VP demonstrated_VBD ][NP a_DT direct_JJ participation_NN ][PP of_IN ][NP c-Fos_NN ][PP in_IN ][NP the_DT AP-1_NN complexes_NNS ][VP induced_VBN ][PP by_IN ][NP anti-AIM_NN mAb_NN ] ._.
[NP Most_JJS ][PP of_IN ][NP the_DT AP-1_NN activity_NN ][VP could_MD be_VB eliminated_VBN ] when_WRB[NP the_DT anti-AIM_NN mAb_NN ][VP was_VBD added_VBN ][PP to_TO ][NP the_DT culture_NN medium_NN ][PP in_IN the_DT presence_NN of_IN ][NP cycloheximide_NN ] ,_,[VP suggesting_VBG ][SBAR that_IN ][NP de_FW novo_FW protein_NN synthesis_NN ][VP is_VBZ ][ADJP crucial_JJ ][PP for_IN ][NP the_DT induction_NN ][PP of_IN ][NP AP-1-binding_JJ activity_NN ] ._.
[NP These_DT data_NNS ][VP provide_VBP ][NP the_DT evidence_NN ][SBAR that_IN ][NP activation_NN ][PP of_IN ][NP human_JJ peripheral_JJ blood_NN T_NN cells_NNS ][PP through_IN ][NP the_DT AIM_NN activation_NN pathway_NN ][VP regulate_VBP ][NP the_DT activity_NN ][PP of_IN ][NP AP-1_NN ] ._.
[ADVP Therefore_RB ] ,_,[NP this_DT pathway_NN ][VP appears_VBZ ][PP as_IN ][NP a_DT crucial_JJ step_NN ][PP in_IN ][NP the_DT initiation_NN ][PP of_IN ][NP early_JJ T_NN cell_NN activation_NN events_NNS ] ._.
[NP cis-acting_JJ sequences_NNS ][VP required_VBN ][PP for_IN ][NP inducible_JJ interleukin-2_NN enhancer_NN function_NN ][VP bind_VBP ][NP a_DT novel_JJ Ets-related_JJ protein_NN ] ,_,[NP Elf-1_NN ] ._.
[NP The_DT recent_JJ definition_NN ][PP of_IN ][NP a_DT consensus_NN DNA_NN binding_NN sequence_NN ][PP for_IN ][NP the_DT Ets_NN family_NN ][PP of_IN ][NP transcription_NN factors_NNS ][VP has_VBZ allowed_VBN ][NP the_DT identification_NN ][PP of_IN ][NP potential_JJ Ets_NN binding_NN sites_NNS ][PP in_IN ][NP the_DT ][NP promoters_NNS ] and_CC[NP enhancers_NNS ][PP of_IN ][NP many_JJ inducible_JJ T-cell_NN genes_NNS ] ._.
[PP In_IN ][NP the_DT studies_NNS ][VP described_VBN ][PP in_IN ][NP this_DT report_NN ] ,_,[NP we_PRP ][VP have_VBP identified_VBN ][NP two_CD potential_JJ Ets_NNS binding_NN sites_NNS ] ,_,[NP EBS1_NN ] and_CC[NP EBS2_NN ] ,_,[NP which_WDT ][VP are_VBP conserved_VBN ][PP in_IN ][NP both_CC the_DT human_JJ and_CC murine_JJ interleukin-2_NN enhancers_NNS ] ._.
[PP Within_IN ][NP the_DT human_JJ enhancer_NN ] ,_,[NP these_DT two_CD sites_NNS ][VP are_VBP ] located_JJ[PP within_IN ][NP the_DT previously_RB defined_VBN DNase_NN I_CD footprints_NNS ] ,_,[NP NFAT-1_NN ] and_CC[NP NFIL-2B_NN ] ,_,[ADJP respectively_RB ] ._.
[NP Electrophoretic_JJ mobility_NN shift_NN ] and_CC[NP methylation_NN interference_NN ][NP analyses_NNS ][VP demonstrated_VBD ][SBAR that_IN ][NP EBS1_NN ] and_CC[NP EBS2_NN ][VP are_VBP ][ADJP essential_JJ ][PP for_IN ][NP the_DT formation_NN ][PP of_IN ] the_DT[NP NFAT-1_NN ] and_CC[NP NFIL-2B_NN ][NP nuclear_JJ protein_NN complexes_NNS ] ._.
[ADVP Furthermore_RB ] ,_,[NP in_FW vitro_FW mutagenesis_NN experiments_NNS ][VP demonstrated_VBD ][SBAR that_IN ][NP inducible_JJ interleukin-2_NN enhancer_NN function_NN ][VP requires_VBZ ][NP the_DT presence_NN ][PP of_IN ] either_CC[NP EBS1_NN ] or_CC[NP EBS2_NN ] ._.
[NP Two_CD well-characterized_JJ Ets_NN family_NN members_NNS ] ,_,[NP Ets-1_NN ] and_CC[NP Ets-2_NN ] ,_,[VP are_VBP reciprocally_RB expressed_VBN ][PP during_IN ][NP T-cell_NN activation_NN ] ._.
[ADVP Surprisingly_RB ] ,_,[ADVP however_RB ] ,_,[NP neither_DT ][PP of_IN ][NP these_DT proteins_NNS ][VP bound_VBD ][ADVP in_FW vitro_FW ][PP to_TO ][NP EBS1_NN ] or_CC[NP EBS2_NN ] ._.
[NP We_PRP ][ADVP therefore_RB ][VP screened_VBD ][NP a_DT T-cell_NN cDNA_NN library_NN ][PP under_IN ][NP low-stringency_NN conditions_NNS ][PP with_IN ][NP a_DT probe_NN ][PP from_IN ][NP the_DT DNA_NN binding_NN domain_NN ][PP of_IN ][NP Ets-1_NN ] and_CC[VP isolated_VBD ][NP a_DT novel_JJ Ets_NN family_NN member_NN ] ,_,[NP Elf-1_NN ] ._.
[NP Elf-1_NN ][VP contains_VBZ ][NP a_DT DNA_NN binding_NN domain_NN ][NP that_WDT ][VP is_VBZ ][ADJP nearly_RB identical_JJ ][PP to_TO ][NP that_DT ][PP of_IN ][NP E74_NN ] ,_,[NP the_DT ecdysone-inducible_JJ Drosophila_NN transcription_NN factor_NN ][VP required_VBN ][PP for_IN ][NP metamorphosis_NN ] (_([ADVP hence_RB ][NP the_DT name_NN Elf-1_NN ] ,_,[PP for_IN ][NP E74-like_JJ factor_NN 1_CD ] )_) ._.
[NP Elf-1_NN ][VP bound_VBD ][PP specifically_RB to_TO ] both_CC[NP EBS1_NN ] and_CC[NP EBS2_NN ][PP in_IN ][NP electrophoretic_JJ mobility_NN shift_NN assays_NNS ] ._.
[NP It_PRP ][ADVP also_RB ][VP bound_VBD ][PP to_TO ][NP the_DT purine-rich_JJ CD3R_NN element_NN ][PP from_IN ][NP the_DT human_JJ immunodeficiency_NN virus_NN type_NN 2_CD long_JJ terminal_JJ repeat_NN ] ,_,[NP which_WDT ][VP is_VBZ required_VBN ][PP for_IN ][NP inducible_JJ virus_NN expression_NN ][PP in_IN response_NN to_TO ][NP signalling_NN ][PP through_IN ][NP the_DT T-cell_NN receptor_NN ] ._.
[VP Taken_VBN ][ADVP together_RB ] ,_,[NP these_DT results_NNS ][VP demonstrate_VBP ][SBAR that_IN ][NP multiple_JJ Ets_NN family_NN members_NNS ][PP with_IN ][NP apparently_RB distinct_JJ DNA_NN binding_NN specificities_NNS ][VP regulate_VBP ][NP differential_JJ gene_NN expression_NN ][PP in_IN ][NP resting_VBG and_CC activated_VBN T_NN cells_NNS ] ._.
[NP Mineralocorticoids_NNPS ] and_CC[NP mineralocorticoid_NN receptors_NNS ][PP in_IN ][NP mononuclear_JJ leukocytes_NNS ][PP in_IN ][NP patients_NNS ][PP with_IN ][NP pregnancy-induced_JJ hypertension_NN ] ._.
[VP To_TO examine_VB ][NP the_DT role_NN ][PP of_IN ][NP mineralocorticoids_NNS ][PP in_IN ][NP the_DT pathophysiology_NN ][PP of_IN ][NP pregnancy-induced_JJ hypertension_NN ] (_([NP PIH_NN ] )_) ,_,[NP we_PRP ][VP studied_VBD ][NP plasma_NN aldosterone_NN ] and_CC[NP 18-hydroxycorticosterone_NN ][NP levels_NNS ][PP in_IN ][NP 25_CD women_NNS ][PP with_IN ][NP PIH_NN ] and_CC[NP 25_CD normal_JJ pregnant_JJ women_NNS ] ,_,[PP as_IN ][NP controls_NNS ] ._.
[ADVP Furthermore_RB ] ,_,[NP we_PRP ][VP evaluated_VBD ] the_DT[NP mineralocorticoid_NN receptor_NN ] (_([NP MR_NN ] )_)[NP status_NN ][PP in_IN ][NP mononuclear_JJ leukocytes_NNS ][PP in_IN ][NP the_DT 2_CD groups_NNS ] ._.
[NP MR_NN count_NN ][VP was_VBD ][ADVP significantly_RB ] (_([NP P_NN ][NP less_JJR than_IN 0.0005_CD ] )_)[VP decreased_VBN ][PP in_IN ][NP the_DT PIH_NN group_NN ] (_([NP 148_CD +/-_CC 9_CD binding_VBG sites/cell_NNS ] )_)[PP compared_VBN ][PP with_IN ][NP the_DT control_NN group_NN ] (_([NP 300_CD +/-_CC 17_CD binding_VBG sites/cell_NNS ] ;_:[NP mean_NN +/-_CC SEM_NN ] )_) ._.
[NP Plasma_NN aldosterone_NN ][PP in_IN ][NP women_NNS ][PP with_IN ][NP PIH_NN ][VP was_VBD ][NP 281_CD +/-_CC 61_CD pmol/L_NN ] ;_:[PP in_IN ][NP normal_JJ pregnant_JJ women_NNS ][NP it_PRP ][VP was_VBD ][NP 697_CD +/-_CC 172_CD pmol/L_NN ] (_([NP P_NN ][NP less_JJR than_IN 0.025_CD ] )_) ._.
[NP Plasma_NN 18-hydroxycorticosterone_NN ][VP was_VBD ][ADVP also_RB ] significantly_RB (_([NP P_NN ][NP less_JJR than_IN 0.025_CD ] )_)[ADJP lower_JJR ] (_([NP PIH_NN ] ,_,[NP 1071_CD +/-_CC 149_CD pmol/L_NN ] ;_:[NP controls_NNS ] ,_,[NP 1907_CD +/-_CC 318_CD pmol/L_NN ] )_) ._.
[NP These_DT values_NNS ][VP were_VBD determined_VBN ][PP at_IN ][NP the_DT onset_NN ][PP of_IN ][NP clinical_JJ symptoms_NNS ][PP of_IN ][NP PIH_NN ] ._.
[NP These_DT results_NNS ][VP can_MD not_RB be_VB explained_VBN ][PP by_IN ][NP receptor_NN down-regulation_NN ][PP due_JJ to_TO ][NP higher_JJR levels_NNS ][PP of_IN ][NP mineralocorticoids_NNS ][PP in_IN ][NP PIH_NN ] ;_:[NP a_DT hitherto_RB unknown_JJ mineralocorticoid_NN ][VP may_MD ] ,_,[ADVP thus_RB ] ,_,[VP be_VB ][ADJP responsible_JJ ][PP for_IN ] the_DT[NP hypertension_NN ] and_CC[NP altered_JJ MR_NN ][NP status_NN ] ._.
[NP Mineralocorticoid_NN effector_NN mechanism_NN ][PP in_IN ][NP preeclampsia_NN ] ._.
[NP Mineralocorticoid_NN effector_NN mechanisms_NNS ][VP were_VBD evaluated_VBN ][PP in_IN ][NP 29_CD patients_NNS ][PP with_IN ][NP preeclampsia_NN ][PP and_CC ][PP in_IN ][NP 25_CD uncomplicated_JJ pregnancies_NNS ][PP by_IN ][NP measurement_NN ][PP of_IN ][NP plasma_NN aldosterone_NN ] ,_,[NP levels_NNS ][PP of_IN ][NP mineralocorticoid_NN receptor_NN ] (_([NP MR_NN ] )_)[PP in_IN ][NP mononuclear_JJ leucocytes_NNS ] ,_, and_CC[NP subtraction_NN potential_NN difference_NN ] (_([NP SPD_NN ] ;_:[NP rectal_JJ minus_CC oral_JJ values_NNS ] )_) ._.
[NP Mean_NN values_NNS ][PP for_IN ][NP plasma_NN aldosterone_NN ][VP were_VBD ] not_RB[ADJP different_JJ ][PP between_IN ][NP the_DT two_CD groups_NNS ] ,_, but_CC[NP significant_JJ differences_NNS ][VP were_VBD observed_VBN ][PP for_IN ][NP MR_NN ] (_([NP preeclampsia_NN ] ,_,[NP 81_CD +/-_CC 44_CD receptors/cell_NNS ] ;_:[NP controls_NNS ] ,_,[NP 306_CD +/-_CC 168_CD ] )_) and_CC[NP SPD_NN ] (_([NP preeclampsia_NN ] ,_,[NP 65_CD +/-_CC 7_CD mV_NN ] ;_:[NP controls_NNS ] ,_,[NP 12_CD +/-_CC 5_CD mV_NN ] )_) ._.
[PP In_IN ][NP six_CD cases_NNS ][NP we_PRP ][VP determined_VBD ][NP MR_NN ] ,_,[NP plasma_NN aldosterone_NN ] ,_, and_CC[NP SPD_NN ][PP in_IN ][NP patients_NNS ][PP with_IN ][NP preeclampsia_NN ][PP before_IN ][PP and_CC ][NP 3_CD months_NNS ][PP after_IN ][NP delivery_NN ] ._.
[NP MR_NNS ][VP were_VBD reduced_VBN ][PP before_IN ][NP delivery_NN ] (_([NP 96_CD +/-_CC 27_CD receptors/cell_NNS ] )_) ,_, and_CC[NP SPD_NN ][VP increased_VBD ] (_([NP 64_CD +/-_CC 8_CD mV_NN ] )_) ,_,[PP with_IN ][NP both_DT parameters_NNS ][VP normalizing_VBG ][PP after_IN ][NP delivery_NN ] (_([NP MR_NN ] ,_,[NP 242_CD +/-_CC 79_CD ] ;_:[NP SPD_NN ] ,_,[NP 14.0_CD +/-_CC 4_CD mV_NN ] )_) ._.
[NP Aldosterone_NN levels_NNS ][VP returned_VBD ][PP to_TO ][NP normal_JJ nonpregnant_JJ values_NNS ][PP after_IN ][NP delivery_NN ] ._.
[NP These_DT data_NNS ][VP suggest_VBP ][NP an_DT important_JJ role_NN ][PP for_IN ][NP abnormalities_NNS ][PP in_IN ][NP mineralocorticoid_NN effector_NN mechanisms_NNS ][PP in_IN ][NP the_DT etiology_NN ][PP of_IN ][NP preeclampsia_NN ] and_CC[VP could_MD be_VB ][NP an_DT useful_JJ marker_NN ][PP for_IN ][NP diagnosis_NN ] ._.
[NP A_DT lymphoid_JJ cell-specific_JJ nuclear_JJ factor_NN ][VP containing_VBG ][NP c-Rel-like_JJ proteins_NNS ][ADVP preferentially_RB ][VP interacts_VBZ ][PP with_IN ][NP interleukin-6_NN kappa_NN B-related_JJ motifs_NNS ][NP whose_WP$ activities_NNS ][VP are_VBP repressed_VBN ][PP in_IN ][NP lymphoid_JJ cells_NNS ] ._.
[NP The_DT proto-oncoprotein_NN c-Rel_NN ][VP is_VBZ ][NP a_DT member_NN ][PP of_IN ][NP the_DT nuclear_JJ factor_NN kappa_NN B_NN transcription_NN factor_NN family_NN ] ,_,[NP which_WDT ][VP includes_VBZ ] the_DT[NP p50_NN ] and_CC[NP p65_NN ][NP subunits_NNS ][PP of_IN ][NP nuclear_JJ factor_NN kappa_NN B_NN ] ._.
[NP We_PRP ][VP show_VBP ][ADVP here_RB ][SBAR that_IN ][NP c-Rel_NN ][VP binds_VBZ ][PP to_TO ][NP kappa_NN B_NN sites_NNS ][PP as_IN ][NP homodimers_NNS ][CONJP as_RB well_RB as_IN ][NP heterodimers_NNS ][PP with_IN ][NP p50_NN ] ._.
[NP These_DT ][NP homodimers_NNS ] and_CC[NP heterodimers_NNS ][VP show_VBP ][NP distinct_JJ DNA-binding_JJ specificities_NNS ] and_CC[NP affinities_NNS ][PP for_IN ][NP various_JJ kappa_NN B_NN motifs_NNS ] ._.
[PP In_IN ][NP particular_JJ ] ,_,[NP the_DT c-Rel_NN homodimer_NN ][VP has_VBZ ][NP a_DT high_JJ affinity_NN ][PP for_IN ][NP interleukin-6_NN ] (_([NP IL-6_NN ] )_) and_CC[NP beta_NN interferon_NN kappa_NN B_NN ][NP sites_NNS ] ._.
[PP In_IN spite_NN of_IN ][NP its_PRP$ association_NN ][PP with_IN ][NP p50_NN ][ADVP in_FW vitro_FW ] ,_,[ADVP however_RB ] ,_,[NP we_PRP ][VP found_VBD ][NP a_DT lymphoid_JJ cell-specific_JJ nuclear_JJ factor_NN ][ADVP in_FW vivo_FW ][NP that_WDT ][VP contains_VBZ ][NP c-Rel_NN ][CONJP but_CC not_RB ][NP p50_NN ][NP epitopes_NNS ] ;_:[NP this_DT factor_NN ] ,_,[VP termed_VBN ][NP IL-6_NN kappa_NN B_NN binding_NN factor_NN II_CD ] ,_,[VP appears_VBZ to_TO contain_VB ][NP the_DT c-Rel_NN homodimer_NN ] and_CC[VP preferentially_RB recognizes_VBZ ][NP several_JJ IL-6_NN kappa_NN B-related_JJ kappa_NN B_NN motifs_NNS ] ._.
[SBAR Although_IN ][NP it_PRP ][VP has_VBZ been_VBN previously_RB shown_VBN ][SBAR that_IN ][NP the_DT IL-6_NN kappa_NN B_NN motif_NN ][VP functions_VBZ ][PP as_IN ][NP a_DT potent_JJ IL-1/tumor_NN necrosis_NN factor-responsive_JJ element_NN ][PP in_IN ][NP nonlymphoid_JJ cells_NNS ] ,_,[NP its_PRP$ activity_NN ][VP was_VBD found_VBN to_TO be_VB repressed_VBN ][PP in_IN ][NP lymphoid_JJ cells_NNS ][PP such_JJ as_IN ][NP a_DT Jurkat_NN T-cell_NN line_NN ] ._.
[NP We_PRP ][ADVP also_RB ][VP present_VBP ][NP evidence_NN ][SBAR that_IN ][NP IL-6_NN kappa_NN B_NN binding_NN factor_NN II_CD ][VP functions_VBZ ][PP as_IN ][NP a_DT repressor_NN ][ADJP specific_JJ ][PP for_IN ][NP IL-6_NN kappa_NN B-related_JJ kappa_NN B_NN motifs_NNS ][PP in_IN ][NP lymphoid_JJ cells_NNS ] ._.
[NP Modulation_NN ][PP of_IN ][NP normal_JJ erythroid_JJ differentiation_NN ][PP by_IN ] the_DT[NP endogenous_JJ thyroid_NN hormone_NN ] and_CC[NP retinoic_JJ acid_NN ][NP receptors_NNS ] :_:[NP a_DT possible_JJ target_NN ][PP for_IN ][NP v-erbA_NN oncogene_NN action_NN ] ._.
[NP The_DT v-erbA_NN oncogene_NN ] ,_,[NP a_DT mutated_VBN version_NN ][PP of_IN ][NP the_DT thyroid_NN hormone_NN receptor_NN alpha_NN ] (_([NP c-erbA/TR-alpha_NN ] )_) ,_,[VP inhibits_VBZ ][NP erythroid_JJ differentiation_NN ] and_CC[VP constitutively_RB represses_VBZ ][NP transcription_NN ][PP of_IN ][NP certain_JJ erythrocyte_NN genes_NNS ] ,_,[VP suggesting_VBG ][NP a_DT normal_JJ function_NN ][PP of_IN ][NP the_DT proto-oncogene_NN c-erbA_NN ][PP in_IN ][NP erythropoiesis_NN ] ._.
[ADVP Here_RB ][NP we_PRP ][VP demonstrate_VBP ][SBAR that_IN ][NP the_DT endogenous_JJ thyroid_NN hormone_NN receptor_NN alpha_NN ] (_([NP c-erbA/TR-alpha_NN ] )_) and_CC[NP the_DT closely_RB related_JJ ][NP retinoic_JJ acid_NN receptor_NN alpha_NN ] (_([NP RAR-alpha_NN ] )_)[VP play_VBP ][NP a_DT role_NN ][PP in_IN ][NP the_DT regulation_NN ][PP of_IN ][NP normal_JJ erythroid_JJ differentiation_NN ] ._.
[NP Retinoic_JJ acid_NN ] (_([NP RA_NN ] )_)[ADVP distinctly_RB ][VP modulated_VBD ][NP the_DT erythroid_JJ differentiation_NN program_NN ][PP of_IN ][NP normal_JJ erythroid_JJ progenitors_NNS ] and_CC[NP erythroblasts_NNS ][VP reversibly_RB transformed_VBN ][PP by_IN ][NP a_DT conditional_JJ tyrosine_NN kinase_NN oncogene_NN ] ._.
[ADVP When_WRB ][VP added_VBN ][ADVP pulsewise_RB ][PP to_TO ][NP immature_JJ cells_NNS ] ,_,[NP differentiation_NN ][VP was_VBD accelerated_VBN ][SBAR while_IN ][NP more_RBR mature_JJ cells_NNS ][VP underwent_VBD ][NP premature_JJ cell_NN death_NN ] ._.
[NP Thyroid_NN hormone_NN ] (_([NP T3_NN ] )_)[ADVP alone_RB ][VP caused_VBD ][NP similar_JJ but_CC weaker_JJR effects_NNS ] ._.
[ADVP Interestingly_RB ] ,_,[NP T3_NN ][ADVP strongly_RB ][VP enhanced_VBD ][NP the_DT action_NN ][PP of_IN ][NP RA_NN ] ,_,[VP suggesting_VBG ][NP cooperative_JJ action_NN ][PP of_IN ][NP the_DT two_CD receptors_NNS ][PP in_IN ][VP modulating_VBG ][NP erythroid_JJ differentiation_NN ] ._.
[NP Expression_NN ][PP of_IN ][NP the_DT human_JJ RAR-alpha_NN ][PP in_IN ][NP receptor-negative_JJ erythroblasts_NNS ][VP conferred_VBD ][NP RA-induced_JJ regulation_NN ][PP of_IN ][NP differentiation_NN ][PP to_TO ][NP the_DT otherwise_RB unresponsive_JJ cells_NNS ] ,_, thus_RB[VP showing_VBG ][SBAR that_IN ][NP the_DT RAR-alpha_NN ][VP is_VBZ ][ADJP essential_JJ ][PP for_IN ][NP the_DT RA_NN effect_NN ] ._.
[ADVP Likewise_RB ] ,_,[NP enhanced_VBN expression_NN ][PP of_IN ][NP exogenous_JJ c-erbA/TR-alpha_NN ][PP in_IN ][NP erythroblasts_NNS ][VP rendered_VBD ][NP them_PRP ][ADJP susceptible_JJ ][PP to_TO ][NP modulation_NN ][PP of_IN ][NP differentiation_NN ][PP by_IN ][NP T3_NN ] ,_,[VP suggesting_VBG ][NP a_DT similar_JJ function_NN ][PP of_IN ][NP both_DT receptors_NNS ] ._.
[NP Leukotriene_NN B4_NN ][VP stimulates_VBZ ][NP c-fos_NN ] and_CC[NP c-jun_NN ][NP gene_NN transcription_NN ] and_CC[NP AP-1_NN binding_NN activity_NN ][PP in_IN ][NP human_JJ monocytes_NNS ] ._.
[NP We_PRP ][VP have_VBP examined_VBN ][NP the_DT effect_NN ][PP of_IN ][NP leukotriene_NN B4_NN ] (_([NP LTB4_NN ] )_) ,_,[NP a_DT potent_JJ lipid_NN proinflammatory_JJ mediator_NN ] ,_,[PP on_IN ][NP the_DT expression_NN ][PP of_IN ][NP the_DT proto-oncogenes_NNS ][NP c-jun_NN ] and_CC[NP c-fos_NN ] ._.
[PP In_IN ][NP addition_NN ] ,_,[NP we_PRP ][VP looked_VBD ][PP at_IN ][NP the_DT modulation_NN ][PP of_IN ][NP nuclear_JJ factors_NNS ][VP binding_VBG ][PP specifically_RB to_TO ][NP the_DT AP-1_NN element_NN ][PP after_IN ][NP LTB4_NN stimulation_NN ] ._.
[NP LTB4_NN ][VP increased_VBD ][NP the_DT expression_NN ][PP of_IN ][NP the_DT c-fos_NN gene_NN ][PP in_IN ] a_DT[NP time-_NN ] and_CC[ADJP concentration-dependent_JJ ][NP manner_NN ] ._.
[NP The_DT c-jun_NN mRNA_NN ] ,_,[ADVP which_WDT ][VP is_VBZ constitutively_RB expressed_VBN ][PP in_IN ][NP human_JJ peripheral-blood_NN monocytes_NNS ][PP at_IN ][NP relatively_RB high_JJ levels_NNS ] ,_,[VP was_VBD also_RB slightly_RB augmented_JJ ][PP by_IN ][NP LTB4_NN ] ,_,[SBAR although_IN ][PP to_TO ][NP a_DT much_RB lower_JJR extent_NN ][PP than_IN ][NP c-fos_NN ] ._.
[NP The_DT kinetics_NNS ][PP of_IN ][NP expression_NN ][PP of_IN ][NP the_DT two_CD genes_NNS ][VP were_VBD ][ADJP also_RB slightly_RB different_JJ ] ,_,[PP with_IN ][NP c-fos_NN mRNA_NN ][VP reaching_VBG ][NP a_DT peak_NN ][PP at_IN ][NP 15_CD min_NN ][PP after_IN ][NP stimulation_NN ] and_CC[NP c-jun_NN ][PP at_IN ][NP 30_CD min_NN ] ._.
[NP Both_DT messages_NNS ][ADVP rapidly_RB ][VP declined_VBD ][ADVP thereafter_RB ] ._.
[NP Stability_NN ][PP of_IN ] the_DT[NP c-fos_NN ] and_CC[NP c-jun_NN ][NP mRNA_NN ][VP was_VBD not_RB affected_VBN ][PP by_IN ][NP LTB4_NN ] ,_,[SBAR as_IN ][VP assessed_VBN ][PP after_IN ][NP actinomycin_NN D_NN treatment_NN ] ._.
[NP Nuclear_JJ transcription_NN studies_NNS ][ADVP in_FW vitro_FW ][VP showed_VBD ][SBAR that_IN ][NP LTB4_NN ][VP increased_VBD ][NP the_DT transcription_NN ][PP of_IN ][NP the_DT c-fos_NN gene_NN ][ADVP 7-fold_RB ] and_CC[NP the_DT c-jun_NN gene_NN ][ADVP 1.4-fold_RB ] ._.
[NP Resting_VBG monocytes_NNS ][VP contained_VBD ][NP nuclear_JJ factors_NNS ][VP binding_VBG ][PP to_TO ][NP the_DT AP-1_NN element_NN ] ,_, but_CC[NP stimulation_NN ][PP of_IN ][NP monocytes_NNS ][PP with_IN ][NP LTB4_NN ][VP induced_VBD ][NP greater_JJR AP-1-binding_JJ activity_NN ][PP of_IN ][NP nuclear_JJ proteins_NNS ] ._.
[NP These_DT results_NNS ][VP indicate_VBP ][SBAR that_IN ][NP LTB4_NN ][VP may_MD regulate_VB ][NP the_DT production_NN ][PP of_IN ][NP different_JJ cytokines_NNS ][PP by_IN ][VP modulating_VBG ][NP the_DT yield_NN ] and/or_CC[NP the_DT function_NN ][PP of_IN ][NP transcription_NN factors_NNS ][PP such_JJ as_IN ][NP AP-1-binding_JJ proto-oncogene_NN products_NNS ] ._.
[NP An_DT 11-base-pair_JJ DNA_NN sequence_NN motif_NN ][ADJP apparently_RB unique_JJ ][PP to_TO ][NP the_DT human_JJ interleukin_NN 4_CD gene_NN ][VP confers_VBZ ][NP responsiveness_NN ][PP to_TO ][NP T-cell_NN activation_NN signals_NNS ] ._.
[NP We_PRP ][VP have_VBP identified_VBN ][NP a_DT DNA_NN segment_NN ][NP that_WDT ][VP confers_VBZ ][NP responsiveness_NN ][PP to_TO ][NP antigen_NN stimulation_NN signals_NNS ][PP on_IN ] the_DT human_JJ[NP interleukin_NN ] (_([NP IL_NN ] )_)[NP 4_CD gene_NN ][PP in_IN ][NP Jurkat_NN cells_NNS ] ._.
[NP The_DT human_JJ IL-4_NN gene_NN ] ,_,[PP of_IN ][NP 10_CD kilobases_NNS ] ,_,[VP is_VBZ composed_VBN ][PP of_IN ][NP four_CD exons_NNS ] and_CC[NP three_CD introns_NNS ] ._.
[NP A_DT cis-acting_JJ element_NN ] (_([NP P_NN sequence_NN ] )_)[VP resides_VBZ ][PP in_IN ] the_DT[NP 5'_JJ ][NP upstream_JJ region_NN ] ;_:[NP no_DT additional_JJ DNA_NN segments_NNS ][PP with_IN ][NP enhancer_NN activity_NN ][VP were_VBD identified_VBN ][PP in_IN ][NP the_DT human_JJ IL-4_NN gene_NN ] ._.
[PP For_IN ][NP further_JJ mapping_NN purposes_NNS ] ,_,[NP a_DT fusion_NN promoter_NN ][VP was_VBD constructed_VBN ][PP with_IN ][NP the_DT granulocyte/macrophage_JJ colony-stimulating_JJ factor_NN basic_JJ promoter_NN ][VP containing_VBG ][NP 60_CD base_NN pairs_NNS ][PP of_IN ][NP sequence_NN ][ADJP upstream_JJ ][PP from_IN ][NP the_DT cap_NN site_NN ][PP of_IN ][NP the_DT mouse_NN granulocyte/macrophage_JJ colony-stimulating_JJ factor_NN gene_NN ] and_CC[NP various_JJ lengths_NNS ][PP of_IN ] the_DT[NP 5'_JJ ][NP upstream_JJ sequence_NN ][PP of_IN ][NP the_DT IL-4_NN gene_NN ] ._.
[NP The_DT P_NN sequence_NN ][VP was_VBD ][ADJP located_JJ ][PP between_IN ][NP positions_NNS ][NP -79_CD ] and_CC[NP -69_CD ][PP relative_JJ to_TO ][NP the_DT transcription_NN start_NN site_NN ][PP of_IN ][NP the_DT human_JJ IL-4_NN gene_NN ] ,_, and_CC[NP this_DT location_NN ][VP was_VBD confirmed_VBN ][PP by_IN ][NP base-substitution_NN mutations_NNS ] ._.
[NP The_DT plasmids_NNS ][VP carrying_VBG ][NP multiple_JJ copies_NNS ][PP of_IN ][NP the_DT P_NN sequence_NN ][VP showed_VBD ][NP higher_JJR responsiveness_NN ][PP to_TO ][NP the_DT stimulation_NN ] ._.
[NP The_DT binding_VBG protein_NN (_( s_NNS ] )_)[NP that_WDT ][VP recognize_VBP ][NP the_DT P_NN sequence_NN ][PP of_IN ][NP the_DT IL-4_NN gene_NN ][VP were_VBD identified_VBN ][PP by_IN ][NP DNA-mobility-shift_JJ assays_NNS ] ._.
[NP The_DT binding_NN ][PP of_IN ][NP NF(P)_NN ] (_([NP a_DT DNA_NN binding_NN protein_NN ][NP that_WDT ][ADVP specifically_RB ][VP recognizes_VBZ ][NP the_DT P_NN sequence_NN ] )_)[PP to_TO ][NP the_DT P_NN sequence_NN ][VP was_VBD abolished_VBN ][ADVP when_WRB ][NP oligonucleotides_NNS ][VP carrying_VBG ][NP base_NN substitutions_NNS ][VP were_VBD used_VBN ] ,_,[VP indicating_VBG ][SBAR that_IN ][NP the_DT NF(P)_NN interaction_NN ][VP is_VBZ ][ADJP sequence-specific_JJ ] and_CC[SBAR that_IN ][NP binding_NN specificity_NN ][PP of_IN ][NP the_DT protein_NN ][VP paralleled_VBD ][NP the_DT sequence_NN requirements_NNS ][PP for_IN ][NP IL-4_NN expression_NN ][ADVP in_FW vivo_FW ] ._.
[NP The_DT P_NN sequence_NN ][VP does_VBZ not_RB share_VB ][NP homology_NN ][PP with_IN ] the_DT[NP 5'_JJ ][NP upstream_JJ sequence_NN ][PP of_IN ][NP the_DT IL-2_NN gene_NN ] ,_,[SBAR even_RB though_IN ][NP surrounding_VBG sequences_NNS ][PP of_IN ][NP the_DT IL-4_NN gene_NN ][VP share_NN ][NP high_JJ homology_NN ][PP with_IN ][NP the_DT IL-2_NN gene_NN ] ._.
[NP We_PRP ][VP conclude_VBP ][SBAR that_IN ][NP a_DT different_JJ set_NN ][PP of_IN ][NP proteins_NNS ][VP recognize_VBP ][NP IL-2_NN ] and_CC[NP IL-4_NN ][NP genes_NNS ] ._.
[NP Glucocorticoid_NN receptor_NN binding_NN ][PP in_IN ][NP three_CD different_JJ cell_NN types_NNS ][PP in_IN ][NP major_JJ depressive_JJ disorder_NN ] :_:[NP lack_NN ][PP of_IN ][NP evidence_NN ][PP of_IN ][NP receptor_NN binding_NN defect_NN ] ._.
[LST 1_LS ] ._.[SBAR In_IN ] order_NN to_TO[ADVP further_RB ][VP understand_VB ][NP the_DT apparent_JJ glucocorticoid_NN resistance_NN ][PP in_IN ][NP major_JJ depressive_JJ disorder_NN ] ,_,[NP circadian_JJ variation_NN ][PP in_IN ][NP cortisol_NN concentration_NN ] ,_,[NP dexamethasone_NN suppression_NN ] and_CC[NP glucocorticoid_NN receptor_NN binding_NN ][PP in_IN ][NP mononuclear_JJ leukocytes_NNS ] ,_,[NP polymorphonuclear_JJ leukocytes_NNS ] and_CC[NP cultured_VBN skin_NN fibroblasts_NNS ][VP were_VBD measured_VBN ][PP in_IN ][NP rigidly_RB defined_VBN major_JJ depressive_JJ disorder_NN patients_NNS ] and_CC[NP non-depressed_JJ psychiatric_JJ controls_NNS ] ._.
[LST 2_LS ] ._.[NP Mononuclear_JJ leukocytes_NNS ][VP binding_VBG ][PP to_TO ][NP glucocorticoid_NN ][VP correlated_VBD ][ADVP significantly_RB ][PP with_IN ][NP polymorphonuclear_JJ leukocytes_NNS ][VP binding_VBG ][PP to_TO ][NP glucocorticoid_NN ] ,_, but_CC[NP both_DT determinations_NNS ][VP failed_VBD to_TO differentiate_VB ][NP major_JJ depressive_JJ disorder_NN ] and_CC[NP control_NN subjects_NNS ] ._.
[LST 3_LS ] ._.[NP Initial_JJ and_CC post-dexamethasone_JJ in_FW vitro_FW fibroblast_NN ][VP binding_VBG ][PP to_TO ][NP glucocorticoid_NN ][VP was_VBD ] not_RB[ADJP different_JJ ][PP between_IN ][NP major_JJ depressive_JJ disorder_NN ] and_CC[NP non-depressed_JJ control_NN subjects_NNS ] ._.
[LST 4_LS ] ._.[NP The_DT phenomenon_NN ][PP of_IN ][NP glucocorticoid_NN resistance_NN ][PP in_IN ][NP major_JJ depressive_JJ disorder_NN ][VP remains_VBZ ][ADJP unexplained_JJ ] ._.
[NP Kinetics_NNS ][PP of_IN ][NP nuclear_JJ translocation_NN ] and_CC[NP turnover_NN ][PP of_IN ][NP the_DT vitamin_NN D_NN receptor_NN ][PP in_IN ][NP human_JJ HL60_NN leukemia_NN cells_NNS ] and_CC[NP peripheral_JJ blood_NN lymphocytes_NNS ] --_:[NP coincident_JJ rise_NN ][PP of_IN ][NP DNA-relaxing_JJ activity_NN ][PP in_IN ][NP nuclear_JJ extracts_NNS ] ._.
[NP High_JJ affinity_NN receptors_NNS ] (_([NP VDR_NN ] )_)[PP for_IN ][NP 1,25-dihydroxycholecalciferol_NN ] (_([NP calcitriol_NN ] )_)[VP are_VBP expressed_VBN ][PP in_IN ][NP HL60_NN human_JJ leukemia_NN cells_NNS ][PP and_CC ][PP in_IN ][NP low_JJ numbers_NNS ][PP in_IN ][NP peripheral_JJ blood_NN lymphocytes_NNS ] (_([NP PBL_NN ] )_) ._.
[NP HL60_NN cells_NNS ] ,_,[VP expressing_VBG ][NP some_DT characteristics_NNS ][PP of_IN ][NP promyelocytes_NNS ] ,_,[VP can_MD be_VB induced_VBN ][PP to_TO ][NP monocytoid_NN differentiation_NN ][PP by_IN ][NP calcitriol_NN ] ._.
[NP Specific_JJ nuclear_JJ translocation_NN ][PP of_IN ][NP (3H)calcitriol/VDR_NN ][VP was_VBD examined_VBN ][PP after_IN ][NP exposure_NN ][PP of_IN ][NP whole_JJ cells_NNS ][PP to_TO ][NP 10(-9)_CD M/l_NN calcitriol_NN ][PP in_IN ][NP the_DT ][NP presence_NN ] and_CC[NP absence_NN ][PP of_IN ][NP a_DT 500-fold_JJ excess_NN ][PP of_IN ][NP unlabeled_JJ ligand_NN ] and_CC[NP subsequent_JJ isolation_NN ][PP of_IN ][NP nuclei_NNS ] ._.
[NP Specific_JJ nuclear_JJ translocation_NN ][PP of_IN ][NP (3H)calcitriol/VDR_NN ][VP was_VBD found_VBN to_TO be_VB ][ADJP time_NN dependent_JJ ][VP reaching_VBG ][NP a_DT maximum_NN ][PP of_IN ][NP approximately_RB 2100_CD binding_VBG sites/nucleus_NNS ][PP after_IN ][NP 3_CD h_NN ][PP of_IN ][NP incubation_NN ][PP in_IN ][NP HL60_NN cells_NNS ] ,_, whereas_IN[NP a_DT maximum_NN ][PP of_IN ][NP approximately_RB 310_CD binding_VBG sites/nucleus_NNS ][VP was_VBD found_VBN ][PP after_IN ][NP 3_CD h_NN ][PP in_IN ][NP PBL_NN ] ._.
[NP Pulse_NN exposure_NN ][PP of_IN ][NP HL60_NN ][PP to_TO ][NP radiolabeled_VBN hormone_NN ][PP for_IN ][NP 3_CD h_NN ][VP followed_VBN ][PP by_IN ][NP culture_NN ][PP in_IN ][NP medium_NN ][PP without_IN ][NP serum_NN ] and_CC[NP calcitriol_NN ][VP lead_VBD ][PP to_TO ][NP nuclear_JJ retention_NN ][PP of_IN ][NP approximately_RB 1600_CD radiolabeled_VBN VDR_NN ][PP by_IN ][NP 8_CD h_NN ] and_CC[NP approximately_RB 1000_CD VDR_NN ][PP by_IN ][NP 24_CD h_NN ] ._.
[NP Radiolabeled_VBN VDR_NN ][VP disappeared_VBD ][PP from_IN ][NP the_DT nuclear_JJ compartment_NN ][PP with_IN ][NP a_DT halflife_NN ][PP of_IN ][NP approximately_RB 30_CD min_NN ][SBAR if_IN ][NP cells_NNS ][VP were_VBD cultured_VBN ][PP with_IN ][NP identical_JJ concentrations_NNS ][PP of_IN ][NP unlabeled_JJ hormone_NN ][PP after_IN ][NP the_DT pulse_NN ] (_([NP pulse/chase-experiments_NNS ] )_) ._.
[NP No_DT difference_NN ][PP of_IN ][NP VDR_NN retention_NN ][PP in_IN ][NP pulse_NN ] and_CC[NP pulse/chase-experiments_NNS ][VP was_VBD seen_VBN ][PP in_IN ][NP PBL_NN ] ,_,[ADVP where_WRB ][NP VDR_NN halflife_NN ][VP was_VBD ][NP approximately_RB 30_CD min_NN ] ._.
[NP No_DT specific_JJ translocation_NN ][PP into_IN ][NP the_DT nuclear_JJ compartment_NN ][VP was_VBD seen_VBN ][ADVP when_WRB ][NP isolated_VBN nuclei_NNS ][VP were_VBD incubated_VBN ][PP in_IN ][NP (3H)calcitriol_NN ] ._.
[NP Radiolabeled_VBN hormone/receptor_NN complexes_NNS ][PP of_IN ][NP nuclei_NNS ][VP isolated_VBN ][PP from_IN ][NP cells_NNS ][VP exposed_VBN ][PP for_IN ][NP 3_CD h_NN ][PP to_TO ][NP radiolabeled_VBN hormone_NN ] --_:[PP in_IN contrast_NN to_TO ][NP identical_JJ experiments_NNS ][PP with_IN ][NP intact_JJ cells_NNS ] --_:[VP did_VBD not_RB disappear_VB ][PP from_IN ][NP the_DT nuclear_JJ compartment_NN ][PP upon_IN ][NP incubation_NN ][PP of_IN ][NP nuclei_NNS ][PP with_IN ][NP identical_JJ concentrations_NNS ][PP of_IN ][NP the_DT unlabeled_JJ compound_NN ] ._.
[NP The_DT activity_NN ][PP of_IN ][NP DNA_NN relaxing_NN enzymes_NNS ] (_([ADVP e.g._FW ][NP topoisomerases_NNS ][NP I_CD ] and_CC[NP II_CD ] )_)[PP in_IN ][NP nuclear_JJ extracts_NNS ][VP was_VBD measured_VBN ][VP using_VBG ][NP a_DT PBR_NN 322-relaxation-assay_NN ] ._.
[NP Enhanced_VBN overall_JJ enzyme_NN activity_NN ][VP was_VBD found_VBN ][PP in_IN ][NP nuclear_JJ extracts_NNS ][PP by_IN ][NP 1_CD h_NN ][PP after_IN ][NP incubation_NN ][PP with_IN ][NP calcitriol_NN ] (_([NP final_JJ ethanol_NN concentration_NN ][NP 0.0001_CD %_NN v/v_NN ] )_)[PP in_IN ][NP HL60_NN ] and_CC[NP PBL_NN ] ._.
[NP The_DT enhanced_VBN activity_NN ][VP disappeared_VBD ][PP after_IN ][NP 2_CD h_NN ][PP in_IN ][NP PBL_NN ] ,_, whereas_IN[NP it_PRP ][VP was_VBD still_RB enhanced_VBN ][PP by_IN ][NP 4_CD h_NN ][PP in_IN ][NP HL60_NN ] ._.
[NP No_DT effect_NN ][VP was_VBD seen_VBN ][PP in_IN ][NP ethanol_NN treated_JJ controls_NNS ] ._.
[NP We_PRP ][VP conclude_VBP ][SBAR that_IN ][NP a_DT specific_JJ nuclear_JJ translocation_NN mechanism_NN ][VP exists_VBZ ][PP for_IN ][NP calcitriol_NN ][PP in_IN ][NP both_DT cell_NN types_NNS ][VP examined_VBN ] ,_,[ADVP most_RBS likely_RB ][PP due_IN to_TO ][NP translocation_NN ][PP of_IN ][NP receptor_NN proteins_NNS ][PP after_IN ][NP hormone_NN binding_NN ] ._.
[NP Translocated_VBN hormone/receptor_NN complexes_NNS ][VP compete_VBP ][PP for_IN ][NP a_DT limited_JJ number_NN ][PP of_IN ][NP specific_JJ nuclear_JJ binding_VBG sites_NNS ] ._.
[NP Enhanced_VBN activity_NN ][PP of_IN ][NP topoisomerases_NNS ][PP in_IN ][NP nuclear_JJ extracts_NNS ][PP upon_IN ][NP translocation_NN ][PP of_IN ][NP VDR_NN ][VP might_MD reflect_VB ][NP interaction_NN ][PP of_IN ][NP both_DT ][PP within_IN ][NP the_DT nuclear_JJ compartment_NN ] ,_,[ADVP thus_RB ][VP initiating_VBG ][NP DNA-unwinding_NN ] ,_,[NP a_DT prerequisite_NN ][PP of_IN ][NP transcription_NN initiation_NN ] ._.
[NP The_DT B_NN cell-specific_JJ nuclear_JJ factor_NN OTF-2_NN ][ADVP positively_RB ][VP regulates_VBZ ][NP transcription_NN ][PP of_IN ][NP the_DT human_JJ class_NN II_CD transplantation_NN gene_NN ] ,_,[NP DRA_NN ] ._.
[NP The_DT promoter_NN ][PP of_IN ][NP the_DT major_JJ histocompatibility_NN class_NN II_CD gene_NN DRA_NN ][VP contains_VBZ ][NP an_DT octamer_NN element_NN ] (_([NP ATTTGCAT_NN ] )_)[NP that_WDT ][VP is_VBZ required_VBN ][PP for_IN ][NP efficient_JJ DRA_NN expression_NN ][PP in_IN ][NP B_NN cells_NNS ] ._.
[NP Several_JJ DNA-binding_JJ proteins_NNS ][VP are_VBP known_VBN to_TO bind_VB ][NP this_DT sequence_NN ] ._.
[ADJP The_DT best_RBS characterized_VBN ][VP are_VBP ][NP the_DT B_NN cell-specific_JJ OTF-2_NN ] and_CC[NP the_DT ubiquitous_JJ OTF-1_NN ] ._.
[NP This_DT report_NN ][ADVP directly_RB ][VP demonstrates_VBZ ][SBAR that_IN ][NP OTF-2_NN ][CONJP but_CC not_RB ][NP OTF-1_NN ][VP regulates_VBZ ][NP the_DT DRA_NN gene_NN ] ._.
[NP In_FW vitro_FW transcription_NN analysis_NN ][VP using_VBG ][NP protein_NN fractions_NNS ][ADJP enriched_VBN ][PP for_IN ][NP the_DT octamer-binding_JJ protein_NN OTF-2_NN ][VP demonstrate_VBP ][NP a_DT positive_JJ functional_JJ role_NN ][PP for_IN ][NP OTF-2_NN ][PP in_IN ][NP DRA_NN gene_NN transcription_NN ] ._.
[PP In_IN ][NP contrast_NN ] ,_,[NP OTF-1-enriched_JJ protein_NN fractions_NNS ][VP did_VBD not_RB affect_VB ][NP DRA_NN gene_NN transcription_NN ][SBAR although_IN ][NP it_PRP ][ADVP functionally_RB ][VP enhanced_VBD ][NP the_DT transcription_NN ][PP of_IN ][NP another_DT gene_NN ] ._.
[NP Recombinant_JJ OTF-2_NN protein_NN ][VP produced_VBN ][PP by_IN ][NP in_FW vitro_FW transcription/translation_NN ][VP could_MD also_RB enhance_VB ][NP DRA_NN gene_NN transcription_NN ][ADVP in_FW vitro_FW ] ._.
[NP In_FW vivo_FW transient_JJ transfection_NN studies_NNS ][VP utilizing_VBG ][NP an_DT OTF-2_NN expression_NN vector_NN ][VP resulted_VBD ][PP in_IN ][NP similar_JJ findings_NNS ] :_:[SBAR that_IN ][NP OTF-2_NN protein_NN ][VP enhanced_VBD ][NP DRA_NN gene_NN transcription_NN ] ,_, and_CC[SBAR that_IN ][NP this_DT effect_NN ][VP requires_VBZ ][NP an_DT intact_JJ octamer_NN element_NN ] ._.
[ADVP Together_RB ][NP these_DT results_NNS ][VP constitute_VBP ][NP the_DT first_JJ direct_JJ evidence_NN ][PP of_IN ][NP a_DT positive_JJ role_NN ][PP for_IN ][NP the_DT lymphoid-specific_JJ octamer-binding_JJ factor_NN ][PP in_IN ][NP DRA_NN gene_NN transcription_NN ] ._.
 (_([NP Regulation_NN ][PP of_IN ][NP intracellular_JJ cholesterol_NN synthesis_NN ][PP in_IN ][NP hypercholesterolemia_NN ][PP by_IN ][NP glucocorticoids_NNS ] )_)
[NP The_DT rate_NN ][PP of_IN ][NP endogenous_JJ cholesterol_NN synthesis_NN ][PP in_IN ][NP blood_NN lymphocytes_NNS ] and_CC[NP skin_NN fibroblasts_NNS ][PP from_IN ][NP patients_NNS ][PP with_IN ][NP type_NN IIa_NN hyperlipidemia_NN ][VP was_VBD found_VBN to_TO be_VB increased_VBN ][PP in_IN comparison_NN with_IN ][NP healthy_JJ donors_NNS ] ._.
[NP The_DT cells_NNS ][PP of_IN ][NP hyperlipidemic_JJ patients_NNS ][VP had_VBD ][NP lowered_JJ levels_NNS ][PP of_IN ][NP glucocorticoid_NN receptors_NNS ][PP concomitantly_RB with_IN ][NP a_DT partial_JJ loss_NN ][PP of_IN ][NP their_PRP$ sensitivity_NN ][PP to_TO ][NP glucocorticoids_NNS ] ._.
[PP In_IN ][NP fibroblasts_NNS ][PP from_IN ][NP patients_NNS ][PP with_IN ][NP hereditary_JJ hypercholesteremia_NN ][PP of_IN ][NP homozygous_JJ type_NN ][NP the_DT number_NN ][PP of_IN ][NP glucocorticoid_NN receptors_NNS ][VP did_VBD not_RB exceed_VB ][NP 10_CD %_NN ][PP of_IN ][NP their_PRP$ content_NN ][PP in_IN ][NP normal_JJ cells_NNS ] ._.
[NP The_DT decrease_NN ][PP of_IN ][NP the_DT number_NN ][PP of_IN ][NP glucocorticoid_NN receptors_NNS ][PP in_IN ][NP patients_NNS ][PP with_IN ][NP type_NN IIa_NN hyperlipidemia_NN ][VP seems_VBZ to_TO be_VB ][NP a_DT compensatory_JJ response_NN ][PP of_IN ][NP cells_NNS ][VP culminating_VBG ][PP in_IN ][NP activation_NN ][PP of_IN ][NP endogenous_JJ cholesterol_NN synthesis_NN ] ._.
[NP Transcription_NN factor_NN activation_NN ] and_CC[NP functional_JJ stimulation_NN ][PP of_IN ][NP human_JJ monocytes_NNS ] ._.
[NP Activation_NN ][PP of_IN ][NP expression_NN ][PP of_IN ][NP genes_NNS ][VP encoding_VBG ][NP transcription_NN factors_NNS ] :_:[NP c-fos_NN ] and_CC[NP c-jun_NN ] and_CC[NP formation_NN ][PP of_IN ][NP AP1_NN transcriptional_JJ complex_NN ][PP in_IN ][NP human_JJ monocytes_NNS ][VP was_VBD investigated_VBN ] ._.
[NP It_PRP ][VP was_VBD found_VBN ][SBAR that_IN ][NP lipopolysaccharide_NN ][VP induced_VBD ][ADVP strongly_RB ] both_CC[NP c-fos_NN ] and_CC[NP c-jun_NN ][NP expression_NN ][CONJP as_RB well_RB as_IN ][NP AP1_NN formation_NN ] ._.
[NP Interferon_NN gamma_NN ][VP activated_VBD ][ADVP strongly_RB ][NP c-fos_NN ] and_CC[ADVP weakly_RB ][NP c-jun_NN ] and_CC[NP AP1_NN ] ._.
[NP Tumor_NN necrosis_NN factor_NN ][VP induced_VBD ][ADVP slightly_RB ][NP c-fos_NN ] and_CC[VP had_VBD ][NP almost_RB no_DT effect_NN ][PP on_IN ][NP c-jun_NN ] and_CC[NP AP1_NN ] ._.
[NP The_DT data_NNS ][VP suggest_VBP ][SBAR that_IN ][NP differences_NNS ][PP in_IN ][NP functional_JJ responses_NNS ][VP elicited_VBN ][PP in_IN ][NP monocytes_NNS ][PP by_IN ][NP all_DT three_CD factors_NNS ][VP may_MD be_VB ][ADJP dependent_JJ ][PP on_IN ][NP different_JJ routes_NNS ][PP on_IN ][NP nuclear_JJ signalling_NN ][VP employed_VBN ][PP by_IN ][NP the_DT factors_NNS ] ._.
[NP Corticosteroid_NN receptors_NNS ] and_CC[NP lymphocyte_NN subsets_NNS ][PP in_IN ][NP mononuclear_JJ leukocytes_NNS ][PP in_IN ][NP aging_NN ] ._.
[NP Plasma_NN cortisol_NN ] and_CC[NP aldosterone_NN ][NP levels_NNS ] and_CC[NP number_NN ][PP of_IN ][NP related_JJ receptors_NNS ][PP in_IN ][NP mononuclear_JJ leukocytes_NNS ][VP were_VBD measured_VBN ][PP in_IN ][NP 49_CD healthy_JJ aged_JJ subjects_NNS ] (_([NP 62-97_CD yr_NN ] )_)[PP and_CC ][PP in_IN ][NP 21_CD adult_JJ controls_NNS ] (_([NP 21-50_CD yr_NN ] )_) ._.
[PP In_IN ][NP all_DT subjects_NNS ] ,_,[PP in_IN ][NP addition_NN ] ,_,[NP lymphocyte_NN subsets_NNS ][VP were_VBD determined_VBN ][PP as_IN ][NP an_DT index_NN ][PP of_IN ][NP corticosteroid_NN action_NN ] ._.
[NP The_DT mean_NN number_NN ][PP of_IN ][NP type_NN I_CD ] and_CC[NP type_NN II_CD ][NP receptors_NNS ][VP was_VBD ][ADJP significantly_RB lower_JJR ][PP in_IN ][NP aged_JJ subjects_NNS ][PP than_IN ][PP in_IN ][NP controls_NNS ] (_([ADVP respectively_RB ] ,_,[NP 198_CD +/-_CC 96_CD and_CC 272_CD +/-_CC 97_CD receptors/cell_NNS ][PP for_IN ][NP type_NN I_CD ] ,_, and_CC[NP 1,794_CD +/-_CC 803_CD and_CC 3,339_CD +/-_CC 918_CD ][PP for_IN ][NP type_NN II_CD ][NP receptors_NNS ] )_) ._.
[NP Plasma_NN ][NP aldosterone_NN ] and_CC[NP cortisol_NN ] and_CC[NP lymphocyte_NN subsets_NNS ][VP were_VBD ] not_RB[ADJP different_JJ ][PP in_IN ][NP the_DT two_CD groups_NNS ] ._.
[NP All_DT ][PP of_IN ][NP the_DT parameters_NNS ][VP were_VBD also_RB tested_VBN ][PP for_IN ][NP correlation_NN ] ,_, and_CC[NP a_DT significant_JJ inverse_JJ correlation_NN ][VP was_VBD found_VBN ][PP between_IN ][NP age_NN ] and_CC[NP type_NN I_CD ] and_CC[NP type_NN II_CD ][NP receptors_NNS ][ADVP when_WRB ][NP all_DT subjects_NNS ][VP were_VBD plotted_VBN ] and_CC[PP between_IN ][NP aged_JJ and_CC CD4_NN and_CC age_NN and_CC CD4/CD8_NN ][PP in_IN ][NP the_DT aged_JJ group_NN ] ._.
[NP These_DT data_NNS ][VP show_VBP ][SBAR that_IN ][NP aged_JJ subjects_NNS ][VP have_VBP ][NP reductions_NNS ][PP of_IN ][NP corticosteroid_NN receptors_NNS ][NP that_WDT ][VP are_VBP not_RB associated_VBN ][PP with_IN ][NP increase_NN ][PP of_IN ][NP related_JJ steroids_NNS ] and_CC[SBAR that_IN ][NP this_DT situation_NN ][ADVP probably_RB ][VP represents_VBZ ][NP a_DT concomitant_NN ][PP of_IN ][NP the_DT normal_JJ aging_NN process_NN ] ._.
[NP Stable_JJ expression_NN ][PP of_IN ][NP HB24_NN ] ,_,[NP a_DT diverged_JJ human_JJ homeobox_NN gene_NN ] ,_,[PP in_IN ][NP T_NN lymphocytes_NNS ][VP induces_VBZ ][NP genes_NNS ][VP involved_VBN ][PP in_IN ][NP T_NN cell_NN ][NP activation_NN ] and_CC[NP growth_NN ] ._.
[NP A_DT diverged_JJ homeobox_NN gene_NN ] ,_,[NP HB24_NN ] ,_,[NP which_WDT ][VP is_VBZ known_VBN to_TO be_VB induced_VBN ][PP following_VBG ][NP lymphocyte_NN activation_NN ] ,_,[VP was_VBD introduced_VBN ][PP into_IN ][NP Jurkat_NN T_NN cells_NNS ][PP under_IN ][NP the_DT control_NN ][PP of_IN ][NP a_DT constitutive_JJ promoter_NN ] ._.
[NP Stable_JJ transfectants_NNS ][PP of_IN ][NP HB24_NN ][VP were_VBD established_VBN ][NP that_WDT ][VP expressed_VBD ][NP high_JJ levels_NNS ][PP of_IN ][NP HB24_NN mRNA_NN ] and_CC[VP possessed_VBD ][NP an_DT altered_JJ phenotype_NN ][ADJP suggestive_JJ ][PP of_IN ][NP activated_VBN T_NN cells_NNS ] ._.
[NP A_DT number_NN ][PP of_IN ][NP genes_NNS ][VP known_VBN to_TO be_VB induced_VBN ][PP following_VBG ][NP T_NN cell_NN activation_NN ] and_CC[VP associated_VBN ][PP with_IN ][NP cell_NN growth_NN ][VP were_VBD increased_VBN ][PP in_IN ][NP the_DT transfectants_NNS ] ,_,[PP including_VBG ][NP c-fos_NN ] ,_,[NP c-myc_NN ] ,_,[NP c-myb_NN ] ,_,[NP HLA-DR_NN ] ,_,[NP lck_NN ] ,_,[NP NF-kappa_NN B_NN ] ,_,[NP interleukin-2_NN ] and_CC[NP interleukin-2_NN receptor_NN alpha_NN ] (_([NP IL-2R_NN alpha_NN ] )_) ._.
[NP Analysis_NN ][PP of_IN ][NP IL-2R_NN alpha_NN expression_NN ][PP by_IN ][NP transient_JJ transfection_NN ][PP of_IN ][NP IL-2R_NN alpha_NN promoter_NN constructs_NNS ][PP into_IN ][NP the_DT HB24_NN transfectants_NNS ][VP revealed_VBD ][NP constitutive_JJ expression_NN ] (_([NP about_RB 60_CD %_NN ][PP of_IN ][NP phytohemagglutinin-_NN ] and_CC[ADJP phorbol_NN ester-activated_JJ ][NP Jurkat_NN cells_NNS ] )_)[NP that_WDT ][VP was_VBD ][ADJP dependent_JJ ][PP on_IN ][NP the_DT kappa_NN B_NN site_NN ][PP in_IN ][NP the_DT IL-2R_NN alpha_NN promoter_NN ] ._.
[ADVP Furthermore_RB ] ,_,[PP as_IN ][NP a_DT consequence_NN ][PP of_IN ][NP the_DT increased_VBN HB24_NN mRNA_NN levels_NNS ] ,_,[NP the_DT Jurkat_NN HB24_NN transfectants_NNS ][VP proliferated_VBD ][ADVP more_RBR rapidly_RB ][PP than_IN ][NP control_NN cell_NN lines_NNS ] ._.
[ADVP Thus_RB ] ,_,[NP stable_JJ expression_NN ][PP of_IN ][NP HB24_NN ][VP confers_VBZ ][NP an_DT activation_NN phenotype_NN ][PP on_IN ][NP a_DT human_JJ T_NN cell_NN line_NN ] ,_,[VP implicating_VBG ][NP this_DT gene_NN ][PP as_IN ][NP an_DT important_JJ transcriptional_JJ factor_NN ][PP during_IN ][NP T_NN cell_NN ][NP activation_NN ] and_CC[NP growth_NN ] ._.
[NP Studies_NNS ][PP on_IN ][NP the_DT biological_JJ activity_NN ][PP of_IN ][NP triiodothyronine_NN sulfate_NN ] ._.
[NP Hepatic_JJ microsomes_NNS ] and_CC[NP isolated_VBN hepatocytes_NNS ][PP in_IN ][NP short_JJ term_NN culture_NN ][VP desulfate_VBP ][NP T3_NN sulfate_NN ] (_([NP T3SO4_NN ] )_) ._.
[NP We_PRP ] ,_,[ADVP therefore_RB ] ,_,[VP wished_VBD to_TO determine_VB ][SBAR whether_IN ][NP T3SO4_NN ][VP could_MD mimic_VB ][NP the_DT action_NN ][PP of_IN ][NP thyroid_NN hormone_NN ][ADVP in_FW vitro_FW ] ._.
[NP T3SO4_NN ][VP had_VBD ][NP no_DT thyromimetic_JJ effect_NN ][PP on_IN ][NP the_DT activity_NN ][PP of_IN ][NP Ca(2+)-ATPase_NN ][PP in_IN ][NP human_JJ erythrocyte_NN membranes_NNS ][PP at_IN ][NP doses_NNS ][NP up_RB to_TO 10,000_CD times_NNS the_DT maximally_RB effective_JJ dose_NN ][PP of_IN ][NP T3_NN ] (_([NP 10/(-10)_CD mol/L_NN ] )_) ._.
[PP In_IN ][NP GH4C1_NN pituitary_JJ cells_NNS ] ,_,[NP T3SO4_NN ][VP failed_VBD to_TO displace_VB ][NP (125I)T3_NN ][PP from_IN ][NP nuclear_JJ receptors_NNS ][PP in_IN ][NP intact_JJ cells_NNS ] or_CC[NP soluble_JJ preparations_NNS ] ._.
[ADVP Thus_RB ] ,_,[NP T3SO4_NN ][VP was_VBD ] not_RB[ADVP directly_RB ][ADJP thyromimetic_JJ ][PP in_IN ] either_CC[NP an_DT isolated_VBN human_JJ membrane_NN system_NN ] or_CC[NP a_DT pituitary_JJ cell_NN system_NN ][PP in_IN ][NP which_WDT ][NP nuclear_JJ receptor_NN occupancy_NN ][VP correlates_VBZ ][PP with_IN ][NP GH_NN synthesis_NN ] ._.
[NP Thyroid_NN hormones_NNS ][VP inhibit_VBP ][NP (3H)glycosaminoglycan_NN synthesis_NN ][PP by_IN ][NP cultured_VBN human_JJ dermal_JJ fibroblasts_NNS ] ,_, and_CC[NP T3SO4_NN ][VP displayed_VBN ][NP about_IN 0.5_CD %_NN ][NP the_DT activity_NN ][PP of_IN ][NP T3_NN ][PP at_IN ][NP 72_CD h_NN ] ._.
[NP Human_JJ fibroblasts_NNS ][VP contained_VBD ][ADVP roughly_RB ][NP the_DT same_JJ level_NN ][PP of_IN ][NP microsomal_JJ p-nitrophenyl_NN sulfatase_NN activity_NN ][PP as_IN ][NP that_DT ][VP previously_RB observed_VBN ][PP in_IN ][NP hepatic_JJ microsomes_NNS ] ._.
[NP Propylthiouracil_NN ] (_([NP 50_CD mumol/L_NN ] )_)[VP did_VBD not_RB affect_VB ][NP the_DT action_NN ][PP of_IN ][NP T3SO4_NN ] ,_,[VP suggesting_VBG ][SBAR that_IN ][NP deiodination_NN ][VP was_VBD ] not_RB[ADJP important_JJ ][PP for_IN ][NP this_DT activity_NN ][PP of_IN ][NP T3SO4_NN ] ._.
[ADVP Thus_RB ] ,_,[NP it_PRP ][VP appears_VBZ ][NP T3SO4_NN ][VP has_VBZ ][NP no_DT intrinsic_JJ biological_JJ activity_NN ] ,_, but_CC ,_,[NP under_IN certain_JJ ][VP circumstances_NNS ] ,_,[VP may_MD be_VB ][PP reactivated_VBN ][NP by_IN ] desulfation_NN
[NP Nuclear_JJ factor_NN ][PP of_IN ][NP activated_VBN T_NN cells_NNS ][VP contains_VBZ ][NP Fos_NN ] and_CC[NP Jun_NN ] ._.
[NP The_DT nuclear_JJ factor_NN NF-AT_NN ] (_([NP ref._NN 1_CD ] )_)[VP is_VBZ induced_VBN ][PP in_IN ][NP T_NN cells_NNS ][VP stimulated_VBN ][PP through_IN ][NP the_DT T-cell_NN receptor/CD3_NN complex_NN ] ,_, and_CC[VP is_VBZ required_VBN ][PP for_IN ][NP interleukin-2_NN ] (_([NP IL-2_NN ] )_)[NP gene_NN induction_NN ] ._.
[SBAR Although_IN ][NP NF-AT_NN ][VP has_VBZ not_RB been_VBN cloned_VBN ] or_CC[VP purified_VBN ] ,_,[NP there_EX ][VP is_VBZ ][NP evidence_NN ][SBAR that_IN ][NP it_PRP ][VP is_VBZ ][NP a_DT major_JJ target_NN ][PP for_IN ][NP immunosuppression_NN ][PP by_IN ][NP cyclosporin_NN A_NN ] (_([NP CsA_NN ] )_) and_CC[NP FK506_NN ] (_([NP refs_NNS ][NP 2-7_CD ] )_) ._.
[NP NF-AT_NN induction_NN ][VP may_MD require_VB ][NP two_CD activation-dependent_JJ events_NNS ] :_:[NP the_DT CsA-sensitive_JJ translocation_NN ][PP of_IN ][NP a_DT pre-existing_JJ component_NN ] and_CC[NP the_DT CsA-resistant_JJ synthesis_NN ][PP of_IN ][NP a_DT nuclear_JJ component_NN ] ._.
[ADVP Here_RB ][NP we_PRP ][VP report_VBP ][SBAR that_IN ][NP the_DT newly_RB synthesized_VBN nuclear_JJ component_NN ][PP of_IN ][NP NF-AT_NN ][VP is_VBZ ][NP the_DT transcription_NN factor_NN AP-1_NN ] ._.
[NP We_PRP ][VP show_VBP ][SBAR that_IN ][NP the_DT inducible_JJ nuclear_JJ form_NN ][PP of_IN ][NP NF-AT_NN ][VP contains_VBZ ][NP Fos_NN ] and_CC[NP Jun_NN ][NP proteins_NNS ] ._.
[ADVP Furthermore_RB ] ,_,[NP we_PRP ][VP identify_VBP ][NP a_DT pre-existing_JJ NF-AT-binding_JJ factor_NN ][NP that_WDT ][VP is_VBZ ][ADJP present_JJ ][PP in_IN ][NP hypotonic_JJ extracts_NNS ][PP of_IN ][NP unstimulated_JJ T_NN cells_NNS ] ._.
[PP On_IN the_DT basis_NN of_IN ][NP binding_NN ] ,_,[NP reconstitution_NN ] and_CC[NP cotransfection_NN ][NP experiments_NNS ] ,_,[NP we_PRP ][VP propose_VBP ][SBAR that_IN ][NP activation_NN ][PP of_IN ][NP NF-AT_NN ][VP occurs_VBZ ][PP in_IN ][NP at_IN least_JJS two_CD stages_NNS ] :_:[NP a_DT CsA-sensitive_JJ stage_NN ][VP involving_VBG ][NP modification_NN ] and/or_CC[NP translocation_NN ][PP of_IN ][NP the_DT pre-existing_JJ NF-AT_NN complex_NN ] ,_, and_CC[NP a_DT CsA-insensitive_JJ stage_NN ][VP involving_VBG ][NP the_DT addition_NN ][PP of_IN ] newly_RB synthesized_VBN[NP Fos_NN ] or_CC[NP Fos/Jun_NN ][NP proteins_NNS ][PP to_TO ][NP the_DT pre-existing_JJ complex_NN ] ._.
[NP Interferon-gamma_NN ][VP potentiates_VBZ ][NP the_DT antiviral_JJ activity_NN ] and_CC[NP the_DT expression_NN ][PP of_IN ][NP interferon-stimulated_JJ genes_NNS ][VP induced_VBN ][PP by_IN ][NP interferon-alpha_NN ][PP in_IN ][NP U937_NN cells_NNS ] ._.
[NP Binding_NN ][PP of_IN ][NP type_NN I_CD interferon_NN ] (_([NP IFN-alpha/beta_NN ] )_)[PP to_TO ][NP specific_JJ receptors_NNS ][VP results_VBZ ][PP in_IN ][NP the_DT rapid_JJ transcriptional_JJ activation_NN ] ,_,[ADJP independent_JJ ][PP of_IN ][NP protein_NN synthesis_NN ] ,_,[PP of_IN ][NP IFN-alpha-stimulated_JJ genes_NNS ] (_([NP ISGs_NNS ] )_)[PP in_IN ][NP human_JJ fibroblasts_NNS ] and_CC[NP HeLa_NN ] and_CC[NP Daudi_NN ][NP cell_NN lines_NNS ] ._.
[NP The_DT binding_NN ][PP of_IN ][NP ISGF3_NN ] (_([NP IFN-stimulated_JJ gene_NN factor_NN 3_CD ] )_)[PP to_TO ][NP the_DT conserved_VBN ][NP IFN-stimulated_JJ response_NN element_NN ] (_([NP ISRE_NN ] )_)[VP results_VBZ ][PP in_IN ][NP transcriptional_JJ activation_NN ] ._.
[NP This_DT factor_NN ][VP is_VBZ composed_VBN ][PP of_IN ][NP a_DT DNA-binding_JJ protein_NN ] (_([NP ISGF3_NN gamma_NN ] )_) ,_,[NP which_WDT ][ADVP normally_RB ][VP is_VBZ ][ADJP present_JJ ][PP in_IN ][NP the_DT cytoplasm_NN ] ,_, and_CC[NP other_JJ IFN-alpha-activated_JJ proteins_NNS ][NP which_WDT ][VP preexist_VBP ][PP as_IN ][NP latent_JJ cytoplasmic_JJ precursors_NNS ] (_([NP ISGF3_NN alpha_NN ] )_) ._.
[NP We_PRP ][VP have_VBP found_VBN ][SBAR that_IN ][NP ISG_NN expression_NN ][PP in_IN ][NP the_DT monocytic_JJ U937_NN cell_NN line_NN ][VP differs_VBZ ][PP from_IN ][NP most_JJS cell_NN lines_NNS ][VP previously_RB examined_VBN ] ._.
[NP U937_NN cells_NNS ][VP express_VBP ] both_CC[NP type_NN I_CD ] and_CC[NP type_NN II_CD ][NP IFN_NN receptors_NNS ] ,_, but_CC[NP only_RB IFN-alpha_NN ][VP is_VBZ ][ADJP capable_JJ ][PP of_IN ][VP inducing_VBG ][NP antiviral_JJ protection_NN ][PP in_IN ][NP these_DT cells_NNS ] ._.
[NP Pretreatment_NN ][PP with_IN ][NP IFN-gamma_NN ][VP potentiates_VBZ ][NP the_DT IFN-alpha-induced_JJ protection_NN ] ,_, but_CC[NP IFN-gamma_NN ][ADVP alone_RB ][VP does_VBZ not_RB have_VB ][NP any_DT antiviral_JJ activity_NN ] ._.
[NP ISG15_NN mRNA_NN accumulation_NN ][PP in_IN ][NP U937_NN cells_NNS ][VP is_VBZ ] not_RB[ADJP detectable_JJ ][PP before_IN ][NP 6_CD h_NN ][PP of_IN ][NP IFN-alpha_NN treatment_NN ] ,_,[VP peaks_VBZ ][PP at_IN ][NP 24_CD h_NN ] ,_, and_CC[VP requires_VBZ ][NP protein_NN synthesis_NN ] ._.
[SBAR Although_IN ][NP IFN-gamma_NN ][ADVP alone_RB ][VP does_VBZ not_RB induce_VB ][NP ISG_NN expression_NN ] ,_,[NP IFN-gamma_NN pretreatment_NN ][ADVP markedly_RB ][VP increases_VBZ ] and_CC[VP hastens_VBZ ][NP ISG_NN expression_NN ] and_CC[NP transcriptional_JJ induction_NN ] ._.
[NP Nuclear_JJ extracts_NNS ][VP assayed_VBN ][PP for_IN ][NP the_DT presence_NN ][PP of_IN ][NP ISRE_NN binding_NN factors_NNS ][PP by_IN ][NP electrophoretic_JJ mobility_NN shift_NN assays_NNS ][VP show_VBP ][SBAR that_IN ][NP ISGF3_NN ][VP is_VBZ induced_VBN ][PP by_IN ][NP IFN-alpha_NN ][PP within_IN ][NP 6_CD h_NN ][PP from_IN ][NP undetectable_JJ basal_JJ levels_NNS ][PP in_IN ][NP untreated_JJ U937_NN cells_NNS ] ._.
[NP Activation_NN ][PP of_IN ][NP ISGF3_NN alpha_NN ] ,_,[NP the_DT latent_JJ component_NN ][PP of_IN ][NP ISGF3_NN ] ,_,[VP occurs_VBZ ][ADVP rapidly_RB ] ._.
[ADVP However_RB ] ,_,[NP the_DT increase_NN ][PP in_IN ][NP ISGF3_NN activity_NN ][ADVP ultimately_RB ][VP correlates_VBZ ][PP with_IN ][NP the_DT accumulation_NN ][PP of_IN ][NP ISGF3_NN gamma_NN ][VP induced_VBN ][PP by_IN ][NP IFN-alpha_NN ] or_CC[NP IFN-gamma_NN ] ._.
 (_([NP ABSTRACT_NN ][VP TRUNCATED_VBN ][PP AT_IN ][NP 250_CD WORDS_NNS ] )_)
[NP The_DT mechanism_NN ][PP of_IN ][NP action_NN ][PP of_IN ][NP cyclosporin_NN A_NN ] and_CC[NP FK506_NN ] ._.
[NP CsA_NN ] and_CC[NP FK506_NN ][VP are_VBP ][NP powerful_JJ suppressors_NNS ][PP of_IN ][NP the_DT immune_JJ system_NN ] ,_,[ADVP most_RBS notably_RB ][PP of_IN ][NP T_NN cells_NNS ] ._.
[NP They_PRP ][VP act_VBP ][PP at_IN ][NP a_DT point_NN ][PP in_IN ][NP activation_NN ][NP that_WDT ][VP lies_VBZ ][PP between_IN ][NP receptor_NN ligation_NN ] and_CC[NP the_DT transcription_NN ][PP of_IN ][NP early_JJ genes_NNS ] ._.
[ADVP Here_RB ] ,_,[NP Stuart_NNP Schreiber_NNP ] and_CC[NP Gerald_NNP Crabtree_NNP ][VP review_VBP ][NP recent_JJ findings_NNS ][NP that_WDT ] indicate_VBP[NP CsA_NN ] and_CC[NP FK506_NN ][VP operate_VBP ][PP as_IN ][NP prodrugs_NNS ] :_:[NP they_PRP ][VP bind_VBP ][NP endogenous_JJ intracellular_JJ receptors_NNS ] ,_,[NP the_DT immunophilins_NNS ] ,_, and_CC[NP the_DT resulting_VBG complex_NN ][VP targets_VBZ ][NP the_DT protein_NN phosphatase_NN ] ,_,[NP calcineurin_NN ] ,_,[VP to_TO exert_VB ][NP the_DT immunosuppressive_JJ effect_NN ] ._.
 (_([NP Plasma_NN cortisol_NN concentration_NN ] and_CC[NP blood_NN leukocyte_NN content_NN ][PP of_IN ][NP glucocorticoid_NN receptors_NNS ][PP in_IN ][NP patients_NNS ][PP with_IN ][NP deficiency-cold_JJ vs_CC deficiency-heat_JJ syndromes_NNS ] )_)
[NP Plasma_NN cortisol_NN concentration_NN ] and_CC[NP blood_NN leukocyte_NN content_NN ][PP of_IN ][NP glucocorticoid_NN receptors_NNS ] (_([NP GCR_NN ] )_)[VP were_VBD assayed_VBN ][PP in_IN ][NP 20_CD patients_NNS ][PP with_IN ][NP deficiency_NN syndromes_NNS ] ,_,[NP 10_CD ][ADJP cold_JJ ][PP in_IN ][NP property_NN ] (_([ADJP deficiency-cold_JJ ] )_) ,_,[NP the_DT other_JJ ][NP 10_CD ][ADJP hot_JJ ][PP in_IN ][NP property_NN ] (_([ADJP deficiency-heat_JJ ] )_) ,_, and_CC also_RB[PP in_IN ][NP 10_CD healthy_JJ individuals_NNS ][PP as_IN ][NP normal_JJ control_NN ][PP for_IN ][NP the_DT purpose_NN ][PP of_IN ][VP investigating_VBG ][NP the_DT nature_NN ][PP of_IN ] cold_NN and_CC[NP heat_NN ][NP syndromes_NNS ] ._.
[PP As_IN ][NP a_DT result_NN ] ,_,[NP the_DT cases_NNS ][PP of_IN ][NP deficiency-cold_JJ syndrome_NN ] (_([NP DCS_NN ] )_)[VP had_VBD ][NP a_DT normal_JJ concentration_NN ][PP of_IN ][NP plasma_NN cortisol_NN ] but_CC[NP a_DT lowered_JJ content_NN ][PP of_IN ][NP GCR_NN ][PP in_IN ][NP leukocytes_NNS ][ADVP when_WRB ][VP compared_VBN ][PP with_IN ][NP the_DT normal_JJ control_NN ] (_([NP P_NN ][NP less_JJR than_IN 0.05_CD ] )_) ;_:[NP the_DT cases_NNS ][PP of_IN ][NP deficiency-heat_JJ syndrome_NN ] (_([NP DHS_NN ] )_)[VP had_VBD ][NP a_DT higher_JJR concentration_NN ][PP of_IN ][NP plasma_NN cortisol_NN ][PP than_IN ][NP the_DT normal_JJ control_NN ] (_([NP P_NN ][NP less_JJR than_IN 0.05_CD ] )_) and_CC[NP a_DT slightly_RB higher_JJR content_NN ][PP of_IN ][NP GCR_NN ][PP in_IN ][NP leukocytes_NNS ] ._.
[NP It_PRP ][VP was_VBD concluded_VBN ][SBAR that_IN ][NP the_DT DCS_NN ][VP is_VBZ characterized_VBN ][PP by_IN ][NP diminished_VBN biological_JJ effects_NNS ][PP of_IN ][NP adrenocortical_JJ activity_NN ] ,_, while_IN[NP the_DT DHS_NN ] ,_,[PP by_IN ][NP augmented_JJ biological_JJ effects_NNS ][PP of_IN ][NP adrenocortical_JJ activity_NN ] ._.
[NP Specific_JJ NF-kappa_NN B_NN subunits_NNS ][VP act_VBP ][PP in_IN concert_NN with_IN ][NP Tat_NN ][VP to_TO stimulate_VB ][NP human_JJ immunodeficiency_NN virus_NN type_NN 1_CD transcription_NN ] ._.
[NP NF-kappa_NN B_NN ][VP is_VBZ ][NP a_DT protein_NN complex_NN ][NP which_WDT ][VP functions_VBZ ][PP in_IN concert_NN with_IN ][NP the_DT tat-I_NN gene_NN product_NN ][VP to_TO stimulate_VB ][NP human_JJ immunodeficiency_NN virus_NN ] (_([NP HIV_NN ] )_)[NP transcription_NN ] ._.
[VP To_TO determine_VB ][SBAR whether_IN ][NP specific_JJ members_NNS ][PP of_IN ][NP the_DT NF-kappa_NN B_NN family_NN ][VP contribute_VBP ][PP to_TO ][NP this_DT effect_NN ] ,_,[NP we_PRP ][VP have_VBP examined_VBN ][NP the_DT abilities_NNS ][PP of_IN ][NP different_JJ NF-kappa_NN B_NN subunits_NNS ][VP to_TO act_VB ][PP with_IN ][NP Tat-I_NN ][VP to_TO stimulate_VB ][NP transcription_NN ][PP of_IN ][NP HIV_NN ][PP in_IN ][NP Jurkat_NN T-leukemia_NN cells_NNS ] ._.
[NP We_PRP ][VP have_VBP found_VBN ][SBAR that_IN ][NP the_DT p49_NN (_( 100_CD )_) DNA_NN binding_NN subunit_NN ] ,_,[PP together_RB with_IN ][NP p65_NN ] ,_,[VP can_MD act_VB ][PP in_IN concert_NN with_IN ][NP Tat-I_NN ][VP to_TO stimulate_VB ][NP the_DT expression_NN ][PP of_IN ][NP HIV-CAT_NN plasmid_NN ] ._.
[NP Little_JJ effect_NN ][VP was_VBD observed_VBN ][PP with_IN ][NP 50-kDa_JJ forms_NNS ][PP of_IN ][NP p105_NN NF-kappa_NN B_NN ] or_CC[NP rel_NN ] ,_,[PP in_IN ][NP combination_NN ][PP with_IN ][NP p65_NN ] or_CC[NP full-length_JJ c-rel_NN ] ,_,[NP which_WDT ][VP do_VBP not_RB stimulate_VB ][NP the_DT HIV_NN enhancer_NN ][PP in_IN ][NP these_DT cells_NNS ] ._.
[NP These_DT findings_NNS ][VP suggest_VBP ][SBAR that_IN ][NP the_DT combination_NN ][PP of_IN ][NP p49_NN (_( 100_CD ] )_) and_CC[NP p65_NN NF-kappa_NN B_NN ][VP can_MD act_VB ][PP in_IN concert_NN with_IN ][NP the_DT tat-I_NN gene_NN product_NN ][VP to_TO stimulate_VB ][NP the_DT synthesis_NN ][PP of_IN ][NP HIV_NN RNA_NN ] ._.
[NP Activation_NN ][PP of_IN ][NP the_DT human_JJ immunodeficiency_NN virus_NN type_NN 1_CD enhancer_NN ][VP is_VBZ ] not_RB[ADJP dependent_JJ ][PP on_IN ][NP NFAT-1_NN ] ._.
[NP The_DT function_NN ][PP of_IN ][NP a_DT putative_JJ NFAT-1_NN site_NN ][PP in_IN ][NP the_DT human_JJ immunodeficiency_NN virus_NN type_NN 1_CD enhancer_NN ][VP has_VBZ been_VBN analyzed_VBN ] ._.
[NP Activation_NN ][PP by_IN ][NP the_DT T-cell_NN antigen_NN receptor_NN ][VP is_VBZ ][ADJP minimal_JJ ][PP in_IN ][NP Jurkat_NN cells_NNS ] and_CC[VP is_VBZ mediated_VBN ][PP by_IN ][NP the_DT kappa_NN B_NN sites_NNS ] ._.
[NP The_DT putative_JJ NFAT-1_NN region_NN ][VP is_VBZ not_RB required_VBN ][PP for_IN ][NP the_DT response_NN ][PP to_TO ][NP anti-CD3_NN ][PP or_CC ][PP to_TO ][NP mitogens_NNS ][PP in_IN ][NP T-cell_NN ] ,_,[NP B-cell_NN ] ,_, or_CC[NP monocyte/macrophage_NN leukemia_NN ][NP lines_NNS ] ,_, nor_CC[VP is_VBZ ][NP it_PRP ][NP a_DT cis-acting_JJ negative_JJ regulatory_JJ element_NN ] ._.
[NP Protein_NN kinase_NN C_NN activation_NN ] and_CC[NP protooncogene_NN expression_NN ][PP in_IN ][NP differentiation/retrodifferentiation_NN ][PP of_IN ][NP human_JJ U-937_NN leukemia_NN cells_NNS ] ._.
[NP Human_JJ U-937_NN leukemia_NN cells_NNS ][VP differentiate_VBP ][PP along_IN ][NP the_DT monocytic_JJ lineage_NN ][PP following_VBG ][NP 3-day_JJ exposures_NNS ][PP to_TO ][NP 12-O-tetradecanoylphorbol-13-acetate_NN ] (_([NP TPA_NN ] )_) ._.
[NP This_DT induction_NN ][PP of_IN ][NP differentiation_NN ][VP is_VBZ accompanied_VBN ][PP by_IN ][NP adherence_NN ] and_CC[NP loss_NN ][PP of_IN ][NP proliferation_NN ] ,_,[CONJP as_RB well_RB as_IN ][NP expression/repression_NN ][PP of_IN ][NP differentiation-associated_JJ genes_NNS ] ._.
[NP Long_JJ term_NN culture_NN ][PP of_IN ][NP TPA-differentiated_JJ U-937_NN cells_NNS ][PP in_IN the_DT absence_NN of_IN ][NP phorbol_NN ester_NN ][PP for_IN ][NP 32-36_CD days_NNS ][VP resulted_VBD ][PP in_IN ][NP a_DT process_NN ][PP of_IN ][NP retrodifferentiation_NN ] ._.
[NP The_DT retrodifferentiated_VBN cells_NNS ][VP detached_VBD ][PP from_IN ][NP the_DT substrate_NN ] and_CC[VP reinitiated_VBD ][NP proliferation_NN ] ._.
[NP Other_JJ cellular_JJ parameters_NNS ] ,_,[PP such_JJ as_IN ][NP glycosidase_NN activities_NNS ] ,_,[NP cytokine_NN release_NN ] ,_, and_CC[NP filament_NN expression_NN ] ,_,[VP returned_VBD ][PP to_TO ][NP levels_NNS ][ADJP similar_JJ ][PP to_TO ][NP that_DT ][VP observed_VBN ][PP in_IN ][NP uninduced_JJ cells_NNS ] ._.
[NP Treatment_NN ][PP of_IN ][NP U-937_NN cells_NNS ][PP with_IN ][NP TPA_NN ][VP resulted_VBD ][PP in_IN ][NP a_DT rapid_JJ translocation_NN ][PP of_IN ][NP protein_NN kinase_NN C_NN ] (_([NP PKC_NN ] )_)[PP from_IN ][NP the_DT cytosol_NN ][PP to_TO ][NP cell_NN membrane_NN fractions_NNS ][PP within_IN ][NP 2-8_CD min_NN ] ._.
[NP Increased_VBN levels_NNS ][PP of_IN ][NP membrane-associated_JJ PKC_NN activity_NN ][VP persisted_VBD ][PP until_IN ][NP 17-29_CD days_NNS ] ._.
[ADVP However_RB ] ,_,[NP longer_JJR periods_NNS ][PP of_IN ][NP incubation_NN ][VP were_VBD associated_VBN ][PP with_IN ][NP a_DT return_NN ][PP to_TO ][NP the_DT distribution_NN ][PP of_IN ][NP PKC_NN ][PP in_IN ][NP control_NN cells_NNS ] ._.
[NP Activation_NN ][PP of_IN ][NP PKC_NN ][VP has_VBZ been_VBN implicated_VBN ][PP in_IN ][NP the_DT regulation_NN ][PP of_IN ][NP certain_JJ immediate_JJ early_JJ response_NN genes_NNS ] ,_, and_CC[PP in_IN ][NP the_DT present_JJ studies_NNS ] ,_,[NP TPA_NN ][ADVP rapidly_RB ][VP induced_VBD ][NP c-fos_NN ] and_CC[NP c-jun_NN ][NP gene_NN expression_NN ] ._.
[NP Levels_NNS ][PP of_IN ][NP c-fos_NN ] and_CC[NP c-jun_NN ][NP transcripts_NNS ][VP remained_VBD ][ADJP elevated_JJ ][PP during_IN ][NP periods_NNS ][PP of_IN ][NP PKC_NN activation_NN ] and_CC also_RB[VP returned_VBD ][PP to_TO ][NP levels_NNS ][VP observed_VBN ][PP in_IN ][NP control_NN cells_NNS ][PP by_IN ][NP 30-36_CD days_NNS ] ,_,[ADVP when_WRB ][NP the_DT cells_NNS ][VP entered_VBD ][NP retrodifferentiation_NN ] ._.
[NP Staurosporine_NN ] ,_,[NP a_DT nonspecific_JJ inhibitor_NN ][PP of_IN ][NP PKC_NN ] ,_,[VP partially_RB blocked_VBD ][NP TPA-induced_JJ adherence_NN ] and_CC[NP growth_NN inhibition_NN ] and_CC[VP concomitantly_RB prevented_VBD ] TPA-induced_JJ[NP c-fos_NN ] and_CC[NP c-jun_NN ][NP gene_NN expression_NN ] ._.
 (_([NP ABSTRACT_NN ][VP TRUNCATED_VBN ][PP AT_IN ][NP 250_CD WORDS_NNS ] )_)
[NP The_DT promoter_NN ][PP of_IN ][NP the_DT CD19_NN gene_NN ][VP is_VBZ ][NP a_DT target_NN ][PP for_IN ][NP the_DT B-cell-specific_JJ transcription_NN factor_NN BSAP_NN ] ._.
[NP The_DT CD19_NN protein_NN ][VP is_VBZ expressed_VBN ][PP on_IN ][NP the_DT surface_NN ][PP of_IN ][NP all_DT B-lymphoid_JJ cells_NNS ][PP with_IN ][NP the_DT exception_NN ][PP of_IN ][NP terminally_RB differentiated_VBN plasma_NN cells_NNS ] and_CC[VP has_VBZ been_VBN implicated_VBN ][PP as_IN ][NP a_DT signal-transducing_JJ receptor_NN ][PP in_IN ][NP the_DT control_NN ][PP of_IN ][NP proliferation_NN ] and_CC[NP differentiation_NN ] ._.
[ADVP Here_RB ][NP we_PRP ][VP demonstrate_VBP ][NP complete_JJ correlation_NN ][PP between_IN ][NP the_DT expression_NN pattern_NN ][PP of_IN ][NP the_DT CD19_NN gene_NN ] and_CC[NP the_DT B-cell-specific_JJ transcription_NN factor_NN BSAP_NN ][PP in_IN ][NP a_DT large_JJ panel_NN ][PP of_IN ][NP B-lymphoid_JJ cell_NN lines_NNS ] ._.
[NP The_DT human_JJ CD19_NN gene_NN ][VP has_VBZ been_VBN cloned_VBN ] ,_, and_CC[NP several_JJ BSAP-binding_JJ sites_NNS ][VP have_VBP been_VBN mapped_VBN ][PP by_IN ][NP in_FW vitro_FW protein-DNA_JJ binding_NN studies_NNS ] ._.
[PP In_IN ][NP particular_JJ ] ,_,[NP a_DT high-affinity_JJ BSAP-binding_JJ site_NN ][CONJP instead_RB of_IN ][NP a_DT TATA_NN sequence_NN ][VP is_VBZ ][ADJP located_JJ ][PP in_IN ][NP the_DT -30_CD promoter_NN region_NN ][ADJP upstream_JJ ][PP of_IN ][NP a_DT cluster_NN ][PP of_IN ][NP heterogeneous_JJ transcription_NN start_NN sites_NNS ] ._.
[ADVP Moreover_RB ] ,_,[NP this_DT site_NN ][VP is_VBZ occupied_VBN ][PP by_IN ][NP BSAP_NN ][ADVP in_FW vivo_FW ][PP in_IN ][NP a_DT CD19-expressing_JJ B-cell_NN line_NN ][PP but_CC ][PP not_RB in_IN ][NP plasma_NN ] or_CC[NP HeLa_NN ][NP cells_NNS ] ._.
[NP This_DT high-affinity_JJ site_NN ][VP has_VBZ been_VBN conserved_VBN ][PP in_IN ][NP the_DT promoters_NNS ][PP of_IN ] both_CC human_JJ and_CC[NP mouse_NN ][NP CD19_NN genes_NNS ] and_CC[VP was_VBD furthermore_RB shown_VBN to_TO confer_VB ][NP B-cell_NN specificity_NN ][PP to_TO ][NP a_DT beta-globin_NN reporter_NN gene_NN ][PP in_IN ][NP transient_JJ transfection_NN experiments_NNS ] ._.
[PP In_IN ][NP addition_NN ] ,_,[NP BSAP_NN ][VP was_VBD found_VBN to_TO be_VB ][NP the_DT only_RB abundant_JJ DNA-binding_JJ activity_NN ][PP of_IN ][NP B-cell_NN nuclear_JJ extracts_NNS ][NP that_WDT ][VP interacts_VBZ ][PP with_IN ][NP the_DT CD19_NN promoter_NN ] ._.
[ADVP Together_RB ] ,_,[NP this_DT evidence_NN ][ADVP strongly_RB ][VP implicates_VBZ ][NP BSAP_NN ][PP in_IN ][NP the_DT regulation_NN ][PP of_IN ][NP the_DT CD19_NN gene_NN ] ._.
[NP Reduced_VBN susceptibility_NN ][PP to_TO ][NP HIV-1_NN infection_NN ][PP of_IN ][NP ethyl-methanesulfonate-treated_JJ CEM_NN subclones_NNS ][VP correlates_VBZ ][PP with_IN ][NP a_DT blockade_NN ][PP in_IN ][NP their_PRP$ protein_NN kinase_NN C_NN signaling_NN pathway_NN ] ._.
[NP We_PRP ][VP have_VBP described_VBN ][NP the_DT isolation_NN ][PP of_IN ][NP chemically_RB induced_VBN CEM_NN subclones_NNS ][NP that_WDT ][VP express_VBP ][NP CD4_NN receptors_NNS ] and_CC[VP bind_VBP ][NP soluble_JJ gp120_NN ] ,_, yet_RB[VP show_VBP ][NP a_DT markedly_RB reduced_VBN susceptibility_NN ][PP to_TO ][NP infection_NN ][PP with_IN ][NP HIV-1_NN ] ._.
[NP Two_CD subclones_NNS ][VP were_VBD found_VBN to_TO have_VB ][NP an_DT abnormal_JJ response_NN ][PP to_TO ] the_DT[NP protein_NN kinase_NN C_NN ] (_([NP PKC_NN ] )_)[NP activator_NN PMA_NN ] ._.
[NP PMA_NN treatment_NN ][VP induced_VBD ][NP CD3_NN ] and_CC[NP CD25_NN ] (_([NP IL-2R_NN ] )_)[NP receptors_NNS ][PP on_IN ][NP the_DT parental_JJ line_NN ] and_CC[PP on_IN ][NP other_JJ ethyl-methanesulfonate-derived_JJ subclones_NNS ][PP ,_, but_CC ][PP not_RB on_IN ][NP these_DT two_CD mutants_NNS ] ._.
[NP Direct_JJ assays_NNS ][PP of_IN ][NP PKC_NN activity_NN ][VP were_VBD conducted_VBN ] ._.
[NP Total_JJ cellular_JJ PKC_NN enzymatic_JJ activity_NN ][VP was_VBD found_VBN to_TO be_VB ][ADJP normal_JJ ][PP in_IN ][NP these_DT subclones_NNS ] ._.
[NP PMA-induced_JJ CD4_NN down-modulation_NN ][VP occurred_VBD ][ADVP normally_RB ] ._.
[PP In_IN ][NP addition_NN ] ,_,[NP activation_NN ][PP of_IN ][NP c-raf_NN kinase_NN ][VP was_VBD ][ADJP normal_JJ ] ._.
[SBAR Since_IN ][NP HIV-1_NN long_JJ terminal_JJ repeat_NN ][VP contains_VBZ ] two_CD functional_JJ[NP nuclear_JJ factor_NN kB_NN ] (_([NP NF-kB_NN ] )_)[NP regulatory_JJ elements_NNS ] ,_,[NP we_PRP ][VP studied_VBD ][NP the_DT ability_NN ][PP of_IN ][NP PMA_NN ][VP to_TO induce_VB ][NP NF-kB_NN binding_NN activity_NN ][PP by_IN ][NP different_JJ assays_NNS ] ._.
[NP Chloramphenicol_NN acetyl_NN transferase_NN ] (_([NP CAT_NN ] )_)[NP assays_NNS ][VP using_VBG ][NP the_DT HIV-1_NN (_( -139_CD )_) long_JJ terminal_JJ repeat-CAT_JJ construct_NN ][VP showed_VBD ][NP no_DT PMA_NN induction_NN ][PP of_IN ][NP CAT_NN activity_NN ][PP in_IN ][NP these_DT subclones_NNS ] (_([PP unlike_IN ][NP the_DT parental_JJ line_NN ] and_CC[NP other_JJ subclones_NNS ] )_) ._.
[NP Okadaic_JJ acid_NN ] ,_,[NP an_DT inhibitor_NN ][PP of_IN ][NP phosphatases_NNS ][NP 1_CD ] and_CC[NP 2A_NN ] ,_,[VP did_VBD not_RB overcome_VB ][NP the_DT defect_NN ][PP in_IN ][NP these_DT subclones_NNS ] ._.
[NP Gel_NN retardation_NN assays_NNS ] ,_,[VP using_VBG ][NP a_DT 32P-probe_NN ][VP containing_VBG ][NP the_DT HIV-1_NN NF-kB_NN probe_NN ] and_CC[NP nuclear_JJ extracts_NNS ][PP from_IN ][NP PMA-treated_JJ cells_NNS ] ,_,[VP showed_VBD ][NP significantly_RB reduced_VBN induction_NN ][PP of_IN ][NP nuclear_JJ NF-kB_NN binding_NN proteins_NNS ][PP in_IN ][NP these_DT two_CD subclones_NNS ][PP compared_VBN ][PP with_IN ][NP wild_JJ type_NN CEM_NN ] and_CC[NP a_DT control_NN subclone_NN ] ._.
[NP Deoxycholate_JJ treatment_NN ][PP of_IN ][NP cytoplasmic_JJ extracts_NNS ][PP from_IN ][NP these_DT subclones_NNS ][VP released_VBD ][NP much_JJ reduced_VBN NF-kB_NN binding_NN proteins_NNS ][PP from_IN ][NP their_PRP$ cytoplasmic_JJ pools_NNS ] ._.
[ADVP Thus_RB ] ,_,[NP reduced_JJ levels_NNS ][PP of_IN ][NP PKC-induced_JJ nuclear_JJ NF-kB_NN activity_NN ][PP in_IN ][NP two_CD T_NN cell_NN subclones_NNS ][VP did_VBD not_RB affect_VB ][NP their_PRP$ normal_JJ cell_NN growth_NN ] ,_, but_CC[VP correlated_VBD ][PP with_IN ][NP a_DT pronounced_JJ reduction_NN ][PP in_IN ][NP their_PRP$ susceptibility_NN ][PP to_TO ][NP HIV-1_NN infection_NN ] ._.
[NP Eicosanoids_NNS ][PP in_IN ][NP breast_NN cancer_NN patients_NNS ][PP before_IN ][PP and_CC ][PP after_IN ][NP mastectomy_NN ] ._.
[PP In_IN ][NP 19_CD patients_NNS ][PP with_IN ][NP a_DT malignant_JJ breast_NN tumor_NN ] ,_,[NP tumor_NN tissue_NN ] and_CC[NP blood_NN ][VP were_VBD taken_VBN ][VP to_TO determine_VB ][NP the_DT ][NP eicosanoid_NN profile_NN ] and_CC[NP platelet_NN aggregation_NN ] ._.
[NP Values_NNS ][VP were_VBD compared_VBN ][PP with_IN ][NP those_DT ][PP of_IN ][NP patients_NNS ][PP with_IN ][NP benign_JJ tumors_NNS ] (_([NP n_NN ][VP =_JJ ][NP 4_CD ] )_) ,_, or_CC[VP undergoing_VBG ][NP a_DT mammary_JJ reduction_NN ] (_([NP n_NN ][VP =_JJ ][NP 7_CD ] )_) ._.
[ADVP Postoperatively_RB ] ,_,[NP blood_NN ][VP was_VBD taken_VBN ][PP as_RB ][ADVP well_RB ][SBAR in_IN ] order_NN to_TO[VP compare_VB ][NP pre-_JJ and_CC postoperative_JJ values_NNS ] ._.
[NP Eicosanoids_NNS ][VP were_VBD measured_VBN ][PP in_IN ][NP peripheral_JJ blood_NN monocytes_NNS ] and_CC[NP mammary_JJ tissue_NN ][PP by_IN means_NNS of_IN ][NP HPLC_NN ] ;_:[ADVP furthermore_RBR ] ,_,[NP TXA2_NN ] ,_,[NP 6-keto-PGF1_NN alpha_NN ] ,_, and_CC[NP PGE2_NN ][VP were_VBD determined_VBN ][PP by_IN ][NP RIA_NN ] ._.
[NP Differences_NNS ][PP in_IN ][NP pre-_JJ and_CC postoperative_JJ values_NNS ][PP of_IN ][NP cancer_NN patients_NNS ][VP were_VBD seen_VBN ][PP in_IN ][NP plasma_NN RIA_NN values_NNS ] :_:[NP PGE2_NN ] and_CC[NP 6-k-PGF1_NN alpha_NN ][VP were_VBD ][ADJP significantly_RB higher_JJR ][ADVP preoperatively_RB ][ADVP when_WRB ][VP compared_VBN ][PP with_IN ][ADVP postoperatively_RB ] ,_, however_RB ,_,[NP such_JJ differences_NNS ][VP were_VBD seen_VBN ][PP in_IN ][NP the_DT control_NN groups_NNS ][PP as_RB ][ADVP well_RB ] ._.
[PP Compared_VBN ][PP to_TO ][NP benign_JJ tumor_NN ] or_CC[NP mammary_JJ reduction_NN ][NP test_NN material_NN ][NP the_DT eicosanoid_NN profile_NN ][PP of_IN ][NP tissue_NN ][VP obtained_VBN ][PP from_IN ][NP malignant_JJ mammary_JJ tumors_NNS ][VP showed_VBD ][NP important_JJ differences_NNS ] ._.
[PP Except_IN for_IN ][NP PGF2_NN alpha_NN ] ,_,[NP HHT_NN ] and_CC[NP 15-HETE_NN ][NP no_DT detectable_JJ quantities_NNS ][PP of_IN ][NP eicosanoids_NNS ][VP were_VBD found_VBN ][PP in_IN ][NP the_DT non-tumor_JJ material_NN ] ,_, whereas_IN[PP in_IN ][NP the_DT malignant_JJ tumor_NN material_NN ][NP substantial_JJ quantities_NNS ][PP of_IN ][NP a_DT number_NN ][PP of_IN ][NP eicosanoid_NN metabolites_NNS ][VP were_VBD ][ADJP present_JJ ] ._.
[NP Statistically_RB significant_JJ correlations_NNS ][VP could_MD be_VB established_VBN ][PP between_IN ][NP patient/histopathology_NN data_NNS ] and_CC[NP the_DT results_NNS ][PP of_IN ][NP the_DT platelet_NN aggregation_NN assays_NNS ][PP ,_, e.g._FW ][PP between_IN ][NP menopausal_JJ status_NN ] and_CC[NP ADP_NN aggregation_NN ] ;_:[NP oestrogen_NN receptor_NN ] (_( +/-_CC )_) and_CC[NP collagen_NN ] and_CC[NP arachidonic_JJ acid_NN aggregation_NN ] ,_,[NP inflammatory_JJ cell_NN infiltration_NN score_NN ] and_CC[NP arachidonic_JJ acid_NN aggregation_NN ] and_CC[NP fibrosis_NN score_NN ] and_CC[NP ADP_NN aggregation_NN ] ._.
[NP The_DT results_NNS ][VP show_VBP ][SBAR that_IN ][NP eicosanoid_NN synthesis_NN ][PP in_IN ][NP material_NN ][PP from_IN ][NP mammary_JJ cancer_NN patients_NNS ][VP is_VBZ ][ADJP different_JJ ][PP from_IN ][NP that_DT ][PP in_IN ][NP benign_JJ mammary_JJ tissue_NN ] ._.
[NP The_DT implications_NNS ] ,_,[PP in_IN ][NP particular_JJ ][PP ,_, in_IN relation_NN to_TO ][NP future_JJ prognosis_NN ][PP of_IN ][NP the_DT patient_NN ] ,_,[VP remain_VBP ][ADJP obscure_JJ ] ._.
[NP c-myc_NN mRNA_NN expression_NN ][PP in_IN ][NP minor_JJ salivary_JJ glands_NNS ][PP of_IN ][NP patients_NNS ][PP with_IN ][NP Sjogren_NN ][NP 's_POS syndrome_NN ] ._.
[NP c-myc_NN protooncogene_NN ][VP is_VBZ implicated_VBN ][PP in_IN ][NP the_DT pathogenesis_NN ][PP of_IN ][NP B_NN cell_NN lymphoid_JJ malignancies_NNS ] and_CC[NP high_JJ levels_NNS ][PP of_IN ][NP c-myc_NN mRNA_NN expression_NN ][VP are_VBP observed_VBN ][PP in_IN ][NP activated_VBN blood_NN mononuclear_JJ cells_NNS ] ._.
[NP Sjogren_NN ][NP 's_POS syndrome_NN ] (_([NP SS_NN ] )_)[VP is_VBZ characterized_VBN ][PP by_IN ][NP lymphocytic_JJ infiltrates_NNS ][PP of_IN ][NP exocrine_JJ glands_NNS ] ,_,[NP remarkable_JJ B_NN cell_NN hyperreactivity_NN ] and_CC[NP a_DT strong_JJ predisposition_NN ][PP to_TO ][NP B_NN cell_NN neoplasia_NN ] ._.
[PP In_IN ][NP this_DT study_NN ] ,_,[NP c-myc_NN protooncogene_NN mRNA_NN expression_NN ][PP in_IN ][NP 29_CD labial_JJ minor_JJ salivary_JJ gland_NN biopsies_NNS ][PP from_IN ][NP patients_NNS ][PP with_IN ][NP primary_JJ SS_NNS ] and_CC[NP 15_CD controls_NNS ][VP was_VBD examined_VBN ][VP using_VBG ][NP in_FW situ_FW hybridization_NN histochemistry_NN ] ._.
[NP Two_CD 40mer_JJ oligonucleotides_NNS ][PP from_IN ][NP the_DT 1st_JJ ] and_CC[NP the_DT 2nd_JJ ][NP exon_NN ][PP of_IN ][NP the_DT c-myc_NN gene_NN ] ,_,[VP labeled_VBN ][PP with_IN ][NP 35S_NN ] ,_,[VP were_VBD used_VBN ][PP as_IN ][NP probes_NNS ] ._.
[VP To_TO detect_VB ][NP the_DT origin_NN ][PP of_IN ][NP the_DT cell_NN ][VP hybridized_VBN ][PP with_IN ][NP a_DT c-myc_NN probe_NN ] ,_,[NP a_DT combined_JJ immunochemistry_NN in_FW situ_FW hybridization_NN histochemistry_NN technique_NN ][VP was_VBD used_VBN ] ._.
[NP High_JJ c-myc_NN mRNA_NN expression_NN ][VP was_VBD detected_VBN ][PP on_IN ][NP acinar_JJ epithelial_JJ cells_NNS ] ._.
[NP c-myc_NN ][VP did_VBD not_RB correlate_VB ][PP with_IN ][NP c-fos_NN ] and_CC[NP c-jun_NN ][NP protein_NN expression_NN ] ._.
[NP Stronger_JJR c-myc_NN mRNA_NN expression_NN ][VP was_VBD detected_VBN ][PP in_IN ][NP labial_JJ salivary_JJ glands_NNS ][PP of_IN ][NP patients_NNS ][PP with_IN ][NP longer_JJR disease_NN duration_NN ] (_([NP p_NN ][NP less_JJR than_IN or_CC equal_JJ to_TO 0.002_CD ] )_) and_CC[NP more_RBR intense_JJ T_NN lymphocyte_NN infiltrates_NNS ] (_([NP p_NN ][NP less_JJR than_IN 0.05_CD ] )_)[SBAR although_IN ][NP these_DT patients_NNS ][VP revealed_VBD ][NP no_DT hypergammaglobulinemia_NN ] ._.
[NP No_DT correlation_NN ][VP was_VBD observed_VBN ][PP between_IN ][NP c-myc_NN mRNA_NN ] and_CC[NP B_NN lymphocyte_NN ][NP monoclonicity_NN ] or_CC[NP lymphoma_NN ] ._.
[PP In_IN ][NP conclusion_NN ] ,_,[NP strong_JJ c-myc_NN mRNA_NN expression_NN ][VP was_VBD observed_VBN ][PP on_IN ][NP epithelial_JJ cells_NNS ][PP of_IN ][NP labial_JJ salivary_JJ glands_NNS ][PP from_IN ][NP patients_NNS ][PP with_IN ][NP primary_JJ SS_NN ] ._.
[NP Our_PRP$ findings_NNS ][VP may_MD indicate_VB ][NP the_DT presence_NN ][PP of_IN ][NP a_DT reactivated_VBN virus_NN ][VP hosted_VBN ][PP in_IN ][NP these_DT cells_NNS ] ._.
[NP Cytoplasmic_JJ domain_NN heterogeneity_NN ] and_CC[NP functions_NNS ][PP of_IN ][NP IgG_NN Fc_NN receptors_NNS ][PP in_IN ][NP B_NN lymphocytes_NNS ] ._.
[NP B_NN lymphocytes_NNS ] and_CC[NP macrophages_NNS ][VP express_VBP ][NP closely_RB related_JJ ][NP immunoglobulin_NN G_NN ] (_([NP IgG_NN ] )_)[NP Fc_NN receptors_NNS ] (_( Fc_NN gamma_NN RII_NN )_)[NP that_WDT ][VP differ_VBP ][ADVP only_RB in_IN ][NP the_DT structures_NNS ][PP of_IN ][NP their_PRP$ cytoplasmic_JJ domains_NNS ] ._.
[PP Because_IN of_IN ][NP cell_NN type-specific_JJ alternative_JJ messenger_NN RNA_NN splicing_NN ] ,_,[NP B-cell_NN Fc_NN gamma_NN RII_NN ][VP contains_VBZ ][NP an_DT insertion_NN ][PP of_IN ][NP 47_CD amino_NN acids_NNS ][NP that_WDT ][VP participates_VBZ ][PP in_IN ][VP determining_VBG ][NP receptor_NN function_NN ][PP in_IN ][NP these_DT cells_NNS ] ._.
[NP Transfection_NN ][PP of_IN ][NP an_DT Fc_NN gamma_NN RII-negative_JJ B-cell_NN line_NN ][PP with_IN ][NP complementary_JJ DNA_NN ][NP 's_POS ][VP encoding_VBG ][NP the_DT two_CD splice_NN products_NNS ] and_CC[NP various_JJ receptor_NN mutants_NNS ][VP indicated_VBD ][SBAR that_IN ][NP the_DT insertion_NN ][VP was_VBD ][ADJP responsible_JJ ][PP for_IN ][VP preventing_VBG ] both_CC[NP Fc_NN gamma_NN RII-mediated_JJ endocytosis_NN ] and_CC[NP Fc_NN gamma_NN RII-mediated_JJ antigen_NN presentation_NN ] ._.
[NP The_DT insertion_NN ][VP was_VBD not_RB required_VBN ][PP for_IN ][NP Fc_NN gamma_NN RII_NN ][VP to_TO modulate_VB ][NP surface_NN immunoglobulin-triggered_JJ B-cell_NN activation_NN ] ._.
[ADVP Instead_RB ] ,_,[NP regulation_NN ][PP of_IN ][NP activation_NN ][VP involved_VBD ][NP a_DT region_NN ][PP of_IN ][NP the_DT cytoplasmic_JJ domain_NN ][ADJP common_JJ ][PP to_TO ] both_CC the_DT[NP lymphocyte_NN ] and_CC[NP macrophage_NN ][NP receptor_NN isoforms_NNS ] ._.
[PP In_IN ][NP contrast_NN ] ,_,[NP the_DT insertion_NN ][VP did_VBD contribute_VB ][PP to_TO ][NP the_DT formation_NN ][PP of_IN ][NP caps_NNS ][PP in_IN response_NN to_TO ][NP receptor_NN cross-linking_NN ] ,_,[ADJP consistent_JJ ][PP with_IN ][NP suggestions_NNS ][SBAR that_IN ] the_DT[NP lymphocyte_NN ][CONJP but_CC not_RB ][NP macrophage_NN ][NP form_NN ][PP of_IN ][NP the_DT receptor_NN ][VP can_MD associate_VB ][PP with_IN ][NP the_DT detergent-insoluble_JJ cytoskeleton_NN ] ._.
[NP Every_DT enhancer_NN ][VP works_VBZ ][PP with_IN ][NP every_DT promoter_NN ][PP for_IN ][NP all_PDT the_DT combinations_NNS ][VP tested_VBN ] :_: could_MD[NP new_JJ regulatory_JJ pathways_NNS ][VP evolve_VBP ][PP by_IN ][NP enhancer_NN shuffling_NN ] ?_.
[NP The_DT ][NP promoters_NNS ] and_CC[NP enhancers_NNS ][PP of_IN ][NP cell_NN type-specific_JJ genes_NNS ][VP are_VBP often_RB conserved_VBN ][PP in_IN ][NP evolution_NN ] ,_, and_CC hence_RB[NP one_NN ][VP might_MD expect_VB ][SBAR that_IN ][NP a_DT given_JJ enhancer_NN ][VP has_VBZ evolved_VBN to_TO work_VB ][ADVP best_RBS ][PP with_IN ][NP its_PRP$ own_JJ promoter_NN ] ._.
[SBAR While_IN ][NP this_DT expectation_NN ][VP may_MD be_VB realized_VBN ][PP in_IN ][NP some_DT cases_NNS ] ,_,[NP we_PRP ][VP have_VBP not_RB found_VBN ][NP evidence_NN ][PP for_IN ][NP it_PRP ] ._.
[NP A_DT total_NN ][PP of_IN ][NP 27_CD combinations_NNS ][PP of_IN ][NP different_JJ ][NP promoters_NNS ] and_CC[NP enhancers_NNS ][VP were_VBD tested_VBN ][PP by_IN ][NP transfection_NN ][PP into_IN ][NP cultured_VBN cells_NNS ] ._.
[NP We_PRP ][VP found_VBD ][SBAR that_IN ][NP the_DT relative_JJ efficiency_NN ][PP of_IN ][NP the_DT enhancers_NNS ][VP is_VBZ ][ADVP approximately_RB ][NP the_DT same_JJ ] ,_,[ADJP irrespective_JJ ][PP of_IN ][NP the_DT type_NN ][PP of_IN ][NP promoter_NN ][VP used_VBN ] ,_, i.e._FW ,_,[NP there_EX ][VP was_VBD ][NP no_DT strong_JJ preference_NN ][PP for_IN ][NP any_DT given_JJ enhancer/promoter_JJ combination_NN ] ._.
[ADVP Notably_RB ] ,_,[NP we_PRP ][VP do_VBP not_RB see_VB ][NP particularly_RB strong_JJ transcription_NN ][ADVP when_WRB ][NP the_DT immunoglobulin_NN kappa_NN enhancer_NN ] (_( or_CC[NP the_DT immunoglobulin_NN heavy_JJ chain_NN enhancer_NN ] )_)[VP is_VBZ used_VBN ][VP to_TO activate_VB ][NP a_DT kappa_NN gene_NN promoter_NN ] ._.
[NP We_PRP ][VP propose_VBP ][SBAR that_IN ][NP a_DT generally_RB permissive_JJ enhancer/promoter_JJ interaction_NN ][VP is_VBZ ][PP of_IN ][NP evolutionary_JJ benefit_NN ][PP for_IN ][NP higher_JJR eukaryotes_NNS ] :_:[PP by_IN ][NP enhancer_NN shuffling_NN ] ,_,[NP genes_NNS ][VP could_MD be_VB easily_RB brought_VBN ][PP under_IN ][NP a_DT new_JJ type_NN ][PP of_IN ][NP inducibility/cell_NN type_NN specificity_NN ] ._.
[NP Heterodimerization_NN ] and_CC[NP transcriptional_JJ activation_NN ][ADVP in_FW vitro_FW ][PP by_IN ][NP NF-kappa_NN B_NN proteins_NNS ] ._.
[NP The_DT NF-kappa_NN B_NN family_NN ][PP of_IN ][NP transcription_NN proteins_NNS ][VP represents_VBZ ][NP multiple_JJ DNA_NN binding_NN ] ,_,[NP rel_NN ][NP related_JJ polypeptides_NNS ][NP that_WDT ][VP contribute_VBP ][PP to_TO ][NP regulation_NN ][PP of_IN ][NP genes_NNS ][VP involved_VBN ][PP in_IN ][NP immune_JJ responsiveness_NN ] and_CC[NP inflammation_NN ] ,_,[CONJP as_RB well_RB as_IN ][NP activation_NN ][PP of_IN ][NP the_DT HIV_NN long_JJ terminal_JJ repeat_NN ] ._.
[PP In_IN ][NP this_DT study_NN ] multiple_JJ[NP NF-kappa_NN B_NN ][NP related_JJ polypeptides_NNS ][VP ranging_VBG ][PP from_IN 85_CD to_TO ] 45_CD kDa_NN[VP were_VBD examined_VBN ][PP for_IN ][NP their_PRP$ capacity_NN ][VP to_TO interact_VB ][PP with_IN ][NP the_DT PRDII_NN regulatory_JJ element_NN ][PP of_IN ][NP interferon_NN beta_NN ] and_CC[VP were_VBD shown_VBN to_TO possess_VB ][NP distinct_JJ intrinsic_JJ DNA_NN binding_NN affinities_NNS ][PP for_IN ][NP this_DT NF-kappa_NN B_NN site_NN ] and_CC[VP form_VB ][NP multiple_JJ DNA_NN binding_NN homo-_JJ and_CC heterodimer_NN complexes_NNS ][PP in_IN ][NP co-renaturation_NN experiments_NNS ] ._.
[ADVP Furthermore_RB ] ,_,[VP using_VBG ][NP DNA_NN templates_NNS ][VP containing_VBG ][NP two_CD copies_NNS ][PP of_IN ][NP the_DT PRDII_NN domain_NN ][VP linked_VBN ][PP to_TO ][NP the_DT rabbit_NN beta_NN globin_NN gene_NN ] ,_,[NP the_DT purified_VBN polypeptides_NNS ][ADVP specifically_RB ][VP stimulated_VBD ][NP NF-kappa_NN B_NN ][NP dependent_JJ transcription_NN ][PP in_IN ][NP an_DT in_FW vitro_FW reconstitution_NN assay_NN ][PP as_IN ][NP heterodimers_NNS ][PP but_CC ][PP not_RB as_IN ][NP p50_NN homodimers_NNS ] ._.
[NP These_DT experiments_NNS ][VP emphasize_VBP ][NP the_DT role_NN ][PP of_IN ][NP NF-kappa_NN B_NN dimerization_NN ][PP as_IN ][NP a_DT distinct_JJ level_NN ][PP of_IN ][NP transcriptional_JJ control_NN ][NP that_WDT ][VP may_MD permit_VB ][NP functional_JJ diversification_NN ][PP of_IN ][NP a_DT limited_JJ number_NN ][PP of_IN ][NP regulatory_JJ proteins_NNS ] ._.
[NP Oct2_NN transactivation_NN ][PP from_IN ][NP a_DT remote_JJ enhancer_NN position_NN ][VP requires_VBZ ][NP a_DT B-cell-restricted_JJ activity_NN ] ._.
[NP Previous_JJ cotransfection_NN experiments_NNS ][VP had_VBD demonstrated_VBN ][SBAR that_IN ][NP ectopic_JJ expression_NN ][PP of_IN ][NP the_DT lymphocyte-specific_JJ transcription_NN factor_NN Oct2_NN ][VP could_MD efficiently_RB activate_VB ][NP a_DT promoter_NN ][VP containing_VBG ][NP an_DT octamer_NN motif_NN ] ._.
[NP Oct2_NN expression_NN ][VP was_VBD ][ADJP unable_JJ ][VP to_TO stimulate_VB ][NP a_DT multimerized_JJ octamer_NN enhancer_NN element_NN ][PP in_IN ][NP HeLa_NN cells_NNS ] ,_,[ADVP however_RB ] ._.
[NP We_PRP ][VP have_VBP tested_VBN ][NP a_DT variety_NN ][PP of_IN ][NP Oct2_NN isoforms_VBZ ][VP generated_VBN ][PP by_IN ][NP alternative_JJ splicing_NN ][PP for_IN ][NP the_DT capability_NN ][VP to_TO activate_VB ][NP an_DT octamer_NN enhancer_NN ][PP in_IN ][NP nonlymphoid_JJ cells_NNS ] and_CC[NP a_DT B-cell_NN line_NN ] ._.
[NP Our_PRP$ analyses_NNS ][VP show_VBP ][SBAR that_IN ][NP several_JJ Oct2_NN isoforms_NNS ][VP can_MD stimulate_VB ][PP from_IN ][NP a_DT remote_JJ position_NN ] but_CC[SBAR that_IN ][NP this_DT stimulation_NN ][VP is_VBZ restricted_JJ ][PP to_TO ][NP B_NN cells_NNS ] ._.
[NP This_DT result_NN ][VP indicates_VBZ ][NP the_DT involvement_NN ][PP of_IN ] either_CC[NP a_DT B-cell-specific_JJ cofactor_NN ] or_CC[NP a_DT specific_JJ modification_NN ][PP of_IN ][NP a_DT cofactor_NN ] or_CC[NP the_DT Oct2_NN protein_NN ][PP in_IN ][NP Oct2-mediated_JJ enhancer_NN activation_NN ] ._.
[NP Mutational_JJ analyses_NNS ][VP indicate_VBP ][SBAR that_IN ][NP the_DT carboxy-terminal_JJ domain_NN ][PP of_IN ][NP Oct2_NN ][VP is_VBZ ][ADJP critical_JJ ][PP for_IN ][NP enhancer_NN activation_NN ] ._.
[ADVP Moreover_RB ] ,_,[NP this_DT domain_NN ][VP conferred_VBD ][NP enhancing_NN activity_NN ] when_WRB[VP fused_VBN ][PP to_TO ][NP the_DT Oct1_NN protein_NN ] ,_,[NP which_WDT ][PP by_IN ][NP itself_PRP ][VP was_VBD ][ADJP unable_JJ ][VP to_TO stimulate_VB ][PP from_IN ][NP a_DT remote_JJ position_NN ] ._.
[NP The_DT glutamine-rich_JJ activation_NN domain_NN ][ADJP present_JJ ][PP in_IN ][NP the_DT amino-terminal_JJ portion_NN ][PP of_IN ][NP Oct2_NN ] and_CC[NP the_DT POU_NN domain_NN ][VP contribute_VBP ][ADVP only_RB marginally_RB ][PP to_TO ][NP the_DT transactivation_NN function_NN ][PP from_IN ][NP a_DT distal_JJ position_NN ] ._.
[NP Induction_NN ][PP of_IN ][NP the_DT POU_NN domain_NN transcription_NN factor_NN Oct-2_NN ][PP during_IN ][NP T-cell_NN activation_NN ][PP by_IN ][NP cognate_JJ antigen_NN ] ._.
[NP Oct-2_NN ][VP is_VBZ ][NP a_DT transcription_NN factor_NN ][NP that_WDT ][VP binds_VBZ ][PP specifically_RB to_TO ][NP octamer_NN DNA_NN motifs_NNS ][PP in_IN ][NP the_DT promoters_NNS ][PP of_IN ][NP immunoglobulin_NN ] and_CC[NP interleukin-2_NN ][NP genes_NNS ] ._.
[NP All_DT tumor_NN cell_NN lines_NNS ][PP from_IN ][NP the_DT B-cell_NN lineage_NN ] and_CC[NP a_DT few_JJ ][PP from_IN ][NP the_DT T-cell_NN lineage_NN ][VP express_VBP ][NP Oct-2_NN ] ._.
[VP To_TO address_VB ][NP the_DT role_NN ][PP of_IN ][NP Oct-2_NN ][PP in_IN ][NP the_DT T-cell_NN lineage_NN ] ,_,[NP we_PRP ][VP studied_VBD ][NP the_DT expression_NN ][PP of_IN ][NP Oct-2_NN mRNA_NN ] and_CC[NP protein_NN ][PP in_IN ] nontransformed_JJ human_JJ and_CC[NP mouse_NN ][NP T_NN cells_NNS ] ._.
[NP Oct-2_NN ][VP was_VBD found_VBN ][PP in_IN ][NP CD4+_JJ and_CC CD8+_JJ T_NN cells_NNS ][VP prepared_VBN ][PP from_IN ][NP human_JJ peripheral_JJ blood_NN ][PP and_CC ][PP in_IN ][NP mouse_NN lymph_NN node_NN T_NN cells_NNS ] ._.
[PP In_IN ][NP a_DT T-cell_NN clone_NN ][ADJP specific_JJ ][PP for_IN ][NP pigeon_NN cytochrome_NN c_NN ][PP in_IN the_DT context_NN of_IN ][NP I-Ek_NN ] ,_,[NP Oct-2_NN ][VP was_VBD induced_VBN ][PP by_IN ][NP antigen_NN stimulation_NN ] ,_,[SBAR with_IN ][NP the_DT increase_NN ][PP in_IN ][NP Oct-2_NN protein_NN ][VP seen_VBN ][ADVP first_RB ][PP at_IN ][NP 3_CD h_NN ][PP after_IN ][NP activation_NN ] and_CC[VP continuing_VBG ][PP for_IN ][NP at_IN least_JJS 24_CD h_NN ] ._.
[NP Oct-2_NN mRNA_NN induction_NN ][PP during_IN ][NP antigen-driven_JJ T-cell_NN activation_NN ][VP was_VBD blocked_VBN ][PP by_IN ][NP cyclosporin_NN A_NN ] ,_,[CONJP as_RB well_RB as_IN ][PP by_IN ][NP protein_NN synthesis_NN inhibitors_NNS ] ._.
[NP These_DT results_NNS ][VP suggest_VBP ][SBAR that_IN ][NP Oct-2_NN ][VP participates_VBZ ][PP in_IN ][NP transcriptional_JJ regulation_NN ][PP during_IN ][NP T-cell_NN activation_NN ] ._.[NP The_DT relatively_RB delayed_VBN kinetics_NNS ][PP of_IN ][NP Oct-2_NN induction_NN ][VP suggests_VBZ ][SBAR that_IN ][NP Oct-2_NN ][VP mediates_VBZ ][NP the_DT changes_NNS ][PP in_IN ][NP gene_NN expression_NN ][NP which_WDT ][VP occur_VBP ][NP many_JJ ][NP hours_NNS ] or_CC[NP days_NNS ][PP following_VBG ][NP antigen_NN stimulation_NN ][PP of_IN ][NP T_NN lymphocytes_NNS ] ._.
 (_([NP Changes_NNS ][PP in_IN ][NP plasma_NN interleukin-1_NN ] and_CC[NP their_PRP$ possible_JJ relationship_NN ][PP with_IN ][NP the_DT changes_NNS ][PP in_IN ][NP glucocorticoid_NN receptor_NN ][PP in_IN ][NP aged_JJ long-distance_JJ runner_NN ] )_)
[PP For_IN ][NP the_DT study_NN ][PP of_IN ][NP the_DT changes_NNS ][PP in_IN ][NP plasma_NN ][NP interleukin-1_NN ] (_([NP IL-1_NN ] )_) and_CC[NP their_PRP$ possible_JJ relationship_NN ][PP with_IN ][NP the_DT changes_NNS ][PP in_IN ][NP glucocorticoid_NN receptor_NN ] (_([NP GR_NN ] )_) ,_,[NP plasma_NN IL-1_NN ] and_CC[NP GR_NN ][PP in_IN ][NP peripheral_JJ blood_NN leukocytes_NNS ][PP in_IN ][NP aged_JJ long-distance_JJ runner_NN ][VP were_VBD measured_VBN ][ADVP simultaneously_RB ] ._.
[NP The_DT activity_NN ][PP of_IN ][NP IL-1_NN ][VP was_VBD expressed_VBN ][PP as_IN ][NP its_PRP$ ability_NN ][VP to_TO stimulate_VB ][NP 3H-TdR_NN incorporation_NN ][PP in_IN ][NP the_DT thymocytes_NNS ][PP of_IN ][NP C57_NN mice_NNS ] ._.
[NP GR_NN ][VP was_VBD determined_VBN ][PP by_IN ][NP whole_JJ cell_NN assay_NN ][PP with_IN ][NP 3H-Dex_NN ] ._.
[NP The_DT results_NNS ][VP showed_VBD ][SBAR that_IN ][NP the_DT activity_NN ][PP of_IN ][NP plasma_NN IL-1_NN ][PP in_IN ][NP aged_JJ long-distance_JJ runner_NN ][VP was_VBD ][NP 209_CD %_NN ] ,_,[NP 223_CD %_NN ] and_CC[NP 145_CD %_NN ][PP of_IN ][NP the_DT control_NN ][PP at_IN ][NP 14.7-18.7_CD ,_, 3.8-7.0_CD and_CC 1.5-2.6_CD KD_NN ][NP fractions_NNS ] ._.
[NP The_DT GR_NN ][PP in_IN ][NP peripheral_JJ blood_NN leukocytes_NNS ][PP in_IN ][NP aged_JJ runner_NN ][VP was_VBD ][NP 65_CD %_NN ][PP of_IN ][NP the_DT control_NN ] ._.
[NP Possible_JJ relationship_NN ][PP between_IN ][NP the_DT changes_NNS ][PP in_IN ][NP IL-1_NN ] and_CC[NP GR_NN ] in_NN[NP aged_JJ long-distance_JJ runner_NN ] and_CC[NP its_PRP$ physiological_JJ significance_NN ][VP are_VBP discussed_VBN ] ._.
[NP Transcription_NN factor_NN AP-2_NN ][VP activates_VBZ ][NP gene_NN expression_NN ][PP of_IN ][NP HTLV-I_NN ] ._.
[NP The_DT HTLV-I_NN LTR_NN ][VP contains_VBZ ][NP three_CD conserved_VBN regulatory_JJ elements_NNS ][VP known_VBN ][PP as_IN ][NP 21_CD base_NN pair_NN repeats_NNS ][NP which_WDT ][VP are_VBP required_VBN ][PP for_IN ][NP stimulation_NN ][PP of_IN ][NP gene_NN expression_NN ][PP by_IN ][NP the_DT transactivator_NN protein_NN tax_NN ] ._.
[NP Mutagenesis_NN ][VP indicates_VBZ ][SBAR that_IN ][NP the_DT 21_CD bp_NN repeats_NNS ][VP can_MD be_VB subdivided_VBN ][PP into_IN ][NP three_CD motifs_NNS ] ,_,[NP A_NN ] ,_,[NP B_NN ] and_CC[NP C_NN ] ,_,[NP each_DT ][PP of_IN ][NP which_WDT ][VP influences_VBZ ][NP the_DT level_NN ][PP of_IN ][NP tax_NN activation_NN ] ._.
[NP The_DT A_NN site_NN ][PP in_IN ][NP the_DT 21_CD bp_NN repeat_NN ][VP has_VBZ ][NP strong_JJ homology_NN ][PP with_IN ][NP previously_RB described_VBN binding_VBG sites_NNS ][PP for_IN ][NP the_DT transcription_NN factor_NN AP-2_NN ] ._.
[NP We_PRP ][VP demonstrated_VBD ][SBAR that_IN ][NP AP-2_NN mRNA_NN ][VP was_VBD ][ADJP present_JJ ][PP in_IN ][NP T-lymphocytes_NNS ] and_CC[SBAR that_IN ][NP cellular_JJ factors_NNS ][PP from_IN ][NP both_CC non-transformed_JJ and_CC transformed_VBN T-lymphocytes_NNS ][ADVP specifically_RB ][VP bound_VBD ][PP to_TO ][NP the_DT consensus_NN motif_NN ][PP for_IN ][NP AP-2_NN ][PP in_IN ][NP each_DT 21_CD bp_NN ] ._.
[VP To_TO determine_VB ][NP the_DT role_NN ][PP of_IN ][NP AP-2_NN ][PP in_IN ][NP the_DT regulation_NN ][PP of_IN ][NP the_DT HTLV-I_NN LTR_NN gene_NN expression_NN ] ,_,[NP we_PRP ][VP used_VBD ][NP an_DT AP-2_NN cDNA_NN ][PP in_IN ][NP DNA_NN binding_NN ] and_CC[NP transient_JJ expression_NN ][NP assays_NNS ] ._.
[NP Gel_NN retardation_NN ] and_CC[NP methylation_NN interference_NN ][NP studies_NNS ][VP revealed_VBD ][SBAR that_IN ][NP bacterially_RB produced_VBN AP-2_NN ][VP bound_VBD ][ADVP specifically_RB ] and_CC[PP with_IN ][NP high_JJ affinity_NN ][PP to_TO ][NP all_DT three_CD 21_CD bp_NN repeats_NNS ] ,_, and_CC[SBAR that_IN ][NP it_PRP ][VP required_VBD ][NP the_DT core_NN sequence_NN AGGC_NN ][PP for_IN ][NP specific_JJ binding_NN ] ._.
[NP Binding_NN ][PP of_IN ][NP AP-2_NN ][VP prevented_VBD ][NP the_DT subsequent_JJ binding_NN ][PP of_IN ][NP members_NNS ][PP of_IN ][NP the_DT CREB/ATF_NN family_NN ][PP to_TO ][NP an_DT adjacent_JJ regulatory_JJ motif_NN ][PP in_IN ][NP the_DT 21_CD bp_NN repeat_NN ] ._.
[NP Transfection_NN ][PP of_IN ][NP an_DT AP-2_NN expression_NN construct_NN ][PP into_IN ][NP T-lymphocytes_NNS ][VP activated_VBD ][NP gene_NN expression_NN ][PP from_IN ][NP the_DT HTLV-I_NN LTR_NN ] ._.
[NP At_IN least_JJS two_CD 21_CD bp_NN repeats_NNS ][VP were_VBD required_VBN ][PP for_IN ][NP high_JJ levels_NNS ][PP of_IN ][NP AP-2_NN activation_NN ] and_CC[NP mutagenesis_NN ][PP of_IN ][NP the_DT AP-2_NN consensus_NN binding_NN sequences_NNS ][PP in_IN ][NP the_DT 21_CD bp_NN repeats_NNS ][VP eliminate_VBP ][NP this_DT activation_NN ] ._.
 (_([NP ABSTRACT_NN ][VP TRUNCATED_VBN ][PP AT_IN ][NP 250_CD WORDS_NNS ] )_)
[NP Cell_NN cycle-dependent_JJ initiation_NN ] and_CC[NP lineage-dependent_JJ abrogation_NN ][PP of_IN ][NP GATA-1_NN expression_NN ][PP in_IN ][NP pure_JJ differentiating_VBG hematopoietic_JJ progenitors_NNS ] ._.
[NP The_DT programmed_VBN activation/repression_NN ][PP of_IN ][NP transcription_NN factors_NNS ][PP in_IN ][NP early_JJ hematopoietic_JJ differentiation_NN ][VP has_VBZ not_RB yet_RB been_VBN explored_VBN ] ._.
[NP The_DT DNA-binding_JJ protein_NN GATA-1_NN ][VP is_VBZ required_VBN ][PP for_IN ][NP normal_JJ erythroid_JJ development_NN ] and_CC[VP regulates_VBZ ][NP erythroid-expressed_JJ genes_NNS ][PP in_IN ][NP maturing_VBG erythroblasts_NNS ] ._.
[NP We_PRP ][VP analyzed_VBD ][NP GATA-1_NN expression_NN ][PP in_IN ][NP early_JJ human_JJ adult_JJ hematopoiesis_NN ][PP by_IN ][VP using_VBG ][NP an_DT in_FW vitro_FW system_NN ][PP in_IN ][NP which_WDT ][NP "_[[DQS]] pure_JJ "_[[DQE]] early_JJ hematopoietic_JJ progenitors_NNS ][VP are_VBP induced_VBN ][PP to_TO ][NP gradual_JJ and_CC synchronized_VBD differentiation_NN ][ADVP selectively_RB ][PP along_IN ][NP the_DT erythroid_JJ or_CC granulocyte-macrophage_JJ pathway_NN ][PP by_IN ][NP differential_JJ treatment_NN ][PP with_IN ][NP hematopoietic_JJ growth_NN factors_NNS ] ._.
[NP The_DT GATA-1_NN gene_NN ] ,_,[SBAR though_IN ][ADJP virtually_RB silent_JJ ][PP in_IN ][NP quiescent_JJ progenitors_NNS ] ,_,[VP is_VBZ activated_VBN ][PP after_IN ][NP entrance_NN ][PP into_IN ][NP the_DT cell_NN cycle_NN ][PP upon_IN ][NP stimulation_NN ][PP with_IN ][NP hematopoietic_JJ growth_NN factors_NNS ] ._.
[ADVP Subsequently_RB ] ,_,[NP increasing_VBG expression_NN ][PP along_IN ][NP the_DT erythroid_JJ pathway_NN ][VP contrasts_VBZ ][PP with_IN ][NP an_DT abrupt_JJ downregulation_NN ][PP in_IN ][NP the_DT granulocyte-macrophage_JJ lineage_NN ] ._.
[NP These_DT results_NNS ][VP suggest_VBP ][NP a_DT microenvironment-directed_JJ ,_, two-step_JJ model_NN ][PP for_IN ][NP GATA-1_NN expression_NN ][PP in_IN ][NP differentiating_VBG hematopoietic_JJ progenitors_NNS ][NP that_WDT ][VP involves_VBZ ][LST (_( i_LS ] )_)[NP cycle-dependent_JJ initiation_NN ] and_CC[LST (_( ii_LS ] )_)[NP lineage-dependent_JJ ][NP maintenance_NN ] or_CC[NP suppression_NN ] ._.
[ADVP Hypothetically_RB ] ,_,[NP on/off_JJ switches_NNS ][PP of_IN ][NP lineage-restricted_JJ transactivators_NNS ][VP may_MD underlie_VB ][NP the_DT binary_JJ fate_NN decisions_NNS ][PP of_IN ][NP hematopoietic_JJ progenitors_NNS ] ._.
 (_([NP Age-related_JJ changes_NNS ][PP in_IN ][NP glucocorticoid_NN ] and_CC[NP mineralocorticoid_NN ][NP receptors_NNS ][PP in_IN ][NP lymphocytes_NNS ][PP of_IN ][NP healthy_JJ persons_NNS ] and_CC[NP patients_NNS ][PP with_IN ][NP hypertension_NN ] )_)
[NP It_PRP ][VP has_VBZ been_VBN found_VBN ][SBAR that_IN ][NP the_DT number_NN ][PP of_IN ][NP glucocorticoid_NN receptors_NNS ][PP in_IN ][NP lymphocytes_NNS ][PP of_IN ][NP the_DT peripheral_JJ blood_NN ][PP of_IN ][NP healthy_JJ elderly_JJ subjects_NNS ][VP increases_VBZ ] ,_,[SBAR while_IN ][NP the_DT number_NN ][PP of_IN ][NP mineralocorticoid_NN receptors_NNS ][VP decreases_VBZ ] ._.
[NP The_DT mechanisms_NNS ][PP of_IN ][NP hormone-receptor_NN interactions_NNS ][PP in_IN ][NP hypertension_NN ][VP are_VBP activated_VBN ] :_:[NP the_DT number_NN ][PP of_IN ][NP glucocorticoid_NN ] and_CC[NP mineralocorticoid_NN ][NP binding_NN sites_NNS ][VP grows_VBZ ][PP in_IN ][NP hypertensive_JJ patients_NNS ] ._.
[ADVP Still_RB ][NP a_DT more_RBR essential_JJ rise_NN ][PP in_IN ][NP the_DT number_NN ][PP of_IN ][NP receptors_NNS ][VP is_VBZ observed_VBN ][PP in_IN ][NP mid-age_JJ hypertensive_NN patients_NNS ][PP than_IN ][PP in_IN ][NP elderly_JJ ones_NNS ] ._.
[NP In_FW vivo_FW footprint_NN analysis_NN ][PP of_IN ][NP the_DT HLA-DRA_NN gene_NN promoter_NN ] :_:[NP cell-specific_JJ interaction_NN ][PP at_IN ][NP the_DT octamer_NN site_NN ] and_CC[NP up-regulation_NN ][PP of_IN ][NP X_NN box_NN binding_NN ][PP by_IN ][NP interferon_NN gamma_NN ] ._.
[NP Analysis_NN ][PP of_IN ][NP the_DT major_JJ histocompatibility_NN complex_NN class_NN II_CD gene_NN promoter_NN DRA_NN ][VP has_VBZ previously_RB identified_VBN ][NP at_IN least_JJS five_CD cis-acting_JJ regions_NNS ][VP required_VBN ][PP for_IN ][NP maximal_JJ expression_NN ] ._.
[NP We_PRP ][VP have_VBP examined_VBN ][NP the_DT DRA_NN promoter_NN ][PP for_IN ][NP protein-DNA_JJ interactions_NNS ][PP in_IN ][NP the_DT intact_JJ cell_NN ] ,_,[NP which_WDT ][VP may_MD mediate_VB ][NP transcriptional_JJ activation_NN ] ._.
[VP Using_VBG ][NP in_FW vivo_FW genomic_JJ footprinting_NN ][NP we_PRP ][VP identified_VBD ][NP interactions_NNS ][PP in_IN ][NP B-cell_NN lines_NNS ][PP at_IN ][NP the_DT octamer_NN site_NN ] and_CC the_DT[NP Y_NN ] ,_,[NP X1_NN ] ,_, and_CC[NP X2_NN ][NP boxes_NNS ] ._.
[NP Class_NN II_CD antigen_NN expressing_VBG T-cell_NN lines_NNS ][VP maintained_VBD ][NP contacts_NNS ][ADJP identical_JJ ][PP to_TO ][NP B-cell_NN lines_NNS ] ,_,[SBAR while_IN ][NP class_NN II-negative_JJ T-cell_NN lines_NNS ][VP exhibited_VBD ][NP no_DT interactions_NNS ] ._.
[PP In_IN ][NP lymphoid_JJ cell_NN lines_NNS ] ,_,[NP the_DT octamer_NN site_NN ][VP is_VBZ occupied_VBN ] and_CC[VP required_VBN ][PP for_IN ][NP maximal_JJ expression_NN ] ._.
[NP This_DT ][VP is_VBZ ][ADVP most_RBS likely_RB ][PP due_JJ to_TO ][NP the_DT presence_NN ][PP of_IN ][NP the_DT lymphoid-specific_JJ OTF-2_NN factor_NN ] ._.
[PP In_IN ][NP contrast_NN ] ,_,[NP the_DT class_NN II-positive_JJ nonlymphoid_JJ glioblastoma_NN cell_NN line_NN ][VP does_VBZ not_RB exhibit_VB ][NP interactions_NNS ][PP at_IN ][NP the_DT octamer_NN site_NN ][PP despite_IN ][NP the_DT presence_NN ][PP of_IN ][NP the_DT ubiquitous_JJ OTF-1_NN factor_NN ] and_CC[NP an_DT open_JJ binding_VBG site_NN ] ._.
[ADVP Thus_RB ] ,_,[NP the_DT DRA_NN promoter_NN ][VP discriminates_VBZ ][PP against_IN ][NP OTF-1_NN activation_NN ][PP at_IN ][NP the_DT level_NN ][PP of_IN ][NP DNA_NN binding_NN ][PP in_IN ][NP the_DT glioblastoma_NN line_NN ] ._.
[NP Interferon_NN gamma_NN ][VP induces_VBZ ][NP class_NN II_CD expression_NN ][PP in_IN ][NP this_DT glioblastoma_NN cell_NN line_NN ] and_CC ,_,[PP in_IN ][NP parallel_NN ][VP ,_, up-regulates_VBZ ][NP X1_NN ] and_CC[NP X2_NN ][NP box_NN protein-DNA_JJ interactions_NNS ] ,_,[SBAR while_IN ][NP all_DT other_JJ interactions_NNS ][VP remain_VBP ][ADJP unchanged_JJ ] ._.
[NP These_DT results_NNS ][VP suggest_VBP ][SBAR that_IN ][NP interferon_NN gamma_NN ][VP functions_VBZ ][PP on_IN ][NP a_DT poised_VBN promoter_NN ][PP by_IN ][VP altering_VBG ][NP weak_JJ ,_, nonproductive_JJ interactions_NNS ][PP at_IN ][NP the_DT X_NN boxes_NNS ][PP to_TO ][NP strong_JJ interactions_NNS ] ._.
[NP These_DT findings_NNS ][VP provide_VBP ][NP direct_JJ in_FW vivo_FW evidence_NN ][VP to_TO strongly_RB suggest_VB ][SBAR that_IN ][NP the_DT modulation_NN ][PP of_IN ][NP X1_NN ] and_CC[NP X2_NN ][NP interactions_NNS ][VP is_VBZ ][NP an_DT important_JJ constituent_NN ][PP of_IN ][NP the_DT interferon_NN gamma_NN induction_NN pathway_NN ] ._.
[NP Simple_JJ derivation_NN ][PP of_IN ][NP TFIID-dependent_JJ RNA_NN polymerase_NN II_CD transcription_NN systems_NNS ][PP from_IN ][NP Schizosaccharomyces_FW pombe_FW ] and_CC[NP other_JJ organisms_NNS ] ,_, and_CC[NP factors_NNS ][VP required_VBN ][PP for_IN ][NP transcriptional_JJ activation_NN ] ._.
[NP Resolution_NN ][PP of_IN ][NP whole_JJ cell_NN extract_NN ][PP through_IN ][NP two_CD chromatographic_JJ steps_NNS ][VP yields_VBZ ][NP a_DT single_JJ protein_NN fraction_NN ][VP requiring_VBG ][NP only_RB the_DT addition_NN ][PP of_IN ][NP TFIID_NN ][PP for_IN ][NP the_DT initiation_NN ][PP of_IN ][NP transcription_NN ][PP at_IN ][NP RNA_NN polymerase_NN II_CD promoters_NNS ] ._.
[NP This_DT approach_NN ][VP allows_VBZ ][NP the_DT convenient_JJ generation_NN ][PP of_IN ][NP RNA_NN polymerase_NN II_CD transcription_NN systems_NNS ][PP from_IN ][NP Saccharomyces_FW cerevisiae_FW ] ,_,[NP human_JJ lymphocytes_NNS ] ,_, and_CC[NP Schizosaccharomyces_FW pombe_FW ] ._.
[NP TFIIDs_NNS ][PP from_IN ][NP all_DT three_CD organisms_NNS ][VP are_VBP ][ADJP interchangeable_JJ ][PP among_IN ][NP all_DT three_CD systems_NNS ] ._.
 The_DT[NP S._FW cerevisiae_FW ] and_CC[NP Sch._FW pombe_FW ][NP systems_NNS ][VP support_VBP ][NP effects_NNS ][PP of_IN ][NP acidic_JJ activator_NN proteins_NNS ] ,_,[PP provided_VBN ][NP a_DT further_JJ protein_NN fraction_NN ][PP from_IN ][NP S._FW cerevisiae_FW ][VP is_VBZ supplied_VBN ] ._.
[NP This_DT further_JJ fraction_NN ][VP is_VBZ ][ADJP distinct_JJ ][PP from_IN ][NP the_DT mediator_NN ][PP of_IN ][NP transcriptional_JJ activation_NN ][VP described_VBN ][ADVP previously_RB ] and_CC[VP represents_VBZ ][NP a_DT second_JJ component_NN ][PP in_IN addition_NN to_TO ][NP general_JJ initiation_NN factors_NNS ][NP that_WDT ][VP may_MD facilitate_VB ][NP a_DT response_NN ][PP to_TO ][NP acidic_JJ activators_NNS ] ._.
[NP NF-kappa_NN B-dependent_JJ induction_NN ][PP of_IN ][NP the_DT NF-kappa_NN B_NN p50_NN subunit_NN gene_NN promoter_NN ][VP underlies_VBZ ][NP self-perpetuation_NN ][PP of_IN ][NP human_JJ immunodeficiency_NN virus_NN transcription_NN ][PP in_IN ][NP monocytic_JJ cells_NNS ] ._.
[NP The_DT molecular_JJ mechanisms_NNS ][VP underlying_VBG ][NP the_DT sustained_JJ nuclear_JJ translocation_NN ][PP of_IN ][NP NF-kappa_NN B_NN ][VP observed_VBN ][PP in_IN ][NP U937_NN monocytic_JJ cells_NNS ][VP chronically_RB infected_VBN ][PP with_IN ][NP human_JJ immunodeficiency_NN virus_NN ] (_([NP HIV_NN ] )_)[VP were_VBD studied_VBN ] ._.
[NP The_DT activity_NN ][PP of_IN ][NP the_DT promoter_NN ][VP regulating_VBG ][NP the_DT synthesis_NN ][PP of_IN ][NP the_DT p105_NN precursor_NN ][PP of_IN ][NP the_DT NF-kappa_NN B_NN p50_NN subunit_NN ][VP was_VBD enhanced_VBN ][PP in_IN ][NP these_DT cells_NNS ] ._.
[NP Deletions_NNS ][PP in_IN ][NP this_DT promoter_NN ][VP indicated_VBD ][SBAR that_IN ][NP this_DT upregulation_NN ][VP was_VBD mediated_VBN ][PP through_IN ][NP the_DT ][NP NF-kappa_NN B-_NN ][CONJP but_CC not_RB ][NP the_DT AP-1-binding_JJ ][NP motif_NN ] ,_,[PP by_IN ][NP bona_FW fide_FW p50/p65_NN heterodimers_NNS ] ._.
[NP Analysis_NN ][PP of_IN ][NP cytosolic_JJ extracts_NNS ][VP indicated_VBD ][SBAR that_IN ][NP NF-kappa_NN B_NN levels_NNS ][VP were_VBD increased_VBN ][PP in_IN ][NP HIV-infected_JJ cells_NNS ] ._.
[PP In_IN contrast_NN to_TO ][NP the_DT transient_JJ NF-kappa_NN B_NN activation_NN ][VP induced_VBN ][PP by_IN ][NP phorbol_NN ester_NN ] ,_,[NP the_DT permanent_JJ NF-kappa_NN B_NN translocation_NN ][VP induced_VBN ][PP by_IN ][NP HIV_NN infection_NN ][VP was_VBD ] not_RB[ADJP dependent_JJ ][PP on_IN ][NP PKC_NN isoenzymes_NNS ][NP alpha_NN ] and_CC[NP beta_NN ][SBAR as_IN ][VP shown_VBN ][PP by_IN ][NP the_DT use_NN ][PP of_IN ][NP a_DT specific_JJ inhibitor_NN ] (_([NP GF_NN 109203X_NN ] )_) ._.
[NP These_DT observations_NNS ][VP indicate_VBP ][SBAR that_IN ][PP during_IN ][NP chronic_JJ HIV_NN infection_NN ][PP of_IN ][NP U937_NN cells_NNS ] ,_, continuous_JJ NF-kappa_NN B_NN (_([NP p50/p65_NN ] )_)[NP translocation_NN ][VP results_VBZ ][PP in_IN ][NP p105_NN promoter_NN upregulation_NN ][PP with_IN ][NP subsequent_JJ cytosolic_JJ NF-kappa_NN B_NN accumulation_NN ] ,_,[ADJP ready_JJ ][PP for_IN ][NP further_JJ translocation_NN ] ._.
[NP This_DT HIV-mediated_JJ mechanism_NN ][VP results_VBZ ][PP in_IN ][NP a_DT self-perpetuating_JJ loop_NN ][PP of_IN ][NP NF-kappa_NN B_NN production_NN ] ._.
[NP The_DT development_NN ][PP of_IN ][NP functionally_RB responsive_JJ T_NN cells_NNS ] ._.
[NP The_DT work_NN ][VP reviewed_VBN ][PP in_IN ][NP this_DT article_NN ][VP separates_VBZ ][NP T_NN cell_NN development_NN ][PP into_IN ][NP four_CD phases_NNS ] ._.
[ADJP First_JJ ][VP is_VBZ ][NP an_DT expansion_NN phase_NN ][PP prior_RB to_TO ][NP TCR_NN rearrangement_NN ] ,_,[NP which_WDT ][VP appears_VBZ to_TO be_VB correlated_VBN ][PP with_IN ][NP programming_NN ][PP of_IN ][NP at_IN least_JJS some_DT response_NN genes_NNS ][PP for_IN ][NP inducibility_NN ] ._.
[NP This_DT phase_NN ][VP can_MD occur_VB ][PP to_TO ][NP some_DT extent_NN ][ADVP outside_IN ][PP of_IN ][NP the_DT thymus_NN ] ._.
[ADVP However_RB ] ,_,[NP the_DT profound_JJ T_NN cell_NN deficit_NN ][PP of_IN ][NP nude_JJ mice_NNS ][VP indicates_VBZ ][SBAR that_IN ][NP the_DT thymus_NN ][VP is_VBZ ][PP by_IN ][ADVP far_RB ][NP the_DT most_RBS potent_JJ site_NN ][PP for_IN ][VP inducing_VBG ][NP the_DT expansion_NN ][ADVP per_FW se_FW ] ,_,[SBAR even_RB if_IN ][NP other_JJ sites_NNS ][VP can_MD induce_VB ][NP some_DT response_NN acquisition_NN ] ._.
[ADJP Second_JJ ][VP is_VBZ ][NP a_DT controlled_JJ phase_NN ][PP of_IN ][NP TCR_NN gene_NN rearrangement_NN ] ._.
[NP The_DT details_NNS ][PP of_IN ][NP the_DT regulatory_JJ mechanism_NN ][NP that_WDT ][VP selects_VBZ ][NP particular_JJ loci_NNS ][PP for_IN ][NP rearrangement_NN ][VP are_VBP still_RB not_RB known_VBN ] ._.
[NP It_PRP ][VP seems_VBZ ][SBAR that_IN ][NP the_DT rearrangement_NN ][PP of_IN ][NP the_DT TCR_NN gamma_NN loci_NNS ][PP in_IN ][NP the_DT gamma_NN delta_NN lineage_NN ][VP may_MD not_RB always_RB take_VB ][NP place_NN ][PP at_IN ][NP a_DT developmental_JJ stage_NN ][ADJP strictly_RB equivalent_JJ ][PP to_TO ][NP the_DT rearrangement_NN ][PP of_IN ][NP TCR_NN beta_NN ][PP in_IN ][NP the_DT alpha_NN beta_NN lineage_NN ] ,_, and_CC[NP it_PRP ][VP is_VBZ ] not_RB[ADJP clear_JJ ][ADVP just_RB how_WRB early_RB ][NP the_DT two_CD lineages_NNS ][VP diverge_VBP ] ._.
[PP In_IN ][NP the_DT TCR_NN alpha_NN beta_NN lineage_NN ] ,_,[ADVP however_RB ] ,_,[NP the_DT final_JJ gene_NN rearrangement_NN events_NNS ][VP are_VBP accompanied_VBN ][PP by_IN ][NP rapid_JJ proliferation_NN ] and_CC[NP an_DT interruption_NN ][PP in_IN ][NP cellular_JJ response_NN gene_NN inducibility_NN ] ._.
[NP The_DT loss_NN ][PP of_IN ][NP conventional_JJ responsiveness_NN ][VP is_VBZ probably_RB caused_VBN ][PP by_IN ][NP alterations_NNS ][PP at_IN ][NP the_DT level_NN ][PP of_IN ][NP signaling_NN ] ,_, and_CC[VP may_MD be_VB ][NP a_DT manifestation_NN ][PP of_IN ][NP the_DT physiological_JJ state_NN ][NP that_WDT ][VP is_VBZ ][NP a_DT precondition_NN ][PP for_IN ][NP selection_NN ] ._.
[ADJP Third_JJ ][VP is_VBZ ][NP the_DT complex_JJ process_NN ][PP of_IN ][NP selection_NN ] ._.
[SBAR Whereas_IN ][NP peripheral_JJ T_NN cells_NNS ][VP can_MD undergo_VB ][NP forms_NNS ][PP of_IN ][NP positive_JJ selection_NN ] (_([PP by_IN ][NP antigen-driven_JJ clonal_JJ expansion_NN ] )_) and_CC[NP negative_JJ selection_NN ] (_([PP by_IN ][NP abortive_JJ stimulation_NN ][VP leading_VBG ][PP to_TO ][NP anergy_NN ] or_CC[NP death_NN ] )_) ,_,[NP neither_DT ][VP is_VBZ ][NP exactly_RB the_DT same_JJ phenomenon_NN ][NP that_WDT ][VP occurs_VBZ ][PP in_IN ][NP the_DT thymic_JJ cortex_NN ] ._.
[NP Negative_JJ selection_NN ][PP in_IN ][NP the_DT cortex_NN ][VP appears_VBZ to_TO be_VB ][NP a_DT suicidal_JJ inversion_NN ][PP of_IN ][NP antigen_NN responsiveness_NN ] :_:[PP instead_RB of_IN ][VP turning_VBG ][PRT on_IN ][NP IL-2_NN expression_NN ] ,_,[NP the_DT activated_VBN cell_NN ][VP destroys_VBZ ][NP its_PRP$ own_JJ chromatin_NN ] ._.
[NP The_DT genes_NNS ][NP that_WDT ][VP need_VBP to_TO be_VB induced_VBN ][PP for_IN ][NP this_DT response_NN ][VP are_VBP not_RB yet_RB identified_VBN ] ,_, but_CC[NP it_PRP ][VP is_VBZ ][ADVP unquestionably_RB ][NP a_DT form_NN ][PP of_IN ][NP activation_NN ] ._.
[NP It_PRP ][VP is_VBZ ][ADJP interesting_JJ ][SBAR that_IN ][PP in_IN ][NP humans_NNS ] and_CC[NP rats_NNS ] ,_,[NP cortical_JJ thymocytes_NNS ][VP undergoing_VBG ][NP negative_JJ selection_NN ][VP can_MD still_RB induce_VB ][NP IL-2R_NN alpha_NN expression_NN ] and_CC[VP even_RB be_VB rescued_VBN ][ADVP in_FW vitro_FW ] ,_,[SBAR if_IN ][NP exogenous_JJ IL-2_NN ][VP is_VBZ provided_VBN ] ._.
[ADVP Perhaps_RB ][NP murine_JJ thymocytes_NNS ][VP are_VBP denied_VBN ][NP this_DT form_NN ][PP of_IN ][NP rescue_NN ][SBAR because_IN ][NP they_PRP ][VP shut_VBD ][PRT off_RP ][NP IL-2R_NN beta_NN chain_NN expression_NN ][PP at_IN ][NP an_DT earlier_JJR stage_NN ] or_CC[SBAR because_IN ][NP they_PRP ][VP may_MD be_VB ] uncommonly_RB[NP Bcl-2_NN ][ADJP deficient_JJ ] (_([VP cf._VBP ][NP Sentman_NNP et_FW al._FW ,_, 1991_CD ] ;_:[NP Strasser_NNP et_FW al._FW ,_, 1991_CD ] )_) ._.
[ADVP Even_RB so_RB ] ,_,[NP medullary_JJ thymocytes_NNS ][VP remain_VBP ][ADJP at_IN least_JJS partially_RB susceptible_JJ ][PP to_TO ][NP negative_JJ selection_NN ][SBAR even_RB as_IN ][NP they_PRP ][VP continue_VBP to_TO mature_VB ] ._.
[NP SRC-related_JJ proto-oncogenes_NNS ] and_CC[NP transcription_NN factors_NNS ][PP in_IN ][NP primary_JJ human_JJ T_NN cells_NNS ] :_:[NP modulation_NN ][PP by_IN ][NP cyclosporin_NN A_NN ] and_CC[NP FK506_NN ] ._.
[NP Activation_NN ][PP of_IN ][NP T_NN lymphocytes_NNS ][VP induces_VBZ ][NP transcription_NN ][PP of_IN ][NP genes_NNS ][VP encoding_VBG ][PP for_IN ][NP lymphokines_NNS ] ._.
[NP Interleukin-2_NN ] (_([NP IL-2_NN ] )_)[NP gene_NN expression_NN ][VP is_VBZ controlled_VBN ][ADVP transcriptionally_RB ][PP by_IN ][NP the_DT cooperative_JJ activity_NN ][PP of_IN ][NP specific_JJ trans-activating_JJ factors_NNS ][NP that_WDT ][VP bind_VBP ][PP to_TO ][NP the_DT IL-2_NN enhancer_NN ] ._.
[NP Cyclosporin_NN A_NN ] (_([NP CsA_NN ] )_) and_CC[NP FK506_NN ][VP inhibit_VBP ][NP the_DT production_NN ][PP of_IN ][NP IL-2_NN ][PP in_IN ][NP T_NN lymphocytes_NNS ][PP at_IN ][NP the_DT level_NN ][PP of_IN ][NP gene_NN transcription_NN ] ._.
[NP A_DT member_NN ][PP of_IN ][NP the_DT src_NN gene_NN family_NN ] ,_,[NP the_DT lymphocyte-specific_JJ protein_NN tyrosine_NN kinase_NN ] ,_,[NP p56lck_NN ] ,_,[VP has_VBZ been_VBN implicated_VBN ][PP in_IN ][NP IL-2_NN production_NN ] ._.
[NP CsA_NN ][VP was_VBD found_VBN not_RB to_TO inhibit_VB ][NP lck_NN gene_NN expression_NN ] ,_, nor_CC[NP the_DT activity_NN ][PP of_IN ][NP the_DT lck_NN gene_NN product_NN ] ._.
[ADVP However_RB ] ,_,[NP CsA_NN ] and_CC[NP FK506_NN ][VP inhibit_VBP ][NP the_DT appearance_NN ][PP of_IN ][NP DNA_NN binding_NN activity_NN ][PP of_IN ][NP factors_NNS ][NP that_WDT ][VP bind_VBP ][PP to_TO ] the_DT[NP NF-AT_NN ] and_CC[NP AP-1_NN ][NP sites_NNS ][PP in_IN ][NP the_DT IL-2_NN enhancer_NN ] ._.
[SBAR Since_IN ][NP the_DT induction_NN ][PP of_IN ][NP NF-AT_NN ] and_CC[NP AP-1_NN ][VP is_VBZ induced_VBN ][PP by_IN ][NP the_DT same_JJ stimuli_NNS ][NP that_WDT ][VP stimulate_VBP ][NP IL-2_NN production_NN ] ,_,[NP these_DT results_NNS ][VP indicate_VBP ][SBAR that_IN ][NP the_DT immunosuppressant_JJ action_NN ][PP of_IN ][NP CsA_NN ] and_CC[NP FK506_NN ][VP is_VBZ exerted_VBN ][PP at_IN ][NP the_DT level_NN ][PP of_IN ][NP these_DT trans-activating_JJ factors_NNS ] ._.
[NP TAR-independent_JJ transactivation_NN ][PP by_IN ][NP Tat_NN ][PP in_IN ][NP cells_NNS ][VP derived_VBN ][PP from_IN ][NP the_DT CNS_NN ] :_:[NP a_DT novel_JJ mechanism_NN ][PP of_IN ][NP HIV-1_NN gene_NN regulation_NN ] ._.
[NP The_DT Tat_NN protein_NN ][PP of_IN ][NP human_JJ immunodeficiency_NN virus_NN type_NN 1_CD ] (_([NP HIV-1_NN ] )_)[VP is_VBZ ][ADJP essential_JJ ][PP for_IN ][NP productive_JJ infection_NN ] and_CC[VP is_VBZ ][NP a_DT potential_JJ target_NN ][PP for_IN ][NP antiviral_JJ therapy_NN ] ._.
[NP Tat_NN ] ,_,[NP a_DT potent_JJ activator_NN ][PP of_IN ][NP HIV-1_NN gene_NN expression_NN ] ,_,[VP serves_VBZ to_TO greatly_RB increase_VB ][NP the_DT rate_NN ][PP of_IN ][NP transcription_NN ][VP directed_VBN ][PP by_IN ][NP the_DT viral_JJ promoter_NN ] ._.
[NP This_DT induction_NN ] ,_,[NP which_WDT ][VP seems_VBZ to_TO be_VB ][NP an_DT important_JJ component_NN ][PP in_IN ][NP the_DT progression_NN ][PP of_IN ][NP acquired_VBN immune_JJ deficiency_NN syndrome_NN ] (_([NP AIDS_NN ] )_) ,_,[VP may_MD be_VB ][PP due_JJ to_TO ][NP increased_VBN transcriptional_JJ initiation_NN ] ,_,[NP increased_VBN transcriptional_JJ elongation_NN ] ,_, or_CC[NP a_DT combination_NN ][PP of_IN ][NP these_DT processes_NNS ] ._.
[NP Much_JJ attention_NN ][VP has_VBZ been_VBN focused_VBN ][PP on_IN ][NP the_DT interaction_NN ][PP of_IN ][NP Tat_NN ][PP with_IN ][NP a_DT specific_JJ RNA_NN target_NN ][VP termed_VBN ][NP TAR_NN ] (_([NP transactivation_NN responsive_NN ] )_)[NP which_WDT ][VP is_VBZ ][ADJP present_JJ ][PP in_IN ][NP the_DT leader_NN sequence_NN ][PP of_IN ][NP all_DT HIV-1_NN mRNAs_NNS ] ._.
[NP This_DT interaction_NN ][VP is_VBZ believed_VBN to_TO be_VB ][NP an_DT important_JJ component_NN ][PP of_IN ][NP the_DT mechanism_NN ][PP of_IN ][NP transactivation_NN ] ._.
[PP In_IN ][NP this_DT report_NN ][NP we_PRP ][VP demonstrate_VBP ][SBAR that_IN ][PP in_IN ][NP certain_JJ CNS-derived_JJ cells_NNS ][NP Tat_NN ][VP is_VBZ ][ADJP capable_JJ ][PP of_IN ][VP activating_VBG ][NP HIV-1_NN ][PP through_IN ][NP a_DT TAR-independent_JJ pathway_NN ] ._.
[NP A_DT Tat-responsive_JJ element_NN ][VP is_VBZ found_VBN ][ADVP upstream_RB ][PP within_IN ][NP the_DT viral_JJ promoter_NN ][NP that_WDT ][PP in_IN ][NP glial-derived_JJ cell_NN lines_NNS ][VP allows_VBZ ][NP transactivation_NN ][PP in_IN the_DT absence_NN of_IN ][NP TAR_NN ] ._.
[NP Deletion_NN mapping_NN ] and_CC[NP hybrid_NN promoter_NN constructs_NNS ][VP demonstrate_VBP ][SBAR that_IN ][NP the_DT newly_RB identified_VBN Tat-responsive_JJ element_NN ][VP corresponds_VBZ ][PP to_TO ][NP a_DT sequence_NN ][PP within_IN ][NP the_DT viral_JJ ][NP long_JJ terminal_JJ repeat_NN ] (_([NP LTR_NN ] )_)[VP previously_RB identified_VBN ][PP as_IN ][NP the_DT HIV-1_NN enhancer_NN ] ,_, or_CC[NP NF-kappa_NN B_NN domain_NN ] ._.
[NP DNA_NN band-shift_JJ analysis_NN ][VP reveals_VBZ ][NP NF-kappa_NN B_NN binding_NN activity_NN ][PP in_IN ][NP glial_JJ cells_NNS ][NP that_WDT ][VP differs_VBZ ][PP from_IN ][NP that_DT ][ADJP present_JJ ][PP in_IN ][NP T_NN lymphoid_JJ cells_NNS ] ._.
[ADVP Further_RB ] ,_,[NP we_PRP ][VP observe_VBP ][SBAR that_IN ][NP TAR-deleted_JJ mutants_NNS ][PP of_IN ][NP HIV-1_NN ][VP demonstrate_VBP ][NP normal_JJ late_JJ gene_NN expression_NN ][PP in_IN ][NP glial_JJ cells_NNS ][SBAR as_IN ][VP evidenced_VBN ][PP by_IN ][NP syncytia_NN ][NP formation_NN ] and_CC[NP production_NN ][PP of_IN ][NP viral_JJ p24_NN antigen_NN ] ._.
 (_([NP ABSTRACT_NN ][VP TRUNCATED_VBN ][PP AT_IN ][NP 250_CD WORDS_NNS ] )_)
[NP Bcl-2_NN ] :_:[NP a_DT repressor_NN ][PP of_IN ][NP lymphocyte_NN death_NN ] ._.
[NP The_DT ][NP genes_NNS ] and_CC[NP mechanisms_NNS ][NP that_WDT ][VP control_VBP ][NP programmed_VBN cell_NN death_NN ][VP are_VBP ][ADVP currently_RB ][NP the_DT subject_NN ][PP of_IN ][NP intense_JJ study_NN ] ._.
[NP The_DT bcl-2_NN gene_NN ] ,_,[NP a_DT repressor_NN ][PP of_IN ][NP lymphocyte_NN death_NN ] ,_,[VP is_VBZ ][ADVP perhaps_RB ][NP the_DT best_JJS understood_VBN ][PP of_IN ] the_DT[NP programmed_VBN cell_NN death_NN ][NP associated_JJ genes_NNS ] ._.
[ADVP Here_RB ] ,_,[NP Stanley_NNP Korsmeyer_NNP ][VP provides_VBZ ][NP a_DT brief_JJ overview_NN ][PP of_IN ][NP bcl-2_NN ] ,_,[VP concentrating_VBG ][PP on_IN ][NP its_PRP$ roles_NNS ][PP in_IN ][NP B-_NN ] and_CC[NP T-cell_NN ][NP development_NN ][PP and_CC ][PP in_IN ][NP oncogenesis_NN ] ._.
[NP Mitogen_NN stimulation_NN ][PP of_IN ][NP T-cells_NNS ][VP increases_VBZ ][NP c-Fos_NN ] and_CC[NP c-Jun_NN ][NP protein_NN levels_NNS ] ,_,[NP AP-1_NN binding_NN ] and_CC[NP AP-1_NN transcriptional_JJ activity_NN ] ._.
[NP We_PRP ][VP have_VBP analysed_VBN ][NP the_DT effect_NN ][PP of_IN ][NP mitogenic_JJ lectins_NNS ][PP on_IN ][NP c-Fos_NN ] and_CC[NP c-Jun_NN ][NP protein_NN levels_NNS ][CONJP as_RB well_RB as_IN ][PP on_IN ][NP activator_NN protein-1_NN ] (_([NP AP-1_NN ] )_)[NP binding_NN ] and_CC[NP enhancer_NN activity_NN ][PP in_IN ][NP Jurkat_NN T-cells_NNS ] ._.
 Both_CC[NP c-Fos_NN ] and_CC[NP c-Jun_NN ][NP protein_NN levels_NNS ][VP were_VBD increased_VBN ][PP after_IN ][NP Con_NN A_NN ] and_CC[NP PHA_NN ][NP stimulation_NN ] ._.
[SBAR Since_IN ][NP T-cell_NN stimulation_NN ][VP increases_VBZ ] both_CC intracellular_JJ[NP Ca2+_NN ] and_CC[NP cAMP_NN ][NP levels_NNS ] and_CC[VP activates_VBZ ][NP protein_NN kinase_NN C_NN ] (_([NP PKC_NN ] )_) ,_,[NP the_DT possible_JJ involvement_NN ][PP of_IN ][NP these_DT intracellular_JJ messengers_NNS ][PP in_IN ][NP c-Fos_NN ] and_CC[NP c-Jun_NN ][NP induction_NN ][VP was_VBD tested_VBN ] ._.
[NP PMA_NN ] ,_,[NP which_WDT ][ADVP directly_RB ][VP activates_VBZ ][NP PKC_NN ] ,_,[VP mimicked_VBD ][NP the_DT effect_NN ][PP of_IN ][NP the_DT lectins_NNS ][PP on_IN ][NP c-Fos_NN ] and_CC[NP c-Jun_NN ] ,_, but_CC[NP elevation_NN ][PP of_IN ] either_CC intracellular_JJ[NP Ca2+_NN ] or_CC[NP cAMP_NN ][NP levels_NNS ][VP had_VBD ][NP little_JJ or_CC no_DT effect_NN ] ._.
[NP The_DT mitogen-induced_JJ increase_NN ][PP of_IN ][NP c-Fos_NN ] and_CC[NP c-Jun_NN ][NP immunoreactivity_NN ][VP was_VBD inhibited_VBN ][PP by_IN ][NP H-7_NN ] ,_,[NP a_DT kinase_NN inhibitor_NN ][PP with_IN ][NP relatively_RB high_JJ specificity_NN ][PP for_IN ][NP PKC_NN ] ,_, and_CC[ADVP less_RBR efficiently_RB ][PP by_IN ][NP H-8_NN ] ,_,[NP a_DT structurally_RB related_JJ kinase_NN inhibitor_NN ][ADJP less_RBR active_JJ ][PP on_IN ][NP PKC_NN ] ,_, but_CC[ADJP more_RBR active_JJ ][PP on_IN ][NP cyclic_JJ nucleotide-dependent_JJ kinases_NNS ] ._.
[NP Con_NN A_NN stimulation_NN ][VP was_VBD found_VBN to_TO increase_VB ] both_CC[NP binding_NN ][PP of_IN ][NP AP-1_NN ][PP to_TO ][NP the_DT AP-1_NN consensus_NN sequence_NN ] ,_,[NP TRE_NN ] ,_, and_CC[NP AP-1_NN enhancer_NN activity_NN ] ,_,[PP in_IN ][NP Jurkat_NN cells_NNS ] ._.
[NP PMA_NN ][VP was_VBD also_RB found_VBN to_TO increase_VB ][NP the_DT AP-1_NN enhancer_NN activity_NN ] ,_, whereas_IN[NP elevation_NN ][PP of_IN ][NP Ca2+_NN ] or_CC[NP cAMP_NN ][VP had_VBD ][NP only_RB minor_JJ effects_NNS ] ._.
[NP We_PRP ][VP conclude_VBP ][SBAR that_IN ][NP stimulation_NN ][PP with_IN ][NP mitogenic_JJ lectins_NNS ][VP is_VBZ ][ADJP sufficient_JJ ][VP to_TO increase_VB ] both_CC[NP c-Fos_NN ] and_CC[NP c-Jun_NN ][NP protein_NN levels_NNS ] ,_,[NP AP-1_NN binding_NN ] and_CC[NP AP-1_NN enhancer_NN activity_NN ][PP in_IN ][NP Jurkat_NN cells_NNS ] and_CC[SBAR that_IN ][NP they_PRP ][VP act_VBP ][PP via_IN ][NP mechanisms_NNS ][NP that_WDT ][VP could_MD involve_VB ][NP the_DT activation_NN ][PP of_IN ][NP PKC_NN ] ._.
[NP Functional_JJ interaction_NN ][PP between_IN ][NP the_DT two_CD zinc_NN finger_NN domains_NNS ][PP of_IN ][NP the_DT v-erb_NN A_NN oncoprotein_NN ] ._.
[NP The_DT v-erb_NN A_NN oncogene_NN ][PP of_IN ][NP avian_JJ erythroblastosis_NN virus_NN ][VP is_VBZ ][NP a_DT mutated_VBN and_CC virally_RB transduced_VBN copy_NN ][PP of_IN ][NP a_DT host_NN cell_NN gene_NN ][VP encoding_VBG ][NP a_DT thyroid_NN hormone_NN receptor_NN ] ._.
[NP The_DT protein_NN ][VP expressed_VBN ][PP by_IN ][NP the_DT v-erb_NN A_NN oncogene_NN ][VP binds_VBZ ][PP to_TO ][NP DNA_NN ] and_CC[VP acts_VBZ ][PP as_IN ][NP a_DT dominant_JJ negative_JJ inhibitor_NN ][PP of_IN ] both_CC[NP the_DT thyroid_NN hormone_NN receptor_NN ] and_CC[NP the_DT closely_RB related_JJ retinoic_JJ acid_NN receptor_NN ] ._.
[NP The_DT v-erb_NN A_NN protein_NN ][VP has_VBZ sustained_VBN ][NP two_CD amino_NN acid_NN alterations_NNS ][PP within_IN ][NP its_PRP$ DNA-binding_JJ domain_NN ][PP relative_JJ to_TO ][NP that_DT ][PP of_IN ][NP c-erb_NN A_NN ] ,_,[NP one_CD ][PP of_IN ][NP which_WDT ] ,_,[PP at_IN ][NP serine_NN 61_CD ] ,_,[VP is_VBZ known_VBN to_TO be_VB ][ADJP important_JJ ][PP for_IN ][NP v-erb_NN A_NN function_NN ][PP in_IN ][NP the_DT neoplastic_JJ cell_NN ] ._.
[NP We_PRP ][VP report_VBP ][ADVP here_RB ][SBAR that_IN ][NP the_DT second_JJ alteration_NN ] ,_,[PP at_IN ][NP threonine_NN 78_CD ] ,_,[ADVP also_RB ][VP plays_VBZ ][NP an_DT important_JJ ,_, although_IN more_RBR indirect_JJ ,_, role_NN ] :_:[NP alteration_NN ][PP of_IN ][NP the_DT sequence_NN ][PP at_IN ][NP threonine_NN 78_CD ][SBAR such_JJ that_IN ][NP it_PRP ][VP resembles_VBZ ][NP that_DT ][PP of_IN ][NP c-erb_NN A_NN ][VP can_MD act_VB ][PP as_IN ][NP an_DT intragenic_JJ suppressor_NN ] and_CC[VP can_MD partially_RB restore_VB ][NP function_NN ][PP to_TO ][NP a_DT v-erb_NN A_NN protein_NN ][VP rendered_VBN ][ADJP defective_JJ ][PP due_JJ to_TO ][NP a_DT mutation_NN ][PP at_IN ][NP position_NN 61_CD ] ._.
[NP Threonine_NN 78_CD ][VP lies_VBZ ][PP within_IN ][NP the_DT D-box_NN ][PP of_IN ][NP the_DT v-erb_NN A_NN protein_NN ] ,_,[NP a_DT region_NN ][VP thought_VBN to_TO mediate_VB ][NP receptor-receptor_JJ dimerizations_NNS ] ,_, and_CC[VP is_VBZ ] not_RB[PP in_IN ][NP physical_JJ proximity_NN ][PP to_TO ][NP the_DT serine_NN ][PP at_IN ][NP position_NN 61_CD ] ._.
[NP It_PRP ][ADVP therefore_RB ][VP appears_VBZ ][SBAR that_IN ][NP an_DT indirect_JJ interaction_NN ][VP occurs_VBZ ][PP between_IN ][NP these_DT two_CD sites_NNS ] and_CC[SBAR that_IN ][NP this_DT interaction_NN ][VP is_VBZ ][ADJP crucial_JJ ][PP for_IN ][NP v-erb_NN A_NN function_NN ] ._.
[NP Pax-5_NN ][VP encodes_VBZ ][NP the_DT transcription_NN factor_NN BSAP_NN ] and_CC[VP is_VBZ expressed_VBN ][PP in_IN ][NP B_NN lymphocytes_NNS ] ,_,[NP the_DT developing_VBG CNS_NNS ] ,_, and_CC[NP adult_JJ testis_NN ] ._.
[NP BSAP_NN ][VP has_VBZ been_VBN identified_VBN ][ADVP previously_RB ][PP as_IN ][NP a_DT transcription_NN factor_NN ][NP that_WDT ][VP is_VBZ expressed_VBN ][PP at_IN ][NP early_JJ ,_, but_CC not_RB late_JJ ,_, stages_NNS ][PP of_IN ][NP B-cell_NN differentiation_NN ] ._.
[NP Biochemical_JJ purification_NN ] and_CC[NP cDNA_NN cloning_NN ][VP has_VBZ now_RB revealed_VBN ][SBAR that_IN ][NP BSAP_NN ][VP belongs_VBZ ][PP to_TO ][NP the_DT family_NN ][PP of_IN ][NP paired_JJ domain_NN proteins_NNS ] ._.
[NP BSAP_NN ][VP is_VBZ encoded_VBN ][PP by_IN ][NP the_DT Pax-5_NN gene_NN ] and_CC[VP has_VBZ been_VBN highly_RB conserved_VBN ][PP between_IN ][NP human_JJ ] and_CC[NP mouse_NN ] ._.
[NP An_DT intact_JJ paired_JJ domain_NN ][VP was_VBD shown_VBN to_TO be_VB ] both_CC[ADJP necessary_JJ ] and_CC[ADJP sufficient_JJ ][PP for_IN ][NP DNA_NN binding_NN ][PP of_IN ][NP BSAP_NN ] ._.
[NP Binding_VBG studies_NNS ][PP with_IN ][NP several_JJ BSAP_NN recognition_NN sequences_NNS ][VP demonstrated_VBD ][SBAR that_IN ][NP the_DT sequence_NN specificity_NN ][PP of_IN ][NP BSAP_NN ][VP differs_VBZ ][PP from_IN ][NP that_DT ][PP of_IN ][NP the_DT distantly_RB related_JJ paired_JJ domain_NN protein_NN Pax-1_NN ] ._.
[PP During_IN ][NP embryogenesis_NN ] ,_,[NP the_DT BSAP_NN gene_NN ][VP is_VBZ transiently_RB expressed_VBN ][PP in_IN ][NP the_DT ][NP mesencephalon_NN ] and_CC[NP spinal_JJ cord_NN ][PP with_IN ][NP a_DT spatial_JJ and_CC temporal_JJ expression_NN pattern_NN ][NP that_WDT ][VP is_VBZ ][ADJP distinct_JJ ][PP from_IN ][NP that_DT ][PP of_IN ][NP other_JJ Pax_NN genes_NNS ][PP in_IN ][NP the_DT developing_VBG ][NP central_JJ nervous_JJ system_NN ] (_([NP CNS_NN ] )_) ._.
[ADVP Later_RB ] ,_,[NP the_DT expression_NN ][PP of_IN ][NP the_DT BSAP_NN gene_NN ][VP shifts_VBZ ][PP to_TO ][NP the_DT fetal_JJ liver_NN ][ADVP where_WRB ][NP it_PRP ][VP correlates_VBZ ][PP with_IN ][NP the_DT onset_NN ][PP of_IN ][NP B_NN lymphopoiesis_NN ] ._.
[NP BSAP_NN expression_NN ][VP persists_VBZ ][PP in_IN ][NP B_NN lymphocytes_NNS ] and_CC[VP is_VBZ also_RB seen_VBN ][PP in_IN ][NP the_DT testis_NN ][PP of_IN ][NP the_DT adult_JJ mouse_NN ] ._.
[NP All_DT ][PP of_IN ][NP this_DT evidence_NN ][VP indicates_VBZ ][SBAR that_IN ][NP the_DT transcription_NN factor_NN BSAP_NN ][VP may_MD ][CONJP not_RB only_RB ][VP play_VB ][NP an_DT important_JJ role_NN ][PP in_IN ][NP B-cell_NN differentiation_NN ][CONJP but_CC also_RB ][PP in_IN ][NP neural_JJ development_NN ] and_CC[NP spermatogenesis_NN ] ._.
[NP Okadaic_JJ acid_NN ][VP is_VBZ ][NP a_DT potent_JJ inducer_NN ][PP of_IN ][NP AP-1_NN ] ,_,[NP NF-kappa_NN B_NN ] ,_, and_CC[NP tumor_NN necrosis_NN factor-alpha_NN ][PP in_IN ][NP human_JJ B_NN lymphocytes_NNS ] ._.
[NP Treatment_NN ][PP of_IN ][NP human_JJ B_NN lymphocytes_NNS ][PP with_IN ][NP an_DT optimal_JJ concentration_NN ][PP of_IN ][NP okadaic_JJ acid_NN ] ,_,[NP an_DT inhibitor_NN ][PP of_IN ][NP phosphatases_NNS ][NP 1_CD ] and_CC[NP 2A_NN ] ,_,[VP resulted_VBD ][PP in_IN ][NP the_DT induction_NN ][PP of_IN ][NP the_DT transcription_NN factor_NN ] ,_,[NP AP-1_NN ] and_CC[NP a_DT marked_JJ increase_NN ][PP in_IN ][NP NF-kappa_NN B_NN levels_NNS ] ._.
[PP In_IN ][NP contrast_NN ] ,_,[NP no_DT effect_NN ][PP on_IN ][NP the_DT levels_NNS ][PP of_IN ][NP the_DT octamer_NN binding_NN proteins_NNS ] ,_,[NP Oct-1_NN ] or_CC[NP Oct-2_NN ] ,_,[VP were_VBD found_VBN ] ._.
[SBAR Since_IN ] both_CC[NP AP-1_NN ] and_CC[NP NF-kappa_NN B_NN ][VP have_VBP been_VBN reported_VBN to_TO be_VB ][ADJP important_JJ ][PP in_IN ][NP the_DT induction_NN ][PP of_IN ] the_DT[NP tumor_NN necrosis_NN factor-alpha_NN ] (_([NP TNF-alpha_NN ] )_)[NP gene_NN ][NP we_PRP ][VP examined_VBD ][NP the_DT effects_NNS ][PP of_IN ][NP okadaic_JJ acid_NN ][PP on_IN ][NP TNF-alpha_NN mRNA_NN levels_NNS ] ._.
[NP Treatment_NN ][PP with_IN ][NP okadaic_JJ acid_NN ][VP resulted_VBD ][PP in_IN ][NP a_DT striking_JJ increase_NN ][PP in_IN ][NP TNF-alpha_NN mRNA_NN transcripts_NNS ][PP within_IN ][NP 1_CD h_NN ][PP of_IN ][NP stimulation_NN ] and_CC[NP large_JJ amounts_NNS ][PP of_IN ][NP TNF-alpha_NN ][VP were_VBD ][NP released_VBN ][PP into_IN ][NP the_DT culture_NN media_NNS ] ._.
[SBAR Although_IN ][NP okadaic_JJ acid_NN ][VP provides_VBZ ][NP a_DT potent_JJ inductive_JJ signal_NN ][PP for_IN ][NP AP-1_NN ] and_CC[NP NF-kappa_NN B_NN ][NP it_PRP ][VP did_VBD not_RB induce_VB ] either_CC[NP B_NN cell_NN proliferation_NN ] or_CC[NP immunoglobulin_NN secretion_NN ] ._.
[NP A_DT novel_JJ Ets-related_JJ transcription_NN factor_NN ] ,_,[NP Elf-1_NN ] ,_,[VP binds_VBZ ][PP to_TO ][NP human_JJ immunodeficiency_NN virus_NN type_NN 2_CD regulatory_JJ elements_NNS ][NP that_WDT ][VP are_VBP required_VBN ][PP for_IN ][NP inducible_JJ trans_JJ activation_NN ][PP in_IN ][NP T_NN cells_NNS ] ._.
[NP Human_JJ immunodeficiency_NN virus_NN type_NN 1_CD ] (_([NP HIV-1_NN ] )_) and_CC[NP HIV-2_NN ][VP are_VBP ][NP structurally_RB related_JJ retroviruses_NNS ][NP which_WDT ][ADVP both_DT ][VP cause_VBP ][NP AIDS_NN ][PP in_IN ][NP humans_NNS ] ._.
[SBAR Although_IN ][NP both_DT viruses_NNS ][VP establish_VBP ][NP latency_NN ][PP in_IN ][NP quiescent_JJ human-peripheral-blood_JJ T_NN cells_NNS ] ,_,[NP the_DT asymptomatic_JJ phase_NN ][PP of_IN ][NP HIV-2_NN infection_NN ][VP may_MD be_VB ][ADJP more_JJR prolonged_JJ ][PP than_IN ][NP that_DT ][PP of_IN ][NP HIV-1_NN ] ._.
[NP The_DT latent_JJ phases_NNS ][PP of_IN ] both_CC[NP HIV-1_NN ] and_CC[NP HIV-2_NN ][NP infection_NN ][VP have_VBP been_VBN shown_VBN to_TO be_VB disrupted_VBN ][PP by_IN ][NP T-cell_NN activation_NN ] ,_,[NP a_DT process_NN ][NP that_WDT ][VP requires_VBZ ][NP host_NN cell_NN transcription_NN factors_NNS ] ._.
[PP In_IN ][NP the_DT case_NN ][PP of_IN ][NP HIV-1_NN ] ,_,[NP the_DT transcription_NN factor_NN NF-kappa_NN B_NN ][VP is_VBZ ][ADJP sufficient_JJ ][PP for_IN ][NP inducible_JJ transcriptional_JJ activation_NN ] ._.
[PP In_IN ][NP contrast_NN ] ,_,[NP factors_NNS ][PP in_IN addition_NN to_TO ][NP NF-kappa_NN B_NN ][VP are_VBP required_VBN to_TO activate_VB ][NP HIV-2_NN transcription_NN ][PP in_IN ][NP infected_JJ T_NN cells_NNS ] ._.
[PP In_IN ][NP this_DT report_NN ] ,_,[NP we_PRP ][VP demonstrate_VBP ][SBAR that_IN ][NP a_DT novel_JJ Ets-related_JJ transcription_NN factor_NN ] ,_,[NP Elf-1_NN ] ,_,[VP binds_VBZ ][ADVP specifically_RB ][PP to_TO ][NP two_CD purine-rich_JJ motifs_NNS ][PP in_IN ][NP the_DT HIV-2_NN enhancer_NN ] ._.
[NP Mutagenesis_NN experiments_NNS ][VP demonstrated_VBD ][SBAR that_IN ][NP these_DT Elf-1_NN binding_NN sites_NNS ][VP are_VBP required_VBN ][PP for_IN ][NP induction_NN ][PP of_IN ][NP HIV-2_NN transcription_NN ][PP following_VBG ][NP T-cell-receptor-mediated_JJ T-cell_NN activation_NN ] ._.
[ADVP Moreover_RB ] ,_,[NP Elf-1_NN ][VP is_VBZ ][NP the_DT only_JJ factor_NN ][ADJP present_JJ ][PP in_IN ][NP activated_VBN T-cell_NN nuclear_JJ extracts_NNS ][NP that_WDT ][VP binds_VBZ ][PP to_TO ][NP these_DT sites_NNS ][PP in_IN ][NP electrophoretic_JJ mobility_NN shift_NN assays_NNS ] ._.
[ADVP Thus_RB ] ,_,[NP Elf-1_NN ][VP is_VBZ ][NP a_DT novel_JJ transcription_NN factor_NN ][NP that_WDT ][VP appears_VBZ to_TO be_VB required_VBN ][PP for_IN ][NP the_DT T-cell-receptor-mediated_JJ trans_JJ activation_NN ][PP of_IN ][NP HIV-2_NN gene_NN expression_NN ] ._.
[NP These_DT results_NNS ][VP may_MD explain_VB ][NP differences_NNS ][PP in_IN ][NP the_DT clinical_JJ spectra_NNS ][PP of_IN ][NP diseases_NNS ][VP caused_VBN ][PP by_IN ][NP HIV-1_NN ] and_CC[NP HIV-2_NN ] and_CC[VP may_MD also_RB have_VB ][NP implications_NNS ][PP for_IN ][NP the_DT design_NN ][PP of_IN ][NP therapeutic_JJ approaches_NNS ][PP to_TO ][NP HIV-2_NN infection_NN ] ._.
[NP Human_JJ immunodeficiency_NN virus_NN type_NN 1_CD Nef_NN protein_NN ][VP inhibits_VBZ ][NP NF-kappa_NN B_NN induction_NN ][PP in_IN ][NP human_JJ T_NN cells_NNS ] ._.
[NP Human_JJ immunodeficiency_NN virus_NN type_NN 1_CD ] (_([NP HIV-1_NN ] )_)[VP can_MD establish_VB ][NP a_DT persistent_JJ and_CC latent_JJ infection_NN ][PP in_IN ][NP CD4+_JJ T_NN lymphocytes_NNS ] (_([NP W.C.Greene_NNP ] ,_,[NP N.Engl.J._NNP Med.324_NNP :_: 308-317_CD ] ,_,[NP 1991_CD ] ;_:[NP S.M.Schnittman_NNP ] ,_,[NP M.C.Psallidopoulos_NNP ] ,_,[NP H.C._NNP Lane_NNP ] ,_,[NP L.Thompson_NNP ] ,_,[NP M.Baseler_NNP ] ,_,[NP F.Massari_NNP ] ,_,[NP C.H.Fox_NNP ] ,_,[NP N.P.Salzman_NNP ] ,_, and_CC[NP A.S.Fauci_NNP ] ,_,[NP Science_NNP 245_CD :_: 305-308_CD ] ,_,[NP 1989_CD ] )_) ._.
[NP Production_NN ][PP of_IN ][NP HIV-1_NN ][PP from_IN ][NP latently_RB infected_JJ cells_NNS ][VP requires_VBZ ][NP host_NN cell_NN activation_NN ][PP by_IN ][NP T-cell_NN mitogens_NNS ] (_([NP T.Folks_NNP ] ,_,[NP D.M.Powell_NNP ] ,_,[NP M.M.Lightfoote_NNP ] ,_,[NP S.Benn_NNP ] ,_,[NP M.A._NNP Martin_NNP ] ,_, and_CC[NP A.S.Fauci_NNP ] ,_,[NP Science_NNP 231_CD :_: 600-602_CD ] ,_,[NP 1986_CD ] ;_:[NP D.Zagury_NNP ] ,_,[NP J._NNP Bernard_NNP ] ,_,[NP R.Leonard_NNP ] ,_,[NP R.Cheynier_NNP ] ,_,[NP M.Feldman_NNP ] ,_,[NP P.S.Sarin_NNP ] ,_, and_CC[NP R.C._NNP Gallo_NNP ] ,_,[NP Science_NNP 231_CD :_: 850-853_CD ] ,_,[NP 1986_CD ] )_) ._.
[NP This_DT activation_NN ][VP is_VBZ mediated_VBN ][PP by_IN ][NP the_DT host_NN transcription_NN factor_NN NF-kappa_NN B_NN ] (_([NP G.Nabel_NNP ] and_CC[NP D.Baltimore_NNP ] ,_,[NP Nature_NNP (_( London_NNP )_) 326_CD :_: 711-717_CD ] ,_,[NP 1987_CD ] )_) ._.
[NP We_PRP ][VP report_VBP ][ADVP here_RB ][SBAR that_IN ][NP the_DT HIV-1-encoded_JJ Nef_NN protein_NN ][VP inhibits_VBZ ][NP the_DT induction_NN ][PP of_IN ][NP NF-kappa_NN B_NN DNA-binding_JJ activity_NN ][PP by_IN ][NP T-cell_NN mitogens_NNS ] ._.
[ADVP However_RB ] ,_,[NP Nef_NN ][VP does_VBZ not_RB affect_VB ][NP the_DT DNA-binding_JJ activity_NN ][PP of_IN ][NP other_JJ transcription_NN factors_NNS ][VP implicated_VBN ][PP in_IN ][NP HIV-1_NN regulation_NN ] ,_,[PP including_VBG ][NP SP-1_NN ] ,_,[NP USF_NN ] ,_,[NP URS_NN ] ,_, and_CC[NP NF-AT_NN ] ._.
[ADVP Additionally_RB ] ,_,[NP Nef_NN ][VP inhibits_VBZ ][NP the_DT induction_NN ][PP of_IN ][NP HIV-1-_NN ] and_CC[ADJP interleukin_NN 2-directed_JJ ][NP gene_NN expression_NN ] ,_, and_CC[NP the_DT effect_NN ][PP on_IN ][NP HIV-1_NN transcription_NN ][VP depends_VBZ ][PP on_IN ][NP an_DT intact_JJ NF-kappa_NN B-binding_JJ site_NN ] ._.
[NP These_DT results_NNS ][VP indicate_VBP ][SBAR that_IN ][NP defective_JJ recruitment_NN ][PP of_IN ][NP NF-kappa_NN B_NN ][VP may_MD underlie_VB ][NP Nef_NN ][NP 's_POS negative_JJ transcriptional_JJ effects_NNS ][PP on_IN ] the_DT[NP HIV-1_NN ] and_CC[NP interleukin_NN 2_CD ][NP promoters_NNS ] ._.
[NP Further_JJ evidence_NN ][VP suggests_VBZ ][SBAR that_IN ][NP Nef_NN ][VP inhibits_VBZ ][NP NF-kappa_NN B_NN induction_NN ][PP by_IN ][VP interfering_VBG ][PP with_IN ][NP a_DT signal_NN ][VP derived_VBN ][PP from_IN ][NP the_DT T-cell_NN receptor_NN complex_NN ] ._.
 (_([NP Effect_NN ][PP of_IN ][NP antihypertensive_JJ therapy_NN ][PP with_IN ][NP captopril_NN ][PP on_IN ][NP gluco-_JJ ] and_CC[NP mineralocorticoid_NN ][NP receptors_NNS ][PP of_IN ][NP peripheral_JJ blood_NN lymphocytes_NNS ][PP in_IN ][NP hypertensive_JJ patients_NNS ][PP of_IN ][NP various_JJ age_NN ] )_)
[NP Binding_NN ][PP of_IN ][NP 3H-dexamethasone_NN ] and_CC[NP 3H-aldosterone_NN ][PP by_IN ][NP peripheral_JJ lymphocyte_NN receptors_NNS ][VP was_VBD investigated_VBN ][PP in_IN ][NP healthy_JJ persons_NNS ] and_CC[NP hypertensive_JJ patients_NNS ][PP before_IN ][PP and_CC ][PP after_IN ][NP 2-week_JJ captopril_NN treatment_NN ] ._.
[NP The_DT number_NN ][PP of_IN ][NP glucocorticoid_NN ] and_CC[NP mineralocorticoid_NN ][NP binding_NN sites_NNS ][VP was_VBD increased_VBN ][PP in_IN ][NP hypertensives_NNS ] vs_CC[NP normotensives_NNS ] ._.
[NP The_DT treatment_NN ][PP with_IN ][NP the_DT ACE_NN inhibitor_NN captopril_NN ][VP led_VBD ][PP to_TO ][NP activation_NN ][PP of_IN ][NP hormone-receptor_NN interactions_NNS ] ._.
[NP There_EX ][VP was_VBD ][NP a_DT more_RBR marked_JJ rise_NN ][PP of_IN ][NP the_DT number_NN ][PP of_IN ][NP receptors_NNS ][PP in_IN ] middle-aged_JJ (_([NP 44-55_CD years_NNS ] )_)[NP hypertensives_NNS ] vs_CC elderly_JJ (_([NP 61-80_CD years_NNS ] )_)[NP subjects_NNS ][PP after_IN ][NP captopril_NN treatment_NN ] ._.
[NP Leukotriene_NN B4_NN ][ADVP transcriptionally_RB ][VP activates_VBZ ][NP interleukin-6_NN expression_NN ][VP involving_VBG ][NP NK-chi_NN B_NN ] and_CC[NP NF-IL6_NN ] ._.
[NP Leukotriene_NN B4_NN ] (_([NP LTB4_NN ] )_)[VP is_VBZ ][NP a_DT notable_JJ participant_NN ][PP in_IN ][NP inflammation_NN ] and_CC[NP chemotaxis_NN ] ._.
[NP It_PRP ][VP is_VBZ ] ,_,[ADVP however_RB ] ,_,[ADJP still_RB unclear_JJ ][SBAR whether_IN ][NP LTB4_NN ][VP acts_VBZ ][PP in_IN ][NP this_DT regard_NN ][ADVP directly_RB ][ADVP or_CC ][ADVP indirectly_RB ][PP by_IN ][VP stimulating_VBG ][NP the_DT release_NN ][PP of_IN ][NP chemotactic_JJ and_CC inflammatory_JJ cytokines_NNS ] ._.
[ADVP Here_RB ][NP we_PRP ][VP report_VBP ][SBAR that_IN ][NP LTB4_NN ][VP induces_VBZ ][NP synthesis_NN ][PP of_IN ][NP interleukin_NN ] (_([NP IL_NN ] )_)[NP -6_CD ][PP by_IN ][NP human_JJ blood_NN monocytes_NNS ][PP through_IN ][NP transcriptional_JJ activation_NN ][PP of_IN ][NP the_DT IL-6_NN gene_NN ] ._.
[NP We_PRP ][ADVP furthermore_RB ][VP demonstrate_VBP ][SBAR that_IN ][NP this_DT process_NN ][VP involves_VBZ ][NP activation_NN ][PP of_IN ][NP the_DT transcription_NN factor_NN NF-chi_NN B_NN ] and_CC ,_,[PP to_TO ][NP a_DT lesser_JJR extent_NN ] ,_,[PP of_IN ][NP NF-IL6_NN ] ,_,[SBAR while_IN ][NP the_DT activity_NN ][PP of_IN ][NP the_DT transcription_NN factor_NN AP-1_NN ] ,_,[VP shown_VBN to_TO otherwise_RB confer_VB ][NP IL-6_NN inducibility_NN ] ,_,[VP appeared_VBD to_TO be_VB unaffected_JJ ][PP by_IN ][NP LTB4_NN ] ._.
[NP Involvement_NN ][PP of_IN ][NP NF-chi_NN B_NN ] and_CC[NP NF-IL6_NN ][PP in_IN ][NP induction_NN ][PP of_IN ][NP IL-6_NN transcription_NN ][PP by_IN ][NP monocytes_NNS ][VP was_VBD demonstrated_VBN ][VP using_VBG ][NP deleted_JJ forms_NNS ][PP of_IN ][NP the_DT IL-6_NN promoter_NN ] ._.
[NP Activation_NN ][PP of_IN ][NP the_DT IL-6_NN promoter_NN ][PP by_IN ][NP LTB4_NN ][VP was_VBD ][CONJP not_RB only_RB ][VP associated_VBN ][PP with_IN ][NP accumulation_NN ][PP of_IN ][NP the_DT respective_JJ transcripts_NNS ] but_CC[VP resulted_VBD ][PP in_IN ][NP synthesis_NN ][PP of_IN ][NP functional_JJ IL-6_NN protein_NN ][PP as_RB ][ADVP well_RB ] ._.
[PP In_IN ][NP addition_NN ] ,_,[NP LTB4_NN ][VP mediated_VBD ][NP transactivation_NN ][PP of_IN ][NP a_DT heterologous_JJ promoter_NN construct_NN ][VP containing_VBG ][NP the_DT NF-chi_NN B_NN ] or_CC[NP the_DT NF-IL6_NN ][NP enhancer_NN ] ,_,[CONJP but_CC not_RB ][NP the_DT AP-1_NN enhancer_NN ] ._.
[NP The_DT signaling_NN events_NNS ][VP mediating_VBG ][NP this_DT effect_NN ][VP appeared_VBD to_TO involve_VB ][NP the_DT release_NN ][PP of_IN ][NP H2O2_NN ] ,_,[SBAR since_IN ][NP LTB4_NN ][VP failed_VBD to_TO induce_VB ][NP NF-chi_NN B_NN ] or_CC[NP NF-IL6_NN ][PP in_IN the_DT presence_NN of_IN ][NP the_DT scavenger_NN ][PP of_IN ][NP H2O2_NN ] ,_,[NP N-acetyl-L-cysteine_NN ] ._.
[NP Estrogen_NN binding_NN sites_NNS ][PP in_IN ][NP peripheral_JJ blood_NN monocytes_NNS ] and_CC[NP effects_NNS ][PP of_IN ][NP danazol_NN ][PP on_IN ][NP their_PRP$ sites_NNS ][ADVP in_FW vitro_FW ] ._.
[LST 1_LS ] ._.[NP This_DT study_NN ][VP was_VBD designed_VBN ][VP to_TO investigate_VB ][NP the_DT presence_NN ][PP of_IN ] estrogen_NN[NP type_NN I_CD ] (_([NP high_JJ affinity_NN ] ,_,[NP low_JJ capacity_NN ] )_) and_CC[NP type_NN II_CD ] (_([NP low_JJ affinity_NN ] ,_,[NP high_JJ capacity_NN ] )_)[NP binding_NN sites_NNS ][PP in_IN ][NP human_JJ peripheral_JJ blood_NN monocytes_NNS ] and_CC[NP the_DT effects_NNS ][PP of_IN ][NP danazol_NN ][PP on_IN ][NP these_DT sites_NNS ] ._.
[LST 2_LS ] ._.[NP These_DT two_CD types_NNS ][PP of_IN ][NP estrogen_NN binding_NN sites_NNS ][VP existed_VBD ][PP in_IN ][NP human_JJ peripheral_JJ blood_NN monocytes_NNS ] ._.
[LST 3_LS ] ._.[NP Danazol_NN ][VP bound_VBD ][PP to_TO ][NP these_DT sites_NNS ][PP in_IN ][NP high_JJ concentration_NN ] (_([NP 10(-6)_CD M_NN ] ,_,[ADJP clinical_JJ ][NP serum_NN concentration_NN ][PP during_IN ][NP danazol_NN therapy_NN ] )_) and_CC[VP decreased_VBD ][NP the_DT number_NN ][PP of_IN ][NP both_DT sites_NNS ] ._.
[LST 4_LS ] ._.[NP It_PRP ][VP is_VBZ suggested_VBN ][SBAR that_IN ][NP danazol_NN ][VP has_VBZ ][NP an_DT anti-estrogenic_JJ action_NN ][PP to_TO ][NP the_DT monocytes_NNS ][PP through_IN ][NP the_DT ][NP competition_NN ] and_CC[NP suppression_NN ][PP of_IN ][NP estrogen_NN binding_NN sites_NNS ][SBAR as_IN ][VP seen_VBN ][PP in_IN ][NP the_DT estrogen_NN target_NN organ_NN ] ._.
 (_([NP Mechanism_NN ][PP of_IN ][NP action_NN ][PP of_IN ][NP steroid_NN hormones_NNS ._. I_LS ._. Estrogens_NNS ] )_)
[NP The_DT steroid_NN hormone_NN ][VP are_VBP ][NP very_RB versatile_JJ molecules_NNS ] :_:[SBAR although_IN ][NP they_PRP ][VP are_VBP ][ADJP related_JJ ][PP among_IN ][NP them_PRP ][PP by_IN ][NP their_PRP$ chemical_JJ structure_NN ] ,_,[NP they_PRP ][VP have_VBP ][NP very_RB diverse_JJ functions_NNS ] and_CC[PP including_VBG ][NP antagonic_JJ ] ._.
[NP Their_PRP$ action_NN mechanism_NN ][VP is_VBZ not_RB completely_RB cleared_VBN ] ._.
[NP The_DT estrogens_NNS ][VP participate_VBP ][PP in_IN ][NP the_DT regulation_NN ][PP of_IN ][NP practically_RB all_PDT the_DT reproductive_JJ and_CC sexual_JJ events_NNS ][PP of_IN ][NP the_DT female_NN ] ,_,[SBAR although_IN ][NP the_DT intracellular_JJ actions_NNS ][PP by_IN ][NP which_WDT ][NP they_PRP ][VP take_VBP ][NP place_NN ][VP are_VBP not_RB well_RB known_VBN ] and_CC[NP the_DT proposed_JJ models_NNS ][VP do_VBP not_RB adequately_RB satisfy_VB ][NP the_DT questions_NNS ] ._.
[ADVP Currently_RB ][NP it_PRP ][VP is_VBZ accepted_VBN ][NP the_DT existence_NN ][PP of_IN ][NP a_DT cytoplasmic_JJ and/or_CC nuclear_JJ receptor_NN ] ,_,[PP without_IN ][VP explaining_VBG ][ADVP satisfactorily_RB ][ADVP how_WRB ][NP the_DT hormones_NNS ][VP come_VBN ][PP to_TO ][NP the_DT nucleus_NN ] ._.
[NP The_DT endocrine_JJ events_NNS ][NP that_WDT ] are_VBP[ADVP rapidly_RB ][VP expressed_VBN ] (_([NP seconds_NNS ] )_)[VP are_VBP ][PP due_JJ to_TO ][NP a_DT possible_JJ interaction_NN ][PP with_IN ][NP cellular_JJ membrane_NN ] ._.
[NP The_DT purpose_NN ][PP of_IN ][NP this_DT review_NN ][VP is_VBZ ][VP to_TO analyze_VB ] and_CC[VP concilliate_VB ][NP the_DT reported_VBN data_NNS ][PP on_IN ][NP the_DT mechanism_NN ][PP of_IN ][NP action_NN ][PP of_IN ][NP estrogens_NNS ] ._.
[NP Stable_JJ expression_NN ][PP of_IN ][NP transdominant_JJ Rev_NN protein_NN ][PP in_IN ][NP human_JJ T_NN cells_NNS ][VP inhibits_VBZ ][NP human_JJ immunodeficiency_NN virus_NN replication_NN ] ._.
 The_DT[NP human_JJ immunodeficiency_NN virus_NN ] (_([NP HIV_NN ] )_)[NP Rev_NN protein_NN ][VP is_VBZ ][ADJP essential_JJ ][PP for_IN ][NP viral_JJ structural_JJ protein_NN expression_NN ] (_([NP Gag_NN ] ,_,[NP Pol_NN ] ,_, and_CC[NP Env_NN ] )_)[PP and_CC ,_, hence_RB ] ,_,[PP for_IN ][NP viral_JJ replication_NN ] ._.
[PP In_IN ][NP transient_JJ transfection_NN assays_NNS ] ,_,[NP mutant_JJ forms_NNS ][PP of_IN ][NP Rev_NN ][VP have_VBP been_VBN identified_VBN ][NP that_WDT ][VP inhibit_VBP ][NP wild-type_JJ Rev_NN activity_NN ] and_CC therefore_RB[VP suppress_VBP ][NP viral_JJ replication_NN ] ._.
[VP To_TO determine_VB ][SBAR whether_IN ][NP such_JJ transdominant_JJ Rev_NN proteins_NNS ][VP could_MD provide_VB ][NP long-term_JJ protection_NN ][PP against_IN ][NP HIV_NN infection_NN ][PP without_IN ][VP affecting_VBG ][NP T_NN cell_NN function_NN ] ,_,[NP T_NN leukemia_NN cell_NN lines_NNS ][VP were_VBD stably_RB transduced_VBN ][PP with_IN ][NP a_DT retroviral_JJ vector_NN ][VP encoding_VBG ][NP a_DT transdominant_JJ mutant_NN ][PP of_IN ][NP the_DT Rev_NN protein_NN ] ,_,[NP M10_NN ] ._.
[SBAR While_IN ][NP all_PDT the_DT M10-expressing_JJ cell_NN lines_NNS ][VP remained_VBD ][ADJP infectable_JJ ][PP by_IN ][NP HIV-1_NN ] ,_,[NP these_DT same_JJ cells_NNS ][VP failed_VBD to_TO support_VB ][NP a_DT productive_JJ replication_NN cycle_NN ][ADVP when_WRB ][VP infected_VBN ][PP with_IN ][NP a_DT cloned_VBN isolate_NN ][PP of_IN ][NP HIV-1_NN ] ._.
[PP In_IN ][NP addition_NN ] ,_,[NP two_CD out_IN of_IN three_CD M10-expressing_JJ CEM_NN clones_NNS ][VP were_VBD ][ADJP also_RB resistant_JJ ][PP to_TO ][NP highly_RB productive_JJ infection_NN ][PP by_IN ][NP a_DT heterogeneous_JJ HIV-1_NN pool_NN ] ._.
[NP Expression_NN ][PP of_IN ][NP M10_NN ][VP did_VBD not_RB affect_VB ][NP induction_NN ][PP of_IN ][NP HIV_NN transcription_NN ][VP mediated_VBN ][PP by_IN ][NP the_DT kappa_NN B_NN regulatory_JJ element_NN ] or_CC[NP Tat_NN ] ._.
[ADVP Importantly_RB ] ,_,[NP constitutive_JJ expression_NN ][PP of_IN ][NP Rev_NN M10_NN ][VP did_VBD not_RB alter_VB ][NP the_DT secretion_NN ][PP of_IN ][NP interleukin_NN 2_CD ][PP in_IN response_NN to_TO ][NP mitogen_NN stimulation_NN ][PP of_IN ][NP EL-4_NN ] and_CC[NP Jurkat_NN ][NP cells_NNS ] ._.
[NP The_DT inhibition_NN ][PP of_IN ][NP HIV_NN infection_NN ][PP in_IN ][NP cells_NNS ][VP stably_RB expressing_VBG ][NP a_DT transdominant_JJ Rev_NN protein_NN ] ,_,[PP in_IN the_DT absence_NN of_IN ][NP any_DT deleterious_JJ effect_NN ][PP on_IN ][NP T_NN cell_NN function_NN ] ,_,[VP suggests_VBZ ][SBAR that_IN ][NP such_PDT a_DT strategy_NN ][VP could_MD provide_VB ][NP a_DT therapeutic_JJ effect_NN ][PP in_IN ][NP the_DT T_NN lymphocytes_NNS ][PP of_IN ][NP acquired_VBN immunodeficiency_NN syndrome_NN patients_NNS ] ._.
[NP Glucocorticoid_NN receptor_NN ][PP in_IN ][NP patients_NNS ][PP with_IN ][NP lupus_NN nephritis_NN ] :_:[NP relationship_NN ][PP between_IN ][NP receptor_NN levels_NNS ][PP in_IN ][NP mononuclear_JJ leukocytes_NNS ] and_CC[NP effect_NN ][PP of_IN ][NP glucocorticoid_NN therapy_NN ] ._.
[NP We_PRP ][VP investigated_VBD ][NP the_DT clinical_JJ significance_NN ][PP of_IN ][NP glucocorticoid_NN receptor_NN determination_NN ][PP in_IN ][NP 20_CD patients_NNS ][PP with_IN ][NP systemic_JJ lupus_NN erythematosus_NN ] (_([NP SLE_NN ] )_)[NP who_WP ][ADVP afterwards_RB ][VP developed_VBD ][NP nephrotic_JJ syndrome_NN ] ._.
[NP Glucocorticoid_NN receptor_NN concentrations_NNS ][PP in_IN ][NP mononuclear_JJ leukocytes_NNS ] (_([NP MNL_NNS ] )_)[PP in_IN ][NP these_DT patients_NNS ][VP were_VBD ][ADJP comparable_JJ ][PP with_IN ][NP those_DT ][PP in_IN ] both_CC[NP other_JJ patients_NNS ][PP with_IN ][NP SLE_NN ] and_CC[NP healthy_JJ persons_NNS ] ._.
[NP Improvement_NN ][PP in_IN ][NP urinary_JJ protein_NN excretion_NN ][PP and_CC ][PP in_IN ][NP disease_NN activity_NN ] ,_,[NP which_WDT ][VP was_VBD scored_VBN ][PP according_VBG ][PP to_TO ][NP the_DT SLE_NNP Disease_NNP Activity_NNP Index_NNP system_NN ][PP of_IN ][NP the_DT University_NNP ][PP of_IN ][NP Toronto_NNP ] ,_,[ADVP closely_RB ][VP related_JJ ][PP to_TO ][NP the_DT glucocorticoid_NN receptor_NN concentrations_NNS ][PP in_IN ][NP MNL_NN ][VP isolated_VBN ][PP from_IN ][NP the_DT corresponding_JJ patients_NNS ] ._.
[PP In_IN ][NP summary_NN ] ,_,[NP glucocorticoid_NN receptor_NN determination_NN ][PP in_IN ][NP patients_NNS ][PP with_IN ][NP lupus_NN nephritis_NN ][VP may_MD be_VB ][NP a_DT predictive_JJ clue_NN ][PP for_IN ][VP assessing_VBG ][NP responsiveness_NN ][PP to_TO ][NP glucocorticoid_NN therapy_NN ] ._.
[NP Selection_NN ][PP of_IN ][NP optimal_JJ kappa_NN B/Rel_NN DNA-binding_JJ motifs_NNS ] :_:[NP interaction_NN ][PP of_IN ][NP both_DT subunits_NNS ][PP of_IN ][NP NF-kappa_NN B_NN ][PP with_IN ][NP DNA_NN ][VP is_VBZ required_VBN ][PP for_IN ][NP transcriptional_JJ activation_NN ] ._.
[NP Analysis_NN ][PP of_IN ] the_DT[NP p50_NN ] and_CC[NP p65_NN ][NP subunits_NNS ][PP of_IN ][NP the_DT NF-kappa_NN B_NN transcription_NN factor_NN complex_NN ][VP has_VBZ revealed_VBN ][SBAR that_IN ][NP both_DT proteins_NNS ][VP can_MD interact_VB ][PP with_IN ][NP related_JJ DNA_NN sequences_NNS ][PP through_IN ] either_CC[NP homo-_JJ ] or_CC[NP heterodimer_NN ][NP formation_NN ] ._.
[PP In_IN ][NP addition_NN ] ,_,[NP the_DT product_NN ][PP of_IN ][NP the_DT proto-oncogene_NN c-rel_NN ][VP can_MD bind_VB ][PP to_TO ][NP similar_JJ DNA_NN motifs_NNS ][PP by_IN ][NP itself_PRP ][PP or_CC ][PP as_IN ][NP a_DT heterodimer_NN ][PP with_IN ][NP p50_NN ] or_CC[NP p65_NN ] ._.
[ADVP However_RB ] ,_,[NP these_DT studies_NNS ][VP have_VBP used_VBN ][NP a_DT limited_JJ number_NN ][PP of_IN ][NP known_JJ kappa_NN B_NN DNA_NN motifs_NNS ] ,_, and_CC[NP the_DT question_NN ][PP of_IN ][NP the_DT optimal_JJ DNA_NN sequences_NNS ][VP preferred_VBN ][PP by_IN ][NP each_DT homodimer_NN ][VP has_VBZ not_RB been_VBN addressed_VBN ] ._.
[VP Using_VBG ] purified_VBN recombinant_JJ[NP p50_NN ] ,_,[NP p65_NN ] ,_, and_CC[NP c-Rel_NN ][NP proteins_NNS ] ,_,[NP optimal_JJ DNA-binding_JJ motifs_NNS ][VP were_VBD selected_VBN ][PP from_IN ][NP a_DT pool_NN ][PP of_IN ][NP random_JJ oligonucleotides_NNS ] ._.
[NP Alignment_NN ][PP of_IN ][NP the_DT selected_VBN sequences_NNS ][VP allowed_VBD ][NP us_PRP ][VP to_TO predict_VB ][NP a_DT consensus_NN sequence_NN ][PP for_IN ][NP binding_NN ][PP of_IN ][NP the_DT individual_JJ homodimeric_JJ Rel-related_JJ proteins_NNS ] ,_, and_CC[NP DNA-protein_NN binding_NN analysis_NN ][PP of_IN ][NP the_DT selected_VBN DNA_NN sequences_VBZ ][VP revealed_VBD ][NP sequence_NN specificity_NN ][PP of_IN ][NP the_DT proteins_NNS ] ._.
[PP Contrary_JJ to_TO ][NP previous_JJ assumptions_NNS ] ,_,[NP we_PRP ][VP observed_VBD ][SBAR that_IN ][NP p65_NN homodimers_NNS ][VP can_MD interact_VB ][PP with_IN ][NP a_DT subset_NN ][PP of_IN ][NP DNA_NN sequences_VBZ ][VP not_RB recognized_VBN ][PP by_IN ][NP p50_NN homodimers_NNS ] ._.
[NP Differential_JJ binding_NN affinities_NNS ][VP were_VBD also_RB obtained_VBN ][PP with_IN ][NP p50-_NN ] and_CC[ADJP c-Rel-selected_JJ ][NP sequences_NNS ] ._.
[VP Using_VBG ] either_CC a_DT[NP p50-_NN ] or_CC[ADJP p65-selected_JJ ][NP kappa_NN B_NN motif_NN ] ,_,[NP which_WDT ][VP displayed_VBD ][NP differential_JJ binding_NN ][PP with_IN respect_NN to_TO ][NP the_DT other_JJ protein_NN ] ,_,[NP little_JJ to_TO no_DT binding_NN ][VP was_VBD observed_VBN ][PP with_IN ][NP the_DT heterodimeric_JJ NF-kappa_NN B_NN complex_NN ] ._.
[ADVP Similarly_RB ] ,_,[PP in_IN ][NP transfection_NN experiments_NNS ][PP in_IN ][NP which_WDT ][NP the_DT selective_JJ kappa_NN B_NN binding_NN sites_NNS ][VP were_VBD used_VBN ][VP to_TO drive_VB ][NP the_DT expression_NN ][PP of_IN ][NP a_DT chloramphenicol_NN acetyltransferase_NN reporter_NN construct_NN ] ,_, the_DT[NP p65-_NN ] and_CC[ADJP p50-selected_JJ ][NP motifs_NNS ][VP were_VBD activated_VBN ][PP only_RB in_IN the_DT presence_NN of_IN ][NP p65_NN ] and_CC[NP p50/65_NN ] (_([NP a_DT chimeric_JJ protein_NN ][PP with_IN ][NP the_DT ][NP p50_NN DNA_NN binding_NN domain_NN ] and_CC[NP p65_NN activation_NN domain_NN ] )_)[NP expression_NN vectors_NNS ] ,_,[ADVP respectively_RB ] ,_, and_CC[NP neither_DT ][VP demonstrated_VBD ][NP a_DT significant_JJ response_NN ][PP to_TO ][NP stimuli_NNS ][NP that_WDT ][VP induce_VBP ][NP NF-kappa_NN B_NN activity_NN ] ._.
[NP These_DT findings_NNS ][VP demonstrate_VBP ][SBAR that_IN ][NP interaction_NN ][PP of_IN ][NP both_DT subunits_NNS ][PP of_IN ][NP the_DT heterodimeric_JJ NF-kappa_NN B_NN complex_NN ][PP with_IN ][NP DNA_NN ][VP is_VBZ required_VBN ][PP for_IN ][NP DNA_NN binding_NN ] and_CC[NP transcriptional_JJ activation_NN ] and_CC[VP suggest_VBP ][SBAR that_IN ][NP transcriptional_JJ activation_NN ][VP mediated_VBN ][PP by_IN ][NP the_DT individual_JJ rel-related_JJ proteins_NNS ][VP will_MD differ_VB ][ADVP dramatically_RB ] ,_,[PP depending_VBG ][PP on_IN ][NP the_DT specific_JJ kappa_NN B_NN motifs_NNS ][ADJP present_JJ ] ._.
[NP Characterization_NN ][PP of_IN ][NP a_DT new_JJ tissue-specific_JJ transcription_NN factor_NN ][VP binding_VBG ][PP to_TO ][NP the_DT simian_JJ virus_NN 40_CD enhancer_NN TC-II_NN (_( NF-kappa_NN B_NN )_) element_NN ] ._.
[NP We_PRP ] have_VBP[ADVP biochemically_RB ] and_CC[ADVP functionally_RB ][VP characterized_VBN ][NP a_DT new_JJ transcription_NN factor_NN ] ,_,[NP NP-TCII_NN ] ,_,[NP which_WDT ][VP is_VBZ ][ADJP present_JJ ][PP in_IN ][NP nuclei_NNS ][PP from_IN ] unstimulated_JJ[NP T_NN ] and_CC[NP B_NN ][NP lymphocytes_NNS ] but_CC[VP is_VBZ not_RB found_VBN ][PP in_IN ][NP nonhematopoietic_JJ cells_NNS ] ._.
[NP This_DT factor_NN ][VP has_VBZ ][NP a_DT DNA-binding_JJ specificity_NN ][ADJP similar_JJ ][PP to_TO ][NP that_DT ][PP of_IN ][NP NF-kappa_NN B_NN ] but_CC[VP is_VBZ ][ADJP unrelated_JJ ][PP to_TO ][NP this_DT or_CC other_JJ Rel_NN proteins_NNS ][PP by_IN ][NP functional_JJ and_CC biochemical_JJ criteria_NNS ] ._.
[NP It_PRP ][VP can_MD also_RB be_VB distinguished_VBN ][PP from_IN ][NP other_JJ previously_RB described_VBN lymphocyte-specific_JJ DNA-binding_JJ proteins_NNS ] ._.
[NP The_DT candidate_NN oncoprotein_NN Bcl-3_NN ][VP is_VBZ ][NP an_DT antagonist_NN ][PP of_IN ][NP p50/NF-kappa_NN B-mediated_JJ inhibition_NN ] ._.
[NP The_DT candidate_NN oncogene_NN bcl-3_NN ][VP was_VBD discovered_VBN ][PP as_IN ][NP a_DT translocation_NN ][PP into_IN ][NP the_DT immunoglobulin_NN alpha-locus_NN ][PP in_IN ][NP some_DT cases_NNS ][PP of_IN ][NP B-cell_NN chronic_JJ lymphocytic_JJ leukaemias_NNS ] ._.
[NP The_DT protein_NN Bcl-3_NN ][VP contains_VBZ ][NP seven_CD so-called_JJ ankyrin_NN repeats_NNS ] ._.
[NP Similar_JJ repeat_NN motifs_NNS ][VP are_VBP found_VBN ][PP in_IN ][NP a_DT number_NN ][PP of_IN ][NP diverse_JJ regulatory_JJ proteins_NNS ] but_CC[NP the_DT motifs_NNS ][PP of_IN ][NP Bcl-3_NN ][VP are_VBP ][ADJP most_RBS closely_RB related_JJ ][PP to_TO ][NP those_DT ][VP found_VBN ][PP in_IN ][NP I_NN kappa_NN B_NN proteins_NNS ][PP in_IN ][NP which_WDT ][NP the_DT ankyrin_NN repeat_NN domain_NN ][VP is_VBZ thought_VBN to_TO be_VB directly_RB involved_VBN ][PP in_IN ][NP inhibition_NN ][PP of_IN ][NP NF-kappa_NN B_NN activity_NN ] ._.
[NP No_DT biological_JJ function_NN ][VP has_VBZ yet_RB been_VBN described_VBN ][PP for_IN ][NP Bcl-3_NN ] ,_, but_CC[NP it_PRP ][VP was_VBD noted_VBN ][ADVP recently_RB ][SBAR that_IN ][NP Bcl-3_NN ][VP interferes_VBZ ][PP with_IN ][NP DNA-binding_NN ][PP of_IN ][NP the_DT p50_NN subunit_NN ][PP of_IN ][NP NF-kappa_NN B_NN ][ADVP in_FW vitro_FW ] ._.
[ADVP Here_RB ][NP we_PRP ][VP demonstrate_VBP ][SBAR that_IN ][NP Bcl-3_NN ][VP can_MD aid_VB ][NP kappa_NN B_NN site-dependent_JJ transcription_NN ][ADVP in_FW vivo_FW ][PP by_IN ][VP counteracting_VBG ][NP the_DT inhibitory_JJ effects_NNS ][PP of_IN ][NP p50/NF-kappa_NN B_NN homodimers_NNS ] ._.
[NP Bcl-3_NN ][VP may_MD therefore_RB aid_VB ][NP activation_NN ][PP of_IN ][NP select_JJ NF-kappa_NN B-regulated_JJ genes_NNS ] ,_,[PP including_VBG ][NP those_DT ][PP of_IN ][NP the_DT human_JJ immunodeficiency_NN virus_NN ] ._.
[NP A_DT microtitre_NN assay_NN system_NN ][PP for_IN ][NP glucocorticoid_NN receptors_NNS ] :_:[NP decreased_VBN receptor_NN concentration_NN ][PP in_IN ][NP myocardial_JJ infarction_NN ] ._.
[NP A_DT major_JJ difficulty_NN ][PP in_IN ][NP determination_NN ][PP of_IN ][NP glucocorticoid_NN receptor_NN sites_NNS ][VP is_VBZ ][NP the_DT very_RB complicated_JJ assay_NN procedure_NN ] ._.
[ADVP Therefore_RB ] ,_,[NP we_PRP ][VP describe_VBP ][NP a_DT microtitre_NN assay_NN system_NN ][PP for_IN ][NP glucocorticoid_NN receptors_NNS ][NP which_WDT ][VP is_VBZ ][NP a_DT whole-cell_JJ competitive_JJ binding_NN radioassay_NN ][VP using_VBG ][NP (3H)-dexamethasone_NN ][PP as_IN ][NP radioligand_NN ] ._.
[NP This_DT modification_NN ][PP of_IN ][NP a_DT previously_RB described_VBN protocol_NN ][VP simplifies_VBZ ] and_CC[VP reduces_VBZ ][NP laboratory_NN work_NN ] and_CC[VP allows_VBZ ][NP assay_NN reproducibility_NN ][VP to_TO be_VB controlled_VBN ][ADVP more_RBR reliably_RB ] ._.
[VP Thus_RB enabled_VBN to_TO perform_VB ][NP the_DT test_NN ][PP on_IN ][NP multiple_JJ blood_NN samples_NNS ][PP in_IN ][NP parallel_NN ] ,_,[NP we_PRP ][VP investigated_VBD ][NP cardiac_JJ infarction_NN patients_NNS ][PP over_IN ][NP a_DT 12-day_JJ period_NN ][VP to_TO test_VB ][SBAR if_IN ][NP glucocorticoid_NN receptor_NN binding_NN ][VP is_VBZ altered_VBN ][PP in_IN ][NP this_DT '_[[DQS]] stressful_JJ '_[[DQE]] disease_NN ] ._.
[PP On_IN ][NP the_DT first_JJ day_NN ][PP of_IN ][NP the_DT disease_NN ] ,_,[NP glucocorticoid_NN receptor_NN capacity_NN ][VP was_VBD significantly_RB decreased_VBN ][PP without_IN ][NP alteration_NN ][PP of_IN ][NP the_DT receptor-ligand_JJ affinity_NN ] ,_, whereas_IN[PP on_IN ][NP days_NNS ][NP 4_CD ] and_CC[NP 12_CD ][NP the_DT number_NN ][PP of_IN ][NP receptor_NN sites_NNS ][VP was_VBD ][ADJP normal_JJ ][ADVP again_RB ] ._.
[NP This_DT result_NN ][VP fits_VBZ ][ADVP well_RB ][PP into_IN ][NP the_DT general_JJ observation_NN ][PP of_IN ][NP stress-induced_JJ down-regulation_NN ][PP of_IN ][NP immune_JJ responses_NNS ] ._.
[NP Regulation_NN ][PP of_IN ][NP c-jun_NN expression_NN ][PP during_IN ][NP induction_NN ][PP of_IN ][NP monocytic_JJ differentiation_NN ][PP by_IN ][NP okadaic_JJ acid_NN ] ._.
[NP The_DT present_JJ work_NN ][VP has_VBZ examined_VBN ][NP the_DT effects_NNS ][PP of_IN ][NP okadaic_JJ acid_NN ] ,_,[NP an_DT inhibitor_NN ][PP of_IN ] type_NN[NP 1_CD ] and_CC[NP 2A_NN ][NP protein_NN phosphatases_NNS ] ,_,[PP on_IN ][NP the_DT regulation_NN ][PP of_IN ][NP c-jun_NN expression_NN ][PP during_IN ][NP monocytic_JJ differentiation_NN ][PP of_IN ][NP U-937_NN leukemia_NN cells_NNS ] ._.
[NP The_DT results_NNS ][VP demonstrate_VBP ][SBAR that_IN ][NP okadaic_JJ acid_NN treatment_NN ][VP is_VBZ associated_VBN ][PP with_IN ][NP induction_NN ][PP of_IN ][NP a_DT differentiated_VBN monocyte_NN phenotype_NN ][VP characterized_VBN ][PP by_IN ] :_:[LST (_( a_LS ] )_)[NP growth_NN arrest_NN ] ;_:[LST (_( b_LS ] )_)[NP increases_NNS ][PP in_IN ][NP Mac-1_NN cell_NN surface_NN antigen_NN expression_NN ] ;_:[LST (_( c_LS ] )_)[NP down-regulation_NN ][PP of_IN ][NP c-myc_NN transcripts_NNS ] ;_: and_CC[LST (_( d_LS ] )_)[NP induction_NN ][PP of_IN ][NP tumor_NN necrosis_NN factor_NN gene_NN expression_NN ] ._.
[NP This_DT induction_NN ][PP of_IN ][NP monocytic_JJ differentiation_NN ][VP was_VBD associated_VBN ][PP with_IN ][NP transient_JJ increases_NNS ][PP in_IN ][NP c-jun_NN mRNA_NN levels_NNS ] ,_,[NP which_WDT ][VP were_VBD ][ADJP maximal_JJ ][PP at_IN ][NP 6_CD h_NN ] ._.
[NP Similar_JJ effects_NNS ][VP were_VBD obtained_VBN ][PP for_IN ][NP the_DT c-fos_NN gene_NN ] ._.
[NP Run-on_JJ analysis_NN ][VP demonstrated_VBD ][NP detectable_JJ levels_NNS ][PP of_IN ][NP c-jun_NN transcription_NN ][PP in_IN ][NP U-937_NN cells_NNS ] and_CC[SBAR that_IN ][NP this_DT rate_NN ][VP is_VBZ increased_VBN ][ADVP approximately_RB 40-fold_RB ][PP following_VBG ][NP okadaic_JJ acid_NN exposure_NN ] ._.
[NP c-jun_NN mRNA_NN levels_NNS ][VP were_VBD superinduced_VBN ][PP in_IN ][NP cells_NNS ][VP treated_VBN ][PP with_IN ] both_CC[NP okadaic_JJ acid_NN ] and_CC[NP cycloheximide_NN ] ,_, whereas_IN[NP inhibition_NN ][PP of_IN ][NP protein_NN synthesis_NN ][VP had_VBD ] little_JJ ,_,[SBAR if_IN ][ADJP any_DT ] ,_,[NP effect_NN ][PP on_IN ][NP okadaic_JJ acid-induced_JJ c-jun_NN transcription_NN ] ._.
[NP The_DT half-life_NN ][PP of_IN ][NP c-jun_NN mRNA_NN ][VP was_VBD ][ADJP similar_JJ ] (_([NP 45-50_CD min_NN ] )_)[PP in_IN ][NP both_CC untreated_JJ and_CC okadaic_JJ acid-induced_JJ cells_NNS ] ._.
[PP In_IN ][NP contrast_NN ] ,_,[NP treatment_NN ][PP with_IN ][NP both_DT ][NP okadaic_JJ acid_NN ] and_CC[NP cycloheximide_NN ][VP was_VBD associated_VBN ][PP with_IN ][NP stabilization_NN ] (_([NP t_NN 1/2_CD ][VP =_JJ ][NP 90_CD min_NN ] )_)[PP of_IN ][NP c-jun_NN transcripts_NNS ] ._.
[VP Taken_VBN ][ADVP together_RB ] ,_,[NP these_DT findings_NNS ][VP indicate_VBP ][SBAR that_IN ][NP the_DT induction_NN ][PP of_IN ][NP c-jun_NN transcription_NN ][PP by_IN ][NP okadaic_JJ acid_NN ][VP is_VBZ controlled_VBN ][ADVP primarily_RB ][PP by_IN ][NP a_DT transcriptional_JJ mechanism_NN ] ._.
[SBAR Since_IN ][NP previous_JJ studies_NNS ][VP have_VBP demonstrated_VBN ][SBAR that_IN ][NP the_DT c-jun_NN gene_NN ][VP is_VBZ autoinduced_VBN ][PP by_IN ][NP Jun/AP-1_NN ] ,_,[NP we_PRP ][ADVP also_RB ][VP studied_VBD ][NP transcription_NN ][PP of_IN ] c-jun_NN promoter_NN (_([NP positions_NNS ][NP -132/+170_CD ] )_)[NP -reporter_JJ gene_NN constructs_NNS ][PP with_IN ][PP and_CC ][PP without_IN ][NP a_DT mutated_VBN AP-1_NN element_NN ] ._.
 (_([NP ABSTRACT_NN ][VP TRUNCATED_VBN ][PP AT_IN ][NP 250_CD WORDS_NNS ] )_)
[NP Activation_NN ][PP of_IN ][NP NF-kappa_NN B_NN ][PP by_IN ][NP interleukin_NN 2_CD ][PP in_IN ][NP human_JJ blood_NN monocytes_NNS ] ._.
[NP We_PRP ][VP report_VBP ][ADVP here_RB ][SBAR that_IN ][NP interleukin_NN 2_CD ] (_([NP IL-2_NN ] )_)[VP acts_VBZ ][PP on_IN ][NP human_JJ blood_NN monocytes_NNS ][PP by_IN ][VP enhancing_VBG ][NP binding_NN activity_NN ][PP of_IN ][NP the_DT transcription_NN factor_NN NF-kappa_NN B_NN ][PP to_TO ][NP its_PRP$ consensus_NN sequence_NN ][PP in_IN ][NP the_DT 5'_JJ regulatory_JJ enhancer_NN region_NN ][PP of_IN ][NP the_DT IL-2_NN receptor_NN alpha_NN chain_NN ] (_([NP p55_NN ] )_) ._.
[ADVP Similarly_RB ] ,_,[NP IL-2_NN ][VP activates_VBZ ][NP NF-kappa_NN B_NN ][PP in_IN ][NP the_DT human_JJ monocytic_JJ cell_NN line_NN U_NN 937_CD ][PP ,_, but_CC ][PP not_RB in_IN ][NP resting_VBG human_JJ T-cells_NNS ] ._.
[NP This_DT effect_NN ][VP is_VBZ ][ADJP detectable_JJ ][PP within_IN ][NP 15_CD min_NN ] and_CC[VP peaks_VBZ ][NP 1_CD h_NN ][PP after_IN ][NP exposure_NN ][PP to_TO ][NP IL-2_NN ] ._.
[NP Enhanced_VBN NF-kappa_NN B_NN binding_NN activity_NN ][VP is_VBZ followed_VBN ][PP by_IN ][NP functional_JJ activation_NN ][PP in_IN ][NP that_IN ][NP inducibility_NN ][PP of_IN ][NP the_DT IL-2_NN receptor_NN alpha_NN chain_NN ][VP is_VBZ mediated_VBN ][PP by_IN ][NP enhanced_VBN NF-kappa_NN B_NN binding_NN ] and_CC[NP that_IN ][NP a_DT heterologous_JJ promoter_NN ][VP containing_VBG ][NP the_DT NF-kappa_NN B_NN consensus_NN sequence_NN ] (_([NP -291_CD ] to_TO[NP -245_CD ] )_)[PP of_IN ][NP the_DT IL-2_NN receptor_NN alpha_NN chain_NN gene_NN ][VP is_VBZ activated_VBN ] ._.
[PP In_IN ][NP addition_NN ] ,_,[NP IL-2_NN ][VP is_VBZ ][ADJP capable_JJ ][PP of_IN ][VP increasing_VBG ][NP transcript_NN levels_NNS ][PP of_IN ][NP the_DT p50_NN gene_NN ][VP coding_VBG ][PP for_IN ][NP the_DT p50_NN subunit_NN ][PP of_IN ][NP the_DT NF-kappa_NN B_NN transcription_NN factor_NN ] ,_, whereas_IN[NP mRNA_NN levels_NNS ][PP of_IN ][NP the_DT p65_NN NF-kappa_NN B_NN gene_NN ][VP remained_VBD ][ADJP unchanged_JJ ] ._.
[NP Single_JJ point_NN estimation_NN ][PP of_IN ][NP glucocorticoid_NN receptors_NNS ][PP in_IN ][NP lymphocytes_NNS ][PP of_IN ][NP normal_JJ subjects_NNS ][PP and_CC ][PP of_IN ][NP children_NNS ][PP under_IN ][NP long_JJ term_NN glucocorticoid_NN treatment_NN ] ._.
[NP A_DT single_JJ point_NN assay_NN ][PP of_IN ][NP glucocorticoid_NN receptors_NNS ] (_([NP GR_NN ] )_)[PP in_IN ][NP human_JJ lymphocytes_NNS ][PP based_VBN ][PP on_IN ][NP the_DT measurement_NN ][PP of_IN ][NP specific_JJ dexamethasone_NN binding_NN ][VP has_VBZ been_VBN developed_VBN ] and_CC[VP compared_VBN ][PP with_IN ][NP a_DT common_JJ multi-point_JJ Scatchard_NN analysis_NN ] ._.
[NP The_DT assay_NN conditions_NN ] -_:[NP concentration_NN ][PP of_IN ][NP the_DT ligand_NN ][NP 20_CD nmol/l_NN ] ,_,[NP incubation_NN time_NN 2_CD h_NN ] and_CC[NP the_DT cell_NN count_NN 2-6_CD mil._CD cells/tube_NNS ][PP in_IN ][NP the_DT assay_NN volume_NN 0.25_CD ml_NN ][VP were_VBD found_VBN to_TO be_VB ][ADJP optimal_JJ ] ._.
[NP An_DT attempt_NN ][VP was_VBD also_RB undertaken_VBN ][VP to_TO use_VB ][NP a_DT cell_NN harvester_NN ][PP for_IN ][NP the_DT separation_NN ][PP of_IN ][NP cells_NNS ][PP from_IN ][NP unbound_JJ ligand_NN ] ._.
[SBAR Though_IN ][NP specifically_RB bound_VBN dexamethasone_NN ][VP measured_VBN ][PP by_IN ][NP whole-cell_JJ assay_NN ] and_CC[NP that_DT ][VP using_VBG ][NP cell_NN harvester_NN ][VP correlated_VBD ][ADVP well_RB ] ,_,[PP almost_RB by_IN ][NP one_CD order_NN ][NP lower_JJR values_NNS ][VP obtained_VBN ][PP with_IN ][NP the_DT latter_JJ method_NN ][VP render_VBP ][NP it_PRP ][ADJP non-applicable_JJ ][PP for_IN ][NP receptor_NN quantitation_NN ] ._.
[NP The_DT results_NNS ][PP from_IN ][NP 9_CD healthy_JJ volunteers_NNS ] (_([NP average_JJ GR_NN concentration_NN ][NP 7131_CD +/-_CC 1256_CD sites/cell_NNS ] )_)[VP correlated_VBD ][ADVP excellently_RB ][PP with_IN ][NP those_DT ][VP obtained_VBN ][PP by_IN ][NP the_DT Scatchard_NN analysis_NN ] ._.
[NP The_DT single_JJ point_NN assay_NN ][VP has_VBZ been_VBN also_RB applied_VBN ][PP for_IN ][NP determination_NN ][PP of_IN ][NP GH_NN ][PP in_IN ][NP 10_CD children_NNS ][VP treated_VBN ][PP with_IN ][NP large_JJ doses_NNS ][PP of_IN ][NP prednisone_NN ] ._.
[NP The_DT average_JJ values_NNS ][PP from_IN ][NP healthy_JJ volunteers_NNS ][VP did_VBD not_RB differ_VB ][ADVP significantly_RB ][PP from_IN ][NP those_DT ][VP found_VBN ][PP in_IN ][NP these_DT children_NNS ] ,_, though_RB[NP much_RB broader_JJR range_NN ][VP was_VBD found_VBN ][PP in_IN ][NP patients_NNS ] ._.
[NP A_DT novel_JJ B_NN cell-derived_JJ coactivator_NN ][VP potentiates_VBZ ][NP the_DT activation_NN ][PP of_IN ][NP immunoglobulin_NN promoters_NNS ][PP by_IN ][NP octamer-binding_JJ transcription_NN factors_NNS ] ._.
[NP A_DT novel_JJ B_NN cell-restricted_JJ activity_NN ] ,_,[VP required_VBN ][PP for_IN ][NP high_JJ levels_NNS ][PP of_IN ][NP octamer/Oct-dependent_JJ transcription_NN ][PP from_IN ] an_DT[NP immunoglobulin_NN heavy_JJ chain_NN ] (_([NP IgH_NN ] )_)[NP promoter_NN ] ,_,[VP was_VBD detected_VBN ][PP in_IN ][NP an_DT in_FW vitro_FW system_NN ][VP consisting_VBG ][PP of_IN ][NP HeLa_NN cell-derived_JJ extracts_NNS ][VP complemented_VBN ][PP with_IN ][NP fractionated_VBN B_NN cell_NN nuclear_JJ proteins_NNS ] ._.
[NP The_DT factor_NN ][ADJP responsible_JJ ][PP for_IN ][NP this_DT activity_NN ][VP was_VBD designated_VBN ][NP Oct_NN coactivator_NN ][PP from_IN ][NP B_NN cells_NNS ] (_([NP OCA-B_NN ] )_) ._.
[NP OCA-B_NN ][VP stimulates_VBZ ][NP the_DT transcription_NN ][PP from_IN ][NP an_DT IgH_NN promoter_NN ][PP in_IN conjunction_NN with_IN ] either_CC[NP Oct-1_NN ] or_CC[NP Oct-2_NN ] but_CC[VP shows_VBZ ][NP no_DT significant_JJ effect_NN ][PP on_IN ][NP the_DT octamer/Oct-dependent_JJ transcription_NN ][PP of_IN ][NP the_DT ubiquitously_RB expressed_VBN histone_NN H2B_NN promoter_NN ] and_CC[NP the_DT transcription_NN ][PP of_IN ][NP USF-_NN ] and_CC[ADJP Sp1-regulated_JJ ][NP promoters_NNS ] ._.
[VP Taken_VBN ][ADVP together_RB ] ,_,[NP our_PRP$ results_NNS ][VP suggest_VBP ][SBAR that_IN ][NP OCA-B_NN ][VP is_VBZ ] a_DT[NP tissue-_NN ] ,_,[NP promoter-_NN ] ,_, and_CC[ADJP factor-specific_JJ ][NP coactivator_NN ] and_CC[SBAR that_IN ][NP OCA-B_NN ][VP may_MD be_VB ][NP a_DT major_JJ determinant_NN ][PP for_IN ][NP B_NN cell-specific_JJ activation_NN ][PP of_IN ][NP immunoglobulin_NN promoters_NNS ] ._.
[PP In_IN light_NN of_IN ][NP the_DT evidence_NN ][VP showing_VBG ][NP physical_JJ and_CC functional_JJ interactions_NNS ][PP between_IN ][NP Oct_NN factors_NNS ] and_CC[NP OCA-B_NN ] ,_,[NP we_PRP ][VP propose_VBP ][NP a_DT mechanism_NN ][PP of_IN ][NP action_NN ][PP for_IN ][NP OCA-B_NN ] and_CC[VP discuss_VBP ][NP the_DT implications_NNS ][PP of_IN ][NP OCA-B_NN ][PP for_IN ][NP the_DT transcriptional_JJ regulation_NN ][PP of_IN ][NP other_JJ tissue-specific_JJ promoters_NNS ] ._.
[NP The_DT regulation_NN ][PP of_IN ][NP the_DT human_JJ tumor_NN necrosis_NN factor_NN alpha_NN promoter_NN region_NN ][PP in_IN ][NP macrophage_NN ] ,_,[NP T_NN cell_NN ] ,_, and_CC[NP B_NN cell_NN ][NP lines_NNS ] ._.
[NP The_DT 1311-base_JJ pair_NN human_JJ tumor_NN necrosis_NN factor_NN (_( TNF_NN )_) alpha_NN promoter_NN region_NN ][VP was_VBD fused_VBN ][PP to_TO ] the_DT[NP luciferase_NN ] (_([NP Luc_NN ] )_)[NP reporter_NN gene_NN ] and_CC[VP studied_VBN ][PP in_IN ][NP a_DT transient_JJ transfection_NN system_NN ][PP in_IN ][NP three_CD TNF_NN producing_NN cell_NN lines_NNS ] ,_,[NP the_DT U937_NN macrophage_NN cell_NN line_NN ] ,_,[NP the_DT MLA_NN 144_CD T_NN cell_NN line_NN ] ,_, and_CC[NP the_DT 729-6_CD B_NN cell_NN line_NN ] ._.
[NP This_DT full_JJ length_NN promoter_NN construct_NN ][VP can_MD be_VB induced_VBN ][PP by_IN ][NP phorbol_NN 13-myristate_NN acetate_NN ] (_([NP PMA_NN ] )_)[PP in_IN ][NP each_DT ][PP of_IN ][NP these_DT cell_NN types_NNS ] ._.
[NP Analysis_NN ][PP of_IN ][NP a_DT series_NN ][PP of_IN ][NP 5'-truncations_NNS ][VP showed_VBD ][NP several_JJ peaks_NNS ][PP of_IN ][NP basal_JJ and_CC PMA_NN induced_JJ activity_NN ][VP suggesting_VBG ][NP the_DT presence_NN ][PP of_IN ][NP several_JJ positive_JJ and_CC negative_JJ regulatory_JJ elements_NNS ] ._.
[NP A_DT PMA_NN responsive_JJ element_NN ][VP was_VBD localized_JJ ][PP to_TO ][NP a_DT region_NN ][PP between_IN ][NP -95_CD ] and_CC[NP -36_CD ][NP bp_NN ][ADJP relative_JJ ][PP to_TO ][NP the_DT transcription_NN start_NN site_NN ] ._.
[PP Within_IN ][NP this_DT region_NN ] ,_,[NP single_JJ AP-2-_NN and_CC AP-1-like_JJ consensus_NN sequences_NNS ][VP were_VBD noted_VBN ] ._.
 These_DT[NP AP-2_NN ] and_CC[NP AP-1_NN ][NP sites_NNS ][VP were_VBD each_DT modified_VBN ][PP with_IN ][NP a_DT double_JJ point_NN mutation_NN ] ._.
 A_DT modest_JJ (_([NP 20-50_CD %_NN ] )_)[NP reduction_NN ][PP in_IN ][NP TNF_NN promoter_NN activity_NN ][VP was_VBD observed_VBN ][PP with_IN ][NP the_DT AP-2_NN site_NN mutation_NN ] ._.
[ADVP However_RB ] ,_,[NP mutation_NN ][PP of_IN ][NP the_DT AP-1_NN site_NN ][ADVP markedly_RB ][VP diminished_VBD ][NP both_CC the_DT basal_JJ and_CC PMA-activated_JJ promoter_NN activity_NN ] ._.
[ADVP Also_RB ][NP co-transfections_NNS ][PP of_IN ][NP the_DT wild-type_JJ promoter_NN construct_NN ][PP with_IN ][NP an_DT AP-1/c-jun_NN expression_NN vector_NN ][VP resulted_VBD ][PP in_IN ][NP augmented_JJ basal_JJ and_CC PMA-induced_JJ promoter_NN activity_NN ] ._.
[NP Redox_NN status_NN ][PP of_IN ][NP cells_NNS ][VP influences_VBZ ][NP constitutive_JJ or_CC induced_VBN NF-kappa_NN B_NN translocation_NN ] and_CC[NP HIV_NN long_JJ terminal_JJ repeat_NN activity_NN ][PP in_IN ] human_JJ[NP T_NN ] and_CC[ADJP monocytic_JJ ][NP cell_NN lines_NNS ] ._.
[NP We_PRP ][VP have_VBP tested_VBN ][NP the_DT hypothesis_NN ][SBAR that_IN ][NP cellular_JJ activation_NN events_NNS ][VP occurring_VBG ][PP in_IN ][NP T_NN lymphocytes_NNS ] and_CC[NP monocytes_NNS ] and_CC[VP mediated_VBN ][PP through_IN ][NP translocation_NN ][PP of_IN ][NP the_DT transcription_NN factor_NN NF-kappa_NN B_NN ][VP are_VBP ][ADJP dependent_JJ ][PP upon_IN ][NP the_DT constitutive_JJ redox_NN status_NN ][PP of_IN ][NP these_DT cells_NNS ] ._.
[NP We_PRP ][VP used_VBD ][NP phenolic_JJ ,_, lipid-soluble_JJ ,_, chain-breaking_JJ antioxidants_NNS ] (_([NP butylated_VBN hydroxyanisole_NN ] (_([NP BHA_NN ] )_) ,_,[NP nordihydroquairetic_JJ acid_NN ] ,_, or_CC[NP alpha-tocopherol_NN ] (_([NP vitamin_NN E_NN ] )_)[VP to_TO show_VB ][SBAR that_IN ][NP peroxyl_JJ radical_JJ scavenging_NN ][PP in_IN ] unstimulated_JJ and_CC[NP PMA-_NN ] or_CC[ADJP TNF-stimulated_JJ ][NP cells_NNS ][VP blocks_VBZ ][NP the_DT functions_NNS ][PP depending_VBG ][PP on_IN ][NP NF-kappa_NN B_NN activation_NN ] ._.
[NP BHA_NN ][VP was_VBD found_VBN to_TO suppress_VB ][CONJP not_RB only_RB ][NP PMA-_NN ] or_CC[ADJP TNF-induced_JJ ] ,_,[CONJP but_CC also_RB ][ADJP constitutive_JJ ][NP ,_, HIV-enhancer_JJ activity_NN ][ADJP concomitant_JJ ][PP to_TO ][NP an_DT inhibition_NN ][PP of_IN ][NP NF-kappa_NN B_NN binding_NN activity_NN ][PP in_IN ] both_CC lymphoblastoid_JJ T_NN (_([NP J.Jhan_NN ] )_) and_CC monocytic_JJ (_([NP U937_NN ] )_)[NP cell_NN lines_NNS ] ._.
[NP This_DT ][VP was_VBD ][ADVP also_RB ][ADJP true_JJ ][PP for_IN ][NP KBF_NN ] (_([NP p50_NN homodimer_NN ] )_)[NP binding_NN activity_NN ][PP in_IN ][NP U937_NN cells_NNS ] ._.
[NP Secretion_NN ][PP of_IN ][NP TNF_NN ] ,_,[NP the_DT product_NN ][PP of_IN ][NP another_DT NF-kappa_NN B-dependent_JJ gene_NN ] ,_,[VP was_VBD abolished_VBN ][PP by_IN ][NP BHA_NN ][PP in_IN ][NP PMA-stimulated_JJ U937_NN cells_NNS ] ._.
[NP The_DT anti-oxidative_JJ effect_NN ][PP of_IN ][NP BHA_NN ][VP was_VBD accompanied_VBN ][PP by_IN ][NP an_DT increase_NN ][PP in_IN ][NP thiol_NN ] ,_,[CONJP but_CC not_RB ][NP glutathione_NN ] ,_,[NP content_NN ][PP in_IN ][NP stimulated_VBN and_CC unstimulated_JJ T_NN cell_NN ] ,_, whereas_IN[NP TNF_NN stimulation_NN ][NP itself_PRP ][ADVP barely_RB ][VP modified_VBD ][NP the_DT cellular_JJ thiol_NN level_NN ] ._.
[NP Oxidative_JJ stress_NN ][VP obtained_VBN ][PP by_IN ][NP the_DT addition_NN ][PP of_IN ][NP H2O2_NN ][PP to_TO ][NP the_DT culture_NN medium_NN ][PP of_IN ][NP J.Jhan_NN ] or_CC[NP U937_NN ][NP cells_NNS ][VP could_MD ] not_RB[PP by_IN ][NP itself_PRP ][VP induce_VB ][NP NF-kappa_NN B_NN activation_NN ] ._.
[NP These_DT observations_NNS ][VP suggest_VBP ][SBAR that_IN ][NP TNF_NN ] and_CC[NP PMA_NN ][VP do_VBP not_RB lead_VB ][PP to_TO ][NP NF-kappa_NN B_NN activation_NN ][PP through_IN ][NP induction_NN ][PP of_IN ][NP changes_NNS ][PP in_IN ][NP the_DT cell_NN redox_NN status_NN ] ._.
[ADVP Rather_RB ] ,_,[NP TNF_NN ] and_CC[NP PMA_NN ][VP can_MD exert_VB ][NP their_PRP$ effect_NN ][SBAR only_RB if_IN ][NP cells_NNS ][VP are_VBP ][PP in_IN ][NP an_DT appropriate_JJ redox_NN status_NN ] ,_,[SBAR because_IN ][NP prior_JJ modification_NN ][PP toward_IN ][NP reduction_NN ][PP with_IN ][NP BHA_NN treatment_NN ][VP prevents_VBZ this_DT activation_NN ] ._.
[NP It_PRP ][VP appears_VBZ ][SBAR that_IN ][NP a_DT basal_JJ redox_NN equilibrium_NN ][VP tending_VBG ][PP toward_IN ][NP oxidation_NN ][VP is_VBZ ][NP a_DT prerequisite_NN ][PP for_IN ][NP full_JJ activation_NN ][PP of_IN ][NP transduction_NN pathways_NNS ][VP regulating_VBG ][NP the_DT activity_NN ][PP of_IN ][NP NF-kappa_NN B-dependent_JJ genes_NNS ] ._.
[NP Expression_NN ][PP of_IN ][NP c-fos_NN ] ,_,[NP c-jun_NN ] and_CC[NP jun_NN B_NN ][PP in_IN ][NP peripheral_JJ blood_NN lymphocytes_NNS ][PP from_IN ][NP young_JJ and_CC elderly_JJ adults_NNS ] ._.
[NP The_DT expression_NN ][PP of_IN ][NP c-fos_NN ] ,_,[NP c-jun_NN ] and_CC[NP jun_NN B_NN ][NP proto-oncogenes_NNS ][VP was_VBD studied_VBN ][PP in_IN ][NP phytohemagglutinin_NN ] (_([NP PHA_NN ] )_)[NP activated_VBN ][NP peripheral_JJ blood_NN lymphocytes_NNS ] (_([NP PBL_NN ] )_)[PP from_IN ][NP young_JJ and_CC aged_JJ humans_NNS ] ._.
[NP Specific_JJ mRNAs_NNS ][PP for_IN ][NP c-fos_NN ] and_CC[NP c-jun_NN ][VP were_VBD ][ADJP detectable_JJ ][PP within_IN ][NP 30_CD min_NN ][PP after_IN ][NP cell_NN activation_NN ] and_CC[VP reached_VBD ][NP maximal_JJ levels_NNS ][PP within_IN ][NP 2_CD h_NN ] ._.
 Both_CC[NP c-fos_NN ] and_CC[NP jun_NN B_NN ][NP mRNAs_NNS ][VP decreased_VBD ][PP to_TO ][NP pre-activation_NN levels_NNS ][PP within_IN ][NP 6_CD h_NN ] ,_,[SBAR while_IN ][NP c-jun_NN mRNA_NN ][VP remained_VBD ][ADJP elevated_JJ ] ._.
[PP In_IN ][NP PHA-activated_JJ PBL_NN ] ,_,[NP no_DT age-related_JJ differences_NNS ][VP were_VBD observed_VBN ][PP in_IN ][NP c-fos_NN ] or_CC[NP jun_NN B_NN ][NP mRNA_NN expression_NN ] ._.
[ADVP However_RB ] ,_,[NP c-jun_NN mRNA_NN levels_NNS ][VP decreased_VBD ][ADVP significantly_RB ] (_([NP 1.73_CD +/-_CC 0.08_CD ] vs._CC[NP 1.16_CD +/-_CC 0.09_CD ][NP arbitrary_JJ units_NNS ] ,_,[NP P_NN ][VP &lt[[SEMICOLON]]_JJR ][NP 0.01_CD ] ,_,[ADJP young_JJ ] vs._CC[ADJP old_JJ ] )_)[PP in_IN ][NP PBL_NN ][PP from_IN ][NP elderly_JJ individuals_NNS ][VP activated_VBN ][PP with_IN ][NP PHA_NN ] ._.
[SBAR Because_IN ][NP previous_JJ work_NN ][VP has_VBZ demonstrated_VBN ][SBAR that_IN ][NP T_NN cells_NNS ][PP from_IN ][NP elderly_JJ individuals_NNS ][VP may_MD display_VB ][NP normal_JJ proliferative_JJ responses_NNS ][ADVP when_WRB ][VP activated_VBN ][PP via_IN ][NP the_DT anti-CD2_JJ pathway_NN ] ,_,[NP c-jun_NN ] and_CC[NP jun_NN B_NN ][NP mRNA_NN expression_NN ][VP was_VBD also_RB studied_VBN ][PP in_IN ][NP anti-CD2-activated_JJ purified_VBN T_NN cells_NNS ] ._.
[NP No_DT age-related_JJ differences_NNS ][VP were_VBD found_VBN ][PP in_IN ][NP the_DT expression_NN ][PP of_IN ][NP either_DT ][PP of_IN ][NP these_DT two_CD proto-oncogenes_NNS ][PP by_IN ][NP anti-CD2_NN activated_JJ T_NN cells_NNS ] ._.
[NP These_DT results_NNS ][VP suggest_VBP ][SBAR that_IN ][NP the_DT decreased_VBN IL-2_NN production_NN ] and_CC[NP proliferative_JJ response_NN ][VP displayed_VBN ][PP by_IN ][NP PHA-activated_JJ PBL_NN ][PP from_IN ][NP elderly_JJ adults_NNS ][VP may_MD be_VB ][ADJP related_JJ ][PP to_TO ][NP age-related_JJ changes_NNS ][PP in_IN ][NP c-jun_NN mRNA_NN expression_NN ][PP and_CC ][PP in_IN ][NP the_DT ratio_NN ][PP of_IN ][NP c-fos_NN ][PP to_TO ][NP c-jun_NN ][NP mRNA_NN ] ._.
[NP Characterization_NN ][PP of_IN ][NP a_DT novel_JJ T_NN lymphocyte_NN protein_NN ][NP which_WDT ][VP binds_VBZ ][PP to_TO ][NP a_DT site_NN ][ADJP related_JJ ][PP to_TO ][NP steroid/thyroid_JJ ][NP hormone_NN receptor_NN response_NN elements_NNS ][PP in_IN ][NP the_DT negative_JJ regulatory_JJ sequence_NN ][PP of_IN ][NP the_DT human_JJ immunodeficiency_NN virus_NN long_JJ terminal_JJ repeat_NN ] ._.
[NP We_PRP ][VP have_VBP previously_RB identified_VBN ][NP a_DT T_NN lymphocyte_NN protein_NN ][NP which_WDT ][VP binds_VBZ ][PP to_TO ][NP a_DT site_NN ][PP within_IN ][NP the_DT LTR_NN ][PP of_IN ][NP the_DT human_JJ immunodeficiency_NN virus_NN type_NN 1_CD ] (_([NP HIV-1_NN ] )_) and_CC[VP exerts_VBZ ][NP an_DT inhibitory_JJ effect_NN ][PP on_IN ][NP virus_NN gene_NN expression_NN ] ._.
[NP The_DT palindromic_JJ site_NN ] (_([NP site_NN B_NN ] )_)[VP recognized_VBN ][PP by_IN ][NP this_DT protein_NN ][VP is_VBZ ][ADJP related_JJ ][PP to_TO ][NP the_DT palindromic_JJ binding_VBG sites_NNS ][PP of_IN ][NP members_NNS ][PP of_IN ] the_DT[NP steroid/thyroid_JJ ][NP hormone_NN receptor_NN family_NN ] ._.
[ADVP Here_RB ][NP we_PRP ][VP characterize_VBP ][NP the_DT T_NN cell_NN protein_NN ][VP binding_VBG ][PP to_TO ][NP this_DT site_NN ][PP as_IN ][NP a_DT 100_CD kD_NN protein_NN ][NP which_WDT ][VP is_VBZ ][ADJP most_RBS abundant_JJ ][PP in_IN ][NP T_NN cells_NNS ] and_CC[NP which_WDT ][VP binds_VBZ ][PP to_TO ][NP site_NN B_NN ][PP as_IN ][NP a_DT 200_CD kD_NN complex_NN ] ._.
[NP This_DT protein_NN ][VP is_VBZ ][ADJP distinct_JJ ][PP from_IN ][NP other_JJ members_NNS ][PP of_IN ] the_DT[NP steroid/thyroid_JJ ][NP hormone_NN receptor_NN family_NN ][PP including_VBG ][NP the_DT COUP_NN protein_NN ][NP which_WDT ][VP has_VBZ ][NP a_DT closely_RB related_JJ DNA_NN binding_NN specificity_NN ] ._.
[NP A_DT mechanism_NN ][PP for_IN ][NP the_DT antiinflammatory_JJ effects_NNS ][PP of_IN ][NP corticosteroids_NNS ] :_:[NP the_DT glucocorticoid_NN receptor_NN ][VP regulates_VBZ ][NP leukocyte_NN adhesion_NN ][PP to_TO ][NP endothelial_JJ cells_NNS ] and_CC[NP expression_NN ][PP of_IN ][NP endothelial-leukocyte_JJ adhesion_NN molecule_NN 1_CD ] and_CC[NP intercellular_JJ adhesion_NN molecule_NN 1_CD ] ._.
[NP Corticosteroids_NNS ][VP are_VBP ][NP the_DT preeminent_JJ antiinflammatory_JJ agents_NNS ][SBAR although_IN ][NP the_DT molecular_JJ mechanisms_NNS ][NP that_WDT ][VP impart_VBP ][NP their_PRP$ efficacy_NN ][VP have_VBP not_RB been_VBN defined_VBN ] ._.
[NP The_DT endothelium_NN ][VP plays_VBZ ][NP a_DT critical_JJ role_NN ][PP in_IN ][NP inflammation_NN ][PP by_IN ][VP directing_VBG ][NP circulating_VBG leukocytes_NNS ][PP into_IN ][NP extravascular_JJ tissues_NNS ][PP by_IN ][VP expressing_VBG ][NP adhesive_JJ molecules_NNS ][PP for_IN ][NP leukocytes_NNS ] (_([PP e.g._FW ][NP ,_, endothelial-leukocyte_JJ adhesion_NN molecule_NN ] 1_CD (_( ELAM-1_NN )_)[NP and_CC intercellular_JJ adhesion_NN molecule_NN ] 1_CD (_( ICAM-1_NN )_) ._.
[NP We_PRP ][ADVP therefore_RB ][VP determined_VBD ][SBAR whether_IN ][NP corticosteroids_NNS ][VP suppress_VBP ][NP inflammation_NN ][PP by_IN ][VP inhibiting_VBG ][NP endothelial_JJ expression_NN ][PP of_IN ][NP adhesion_NN molecules_NNS ][PP for_IN ][NP neutrophils_NNS ] (_([NP polymorphonuclear_JJ leukocytes_NNS ] )_) ._.
[NP Preincubation_NN ][PP of_IN ][NP endothelial_JJ cells_NNS ][PP with_IN ][NP endotoxin_NN ] (_([NP lipopolysaccharide_NN ] (_([NP LPS_NN ] )_) ,_,[NP 1_CD microgram/ml_NN ] )_)[VP led_VBD ][PP to_TO ][NP a_DT 4-fold_JJ increase_NN ][PP in_IN ][NP subsequent_JJ adherence_NN ][PP of_IN ][NP polymorphonuclear_JJ leukocytes_NNS ] (_([NP P_NN ][VP <_JJR ][NP 0.0001_CD ] ,_,[NP n_NN ][VP =_JJ ][NP 10_CD ] )_)[PP to_TO ][NP endothelial_JJ cells_NNS ] ,_,[NP an_DT increase_NN ][NP that_WDT ][VP was_VBD markedly_RB attenuated_VBN ][ADVP when_WRB ][NP endothelial_JJ cells_NNS ][VP were_VBD treated_VBN ][PP with_IN ][NP dexamethasone_NN ] (_([NP IC50_NN ][VP <_JJR ][NP 1_CD nM_NN ] ,_,[NP P_NN ][VP <_JJR ][NP 0.0001_CD ] ,_,[NP n_NN ][VP =_JJ ][NP 6_CD ] or_CC[NP 7_CD ] )_)[PP during_IN ][NP preincubation_NN ][PP with_IN ][NP LPS_NN ] ._.
[ADVP Moreover_RB ] ,_,[NP the_DT steroid_NN receptor_NN agonist_NN cortisol_NN ] (_([NP 10_CD microM_NN ] )_) ,_,[CONJP but_CC not_RB ][NP its_PRP$ inactive_JJ metabolite_NN tetrahydrocortisol_NN ] (_([NP 10_CD microM_NN ] )_) ,_,[VP diminished_VBD ][NP LPS-induced_JJ endothelial_JJ cell_NN adhesiveness_NN ] ._.
[NP Further_JJ evidence_NN ][SBAR that_IN ][NP the_DT action_NN ][PP of_IN ][NP dexamethasone_NN ][VP was_VBD mediated_VBN ][PP through_IN ][NP ligation_NN ][PP of_IN ][NP corticosteroid_NN receptors_NNS ] (_([NP human_JJ glucocorticoid_NN receptors_NNS ] (_([NP hGRs_NNS ] )_) )_)[VP was_VBD provided_VBN ][PP by_IN ][NP experiments_NNS ][VP utilizing_VBG ][NP the_DT steroid_NN antagonist_NN RU-486_NN ] ._.
[NP RU-486_NN ] (_([NP 10_CD microM_NN ] )_) ,_,[NP which_WDT ][VP prevents_VBZ ][NP translocation_NN ][PP of_IN ][NP ligated_VBN hGR_NN ][PP to_TO ][NP the_DT nucleus_NN ][PP by_IN ][VP inhibiting_VBG ][NP dissociation_NN ][PP of_IN ][NP hGR_NN ][PP from_IN ][NP heat_NN shock_NN protein_NN 90_CD ] ,_,[ADVP completely_RB ][VP aborted_VBD ][NP the_DT effect_NN ][PP of_IN ][NP dexamethasone_NN ][PP on_IN ][NP adhesiveness_NN ][PP of_IN ][NP endothelial_JJ cells_NNS ] (_([NP P_NN ][VP <_JJR ][NP 0.0005_CD ] ,_,[NP n_NN ][VP =_JJ ][NP 3_CD ] )_) ._.
[NP Treatment_NN ][PP of_IN ][NP endothelial_JJ cells_NNS ][PP with_IN ][NP LPS_NN ] (_([NP 1_CD microgram/ml_NN ] )_)[VP stimulated_VBD ][NP transcription_NN ][PP of_IN ][NP ELAM-1_NN ] ,_,[SBAR as_IN ][VP shown_VBN ][PP by_IN ][NP Northern_NN blot_NN analysis_NN ] ,_, and_CC[NP expression_NN ][PP of_IN ][NP membrane-associated_JJ ][NP ELAM-1_NN ] and_CC[NP ICAM-1_NN ] ,_,[SBAR as_IN ][VP shown_VBN ][PP by_IN ][NP quantitative_JJ immunofluorescence_NN ] (_([NP both_DT P_NN ][VP <_JJR ][NP 0.001_CD ] ,_,[NP n_NN ][VP =_JJ ][NP 9_CD ] )_) ._.
[NP Dexamethasone_NN ][ADVP markedly_RB ][VP inhibited_VBD ][NP LPS-stimulated_JJ accumulation_NN ][PP of_IN ][NP mRNA_NN ][PP for_IN ][NP ELAM-1_NN ] and_CC[NP expression_NN ][PP of_IN ][NP ELAM-1_NN ] and_CC[NP ICAM-1_NN ] (_([NP IC50_NN ][VP <_JJR ][NP 10_CD nM_NN ] ,_,[NP both_DT P_NN ][VP <_JJR ][NP 0.001_CD ] ,_,[NP n_NN ][VP =_JJ ][NP 4-9_CD ] )_) ;_:[NP inhibition_NN ][PP of_IN ][NP expression_NN ][PP by_IN ][NP dexamethasone_NN ][VP was_VBD reversed_VBN ][PP by_IN ][NP RU-486_NN ] (_([NP both_DT P_NN ][VP <_JJR ][NP 0.005_CD ] ,_,[NP n_NN ][VP =_JJ ][NP 4-6_CD ] )_) ._.
[SBAR As_IN ][PP in_IN ][NP the_DT adhesion_NN studies_NNS ] ,_,[NP cortisol_NN ][CONJP but_CC not_RB ][NP tetrahydrocortisol_NN ][VP inhibited_VBD ][NP expression_NN ][PP of_IN ][NP ELAM-1_NN ] and_CC[NP ICAM-1_NN ] (_([NP both_DT P_NN ][VP <_JJR ][NP 0.005_CD ] ,_,[NP n_NN ][VP =_JJ ][NP 3_CD ] or_CC[NP 4_CD ] )_) ._.
[PP In_IN ][NP contrast_NN ] ,_,[NP sodium_NN salicylate_NN ] (_([NP 1_CD mM_NN ] )_)[VP inhibited_VBD ] neither_CC[NP adhesion_NN ] nor_CC[NP expression_NN ][PP of_IN ][NP these_DT adhesion_NN molecules_NNS ] ._.
[NP These_DT studies_NNS ][VP suggest_VBP ][SBAR that_IN ][NP antagonism_NN ][PP by_IN ][NP dexamethasone_NN ][PP of_IN ][NP endotoxin-induced_JJ inflammation_NN ][VP is_VBZ ][NP a_DT specific_JJ instance_NN ][PP of_IN ][NP the_DT general_JJ biological_JJ principle_NN ][SBAR that_IN ][NP the_DT glucocorticoid_NN receptor_NN ][VP is_VBZ ][NP a_DT hormone-dependent_JJ regulator_NN ][PP of_IN ][NP transcription_NN ] ._.
[NP Membrane_NN receptors_NNS ][PP for_IN ][NP aldosterone_NN ] :_:[NP a_DT novel_JJ pathway_NN ][PP for_IN ][NP mineralocorticoid_NN action_NN ] ._.
[NP Rapid_JJ nongenomic_JJ in_FW vitro_FW effects_NNS ][PP of_IN ][NP aldosterone_NN ][PP on_IN ][NP intracellular_JJ electrolytes_NNS ] ,_,[NP cell_NN volume_NN ] ,_, and_CC[NP Na(+)-H+_JJ antiport_NN ][VP have_VBP been_VBN found_VBN ][PP in_IN ][NP human_JJ mononuclear_JJ leukocytes_NNS ] (_([NP HML_NN ] )_) ._.
[NP Binding_NN ][PP of_IN ][NP 125I-labeled_JJ aldosterone_NN ][PP to_TO ][NP plasma_NN membranes_NNS ][PP of_IN ][NP HML_NN ][VP shares_VBZ ][NP important_JJ features_NNS ][PP with_IN ][NP these_DT functional_JJ data_NNS ] ._.
[NP This_DT ][VP includes_VBZ ][NP a_DT very_RB low_JJ apparent_JJ ][NP dissociation_NN constant_NN ] (_([NP Kd_NN ] )_)[PP of_IN ][NP 0.1_CD nM_NN ][PP for_IN ] both_CC[NP aldosterone_NN ] and_CC[NP the_DT effect_NN ][PP on_IN ][NP the_DT Na(+)-H(+)-antiport_NN ] ,_,[NP a_DT high_JJ turnover_NN rate_NN ] ,_, and_CC[NP the_DT almost_RB exclusive_JJ binding_NN selectivity_NN ][PP for_IN ][NP aldosterone_NN ] ._.
[NP Dexamethasone_NN ] ,_,[NP RU_NN 26988_CD ] ,_,[NP corticosterone_NN ] ,_,[NP ouabain_NN ] ,_,[NP amiloride_NN ] ,_, and_CC[NP 18-hydroxyprogesterone_NN ][VP were_VBD ][ADJP inactive_JJ ][PP as_IN ][NP ligands_NNS ] ._.
[NP Deoxycorticosterone_NN acetate_NN ][VP had_VBD ][NP an_DT intermediate_JJ activity_NN ][PP with_IN ][NP an_DT apparent_JJ Kd_NN ][PP of_IN ][NP 100_CD nM_NN ] ._.
[NP These_DT findings_NNS ][VP are_VBP ][NP the_DT first_JJ ][VP to_TO demonstrate_VB ][NP membrane_NN binding_NN ][PP of_IN ][NP aldosterone_NN ][VP being_VBG ][ADJP compatible_JJ ][PP with_IN ][NP major_JJ aspects_NNS ][PP of_IN ][NP its_PRP$ nongenomic_JJ effects_NNS ] ._.
[NP Reticuloendotheliosis_NN virus_NN long_JJ terminal_JJ repeat_NN elements_NNS ][VP are_VBP ][NP efficient_JJ promoters_NNS ][PP in_IN ][NP cells_NNS ][PP of_IN ][NP various_JJ ][NP species_NNS ] and_CC[NP tissue_NN ][NP origin_NN ] ,_,[PP including_VBG ][NP human_JJ lymphoid_JJ cells_NNS ] ._.
[NP Promiscuous_JJ transcriptional_JJ activity_NN ][PP of_IN ][NP the_DT reticuloendotheliosis_NN virus_NN ] (_([NP REV_NN ] )_)[NP long_JJ terminal_JJ repeat_NN ] (_([NP LTR_NN ] )_)[VP was_VBD detected_VBN ][PP in_IN ][NP transient_JJ expression_NN assays_NNS ][VP using_VBG ][NP LTR-chloramphenicol_NN acetyltransferase-encoding_JJ gene_NN chimeras_NNS ] ,_, and_CC[NP cells_NNS ][PP of_IN ][NP diverse_JJ ][NP species_NNS ] and_CC[NP tissue_NN ][NP type_NN ] ;_:[NP levels_NNS ][PP of_IN ][NP expression_NN ][PP from_IN ][NP two_CD different_JJ REV_NN LTRs_NNS ][VP correlate_VBP ][PP with_IN ][NP reports_NNS ][PP of_IN ][NP pathogenicity_NN ][PP of_IN ][NP the_DT respective_JJ viruses_NNS ][ADVP in_FW vivo_FW ] ._.
[NP REVs_NNS ][VP do_VBP not_RB encode_VB ][NP a_DT transactivator_NN ][VP targeted_VBN ][PP to_TO ][NP the_DT viral_JJ LTR_NN ] ,_, and_CC[NP cells_NNS ][VP infected_VBN ][PP with_IN ][NP Marek_NN ][NP 's_POS disease_NN virus_NN ] ,_,[NP a_DT herpesvirus_NN ][PP with_IN ][NP an_DT overlapping_VBG host_NN range_NN ] ,_,[VP do_VBP not_RB express_VB ][NP factors_NNS ][NP that_WDT ][ADVP preferentially_RB ][VP enhance_VBP ][NP expression_NN ][PP from_IN ][NP REV_NN ] or_CC[NP avian_JJ sarcoma/leukemia_NN virus_NN LTRs_NNS ] ._.
[NP REV_NN LTRs_NNS ][VP work_VBP ][ADVP efficiently_RB ][PP in_IN ][NP human_JJ lymphoid_JJ cells_NNS ] ,_, and_CC[VP are_VBP ][NP viable_JJ alternatives_NNS ][PP to_TO ][NP promoters_NNS ][VP commonly_RB used_VBN ][PP for_IN ][NP expression_NN ][PP of_IN ][NP cloned_VBN genes_NNS ] ._.
[NP They_PRP ][VP may_MD also_RB prove_VB ][ADJP useful_JJ ][PP in_IN ][NP the_DT identification_NN ][PP of_IN ][NP new_JJ ,_, ubiquitous_JJ cellular_JJ transcription_NN factors_NNS ] ._.
[NP Natural_JJ variants_NNS ][PP of_IN ][NP the_DT HIV-1_NN long_JJ terminal_JJ repeat_NN ] :_:[NP analysis_NN ][PP of_IN ][NP promoters_NNS ][PP with_IN ][NP duplicated_JJ DNA_NN regulatory_JJ motifs_NNS ] ._.
[NP Sequence_NN variation_NN ][PP in_IN ] the_DT[NP long_JJ terminal_JJ repeat_NN ] (_([NP LTR_NN ] )_)[NP region_NN ][PP of_IN ][NP HIV-1_NN ][VP was_VBD analyzed_VBN ][PP in_IN ][NP viral_JJ isolates_NNS ][PP of_IN ][NP 17_CD infected_JJ individuals_NNS ] ._.
[NP Two_CD classes_NNS ][PP of_IN ][NP LTR_NN size_NN variants_NNS ][VP were_VBD found_VBN ] ._.
[NP One_CD HIV-1_NN variant_NN ][VP was_VBD detected_VBN containing_VBG ][NP an_DT additional_JJ binding_VBG site_NN ][PP for_IN ][NP the_DT transcription_NN factor_NN Sp1_NN ] ._.
[NP Another_DT LTR_NN size_NN variation_NN ][VP was_VBD observed_VBN ][PP in_IN ][NP four_CD patients_NNS ][PP in_IN ][NP a_DT region_NN ][ADJP just_RB upstream_JJ ][PP of_IN ][NP the_DT NF-kappa_NN B_NN enhancer_NN ] ._.
[NP This_DT variation_NN ][VP was_VBD ][NP the_DT result_NN ][PP of_IN ][NP a_DT duplication_NN ][PP of_IN ][NP a_DT short_JJ DNA_NN sequence_NN ] (_([NP CTG-motif_NN ] )_) ._.
[NP Cell_NN culture_NN experiments_NNS ][VP demonstrated_VBD ][SBAR that_IN ][NP the_DT natural_JJ variant_NN ][PP with_IN ][NP four_CD Sp1_NN sites_NNS ][VP had_VBD ][NP a_DT slightly_RB higher_JJR ][NP promoter_NN activity_NN ] and_CC[NP viral_JJ replication_NN rate_NN ][PP than_IN ][NP the_DT isogenic_JJ control_NN LTR_NN ][PP with_IN ][NP three_CD Sp1_NN sites_NNS ] ._.
[NP No_DT positive_JJ effect_NN ][PP of_IN ][NP the_DT duplicated_JJ CTG-motif_NN ][VP could_MD be_VB detected_VBN ] ._.
[SBAR In_IN ] order_NN to_TO[VP measure_VB ][NP small_JJ differences_NNS ][PP in_IN ][NP virus_NN production_NN ][ADVP more_RBR accurately_RB ] ,_,[NP equal_JJ amounts_NNS ][PP of_IN ][NP a_DT size_NN variant_NN ] and_CC[NP the_DT wild-type_JJ plasmid_NN ][VP were_VBD cotransfected_VBN ][PP into_IN ][NP T-cells_NNS ] ._.
[NP The_DT virus_NN ][PP with_IN ][NP four_CD Sp1_NN sites_NNS ][VP did_VBD outgrow_VB ][NP the_DT three_CD Sp1_NN virus_NN ][PP in_IN ][NP 35_CD days_NNS ][PP of_IN ][NP culture_NN ] and_CC[NP CTG-monomer_NN virus_NN ][VP outcompeted_VBD ][NP the_DT CTG-dimer_NN virus_NN ][PP in_IN ][NP 42_CD days_NNS ] ._.
[PP Based_VBN ][PP on_IN ][NP these_DT results_NNS ][NP we_PRP ][VP estimate_VBP ][NP a_DT 5-10_CD %_NN difference_NN ][PP in_IN ][NP virus_NN production_NN ][PP of_IN ][NP the_DT LTR_NN variants_NNS ][ADVP when_WRB ][VP compared_VBN ][PP to_TO ][NP that_DT ][PP of_IN ][NP wild-type_NN ] ._.
[NP SCL_NN ] and_CC[NP related_JJ hemopoietic_JJ helix-loop-helix_JJ transcription_NN factors_NNS ] ._.
 The_DT helix-loop-helix_JJ (_([ADJP HLH_JJ ] )_)[NP proteins_NNS ][VP are_VBP ][NP a_DT family_NN ][PP of_IN ][NP transcription_NN factors_NNS ][NP that_WDT ][VP include_VBP ][NP proteins_NNS ][ADJP critical_JJ ][PP to_TO ][NP differentiation_NN ] and_CC[NP development_NN ][PP in_IN ][NP species_NNS ][VP ranging_VBG ][PP from_IN ][NP plants_NNS ][PP to_TO ][NP mammals_NNS ] ._.
[NP Five_CD members_NNS ][PP of_IN ][NP this_DT family_NN ] (_([NP MYC_NN ] ,_,[NP SCL_NN ] ,_,[NP TAL-2_NN ] ,_,[NP LYL-1_NN ] and_CC[NP E2A_NN ] )_)[VP are_VBP implicated_VBN ][PP in_IN ][NP oncogenic_JJ events_NNS ][PP in_IN ][NP human_JJ lymphoid_JJ tumors_NNS ][PP because_IN of_IN ][NP their_PRP$ consistent_JJ involvement_NN ][PP in_IN ][NP chromosomal_JJ translocations_NNS ] ._.
[SBAR Although_IN ][VP activated_VBN ][PP in_IN ][NP T_NN cell_NN leukemias_NNS ] ,_,[NP expression_NN ][PP of_IN ][NP SCL_NN ] and_CC[NP LYL-1_NN ][VP is_VBZ ][ADJP low_JJ ] or_CC[ADJP undetectable_JJ ][PP in_IN ][NP normal_JJ T_NN cell_NN populations_NNS ] ._.
[NP SCL_NN ][VP is_VBZ expressed_VBN ][PP in_IN ] erythroid_JJ ,_,[NP megakaryocyte_NN ] and_CC[NP mast_NN cell_NN ][NP populations_NNS ] (_([NP the_DT same_JJ cell_NN lineages_NNS ][PP as_IN ][NP GATA-1_NN ] ,_,[NP a_DT zinc-finger_NN transcription_NN factor_NN ] )_) ._.
[PP In_IN ][NP addition_NN ] ,_, both_CC[NP SCL_NN ] and_CC[NP GATA-1_NN ][VP undergo_VBP ][NP coordinate_JJ modulation_NN ][PP during_IN ][NP chemically_RB induced_VBN erythroid_JJ differentiation_NN ][PP of_IN ][NP mouse_NN erythroleukemia_NN cells_NNS ] and_CC[VP are_VBP down-modulated_VBN ][PP during_IN ][NP myeloid_JJ differentiation_NN ][PP of_IN ][NP human_JJ K562_NN cells_NNS ] ,_,[ADVP thus_RB ][VP implying_VBG ][NP a_DT role_NN ][PP for_IN ][NP SCL_NN ][PP in_IN ][NP erythroid_JJ differentiation_NN events_NNS ] ._.
[ADVP However_RB ] ,_,[PP in_IN contrast_NN to_TO ][NP GATA-1_NN ] ,_,[NP SCL_NN ][VP is_VBZ expressed_VBN ][PP in_IN ][NP the_DT developing_VBG brain_NN ] ._.
[NP Studies_NNS ][PP of_IN ][NP the_DT function_NN ][PP of_IN ][NP SCL_NN ][VP suggest_VBP ][NP it_PRP ][VP is_VBZ ][ADJP also_RB important_JJ ][PP in_IN ][NP proliferation_NN ] and_CC[ADJP self-renewal_JJ ][NP events_NNS ][PP in_IN ][NP erythroid_JJ cells_NNS ] ._.
[NP Transcription_NN ][PP of_IN ][NP the_DT hypersensitive_JJ site_NN HS2_NN enhancer_NN ][PP in_IN ][NP erythroid_JJ cells_NNS ] ._.
[PP In_IN ][NP the_DT human_JJ genome_NN ] ,_,[NP the_DT erythroid-specific_JJ hypersensitive_JJ site_NN HS2_NN enhancer_NN ][VP regulates_VBZ ][NP the_DT transcription_NN ][PP of_IN ][NP the_DT downstream_JJ beta-like_JJ globin_NN genes_NNS ][NP 10-50_CD kilobases_NNS ][ADVP away_RB ] ._.
[NP The_DT mechanism_NN ][PP of_IN ][NP HS2_NN enhancer_NN function_NN ][VP is_VBZ not_RB known_VBN ] ._.
[NP The_DT present_JJ study_NN ][VP employs_VBZ ][NP RNA_NN protection_NN assays_NNS ][VP to_TO analyze_VB ][NP the_DT transcriptional_JJ status_NN ][PP of_IN ][NP the_DT HS2_NN enhancer_NN ][PP in_IN ] transfected_VBN recombinant_JJ[NP chloramphenicol_NN acetyltransferase_NN ] (_([NP CAT_NN ] )_)[NP plasmids_NNS ] ._.
[PP In_IN ][NP erythroid_JJ K562_NN cells_NNS ][PP in_IN ][NP which_WDT ][NP the_DT HS2_NN enhancer_NN ][VP is_VBZ ][ADJP active_JJ ] ,_,[NP the_DT HS2_NN sequence_NN ][VP directs_VBZ ][NP the_DT synthesis_NN ][PP of_IN ][NP long_JJ enhancer_NN transcripts_NNS ][NP that_WDT ][VP are_VBP initiated_VBN ][ADVP apparently_RB ][PP from_IN ][PP within_IN ][NP the_DT enhancer_NN ] and_CC[VP elongated_VBN ][PP through_IN ][NP the_DT intervening_VBG DNA_NN ][PP into_IN ][NP the_DT cis-linked_JJ CAT_NN gene_NN ] ._.
[PP In_IN ][NP nonerythroid_JJ HL-60_NN cells_NNS ][PP in_IN ][NP which_WDT ][NP the_DT HS2_NN enhancer_NN ][VP is_VBZ ][ADJP inactive_JJ ] ,_,[NP long_JJ enhancer_NN transcripts_NNS ][VP are_VBP ] not_RB[ADJP detectable_JJ ] ._.
[VP Splitting_VBG ][NP the_DT HS2_NN enhancer_NN ][PP between_IN ][NP two_CD tandem_JJ Ap1_NN sites_NNS ][VP abolishes_VBZ ][NP the_DT synthesis_NN ][PP of_IN ][NP a_DT group_NN ][PP of_IN ][NP long_JJ enhancer_NN transcripts_NNS ] and_CC[VP results_VBZ ][PP in_IN ][NP loss_NN ][PP of_IN ][NP enhancer_NN function_NN ] and_CC[NP transcriptional_JJ silencing_NN ][PP of_IN ][NP the_DT cis-linked_JJ CAT_NN gene_NN ] ._.
[PP In_IN ][VP directing_VBG ][NP the_DT synthesis_NN ][PP of_IN ][NP RNA_NN ][PP through_IN ][NP the_DT intervening_VBG DNA_NN ] and_CC[NP the_DT gene_NN ][PP by_IN ] a_DT[NP tracking_NN ] and_CC[NP transcription_NN ][NP mechanism_NN ] ,_,[NP the_DT HS2_NN enhancer_NN ] may_MD (_( i_LS )_)[NP open_VB up_RP the_DT ] chromatin_NN[NP structure_NN of_IN a_DT ][VP gene_NN ] domain_NN and_CC (_( ii_LS )_) deliver_VB[NP enhancer_NN binding_NN proteins_NNS ] to_TO[NP the_DT ][VP promoter_NN sequence_NN ][NP where_WRB they_PRP ] may_MD[NP stimulate_VB the_DT ] transcription_NN[NP of_IN the_DT gene_NN ] at_IN
[NP Phorbol_NN ester_NN ][VP reduces_VBZ ][NP constitutive_JJ nuclear_JJ NF_NN kappa_NN B_NN ] and_CC[VP inhibits_VBZ ][NP HIV-1_NN production_NN ][PP in_IN ][NP mature_JJ human_JJ monocytic_JJ cells_NNS ] ._.
[NP NF_NN kappa_NN B_NN ][VP is_VBZ ][NP a_DT potent_JJ mediator_NN ][PP of_IN ][NP specific_JJ gene_NN expression_NN ][PP in_IN ][NP human_JJ monocytes_NNS ] and_CC[VP has_VBZ been_VBN shown_VBN to_TO play_VB ][NP a_DT role_NN ][PP in_IN ][NP transcription_NN ][PP of_IN ][NP the_DT HIV-1_NN genome_NN ][PP in_IN ][NP promonocytic_JJ leukemias_NNS ] ._.
[NP There_EX ][VP is_VBZ ][NP little_JJ information_NN ][ADJP available_JJ ][PP on_IN ][NP the_DT response_NN ][PP of_IN ][NP NF_NN kappa_NN B_NN ][PP to_TO ][NP cytokines_NNS ][PP in_IN ][NP normal_JJ human_JJ monocytes_NNS ] ._.
[NP We_PRP ][VP have_VBP used_VBN ][NP a_DT 32P-labeled_JJ oligonucleotide_NN ][VP derived_VBN ][PP from_IN ][NP human_JJ immunodeficiency_NN virus_NN ] (_([NP HIV-1_NN ] )_)[NP long_JJ terminal_JJ repeat_NN ] ,_,[NP which_WDT ][VP contains_VBZ ][NP a_DT tandem_JJ repeat_NN ][PP of_IN ][NP the_DT NF_NN kappa_NN B_NN binding_NN sequence_NN ] ,_,[PP as_IN ][NP a_DT probe_NN ][PP in_IN ][NP a_DT gel_NN retardation_NN assay_NN ][VP to_TO study_VB ][NP this_DT transcription_NN factor_NN ] ._.
[VP Using_VBG ][NP this_DT assay_NN ] ,_,[NP we_PRP ][VP have_VBP detected_VBN ][NP NF_NN kappa_NN B_NN ][PP in_IN ][NP extracts_NNS ][PP of_IN ][NP nuclei_NNS ][PP from_IN ][NP normal_JJ human_JJ monocytes_NNS ] ._.
[NP Treatment_NN ][PP of_IN ][NP normal_JJ monocytes_NNS ][PP with_IN ][NP 12-0-tetradecanoyl_JJ phorbol-13-acetate_NN ] (_([NP TPA_NN ] )_)[PP for_IN ][NP 4-24_CD h_NN ][VP caused_VBD ][NP the_DT complete_JJ disappearance_NN ][PP of_IN ][NP NF_NN kappa_NN B_NN ][PP from_IN ][NP nuclear_JJ extracts_NNS ][PP of_IN ][NP monocytes_NNS ] ._.
[NP A_DT similar_JJ result_NN ][VP was_VBD obtained_VBN ][PP with_IN ][NP the_DT mature_JJ monocytic_JJ leukemia_NN cell_NN line_NN THP-1_NN ] ._.
[NP The_DT constitutive_JJ transcription_NN factor_NN SP1_NN ][VP was_VBD unaffected_JJ ][PP by_IN ][NP addition_NN ][PP of_IN ][NP TPA_NN ] ._.
[NP The_DT disappearance_NN ][PP of_IN ][NP NF_NN kappa_NN B_NN ][PP from_IN ][NP the_DT nucleus_NN ][VP was_VBD ][NP concentration_NN ][ADJP dependent_JJ ][PP between_IN ][NP 10_CD and_CC 50_CD ng/ml_NN ][PP of_IN ][NP phorbol_NN ester_NN ] ._.
[PP In_IN ][NP THP-1_NN cells_NNS ] ,_,[NP TPA_NN ][ADVP also_RB ][VP induced_VBD ][NP a_DT new_JJ ,_, faster-migrating_JJ NF_NN kappa_NN B_NN species_NNS ][VP not_RB induced_VBN ][PP in_IN ][NP monocytes_NNS ] ._.
[NP Protein_NN kinase_NN C_NN inhibitor_NN staurosporine_NN ] ,_,[CONJP but_CC not_RB ][NP cyclic_JJ nucleotide-dependent_JJ protein_NN kinase_NN inhibitor_NN HA-1004_NN ] ,_,[ADVP also_RB ][ADVP dramatically_RB ][VP reduced_VBD ][NP constitutive_JJ levels_NNS ][PP of_IN ][NP nuclear_JJ NF_NN kappa_NN B_NN ] ._.
[ADVP Finally_RB ] ,_,[NP TPA_NN addition_NN ][PP to_TO ][NP monocytes_NNS ][VP infected_VBN ][PP with_IN ][NP HIV-1_NN ][VP inhibited_VBD ][NP HIV-1_NN replication_NN ] ,_,[SBAR as_IN ][VP determined_VBN ][PP by_IN ][NP reverse_JJ transcriptase_NN assays_NNS ] ,_,[PP in_IN ][NP a_DT concentration-dependent_JJ manner_NN ] ._.
[NP These_DT results_NNS ][VP are_VBP ][PP in_IN ][NP striking_JJ contrast_NN ][PP to_TO ][NP the_DT increase_NN ][PP in_IN ][NP nuclear_JJ NF_NN kappa_NN B_NN ] and_CC[NP HIV-1_NN replication_NN ][VP induced_VBN ][PP by_IN ][NP phorbol_NN esters_NNS ][PP in_IN ][NP promonocytic_JJ leukemia_NN cells_NNS ][NP U937_NN ] and_CC[NP HL-60_NN ] ,_, and_CC[VP emphasize_VBP ][NP the_DT importance_NN ][PP of_IN ][VP studying_VBG ][NP cytokine_NN regulation_NN ][PP of_IN ][NP HIV-1_NN ][PP in_IN ][NP normal_JJ monocytes_NNS ] ._.
[NP Ablation_NN ][PP of_IN ][NP transplanted_VBN HTLV-I_NN Tax-transformed_JJ tumors_NNS ][PP in_IN ][NP mice_NNS ][PP by_IN ][NP antisense_JJ inhibition_NN ][PP of_IN ][NP NF-kappa_NN B_NN ] (_([NP published_VBN erratum_NN ][VP appears_VBZ ][PP in_IN ][NP Science_NNP 1993_CD Mar_NNP 12_CD ;_: 259_CD (_( 5101_CD )_) :_: 1523_CD ] )_)
[NP Mice_NNS ][ADJP transgenic_JJ ][PP for_IN ] the_DT[NP human_JJ T_NN cell_NN leukemia_NN virus_NN ] (_([NP HTLV-I_NN ] )_)[NP Tax_NN gene_NN ][VP develop_VBP ][NP fibroblastic_JJ tumors_NNS ][NP that_WDT ][VP express_VBP ][NP NF-kappa_NN B-inducible_JJ early_JJ genes_NNS ] ._.
[NP In_FW vitro_FW inhibition_NN ][PP of_IN ][NP NF-kappa_NN B_NN expression_NN ][PP by_IN ][NP antisense_JJ ][NP oligodeoxynucleotides_NNS ] (_([NP ODNs_NNS ] )_)[VP inhibited_VBD ][NP growth_NN ][PP of_IN ][NP these_DT culture-adapted_JJ Tax-transformed_JJ fibroblasts_NNS ][CONJP as_RB well_RB as_IN ][NP an_DT HTLV-I-transformed_JJ human_JJ lymphocyte_NN line_NN ] ._.
[PP In_IN ][NP contrast_NN ] ,_,[NP antisense_JJ inhibition_NN ][PP of_IN ][NP Tax_NN ][NP itself_PRP ][VP had_VBD ][NP no_DT apparent_JJ effect_NN ][PP on_IN ][NP cell_NN growth_NN ] ._.
[NP Mice_NNS ][VP treated_VBN ][PP with_IN ][NP antisense_NN ][PP to_TO ][NP NF-kappa_NN B_NN ODNs_NNS ][VP showed_VBD ][NP rapid_JJ regression_NN ][PP of_IN ][NP transplanted_VBN fibrosarcomas_NNS ] ._.
[NP This_DT ][VP suggests_VBZ ][SBAR that_IN ][NP NF-kappa_NN B_NN expression_NN ][VP may_MD be_VB ][ADJP necessary_JJ ][PP for_IN ][NP the_DT maintenance_NN ][PP of_IN ][NP the_DT malignant_JJ phenotype_NN ] and_CC[VP provides_VBZ ][NP a_DT therapeutic_JJ approach_NN ][PP for_IN ][NP HTLV-I-associated_JJ disease_NN ] ._.
[NP Inhibition_NN ][PP of_IN ][NP anti-CD3_JJ monoclonal_JJ antibody-induced_JJ T-cell_NN proliferation_NN ][PP by_IN ][NP dexamethasone_NN ] ,_,[NP isoproterenol_NN ] ,_, or_CC[NP prostaglandin_NN E2_NN ] either_CC[ADVP alone_RB ] or_CC[PP in_IN ][NP combination_NN ] ._.
[LST 1_LS ] ._.[NP The_DT purpose_NN ][PP of_IN ][NP these_DT studies_NNS ][VP was_VBD ][VP to_TO investigate_VB ][NP the_DT modulation_NN ][PP of_IN ][NP the_DT proliferation_NN ][PP of_IN ][NP human_JJ T_NN cells_NNS ][VP obtained_VBN ][PP from_IN ][NP peripheral_JJ blood_NN ][PP by_IN ][NP dexamethasone_NN ] (_([NP DEX_NN ] )_) ,_,[NP isoproterenol_NN ] (_([NP ISO_NN ] )_) ,_, and_CC[NP prostaglandin_NN E2_NN ] (_([NP PGE2_NN ] )_) ._.
[NP The_DT former_JJ two_CD substances_NNS ][VP interact_VBP ][PP with_IN ][NP T_NN cells_NNS ][PP via_IN ] the_DT[NP glucocorticoid_NN ] and_CC[ADJP beta-adrenergic_JJ ][NP receptors_NNS ][ADVP respectively_RB ] ._.
[ADVP When_WRB ][VP occupied_VBN ][PP by_IN ][NP their_PRP$ natural_JJ ligands_NNS ] ,_,[NP glucocorticosteroids_NNS ] and_CC[NP catecholamines_NNS ] ,_,[NP these_DT receptors_NNS ][VP have_VBP ][NP a_DT role_NN ][PP in_IN ][VP modulating_VBG ][NP T-cell_NN function_NN ][PP during_IN ][NP stress_NN ] ._.
[PP During_IN ][NP the_DT inflammatory_JJ response_NN ][NP increased_VBN levels_NNS ][PP of_IN ][NP PGE2_NN ][VP bind_VBP ][PP to_TO ][NP their_PRP$ receptors_NNS ][PP on_IN ][NP T_NN cells_NNS ] and_CC thus_RB[VP alter_VBP ][NP responsiveness_NN ] ._.
[NP Proliferation_NN ][PP of_IN ][NP T_NN cells_NNS ][VP was_VBD induced_VBN ][PP by_IN ][NP immobilized_VBN anti-CD3_JJ ][NP monoclonal_JJ antibody_NN ] (_([NP mAb_NN ] )_)[PP in_IN ][NP the_DT ][NP presence_NN ] or_CC[NP absence_NN ][PP of_IN ][NP an_DT additional_JJ costimulatory_JJ signal_NN ][VP delivered_VBN ][PP by_IN ][NP anti-CD28_JJ mAb_NN ] ._.
[LST 2_LS ] ._.[NP Various_JJ physiologic_JJ concentrations_NNS ][PP of_IN ][NP DEX_NN ] ,_,[NP ISO_NN ] ,_, or_CC[NP PGE2_NN ][VP were_VBD added_VBN ][PP at_IN ][NP the_DT time_NN ][PP of_IN ][NP initiation_NN ][PP of_IN ][NP the_DT cultures_NNS ] and_CC[NP subsequent_JJ proliferation_NN ][PP of_IN ][NP the_DT unstimulated_JJ T_NN cells_NNS ][VP was_VBD determined_VBN ] ._.
[NP The_DT results_NNS ][VP demonstrate_VBP ][SBAR that_IN ][NP physiologic_JJ concentrations_NNS ][PP of_IN ][NP all_DT three_CD ][PP of_IN ][NP these_DT agents_NNS ][VP inhibit_VBP ][NP the_DT anti-CD3_JJ mAb-induced_JJ proliferation_NN ][PP of_IN ][NP T_NN cells_NNS ] ._.
[LST 3_LS ] ._.[SBAR Although_IN ][NP DEX_NN ] and_CC[NP PGE2_NN ][VP were_VBD ][ADJP equipotent_JJ ][PP in_IN ][VP suppressing_JJ ][NP T-cell_NN proliferation_NN ] ,_,[NP ISO_NN ][VP was_VBD ][ADJP much_RB less_RBR effective_JJ ] ._.
[LST 4_LS ] ._.[SBAR Because_IN ][NP concomitant_JJ elevations_NNS ][PP in_IN ][NP the_DT peripheral_JJ levels_NNS ][PP of_IN ][NP these_DT substances_NNS ][VP may_MD occur_VB ] ,_,[NP experiments_NNS ][VP were_VBD performed_VBN ][VP to_TO determine_VB ][NP the_DT T-cell_NN inhibitory_JJ effects_NNS ][PP of_IN ][NP DEX_NN ][PP together_RB with_IN ] either_CC[NP PGE2_NN ] or_CC[NP ISO_NN ] ._.
[NP Synergistic_JJ suppression_NN ][PP of_IN ][NP T-cell_NN proliferation_NN ][VP was_VBD observed_VBN ][ADVP when_WRB ][NP various_JJ concentrations_NNS ][PP of_IN ][NP DEX_NN ] and_CC[NP PGE2_NN ] ,_,[CONJP but_CC not_RB ][NP DEX_NN ] and_CC[NP ISO_NN ] ,_,[VP were_VBD added_VBN ][PP to_TO ][NP cultures_NNS ] ._.
[NP This_DT synergistic_JJ suppression_NN ][VP could_MD not_RB be_VB explained_VBN ][PP by_IN ][NP an_DT increase_NN ][PP in_IN ][NP cAMP_NN accumulation_NN ][PP in_IN ][NP T_NN cells_NNS ][VP stimulated_VBN ][PP with_IN ][NP DEX_NN ] and_CC[NP PGE2_NN ] ._.
[LST 5_LS ] ._.[ADVP Finally_RB ] ,_,[NP the_DT addition_NN ][PP of_IN ][NP anti-CD28_JJ mAb_NN ][PP to_TO ][NP anti-CD3_JJ mAb-stimulated_JJ T_NN cells_NNS ][VP overcame_VBD ][NP much_JJ ][PP of_IN ][NP the_DT suppression_NN ][PP of_IN ][NP proliferation_NN ][VP induced_VBN ][PP by_IN ][NP PGE2_NN ] or_CC[NP ISO_NN ] but_CC[ADVP less_RBR so_RB ][PP than_IN ][NP that_DT ][VP induced_VBN ][PP by_IN ][NP DEX_NN ] ._.
[NP Targeted_VBN degradation_NN ][PP of_IN ][NP c-Fos_NN ] ,_,[CONJP but_CC not_RB ][NP v-Fos_NN ] ,_,[PP by_IN ][NP a_DT phosphorylation-dependent_JJ signal_NN ][PP on_IN ][NP c-Jun_NN ] ._.
[NP The_DT proto-oncogene_NN products_NNS ][NP c-Fos_NN ] and_CC[NP c-Jun_NN ][VP heterodimerize_VBP ][PP through_IN ][NP their_PRP$ leucine_NN zippers_NNS ][VP to_TO form_VB ][NP the_DT AP-1_NN transcription_NN factor_NN ] ._.
[NP The_DT transcriptional_JJ activity_NN ][PP of_IN ][NP the_DT heterodimer_NN ][VP is_VBZ regulated_VBN ][PP by_IN ] signal-dependent_JJ[NP phosphorylation_NN ] and_CC[NP dephosphorylation_NN ][NP events_NNS ] ._.
[NP The_DT stability_NN ][PP of_IN ][NP c-Fos_NN ][VP was_VBD found_VBN to_TO also_RB be_VB controlled_VBN ][PP by_IN ][NP intracellular_JJ signal_NN transduction_NN ] ._.
[PP In_IN ][NP transient_JJ expression_NN ] and_CC[NP in_FW vitro_FW degradation_NN ][NP experiments_NNS ] ,_,[NP the_DT stability_NN ][PP of_IN ][NP c-Fos_NN ][VP was_VBD decreased_VBN ][ADVP when_WRB ][NP the_DT protein_NN ][VP was_VBD dimerized_JJ ][PP with_IN ][NP phosphorylated_VBN c-Jun_NN ] ._.
[NP c-Jun_NN protein_NN ][VP isolated_VBN ][PP from_IN ][NP phorbol_NN ester-induced_JJ cells_NNS ][VP did_VBD not_RB target_VB ][NP c-Fos_NN ][PP for_IN ][NP degradation_NN ] ,_,[NP which_WDT ][VP suggests_VBZ ][SBAR that_IN ][NP c-Fos_NN ][VP is_VBZ transiently_RB stabilized_VBN ][PP after_IN ][NP stimulation_NN ][PP of_IN ][NP cell_NN growth_NN ] ._.
[NP v-Fos_NN protein_NN ] ,_,[NP the_DT retroviral_JJ counterpart_NN ][PP of_IN ][NP c-Fos_NN ] ,_,[VP was_VBD ] not_RB[ADJP susceptible_JJ ][PP to_TO ][NP degradation_NN ][VP targeted_VBN ][PP by_IN ][NP c-Jun_NN ] ._.
[NP Mutations_NNS ][PP in_IN ][NP the_DT Pit-1_NN gene_NN ][PP in_IN ][NP children_NNS ][PP with_IN ][NP combined_JJ pituitary_JJ hormone_NN deficiency_NN ] ._.
[NP Pit-1_NN ][VP is_VBZ ][NP a_DT pituitary-specific_JJ transcription_NN factor_NN ][NP that_WDT ][VP binds_VBZ ][PP to_TO ] and_CC[VP transactivates_VBZ ][NP promoters_NNS ][PP of_IN ][NP growth_NN hormone_NN ] and_CC[NP prolactin_NN genes_NNS ] ._.
[PP In_IN ][NP three_CD unrelated_JJ Japanese_JJ children_NNS ][PP with_IN ][NP combined_JJ pituitary_JJ hormone_NN deficiency_NN ] ,_,[NP we_PRP ][VP identified_VBD ][NP three_CD point_NN mutations_NNS ][PP in_IN ][NP the_DT Pit-1_NN gene_NN ] ,_,[NP Pro24Leu_NN ] ,_,[NP Arg143Gln_NN ] ,_, and_CC[NP Arg271Trp_NN ] ,_, located_JJ[PP on_IN ][NP the_DT major_JJ transactivation_NN region_NN ] ,_,[NP POU-specific_JJ domain_NN ] ,_, and_CC[NP POU-homeodomain_NN ] ,_,[ADJP respectively_RB ] ._.
[NP Calcitriol_NN ] :_:[NP a_DT hematolymphopoietrope_NN ] ?_. (_([NP editorial_NN ] )_)
[NP A_DT MEDLINE_NN search_NN ][PP of_IN ][NP the_DT English-language_JJ literature_NN ][VP was_VBD conducted_VBN ][VP using_VBG ][NP the_DT indexing_NN terms_NNS ] '_[[DQS]][NP immunology_NN ] ,_,[NP calcitriol_NN ] and_CC[NP vitamin_NN D_NN ] '_[[DQE]][VP to_TO identify_VB ][NP studies_NNS ][VP indicating_VBG ][NP a_DT role_NN ][PP for_IN ][NP calcitriol_NN ][PP as_IN ][NP a_DT primary_JJ immunomodulator_NN ] ._.
[NP Sixty-six_CD papers_NNS ][VP published_VBN ][PP between_IN ][NP January_NNP 1956_CD ] and_CC[NP June_NNP 1991_CD ][VP were_VBD identified_VBN ] ._.
[NP Forty-five_CD ][PP of_IN ][NP these_DT reports_NNS ][VP are_VBP cited_VBN ][PP in_IN ][NP this_DT review_NN ] ._.
[NP The_DT data_NNS ][ADVP strongly_RB ][VP suggest_VBP ][NP an_DT endocrine_NN ,_, autocrine_NN and/or_CC paracrine_NN role_NN ][PP for_IN ][NP calcitriol_NN ][PP in_IN ][NP immune_JJ regulation_NN ] ._.
[NP No_DT unifying_JJ hypothesis_NN ][VP has_VBZ yet_RB emerged_VBN explaining_VBG ][NP this_DT collection_NN ][PP of_IN ][NP data_NNS ] ._.
[NP This_DT paper_NN ][VP provides_VBZ ][NP a_DT brief_JJ review_NN ][PP of_IN ][NP immune_JJ properties_NNS ][VP currently_RB attributed_VBN ][PP to_TO ][NP calcitriol_NN ] ._.
[NP Activation_NN ][PP of_IN ][NP protein_NN kinase_NN C_NN ] and_CC[NP elevation_NN ][PP of_IN ][NP cAMP_NN ][VP interact_VBP synergistically_RB to_TO raise_VB ][NP c-Fos_NN ] and_CC[NP AP-1_NN ][NP activity_NN ][PP in_IN ][NP Jurkat_NN cells_NNS ] ._.
[NP We_PRP ][VP have_VBP earlier_RBR found_VBN ][SBAR that_IN ][PP in_IN ][NP Jurkat_NN cells_NNS ][NP activation_NN ][PP of_IN ][NP protein_NN kinase_NN C_NN ] (_([NP PKC_NN ] )_)[VP enhances_VBZ ] the_DT[NP cyclic_JJ adenosine_NN monophosphate_NN ] (_([NP cAMP_NN ] )_)[NP accumulation_NN ][VP induced_VBN ][PP by_IN ][NP adenosine_NN receptor_NN stimulation_NN ] or_CC[NP activation_NN ][PP of_IN ][NP Gs_NN ] ._.
[ADVP Here_RB ][NP we_PRP ][VP have_VBP therefore_RB examined_VBN ][NP the_DT effect_NN ][PP of_IN ][NP the_DT phorbol_NN ester_NN ][NP PMA_NN ] (_([NP phorbol_NN 12-myristate_NN 13-acetate_NN ] )_)[NP which_WDT ][VP stimulates_VBZ ][NP PKC_NN ] and_CC[NP a_DT combination_NN ][PP of_IN ][NP the_DT adenosine_NN receptor_NN agonist_NN ][NP NECA_NN ] (_([NP 5'-(N-ethyl)-carboxamido_JJ|NN adenosine_NN ] )_) and_CC[NP forskolin_NN ][VP to_TO raise_VB ][NP cAMP_NN ] ,_,[PP on_IN ][NP the_DT levels_NNS ][PP of_IN ][NP c-Fos_NN ] and_CC[NP Jun_NN ][PP and_CC ][PP on_IN ][NP the_DT ][NP binding_VBG ] and_CC[NP transcriptional_JJ activity_NN ][PP of_IN ][NP the_DT transcription_NN factor_NN ] ,_,[NP activator_NN protein-1_NN ] (_([NP AP-1_NN ] )_) ._.
[NP PMA_NN treatment_NN ][VP caused_VBD ] a_DT[NP concentration-_NN ] and_CC[ADJP time-dependent_JJ ][NP increase_NN ][PP in_IN ] both_CC[NP c-Fos_NN ] and_CC[NP Jun_NN ][NP immunoreactivity_NN ][PP in_IN contrast_NN to_TO ][NP cAMP_NN elevation_NN ][NP that_WDT ][VP had_VBD ][NP only_RB a_DT slight_JJ effect_NN ] ._.
 Both_CC[NP PMA_NN ] and_CC[NP the_DT combination_NN ][PP of_IN ][NP NECA_NN ] and_CC[NP forskolin_NN ][VP acted_VBD ][ADVP together_RB ] either_CC[VP to_TO increase_VB ] (_([NP c-Fos_NN ] )_) or_CC[VP decrease_VB ] (_([NP Jun_NN ] )_)[NP protein_NN levels_NNS ][PP as_RB well_RB as_IN ][VP increasing_VBG ][NP AP-1_NN binding_NN ] ,_,[SBAR as_IN ][VP judged_VBN ][PP by_IN ][NP gel-shift_NN assay_NN ] ,_, and_CC[NP AP-1_NN transcriptional_JJ activity_NN ] ._.
[ADVP Furthermore_RB ][NP there_EX ][VP was_VBD ][NP a_DT clear-cut_JJ synergy_NN ][PP between_IN ][NP the_DT PKC_NN stimulator_NN ] and_CC[NP the_DT cAMP_NN elevating_NN agents_NNS ] ._.
[NP The_DT results_NNS ][VP demonstrate_VBP ][SBAR that_IN ][NP the_DT simultaneous_JJ ][NP activation_NN ][PP of_IN ][NP PKC_NN ] and_CC[NP elevation_NN ][PP of_IN ][NP cAMP_NN ][VP leads_VBZ ][PP to_TO ][NP an_DT enhanced_VBN AP-1_NN transcriptional_JJ activity_NN ][PP in_IN ][NP a_DT T-leukemia_NN cell_NN line_NN ] ,_,[VP suggesting_VBG ][SBAR that_IN ][NP the_DT previously_RB observed_VBN interaction_NN ][PP between_IN ][NP the_DT parallel_JJ signal_NN transduction_NN pathways_NNS ][VP may_MD have_VB ][NP functional_JJ consequences_NNS ][PP at_IN ][NP the_DT level_NN ][PP of_IN ][NP gene_NN transcription_NN ] ._.
[NP The_DT use_NN ][PP of_IN ][NP interferon-gamma-treated_JJ U937_NN cells_NNS ][PP in_IN ][NP chemiluminescence_NN assays_NNS ][VP to_TO detect_VB ][NP red_JJ cell_NN ] ,_,[NP platelet_NN ] and_CC[NP granulocyte_NN antibodies_NNS ][PP of_IN ][NP potential_JJ clinical_JJ significance_NN ] ._.
 The_DT chemiluminescent_JJ (_([ADJP CL_JJ ] )_)[NP response_NN ][PP of_IN ][NP interferon-gamma-treated_JJ U937_NN ] (_([NP IFN-U937_NN ] )_)[NP cells_NNS ][PP to_TO ][NP sensitized_VBN target_NN cells_NNS ][VP has_VBZ been_VBN used_VBN ][VP to_TO detect_VB ][NP red_JJ cell_NN ] ,_,[NP platelet_NN ] and_CC[NP granulocyte_NN antibodies_NNS ] ._.
[NP A_DT clone_NN ][PP of_IN ][NP U937_NN cells_NNS ][VP was_VBD selected_VBN ][NP which_WDT ][VP expressed_VBD ][NP Fc_NN receptor_NN I_NN ] (_([NP Fc_NN gamma_NN RI_NN ] )_) and_CC[NP which_WDT ] ,_,[PP after_IN ][NP incubation_NN ][PP with_IN ][NP IFN-gamma_NN ][PP for_IN ][NP 72_CD h_NN ] ,_,[VP was_VBD ][ADJP capable_JJ ][PP of_IN ][VP generating_VBG ][NP high_JJ levels_NNS ][PP of_IN ][NP lucigenin-enhanced_JJ CL_NN ] ._.
[NP The_DT CL_NN responses_NNS ][PP of_IN ][NP IFN-U937_NN cells_NNS ] and_CC[NP peripheral_JJ blood_NN human_JJ monocytes_NNS ][PP to_TO ][NP sensitized_VBN ][NP red_JJ cells_NNS ] ,_,[NP platelets_NNS ] or_CC[NP granulocytes_NNS ][VP were_VBD then_RB compared_VBN ] ._.
[NP Assays_NNS ][VP using_VBG ][NP monocytes_NNS ] or_CC[NP IFN-U937_NN cells_NNS ][VP were_VBD ][PP of_IN ][NP comparable_JJ sensitivity_NN ][PP for_IN ][NP detection_NN ][PP of_IN ][NP antibodies_NNS ][PP against_IN ][NP all_DT three_CD types_NNS ][PP of_IN ][NP target_NN cell_NN ] ._.
[PP In_IN ][NP addition_NN ] ,_,[NP the_DT use_NN ][PP of_IN ][NP IFN-U937_NN cells_NNS ][VP reduced_VBD ][NP interassay_JJ variation_NN ] and_CC[VP simplified_VBD|VBN ][NP assay_NN performance_NN ] ._.
[NP The_DT potential_JJ clinical_JJ usefulness_NN ][PP of_IN ][NP these_DT CL_NN assays_NNS ][VP was_VBD suggested_VBN ][PP by_IN ][NP the_DT ability_NN ][PP of_IN ] both_CC[NP monocytes_NNS ] and_CC[NP IFN-U937_NN cells_NNS ][VP to_TO respond_VB ][PP to_TO ][NP red_JJ cells_NNS ] ,_,[NP platelets_NNS ] or_CC[NP granulocytes_NNS ][VP sensitized_VBN ][PP with_IN ][NP sera_NN ][PP from_IN ][NP pregnant_JJ women_NNS ][NP whose_WP$ babies_NNS ][VP had_VBD ] either_CC[NP haemolytic_JJ disease_NN of_IN the_DT newborn_JJ ] (_([NP HDN_NN ] )_) ,_,[NP alloimmune_JJ thrombocytopenia_NN ] or_CC[NP alloimmune_JJ neutropenia_NN ][ADVP respectively_RB ] ._.
[PP In_IN ][NP addition_NN ] ,_,[NP monocytes_NNS ] and_CC[NP IFN-U937_NN cells_NNS ][NP both_DT ][VP responded_VBD ][PP to_TO ][NP red_JJ cells_NNS ][VP sensitized_VBN ][PP with_IN ][NP antibodies_NNS ][PP against_IN ][NP a_DT variety_NN ][PP of_IN ][NP specificities_NNS ][PP of_IN ][NP assumed_VBN (_( although_IN not_RB documented_VBN )_) clinical_JJ significance_NN ][PP for_IN ][NP blood_NN transfusion_NN recipients_NNS ] ._.
[PP In_IN ][NP contrast_NN ] ,_,[NP monocytes_NNS ] and_CC[NP IFN-U937_NN cells_NNS ][VP responded_VBD ][ADVP only_RB weakly_RB ][PP to_TO ][NP red_JJ cells_NNS ][VP sensitized_VBN ][PP with_IN either_CC ][NP anti-D_JJ ][PP in_IN ][NP sera_NN ][PP from_IN ][NP mothers_NNS ][PP of_IN ][NP babies_NNS ][VP unaffected_JJ ][PP by_IN ][NP HDN_NN ][PP ,_, or_CC ][PP with_IN ][NP antisera_NNS ][VP containing_VBG ][NP high_JJ titre_NN antibodies_NNS ][PP with_IN ][NP specificities_NNS ][VP not_RB normally_RB associated_VBN ][PP with_IN ][NP significantly_RB reduced_VBN red_JJ cell_NN survival_NN ] ._.
[NP Photoaffinity_NN labeling_NN ][PP of_IN ][NP plasma_NN membrane_NN receptors_NNS ][PP for_IN ][NP aldosterone_NN ][PP from_IN ][NP human_JJ mononuclear_JJ leukocytes_NNS ] ._.
[NP Non-genomic_JJ effects_NNS ][PP of_IN ][NP aldosterone_NN ][PP on_IN ][NP the_DT sodium-proton-antiport_NN ][VP have_VBP been_VBN shown_VBN ][PP in_IN ][NP human_JJ mononuclear_JJ leukocytes_NNS ][NP which_WDT ][VP could_MD be_VB ][ADJP related_JJ ][PP to_TO ][NP a_DT new_JJ aldosterone_NN membrane_NN receptor_NN ] ._.
[PP In_IN ][NP the_DT present_JJ paper_NN ][NP plasma_NN membranes_NNS ][PP from_IN ][NP human_JJ mononuclear_JJ leukocytes_NNS ][VP were_VBD covalently_RB photolabeled_VBN ][PP with_IN ][NP a_DT (125I)-aldosterone_NN derivative_NN ] ._.
[NP Sodium_NN dodecyl_NN sulfate-polyacrylamide_JJ gel_NN electrophoresis_NN ][VP showed_VBD ][NP significant_JJ aldosterone_NN binding_NN ][PP at_IN ][NP a_DT molecular_JJ weight_NN ][PP of_IN ][NP approximately_RB 50000_CD Dalton_NN ][NP which_WDT ][VP was_VBD ][ADJP absent_JJ ][PP with_IN ][NP 1_CD microM_NN ][NP cold_JJ aldosterone_NN ] ,_,[CONJP but_CC not_RB ][NP cortisol_NN ][PP in_IN ][NP the_DT binding_VBG media_NNS ] ._.
[NP The_DT presence_NN ][PP of_IN ][NP the_DT sulfhydryl_NN agent_NN dithiothreitol_NN ][VP did_VBD not_RB affect_VB ][NP results_NNS ][VP suggesting_VBG ][NP the_DT absence_NN ][PP of_IN ][NP disulfide_NN bridges_NNS ][PP in_IN ][NP the_DT steroid_NN binding_NN domain_NN ][PP of_IN ][NP the_DT receptor_NN ] ._.
[NP These_DT data_NNS ][VP are_VBP ][NP the_DT first_JJ ][VP to_TO define_VB ][NP the_DT molecular_JJ weight_NN ][PP of_IN ][NP the_DT membrane_NN receptor_NN ][PP for_IN ][NP aldosterone_NN ] ._.
[NP Alpha-lipoic_JJ acid_NN ][VP is_VBZ ][NP a_DT potent_JJ inhibitor_NN ][PP of_IN ][NP NF-kappa_NN B_NN activation_NN ][PP in_IN ][NP human_JJ T_NN cells_NNS ] ._.
[NP Acquired_VBN immunodeficiency_NN syndrome_NN ] (_([NP AIDS_NN ] )_)[VP results_VBZ ][PP from_IN ][NP infection_NN ][PP with_IN ][NP a_DT human_JJ immunodeficiency_NN virus_NN ] (_([NP HIV_NN ] )_) ._.
 The_DT[NP long_JJ terminal_JJ repeat_NN ] (_([NP LTR_NN ] )_)[NP region_NN ][PP of_IN ][NP HIV_NN proviral_JJ DNA_NN ][VP contains_VBZ ][NP binding_VBG sites_NNS ][PP for_IN ][NP nuclear_JJ factor_NN kappa_NN B_NN ] (_([NP NF-kappa_NN B_NN ] )_) ,_, and_CC[NP this_DT transcriptional_JJ activator_NN ][VP appears_VBZ to_TO regulate_VB ][NP HIV_NN activation_NN ] ._.
[NP Recent_JJ findings_NNS ][VP suggest_VBP ][NP an_DT involvement_NN ][PP of_IN ][NP reactive_JJ oxygen_NN species_NNS ] (_([NP ROS_NN ] )_)[PP in_IN ][NP signal_NN transduction_NN pathways_NNS ][VP leading_VBG ][PP to_TO ][NP NF-kappa_NN B_NN activation_NN ] ._.
[NP The_DT present_JJ study_NN ][VP was_VBD based_VBN ][PP on_IN ][NP reports_NNS ][SBAR that_IN ][NP antioxidants_NNS ][NP which_WDT ][VP eliminate_VBP ][NP ROS_NN ][VP should_MD block_VB ][NP the_DT activation_NN ][PP of_IN ][NP NF-kappa_NN B_NN ] and_CC[ADVP subsequently_RB ][NP HIV_NN transcription_NN ] ,_, and_CC thus_RB[NP antioxidants_NNS ][VP can_MD be_VB used_VBN ][PP as_IN ][NP therapeutic_JJ agents_NNS ][PP for_IN ][NP AIDS_NN ] ._.
[NP Incubation_NN ][PP of_IN ][NP Jurkat_NN T_NN cells_NNS ] (_([NP 1_CD x_CC 10(6)_CD cells/ml_NNS ] )_)[PP with_IN ][NP a_DT natural_JJ thiol_NN antioxidant_NN ,_, alpha-lipoic_JJ acid_NN ] ,_,[PP prior_JJ to_TO ][NP the_DT stimulation_NN ][PP of_IN ][NP cells_NNS ][VP was_VBD found_VBN to_TO inhibit_VB ][NP NF-kappa_NN B_NN activation_NN ][VP induced_VBN ][PP by_IN ][NP tumor_NN necrosis_NN factor-alpha_NN ] (_([NP 25_CD ng/ml_NN ] )_)[PP or_CC ][PP by_IN ][NP phorbol_NN 12-myristate_NN 13-acetate_NN ] (_([NP 50_CD ng/ml_NN ] )_) ._.
[NP The_DT inhibitory_JJ action_NN ][PP of_IN ][NP alpha-lipoic_JJ acid_NN ][VP was_VBD found_VBN to_TO be_VB ][ADJP very_RB potent_JJ ][SBAR as_IN ][NP only_RB 4_CD mM_NN ][VP was_VBD needed_VBN ][PP for_IN ][NP a_DT complete_JJ inhibition_NN ] ,_, whereas_IN[NP 20_CD mM_NN ][VP was_VBD required_VBN ][PP for_IN ][NP N-acetylcysteine_NN ] ._.
[NP These_DT results_NNS ][VP indicate_VBP ][SBAR that_IN ][NP alpha-lipoic_JJ acid_NN ][VP may_MD be_VB ][ADJP effective_JJ ][PP in_IN ][NP AIDS_NN therapeutics_NNS ] ._.
[NP Activation_NN ][PP of_IN ][NP lymphokine_NN genes_NNS ][PP in_IN ][NP T_NN cells_NNS ] :_:[NP role_NN ][PP of_IN ][NP cis-acting_JJ DNA_NN elements_NNS ][NP that_WDT ][VP respond_VBP ][PP to_TO ][NP T_NN cell_NN activation_NN signals_NNS ] ._.
[NP Activation_NN ][PP of_IN ][NP T_NN cells_NNS ][VP is_VBZ initiated_VBN ][PP by_IN ][NP the_DT recognition_NN ][PP of_IN ][NP antigen_NN ][PP on_IN ][NP antigen_NN presenting_NN cells_NNS ][VP to_TO exert_VB ][NP the_DT effector_NN functions_NNS ][PP in_IN ][NP immune_JJ and_CC inflammatory_JJ responses_NNS ] ._.
[NP Two_CD types_NNS ][PP of_IN ][NP helper_NN T_NN cell_NN ] (_([NP Th_NN ] )_)[NP clones_NNS ] (_([NP Th1_NN ] and_CC[NP Th2_NN ] )_)[VP are_VBP defined_VBN ][PP on_IN the_DT basis_NN of_IN ][NP different_JJ patterns_NNS ][PP of_IN ][NP cytokine_NN ] (_([NP lymphokine_NN ] )_)[NP secretion_NN ] ._.
[NP They_PRP ][VP determine_VBP ][NP the_DT outcome_NN ][PP of_IN ][NP an_DT antigenic_JJ response_NN ][PP toward_IN ][NP humoral_JJ or_CC cell-mediated_JJ immunity_NN ] ._.
[SBAR Although_IN ][NP lymphokine_NN genes_NNS ][VP are_VBP coordinately_RB regulated_VBN ][PP upon_IN ][NP antigen_NN stimulation_NN ] ,_,[NP they_PRP ][VP are_VBP regulated_VBN ][PP by_IN ][NP the_DT mechanisms_NNS ][ADJP common_JJ ][PP to_TO ][NP all_DT ][CONJP as_RB well_RB as_IN ][NP those_DT ][NP which_WDT ][VP are_VBP ][ADJP unique_JJ ][PP to_TO ][NP each_DT gene_NN ] ._.
[PP For_IN ][NP most_JJS lymphokine_NN genes_NNS ] ,_,[NP a_DT combination_NN ][PP of_IN ][NP phorbol_NN esters_NNS ] (_([NP phorbol_NN 12-myristate_NN 13_CD acetate_NN ] ,_,[NP PMA_NN ] )_) and_CC[NP calcium_NN ionophores_NNS ] (_([NP A23187_NN ] )_)[VP is_VBZ required_VBN ][PP for_IN ][NP their_PRP$ maximal_JJ induction_NN ] ._.
 Yet_RB[NP phorbol_NN ester_NN ][ADVP alone_RB ] or_CC[NP calcium_NN ionophore_NN ][ADVP alone_RB ][VP produce_VBP ][NP several_JJ lymphokines_NNS ] ._.
[NP The_DT production_NN ][PP of_IN ][NP the_DT granulocyte-macrophage_JJ colony_NN stimulating_NN factor_NN ] (_([NP GM-CSF_NN ] )_)[VP is_VBZ ][ADJP completely_RB dependent_JJ ][PP on_IN ][NP the_DT two_CD signals_NNS ] ._.
[NP We_PRP ][VP have_VBP previously_RB found_VBN ][NP a_DT cis-acting_JJ region_NN ][VP spanning_VBG ][NP the_DT GM-CSF_NN promoter_NN region_NN ] (_([NP positions_NNS ][NP -95_CD ] to_TO[NP +27_CD ] )_)[NP that_WDT ][VP confers_VBZ ][NP inducibility_NN ][PP to_TO ][NP reporter_NN genes_NNS ][PP in_IN ][NP transient_JJ transfection_NN assays_NNS ] ._.
[NP Further_JJ analysis_NN ][VP identified_VBD ][NP three_CD elements_NNS ][VP required_VBN ][PP for_IN ][NP efficient_JJ induction_NN ] ,_,[VP referred_VBN ][PP to_TO ][PP as_IN ][NP GM2_NN ] ,_,[NP GC-box_NN ] and_CC[NP conserved_VBN lymphokine_NN element_NN ] (_([NP CLE0_NN ] )_) ._.
[NP GM2_NN ][VP defines_VBZ ][NP a_DT binding_VBG site_NN ][PP for_IN ][NP protein_NN (_( s_NNS ] )_)[NP whose_WP$ binding_NN ][VP is_VBZ ][ADJP inducible_JJ ][PP by_IN ][NP PMA_NN ] ._.
[NP One_CD protein_NN ] ,_,[NP NF-GM2_NN ][VP is_VBZ ][ADJP similar_JJ ][PP to_TO ][NP the_DT transcription_NN factor_NN NF-kB_NN ] ._.
[NP GC-box_NN ][VP is_VBZ ][NP a_DT binding_VBG site_NN ][PP for_IN ][NP constitutively_RB bound_VBN proteins_NNS ] ._.
[NP CLEO_NN ][VP defines_VBZ ][NP a_DT binding_VBG site_NN ][PP for_IN ][NP protein_NN (_( s_NNS ] )_)[NP whose_WP$ optimum_NN binding_NN ][VP is_VBZ stimulated_VBN ][PP by_IN ][NP PMA_NN ] and_CC[NP A23187_NN ] ._.
[NP Viral_JJ trans-activators_NNS ][PP such_JJ as_IN ][NP Tax_NN ] (_([NP human_JJ T_NN cell_NN leukemia_NN virus-1_NN ] ,_,[NP HTLV-1_NN ] )_) and_CC[NP E2_NN ] (_([NP bovine_JJ papilloma_NN virus_NN ] ,_,[NP BPV_NN ] )_)[NP proteins_NNS ][VP are_VBP ][NP other_JJ agents_NNS ][NP which_WDT ][VP activate_VBP ][NP lymphokine_NN gene_NN expression_NN ][PP by_IN ][VP bypassing_VBG ][NP T_NN cell_NN receptor_NN ] (_([NP TCR_NN ] )_)[NP mediated_JJ signaling_NN ] ._.
[NP The_DT trans-activation_NN domain_NN ][PP of_IN ][NP E2_NN ] and_CC[NP Tax_NN ][VP is_VBZ ][ADJP interchangeable_JJ ][SBAR although_IN ][NP they_PRP ][VP have_VBP ][NP no_DT obvious_JJ sequence_NN homology_NN ][PP between_IN ][NP them_PRP ] ._.
[NP The_DT viral_JJ trans-activators_NNS ][VP appear_VBP to_TO target_VB ][NP specific_JJ DNA_NN binding_NN protein_NN ][PP such_JJ as_IN ][NP NF-kB_NN ] and_CC[NP Sp1_NN ][PP to_TO ][NP cis-acting_JJ DNA_NN site_NN ] and_CC[VP promote_VB ][NP lymphokine_NN gene_NN expression_NN ][PP without_IN ][NP TCR-mediated_JJ stimulation_NN ] ._.
[NP I_NN kappa_NN B/MAD-3_NN ][VP masks_VBZ ][NP the_DT nuclear_JJ localization_NN signal_NN ][PP of_IN ][NP NF-kappa_NN B_NN p65_NN ] and_CC[VP requires_VBZ ][NP the_DT transactivation_NN domain_NN ][VP to_TO inhibit_VB ][NP NF-kappa_NN B_NN p65_NN DNA_NN binding_NN ] ._.
[NP The_DT active_JJ nuclear_JJ form_NN ][PP of_IN ][NP the_DT NF-kappa_NN B_NN transcription_NN factor_NN complex_NN ][VP is_VBZ composed_VBN ][PP of_IN ][NP two_CD DNA_NN binding_NN subunits_NNS ] ,_,[NP NF-kappa_NN B_NN p65_NN ] and_CC[NP NF-kappa_NN B_NN p50_NN ] ,_,[NP both_DT ][PP of_IN ][NP which_WDT ][VP share_VBP ][NP extensive_JJ N-terminal_JJ sequence_NN homology_NN ][PP with_IN ][NP the_DT v-rel_NN oncogene_NN product_NN ] ._.
[NP The_DT NF-kappa_NN B_NN p65_NN subunit_NN ][VP provides_VBZ ][NP the_DT transactivation_NN activity_NN ][PP in_IN ][NP this_DT complex_JJ ] and_CC[VP serves_VBZ ][PP as_IN ][NP an_DT intracellular_JJ receptor_NN ][PP for_IN ][NP a_DT cytoplasmic_JJ inhibitor_NN ][PP of_IN ][NP NF-kappa_NN B_NN ] ,_,[VP termed_VBN ][NP I_NN kappa_NN B_NN ] ._.
[PP In_IN ][NP contrast_NN ] ,_,[NP NF-kappa_NN B_NN p50_NN ][ADVP alone_RB ][VP fails_VBZ to_TO stimulate_VB ][NP kappa_NN B-directed_JJ transcription_NN ] ,_, and_CC[PP based_VBN ][PP on_IN ][NP prior_JJ in_FW vitro_FW studies_NNS ] ,_,[VP is_VBZ not_RB directly_RB regulated_VBN ][PP by_IN ][NP I_NN kappa_NN B_NN ] ._.
[VP To_TO investigate_VB ][NP the_DT molecular_JJ basis_NN ][PP for_IN ][NP the_DT critical_JJ regulatory_JJ interaction_NN ][PP between_IN ][NP NF-kappa_NN B_NN ] and_CC[NP I_NN kappa_NN B/MAD-3_NN ] ,_,[NP a_DT series_NN ][PP of_IN ][NP human_JJ NF-kappa_NN B_NN p65_NN mutants_NNS ][VP was_VBD identified_VBN ][NP that_WDT ][ADVP functionally_RB ][VP segregated_VBD ][NP DNA_NN binding_NN ] ,_,[NP I_NN kappa_NN B-mediated_JJ inhibition_NN ] ,_, and_CC[NP I_NN kappa_NN B-induced_JJ nuclear_JJ exclusion_NN ][PP of_IN ][NP this_DT transcription_NN factor_NN ] ._.
[NP Results_NNS ][PP from_IN ][NP in_FW vivo_FW expression_NN studies_NNS ][VP performed_VBN ][PP with_IN ][NP these_DT NF-kappa_NN B_NN p65_NN mutants_NNS ][VP revealed_VBD ][NP the_DT following_NN ] :_:[LST 1_LS ] )_)[NP I_NN kappa_NN B/MAD-3_NN ][ADVP completely_RB ][VP inhibits_VBZ ][NP NF-kappa_NN B_NN p65-dependent_JJ transcriptional_JJ activation_NN ][VP mediated_VBN ][PP through_IN ][NP the_DT human_JJ immunodeficiency_NN virus_NN type_NN 1_CD kappa_NN B_NN enhancer_NN ][PP in_IN ][NP human_JJ T_NN lymphocytes_NNS ] ,_,[LST 2_LS ] )_)[NP the_DT binding_NN ][PP of_IN ][NP I_NN kappa_NN B/MAD-3_NN ][PP to_TO ][NP NF-kappa_NN B_NN p65_NN ][VP is_VBZ ][ADJP sufficient_JJ ][VP to_TO retarget_VB ][NP NF-kappa_NN B_NN p65_NN ][PP from_IN ][NP the_DT nucleus_NN ][PP to_TO ][NP the_DT cytoplasm_NN ] ,_,[LST 3_LS ] )_)[NP selective_JJ deletion_NN ][PP of_IN ][NP the_DT functional_JJ nuclear_JJ localization_NN signal_NN ][ADJP present_JJ ][PP in_IN ][NP the_DT Rel_NN homology_NN domain_NN ][PP of_IN ][NP NF-kappa_NN B_NN p65_NN ][VP disrupts_VBZ ][NP its_PRP$ ability_NN ][VP to_TO engage_VB ][NP I_NN kappa_NN B/MAD-3_NN ] ,_, and_CC[LST 4_LS ] )_)[NP the_DT unique_JJ C-terminus_NN ][PP of_IN ][NP NF-kappa_NN B_NN p65_NN ][VP attenuates_VBZ ][NP its_PRP$ own_JJ nuclear_JJ localization_NN ] and_CC[VP contains_VBZ ][NP sequences_NNS ][NP that_WDT ][VP are_VBP required_VBN ][PP for_IN ][NP I_NN kappa_NN B-mediated_JJ inhibition_NN ][PP of_IN ][NP NF-kappa_NN B_NN p65_NN DNA_NN binding_NN activity_NN ] ._.
[ADVP Together_RB ] ,_,[NP these_DT findings_NNS ][VP suggest_VBP ][SBAR that_IN ][NP the_DT ][NP nuclear_JJ localization_NN signal_NN ] and_CC[NP transactivation_NN domain_NN ][PP of_IN ][NP NF-kappa_NN B_NN p65_NN ][VP constitute_VBP ][NP a_DT bipartite_JJ system_NN ][NP that_WDT ][VP is_VBZ critically_RB involved_VBN ][PP in_IN ][NP the_DT inhibitory_JJ function_NN ][PP of_IN ][NP I_NN kappa_NN B/MAD-3_NN ] ._.
[ADVP Unexpectedly_RB ] ,_,[NP our_PRP$ in_FW vivo_FW studies_NNS ][ADVP also_RB ][VP demonstrate_VBP ][SBAR that_IN ][NP I_NN kappa_NN B/MAD-3_NN ][VP binds_VBZ ][ADVP directly_RB ][PP to_TO ][NP NF-kappa_NN B_NN p50_NN ] ._.
[NP This_DT interaction_NN ][VP is_VBZ ][ADJP functional_JJ ][SBAR as_IN ][NP it_PRP ][VP leads_VBZ ][PP to_TO ][NP retargeting_NN ][PP of_IN ][NP NF-kappa_NN B_NN p50_NN ][PP from_IN ][NP the_DT nucleus_NN ][PP to_TO ][NP the_DT cytoplasm_NN ] ._.
[ADVP However_RB ] ,_,[NP no_DT loss_NN ][PP of_IN ][NP DNA_NN binding_NN activity_NN ][VP is_VBZ observed_VBN ] ,_,[ADVP presumably_RB ][VP reflecting_VBG ][NP the_DT unique_JJ C-terminal_JJ domain_NN ][NP that_WDT ][VP is_VBZ ][ADJP distinct_JJ ][PP from_IN ][NP that_DT ][ADJP present_JJ ][PP in_IN ][NP NF-kappa_NN B_NN p65_NN ] ._.
[NP Surrogate_NN thyroglobulin_NN receptors_NNS ] and_CC[NP T_NN cell_NN proliferation_NN ][PP in_IN ][NP Hashimoto_NN ][NP 's_POS thyroiditis_NN ] ._.
[NP Immunoglobulin_NN molecules_NNS ][PP on_IN ][NP the_DT surface_NN ][PP of_IN ][NP a_DT B_NN lymphocyte_NN ][VP are_VBP ][NP the_DT endogenous_JJ "_[[DQS]] receptors_NNS ] "_[[DQE]][PP to_TO ][NP which_WDT ][NP specific_JJ antigens_NNS ][VP bind_VBP ] ._.
[NP Studies_NNS ][PP in_IN ][NP mice_NNS ][VP have_VBP shown_VBN ][SBAR that_IN ][NP a_DT monoclonal_JJ antibody_NN ] ,_,[VP conjugated_VBN ][PP with_IN ][NP palmitate_NN ][VP to_TO provide_VB ][NP a_DT lipid_NN tail_NN ] ,_,[VP can_MD be_VB inserted_VBN ][PP into_IN ][NP the_DT cell_NN membrane_NN ][VP to_TO provide_VB ][NP a_DT "_[[DQS]] surrogate_JJ "_[[DQE]] antigen_NN receptor_NN ] ._.
[NP We_PRP ][VP have_VBP investigated_VBN ][SBAR whether_IN ][NP a_DT palmitate_JJ conjugate_NN ][PP of_IN ][NP a_DT human_JJ monoclonal_JJ antibody_NN ][ADJP specific_JJ ][PP for_IN ][NP thyroglobulin_NN ] (_([NP TG_NN ] )_)[VP could_MD function_VB ][PP as_IN ][NP a_DT surrogate_JJ TG_NN receptor_NN ][PP on_IN ][NP blood_NN mononuclear_JJ cells_NNS ][VP separated_VBN ][PP into_IN ][NP fractions_NNS ][VP enriched_VBN ][PP for_IN ][NP T_NN cells_NNS ] or_CC[VP depleted_VBN ][PP of_IN ][NP T_NN cells_NNS ] (_([NP non-T_JJ cells_NNS ] )_) ._.
[VP Using_VBG ][NP flow_NN cytometry_NN ] ,_,[NP we_PRP ][VP detected_VBD ][NP surrogate_JJ TG_NN receptors_NNS ][PP on_IN ][NP non-T_JJ ][PP (_( but_CC ][PP not_RB on_IN ][NP T_NN ] )_)[NP cells_NNS ][PP from_IN ][NP 11_CD of_IN 11_CD individuals_NNS ][VP studied_VBN ] (_([NP 5_CD Hashimoto_NN patients_NNS ] and_CC[NP 6_CD control_NN donors_NNS ] )_) ._.
[PP In_IN ][NP contrast_NN ] ,_,[NP endogenous_JJ TG_NN receptors_NNS ][VP could_MD only_RB be_VB detected_VBN ][PP on_IN ][NP non-T_JJ cells_NNS ][PP from_IN ][NP 1_CD of_IN 3_CD Hashimoto_NN patients_NNS ][PP and_CC ][PP from_IN ][NP 0_CD of_IN 4_CD control_NN donors_NNS ] ._.
[PP Because_IN of_IN ][NP the_DT efficient_JJ binding_NN ][PP of_IN ][NP TG_NN ][PP by_IN ][NP surrogate_JJ receptors_NNS ][PP on_IN ][NP non-T_JJ cells_NNS ] ,_,[NP we_PRP ][VP assessed_VBD ][NP the_DT ability_NN ][PP of_IN ][NP such_JJ cells_NNS ][VP to_TO present_VB ][NP TG_NN ][PP to_TO ][NP T_NN cells_NNS ] ._.
[NP Proliferation_NN ][PP in_IN response_NN to_TO ][NP TG_NN ][VP was_VBD observed_VBN ][PP in_IN ][NP T_NN cells_NNS ][PP from_IN ][NP only_RB 1_CD of_IN 5_CD Hashimoto_NN patients_NNS ] ._.
[NP This_DT low_JJ frequency_NN ][PP of_IN ][NP response_NN ][VP was_VBD ][ADJP no_RB different_JJ ][PP from_IN ][NP that_DT ][VP previously_RB detected_VBN ][VP using_VBG ][NP cultures_NNS ][PP of_IN ][NP T_NN cells_NNS ] and_CC[NP autologous_JJ dendritic_JJ cells_NNS ] ._.
[ADVP Therefore_RB ] ,_,[NP the_DT successful_JJ generation_NN ][PP of_IN ][NP surrogate_JJ receptors_NNS ][PP on_IN ][NP non-T_JJ cells_NNS ][VP is_VBZ not_RB associated_VBN ][PP with_IN ][NP more_RBR efficient_JJ TG_NN presentation_NN ][PP of_IN ][NP T_NN cells_NNS ] ._.
[ADVP Furthermore_RB ] ,_,[NP the_DT significance_NN ][PP of_IN ][NP the_DT present_JJ study_NN ][VP is_VBZ ][SBAR that_IN ][NP the_DT T_NN cells_NNS ][NP ,_, not_RB ][NP the_DT antigen-presenting_JJ cells_NNS ] ,_,[VP are_VBP ][ADJP likely_JJ ][VP to_TO be_VB ][NP the_DT limiting_VBG element_NN ][PP in_IN ][NP the_DT T_NN cell_NN proliferative_JJ response_NN ][PP to_TO ][NP TG_NN ] and_CC[NP other_JJ thyroid_NN autoantigens_NNS ] ._.
[NP Aldosterone-specific_JJ membrane_NN receptors_NNS ] and_CC[NP rapid_JJ non-genomic_JJ actions_NNS ][PP of_IN ][NP mineralocorticoids_NNS ] ._.
[NP Functional_JJ studies_NNS ][PP in_IN ][NP extrarenal_JJ ,_, non-epithelial_JJ cells_NNS ][PP such_JJ as_IN ][NP smooth_JJ muscle_NN cells_NNS ] and_CC[ADVP more_RBR recently_RB ][NP circulating_VBG human_JJ lymphocytes_NNS ][VP have_VBP provided_VBN ][NP increasing_VBG evidence_NN ][SBAR that_IN ][NP aldosterone_NN ][VP produces_VBZ ][CONJP not_RB only_RB ][NP classical_JJ genomic_JJ effects_NNS ] ,_,[CONJP but_CC also_RB ][NP rapid_JJ ,_, non-genomic_JJ effects_NNS ][PP on_IN ][NP transmembrane_NN electrolyte_NN movements_NNS ] ._.
[NP These_DT ][VP involve_VBP ][NP activation_NN ][PP of_IN ][NP the_DT sodium/proton_NN exchanger_NN ][PP of_IN ][NP the_DT cell_NN membrane_NN ][PP at_IN ][NP very_RB low_JJ ,_, physiological_JJ concentrations_NNS ][PP of_IN ][NP aldosterone_NN ][PP with_IN ][NP an_DT acute_JJ onset_NN ][PP within_IN ][NP 1-2_CD min_NN ] ._.
[NP A_DT second_JJ messenger_NN cascade_NN ][VP involved_VBN ][VP is_VBZ ][NP the_DT inositol_NN 1,4,5-trisphosphate/calcium_NN pathway_NN ][NP which_WDT ][VP responds_VBZ ][PP over_IN ][NP the_DT same_JJ rapid_JJ time_NN course_NN ] ._.
[NP Such_JJ changes_NNS ][ADVP clearly_RB ][VP can_MD not_RB be_VB explained_VBN ][PP by_IN ][NP genomic_JJ mechanisms_NNS ] ,_,[NP which_WDT ][VP are_VBP ][ADJP responsible_JJ ][PP for_IN ][NP later_JJ effects_NNS ][PP than_IN ] the_DT[NP membrane_NN ][NP related_JJ rapid_JJ responses_NNS ] ._.
[NP The_DT mechanisms_NNS ][VP underlying_VBG ][NP these_DT rapid_JJ effects_NNS ][PP of_IN ][NP aldosterone_NN ][PP on_IN ][NP electrolytes_NNS ][VP have_VBP been_VBN extensively_RB studied_VBN ][PP in_IN ][NP human_JJ lymphocytes_NNS ] ,_,[NP which_WDT ][ADVP thus_RB ][VP may_MD represent_VB ][NP valuable_JJ tools_NNS ][PP in_IN ][NP the_DT delineation_NN ][PP of_IN ][NP the_DT receptor-effector_JJ mechanisms_NNS ][VP involved_VBN ] ._.
[NP The_DT unique_JJ characteristics_NNS ][PP of_IN ][NP this_DT new_JJ pathway_NN ][PP for_IN ][NP steroid_NN action_NN ][VP include_VBP ][NP its_PRP$ rapid_JJ time_NN course_NN ] ,_,[NP 10,000-fold_JJ selectivity_NN ][PP for_IN ][NP aldosterone_NN ][PP over_IN ][NP cortisol_NN ] and_CC[NP the_DT ineffectiveness_NN ][PP of_IN ][NP spironolactones_NNS ] ,_,[NP classical_JJ mineralocorticoid_NN antagonists_NNS ] ,_,[PP as_IN ][NP antagonists_NNS ][PP of_IN ][NP the_DT response_NN ] ._.
 Cellular_JJ immune_JJ and_CC[NP cytokine_NN ][NP pathways_NNS ][VP resulting_VBG ][PP in_IN ][NP tissue_NN factor_NN expression_NN ] and_CC[NP relevance_NN ][PP to_TO ][NP septic_JJ shock_NN ] ._.
[NP Cells_NNS ][PP of_IN ][NP monocyte_NN lineage_NN ][VP serve_VBP ][PP as_IN ][NP effector_NN cells_NNS ][PP in_IN ][NP the_DT cellular_JJ immune_JJ response_NN ] ._.
[PP In_IN ][NP addition_NN ] ,_,[NP they_PRP ][VP respond_VBP ][PP to_TO ][NP LPS_NN ] and_CC[NP cytokines_NNS ][PP with_IN ][NP activation_NN ] and_CC[NP expression_NN ][PP of_IN ][NP inflammatory_JJ effector_NN gene_NN products_NNS ][ADJP similar_JJ ][PP to_TO ][NP those_DT ][VP elicited_VBN ][PP by_IN ] the_DT[NP antigen_NN ][NP driven_JJ response_NN ] ._.
[NP The_DT response_NN ][PP to_TO ][NP antigen_NN ][VP proceeds_VBZ ][PP at_IN ][NP the_DT T_NN helper_NN cell_NN level_NN ][PP through_IN ][NP two_CD independent_JJ forms_NNS ][PP of_IN ][NP cellular_JJ collaboration_NN ] ,_,[NP contact_NN ] and_CC[NP lymphokine_NN ] ._.
[NP We_PRP ][VP review_VBP ][NP the_DT control_NN ][PP of_IN ][NP expression_NN ][PP of_IN ] the_DT[NP Tissue_NN Factor_NN ] (_([NP TF_NN ] )_)[NP gene_NN ] and_CC[NP the_DT function_NN ][PP of_IN ][NP the_DT TF_NN protein_NN ] ._.
[NP The_DT enhanced_VBN initiation_NN ][PP of_IN ][NP transcription_NN ][PP of_IN ][NP the_DT TF_NN gene_NN ][VP appears_VBZ to_TO require_VB ][NP engagement_NN ][PP of_IN ][NP a_DT 56_CD bp_NN LPS_NN Response_NN Element_NN ] ,_,[NP an_DT enhancer_NN ][NP that_WDT ][VP is_VBZ engaged_VBN ][PP by_IN ][NP both_DT ][NP AP-1_NN type_NN heterodimeric_JJ complexes_NNS ][CONJP as_RB well_RB as_IN ][NP NF_NN kappa_NN B_NN ][NP like_IN heterodimeric_JJ complexes_NNS ] ._.
[NP Dissociation_NN ][PP of_IN ][NP NF_NN kappa_NN B_NN ][PP from_IN ][NP Ig_NN kappa_NN B_NN ][PP by_IN ][NP cytokine_NN ] and_CC[NP LPS_NN ][NP stimulation_NN ] ,_, and_CC[ADVP possibly_RB ][NP activated_VBN T_NN cells_NNS ] ,_,[VP may_MD represent_VB ][NP a_DT common_JJ pathway_NN ][PP to_TO ][NP induction_NN ][PP of_IN ][NP the_DT ][NP TF_NN ] and_CC[NP other_JJ inflammatory_JJ ][NP genes_NNS ] ._.
[NP Enhancement_NN ][PP of_IN ][NP expression_NN ][PP of_IN ][NP TF_NN ][VP is_VBZ observed_VBN ][PP upon_IN ][NP adhesion_NN ][PP of_IN ][NP Mo_NN ][PP to_TO ][NP endothelial_JJ cells_NNS ] and_CC[NP extracellular_JJ matrix_JJ proteins_NNS ] ,_,[CONJP as_RB well_RB as_IN ][PP upon_IN ][NP engagement_NN ][PP of_IN ][NP leukocyte_NN integrins_NNS ] ._.
[NP The_DT biological_JJ effects_NNS ][NP that_WDT ][VP follow_VBP ][PP from_IN ][NP expression_NN ][PP of_IN ][NP TF_NN ][PP by_IN ][NP vascular_JJ cells_NNS ][VP have_VBP been_VBN resolved_VBN ][PP by_IN ][NP analysis_NN ][PP of_IN ][NP function_NN ][VP aided_VBN ][PP by_IN ][NP the_DT use_NN ][PP of_IN ][NP recombinant_JJ full_JJ length_NN TF_NN ] and_CC[NP truncated_VBN surface_NN domain_NN ][PP of_IN ][NP TF_NN ] ._.
[NP The_DT rules_NNS ][PP of_IN ][NP assembly_NN ][PP of_IN ][NP the_DT cognate_JJ ligands_NNS ][PP of_IN ][NP TF_NN ][NP ,_, namely_RB ][NP the_DT zymogen_NN plasma_NN factors_NNS VII_NN ] and_CC[NP the_DT serine_NN protease_NN factor_NN VIIa_NN ] ,_,[PP with_IN ][NP the_DT soluble_JJ surface_NN domain_NN ][PP of_IN ][NP TF_NN ][PP in_IN ][NP free_JJ solution_NN ] ,_,[PP in_IN ][NP the_DT presence_NN ][PP of_IN ][NP phospholipid_JJ surfaces_NNS ] and_CC[NP cell_NN surface_NN ][PP and_CC ][PP of_IN ][NP the_DT anchored_VBN TF_NN molecule_NN ][VP have_VBP been_VBN described_VBN ] ._.
[NP It_PRP ][VP is_VBZ ][ADJP evident_JJ ][SBAR that_IN ][NP assembly_NN ][PP of_IN ][NP the_DT surface_NN domain_NN ][PP of_IN ][NP TF_NN ][PP with_IN ][NP VIIa_NN ][VP to_TO form_VB ][NP the_DT binary_JJ TF.VIIa_NN complex_NN ][VP induces_VBZ ][NP a_DT significant_JJ increase_NN ][PP in_IN ][NP the_DT Kcat_NN ][PP of_IN ][NP the_DT catalytic_JJ domain_NN ][PP of_IN ][NP VIIa_NN ][PP for_IN ][NP small_JJ peptidyl_JJ substrates_NNS ][PP and_CC ][ADVP more_JJR profoundly_RB ][PP for_IN ][NP protein_NN substrate_NN ] ._.
[NP This_DT ][VP provides_VBZ ][NP substantial_JJ evidence_NN ][PP for_IN ][NP an_DT allosteric_JJ effect_NN ][PP on_IN ][NP the_DT catalytic_JJ cleft_NN ][PP of_IN ][NP VIIa_NN ][NP that_WDT ][VP is_VBZ imparted_VBN ][PP by_IN ][VP binding_VBG ][PP to_TO ][NP TF_NN ] ,_,[NP its_PRP$ cognate_JJ catalytic_JJ cofactor_NN ] ._.
[NP It_PRP ][VP is_VBZ ][ADJP also_RB evident_JJ ][SBAR that_IN ][NP the_DT TF.VIIa_NN complex_NN ][VP is_VBZ ][ADJP proteolytically_RB active_JJ ] and_CC[VP can_MD activate_VB ][NP the_DT zymogen_NN plasma_NN factor_NN X_NN ][PP to_TO ][NP the_DT serine_NN protease_NN Xa_NN ][PP in_IN ][NP free_JJ solution_NN ] ,_,[VP inferring_VBG ][SBAR that_IN ][NP extended_VBN substrate_NN recognition_NN ][PP by_IN ][NP induced_VBN structural_JJ loci_NNS ][PP of_IN ][NP the_DT TF.VIIa_NN complex_NN ][VP are_VBP created_VBN ][PP from_IN ][NP either_DT ] or_CC[NP both_DT ][NP proteins_NNS ][VP to_TO constitute_VB ][NP a_DT new_JJ recognition_NN structure_NN ] ._.
[NP It_PRP ][VP is_VBZ ][ADJP also_RB evident_JJ ][SBAR that_IN ][NP association_NN ][PP of_IN ][NP X_NN ][PP with_IN ][NP charged_JJ phospholipid_JJ surfaces_NNS ][VP enhances_VBZ ][NP the_DT proteolytic_JJ activation_NN ][PP of_IN ][NP this_DT zymogen_NN ][PP by_IN ][VP increasing_VBG ][NP recognition_NN ] and_CC[NP susceptibility_NN ][PP of_IN ][NP the_DT sessile_NN peptide_NN bond_NN ][VP deduced_VBN ][PP from_IN ][NP the_DT ][ADVP markedly_RB ][NP decreased_VBN Km_NN ] and_CC[NP increased_VBN Kcat_NN ] ._.
